DDI-DrugBank.d103.s4.p19	steroids	None	group	beta2-agonists	None	True	effect	group	Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.
DDI-DrugBank.d105.s0.p4	Anticoagulants	None	group	ardeparin	DB00407	True	effect	drug	Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.
DDI-DrugBank.d106.s3.p0	phenytoin	DB00252	drug	SULAR	None	True	mechanism	brand	Coadministration of phenytoin with 40 mg SULAR tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.
DDI-DrugBank.d107.s3.p1	enalapril	DB00584	drug	antihypertensive agents	None	True	effect	group	Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).
DDI-DrugBank.d107.s4.p2	nonsteroidal anti-inflammatory drugs	None	group	enalapril	DB00584	True	effect	drug	Non-steroidal Anti-inflammatory Agents: In some patients with compromised renal function who are being treated with nonsteroidal anti-inflammatory drugs, the co-administration of enalapril may result in a further deterioration of renal function.
DDI-DrugBank.d108.s0.p0	Isocarboxazid	DB01247	drug	Antabuse	None	True	advise	brand	Isocarboxazid should be administered with caution to patients receiving Antabuse (disulfiram, Wyeth-Ayerst Laboratories).
DDI-DrugBank.d11.s0.p4	STRATTERA	None	brand	albuterol	None	True	advise	drug	Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2 agonists) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.
DDI-DrugBank.d110.s0.p9	norepinephrine	DB00368	drug	monoamine oxidase inhibitors	None	True	effect	group	The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.
DDI-DrugBank.d114.s11.p2	interleukin-2	None	drug	radiographic iodinated contrast media	None	True	effect	group	Delayed Adverse Reactions to Iodinated Contrast Media: A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various interleukin-2 containing regimens who were subsequently administered radiographic iodinated contrast media experienced acute, atypical adverse reactions.
DDI-DrugBank.d103.s3.p10	FORADIL	None	brand	tricyclic antidepressants	None	True	advise	group	Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.
DDI-DrugBank.d104.s0.p2	Fenfluramine	DB00574	drug	methyldopa	DB00968	True	effect	drug	Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, methyldopa, reserpine.
DDI-DrugBank.d104.s0.p3	Fenfluramine	DB00574	drug	reserpine	DB00206	True	effect	drug	Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, methyldopa, reserpine.
DDI-DrugBank.d106.s8.p0	Quinidine	DB00908	drug	nisoldipine	DB00401	True	mechanism	drug	Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.
DDI-DrugBank.d107.s12.p2	enalapril	DB00584	drug	thiazide-type diuretics	None	True	effect	group	Agents Increasing Serum Potassium: Enalapril and enalapril IV attenuate potassium loss caused by thiazide-type diuretics.
DDI-DrugBank.d11.s3.p1	STRATTERA	None	brand	fluoxetine	DB00472	True	advise	drug	Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, fluoxetine, and quinidine.
DDI-DrugBank.d113.s1.p0	meclofenamate sodium	None	drug	warfarin	DB00682	True	advise	drug	Therefore, when meclofenamate sodium is given to a patient receiving warfarin, the dosage of warfarin should be reduced to prevent excessive prolongation of the prothrombin time.
DDI-DrugBank.d114.s10.p0	glucocorticoids	None	group	PROLEUKIN	None	True	effect	brand	Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.
DDI-DrugBank.d114.s2.p20	asparaginase	DB00023	drug	PROLEUKIN	None	True	effect	brand	Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.
DDI-DrugBank.d103.s4.p20	diuretics	None	group	beta2-agonists	None	True	effect	group	Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.
DDI-DrugBank.d104.s0.p1	Fenfluramine	DB00574	drug	guanethidine	DB01170	True	effect	drug	Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, methyldopa, reserpine.
DDI-DrugBank.d106.s4.p0	SULAR	None	brand	phenytoin	DB00252	True	advise	drug	Coadministration of SULAR with phenytoin or any known CYP3A4 inducer should be avoided and alternative antihypertensive therapy should be considered.
DDI-DrugBank.d107.s1.p4	enalaprilat	None	drug	diuretic	None	True	effect	drug	The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.
DDI-DrugBank.d107.s16.p5	lithium	DB01356	drug	ACE inhibitors	None	True	effect	group	Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.
DDI-DrugBank.d107.s9.p0	NSAIDs	None	group	ACE inhibitors	None	True	advise	group	This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.
DDI-DrugBank.d108.s0.p1	Isocarboxazid	DB01247	drug	disulfiram	DB00822	True	advise	drug	Isocarboxazid should be administered with caution to patients receiving Antabuse (disulfiram, Wyeth-Ayerst Laboratories).
DDI-DrugBank.d11.s4.p3	fluoxetine	DB00472	drug	atomoxetine	DB00289	True	mechanism	drug	In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.
DDI-DrugBank.d110.s0.p10	norepinephrine	DB00368	drug	tricyclic antidepressants	None	True	effect	group	The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.
DDI-DrugBank.d110.s0.p3	anesthetic solutions	None	group	tricyclic antidepressants	None	True	effect	group	The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.
DDI-DrugBank.d114.s2.p14	cytotoxic	None	group	PROLEUKIN	None	True	effect	brand	Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.
DDI-DrugBank.d114.s5.p0	PROLEUKIN	None	brand	antineoplastic agents	None	True	effect	group	Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.
DDI-DrugBank.d12.s7.p0	lovastatin	DB00227	drug	fibrate	None	True	effect	group	For these reasons, it is felt that, in most subjects who have had an unsatisfactory lipid response to either drug alone, the possible benefits of combined therapy with lovastatin and a fibrate do not outweigh the risks of severe myopathy, rhabdomyolysis, and acute renal failure.
DDI-DrugBank.d121.s1.p0	probenecid	DB01032	drug	cefprozil	DB01150	True	mechanism	drug	Concomitant administration of probenecid doubled the AUC for cefprozil.
DDI-DrugBank.d122.s0.p2	cephalosporins	None	group	furosemide	DB00695	True	effect	drug	Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent diuretics such as furosemide.
DDI-DrugBank.d123.s16.p5	quinolones	None	group	theophylline	DB00277	True	mechanism	drug	Theophylline: As with some other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.
DDI-DrugBank.d123.s3.p4	ciprofloxacin	DB00537	drug	glyburide	DB01016	True	effect	drug	Glyburide: The concomitant administration of ciprofloxacin with the sulfonylurea glyburide has, on rare occasions, resulted in severe hypoglycemia.
DDI-DrugBank.d123.s8.p1	quinolone	None	group	magnesium	DB01378	True	mechanism	drug	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
DDI-DrugBank.d123.s8.p7	quinolone	None	group	iron	DB01592	True	mechanism	drug	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
DDI-DrugBank.d115.s16.p0	acetaminophen	DB00316	drug	Gleevec	None	True	mechanism	brand	Systemic exposure to acetaminophen is expected to be increased when coadministered with Gleevec.
DDI-DrugBank.d115.s9.p0	Gleevec	None	brand	cyclosporine	DB00091	True	advise	drug	Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or pimozide).
DDI-DrugBank.d122.s0.p1	cephalosporins	None	group	diuretics	None	True	effect	group	Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent diuretics such as furosemide.
DDI-DrugBank.d123.s14.p2	phenytoin	DB00252	drug	ciprofloxacin	DB00537	True	mechanism	drug	Phenytoin: Altered serum levels of phenytoin (increased and decreased) have been reported in patients receiving concomitant ciprofloxacin.
DDI-DrugBank.d123.s8.p18	ciprofloxacin	DB00537	drug	ciprofloxacin	DB00537	True	mechanism	drug	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
DDI-DrugBank.d124.s26.p129	fentanyl	DB00813	drug	saquinavir	DB01232	True	mechanism	drug	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DDI-DrugBank.d124.s26.p135	triazolam	DB00897	drug	saquinavir	DB01232	True	mechanism	drug	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DDI-DrugBank.d124.s26.p57	quinine	DB00468	drug	saquinavir	DB01232	True	mechanism	drug	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DDI-DrugBank.d110.s0.p8	epinephrine	DB00668	drug	phenothiazines	None	True	effect	group	The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.
DDI-DrugBank.d111.s0.p14	L-tyrosine	DB00135	drug	MAO inhibitors	None	True	effect	group	Non-selective MAO inhibitors including tranylcypromine sulfate, phenelzine sulfate, and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.
DDI-DrugBank.d115.s0.p12	Gleevec	None	brand	itraconazole	DB01167	True	advise	drug	Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).
DDI-DrugBank.d115.s10.p2	Gleevec	None	brand	HMG-CoA reductase inhibitors	None	True	mechanism	group	Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.).
DDI-DrugBank.d12.s0.p0	anticoagulants	None	group	Atromid-S	None	True	advise	brand	Caution should be exercised when anticoagulants are given in conjunction with Atromid-S.
DDI-DrugBank.d12.s3.p0	Atromid-S	None	brand	phenytoin	DB00252	True	mechanism	drug	Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites.
DDI-DrugBank.d121.s0.p0	aminoglycoside antibiotics	None	group	cephalosporin antibiotics	None	True	effect	group	Nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporin antibiotics.
DDI-DrugBank.d123.s15.p4	Probenecid	DB01032	drug	ciprofloxacin	DB00537	True	mechanism	drug	Probenecid: Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.
DDI-DrugBank.d123.s19.p4	Quinolones	None	group	warfarin	DB00682	True	effect	drug	Warfarin: Quinolones have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives.
DDI-DrugBank.d123.s3.p3	ciprofloxacin	DB00537	drug	sulfonylurea	None	True	effect	group	Glyburide: The concomitant administration of ciprofloxacin with the sulfonylurea glyburide has, on rare occasions, resulted in severe hypoglycemia.
DDI-DrugBank.d124.s26.p44	disopyramide	DB00280	drug	saquinavir	DB01232	True	mechanism	drug	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DDI-DrugBank.d124.s26.p69	amiodarone	DB01118	drug	saquinavir	DB01232	True	mechanism	drug	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DDI-DrugBank.d124.s28.p0	INVIRASE	None	brand	ritonavir	DB00503	True	advise	drug	Since INVIRASE is coadministered with ritonavir, the ritonavir label should be reviewed for additional drugs that should not be coadministered.
DDI-DrugBank.d13.s0.p1	Flupenthixol	None	drug	MAOI	None	True	int	group	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants
DDI-DrugBank.d13.s0.p30	MAOI	None	group	flupenthixol	None	True	effect	drug	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants
DDI-DrugBank.d130.s0.p0	Lincomycin	DB01627	drug	neuromuscular blocking agents	None	True	effect	group	Lincomycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents.
DDI-DrugBank.d131.s10.p10	alprazolam	DB00404	drug	nifedipine	DB01115	True	int	drug	Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.
DDI-DrugBank.d131.s10.p3	benzodiazepines	None	group	amiodarone	DB01118	True	int	drug	Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.
DDI-DrugBank.d124.s30.p3	phenobarbital	DB01174	drug	saquinavir	DB01232	True	mechanism	drug	Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.
DDI-DrugBank.d124.s30.p9	carbamazepine	DB00564	drug	saquinavir	DB01232	True	mechanism	drug	Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.
DDI-DrugBank.d130.s2.p0	lincomycin	DB01627	drug	erythromycin	DB00199	True	effect	drug	Antagonism between lincomycin and erythromycin in vitro has been demonstrated.
DDI-DrugBank.d131.s1.p1	imipramine	DB00458	drug	alprazolam	DB00404	True	mechanism	drug	The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.
DDI-DrugBank.d131.s10.p4	benzodiazepines	None	group	nicardipine	DB00622	True	int	drug	Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.
DDI-DrugBank.d131.s10.p8	alprazolam	DB00404	drug	amiodarone	DB01118	True	int	drug	Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.
DDI-DrugBank.d131.s6.p0	propoxyphene	None	drug	alprazolam	DB00404	True	mechanism	drug	Coadministration of propoxyphene decreased the maximum plasma concentration of alprazolam by 6%, decreased clearance by 38%, and increased half-life by 58%.
DDI-DrugBank.d132.s11.p3	diflunisal	DB00861	drug	acetaminophen	DB00316	True	mechanism	drug	Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.
DDI-DrugBank.d132.s17.p0	Nonsteroidal anti-inflammatory drugs	None	group	methotrexate	DB00563	True	mechanism	drug	Nonsteroidal anti-inflammatory drugs have been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity.
DDI-DrugBank.d132.s6.p0	Diflunisal	DB00861	drug	hydrochlorothiazide	DB00999	True	effect	drug	Diflunisal decreased the hyperuricemic effect of hydrochlorothiazide.
DDI-DrugBank.d123.s8.p10	ciprofloxacin	DB00537	drug	magnesium	DB01378	True	mechanism	drug	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
DDI-DrugBank.d123.s8.p5	quinolone	None	group	VIDEX	None	True	mechanism	brand	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
DDI-DrugBank.d129.s3.p0	androgens	None	group	insulin	None	True	effect	drug	In diabetic patients, the metabolic effects of androgens may decrease blood glucose and therefore, insulin requirements.
DDI-DrugBank.d131.s5.p7	fluoxetine	DB00472	drug	alprazolam	DB00404	True	mechanism	drug	Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.
DDI-DrugBank.d131.s8.p64	alprazolam	DB00404	drug	isoniazid	DB00951	True	int	drug	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
DDI-DrugBank.d131.s8.p65	alprazolam	DB00404	drug	macrolide antibiotics	None	True	int	group	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
DDI-DrugBank.d131.s7.p0	contraceptives	None	group	alprazolam	DB00404	True	mechanism	drug	Coadministration of oral contraceptives increased the maximum plasma concentration of alprazolam by 18%, decreased clearance by 22%, and increased half-life by 29%.
DDI-DrugBank.d132.s19.p0	NSAIDs	None	group	cyclosporine	DB00091	True	advise	drug	NSAIDs should be used with caution in patients taking cyclosporine, and renal function should be carefully monitored.
DDI-DrugBank.d133.s0.p0	BOTOX	None	brand	aminoglycosides	None	True	advise	group	Co-administration of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.
DDI-DrugBank.d137.s10.p2	tricyclic anti-depressants	None	group	bepridil hydrochloride	None	True	effect	drug	Anti-arrhythmics and tricyclic anti-depressants could exaggerate the prolongation of the QT interval observed with bepridil hydrochloride.
DDI-DrugBank.d139.s5.p3	mineral oil	None	drug_n	vitamin K	None	True	mechanism	group	Mineral Oil-Concomitant intake of mineral oil and vitamin K may reduce the absorption of vitamin K.
DDI-DrugBank.d140.s9.p5	atorvastatin	DB01076	drug	erythromycin	DB00199	True	mechanism	drug	Erythromycin: In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of atorvastatin and erythromycin, a known inhibitor of cytochrome P450 3A4.
DDI-DrugBank.d142.s0.p2	LEVSIN	None	brand	haloperidol	DB00502	True	effect	drug	Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.
DDI-DrugBank.d144.s1.p5	ketoconazole	DB01026	drug	budesonide	DB01222	True	advise	drug	If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.
DDI-DrugBank.d146.s2.p0	Colchicine	DB01394	drug	CNS depressants	None	True	effect	group	Colchicine may increase sensitivity to the CNS depressants.
DDI-DrugBank.d150.s1.p0	FLEXERIL	None	brand	alcohol	None	True	effect	drug	FLEXERIL may enhance the effects of alcohol, barbiturates, and other CNS depressants.
DDI-DrugBank.d150.s3.p0	Tricyclic antidepressants	None	group	tramadol	DB00193	True	effect	drug	Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol
DDI-DrugBank.d133.s2.p0	botulinum toxin	None	group	botulinum toxin	None	True	effect	group	Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.
DDI-DrugBank.d135.s7.p2	ketoconazole	DB01026	drug	lapatinib	DB01259	True	mechanism	drug	Ketoconazole: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.
DDI-DrugBank.d139.s3.p3	cholestyramine	DB01432	drug	vitamin K	None	True	mechanism	group	Cholestyramine-Concomitant intake of cholestyramine and vitamin K may reduce the absorption of vitamin K.
DDI-DrugBank.d142.s0.p1	LEVSIN	None	brand	amantadine	DB00915	True	effect	drug	Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.
DDI-DrugBank.d144.s1.p10	intraconazole	None	drug	budesonide	DB01222	True	advise	drug	If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.
DDI-DrugBank.d144.s1.p17	indinavir	DB00224	drug	budesonide	DB01222	True	advise	drug	If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.
DDI-DrugBank.d146.s1.p0	colchicine	DB01394	drug	alkalinizing agents	None	True	mechanism	group	The action of colchicine is potentiated by alkalinizing agents.
DDI-DrugBank.d148.s6.p1	Argatroban	DB00278	drug	thrombolytics	None	True	effect	group	Co-administration: Concomitant use of Argatroban with antiplatelet agents, thrombolytics, and other anticoagulants may increase the risk of bleeding.
DDI-DrugBank.d148.s6.p2	Argatroban	DB00278	drug	anticoagulants	None	True	effect	group	Co-administration: Concomitant use of Argatroban with antiplatelet agents, thrombolytics, and other anticoagulants may increase the risk of bleeding.
DDI-DrugBank.d153.s4.p1	Phenothiazines	None	group	epinephrine	DB00668	True	effect	drug	Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.
DDI-DrugBank.d132.s0.p4	diflunisal	DB00861	drug	warfarin	DB00682	True	effect	drug	Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.
DDI-DrugBank.d132.s16.p2	diflunisal	DB00861	drug	methotrexate	DB00563	True	advise	drug	Methotrexate: Caution should be used if diflunisal is administered concomitantly with methotrexate.
DDI-DrugBank.d138.s3.p0	Tricyclic antidepressants	None	group	clonidine	DB00575	True	effect	drug	Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.It is not known whether the concurrent use of these agents with ALPHAGAN P in humans can lead to resulting interference with the IOP lowering effect.
DDI-DrugBank.d139.s4.p3	colestipol	DB00375	drug	vitamin K	None	True	mechanism	group	Colestipol-Concomitant intake of colestipol and vitamin K may reduce the absorption of vitamin K.
DDI-DrugBank.d139.s8.p2	Vitamin K	None	group	warfarin	DB00682	True	effect	drug	Warfarin-Vitamin K can antagonize the effect of warfarin
DDI-DrugBank.d14.s0.p0	nitroglycerin	DB00727	drug	vasodilators	None	True	effect	group	The vasodilating effects of nitroglycerin may be additive with those of other vasodilators.
DDI-DrugBank.d14.s2.p0	calcium channel blockers	None	group	nitrates	None	True	effect	group	Marked symptomatic orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used in combination.
DDI-DrugBank.d140.s1.p3	atorvastatin	DB01076	drug	Maalox TC	None	True	mechanism	brand	Antacid: When atorvastatin and Maalox TC suspension were coadministered, plasma concentrations of atorvastatin decreased approximately 35%.
DDI-DrugBank.d140.s10.p6	atorvastatin	DB01076	drug	ethinyl estradiol	DB00977	True	mechanism	drug	Oral Contraceptives: Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.
DDI-DrugBank.d140.s4.p5	colestipol	DB00375	drug	atorvastatin	DB01076	True	mechanism	drug	Colestipol: Plasma concentrations of atorvastatin decreased approximately 25% when colestipol and atorvastatin were coadministered.
DDI-DrugBank.d141.s4.p0	cerivastatin sodium	None	drug	cholestyramine	DB01432	True	mechanism	drug	In the first study, concomitant administration of 0.2 mg cerivastatin sodium and 12 g cholestyramine resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing cerivastatin sodium alone.
DDI-DrugBank.d0.s2.p0	naltrexone	DB00704	drug	Acamprosate	DB00659	True	mechanism	drug	Co-administration of naltrexone with Acamprosate produced a 25% increase in AUC and a 33% increase in the Cmax of acamprosate.
DDI-DrugBank.d105.s0.p11	nonsteroidal anti-inflammatory drugs	None	group	ardeparin	DB00407	True	effect	drug	Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.
DDI-DrugBank.d107.s1.p1	enalapril	DB00584	drug	diuretic	None	True	effect	drug	The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.
DDI-DrugBank.d107.s17.p2	enalapril	DB00584	drug	lithium	DB01356	True	advise	drug	It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium.
DDI-DrugBank.d110.s0.p11	norepinephrine	DB00368	drug	phenothiazines	None	True	effect	group	The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.
DDI-DrugBank.d110.s0.p4	anesthetic solutions	None	group	phenothiazines	None	True	effect	group	The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.
DDI-DrugBank.d110.s0.p6	epinephrine	DB00668	drug	monoamine oxidase inhibitors	None	True	effect	group	The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.
DDI-DrugBank.d114.s10.p19	Beta-blockers	None	group	PROLEUKIN	None	True	effect	brand	Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.
DDI-DrugBank.d100.s0.p0	cephalosporins	None	group	aminoglycoside antibiotics	None	True	effect	group	Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.
DDI-DrugBank.d103.s2.p0	sympathomimetic agents	None	group	FORADIL	None	True	effect	brand	Concomitant administration of other sympathomimetic agents may potentiate the undesirable effects of FORADIL.
DDI-DrugBank.d104.s0.p0	Fenfluramine	DB00574	drug	antihypertensive drugs	None	True	effect	group	Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, methyldopa, reserpine.
DDI-DrugBank.d104.s1.p0	CNS depressant drugs	None	group	fenfluramine	DB00574	True	advise	drug	Other CNS depressant drugs should be used with caution in patients taking fenfluramine, since the effects may be additive.
DDI-DrugBank.d107.s0.p0	diuretics	None	drug	enalapril	DB00584	True	effect	drug	Hypotension: Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril or enalaprilat.
DDI-DrugBank.d107.s3.p3	enalapril	DB00584	drug	antihypertensive agents	None	True	effect	group	Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).
DDI-DrugBank.d11.s4.p1	paroxetine	DB00715	drug	atomoxetine	DB00289	True	mechanism	drug	In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.
DDI-DrugBank.d110.s0.p7	epinephrine	DB00668	drug	tricyclic antidepressants	None	True	effect	group	The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.
DDI-DrugBank.d110.s3.p0	vasopressor drugs	None	group	ergot-type oxytocic drugs	None	True	effect	group	Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.
DDI-DrugBank.d112.s0.p0	probenecid	DB01032	drug	penciclovir	DB00299	True	mechanism	drug	Concurrent use with probenecid or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of penciclovir.
DDI-DrugBank.d103.s3.p9	FORADIL	None	brand	monoamine oxidase inhibitors	None	True	advise	group	Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.
DDI-DrugBank.d105.s0.p8	platelet aggregation inhibitors	None	group	ardeparin	DB00407	True	effect	drug	Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.
DDI-DrugBank.d106.s0.p0	nisoldipine	DB00401	drug	cimetidine 400 mg	None	True	mechanism	drug	A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.
DDI-DrugBank.d106.s9.p0	nisoldipine	DB00401	drug	quinidine	DB00908	True	mechanism	drug	The immediate release, but not the coat-core formulation of nisoldipine increased plasma quinidine concentrations by about 20%.
DDI-DrugBank.d107.s0.p1	diuretics	None	drug	enalaprilat	None	True	effect	drug	Hypotension: Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril or enalaprilat.
DDI-DrugBank.d107.s12.p1	Enalapril	DB00584	drug	thiazide-type diuretics	None	True	effect	group	Agents Increasing Serum Potassium: Enalapril and enalapril IV attenuate potassium loss caused by thiazide-type diuretics.
DDI-DrugBank.d107.s3.p2	enalapril	DB00584	drug	diuretics	None	True	effect	group	Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).
DDI-DrugBank.d107.s8.p0	NSAIDs	None	group	ACE inhibitors	None	True	effect	group	However, reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors.
DDI-DrugBank.d108.s1.p0	MAO inhibitor	None	group	disulfiram	DB00822	True	effect	drug	In a single study, rats given high intraperitoneal doses of an MAO inhibitor plus disulfiram experienced severe toxicity, including convulsions and death.
DDI-DrugBank.d11.s3.p0	STRATTERA	None	brand	paroxetine	DB00715	True	advise	drug	Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, fluoxetine, and quinidine.
DDI-DrugBank.d103.s4.p17	xanthine derivatives	None	group	beta2-agonists	None	True	effect	group	Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.
DDI-DrugBank.d105.s0.p13	NSAIDs	None	group	ardeparin	DB00407	True	effect	drug	Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.
DDI-DrugBank.d105.s0.p14	aspirin	None	brand	ardeparin	DB00407	True	effect	drug	Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.
DDI-DrugBank.d107.s3.p4	enalapril	DB00584	drug	diuretics	None	True	effect	group	Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).
DDI-DrugBank.d108.s2.p0	Isocarboxazid	DB01247	drug	psychotropic agents	None	True	advise	group	Concomitant use of Isocarboxazid and other psychotropic agents is generally not recommended because of possible potentiating effects.
DDI-DrugBank.d11.s3.p2	STRATTERA	None	brand	quinidine	DB00908	True	advise	drug	Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, fluoxetine, and quinidine.
DDI-DrugBank.d113.s0.p0	Warfarin	DB00682	drug	Meclofenamate sodium	None	True	effect	drug	Warfarin: Meclofenamate sodium enhances the effect of warfarin.
DDI-DrugBank.d113.s2.p2	aspirin	None	brand	meclofenamate sodium	None	True	mechanism	drug	Aspirin: Concurrent administration of aspirin may lower meclofenamate sodium plasma levels, possibly by competing for protein-binding sites.
DDI-DrugBank.d114.s2.p10	indomethacin	DB00328	drug	PROLEUKIN	None	True	effect	brand	Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.
DDI-DrugBank.d114.s2.p19	methotrexate	DB00563	drug	PROLEUKIN	None	True	effect	brand	Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.
DDI-DrugBank.d0.s6.p0	Acamprosate	DB00659	drug	antidepressants	None	True	effect	group	Patients taking Acamprosate concomitantly with antidepressants more commonly reported both weight gain and weight loss, compared with patients taking either medication alone.
DDI-DrugBank.d10.s2.p0	Betaseron	None	brand	antipyrine	DB01435	True	mechanism	drug	Betaseron administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of antipyrine elimination.14 The effect of alternate-day administration of 0.25 mg of Betaseron on drug metabolism in MS patients is unknown.
DDI-DrugBank.d106.s6.p0	Propranolol	DB00571	drug	nisoldipine	DB00401	True	effect	drug	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.
DDI-DrugBank.d106.s7.p0	SULAR	None	brand	atenolol	DB00335	True	effect	drug	The blood pressure effect of SULAR tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.
DDI-DrugBank.d114.s5.p1	PROLEUKIN	None	brand	dacarbazine	DB00851	True	effect	drug	Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.
DDI-DrugBank.d114.s8.p0	PROLEUKIN	None	brand	interferon-alfa	None	True	effect	drug	Myocardial injury, including myocardial infarction, myocarditis, ventricular hypokinesia, and severe rhabdomyolysis appear to be increased in patients receiving PROLEUKIN and interferon-alfa concurrently.
DDI-DrugBank.d12.s9.p0	lovastatin	DB00227	drug	fibrates	None	True	advise	group	Therefore, the combined use of lovastatin with fibrates should generally be avoided.
DDI-DrugBank.d122.s3.p0	Chloramphenicol	DB00446	drug	beta-lactam antibiotics	None	True	effect	group	Chloramphenicol has been shown to be antagonistic to beta-lactam antibiotics, including ceftazidime, based on in vitro studies and time kill curves with enteric gram-negative bacilli.
DDI-DrugBank.d123.s0.p1	quinolones	None	group	caffeine	DB00201	True	mechanism	drug	Some quinolones, including ciprofloxacin, have also been shown to interfere with the metabolism of caffeine.
DDI-DrugBank.d123.s15.p3	Probenecid	DB01032	drug	ciprofloxacin	DB00537	True	mechanism	drug	Probenecid: Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.
DDI-DrugBank.d154.s1.p0	fenoprofen	DB00573	drug	aspirin	None	True	mechanism	brand	Although the mechanism of interaction between fenoprofen and aspirin is not totally known, enzyme induction and displacement of fenoprofen from plasma albumin binding sites are possibilities.
DDI-DrugBank.d157.s1.p0	Femara	None	brand	tamoxifen	DB00675	True	mechanism	drug	(See CLINICAL PHARMACOLOGY) Coadministration of Femara and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels by 38% on average.
DDI-DrugBank.d158.s0.p2	sodium acid phosphate	None	drug	amphetamine	DB00182	True	mechanism	drug	Urinary acidifying agents These agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.
DDI-DrugBank.d158.s17.p2	amphetamines	None	group	methenamine	None	True	mechanism	drug	Methenamine therapy Urinary excretion of amphetamines is increased, and efficacy is reduced by acidifying agents used in methenamine therapy.
DDI-DrugBank.d158.s3.p7	Amphetamines	None	group	tricyclic antidepressants	None	True	effect	drug	Antidepressants, tricyclic Amphetamines may enhance the activity of tricyclic antidepressants or sympathomimetic agents;
DDI-DrugBank.d158.s4.p2	d-amphetamine	None	drug	tricyclics	None	True	mechanism	group	d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;
DDI-DrugBank.d162.s10.p1	Diuretic agents	None	group	lithium	DB01356	True	effect	drug	Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.
DDI-DrugBank.d162.s11.p0	lithium	DB01356	drug	Hydrochlorothiazide	DB00999	True	advise	drug	Refer to the package insert for lithium preparations before use of such preparations with Hydrochlorothiazide.
DDI-DrugBank.d162.s4.p9	hydrochlorothiazide	DB00999	drug	anionic exchange resins	None	True	mechanism	group	Cholestyramine and colestipol resins: Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins.
DDI-DrugBank.d165.s15.p0	Itraconazole	DB01167	drug	cyclosporine	DB00091	True	mechanism	drug	Coadministration of Itraconazole and cyclosporine, tacrolimus or digoxin has led to increased plasma concentrations of the latter three drugs.
DDI-DrugBank.d165.s15.p1	Itraconazole	DB01167	drug	tacrolimus	DB00864	True	mechanism	drug	Coadministration of Itraconazole and cyclosporine, tacrolimus or digoxin has led to increased plasma concentrations of the latter three drugs.
DDI-DrugBank.d114.s2.p5	aminoglycosides	None	group	PROLEUKIN	None	True	effect	brand	Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.
DDI-DrugBank.d114.s9.p0	interferon-alfa	None	drug	PROLEUKIN	None	True	effect	brand	Exacerbation or the initial presentation of a number of autoimmune and inflammatory disorders has been observed following concurrent use of interferon-alfa and PROLEUKIN, including crescentic IgA glomerulonephritis, oculo-bulbar myasthenia gravis, inflammatory arthritis, thyroiditis, bullous pemphigoid, and Stevens-Johnson syndrome.
DDI-DrugBank.d12.s3.p1	Atromid-S	None	brand	tolbutamide	DB01124	True	mechanism	drug	Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites.
DDI-DrugBank.d122.s0.p0	cephalosporins	None	group	aminoglycoside antibiotics	None	True	effect	group	Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent diuretics such as furosemide.
DDI-DrugBank.d123.s0.p2	ciprofloxacin	DB00537	drug	caffeine	DB00201	True	mechanism	drug	Some quinolones, including ciprofloxacin, have also been shown to interfere with the metabolism of caffeine.
DDI-DrugBank.d123.s8.p15	ciprofloxacin	DB00537	drug	calcium	DB01373	True	mechanism	drug	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
DDI-DrugBank.d124.s26.p15	calcium channel blockers	None	group	saquinavir	DB01232	True	mechanism	drug	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DDI-DrugBank.d13.s0.p65	Flupenthixol	None	drug	Tricyclic antidepressants	None	True	effect	group	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants
DDI-DrugBank.d153.s4.p2	butyrophenones	None	group	epinephrine	DB00668	True	effect	drug	Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.
DDI-DrugBank.d158.s12.p3	Chlorpromazine	DB00477	drug	amphetamines	None	True	effect	group	Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines and can be used to treat amphetamine poisoning.
DDI-DrugBank.d162.s12.p4	non-steroidal anti-inflammatory agent	None	group	loop diuretics	None	True	effect	group	Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.
DDI-DrugBank.d162.s5.p4	colestipol	DB00375	drug	hydrochlorothiazide	DB00999	True	mechanism	drug	Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.
DDI-DrugBank.d163.s0.p4	Accutane	None	brand	vitamin A	DB00162	True	effect	group	Vitamin A: Because of the relationship of Accutane to vitamin A, patients should be advised against taking vitamin supplements containing vitamin A to avoid additive toxic effects
DDI-DrugBank.d163.s2.p4	Accutane	None	brand	tetracyclines	None	True	advise	group	Tetracyclines: Concomitant treatment with Accutane and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines
DDI-DrugBank.d165.s17.p1	HMG-CoA reductase inhibitors	None	group	cyclosporine	DB00091	True	effect	drug	Rhabdomyolysis has been observed in patients receiving HMG-CoA reductase inhibitors administered alone (at recommended dosages) or concomitantly with immunosuppressive drugs including cyclosporine.
DDI-DrugBank.d165.s25.p2	Itraconazole	DB01167	drug	isoniazid	DB00951	True	advise	drug	Itraconazole plasma concentrations should be monitored when Itraconazole and isoniazid are coadministered.
DDI-DrugBank.d165.s9.p0	itraconazole	DB01167	drug	cisapride	DB00604	True	mechanism	drug	In vitro data suggest that itraconazole also markedly inhibits the biotransformation system mainly responsible for the metabolism of cisapride;
DDI-DrugBank.d166.s2.p0	ethionamide	DB00609	drug	cycloserine	DB00260	True	effect	drug	In particular, convulsions have been reported when ethionamide is administered with cycloserine and special care should be taken when the treatment regimen includes both of these drugs.
DDI-DrugBank.d17.s25.p2	steroidal anti-inflammatory agent	None	group	thiazide diuretics	None	True	effect	group	(In some patients, the steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics.
DDI-DrugBank.d170.s3.p3	erythromycin	DB00199	drug	fentanyl	DB00813	True	mechanism	drug	The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.
DDI-DrugBank.d170.s5.p13	DURAGESIC	None	brand	central nervous system depressants	None	True	effect	group	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
DDI-DrugBank.d170.s5.p18	DURAGESIC	None	brand	benzodiazepines	None	True	effect	group	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
DDI-DrugBank.d170.s5.p21	DURAGESIC	None	brand	skeletal muscle relaxants	None	True	effect	group	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
DDI-DrugBank.d170.s5.p22	DURAGESIC	None	brand	alcohol	None	True	effect	drug	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
DDI-DrugBank.d123.s16.p7	ciprofloxacin	DB00537	drug	theophylline	DB00277	True	mechanism	drug	Theophylline: As with some other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.
DDI-DrugBank.d123.s8.p6	quinolone	None	group	calcium	DB01373	True	mechanism	drug	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
DDI-DrugBank.d124.s26.p107	cyclosporine	DB00091	drug	saquinavir	DB01232	True	mechanism	drug	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DDI-DrugBank.d124.s26.p114	ergot derivatives	None	group	saquinavir	DB01232	True	mechanism	drug	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DDI-DrugBank.d124.s26.p99	tacrolimus	DB00864	drug	saquinavir	DB01232	True	mechanism	drug	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DDI-DrugBank.d124.s30.p8	dexamethasone	DB01234	drug	saquinavir	DB01232	True	mechanism	drug	Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.
DDI-DrugBank.d131.s0.p3	benzodiazepines	None	group	antihistaminics	None	True	effect	group	The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.
DDI-DrugBank.d132.s0.p5	diflunisal	DB00861	drug	acenocoumarol	DB01418	True	effect	drug	Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.
DDI-DrugBank.d132.s0.p6	diflunisal	DB00861	drug	phenprocoumon	DB00946	True	effect	drug	Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.
DDI-DrugBank.d132.s1.p0	diflunisal	DB00861	drug	coumarins	None	True	mechanism	group	This may occur because diflunisal competitively displaces coumarins from protein binding sites.
DDI-DrugBank.d135.s8.p2	carbamazepine	DB00564	drug	lapatinib	DB01259	True	mechanism	drug	Carbamazepine: In healthy subjects receiving the CYP3A4 inducer, carbamazepine, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to lapatinib was decreased approximately 72%.
DDI-DrugBank.d138.s0.p1	ALPHAGAN P	None	brand	alcohol	None	True	advise	drug	Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.
DDI-DrugBank.d138.s0.p5	ALPHAGAN P	None	brand	anesthetics	None	True	advise	group	Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.
DDI-DrugBank.d140.s10.p5	atorvastatin	DB01076	drug	norethindrone	DB00717	True	mechanism	drug	Oral Contraceptives: Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.
DDI-DrugBank.d140.s5.p0	atorvastatin	DB01076	drug	colestipol	DB00375	True	effect	drug	However, LDL-C reduction was greater when atorvastatin and colestipol were coadministered than when either drug was given alone.
DDI-DrugBank.d142.s0.p5	LEVSIN	None	brand	tricyclic antidepressants	None	True	effect	group	Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.
DDI-DrugBank.d142.s0.p0	LEVSIN	None	brand	antimuscarinics	None	True	effect	group	Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.
DDI-DrugBank.d143.s10.p0	amiodarone	DB01118	drug	indinavir	DB00224	True	mechanism	drug	A case report of one patient taking amiodarone 200 mg and indinavir 800 mg three times a day resulted in increases in amiodarone concentrations from 0.9 mg/L to 1.3 mg/L.
DDI-DrugBank.d145.s0.p0	anticonvulsant agents	None	group	cisplatin	DB00515	True	mechanism	drug	Plasma levels of anticonvulsant agents may become subtherapeutic during cisplatin therapy.
DDI-DrugBank.d146.s3.p0	sympathomimetic agents	None	group	colchicine	DB01394	True	effect	drug	Response to sympathomimetic agents may be enhanced by colchicine.
DDI-DrugBank.d154.s2.p14	Nalfon	None	brand	salicylates	None	True	advise	group	Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.
DDI-DrugBank.d158.s0.p1	ammonium chloride	None	drug	amphetamine	DB00182	True	mechanism	drug	Urinary acidifying agents These agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.
DDI-DrugBank.d158.s18.p2	Amphetamines	None	group	norepinephrine	DB00368	True	effect	drug	Norepinephrine: Amphetamines enhance the adrenergic effect of norepinephrine.
DDI-DrugBank.d158.s19.p2	Amphetamines	None	group	phenobarbital	DB01174	True	mechanism	drug	Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;
DDI-DrugBank.d162.s5.p2	cholestyramine	DB01432	drug	hydrochlorothiazide	DB00999	True	mechanism	drug	Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.
DDI-DrugBank.d165.s16.p4	tacrolimus	DB00864	drug	Itraconazole	DB01167	True	advise	drug	Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.
DDI-DrugBank.d166.s1.p0	Trecator	None	brand	antituberculous drugs	None	True	effect	group	Trecator may potentiate the adverse effects of other antituberculous drugs administered concomitantly.
DDI-DrugBank.d170.s5.p15	DURAGESIC	None	brand	sedatives	None	True	effect	group	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
DDI-DrugBank.d170.s5.p16	DURAGESIC	None	brand	hypnotics	None	True	effect	group	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
DDI-DrugBank.d170.s5.p20	DURAGESIC	None	brand	phenothiazines	None	True	effect	group	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
DDI-DrugBank.d170.s5.p25	fentanyl	DB00813	drug	sedatives	None	True	effect	group	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
DDI-DrugBank.d172.s6.p1	celecoxib	DB00482	drug	lithium	DB01356	True	int	drug	Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.
DDI-DrugBank.d172.s7.p1	nonsteroidal anti-inflammatory drugs	None	group	furosemide	DB00695	True	int	drug	Experience with nonsteroidal anti-inflammatory drugs (NSAIDs) suggests the potential for interactions with furosemide and ACE inhibitors.
DDI-DrugBank.d172.s9.p2	NSAIDs	None	group	Angiotensin Converting Enzyme (ACE) inhibitors	None	True	effect	group	ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors.
DDI-DrugBank.d177.s3.p0	vitamin K antagonists	None	group	nilutamide	DB00665	True	advise	drug	For example, when vitamin K antagonists are administered concomitantly with nilutamide, prothrombin time should be carefully monitored and if necessary, the dosage of vitamin K antagonists should be reduced.
DDI-DrugBank.d178.s0.p7	sulfonylureas	None	group	beta adrenergic blocking agents	None	True	effect	group	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
DDI-DrugBank.d179.s1.p0	Sulfapyridine	DB00891	drug	Acetaminophen	DB00316	True	int	drug	Sulfapyridine may interact with any of the following: - Acetaminophen (e.g., Tylenol) (with long-term, high-dose use) or
DDI-DrugBank.d18.s1.p1	Lorazepam	DB00186	drug	ethyl alcohol	None	True	effect	drug	Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
DDI-DrugBank.d181.s0.p1	Oxytocin	DB00107	drug	dinoprost	None	True	effect	drug	Oxytocin or other oxytocics (concurrent use with dinoprost may result in uterine hypertonus, possibly causing uterine rupture or cervical laceration, especially in the absence of adequate cervical dilatation;
DDI-DrugBank.d186.s3.p4	antipsychotic agents	None	group	alcohol	None	True	effect	drug	As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.
DDI-DrugBank.d19.s1.p0	DISULFIRAM	DB00822	drug	PHENYTOIN	DB00252	True	advise	drug	DISULFIRAM SHOULD BE USED WITH CAUTION IN THOSE PATIENTS REVEIVING PHENYTOIN AND ITS CONGENERS.
DDI-DrugBank.d191.s1.p7	Edetate calcium disodium	None	drug	zinc insulin	None	True	mechanism	drug	Steroids enhance the renal toxicity of edetate calcium disodium in animals. 7 Edetate calcium disodium interferes with the action of zinc insulin preparations by chelating the zinc. 7
DDI-DrugBank.d194.s0.p0	ETOPOPHOS	None	brand	levamisole hydrochloride	None	True	advise	drug	Caution should be exercised when administering ETOPOPHOS with drugs that are known to inhibit phosphatase activities (e.g., levamisole hydrochloride).
DDI-DrugBank.d196.s0.p0	PEGASYS	None	brand	theophylline	DB00277	True	mechanism	drug	Treatment with PEGASYS once weekly for 4 weeks in healthy subjects was associated with an inhibition of P450 1A2 and a 25% increase in theophylline AUC.
DDI-DrugBank.d198.s27.p0	nifedipine	DB01115	drug	Vardenafil	DB00862	True	effect	drug	In these patients whose hypertension was controlled with nifedipine, Vardenafil 20 mg produced mean additional supine systolic/diastolic blood pressure reductions of 6/5 mm Hg compared to placebo.
DDI-DrugBank.d198.s30.p0	Vardenafil	DB00862	drug	terazosin	DB01162	True	effect	drug	With simultaneous dosing of Vardenafil 20 mg and terazosin 10 mg, 2 of 9 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.
DDI-DrugBank.d198.s32.p2	Vardenafil	DB00862	drug	tamsulosin	DB00706	True	effect	drug	In a similar study with tamsulosin in healthy volunteers, 1 of 24 subjects dosed with Vardenafil 20 mg and tamsulosin 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.
DDI-DrugBank.d207.s4.p4	itraconazole	DB01167	drug	gefitinib	DB00317	True	mechanism	drug	Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.
DDI-DrugBank.d208.s0.p2	Benzthiazide	DB00562	drug	decongestant drugs	None	True	int	group	Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.
DDI-DrugBank.d21.s1.p0	methotrexate	DB00563	drug	ELSPAR	None	True	advise	brand	These results would seem to dictate against the clinical use of methotrexate with ELSPAR, or during the period following ELSPAR therapy when plasma asparagine levels are below normal.
DDI-DrugBank.d210.s13.p4	NSAIDs	None	group	thiazides	None	True	effect	group	Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.
DDI-DrugBank.d210.s28.p2	VIOXX	None	brand	theophylline	DB00277	True	advise	drug	Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline.
DDI-DrugBank.d210.s3.p3	aspirin	None	brand	VIOXX	None	True	effect	brand	Aspirin: Concomitant administration of low-dose aspirin with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone.
DDI-DrugBank.d215.s0.p0	anileridine	DB00913	drug	opioids	None	True	advise	group	Caution should be observed when anileridine is coadministered with other opioids, sedatives, phenothiazines, or anesthetics, as these agents may increase respiratory and circulatory depression.
DDI-DrugBank.d217.s0.p0	theophylline	DB00277	drug	quinolone	None	True	mechanism	group	Elevated plasma levels of theophylline have been reported with concomitant quinolone use.
DDI-DrugBank.d219.s22.p2	warfarin	DB00682	drug	NSAIDs	None	True	effect	group	Warfarin: The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than that of users of either drug alone.
DDI-DrugBank.d219.s23.p1	warfarin	DB00682	drug	etodolac	DB00749	True	mechanism	drug	Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and Lodine  (etodolac capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free warfarin.
DDI-DrugBank.d219.s7.p1	Lodine	None	brand	cyclosporine	DB00091	True	mechanism	drug	Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.
DDI-DrugBank.d22.s1.p0	digoxin	DB00390	drug	aminosalicylic acid	DB00233	True	advise	drug	In the case that you are taking digoxin while taking aminosalicylic acid, higher doses of digoxin may be needed.
DDI-DrugBank.d220.s11.p18	phenytoin	DB00252	drug	Mefloquine	DB00358	True	effect	drug	In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.
DDI-DrugBank.d220.s9.p1	Mefloquine	DB00358	drug	beta-adrenergic blocking agents	None	True	effect	group	This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.
DDI-DrugBank.d220.s9.p5	Mefloquine	DB00358	drug	tricyclic antidepressants	None	True	effect	group	This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.
DDI-DrugBank.d222.s0.p0	atropine	DB00572	drug	pralidoxime	DB00733	True	effect	drug	When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.
DDI-DrugBank.d222.s2.p0	barbiturates	None	group	anticholinesterases	None	True	advise	group	Since barbiturates are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsions.
DDI-DrugBank.d223.s20.p0	MAO inhibitors	None	group	SINEQUAN	None	True	advise	brand	Therefore, MAO inhibitors should be discontinued at least two weeks prior to the cautious initiation of therapy with SINEQUAN.
DDI-DrugBank.d224.s1.p3	IOPIDINE	None	brand	opiates	None	True	advise	group	Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.
DDI-DrugBank.d225.s0.p1	sulfonylureas	None	group	azoles	None	True	effect	group	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
DDI-DrugBank.d225.s0.p7	sulfonylureas	None	group	monoamine oxidase inhibitors	None	True	effect	group	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
DDI-DrugBank.d226.s1.p1	Digoxin	DB00390	drug	Adenocard	None	True	effect	brand	Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard.
DDI-DrugBank.d228.s1.p0	ethanol	DB00898	drug	Antizol	None	True	mechanism	brand	Similarly, ethanol decreased the rate of elimination of Antizol (by approximately 50%) by the same mechanism.
DDI-DrugBank.d229.s3.p0	cromolyn sodium	None	drug	isoproterenol	None	True	effect	drug	The addition of 540 mg/kg/day of cromolyn sodium (approximately 340 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) to 2.7 mg/kg/day of isoproterenol (approximately 7 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) appears to have increased the incidence of both resorptions and malformations.
DDI-DrugBank.d231.s0.p0	Furosemide	DB00695	drug	aminoglycoside antibiotics	None	True	effect	group	Furosemide may increase the ototoxic potential of aminoglycoside antibiotics, especially in the presence of impaired renal function.
DDI-DrugBank.d232.s0.p2	AVONEX	None	brand	TYSABRI	None	True	mechanism	brand	After multiple dosing, interferon beta-1a (AVONEX  30 mcg IM once weekly) reduced TYSABRI  clearance by approximately 30%.
DDI-DrugBank.d236.s10.p5	furazolidone	DB00614	drug	amphetamine	DB00182	True	mechanism	group	MAO inhibitors: MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.
DDI-DrugBank.d236.s21.p3	amphetamines	None	group	acidifying agents	None	True	mechanism	group	Methenamine therapy: Urinary excretion of amphetamines is increased, and efficacy is reduced, by acidifying agents used in methenamine therapy.
DDI-DrugBank.d236.s5.p2	thiazides	None	group	amphetamine	DB00182	True	mechanism	drug	Urinary alkalinizing agents (acetazolamide, some thiazides) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion.
DDI-DrugBank.d236.s8.p0	d-amphetamine	None	drug	desipramine	DB01151	True	mechanism	drug	d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;
DDI-DrugBank.d236.s8.p1	d-amphetamine	None	drug	protriptyline	DB00344	True	mechanism	drug	d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;
DDI-DrugBank.d237.s12.p7	ritonavir	DB00503	drug	cisapride	DB00604	True	mechanism	drug	Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
DDI-DrugBank.d237.s2.p12	troleandomycin	DB01361	drug	cisapride	DB00604	True	mechanism	drug	Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
DDI-DrugBank.d237.s7.p10	itraconazole	DB01167	drug	cisapride	DB00604	True	mechanism	drug	Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
DDI-DrugBank.d237.s8.p0	ketoconazole	DB01026	drug	cisapride	DB00604	True	mechanism	drug	Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.
DDI-DrugBank.d238.s4.p1	tricyclic antidepressants	None	group	clonidine	DB00575	True	effect	drug	Several tricyclic antidepressants have been reported to block the pharmacologic effects of guanethidine, clonidine, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.
DDI-DrugBank.d238.s6.p19	barbiturates	None	group	CMI	None	True	mechanism	drug	plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.
DDI-DrugBank.d238.s6.p2	tricyclic antidepressants	None	group	fluoxetine	DB00472	True	mechanism	drug	plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.
DDI-DrugBank.d246.s5.p0	STADOL NS	None	brand	sumatriptan	DB00669	True	mechanism	drug	When the STADOL NS was administered 30 minutes after the sumatriptan nasal spray, the AUC of butorphanol increased 11% and Cmax decreased 18%.
DDI-DrugBank.d247.s2.p0	Epinephrine	DB00668	drug	sympathomimetic drugs	None	True	advise	group	Epinephrine should not be administered concomitantly with other sympathomimetic drugs (such as isoproterenol) because of possible additive effects and increased toxicity.
DDI-DrugBank.d170.s5.p27	fentanyl	DB00813	drug	tranquilizers	None	True	effect	group	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
DDI-DrugBank.d170.s5.p30	fentanyl	DB00813	drug	phenothiazines	None	True	effect	group	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
DDI-DrugBank.d171.s0.p6	Tagamet	None	brand	tricyclic antidepressants	None	True	mechanism	group	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
DDI-DrugBank.d171.s0.p7	Tagamet	None	brand	lidocaine	DB00281	True	mechanism	drug	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
DDI-DrugBank.d172.s7.p4	NSAIDs	None	group	ACE inhibitors	None	True	int	group	Experience with nonsteroidal anti-inflammatory drugs (NSAIDs) suggests the potential for interactions with furosemide and ACE inhibitors.
DDI-DrugBank.d175.s6.p1	nitroglycerin	DB00727	drug	captopril	DB01197	True	advise	drug	therefore, nitroglycerin or other nitrates (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting captopril.
DDI-DrugBank.d178.s0.p5	sulfonylureas	None	group	coumarins	None	True	effect	group	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
DDI-DrugBank.d18.s0.p2	benzodiazepines	None	group	alcohol	None	True	effect	drug	Tablets: The benzodiazepines, including lorazepam, produce CNS-depressant effects when administered with such medications as barbiturates or alcohol.
DDI-DrugBank.d18.s0.p3	lorazepam	DB00186	drug	barbiturates	None	True	effect	group	Tablets: The benzodiazepines, including lorazepam, produce CNS-depressant effects when administered with such medications as barbiturates or alcohol.
DDI-DrugBank.d18.s1.p4	Lorazepam	DB00186	drug	MAO inhibitors	None	True	effect	group	Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
DDI-DrugBank.d180.s0.p0	Digitalis	None	group	Bretylium Tosylate	None	True	effect	drug	Digitalis toxicity may be aggravated by the initial release of norepinephrine caused by Bretylium Tosylate Injection.
DDI-DrugBank.d183.s2.p2	nitric oxide donor compounds	None	group	INOmax	None	True	effect	brand	Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.
DDI-DrugBank.d186.s3.p1	antipsychotic agents	None	group	CNS depressants	None	True	effect	group	As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.
DDI-DrugBank.d186.s4.p0	haloperidol	DB00502	drug	rifampin	None	True	mechanism	drug	In a study of 12 schizophrenic patients coadministered oral haloperidol and rifampin, plasma haloperidol levels were decreased by a mean of 70% and mean scores on the Brief Psychiatric Rating Scale were increased from baseline.
DDI-DrugBank.d197.s4.p6	PRECEDEX	None	brand	sedative	None	True	advise	group	However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, hypnotic or opioid may be required.
DDI-DrugBank.d197.s4.p7	PRECEDEX	None	brand	hypnotic	None	True	advise	group	However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, hypnotic or opioid may be required.
DDI-DrugBank.d197.s4.p8	PRECEDEX	None	brand	opioid	None	True	advise	group	However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, hypnotic or opioid may be required.
DDI-DrugBank.d198.s14.p0	Ritonavir	DB00503	drug	vardenafil	DB00862	True	mechanism	drug	Ritonavir significantly prolonged the half-life of vardenafil to 26 hours.
DDI-DrugBank.d198.s24.p2	Vardenafil	DB00862	drug	nitrates	None	True	advise	group	Potentiation of the hypotensive effects of nitrates for patients with ischemic heart disease has not been evaluated, and concomitant use of Vardenafil and nitrates is contraindicated.
DDI-DrugBank.d198.s7.p0	Ketoconazole	DB01026	drug	vardenafil	DB00862	True	mechanism	drug	Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.
DDI-DrugBank.d20.s7.p1	INSPRA	None	brand	enalapril	DB00584	True	effect	drug	In a study in diabetics with microalbuminuria INSPRA 200 mg combined with the ACE inhibitor enalapril 10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on enalapril alone to 38%.
DDI-DrugBank.d200.s0.p0	probenecid	DB01032	drug	acyclovir	None	True	mechanism	drug	Co-administration of probenecid with acyclovir has been shown to increase the mean half-life and the area under the concentration-time curve.
DDI-DrugBank.d202.s16.p5	tricyclic antidepressants	None	group	flecainide	DB01195	True	advise	drug	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.
DDI-DrugBank.d202.s4.p0	tricyclic antidepressants	None	group	cimetidine	DB00501	True	effect	drug	The therapeutic efficacy of tricyclic antidepressants may be compromised in these patients when cimetidine is discontinued.
DDI-DrugBank.d202.s6.p1	antidepressants	None	group	fluoxetine hydrochloride	None	True	mechanism	drug	There have been greater than 2-fold increases in previously stable plasma levels of other antidepressants, including nortriptyline, when fluoxetine hydrochloride has been administered in combination with these agents.
DDI-DrugBank.d202.s9.p0	nortriptyline hydrochloride	None	drug	anticholinergic drugs	None	True	advise	group	Close supervision and careful adjustment of the dosage are required when nortriptyline hydrochloride is used with other anticholinergic drugs or sympathomimetic drugs.
DDI-DrugBank.d207.s7.p4	ranitidine	DB00863	drug	IRESSA	None	True	mechanism	brand	Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as ranitidine or cimetidine) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.
DDI-DrugBank.d142.s1.p0	Antacids	None	group	LEVSIN	None	True	mechanism	brand	Antacids may interfere with the absorption of LEVSIN.
DDI-DrugBank.d144.s0.p0	ketoconazole	DB01026	drug	budesonide	DB01222	True	mechanism	drug	Concomitant oral administration of ketoconazole (a known inhibitor of CYP3A4 activity in the liver and in the intestinal mucosa) caused an eight-fold increase of the systemic exposure to oral budesonide.
DDI-DrugBank.d148.s4.p0	Argatroban	DB00278	drug	warfarin	DB00682	True	effect	drug	However, the concomitant use of Argatroban and warfarin (5-7.5 mg initial oral dose followed by 2.5-6 mg/day orally for 6-10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR).
DDI-DrugBank.d149.s0.p1	HUMORSOL	None	brand	anticholinesterase agents	None	True	int	group	Possible drug interactions of HUMORSOL with succinylcholine or with other anticholinesterase agents.
DDI-DrugBank.d150.s2.p0	Tricyclic antidepressants	None	group	guanethidine	DB01170	True	effect	drug	Tricyclic antidepressants may block the antihypertensive action of guanethidine and similarly acting compounds.
DDI-DrugBank.d151.s0.p2	Folic acid	DB00158	drug	primidone	DB00794	True	effect	drug	Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.
DDI-DrugBank.d153.s0.p7	norepinephrine	DB00368	drug	monoamine oxidase inhibitors	None	True	effect	group	The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.
DDI-DrugBank.d158.s10.p2	Amphetamines	None	group	antihistamines	None	True	effect	group	Antihistamines: Amphetamines may counteract the sedative effect of antihistamines.
DDI-DrugBank.d158.s11.p2	Amphetamines	None	group	antihypertensives	None	True	effect	drug	Antihypertensives: Amphetamines may antagonize the hypotensive effects of antihypertensives.
DDI-DrugBank.d158.s13.p2	Amphetamines	None	group	ethosuximide	DB00593	True	mechanism	drug	Ethosuximide: Amphetamines may delay intestinal absorption of ethosuximide.
DDI-DrugBank.d158.s14.p2	Haloperidol	DB00502	drug	amphetamines	None	True	effect	group	Haloperidol: Haloperidol blocks dopamine receptors, thus inhibiting the central stimulant effects of amphetamines.
DDI-DrugBank.d16.s2.p0	hydroxyurea	DB01005	drug	uricosuric medication	None	True	effect	group	Since hydroxyurea may raise the serum uric acid level, dosage adjustment of uricosuric medication may be necessary
DDI-DrugBank.d162.s12.p6	non-steroidal anti-inflammatory agent	None	group	thiazide diuretics	None	True	effect	group	Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.
DDI-DrugBank.d162.s9.p0	Lithium	DB01356	drug	diuretics	None	True	advise	group	Lithium: generally should not be given with diuretics.
DDI-DrugBank.d163.s2.p9	Accutane	None	brand	tetracyclines	None	True	effect	group	Tetracyclines: Concomitant treatment with Accutane and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines
DDI-DrugBank.d165.s11.p0	Itraconazole	DB01167	drug	midazolam	DB00683	True	mechanism	drug	Coadministration of Itraconazole with oral midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.
DDI-DrugBank.d165.s18.p0	Itraconazole	DB01167	drug	phenytoin	DB00252	True	mechanism	drug	When Itraconazole was coadministered with phenytoin, rifampin, or H2antagonists, reduced plasma concentrations of itraconazole were reported.
DDI-DrugBank.d165.s20.p0	Itraconazole	DB01167	drug	phenytoin	DB00252	True	mechanism	drug	Although no studies have been conducted, concomitant administration of Itraconazole and phenytoin may alter the metabolism of phenytoin;
DDI-DrugBank.d165.s22.p0	Itraconazole	DB01167	drug	coumarin	None	True	effect	group	It has been reported that Itraconazole enhances the anticoagulant effect of coumarin-like drugs.
DDI-DrugBank.d165.s23.p0	Itraconazole	DB01167	drug	coumarin	None	True	advise	group	Therefore, prothrombin time should be carefully monitored in patients receiving Itraconazole and coumarin-like drugs simultaneously.
DDI-DrugBank.d17.s25.p1	steroidal anti-inflammatory agent	None	group	potassium sparing diuretics	None	True	effect	group	(In some patients, the steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics.
DDI-DrugBank.d17.s26.p0	hydroflumethiazide	DB00774	drug	nonsteroidal anti-inflammatory agents	None	True	advise	group	Therefore, when hydroflumethiazide and nonsteroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.)
DDI-DrugBank.d17.s31.p0	Thiazide drugs	None	group	tubocurarine	DB01199	True	effect	drug	(Thiazide drugs may increase the responsiveness to tubocurarine.)
DDI-DrugBank.d170.s2.p0	fentanyl	DB00813	drug	ritonavir	DB00503	True	mechanism	drug	The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.
DDI-DrugBank.d170.s2.p3	fentanyl	DB00813	drug	troleandomycin	DB01361	True	mechanism	drug	The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.
DDI-DrugBank.d172.s11.p3	NSAIDs	None	group	furosemide	DB00695	True	effect	drug	Furosemide: Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.
DDI-DrugBank.d172.s11.p4	NSAIDs	None	group	thiazides	None	True	effect	group	Furosemide: Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.
DDI-DrugBank.d172.s17.p0	celecoxib	DB00482	drug	fluconazole	DB00196	True	mechanism	drug	This increase is due to the inhibition of celecoxib metabolism via P450 2C9 by fluconazole (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism).
DDI-DrugBank.d172.s18.p0	CELEBREX	None	brand	fluconazole	DB00196	True	advise	drug	CELEBREX should be introduced at the lowest recommended dose in patients receiving fluconazole.
DDI-DrugBank.d174.s1.p2	warfarin	DB00682	drug	NSAIDs	None	True	int	group	Caution should be exercised when administering nabumetone with warfarin since interactions have been seen with other NSAIDs.
DDI-DrugBank.d175.s6.p2	nitrates	None	group	captopril	DB01197	True	advise	drug	therefore, nitroglycerin or other nitrates (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting captopril.
DDI-DrugBank.d176.s0.p2	diuretics	None	group	fosinopril sodium	None	True	effect	drug	Diuretics: Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium.
DDI-DrugBank.d176.s9.p30	simethicone	None	drug	fosinopril	DB00492	True	mechanism	drug	Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.
DDI-DrugBank.d178.s0.p3	sulfonylureas	None	group	chloramphenicol	DB00446	True	effect	drug	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
DDI-DrugBank.d178.s0.p6	sulfonylureas	None	group	monoamine oxidase inhibitors	None	True	effect	group	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
DDI-DrugBank.d178.s7.p0	glyburide	DB01016	drug	ciprofloxacin	DB00537	True	int	drug	A possible interaction between glyburide and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.
DDI-DrugBank.d179.s1.p1	Sulfapyridine	DB00891	drug	Tylenol	None	True	int	brand	Sulfapyridine may interact with any of the following: - Acetaminophen (e.g., Tylenol) (with long-term, high-dose use) or
DDI-DrugBank.d179.s37.p3	antidiabetics	None	group	sulfapyridine	DB00891	True	effect	drug	Antidiabetics, oral (diabetes medicine you take by mouth) use of oral Antidiabetics with sulfapyridine may increase The chance of side effects affecting The blood and/or The side effects or oral Antidiabetics
DDI-DrugBank.d179.s38.p7	methotrexate	DB00563	drug	sulfapyridine	DB00891	True	effect	drug	Methotrexate (e.g., Mexate) use of Methotrexate with sulfapyridine may increase The chance of side effects affecting The liver and/or The side effects of Methotrexate
DDI-DrugBank.d18.s1.p3	Lorazepam	DB00186	drug	barbiturates	None	True	effect	group	Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
DDI-DrugBank.d249.s0.p4	diclofenac	DB00586	drug	aspirin	None	True	advise	brand	Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.
DDI-DrugBank.d249.s11.p1	insulin	None	drug	diclofenac	DB00586	True	effect	drug	There are rare reports, however, from marketing experiences, of changes in effects of insulin or oral hypoglycemic agents in the presence of diclofenac that necessitated changes in the doses of such agents.
DDI-DrugBank.d249.s4.p1	diclofenac	DB00586	drug	methotrexate	DB00563	True	mechanism	drug	Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.
DDI-DrugBank.d249.s8.p3	Diclofenac	DB00586	drug	lithium	DB01356	True	mechanism	drug	Lithium: Diclofenac decreases lithium renal clearance and increases lithium plasma levels.
DDI-DrugBank.d250.s2.p5	Curariform muscle relaxants	None	brand	Coly-Mycin M	None	True	effect	brand	Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.
DDI-DrugBank.d253.s1.p0	Beta-adrenergic blocking agents	None	group	arbutamine	DB01102	True	advise	drug	Beta-adrenergic blocking agents should be withdrawn at least 48 hours before conducting an arbutamine-mediated stress test.
DDI-DrugBank.d256.s0.p0	Clindamycin	DB01190	drug	neuromuscular blocking agents	None	True	effect	group	Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents.
DDI-DrugBank.d256.s2.p0	clindamycin	DB01190	drug	erythromycin	DB00199	True	effect	drug	Antagonism has been demonstrated between clindamycin and erythromycin in vitro.
DDI-DrugBank.d257.s0.p10	Levo-Dromoran	None	brand	skeletal muscle relaxants	None	True	effect	group	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
DDI-DrugBank.d257.s0.p6	Levo-Dromoran	None	brand	barbiturates	None	True	effect	group	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
DDI-DrugBank.d257.s0.p8	Levo-Dromoran	None	brand	phenothiazines	None	True	effect	group	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
DDI-DrugBank.d257.s3.p2	Levo-Dromoran	None	brand	MAO inhibitors	None	True	advise	group	Although no interaction between MAO inhibitors and Levo-Dromoran has been observed, it is not recommended for use with MAO inhibitors.
DDI-DrugBank.d26.s0.p14	anesthetics	None	group	DILAUDID	None	True	effect	brand	Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.
DDI-DrugBank.d260.s0.p18	Probenecid	DB01032	drug	aminosalicylic acid	DB00233	True	mechanism	drug	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
DDI-DrugBank.d260.s2.p0	Zidovudine	DB00495	drug	probenecid	DB01032	True	advise	drug	Zidovudine should either be temporarily discontinued or decreased by 50% when coadministered with probenecid on the day of VISTIDE infusion.
DDI-DrugBank.d263.s17.p0	pentamidine	DB00738	drug	HIVID	None	True	advise	drug	If intravenous pentamidine is required to treat Pneumocystis carinii pneumonia, treatment with HIVID should be interrupted.
DDI-DrugBank.d263.s25.p2	Doxorubicin	DB00997	drug	zalcitabine	DB00943	True	effect	drug	Doxorubicin: Doxorubicin caused a decrease in zalcitabine phosphorylation ( 50% inhibition of total phosphate formation) in U937/Molt 4 cells.
DDI-DrugBank.d263.s3.p2	lamivudine	DB00709	drug	zalcitabine	DB00943	True	effect	drug	Lamivudine: In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that lamivudine significantly inhibited zalcitabine phosphorylation in a dose dependent manner.
DDI-DrugBank.d263.s5.p0	Zalcitabine	DB00943	drug	lamivudine	DB00709	True	effect	drug	Zalcitabine inhibited lamivudine phosphorylation at high concentration ratios (10 and 100);
DDI-DrugBank.d131.s0.p4	benzodiazepines	None	group	ethanol	DB00898	True	effect	drug	The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.
DDI-DrugBank.d131.s0.p6	alprazolam	DB00404	drug	anticonvulsants	None	True	effect	group	The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.
DDI-DrugBank.d131.s0.p7	alprazolam	DB00404	drug	antihistaminics	None	True	effect	group	The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.
DDI-DrugBank.d131.s10.p2	benzodiazepines	None	group	cyclosporine	DB00091	True	int	drug	Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.
DDI-DrugBank.d131.s10.p7	alprazolam	DB00404	drug	cyclosporine	DB00091	True	int	drug	Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.
DDI-DrugBank.d131.s8.p67	alprazolam	DB00404	drug	clarithromycin	DB01211	True	int	drug	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
DDI-DrugBank.d132.s13.p2	diflunisal	DB00861	drug	acetaminophen	DB00316	True	advise	drug	Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and acetaminophen should be used cautiously, with careful monitoring of patients.
DDI-DrugBank.d132.s20.p3	diflunisal	DB00861	drug	indomethacin	DB00328	True	mechanism	drug	Nonsteroidal Anti-Inflammatory Drugs: The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin.
DDI-DrugBank.d267.s5.p0	NUROMAX	None	brand	antibiotics	None	True	effect	group	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d267.s5.p7	NUROMAX	None	brand	colistin	DB00803	True	effect	drug	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d267.s6.p1	nondepolarizing neuromuscular blocking agents	None	group	phenytoin	DB00252	True	effect	drug	As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.
DDI-DrugBank.d267.s6.p3	NUROMAX	None	brand	phenytoin	DB00252	True	effect	drug	As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.
DDI-DrugBank.d269.s3.p0	agents with b-blocking properties	None	group	reserpine	DB00206	True	effect	drug	Catecholamine-depleting Agents: Patients taking both agents with b-blocking properties and a drug that can deplete catecholamines (e.g., reserpine and monoamine oxidase inhibitors) should be observed closely for signs of hypotension and/or severe bradycardia.
DDI-DrugBank.d269.s3.p1	agents with b-blocking properties	None	group	monoamine oxidase inhibitors	None	True	effect	group	Catecholamine-depleting Agents: Patients taking both agents with b-blocking properties and a drug that can deplete catecholamines (e.g., reserpine and monoamine oxidase inhibitors) should be observed closely for signs of hypotension and/or severe bradycardia.
DDI-DrugBank.d270.s9.p1	nevirapine	DB00238	drug	warfarin	DB00682	True	int	drug	The in vitro interaction between nevirapine and the antithrombotic agent warfarin is complex.
DDI-DrugBank.d272.s0.p2	alcohol	None	drug	bromocriptine mesylate	None	True	effect	drug	The risk of using bromocriptine mesylate in combination with other drugs has not been systematically evaluated, but alcohol may potentiate the side effects of bromocriptine mesylate.
DDI-DrugBank.d276.s0.p2	magnesium trisilicate	None	drug	nitrofurantoin	DB00698	True	mechanism	drug	Antacids containing magnesium trisilicate, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption.
DDI-DrugBank.d276.s1.p0	nitrofurantoin	DB00698	drug	magnesium trisilicate	None	True	mechanism	drug	The mechanism for this interaction probably is adsorption of nitrofurantoin onto the surface of magnesium trisilicate.
DDI-DrugBank.d277.s10.p12	tiagabine	DB00906	drug	carbamazepine	DB00564	True	mechanism	drug	Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs.
DDI-DrugBank.d279.s8.p0	prochlorperazine	DB00433	drug	CAMPTOSAR	None	True	effect	brand	The incidence of akathisia in clinical trials of the weekly dosage schedule was greater (8.5%, 4/47 patients) when prochlorperazine was administered on the same day as CAMPTOSAR than when these drugs were given on separate days (1.3%, 1/80 patients).
DDI-DrugBank.d282.s0.p0	DOSTINEX	None	brand	phenothiazines	None	True	advise	group	DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.
DDI-DrugBank.d282.s0.p1	DOSTINEX	None	brand	butyrophenones	None	True	advise	group	DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.
DDI-DrugBank.d283.s3.p2	TRICOR	None	brand	HMG-CoA reductase inhibitors	None	True	advise	group	HMG-CoA reductase inhibitors: The combined use of TRICOR and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination.
DDI-DrugBank.d283.s5.p3	cyclosporine	DB00091	drug	fibrate drugs	None	True	effect	group	Cyclosporine: Because cyclosporine can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including TRICOR, there is a risk that an interaction will lead to deterioration.
DDI-DrugBank.d286.s0.p1	Ethoxzolamide	DB00311	drug	amphetamines	None	True	effect	group	Ethoxzolamide may increase the action of tricyclics, amphetamines, procainamide, and quinidine.
DDI-DrugBank.d286.s0.p3	Ethoxzolamide	DB00311	drug	quinidine	DB00908	True	effect	drug	Ethoxzolamide may increase the action of tricyclics, amphetamines, procainamide, and quinidine.
DDI-DrugBank.d289.s27.p0	Bosentan	DB00559	drug	statins	None	True	mechanism	group	Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.
DDI-DrugBank.d291.s0.p8	Bezalip	None	brand	anticoagulants of the coumarin type	None	True	effect	group	When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of anticoagulants of the coumarin type.
DDI-DrugBank.d291.s11.p4	MAO-inhibitors	None	group	Bezalip retard	None	True	advise	brand	Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.
DDI-DrugBank.d291.s3.p3	insulin	None	drug	Bezalip	None	True	effect	brand	The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard.
DDI-DrugBank.d291.s9.p5	Bezalip retard	None	brand	anion-exchange resins	None	True	advise	group	When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired
DDI-DrugBank.d296.s0.p2	Diphenhydramine hydrochloride	None	drug	hypnotics	None	True	effect	group	Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).
DDI-DrugBank.d297.s4.p0	ORENCIA	None	brand	TNF antagonists	None	True	advise	group	Concurrent therapy with ORENCIA and TNF antagonists is not recommended.
DDI-DrugBank.d297.s5.p0	ORENCIA	None	brand	anakinra	DB00026	True	advise	drug	There is insufficient experience to assess the safety and efficacy of ORENCIA administered concurrently with anakinra, and therefore such use is not recommended.
DDI-DrugBank.d30.s9.p4	losartan	DB00678	drug	indomethacin	DB00328	True	effect	drug	As with other antihypertensive agents, the antihypertensive effect of losartan may be blunted by the non-steroidal anti-inflammatory drug indomethacin
DDI-DrugBank.d303.s2.p0	cephalexin	DB00567	drug	metformin	DB00331	True	mechanism	drug	Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems.
DDI-DrugBank.d303.s4.p5	cephalexin	DB00567	drug	probenecid	DB01032	True	mechanism	drug	Probenecid: As with other b-lactams, the renal excretion of cephalexin is inhibited by probenecid.
DDI-DrugBank.d185.s6.p1	dapsone	DB00250	drug	pyrimethamine	DB00205	True	effect	drug	With oral dapsone treatment, folic acid antagonists such as pyrimethamine have been noted to possibly increase the likelihood of hematologic reactions
DDI-DrugBank.d186.s3.p5	HALDOL	None	brand	CNS depressants	None	True	effect	group	As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.
DDI-DrugBank.d186.s6.p0	rifampin	None	drug	haloperidol	DB00502	True	advise	drug	Thus, careful monitoring of clinical status is warranted when rifampin is administered or discontinued in haloperidol-treated patients.
DDI-DrugBank.d187.s7.p6	Isoniazid	DB00951	drug	carbamazepine	DB00564	True	mechanism	drug	Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.
DDI-DrugBank.d188.s0.p5	Cimetidine	DB00501	drug	altretamine	DB00488	True	mechanism	drug	Concurrent administration of HEXALEN and antidepressants of the MAO inhibitor class may cause severe orthostatic hypotension.Cimetidine, an inhibitor of microsomal drug metabolism, increased altretamines half-life and toxicity in a rat model.
DDI-DrugBank.d19.s9.p0	disulfiram	DB00822	drug	nitrite	None	True	effect	drug	In rats, simultaneous ingestion of disulfiram and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.
DDI-DrugBank.d192.s0.p0	Dexbrompheniramine	DB00405	drug	alcohol	None	True	effect	drug	Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
DDI-DrugBank.d194.s1.p0	cyclosporin A	None	drug	etoposide	DB00773	True	mechanism	drug	High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.
DDI-DrugBank.d196.s6.p7	Ribavirin	DB00811	drug	stavudine	DB00649	True	effect	drug	Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.
DDI-DrugBank.d198.s12.p0	Ritonavir	DB00503	drug	Vardenafil	DB00862	True	mechanism	drug	Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.
DDI-DrugBank.d198.s28.p2	Vardenafil	DB00862	drug	terazosin	DB01162	True	effect	drug	Alpha-blockers: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin, significant hypotension developed in a substantial number of subjects.
DDI-DrugBank.d198.s6.p0	Vardenafil	DB00862	drug	erythromycin	DB00199	True	advise	drug	It is recommended not to exceed a single 5 mg dose of Vardenafil in a 24-hour period when used in combination with erythromycin.
DDI-DrugBank.d20.s6.p7	INSPRA	None	brand	ACE inhibitors	None	True	effect	group	ACE Inhibitors and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).
DDI-DrugBank.d202.s0.p0	tricyclic antidepressants	None	group	cimetidine	DB00501	True	mechanism	drug	Steady-state serum concentrations of tricyclic antidepressants are reported to fluctuate significantly when cimetidine is either added or deleted from the drug regimen.
DDI-DrugBank.d207.s7.p5	cimetidine	DB00501	drug	IRESSA	None	True	mechanism	brand	Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as ranitidine or cimetidine) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.
DDI-DrugBank.d207.s8.p5	IRESSA	None	brand	vinorelbine	DB00361	True	effect	drug	Phase II clinical trial data, where IRESSA and vinorelbine have been used concomitantly, indicate that IRESSA may exacerbate the neutropenic effect of vinorelbine.
DDI-DrugBank.d208.s0.p6	Benzthiazide	DB00562	drug	Aleve	None	True	int	brand	Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.
DDI-DrugBank.d208.s0.p7	Benzthiazide	DB00562	drug	Ibuprofen	DB01050	True	int	drug	Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.
DDI-DrugBank.d210.s18.p0	VIOXX	None	brand	lithium	DB01356	True	advise	drug	Thus, when VIOXX and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.
DDI-DrugBank.d210.s31.p2	VIOXX	None	brand	warfarin	DB00682	True	advise	drug	Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing VIOXX therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding complications.
DDI-DrugBank.d210.s32.p0	warfarin	DB00682	drug	rofecoxib	DB00533	True	effect	drug	In single and multiple dose studies in healthy subjects receiving both warfarin and rofecoxib, prothrombin time (measured as INR) was increased by approximately 8% to 11%.
DDI-DrugBank.d211.s2.p11	erythromycins	None	drug	penicillins	None	True	effect	group	Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.
DDI-DrugBank.d213.s1.p2	digitoxin	DB01396	drug	antithyroid agents	None	True	mechanism	group	Serum concentration of digoxin and digitoxin may increase when patients take antithyroid agents.
DDI-DrugBank.d215.s0.p2	anileridine	DB00913	drug	phenothiazines	None	True	advise	group	Caution should be observed when anileridine is coadministered with other opioids, sedatives, phenothiazines, or anesthetics, as these agents may increase respiratory and circulatory depression.
DDI-DrugBank.d216.s3.p2	eszopiclone	DB00402	drug	olanzapine	DB00334	True	effect	drug	Olanzapine: Coadministration of eszopiclone 3 mg and olanzapine 10 mg produced a decrease in DSST scores.
DDI-DrugBank.d216.s7.p0	eszopiclone	DB00402	drug	ketoconazole	DB01026	True	mechanism	drug	The AUC of eszopiclone was increased 2.2-fold by coadministration of ketoconazole, a potent inhibitor of CYP3A4, 400 mg daily for 5 days.
DDI-DrugBank.d217.s13.p0	quinolones	None	group	caffeine	DB00201	True	mechanism	drug	Some quinolones have also been shown to interfere with the metabolism of caffeine.
DDI-DrugBank.d217.s5.p4	norfloxacin	DB01059	drug	warfarin	DB00682	True	effect	drug	Quinolones, including norfloxacin, may enhance the effects of oral anticoagulants, including warfarin or its derivatives or similar agents.
DDI-DrugBank.d219.s23.p0	warfarin	DB00682	drug	Lodine	None	True	mechanism	brand	Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and Lodine  (etodolac capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free warfarin.
DDI-DrugBank.d219.s7.p2	Lodine	None	brand	digoxin	DB00390	True	mechanism	drug	Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.
DDI-DrugBank.d22.s0.p1	Aminosalicylic acid	DB00233	drug	Lanoxin	None	True	mechanism	brand	Aminosalicylic acid may decrease the amount of digoxin (Lanoxin, Lanoxicaps) that gets absorbed into your body.
DDI-DrugBank.d22.s3.p0	vitamin B12	None	drug	aminosalicylic acid	DB00233	True	advise	drug	Therefore you may need to take a vitamin B12 supplement while taking aminosalicylic acid.
DDI-DrugBank.d220.s11.p13	carbamazepine	DB00564	drug	Mefloquine	DB00358	True	effect	drug	In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.
DDI-DrugBank.d220.s5.p0	Mefloquine	DB00358	drug	quinine	DB00468	True	effect	drug	Concomitant administration of Mefloquine and other related compounds (eg, quinine, quinidine and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.
DDI-DrugBank.d220.s9.p3	Mefloquine	DB00358	drug	antihistamines	None	True	effect	group	This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.
DDI-DrugBank.d223.s16.p5	SSRIs	None	group	doxepin	DB01142	True	mechanism	drug	Inhibitors or substrates of CYP2D6 (i.e., quinidine, selective serotonin reuptake inhibitors [SSRIs]) may increase the plasma concentration of doxepin when administered concomitantly.
DDI-DrugBank.d223.s22.p2	Cimetidine	DB00501	drug	tricyclic antidepressants	None	True	mechanism	group	Cimetidine: Cimetidine has been reported to produce clinically significant fluctuations in steady-state serum concentrations of various tricyclic antidepressants.
DDI-DrugBank.d223.s23.p0	tricyclic antidepressant	None	group	cimetidine	DB00501	True	effect	drug	Serious anticholinergic symptoms (i.e., severe dry mouth, urinary retention and blurred vision) have been associated with elevations in the serum levels of tricyclic antidepressant when cimetidine therapy is initiated.
DDI-DrugBank.d305.s7.p0	dantrolene	DB01219	drug	vecuronium	DB01339	True	effect	drug	Administration of dantrolene may potentiate vecuronium-induced neuromuscular block.
DDI-DrugBank.d307.s35.p2	phenytoin	DB00252	drug	Trileptal	None	True	mechanism	brand	1- nc denotes a mean change of less than 10% 2- Pediatrics 3- Mean increase in adults at high Trileptal doses In vivo, the plasma levels of phenytoin increased by up to 40%, when Trileptal was given at doses above 1200 mg/day.
DDI-DrugBank.d307.s36.p0	Trileptal	None	brand	phenytoin	DB00252	True	advise	drug	Therefore, when using doses of Trileptal greater than 1200 mg/day during adjunctive therapy, a decrease in the dose of phenytoin may be required.
DDI-DrugBank.d307.s43.p0	Trileptal	None	brand	hormonal contraceptives	None	True	effect	group	Therefore, concurrent use of Trileptal with hormonal contraceptives may render these contraceptives less effective.
DDI-DrugBank.d308.s0.p0	HYDROXYZINE	DB00557	drug	CENTRAL NERVOUS SYSTEM DEPRESSANTS	None	True	effect	group	THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES.
DDI-DrugBank.d308.s0.p2	HYDROXYZINE	DB00557	drug	NON-NARCOTIC ANALGESICS	None	True	effect	group	THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES.
DDI-DrugBank.d309.s0.p3	antihistamines	None	group	alcohol	None	True	effect	drug	Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol.
DDI-DrugBank.d31.s7.p0	NSAIDs	None	group	hydralazine	DB01275	True	effect	drug	NSAIDs may decrease the hemodynamic effects of hydralazine;
DDI-DrugBank.d311.s0.p0	rauwolfia alkaloid	None	group	MAO inhibitors	None	True	effect	group	Taking a rauwolfia alkaloid while you are taking or within 2 weeks of taking MAO inhibitors may increase the risk of central nervous system depression or may cause a severe high blood pressure reaction.
DDI-DrugBank.d314.s23.p0	ketoconazole	DB01026	drug	corticosteroid	None	True	effect	drug	In addition, ketoconazole alone can inhibit adrenal corticosteroid synthesis and may cause adrenal insufficiency during corticosteroid withdrawal.
DDI-DrugBank.d314.s24.p8	aspirin	None	brand	corticosteroids	None	True	effect	group	Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects.
DDI-DrugBank.d316.s14.p5	felodipine	DB01023	drug	anticonvulsant	None	True	mechanism	group	Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.
DDI-DrugBank.d318.s12.p3	amphotericin B	DB00681	drug	skeletal muscle relaxants	None	True	effect	group	Skeletal muscle relaxants: amphotericin B-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., tubocurarine).
DDI-DrugBank.d318.s2.p2	Corticosteroids	None	group	amphotericin B	DB00681	True	effect	drug	Corticosteroids and Corticotropin (ACTH): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.
DDI-DrugBank.d318.s2.p4	Corticotropin	DB01285	drug	amphotericin B	DB00681	True	effect	drug	Corticosteroids and Corticotropin (ACTH): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.
DDI-DrugBank.d318.s2.p5	ACTH	None	group	amphotericin B	DB00681	True	effect	drug	Corticosteroids and Corticotropin (ACTH): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.
DDI-DrugBank.d320.s0.p0	Chirocaine	None	brand	anesthetics	None	True	advise	group	Chirocaine   should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics since the toxic effects of these drugs could be additive.
DDI-DrugBank.d322.s0.p5	MAOIs	None	group	clidinium	DB00771	True	effect	drug	Amantadine, tricyclic antidepressants, and MAOIs may increase anticholinergic effect of clidinium.
DDI-DrugBank.d325.s7.p2	Butyrophenones	None	group	dopamine	DB00988	True	effect	drug	Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.
DDI-DrugBank.d325.s8.p1	Cyclopropane	None	drug	catecholamines	None	True	effect	group	Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.
DDI-DrugBank.d326.s0.p2	piperazine	DB00592	drug	phenothiazine	None	True	effect	group	Phenothiazines - Taking piperazine and a phenothiazine together may increase the risk of convulsions (seizures).
DDI-DrugBank.d114.s10.p20	antihypertensives	None	group	PROLEUKIN	None	True	effect	brand	Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.
DDI-DrugBank.d114.s5.p3	PROLEUKIN	None	brand	tamoxifen	DB00675	True	effect	drug	Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.
DDI-DrugBank.d123.s2.p2	ciprofloxacin	DB00537	drug	cyclosporine	DB00091	True	effect	drug	Some quinolones, including ciprofloxacin, have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.
DDI-DrugBank.d123.s8.p13	ciprofloxacin	DB00537	drug	sucralfate	DB00364	True	mechanism	drug	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
DDI-DrugBank.d123.s8.p16	ciprofloxacin	DB00537	drug	iron	DB01592	True	mechanism	drug	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
DDI-DrugBank.d123.s8.p2	quinolone	None	group	aluminum	None	True	mechanism	drug	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
DDI-DrugBank.d124.s26.p125	carbamazepine	DB00564	drug	saquinavir	DB01232	True	mechanism	drug	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DDI-DrugBank.d328.s44.p0	valdecoxib	DB00580	drug	Ortho-Novum	None	True	mechanism	brand	Coadministration of valdecoxib and Ortho-Novum 1/35  increased the exposure of norethindrone and ethinyl estradiol by 20% and 34%, respectively.
DDI-DrugBank.d328.s8.p2	NSAIDs	None	group	ACE-inhibitors	None	True	effect	group	ACE-inhibitors:Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors.
DDI-DrugBank.d329.s0.p5	probenecid	DB01032	drug	ertapenem	DB00303	True	mechanism	drug	When ertapenem is co-administered with probenecid (500 mg p.o. every 6 hours), probenecid competes for active tubular secretion and reduces the renal clearance of ertapenem.
DDI-DrugBank.d332.s0.p1	doxapram	DB00561	drug	monoamine oxidase inhibiting drugs	None	True	effect	group	Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect .
DDI-DrugBank.d334.s1.p2	diuretic	None	group	PRINIVIL	None	True	effect	brand	The possibility of hypotensive effects with PRINIVIL can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with PRINIVIL.
DDI-DrugBank.d334.s15.p2	PRINIVIL	None	brand	triamterene	DB00384	True	effect	drug	Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
DDI-DrugBank.d334.s15.p3	PRINIVIL	None	brand	amiloride	DB00594	True	effect	drug	Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
DDI-DrugBank.d338.s1.p3	benzodiazepines	None	group	barbiturates	None	True	effect	group	The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.
DDI-DrugBank.d338.s1.p4	benzodiazepines	None	group	monoamine oxidase inhibitors	None	True	effect	group	The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.
DDI-DrugBank.d338.s4.p4	estazolam	DB01215	drug	estazolam	DB01215	True	mechanism	drug	While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.
DDI-DrugBank.d338.s8.p2	benzodiazepines	None	group	cimetidine	DB00501	True	mechanism	drug	The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, diltiazem, isoniazide, and some macrolide antibiotics.
DDI-DrugBank.d338.s8.p3	benzodiazepines	None	group	diltiazem	DB00343	True	mechanism	drug	The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, diltiazem, isoniazide, and some macrolide antibiotics.
DDI-DrugBank.d339.s2.p1	Warfarin	DB00682	drug	cefixime	DB00671	True	effect	drug	Warfarin and Anticoagulants: Increased prothrombin time, with or without clinical bleeding, has been reported when cefixime is administered concomitantly.
DDI-DrugBank.d340.s11.p0	VIRACEPT	None	brand	terfenadine	DB00342	True	advise	drug	therefore, VIRACEPT should not be administered concurrently with terfenadine because of the potential for serious and/or life-threatening cardiac arrhythmias.
DDI-DrugBank.d340.s14.p4	indinavir	DB00224	drug	VIRACEPT	None	True	mechanism	brand	Indinavir: Coadministration of indinavir with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A.C.
DDI-DrugBank.d340.s27.p0	zidovudine	DB00495	drug	VIRACEPT	None	True	advise	brand	A dose adjustment is not needed when zidovudine is administered with VIRACEPT.
DDI-DrugBank.d340.s6.p10	VIRACEPT	None	brand	midazolam	DB00683	True	advise	drug	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
DDI-DrugBank.d340.s6.p4	VIRACEPT	None	brand	astemizole	DB00637	True	advise	drug	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
DDI-DrugBank.d345.s11.p14	gemfibrozil	DB01241	drug	colestipol hydrochloride	None	True	mechanism	drug	The absorption of tetracycline, furosemide, penicillin G, hydrochlorothiazide, and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride;
DDI-DrugBank.d345.s11.p4	tetracycline	DB00759	drug	colestipol hydrochloride	None	True	mechanism	drug	The absorption of tetracycline, furosemide, penicillin G, hydrochlorothiazide, and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride;
DDI-DrugBank.d346.s4.p1	REVIA	None	brand	opioid analgesics	None	True	effect	group	Patients taking REVIA may not benefit from opioid containing medicines, such as cough and cold preparations, antidiarrheal preparations, and opioid analgesics.
DDI-DrugBank.d347.s7.p29	ferrous sulfate	None	drug	FACTIVE	None	True	advise	brand	Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.
DDI-DrugBank.d347.s7.p8	Magnesium	DB01378	drug	FACTIVE	None	True	advise	brand	Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.
DDI-DrugBank.d35.s0.p1	EPA	None	drug	non-steroidal anti-inflammatory drugs	None	True	int	group	Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).
DDI-DrugBank.d350.s14.p1	CANCIDAS	None	brand	nevirapine	DB00238	True	advise	drug	When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered
DDI-DrugBank.d353.s10.p3	acitretin	DB00459	drug	phenytoin	DB00252	True	mechanism	drug	Phenytoin: If acitretin is given concurrently with phenytoin, the protein binding of phenytoin may be reduced.
DDI-DrugBank.d353.s6.p0	progestin	None	drug	Soriatane	None	True	advise	drug	Microdosed minipill progestin preparations are not recommended for use with Soriatane.
DDI-DrugBank.d356.s0.p0	amiloride	DB00594	drug	angiotensin-converting enzyme inhibitor	None	True	effect	group	When amiloride HCl is administered concomitantly with an angiotensin-converting enzyme inhibitor, the risk of hyperkalemia may be increased.
DDI-DrugBank.d357.s0.p24	apomorphine	DB00714	drug	5HT3 antagonist class	None	True	advise	group	5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
DDI-DrugBank.d357.s0.p29	apomorphine	DB00714	drug	alosetron	DB00969	True	advise	drug	5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
DDI-DrugBank.d357.s3.p43	thioxanthenes	None	group	APOKYN	None	True	effect	brand	Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.
DDI-DrugBank.d358.s1.p1	omeprazole	DB00338	drug	cilostazol	DB01166	True	mechanism	drug	Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites.
DDI-DrugBank.d359.s3.p1	phenytoin	DB00252	drug	coumarin anticoagulants	None	True	mechanism	group	Presumably, phenytoin acts as a stimulator of coumarin metabolism and has been reported to cause decreased serum levels of the coumarin anticoagulants and increased prothrombin-proconvertin concentrations.
DDI-DrugBank.d359.s6.p0	PEGANONE	None	brand	coumarin anticoagulants	None	True	advise	group	Caution is therefore advised when administering PEGANONE to patients receiving coumarin anticoagulants.
DDI-DrugBank.d364.s15.p1	alosetron	DB00969	drug	procainamide	DB01035	True	effect	drug	Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.
DDI-DrugBank.d364.s5.p0	alosetron	DB00969	drug	quinolone antibiotics	None	True	advise	group	Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.
DDI-DrugBank.d368.s9.p0	Acetazolamide	DB00819	drug	amphetamine	DB00182	True	mechanism	drug	Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect.
DDI-DrugBank.d371.s1.p1	docetaxel	DB01248	drug	terfenadine	DB00342	True	mechanism	drug	In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and troleandomycin.
DDI-DrugBank.d373.s11.p5	cimetidine	DB00501	drug	nifedipine	DB01115	True	mechanism	drug	Cimetidine: A study in 6 healthy volunteers has shown a significant increase in peak nifedipine plasma levels (80%) and area-under-the-curve (74%) after a 1 week course of cimetidine at 1000 mg per day and nifedipine at 40 mg per day.
DDI-DrugBank.d373.s7.p2	digoxin	DB00390	drug	nifedipine	DB01115	True	advise	drug	Since there have been isolated reports of patients with elevated digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.
DDI-DrugBank.d378.s1.p0	cephalosporins	None	group	diuretics	None	True	effect	group	Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide.
DDI-DrugBank.d378.s1.p1	cephalosporins	None	group	furosemide	DB00695	True	effect	drug	Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide.
DDI-DrugBank.d379.s1.p21	sulfonylureas	None	group	LEVULAN KERASTICK	None	True	effect	brand	It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.
DDI-DrugBank.d379.s1.p6	photosensitizing agents	None	group	LEVULAN KERASTICK	None	True	effect	brand	It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.
DDI-DrugBank.d382.s11.p0	dexamethasone	DB01234	drug	Aprepitant	DB00673	True	mechanism	drug	The daily dose of dexamethasone administered in clinical studies with Aprepitant reflects an approximate 50% reduction of the dose of dexamethasone.
DDI-DrugBank.d382.s14.p1	methylprednisolone	DB00959	drug	Aprepitant	DB00673	True	advise	drug	The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.
DDI-DrugBank.d382.s19.p7	Aprepitant	DB00673	drug	ethinyl estradiol	DB00977	True	mechanism	drug	Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;
DDI-DrugBank.d382.s31.p6	Aprepitant	DB00673	drug	nelfinavir	DB00220	True	advise	drug	Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.
DDI-DrugBank.d382.s4.p0	Aprepitant	DB00673	drug	S(-) warfarin	None	True	mechanism	drug	Aprepitant has been shown to induce the metabolism of S(-) warfarin and tolbutamide, which are metabolized through CYP2C9.
DDI-DrugBank.d386.s23.p2	desipramine hydrochloride	None	drug	sedative	None	True	effect	group	If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.
DDI-DrugBank.d389.s0.p0	Antihistamines	None	group	tricyclic antidepressants	None	True	effect	group	Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.
DDI-DrugBank.d389.s0.p2	Antihistamines	None	group	alcohol	None	True	effect	drug	Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.
DDI-DrugBank.d389.s0.p3	Antihistamines	None	group	CNS depressants	None	True	effect	group	Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.
DDI-DrugBank.d389.s2.p2	Sympathomimetic amines	None	group	methyldopa	DB00968	True	effect	drug	Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa and mecamylamine.
DDI-DrugBank.d389.s3.p0	sympathomimetics	None	group	MAO inhibitors	None	True	effect	group	Effects of sympathomimetics are increased with MAO inhibitors and beta adrenergic blockers.
DDI-DrugBank.d392.s0.p1	Panretin	None	brand	N-diethyl-m-toluamide	None	True	advise	drug	Patients who are applying Panretin gel should not concurrently use products that contain DEET (N, N-diethyl-m-toluamide), a common component of insect repellent products.
DDI-DrugBank.d394.s0.p1	sodium nitroprusside	None	drug	ganglionic blocking agents	None	True	effect	group	The hypotensive effect of sodium nitroprusside is augmented by that of most other hypotensive drugs, including ganglionic blocking agents, negative inotropic agents, and inhaled anesthetics.
DDI-DrugBank.d395.s1.p0	enoxacin	DB00467	drug	bismuth subsalicylate	DB01294	True	advise	drug	Thus, concomitant administration of enoxacin and bismuth subsalicylate should be avoided.
DDI-DrugBank.d210.s10.p2	cimetidine	DB00501	drug	rofecoxib	DB00533	True	mechanism	drug	Cimetidine: Co-administration with high doses of cimetidine [800 mg twice daily] increased the Cmax of rofecoxib by 21%, the AUC0-120hr by 23% and the t1/2 by 15%.
DDI-DrugBank.d210.s21.p3	methotrexate	DB00563	drug	rofecoxib	DB00533	True	mechanism	drug	At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of rofecoxib (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL).
DDI-DrugBank.d210.s27.p3	VIOXX	None	brand	theophylline	DB00277	True	mechanism	drug	Theophylline VIOXX 12.5, 25, and 50 mg administered once daily for 7 days increased plasma theophylline concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of theophylline.
DDI-DrugBank.d213.s0.p1	Iodine	None	drug	Carbimazole	DB00389	True	effect	drug	Iodine or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of Carbimazole.
DDI-DrugBank.d213.s1.p1	digoxin	DB00390	drug	antithyroid agents	None	True	mechanism	group	Serum concentration of digoxin and digitoxin may increase when patients take antithyroid agents.
DDI-DrugBank.d217.s12.p3	Didanosine	DB00900	drug	norfloxacin	DB01059	True	advise	drug	Videx (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.
DDI-DrugBank.d217.s5.p1	Quinolones	None	group	anticoagulants	None	True	effect	group	Quinolones, including norfloxacin, may enhance the effects of oral anticoagulants, including warfarin or its derivatives or similar agents.
DDI-DrugBank.d219.s20.p0	etodolac	DB00749	drug	phenylbutazone	DB00812	True	advise	drug	Although in vivo studies have not been done to see if etodolac clearance is changed by coadministration of phenylbutazone, it is not recommended that they be coadministered.
DDI-DrugBank.d219.s4.p3	Lodine	None	brand	aspirin	None	True	mechanism	brand	Aspirin: When Lodine is administered with aspirin, its protein binding is reduced, although the clearance of free etodolac is not altered.
DDI-DrugBank.d220.s11.p9	valproic acid	DB00313	drug	Mefloquine	DB00358	True	effect	drug	In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.
DDI-DrugBank.d220.s5.p1	Mefloquine	DB00358	drug	quinidine	DB00908	True	effect	drug	Concomitant administration of Mefloquine and other related compounds (eg, quinine, quinidine and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.
DDI-DrugBank.d224.s6.p0	clonidine	DB00575	drug	neuroleptic	None	True	effect	group	An additive hypotensive effect has been reported with the combination of systemic clonidine and neuroleptic therapy.
DDI-DrugBank.d224.s8.p1	apraclonidine	DB00964	drug	antihypertensives	None	True	advise	group	Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), antihypertensives, and cardiac glycosides is advised.
DDI-DrugBank.d225.s0.p3	sulfonylureas	None	group	sulfonamides	None	True	effect	group	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
DDI-DrugBank.d226.s4.p0	adenosine	DB00640	drug	methylxanthines	None	True	effect	group	The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.
DDI-DrugBank.d226.s4.p2	adenosine	DB00640	drug	theophylline	DB00277	True	effect	drug	The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.
DDI-DrugBank.d231.s2.p0	Furosemide	DB00695	drug	ethacrynic acid	DB00903	True	advise	drug	Furosemide should not be used concomitantly with ethacrynic acid because of the possibility of ototoxicity.
DDI-DrugBank.d231.s3.p0	salicylates	None	group	furosemide	DB00695	True	effect	drug	Patients receiving high doses of salicylates concomitantly with furosemide, as in rheumatic disease, may experience salicylate toxicity at lower doses because of competitive renal excretory sites.
DDI-DrugBank.d231.s5.p0	Lithium	DB01356	drug	diuretics	None	True	advise	group	Lithium generally should not be given with diuretics because they reduce lithiums renal clearance and add a high risk of lithium toxicity.
DDI-DrugBank.d233.s1.p0	azathioprine	DB00993	drug	allopurinol	DB00437	True	advise	drug	Patients receiving azathioprine and allopurinol concomitantly should have a dose reduction of azathioprine, to approximately 1/3 to 1/4 the usual dose.
DDI-DrugBank.d395.s21.p0	Enoxacin	DB00467	drug	theophylline	DB00277	True	mechanism	drug	Enoxacin interferes with the metabolism of theophylline resulting in a 42% to 74% dose-related decrease in theophylline clearance and a subsequent 260% to 350% increase in serum theophylline levels.
DDI-DrugBank.d395.s23.p7	enoxacin	DB00467	drug	R-warfarin	None	True	mechanism	drug	Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.
DDI-DrugBank.d395.s6.p5	cyclosporine	DB00091	drug	quinolone class	None	True	mechanism	group	Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class.
DDI-DrugBank.d395.s8.p4	enoxacin	DB00467	drug	digoxin	DB00390	True	effect	drug	If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.
DDI-DrugBank.d396.s0.p9	antipsychotics	None	group	hydrocodone	DB00956	True	effect	drug	Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.
DDI-DrugBank.d396.s3.p0	anticholinergics	None	group	hydrocodone	DB00956	True	effect	drug	The concurrent use of anticholinergics with hydrocodone may produce paralytic ileus.
DDI-DrugBank.d397.s2.p0	erythromycin	DB00199	drug	digoxin	DB00390	True	mechanism	drug	Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.
DDI-DrugBank.d397.s6.p1	Erythromycin	DB00199	drug	midazolam	DB00683	True	mechanism	drug	Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.
DDI-DrugBank.d397.s6.p2	Erythromycin	DB00199	drug	benzodiazepines	None	True	effect	group	Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.
DDI-DrugBank.d397.s8.p0	erythromycin	DB00199	drug	carbamazepine	DB00564	True	int	drug	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
DDI-DrugBank.d398.s1.p1	dextromethorphan	DB00514	drug	MAOIs	None	True	effect	group	Serious toxicity may result if dextromethorphan is coadministered with monoamine oxidase inhibitors (MAOIs).
DDI-DrugBank.d399.s0.p0	dapsone	DB00250	drug	Lamprene	None	True	effect	brand	Preliminary data which suggest that dapsone may inhibit the anti-inflammatory activity of Lamprene have not been confirmed.
DDI-DrugBank.d40.s10.p15	phenytoin	DB00252	drug	phenylbutazone	DB00812	True	mechanism	drug	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
DDI-DrugBank.d40.s10.p18	phenytoin	DB00252	drug	sulfonamides	None	True	mechanism	group	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
DDI-DrugBank.d40.s10.p20	phenytoin	DB00252	drug	trazodone	DB00656	True	mechanism	drug	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
DDI-DrugBank.d40.s10.p6	phenytoin	DB00252	drug	disulfiram	DB00822	True	mechanism	drug	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
DDI-DrugBank.d40.s12.p2	phenytoin	DB00252	drug	reserpine	DB00206	True	mechanism	drug	Drugs that may decrease plasma Phenytoin concentrations include: carbamazepine, chronic alcohol abuse, reserpine
DDI-DrugBank.d40.s14.p0	phenytoin	DB00252	drug	phenobarbital	DB01174	True	mechanism	drug	Drugs that may either increase or decrease plasma Phenytoin concentrations include: phenobarbital, vaiproic acid, and sodium valproate.
DDI-DrugBank.d40.s15.p1	phenytoin	DB00252	drug	valproic acid	DB00313	True	effect	drug	Similarly, the effects of phenytoin on phenobarbital, valproic acid and sodium plasma valproate concentrations are unpredictable
DDI-DrugBank.d40.s17.p0	tricyclic antidepressants	None	group	Cerebyx	None	True	effect	brand	- Although not a true drug interaction, tricyclic antidepressants may precipitate seizures in susceptible patients and Cerebyx dosage may need to be adjusted
DDI-DrugBank.d40.s19.p6	phenytoin	DB00252	drug	furosemide	DB00695	True	effect	drug	Drugs whose efficacy is impaired by Phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
DDI-DrugBank.d400.s14.p13	magnesium hydroxide	None	drug	mefenamic acid	DB00784	True	mechanism	drug	Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and trimethoprim.
DDI-DrugBank.d400.s5.p0	NSAIDs	None	group	ACE inhibitors	None	True	advise	group	This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.
DDI-DrugBank.d401.s0.p4	anticholinergic	None	group	antipsychotics	None	True	effect	group	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
DDI-DrugBank.d404.s15.p4	Magnesium	DB01378	drug	vitamin D	None	True	effect	group	Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.
DDI-DrugBank.d404.s7.p2	Vitamin D	None	group	digitalis	None	True	advise	group	Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.
DDI-DrugBank.d405.s1.p4	barbiturates	None	group	ethchlorvynol	DB00189	True	effect	drug	Other depressasnts such as alcohol, barbiturates, and MAOIs may enhance CNS depression when administered with ethchlorvynol.
DDI-DrugBank.d405.s1.p5	MAOIs	None	group	ethchlorvynol	DB00189	True	effect	drug	Other depressasnts such as alcohol, barbiturates, and MAOIs may enhance CNS depression when administered with ethchlorvynol.
DDI-DrugBank.d409.s0.p0	tetracyclines	None	group	anticoagulant	None	True	advise	group	Because the tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.
DDI-DrugBank.d411.s3.p13	levothyroxine sodium	None	drug	phenylbutazone	DB00812	True	mechanism	drug	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
DDI-DrugBank.d411.s3.p16	levothyroxine sodium	None	drug	tamoxifen	DB00675	True	mechanism	drug	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
DDI-DrugBank.d411.s3.p7	levothyroxine sodium	None	drug	furosemide	DB00695	True	mechanism	drug	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
DDI-DrugBank.d411.s3.p8	levothyroxine sodium	None	drug	glucocorticoids	None	True	mechanism	group	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
DDI-DrugBank.d411.s3.p9	levothyroxine sodium	None	drug	meclofenamic acid	DB00939	True	mechanism	drug	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
DDI-DrugBank.d413.s2.p9	Allopurinol	DB00437	drug	mercaptopurine	DB01033	True	mechanism	drug	Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.
DDI-DrugBank.d413.s22.p2	cyclosporine	DB00091	drug	allopurinol sodium	None	True	mechanism	drug	Cyclosporin: Reports indicate that cyclosporine levels may be increased during concomitant treatment with allopurinol sodium for injection.
DDI-DrugBank.d414.s6.p1	non- steroidal antiinflammatory agent	None	group	potassium- sparing diuretics	None	True	effect	group	In some patients, the administration of a non- steroidal antiinflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium- sparing and thiazide diuretics.
DDI-DrugBank.d414.s7.p0	EDECRIN	None	brand	non- steroidal anti- inflammatory agents	None	True	effect	group	Therefore, when EDECRIN and non- steroidal anti- inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.
DDI-DrugBank.d415.s15.p0	ibuprofen	DB01050	drug	lithium	DB01356	True	advise	drug	Thus, when ibuprofen and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.
DDI-DrugBank.d415.s2.p4	aspirin	None	brand	ibuprofen	DB01050	True	effect	drug	Aspirin: Animal studies wshow that aspirin given with nonsteroidal anti-inflammatory agents, including ibuprofen, yields a net decrease in anti-inflammatory activity with lowered blood levels of the non-aspirin drug.
DDI-DrugBank.d42.s5.p2	dolasetron mesylate	None	drug	atenolol	DB00335	True	mechanism	drug	Clearance of hydrodolasetron decreased by about 27% when dolasetron mesylate was administered intravenously concomitantly with atenolol.
DDI-DrugBank.d422.s15.p1	BREVIBLOC	None	brand	epinephrine	DB00668	True	advise	drug	Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.
DDI-DrugBank.d422.s9.p0	succinylcholine	DB00202	drug	BREVIBLOC	None	True	effect	brand	The onset of neuromuscular blockade by succinylcholine was unaffected by BREVIBLOC, but the duration of neuromuscular blockade was prolonged from 5 minutes to 8 minutes.
DDI-DrugBank.d423.s0.p15	selegiline hydrochloride	None	drug	serotoninergic agents	None	True	effect	group	In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
DDI-DrugBank.d423.s0.p17	selegiline hydrochloride	None	drug	fluvoxamine	DB00176	True	effect	drug	In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
DDI-DrugBank.d423.s0.p2	monoamine oxidase inhibitors	None	group	serotoninergic agents	None	True	effect	group	In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
DDI-DrugBank.d423.s4.p2	selective serotonin reuptake inhibitors	None	group	sumatriptan succinate	None	True	effect	drug	A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.
DDI-DrugBank.d423.s6.p0	Dexfenfluramine	DB01191	drug	serotoninergic agents	None	True	advise	group	Dexfenfluramine should not be administered with other serotoninergic agents.
DDI-DrugBank.d426.s1.p8	dihydroergotamine	DB00320	drug	FROVA	None	True	advise	brand	Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).
DDI-DrugBank.d426.s3.p5	Selective serotonin reuptake inhibitors	None	group	5-HT1 agonists	None	True	effect	group	Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
DDI-DrugBank.d43.s12.p1	quinolone antibiotics	None	group	magnesium	DB01378	True	mechanism	drug	Plasma concentrations of quinolone antibiotics are decreased when administered with antacids containing magnesium, calcium, or aluminum.
DDI-DrugBank.d43.s2.p5	allopurinol	DB00437	drug	VIDEX	None	True	mechanism	brand	Allopurinol: The AUC of didanosine was increased about 4-fold when allopurinol at 300 mg/day was coadministered with a single 200-mg dose of VIDEX to two patients with renal impairment (CLcr=15 and 18 mL/min).
DDI-DrugBank.d43.s9.p2	ciprofloxacin	DB00537	drug	VIDEX	None	True	mechanism	brand	In eight HIV-infected patients, the steady-state AUC of ciprofloxacin was decreased an average of 26% (95% CI = 14%, 37%) when ciprofloxacin was administered 2 hours prior to a marketed chewable/dispersible tablet formulation of VIDEX.
DDI-DrugBank.d431.s12.p3	lansoprazole	DB00448	drug	digoxin	DB00390	True	mechanism	drug	therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).
DDI-DrugBank.d431.s5.p0	theophylline	DB00277	drug	lansoprazole	DB00448	True	advise	drug	Nonetheless, individual patients may require additional titration of their theophylline dosage when lansoprazole is started or stopped to ensure clinically effective blood levels.
DDI-DrugBank.d431.s7.p9	proton pump inhibitors	None	group	sucralfate	DB00364	True	mechanism	drug	In a single-dose crossover study examining lansoprazole 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate.
DDI-DrugBank.d434.s30.p33	phenytoin	DB00252	drug	Felbatol	None	True	mechanism	brand	Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.
DDI-DrugBank.d437.s13.p0	Amprenavir	DB00701	drug	ritonavir	DB00503	True	effect	drug	Laboratory Tests: The combination of Amprenavir and low-dose ritonavir has been associated with elevations of cholesterol and triglycerides, SGOT (AST), and SGPT (ALT) in some patients.
DDI-DrugBank.d437.s8.p0	Nelfinavir	DB00220	drug	amprenavir	DB00701	True	mechanism	drug	Nelfinavir steady-state Cmax, A.C. and Cmin were increased by 12%, 15%, and 14%, respectively, by concomitant amprenavir.
DDI-DrugBank.d437.s9.p3	amprenavir	DB00701	drug	methadone	DB00333	True	effect	drug	Methadone: Coadministration of amprenavir and methadone can decrease plasma levels of methadone.
DDI-DrugBank.d438.s37.p5	Maalox	None	brand	gabapentin	DB00996	True	mechanism	drug	Antacid (Maalox ): Maalox reduced the bioavailability of gabapentin (N=16) by about 20%.
DDI-DrugBank.d44.s2.p4	live vaccines	None	group	RAPTIVA	None	True	advise	brand	Acellular, live and live-attenuated vaccines should not be administered during RAPTIVA treatment.
DDI-DrugBank.d44.s2.p5	live-attenuated vaccines	None	group	RAPTIVA	None	True	advise	brand	Acellular, live and live-attenuated vaccines should not be administered during RAPTIVA treatment.
DDI-DrugBank.d440.s1.p6	aluminum	None	drug	Ibandronate	DB00710	True	mechanism	drug	Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.
DDI-DrugBank.d441.s1.p1	linezolid	DB00601	drug	serotonergic agents	None	True	int	group	Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents.
DDI-DrugBank.d441.s2.p6	ZYVOX	None	brand	dopaminergic agents	None	True	effect	group	Adrenergic Agents:Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents.
DDI-DrugBank.d441.s6.p3	ZYVOX	None	brand	SSRIs	None	True	effect	group	Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and serotonergic agents, including antidepressants such as selective serotonin reuptake inhibitors (SSRIs), have been reported.
DDI-DrugBank.d443.s0.p4	Aspirin	None	brand	probenecid	DB01032	True	effect	drug	Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.
DDI-DrugBank.d443.s1.p0	Alcohol	None	drug	aspirin	None	True	effect	brand	Alcohol: Has a synergistic effect with aspirin in causing gastrointestinal bleeding.
DDI-DrugBank.d446.s0.p2	Chlorotrianisene	DB00269	drug	barbiturates	None	True	int	group	Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
DDI-DrugBank.d446.s0.p6	Chlorotrianisene	DB00269	drug	corticotropin	DB01285	True	int	drug	Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
DDI-DrugBank.d448.s3.p8	reserpine	DB00206	drug	sympathomimetics	None	True	effect	group	The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics.
DDI-DrugBank.d449.s1.p5	cimetidine	DB00501	drug	Xanax	None	True	advise	brand	Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction).
DDI-DrugBank.d45.s0.p0	etanercept	DB00005	drug	anakinra	DB00026	True	effect	drug	Concurrent administration of etanercept (another TNF -blocking agent) and anakinra (an interleukin-1 antagonist) has been associated with an increased risk of serious infections, and increased risk of neutropenia and no additional benefit compared to these medicinal products alone.
DDI-DrugBank.d450.s10.p0	digoxin	DB00390	drug	sympathomimetics	None	True	effect	group	Concomitant use of digoxin and sympathomimetics increases the risk of cardiac arrhythmias.
DDI-DrugBank.d450.s12.p2	calcium channel blockers	None	group	digoxin	DB00390	True	effect	drug	Although beta-adrenergic blockers or calcium channel blockers and digoxin may be useful in combination to control atrial fibrillation, their additive effects on AV node conduction can result in advanced or complete heart block.
DDI-DrugBank.d450.s2.p37	itraconazole	DB01167	drug	digoxin	DB00390	True	mechanism	drug	Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
DDI-DrugBank.d450.s6.p19	cholestyramine	DB01432	drug	digoxin	DB00390	True	mechanism	drug	Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.
DDI-DrugBank.d450.s7.p0	Rifampin	None	drug	digoxin	DB00390	True	mechanism	drug	Rifampin may decrease serum digoxin concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of digoxin.
DDI-DrugBank.d454.s4.p0	tricyclic antidepressants	None	group	lofexidine	DB04948	True	effect	drug	Concomitant use of tricyclic antidepressants may reduce The efficacy of lofexidine.
DDI-DrugBank.d456.s1.p0	TARCEVA	None	brand	ketoconazole	DB01026	True	advise	drug	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
DDI-DrugBank.d457.s0.p4	Barbiturates	None	group	corticosteroids	None	True	effect	group	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.
DDI-DrugBank.d457.s0.p6	Barbiturates	None	group	beta blockers	None	True	effect	group	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.
DDI-DrugBank.d458.s10.p0	Ketoconazole	DB01026	drug	cyclosporine	DB00091	True	mechanism	drug	Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.
DDI-DrugBank.d458.s25.p1	INH	None	drug	ketoconazole	DB01026	True	mechanism	drug	INH (Isoniazid) is also reported to affect ketoconazole concentrations adversely.
DDI-DrugBank.d458.s25.p2	Isoniazid	DB00951	drug	ketoconazole	DB01026	True	mechanism	drug	INH (Isoniazid) is also reported to affect ketoconazole concentrations adversely.
DDI-DrugBank.d458.s7.p0	ketoconazole	DB01026	drug	cisapride	DB00604	True	mechanism	drug	Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride.
DDI-DrugBank.d459.s0.p1	ENABLEX	None	brand	itraconazole	DB01167	True	advise	drug	The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .
DDI-DrugBank.d459.s0.p2	ENABLEX	None	brand	ritonavir	DB00503	True	advise	drug	The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .
DDI-DrugBank.d459.s2.p0	ENABLEX	None	brand	anticholinergic agents	None	True	effect	group	The concomitant use of ENABLEX with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision and other anticholinergic pharmacological effects.
DDI-DrugBank.d46.s15.p0	Lithium	DB01356	drug	diuretics	None	True	advise	group	Lithium: Generally should not be given with diuretics.
DDI-DrugBank.d46.s17.p0	lithium	DB01356	drug	chlorothiazide	DB00880	True	advise	drug	Refer to the package insert for lithium preparations before use of such preparations with chlorothiazide
DDI-DrugBank.d46.s20.p0	chlorothiazide	DB00880	drug	non-steroidal anti-inflammatory agents	None	True	advise	group	Therefore, when chlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained
DDI-DrugBank.d460.s15.p13	sympathomimetics	None	group	antidiabetic drugs	None	True	effect	group	Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.
DDI-DrugBank.d460.s15.p7	corticosteroids	None	group	Starlix	None	True	effect	brand	Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.
DDI-DrugBank.d463.s0.p0	buspirone hydrochloride	None	drug	MAO inhibitors	None	True	advise	group	It is recommended that buspirone hydrochloride not be used concomitantly with MAO inhibitors Because the effects of concomitant administration of buspirone HCl with most other psychotropic drugs have not been studied, the concomitant use of buspirone HCl with other CNS-active drugs should be approached with caution.
DDI-DrugBank.d463.s1.p1	trazodone hydrochloride	None	drug	buspirone HCl	None	True	effect	drug	There is one report suggesting that the concomitant use of trazodone hydrochloride (Desyrel) and buspirone HCl may have caused 3- to 6-fold elevations on SGPT (ALT) in a few patients.
DDI-DrugBank.d463.s3.p0	buspirone HCl	None	drug	haloperidol	DB00502	True	mechanism	drug	In a study in normal volunteers, concomitant administration of buspirone HCl and haloperidol resulted in increased serum haloperidol concentrations.
DDI-DrugBank.d464.s0.p1	Codeine	DB00318	drug	anesthetics	None	True	effect	group	Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.
DDI-DrugBank.d464.s0.p2	Codeine	DB00318	drug	phenothiazines	None	True	effect	group	Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.
DDI-DrugBank.d466.s17.p1	ketoconazole	DB01026	drug	fexofenadine	DB00950	True	mechanism	drug	These studies indicate that ketoconazole or erythromycin co-administration enhances fexofenadine gastrointestinal absorption.
DDI-DrugBank.d467.s2.p14	gemfibrozil	DB01241	drug	bexarotene	DB00307	True	mechanism	drug	On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.
DDI-DrugBank.d467.s2.p8	ketoconazole	DB01026	drug	bexarotene	DB00307	True	mechanism	drug	On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.
DDI-DrugBank.d467.s3.p5	phenobarbital	DB01174	drug	bexarotene	DB00307	True	mechanism	drug	Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.
DDI-DrugBank.d469.s0.p0	TRACRIUM	None	brand	enflurane	DB00228	True	effect	drug	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;
DDI-DrugBank.d469.s7.p7	TRACRIUM	None	brand	magnesium	DB01378	True	effect	drug	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.
DDI-DrugBank.d469.s7.p9	TRACRIUM	None	brand	quinidine	DB00908	True	effect	drug	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.
DDI-DrugBank.d476.s1.p1	reserpine	DB00206	drug	ZEBETA	None	True	effect	brand	Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of ZEBETA may produce excessive reduction of sympathetic activity.
DDI-DrugBank.d476.s3.p6	ZEBETA	None	brand	antiarrhythmic agents	None	True	advise	group	ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.
DDI-DrugBank.d476.s3.p7	ZEBETA	None	brand	disopyramide	DB00280	True	advise	drug	ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.
DDI-DrugBank.d477.s1.p0	DIDREX	None	brand	CNS stimulants	None	True	advise	group	DIDREX should not be used concomitantly with other CNS stimulants.
DDI-DrugBank.d478.s1.p8	dihydroergotamine	DB00320	drug	naratriptan	DB00952	True	advise	drug	Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.
DDI-DrugBank.d478.s1.p9	methysergide	DB00247	drug	naratriptan	DB00952	True	advise	drug	Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.
DDI-DrugBank.d48.s1.p3	SPRYCEL	None	brand	clarithromycin	DB01211	True	mechanism	drug	Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
DDI-DrugBank.d48.s1.p9	SPRYCEL	None	brand	saquinavir	DB01232	True	mechanism	drug	Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
DDI-DrugBank.d48.s11.p19	famotidine	DB00927	drug	dasatinib	DB01254	True	effect	drug	H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.
DDI-DrugBank.d48.s15.p84	tacrolimus	DB00864	drug	SPRYCEL	None	True	advise	brand	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
DDI-DrugBank.d48.s9.p0	SPRYCEL	None	brand	antacids	None	True	advise	group	Simultaneous administration of SPRYCEL with antacids should be avoided.
DDI-DrugBank.d480.s15.p7	rifampin	None	drug	Clozapine	DB00363	True	mechanism	drug	Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.
DDI-DrugBank.d480.s17.p2	Cimetidine	DB00501	drug	Clozapine	DB00363	True	mechanism	drug	Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.
DDI-DrugBank.d480.s30.p1	clozapine	DB00363	drug	phenothiazines	None	True	advise	group	Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
DDI-DrugBank.d480.s4.p0	Clozapine	DB00363	drug	alcohol	None	True	effect	drug	Given the primary CNS effects of Clozapine, caution is advised in using it concomitantly with other CNS-active drugs or alcohol.
DDI-DrugBank.d480.s9.p1	Clozapine	DB00363	drug	atropine	DB00572	True	effect	drug	Clozapine may potentiate the hypotensive effects of antihypertensive drugs and the anticholinergic effects of atropine-type drugs.
DDI-DrugBank.d484.s0.p15	Etonogestrel	DB00294	drug	Sporanox	None	True	int	brand	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d484.s0.p20	Etonogestrel	DB00294	drug	cyclosporine	DB00091	True	int	drug	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d484.s0.p23	Etonogestrel	DB00294	drug	protease inhibitors	None	True	int	group	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d484.s0.p39	Etonogestrel	DB00294	drug	rifampin	None	True	int	drug	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d485.s10.p2	hormonal contraceptives	None	group	coumarin derivatives	None	True	effect	group	Anticoagulants: Combination hormonal contraceptives may increase or decrease the effects of coumarin derivatives.
DDI-DrugBank.d485.s12.p21	phenobarbital	DB01174	drug	progestins	None	True	mechanism	group	Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.
DDI-DrugBank.d485.s12.p24	phenytoin	DB00252	drug	progestins	None	True	mechanism	group	Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.
DDI-DrugBank.d487.s1.p3	phenobarbital	DB01174	drug	corticosteroid	None	True	advise	group	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.
DDI-DrugBank.d487.s1.p5	phenytoin	DB00252	drug	corticosteroids	None	True	mechanism	group	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.
DDI-DrugBank.d487.s7.p0	corticosteroids	None	group	anticoagulants	None	True	effect	group	The effect of corticosteroids on oral anticoagulants is variable.
DDI-DrugBank.d488.s4.p0	heparin	DB01109	drug	antithrombin III	None	True	advise	drug	Thus in order to avoid bleeding, reduced dosage of heparin is recommended during treatment with antithrombin III (human).
DDI-DrugBank.d488.s6.p13	nicotine	DB00184	drug	heparin sodium	None	True	effect	drug	Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.
DDI-DrugBank.d489.s4.p0	beta-blockers	None	group	clonidine	DB00575	True	advise	drug	Should it be decided to discontinue therapy in patients receiving beta-blockers and clonidine concurrently, the beta-blocker should be discontinued slowly over several days before the gradual withdrawal of clonidine.
DDI-DrugBank.d492.s1.p2	Antihistamines	None	group	hypnotics	None	True	effect	group	Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.
DDI-DrugBank.d494.s1.p0	calcium acetate	DB00258	drug	digitalis glycosides	None	True	effect	group	Using calcium acetate with digitalis glycosides (heart medicine) may cause hypercalcemia (too much calcium in the blood), which could increase the chance of developing an irregular heartbeat.
DDI-DrugBank.d495.s0.p0	clonidine hydrochloride	None	drug	tricyclic antidepressants	None	True	effect	group	Tablet If a patient receiving clonidine hydrochloride is also taking tricyclic antidepressants, the effect of clonidine may be reduced, thus necessitating an increase in dosage.
DDI-DrugBank.d495.s1.p0	Clonidine hydrochloride	None	drug	alcohol	None	True	effect	drug	Clonidine hydrochloride may enhance the CNS-depressive effects of alcohol, barbiturates or other sedatives.
DDI-DrugBank.d495.s10.p0	clonidine	DB00575	drug	anesthetics	None	True	effect	group	Epidural clonidine may prolong the duration of pharmacologic effects of epidural local anesthetics, including both sensory and motor blockade.
DDI-DrugBank.d495.s4.p0	Tricyclic antidepressants	None	group	clonidine	DB00575	True	effect	drug	Tricyclic antidepressants may antagonize the hypotensive effects of clonidine.
DDI-DrugBank.d495.s7.p0	clonidine	DB00575	drug	digitalis	None	True	advise	group	Also, due to the potential for additive effects such as bradycardia and AV block, caution is warranted in patients receiving clonidine with agents known to affect sinus node function or AV nodal conduction (e.g., digitalis, calcium channel blockers, and beta-blockers.)
DDI-DrugBank.d5.s17.p3	bupropion	DB01156	drug	desipramine	DB01151	True	advise	drug	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
DDI-DrugBank.d5.s17.p8	bupropion	DB01156	drug	haloperidol	DB00502	True	advise	drug	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
DDI-DrugBank.d500.s3.p0	tetracycline	DB00759	drug	bismuth subsalicylate	DB01294	True	mechanism	drug	Absorption of tetracycline is impaired by bismuth subsalicylate.
DDI-DrugBank.d500.s4.p4	carbamazepine	DB00564	drug	doxycycline	DB00254	True	mechanism	drug	Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.
DDI-DrugBank.d500.s5.p1	tetracycline	DB00759	drug	methoxyflurane	DB01028	True	effect	drug	The concurrent use of tetracycline and Penthrane (methoxyflurane) has been reported to result in fatal renal toxicity.
DDI-DrugBank.d508.s1.p14	Abciximab	DB00054	drug	Activase	None	True	effect	brand	In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole and Abciximab) may increase the risk of bleeding if administered prior to, during, or after Activase therapy.
DDI-DrugBank.d509.s16.p2	quinidine	DB00908	drug	aripiprazole	DB01238	True	advise	drug	Aripiprazole dose should be reduced to one-half of its normal dose when concomitant administration of quinidine with aripiprazole occurs.
DDI-DrugBank.d511.s0.p0	FOSCAVIR	None	brand	pentamidine	DB00738	True	int	drug	A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described.
DDI-DrugBank.d514.s2.p4	heroin	DB01452	drug_n	Valium	None	True	effect	brand	Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.
DDI-DrugBank.d514.s2.p5	heroin	DB01452	drug_n	methadone	DB00333	True	effect	drug	Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.
DDI-DrugBank.d516.s24.p4	Quinolones	None	group	warfarin	DB00682	True	effect	drug	Warfarin: Quinolones may enhance the effects of the oral anticoagulant, warfarin, or its derivatives.
DDI-DrugBank.d516.s3.p34	Videx	None	brand	lomefloxacin	DB00978	True	mechanism	drug	Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.
DDI-DrugBank.d518.s0.p1	barbiturates	None	group	ketamine	DB01221	True	effect	drug	Prolonged recovery time may occur if barbiturates and/or narcotics are used concurrently with ketamine.
DDI-DrugBank.d521.s1.p10	glimepiride	DB00222	drug	bismuth subsalicylate	DB01294	True	advise	drug	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
DDI-DrugBank.d521.s1.p11	glimepiride	DB00222	drug	Pepto-Bismol	None	True	advise	brand	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
DDI-DrugBank.d521.s1.p5	glimepiride	DB00222	drug	Disalcid	None	True	advise	brand	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
DDI-DrugBank.d522.s23.p4	erythromycin	DB00199	drug	dihydroergotamine	DB00320	True	effect	drug	Ergotamine: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.
DDI-DrugBank.d236.s0.p20	ascorbic acid	None	drug	amphetamines	None	True	mechanism	group	Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.
DDI-DrugBank.d236.s20.p2	Amphetamines	None	group	meperidine	None	True	effect	drug	Meperidine: Amphetamines potentiate the analgesic effect of meperidine.
DDI-DrugBank.d236.s28.p2	Amphetamines	None	group	veratrum alkaloids	None	True	effect	group	Veratrum alkaloids: Amphetamines inhibit the hypotensive effect of veratrum alkaloids.
DDI-DrugBank.d237.s11.p2	ranitidine	DB00863	drug	cisapride	DB00604	True	mechanism	drug	The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.
DDI-DrugBank.d237.s14.p2	Cisapride	DB00604	drug	procainamide	DB01035	True	advise	drug	Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);
DDI-DrugBank.d237.s2.p10	erythromycin	DB00199	drug	cisapride	DB00604	True	mechanism	drug	Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
DDI-DrugBank.d237.s7.p12	ketoconazole	DB01026	drug	cisapride	DB00604	True	mechanism	drug	Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
DDI-DrugBank.d241.s1.p1	antiplatelet agents	None	group	FLOLAN	None	True	effect	brand	When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for FLOLAN to increase the risk of bleeding.
DDI-DrugBank.d241.s3.p49	digoxin	DB00390	drug	FLOLAN	None	True	mechanism	brand	In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
DDI-DrugBank.d242.s1.p4	quinolones	None	group	cyclosporine	DB00091	True	effect	drug	However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.
DDI-DrugBank.d246.s0.p0	butorphanol	DB00611	drug	central nervous system depressants	None	True	effect	group	Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.
DDI-DrugBank.d246.s0.p2	butorphanol	DB00611	drug	barbiturates	None	True	effect	group	Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.
DDI-DrugBank.d246.s7.p0	STADOL NS	None	brand	sumatriptan	DB00669	True	effect	drug	These results suggest that the analgesic effect of STADOL NS may be diminished when it is administered shortly after sumatriptan nasal spray, but by 30 minutes any such reduction in effect should be minimal.
DDI-DrugBank.d247.s7.p1	Epinephrine	DB00668	drug	glycosides	None	True	advise	group	Epinephrine also should be used cautiously with other drugs (e.g., digitalis, glycosides) that sensitize the myocardium to the actions of sympathomimetic drugs.
DDI-DrugBank.d249.s1.p4	diclofenac	DB00586	drug	NSAIDs	None	True	advise	group	Anticoagulants: While studies have not shown diclofenac to interact with anticoagulants of the warfarin type, caution should be exercised, nonetheless, since interactions have been seen with other NSAIDs.
DDI-DrugBank.d249.s18.p0	diclofenac	DB00586	drug	salicylic acid	None	True	mechanism	drug	Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.
DDI-DrugBank.d249.s2.p7	diclofenac	DB00586	drug	warfarin	DB00682	True	advise	drug	Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.
DDI-DrugBank.d249.s4.p0	diclofenac	DB00586	drug	digoxin	DB00390	True	mechanism	drug	Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.
DDI-DrugBank.d522.s24.p9	erythromycin	DB00199	drug	lovastatin	DB00227	True	int	drug	Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.
DDI-DrugBank.d529.s2.p5	nonsteroidal anti-inflammatory drugs	None	group	anti-coagulants	None	True	effect	group	Anticoagulants: Flurbiprofen like other nonsteroidal anti-inflammatory drugs, has been shown to affect bleeding parameters in patients receiving anti-coagulants, and serious clinical bleeding has been reported.
DDI-DrugBank.d53.s8.p2	fluconazole	DB00196	drug	azithromycin	DB00207	True	mechanism	drug	Co-administration with efavirenz or fluconazole had a modest effect on the pharmacokinetics of azithromycin.
DDI-DrugBank.d531.s39.p0	indinavir	DB00224	drug	SUSTIVA	None	True	mechanism	brand	When indinavir at an increased dose (1000 mg every 8 hours) was given with SUSTIVA (600 mg once daily), the indinavir AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when indinavir (800 mg every 8 hours) was given alone.
DDI-DrugBank.d533.s4.p3	ketoconazole	DB01026	drug	aliskiren	DB01258	True	mechanism	drug	Ketoconazole: Co-administration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.
DDI-DrugBank.d536.s4.p13	amylase	None	drug	Acarbose	DB00284	True	mechanism	drug	Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.
DDI-DrugBank.d537.s0.p3	Bentiromide	DB00522	drug	Chloromycetin	None	True	int	brand	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
DDI-DrugBank.d537.s0.p6	Bentiromide	DB00522	drug	lidocaine	DB00281	True	int	drug	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
DDI-DrugBank.d54.s14.p0	thyroid	None	group	estrogens	None	True	advise	group	Therefore, patients without a functioning thyroid gland who are on thyroid replacement therapy may need to increase their thyroid dose if estrogens or estrogen-containing oral contraceptives are given.
DDI-DrugBank.d54.s8.p4	Cholestyramine	DB01432	drug	T4	None	True	mechanism	drug	Cholestyramine: Cholestyramine binds both T4 and T3 in the intestine, thus impairing absorption of these thyroid hormones.
DDI-DrugBank.d542.s0.p9	Nicotinic acid	None	drug	ganglionic blocking agents	None	True	effect	group	Interactions for Vitamin B3 (Niacin): Antihypertensive Therapy: Nicotinic acid may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension.
DDI-DrugBank.d544.s3.p0	Simulect	None	brand	azathioprine	DB00993	True	mechanism	drug	Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids.
DDI-DrugBank.d547.s2.p7	lithium	DB01356	drug	ACE inhibitors	None	True	mechanism	group	Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, and with some angiotensin II receptor antagonists.
DDI-DrugBank.d548.s10.p5	TCA	None	group	Duloxetine	DB00476	True	advise	drug	Plasma TCA concentrations may need to be monitored and the dose of the TCA may need to be reduced if a TCA is co-administered with Duloxetine.
DDI-DrugBank.d548.s8.p0	duloxetine	DB00476	drug	desipramine	DB01151	True	mechanism	drug	When duloxetine was administered (at a dose of 60 mg BID) in conjunction with a single 50-mg dose of desipramine, a CYP2D6 substrate, the AUC of desipramine increased 3-fold.
DDI-DrugBank.d548.s9.p0	Duloxetine	DB00476	drug	antidepressants	None	True	advise	group	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
DDI-DrugBank.d548.s9.p9	Duloxetine	DB00476	drug	flecainide	DB01195	True	advise	drug	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
DDI-DrugBank.d549.s1.p0	iloprost	DB01088	drug	vasodilators	None	True	effect	group	However, iloprost has the potential to increase the hypotensive effect of vasodilators and antihypertensive agents.
DDI-DrugBank.d549.s2.p0	iloprost	DB01088	drug	anticoagulants	None	True	effect	group	Since iloprost inhibits platelet function, there is a potential for increased risk of bleeding, particularly in patients maintained on anticoagulants.
DDI-DrugBank.d550.s1.p0	cefditoren pivoxil	None	drug	antacids	None	True	advise	group	Although the clinical significance is not known, it is not recommended that cefditoren pivoxil be taken concomitantly with antacids.
DDI-DrugBank.d551.s2.p1	WelChol	None	brand	Calan SR	None	True	mechanism	brand	WelChol  decreased the Cmax and AUC of sustained-release verapamil (Calan SR ) by approximately 31% and 11%, respectively.
DDI-DrugBank.d552.s0.p2	Nabilone	DB00486	drug	alcohol	None	True	advise	drug	Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).
DDI-DrugBank.d552.s1.p0	Nabilone	DB00486	drug	diazepam	DB00829	True	effect	drug	Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.
DDI-DrugBank.d558.s22.p4	metformin	DB00331	drug	dofetilide	DB00204	True	advise	drug	In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.
DDI-DrugBank.d558.s25.p10	macrolide antibiotics	None	group	TIKOSYN	None	True	advise	brand	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
DDI-DrugBank.d558.s3.p0	Cimetidine	DB00501	drug	dofetilide	DB00204	True	mechanism	drug	Cimetidine at doses of 100 mg BID (OTC dose) resulted in a 13% increase in dofetilide plasma levels (500 mcg single dose).
DDI-DrugBank.d559.s1.p11	acetaminophen	DB00316	drug	alcohol	None	True	effect	drug	Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
DDI-DrugBank.d559.s1.p21	caffeine	DB00201	drug	chlordiazepoxide	DB00475	True	effect	drug	Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
DDI-DrugBank.d560.s1.p0	steroid	None	group	bitolterol	DB00901	True	advise	drug	If you are also using a steroid inhaler, take bitolterol first and then wait about 15 minutes before using the steroid inhaler.
DDI-DrugBank.d561.s9.p0	diuretic	None	group	lithium	DB01356	True	effect	drug	If a diuretic is also used, the risk of lithium toxicity may be increased.
DDI-DrugBank.d562.s0.p0	theophylline	DB00277	drug	quinolones	None	True	mechanism	group	Elevated plasma levels of theophylline have been reported with concomitant use of some quinolones.
DDI-DrugBank.d564.s1.p2	butyrophenones	None	group	epinephrine	DB00668	True	effect	drug	Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.
DDI-DrugBank.d565.s34.p1	midazolam	DB00683	drug	diltiazem	DB00343	True	mechanism	drug	The elimination half life of midazolam and triazolam also increased (1.5-2.5 fold) during coadministration with diltiazem.
DDI-DrugBank.d565.s35.p0	diltiazem	DB00343	drug	midazolam	DB00683	True	effect	drug	These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and triazolam.
DDI-DrugBank.d568.s16.p5	SSRI	None	group	sumatriptan	DB00669	True	effect	drug	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.
DDI-DrugBank.d568.s17.p3	sumatriptan	DB00669	drug	paroxetine	DB00715	True	advise	drug	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.
DDI-DrugBank.d568.s25.p4	citalopram	DB00215	drug	ketoconazole	DB01026	True	mechanism	drug	Ketoconazole - Combined administration of racemic citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.
DDI-DrugBank.d569.s1.p1	Angiomax	None	brand	warfarin	DB00682	True	effect	drug	In clinical trials in patients undergoing PTCA/PCI, co-administration of Angiomax with heparin, warfarin, thrombolytics or glycoprotein IIb/IIIa inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications.
DDI-DrugBank.d569.s1.p2	Angiomax	None	brand	thrombolytics	None	True	effect	group	In clinical trials in patients undergoing PTCA/PCI, co-administration of Angiomax with heparin, warfarin, thrombolytics or glycoprotein IIb/IIIa inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications.
DDI-DrugBank.d572.s0.p2	cholestyramine	DB01432	drug	ezetimibe	DB00973	True	mechanism	drug	Cholestyramine: Concomitant cholestyramine administration decreased the mean AUC of total ezetimibe approximately 55%.
DDI-DrugBank.d576.s5.p0	Salicylates	None	group	antidiabetic drugs	None	True	effect	group	Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class.
DDI-DrugBank.d577.s6.p0	Sulfonamides	None	group	methotrexate	DB00563	True	mechanism	drug	Sulfonamides can also displace methotrexate from plasma protein-binding sites, thus increasing free methotrexate concentrations.
DDI-DrugBank.d578.s4.p8	rifampin	None	drug	methylprednisolone	DB00959	True	advise	drug	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response.
DDI-DrugBank.d585.s0.p13	anticholinergic drugs	None	group	tricyclic antidepressants	None	True	effect	group	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
DDI-DrugBank.d585.s0.p3	anticholinergic drugs	None	group	antihistamines	None	True	effect	group	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
DDI-DrugBank.d585.s0.p7	anticholinergic drugs	None	group	MAO inhibitors	None	True	effect	group	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
DDI-DrugBank.d588.s1.p2	MYKROX	None	brand	antihypertensive drugs	None	True	advise	group	Other Antihypertensives: When MYKROX Tablets are used with other antihypertensive drugs, care must be taken, especially during initial therapy.
DDI-DrugBank.d588.s11.p2	Metolazone	DB00524	drug	norepinephrine	DB00368	True	effect	drug	Sympathomimetics: Metolazone may decrease arterial responsiveness to norepinephrine, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.
DDI-DrugBank.d59.s0.p2	triacetyloleandomycin	None	drug	ergotamine	DB00696	True	mechanism	drug	The effects of ERGOMAR may be potentiated by triacetyloleandomycin which inhibits the metabolism of ergotamine.
DDI-DrugBank.d597.s14.p3	NSAIDs	None	group	furosemide	DB00695	True	effect	drug	Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients.
DDI-DrugBank.d60.s1.p0	NIMBEX	None	brand	succinylcholine	DB00202	True	effect	drug	The time to onset of maximum block following NIMBEX is approximately 2 minutes faster with prior administration of succinylcholine.
DDI-DrugBank.d60.s12.p19	NIMBEX	None	brand	polymyxins	None	True	effect	group	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d60.s12.p23	NIMBEX	None	brand	sodium colistemethate	None	True	effect	drug	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d60.s12.p4	nondepolarizing agents	None	group	bacitracin	DB00626	True	effect	drug	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d60.s12.p8	nondepolarizing agents	None	group	colistin	DB00803	True	effect	drug	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d60.s9.p1	enflurane	DB00228	drug	NIMBEX	None	True	advise	brand	In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.
DDI-DrugBank.d603.s2.p13	ephedrine	DB01364	drug	ProAmatine	None	True	effect	brand	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction.
DDI-DrugBank.d603.s2.p18	dihydroergotamine	DB00320	drug	ProAmatine	None	True	effect	brand	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction.
DDI-DrugBank.d605.s0.p1	SKELAXIN	None	brand	barbiturates	None	True	effect	group	SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.
DDI-DrugBank.d608.s5.p3	nonsteroidal anti-inflammatory drugs	None	group	methotrexate	DB00563	True	mechanism	drug	TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate.
DDI-DrugBank.d611.s0.p1	beta adrenergic aerosol bronchodilators	None	group	metaproterenol sulfate	None	True	advise	drug	Other beta adrenergic aerosol bronchodilators should not be used concomitantly with Alupent    (metaproterenol sulfate USP) because they may have additive effects.
DDI-DrugBank.d613.s1.p0	vigabatrin	DB01080	drug	phenytoin	DB00252	True	mechanism	drug	In 1984, Drs Rimmer and Richens at the University of Wales reported that administering vigabatrin with phenytoin lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy.
DDI-DrugBank.d618.s1.p4	heparin	DB01109	drug	Retavase	None	True	effect	brand	In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.
DDI-DrugBank.d619.s5.p1	selegiline	DB01037	drug	ephedrine	DB01364	True	effect	drug	One case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a sympathomimetic medication (ephedrine).
DDI-DrugBank.d62.s0.p3	Dexbrompheniramine	DB00405	drug	anticholinergics	None	True	int	group	Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
DDI-DrugBank.d622.s2.p2	barbiturates	None	group	anticholinesterases	None	True	effect	group	2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of pralidoxime: since barbiturates are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsions;
DDI-DrugBank.d623.s1.p0	Aminoglutethimide	DB00357	drug	depo-subQ provera 104	None	True	mechanism	brand	Aminoglutethimide administered concomitantly with depo-subQ provera 104 may significantly decrease the serum concentrations of MPA.
DDI-DrugBank.d628.s0.p1	DIPRIVAN	None	brand	morphine	DB00295	True	effect	drug	The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.)
DDI-DrugBank.d631.s3.p0	lorazepam	DB00186	drug	pyrimethamine	DB00205	True	effect	drug	Mild hepatotoxicity has been reported in some patients when lorazepam and pyrimethamine were administered concomitantly.
DDI-DrugBank.d632.s0.p2	SYMLIN	None	brand	alpha glucosidase inhibitors	None	True	advise	group	Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors).
DDI-DrugBank.d110.s5.p0	chloroprocaine	DB01161	drug	sulfonamide drug	None	True	advise	group	Therefore, chloroprocaine should not be used in any condition in which a sulfonamide drug is being employed.
DDI-DrugBank.d114.s2.p17	doxorubicin	DB00997	drug	PROLEUKIN	None	True	effect	brand	Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.
DDI-DrugBank.d114.s5.p2	PROLEUKIN	None	brand	cis-platinum	None	True	effect	drug	Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.
DDI-DrugBank.d115.s0.p13	Gleevec	None	brand	erythromycin	DB00199	True	advise	drug	Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).
DDI-DrugBank.d115.s0.p14	Gleevec	None	brand	clarithromycin	DB01211	True	advise	drug	Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).
DDI-DrugBank.d115.s10.p0	Gleevec	None	brand	benzodiazepines	None	True	mechanism	group	Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.).
DDI-DrugBank.d12.s5.p0	tolbutamide	DB01124	drug	Atromid-S	None	True	effect	brand	The hypoglycemic effect of tolbutamide has been reported to increase when Atromid-S is given concurrently.
DDI-DrugBank.d120.s2.p4	diphenidol	DB01231	drug	apomorphine	DB00714	True	effect	drug	apomorphine - prior ingestion of diphenidol may decrease the emetic response to apomorphine in the treatment of poisoning.
DDI-DrugBank.d122.s3.p1	Chloramphenicol	DB00446	drug	ceftazidime	DB00438	True	effect	drug	Chloramphenicol has been shown to be antagonistic to beta-lactam antibiotics, including ceftazidime, based on in vitro studies and time kill curves with enteric gram-negative bacilli.
DDI-DrugBank.d123.s2.p1	quinolones	None	group	cyclosporine	DB00091	True	effect	drug	Some quinolones, including ciprofloxacin, have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.
DDI-DrugBank.d123.s8.p11	ciprofloxacin	DB00537	drug	aluminum	None	True	mechanism	drug	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
DDI-DrugBank.d123.s8.p12	ciprofloxacin	DB00537	drug	antacids	None	True	mechanism	group	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
DDI-DrugBank.d123.s8.p14	ciprofloxacin	DB00537	drug	VIDEX	None	True	mechanism	brand	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
DDI-DrugBank.d123.s8.p8	quinolone	None	group	zinc	DB01593	True	mechanism	drug	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
DDI-DrugBank.d13.s0.p0	Flupenthixol	None	drug	Monoamine oxidase inhibitors	None	True	int	group	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants
DDI-DrugBank.d131.s0.p1	benzodiazepines	None	group	psychotropic medications	None	True	effect	group	The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.
DDI-DrugBank.d131.s10.p5	benzodiazepines	None	group	nifedipine	DB01115	True	int	drug	Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.
DDI-DrugBank.d131.s10.p6	alprazolam	DB00404	drug	ergotamine	DB00696	True	int	drug	Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.
DDI-DrugBank.d131.s9.p3	alprazolam	DB00404	drug	sertraline	DB01104	True	int	drug	Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine.
DDI-DrugBank.d132.s2.p0	diflunisal	DB00861	drug	anticoagulants	None	True	advise	group	Accordingly, when diflunisal is administered with oral anticoagulants, the prothrombin time should be closely monitored during and for several days after concomitant drug administration.
DDI-DrugBank.d132.s23.p0	diflunisal	DB00861	drug	NSAIDs	None	True	effect	group	The concomitant use of diflunisal tablets and other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.
DDI-DrugBank.d132.s27.p4	diflunisal	DB00861	drug	naproxen	DB00788	True	mechanism	drug	Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.
DDI-DrugBank.d138.s0.p3	ALPHAGAN P	None	brand	opiates	None	True	advise	group	Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.
DDI-DrugBank.d139.s6.p2	Orlistat	DB01083	drug	vitamin K	None	True	mechanism	group	Orlistat-Orlistat may decrease the absorption of vitamin K.
DDI-DrugBank.d140.s10.p4	atorvastatin	DB01076	drug	contraceptive	None	True	mechanism	group	Oral Contraceptives: Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.
DDI-DrugBank.d140.s7.p3	atorvastatin	DB01076	drug	digoxin	DB00390	True	mechanism	drug	Digoxin: When multiple doses of atorvastatin and digoxin were coadministered, steady-state plasma digoxin concentrations increased by approximately 20%.
DDI-DrugBank.d632.s3.p0	analgesics	None	group	SYMLIN	None	True	advise	brand	When the rapid onset of a concomitant orally administered agent is a critical determinant of effectiveness (such as analgesics), the agent should be administered at least 1 hour prior to or 2 hours after SYMLIN injection.
DDI-DrugBank.d632.s6.p5	SYMLIN	None	brand	human insulin	None	True	mechanism	drug	Mixing SYMLIN and Insulin The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection.
DDI-DrugBank.d636.s3.p1	Mephenytoin	DB00532	drug	warfarin	DB00682	True	effect	drug	Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.
DDI-DrugBank.d638.s2.p1	Ritalin	None	brand	anticonvulsants	None	True	mechanism	group	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).
DDI-DrugBank.d638.s2.p5	Ritalin	None	brand	phenylbutazone	DB00812	True	mechanism	drug	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).
DDI-DrugBank.d638.s2.p7	Ritalin	None	brand	imipramine	DB00458	True	mechanism	drug	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).
DDI-DrugBank.d639.s0.p10	SUTENT	None	brand	voriconizole	None	True	mechanism	drug	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
DDI-DrugBank.d639.s0.p2	SUTENT	None	brand	clarithromycin	DB01211	True	mechanism	drug	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
DDI-DrugBank.d141.s5.p0	cholestyramine	DB01432	drug	cerivastatin sodium	None	True	mechanism	drug	However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone.
DDI-DrugBank.d143.s13.p2	amiodarone	DB01118	drug	protease inhibitor	None	True	advise	group	Monitoring for amiodarone toxicity and serial measurement of amiodarone serum concentration during concomitant protease inhibitor therapy should be considered.
DDI-DrugBank.d146.s0.p0	Colchicine	DB01394	drug	acidifying agents	None	True	mechanism	group	Colchicine is inhibited by acidifying agents.
DDI-DrugBank.d148.s6.p0	Argatroban	DB00278	drug	antiplatelet agents	None	True	effect	group	Co-administration: Concomitant use of Argatroban with antiplatelet agents, thrombolytics, and other anticoagulants may increase the risk of bleeding.
DDI-DrugBank.d149.s0.p0	HUMORSOL	None	brand	succinylcholine	DB00202	True	int	drug	Possible drug interactions of HUMORSOL with succinylcholine or with other anticholinesterase agents.
DDI-DrugBank.d151.s0.p1	Folic acid	DB00158	drug	phenytoin	DB00252	True	effect	drug	Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.
DDI-DrugBank.d151.s3.p0	Leucovorin	DB00650	drug	5-fluorouracil	None	True	effect	drug	Leucovorin may enhance the toxicity of 5-fluorouracil.
DDI-DrugBank.d154.s11.p0	Nalfon	None	brand	steroid	None	True	advise	group	In patients receiving Nalfon and a steroid concomitantly, any reduction in steroid dosage should be gradual in order to avoid the possible complications of sudden steroid withdrawal.
DDI-DrugBank.d154.s4.p0	phenobarbital	DB01174	drug	Nalfon	None	True	advise	brand	When phenobarbital is added to or withdrawn from treatment, dosage adjustment of Nalfon may be required.
DDI-DrugBank.d158.s3.p8	Amphetamines	None	group	sympathomimetic agents	None	True	effect	group	Antidepressants, tricyclic Amphetamines may enhance the activity of tricyclic antidepressants or sympathomimetic agents;
DDI-DrugBank.d158.s4.p1	d-amphetamine	None	drug	protriptyline	DB00344	True	mechanism	drug	d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;
DDI-DrugBank.d158.s6.p5	furazolidone	DB00614	drug	amphetamine	DB00182	True	mechanism	drug	MAO inhibitors MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.
DDI-DrugBank.d160.s1.p0	ethambutol	DB00330	drug	aluminum hydroxide	DB06723	True	advise	drug	It is recommended to avoid concurrent administration of ethambutol with aluminum hydroxide containing antacids for at least 4 hours following ethambutol administration.
DDI-DrugBank.d162.s12.p5	non-steroidal anti-inflammatory agent	None	group	potassium-sparing diuretics	None	True	effect	group	Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.
DDI-DrugBank.d163.s4.p4	progesterone	DB00396	drug	Accutane	None	True	effect	brand	Micro-dosed Progesterone Preparations: Micro-dosed progesterone preparations (minipills that do not contain an estrogen) may be an inadequate method of contraception during Accutane therapy.
DDI-DrugBank.d166.s0.p0	Trecator	None	brand	isoniazid	DB00951	True	mechanism	drug	Trecator has been found to temporarily raise serum concentrations of isoniazid.
DDI-DrugBank.d17.s28.p0	Thiazides	None	group	norepinephrine	DB00368	True	effect	drug	(Thiazides may decrease arterial responsiveness to norepinephrine.
DDI-DrugBank.d170.s2.p5	fentanyl	DB00813	drug	nelfinavir	DB00220	True	mechanism	drug	The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.
DDI-DrugBank.d170.s5.p29	fentanyl	DB00813	drug	anesthetics	None	True	effect	group	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
DDI-DrugBank.d171.s0.p0	Tagamet	None	brand	warfarin-type anticoagulants	None	True	mechanism	group	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
DDI-DrugBank.d171.s0.p3	Tagamet	None	brand	nifedipine	DB01115	True	mechanism	drug	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
DDI-DrugBank.d171.s0.p4	Tagamet	None	brand	chlordiazepoxide	DB00475	True	mechanism	drug	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
DDI-DrugBank.d172.s10.p0	CELEBREX	None	brand	ACE-inhibitors	None	True	advise	group	This interaction should be given consideration in patients taking CELEBREX concomitantly with ACE-inhibitors.
DDI-DrugBank.d176.s9.p19	aluminum hydroxide	DB06723	drug	fosinopril	DB00492	True	mechanism	drug	Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.
DDI-DrugBank.d18.s0.p1	benzodiazepines	None	group	barbiturates	None	True	effect	group	Tablets: The benzodiazepines, including lorazepam, produce CNS-depressant effects when administered with such medications as barbiturates or alcohol.
DDI-DrugBank.d18.s1.p2	Lorazepam	DB00186	drug	phenothiazines	None	True	effect	group	Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
DDI-DrugBank.d180.s1.p5	norepinephrine	DB00368	drug	Bretylium Tosylate	None	True	effect	drug	The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium Tosylate.
DDI-DrugBank.d185.s6.p0	dapsone	DB00250	drug	folic acid antagonists	None	True	effect	group	With oral dapsone treatment, folic acid antagonists such as pyrimethamine have been noted to possibly increase the likelihood of hematologic reactions
DDI-DrugBank.d186.s3.p2	antipsychotic agents	None	group	anesthetics	None	True	effect	group	As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.
DDI-DrugBank.d19.s7.p0	isoniazid	DB00951	drug	disulfiram	DB00822	True	advise	drug	Patients taking isoniazid when disulfiram is given should be observed for the appearance of unsteady gait or marked changes in mental status;
DDI-DrugBank.d192.s0.p1	Dexbrompheniramine	DB00405	drug	CNS depressants	None	True	effect	group	Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
DDI-DrugBank.d197.s1.p26	PRECEDEX	None	brand	anesthetics	None	True	effect	group	Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.
DDI-DrugBank.d197.s1.p28	PRECEDEX	None	brand	hypnotics	None	True	effect	group	Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.
DDI-DrugBank.d198.s31.p0	Vardenafil	DB00862	drug	terazosin	DB01162	True	effect	drug	When Vardenafil dosing was separated from terazosin 10 mg by 6 hours, 7 of 28 subjects who received 20 mg of Vardenafil experienced a decrease in standing systolic blood pressure below 85 mm Hg.
DDI-DrugBank.d198.s36.p7	Vardenafil	DB00862	drug	ritonavir	DB00503	True	mechanism	drug	Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.
DDI-DrugBank.d198.s37.p0	Vardenafil	DB00862	drug	indinavir	DB00224	True	mechanism	drug	Upon administration of 10 mg of Vardenafil with 800 mg TID indinavir, the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.
DDI-DrugBank.d198.s8.p0	Vardenafil	DB00862	drug	ketoconazole	DB01026	True	advise	drug	A 5-mg Vardenafil dose should not be exceeded when used in combination with 200 mg once daily ketoconazole.
DDI-DrugBank.d199.s0.p3	MONUROL	None	brand	metoclopramide	DB01233	True	mechanism	drug	Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.
DDI-DrugBank.d20.s1.p0	INSPRA	None	brand	ketoconazole	DB01026	True	mechanism	drug	A pharmacokinetic study evaluating the administration of a single dose of INSPRA 100 mg with ketoconazole 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of eplerenone and a 5.4-fold increase in AUC of eplerenone.
DDI-DrugBank.d202.s16.p0	tricyclic antidepressants	None	group	antidepressants	None	True	advise	group	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.
DDI-DrugBank.d202.s16.p2	tricyclic antidepressants	None	group	carbamazepine	DB00564	True	advise	drug	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.
DDI-DrugBank.d202.s9.p1	nortriptyline hydrochloride	None	drug	sympathomimetic drugs	None	True	advise	group	Close supervision and careful adjustment of the dosage are required when nortriptyline hydrochloride is used with other anticholinergic drugs or sympathomimetic drugs.
DDI-DrugBank.d205.s0.p15	ethosuximide	DB00593	drug	phenytoin	DB00252	True	mechanism	drug	Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).
DDI-DrugBank.d205.s0.p20	valproic acid	DB00313	drug	ethosuximide	DB00593	True	mechanism	drug	Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).
DDI-DrugBank.d210.s0.p2	NSAIDs	None	group	Angiotensin Converting Enzyme (ACE) inhibitors	None	True	effect	group	ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors.
DDI-DrugBank.d210.s16.p3	NSAIDs	None	group	lithium	DB01356	True	mechanism	drug	Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.
DDI-DrugBank.d217.s5.p3	norfloxacin	DB01059	drug	anticoagulants	None	True	effect	group	Quinolones, including norfloxacin, may enhance the effects of oral anticoagulants, including warfarin or its derivatives or similar agents.
DDI-DrugBank.d219.s11.p1	Lodine	None	brand	thiazides	None	True	effect	group	Nevertheless, clinical studies, as well as postmarketing observations have shown that Lodine can reduce the natriuretic effect of furosemide and thiazides in some patients.
DDI-DrugBank.d219.s15.p3	NSAIDs	None	group	lithium	DB01356	True	mechanism	drug	Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.
DDI-DrugBank.d219.s6.p2	Lodine	None	brand	aspirin	None	True	advise	brand	however, as with other NSAIDs, concomitant administration of Lodine and aspirin is not generally recommended because of the potential of increased adverse effects.
DDI-DrugBank.d219.s7.p4	NSAIDs	None	group	cyclosporine	DB00091	True	mechanism	drug	Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.
DDI-DrugBank.d22.s0.p0	Aminosalicylic acid	DB00233	drug	digoxin	DB00390	True	mechanism	drug	Aminosalicylic acid may decrease the amount of digoxin (Lanoxin, Lanoxicaps) that gets absorbed into your body.
DDI-DrugBank.d22.s2.p0	Aminosalicylic acid	DB00233	drug	vitamin B12	None	True	mechanism	drug	Aminosalicylic acid may also decrease the absorption of vitamin B12, which can lead to a deficiency.
DDI-DrugBank.d220.s16.p0	Mefloquine	DB00358	drug	anticoagulants	None	True	advise	group	Nevertheless, the effects of Mefloquine on travelers receiving comedication, particularly diabetics or patients using anticoagulants, should be checked before departure.
DDI-DrugBank.d220.s5.p2	Mefloquine	DB00358	drug	chloroquine	DB00608	True	effect	drug	Concomitant administration of Mefloquine and other related compounds (eg, quinine, quinidine and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.
DDI-DrugBank.d220.s9.p2	Mefloquine	DB00358	drug	calcium channel blockers	None	True	effect	group	This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.
DDI-DrugBank.d223.s10.p0	TCAs	None	group	SSRIs	None	True	advise	group	Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other.
DDI-DrugBank.d223.s26.p2	alcohol	None	drug	SINEQUAN	None	True	mechanism	brand	Alcohol: It should be borne in mind that alcohol ingestion may increase the danger inherent in any intentional or unintentional SINEQUAN overdosage.
DDI-DrugBank.d224.s1.p4	IOPIDINE	None	brand	sedatives	None	True	advise	group	Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.
DDI-DrugBank.d225.s0.p2	sulfonylureas	None	group	salicylates	None	True	effect	group	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
DDI-DrugBank.d227.s0.p1	Isoflurane	DB00753	drug	nondepolarizing muscle relaxants	None	True	effect	group	Isoflurane potentiates the muscle relaxant effect of all muscle relaxants, most notably nondepolarizing muscle relaxants, and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O.
DDI-DrugBank.d236.s0.p19	glutamic acid HCl	None	drug	amphetamines	None	True	mechanism	group	Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.
DDI-DrugBank.d236.s1.p2	Urinary acidifying agents	None	group	amphetamine	DB00182	True	mechanism	drug	Urinary acidifying agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.
DDI-DrugBank.d236.s16.p3	Chlorpromazine	DB00477	drug	amphetamines	None	True	effect	group	Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat amphetamine poisoning.
DDI-DrugBank.d236.s17.p2	Amphetamines	None	group	ethosuximide	DB00593	True	mechanism	drug	Ethosuximide: Amphetamines may delay intestinal absorption of ethosuximide.
DDI-DrugBank.d236.s23.p2	Amphetamines	None	group	phenobarbital	DB01174	True	mechanism	drug	Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;
DDI-DrugBank.d236.s3.p2	Adrenergic blockers	None	group	amphetamines	None	True	effect	group	Adrenergic blockers: Adrenergic blockers are inhibited by amphetamines.
DDI-DrugBank.d236.s4.p0	sodium bicarbonate	DB01390	drug	amphetamines	None	True	mechanism	drug	Alkalinizing agents: Gastrointestinal alkalinizing agents (sodium bicarbonate, etc.) increase absorption of amphetamines.
DDI-DrugBank.d237.s14.p0	Cisapride	DB00604	drug	antiarrhythmics	None	True	advise	group	Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);
DDI-DrugBank.d237.s2.p7	clarithromycin	DB01211	drug	cisapride	DB00604	True	mechanism	drug	Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
DDI-DrugBank.d237.s5.p0	cisapride	DB00604	drug	anticoagulant	None	True	advise	group	It is advisable to check coagulation time within the first few days after the start and discontinuation of cisapride therapy, with an appropriate adjustment of the anticoagulant dose, if necessary.
DDI-DrugBank.d237.s6.p3	nefazodone	DB01149	drug	cisapride	DB00604	True	mechanism	drug	Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
DDI-DrugBank.d238.s4.p3	tricyclic antidepressants	None	group	tricyclic antidepressants	None	True	effect	group	Several tricyclic antidepressants have been reported to block the pharmacologic effects of guanethidine, clonidine, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.
DDI-DrugBank.d238.s7.p0	CMI	None	drug	phenobarbital	DB01174	True	mechanism	drug	Administration of CMI has been reported to increase the plasma levels of phenobarbital, if given concomitantly.
DDI-DrugBank.d241.s0.p2	FLOLAN	None	brand	vasodilators	None	True	effect	group	Additional reductions in blood pressure may occur when FLOLAN is administered with diuretics, antihypertensive agents, or other vasodilators.
DDI-DrugBank.d241.s5.p1	digoxin	DB00390	drug	FLOLAN	None	True	mechanism	brand	However, patients on digoxin may show elevations of digoxin concentrations after initiation of therapy with FLOLAN, which may be clinically significant in patients prone to digoxin toxicity.
DDI-DrugBank.d245.s0.p7	sulfonylurea	None	group	beta adrenergic blocking agents	None	True	effect	group	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
DDI-DrugBank.d247.s5.p1	epinephrine	DB00668	drug	halogenated hydrocarbon general anesthetics	None	True	effect	group	Administration of epinephrine to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..
DDI-DrugBank.d249.s0.p9	diclofenac	DB00586	drug	aspirin	None	True	mechanism	brand	Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.
DDI-DrugBank.d249.s13.p0	diclofenac	DB00586	drug	insulin	None	True	effect	drug	A direct causal relationship has not been established, but physicians should consider the possibility that diclofenac may alter a diabetic patient s response to insulin or oral hypoglycemic agents.
DDI-DrugBank.d249.s14.p5	NSAIDs	None	group	diuretics	None	True	effect	group	Diuretics: Diclofenac and other NSAIDs can inhibit the activity of diuretics.
DDI-DrugBank.d249.s9.p0	diclofenac	DB00586	drug	lithium	DB01356	True	effect	drug	In patients taking diclofenac and lithium concomitantly, lithium toxicity may develop.
DDI-DrugBank.d252.s4.p1	beta-adrenergic blocking agents	None	group	calcium antagonist	None	True	effect	group	The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects on prolonging atrioventricular conduction time.
DDI-DrugBank.d257.s0.p0	Levo-Dromoran	None	brand	central nervous system depressants	None	True	effect	group	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
DDI-DrugBank.d257.s0.p7	Levo-Dromoran	None	brand	tricyclic antidepressants	None	True	effect	group	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
DDI-DrugBank.d257.s0.p9	Levo-Dromoran	None	brand	tranquilizers	None	True	effect	group	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
DDI-DrugBank.d257.s6.p20	pentazocine	DB00652	drug	Levo-Dromoran	None	True	advise	brand	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.
DDI-DrugBank.d260.s0.p27	Probenecid	DB01032	drug	theophylline	DB00277	True	mechanism	drug	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
DDI-DrugBank.d261.s0.p1	Tetracycline	DB00759	drug	penicillin	None	True	effect	drug	Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.
DDI-DrugBank.d263.s16.p0	pentamidine	DB00738	drug	HIVID	None	True	effect	drug	Death due to fulminant pancreatitis possibly related to intravenous pentamidine and HIVID has been reported.
DDI-DrugBank.d263.s18.p25	aminoglycosides	None	group	HIVID	None	True	effect	drug	Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).
DDI-DrugBank.d263.s20.p10	probenecid	DB01032	drug	zalcitabine	DB00943	True	mechanism	drug	Probenecid or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.
DDI-DrugBank.d263.s24.p2	zalcitabine	DB00943	drug	metoclopramide	DB01233	True	mechanism	drug	Metoclopramide: Bioavailability is mildly reduced (approximately 10%) when zalcitabine and metoclopramide are coadministered.
DDI-DrugBank.d267.s5.p13	NUROMAX	None	brand	quinidine	DB00908	True	effect	drug	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d269.s10.p2	carvedilol	DB01136	drug	cyclosporine	DB00091	True	advise	drug	Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of carvedilol therapy and that the dose of cyclosporine be adjusted as appropriate.
DDI-DrugBank.d269.s18.p8	Agents with b-blocking properties	None	group	hypoglycemics	None	True	effect	group	Insulin or Oral Hypoglycemics: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics.
DDI-DrugBank.d270.s11.p0	warfarin	DB00682	drug	nevirapine	DB00238	True	advise	drug	When warfarin is co-administered with nevirapine, anticoagulation levels should be monitored frequently.
DDI-DrugBank.d270.s39.p1	lopinavir	DB01601	drug	nevirapine	DB00238	True	advise	drug	A dose increase of lopinavir/ritonavir to 533/133 mg twice daily with food isrecommended in combination with nevirapine.
DDI-DrugBank.d272.s1.p1	Bromocriptine mesylate	None	drug	butyrophenones	None	True	int	group	Bromocriptine mesylate may interact with dopamine antagonists, butyrophenones, and certain other agents.
DDI-DrugBank.d276.s2.p2	Uricosuric drugs	None	group	nitrofurantoin	DB00698	True	mechanism	drug	Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.
DDI-DrugBank.d276.s2.p5	sulfinpyrazone	DB01138	drug	nitrofurantoin	DB00698	True	mechanism	drug	Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.
DDI-DrugBank.d282.s0.p2	DOSTINEX	None	brand	thioxanthines	None	True	advise	group	DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.
DDI-DrugBank.d283.s4.p5	TRICOR	None	brand	bile acid binding resin	None	True	mechanism	group	Resins: Since bile acid sequestrants may bind other drugs given concurrently, patients should take TRICOR at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption.
DDI-DrugBank.d284.s0.p0	adrenergic drugs	None	group	BROVANA	None	True	advise	brand	If additional adrenergic drugs are to be administered by any route, they should be used with caution because the pharmacologically predictable sympathetic effects of BROVANA may be potentiated.
DDI-DrugBank.d284.s4.p7	thiazide diuretics	None	group	beta-agonists	None	True	effect	group	The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded.
DDI-DrugBank.d286.s2.p1	ethoxzolamide	DB00311	drug	amphotericin B	DB00681	True	effect	drug	Coadministration of ethoxzolamide with other diuretics, amphotericin B, and corticosteroids may cause hypokalemia.
DDI-DrugBank.d288.s1.p2	TAXOL	None	brand	cisplatin	DB00515	True	mechanism	drug	Pharmacokinetic data from these patients demonstrated a decrease in paclitaxel clearance of approximately 33% when TAXOL was administered following cisplatin.
DDI-DrugBank.d288.s5.p5	paclitaxel	DB01229	drug	doxorubicin	DB00997	True	mechanism	drug	Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite doxorubicinol) may be increased when paclitaxel and doxorubicin are used in combination.
DDI-DrugBank.d289.s13.p0	bosentan	DB00559	drug	cyclosporine A	None	True	mechanism	drug	Co-administration of bosentan decreased the plasma concentrations of cyclosporine A (a CYP3A4 substrate) by approximately 50%.
DDI-DrugBank.d289.s25.p5	bosentan	DB00559	drug	simvastatin	DB00641	True	mechanism	drug	Simvastatin and Other Statins: Co-administration of bosentan decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.
DDI-DrugBank.d289.s30.p4	bosentan	DB00559	drug	R-warfarin	None	True	mechanism	drug	Warfarin: Co-administration of bosentan 500 mg b.i.d. for 6 days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29 and 38%, respectively.
DDI-DrugBank.d29.s12.p1	esomeprazole	DB00736	drug	iron	DB01592	True	mechanism	drug	Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).
DDI-DrugBank.d29.s6.p0	proton pump inhibitors	None	group	warfarin	DB00682	True	effect	drug	Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.
DDI-DrugBank.d291.s0.p9	Bezalip retard	None	brand	anticoagulants of the coumarin type	None	True	effect	group	When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of anticoagulants of the coumarin type.
DDI-DrugBank.d291.s11.p3	MAO-inhibitors	None	group	Bezalip	None	True	advise	brand	Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.
DDI-DrugBank.d291.s9.p2	Bezalip	None	brand	cholestryramine	None	True	advise	drug	When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired
DDI-DrugBank.d296.s1.p0	MAO inhibitors	None	group	antihistamines	None	True	effect	group	MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines.
DDI-DrugBank.d299.s1.p3	ergotamine	DB00696	drug	AXERT	None	True	advise	brand	Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.
DDI-DrugBank.d299.s11.p11	ritonavir	DB00503	drug	almotriptan	DB00918	True	advise	drug	Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.
DDI-DrugBank.d299.s2.p2	moclobemide	DB01171	drug	almotriptan	DB00918	True	mechanism	drug	Monoamine Oxidase Inhibitors: Coadministration of moclobemide resulted in a 27% decrease in almotriptan clearance and an increase in Cmax of approximately 6%.
DDI-DrugBank.d3.s18.p6	TORADOL	None	brand	carbamazepine	DB00564	True	effect	drug	Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (phenytoin, carbamazepine).
DDI-DrugBank.d3.s19.p6	TORADOL	None	brand	fluoxetine	DB00472	True	effect	drug	Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).
DDI-DrugBank.d304.s0.p1	cholestyramine	DB01432	drug	thiazide diuretics	None	True	effect	group	May interact with the following: cholestyramine, colestipol (use with thiazide diuretics may prevent the diuretic from working properly;
DDI-DrugBank.d305.s6.p1	dantrolene sodium	None	drug	verapamil	DB00661	True	advise	drug	It is recommended that the combination of intravenous dantrolene sodium and calcium channel blockers, such as verapamil, not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established.
DDI-DrugBank.d308.s1.p0	central nervous system depressants	None	group	hydroxyzine	DB00557	True	advise	drug	Therefore when central nervous system depressants are administered concomitantly with hydroxyzine their dosage should be reduced.
DDI-DrugBank.d310.s0.p0	calcium channel blockers	None	group	Nimotop	None	True	effect	brand	It is possible that the cardiovascular action of other calcium channel blockers could be enhanced by the addition of Nimotop .
DDI-DrugBank.d314.s17.p5	Estrogens	None	group	corticosteroids	None	True	mechanism	group	Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.
DDI-DrugBank.d314.s18.p3	barbiturates	None	group	corticosteroids	None	True	mechanism	group	Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.
DDI-DrugBank.d314.s19.p2	ketoconazole	DB01026	drug	corticosteroids	None	True	mechanism	group	Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.
DDI-DrugBank.d314.s22.p3	Ketoconazole	DB01026	drug	corticosteroids	None	True	mechanism	group	Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects.
DDI-DrugBank.d318.s12.p4	amphotericin B	DB00681	drug	tubocurarine	DB01199	True	effect	drug	Skeletal muscle relaxants: amphotericin B-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., tubocurarine).
DDI-DrugBank.d32.s7.p1	ranitidine	DB00863	drug	ceftibuten	DB01415	True	mechanism	drug	however, 150 mg of ranitidine q12h for 3 days increased the ceftibuten C max by 23% and ceftibuten AUC by 16%.
DDI-DrugBank.d320.s3.p2	levobupivacaine	DB01002	drug	rifampin	None	True	mechanism	drug	Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;
DDI-DrugBank.d321.s4.p3	Albendazole sulfoxide	None	drug	cimetidine	DB00501	True	mechanism	drug	Cimetidine: Albendazole sulfoxide concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with cimetidine (10 mg/kg/day) (n=7) compared with albendazole (20 mg/kg/day) alone (n=12).
DDI-DrugBank.d322.s0.p4	tricyclic antidepressants	None	group	clidinium	DB00771	True	effect	drug	Amantadine, tricyclic antidepressants, and MAOIs may increase anticholinergic effect of clidinium.
DDI-DrugBank.d324.s20.p0	zaleplon	DB00962	drug	erythromycin	DB00199	True	mechanism	drug	Coadministration of single, oral doses of zaleplon with erythromycin (10 mg and 800 mg, respectively), a strong, selective CYP3A4 inhibitor produced a 34% increase in zaleplons maximal plasma concentrations and a 20% increase in the area under the plasma concentration-time curve.
DDI-DrugBank.d324.s28.p2	Cimetidine	DB00501	drug	zaleplon	DB00962	True	mechanism	drug	Drugs That Inhibit Both Aldehyde Oxidase and CYP3A4 Cimetidine: Cimetidine inhibits both aldehyde oxidase (in vitro) and CYP3A4 (in vitro and in vivo), the primary and secondary enzymes, respectively, responsible for zaleplon metabolism.
DDI-DrugBank.d325.s1.p0	MAO inhibitors	None	group	dopamine HCl	None	True	advise	drug	Patients who have been treated with MAO inhibitors within two to three weeks prior to the administration of dopamine HCl should receive initial doses of dopamine HCl no greater than one-tenth (1/10) of the usual dose.
DDI-DrugBank.d325.s4.p1	dopamine	DB00988	drug	propranolol	DB00571	True	effect	drug	Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.
DDI-DrugBank.d325.s8.p3	halogenated hydrocarbon anesthetics	None	group	catecholamines	None	True	effect	group	Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.
DDI-DrugBank.d328.s13.p0	valdecoxib	DB00580	drug	phenytoin	DB00252	True	advise	drug	Patients already stabilized on valdecoxib should be closely monitored for loss of symptom control with phenytoin coadministration.
DDI-DrugBank.d328.s20.p3	Valdecoxib	DB00580	drug	lithium	DB01356	True	mechanism	drug	Lithium: Valdecoxib 40 mg BID for 7 days produced significant decreases in lithium serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone.
DDI-DrugBank.d328.s28.p0	valdecoxib	DB00580	drug	ketoconazole	DB01026	True	mechanism	drug	Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.
DDI-DrugBank.d329.s1.p0	ertapenem	DB00303	drug	probenecid	DB01032	True	mechanism	drug	Based on total ertapenem concentrations, probenecid increased the AUC by 25% and reduced the plasma and renal clearances by 20% and 35%, respectively.
DDI-DrugBank.d330.s2.p3	neomycin	DB00994	drug	5-fluorouracil	None	True	mechanism	drug	Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.
DDI-DrugBank.d331.s0.p0	bumetanide	DB00887	drug	aminoglycoside antibiotics	None	True	advise	group	Drugs with ototoxic potential: Especially in The presence of impaired renal function, The use of parenterally administered bumetanide in patients to whom aminoglycoside antibiotics are also being given should be avoided, except in life-threatening conditions.
DDI-DrugBank.d331.s3.p4	Lithium	DB01356	drug	diuretics	None	True	advise	group	Lithium: Lithium should Generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of Lithium toxicity.
DDI-DrugBank.d331.s3.p5	Lithium	DB01356	drug	bumetanide	DB00887	True	advise	drug	Lithium: Lithium should Generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of Lithium toxicity.
DDI-DrugBank.d331.s6.p0	probenecid	DB01032	drug	bumetanide	DB00887	True	advise	drug	Thus, probenecid should not be administered concurrently with bumetanide.
DDI-DrugBank.d331.s9.p2	Bumetanide	DB00887	drug	antihypertensive drugs	None	True	effect	group	Antihypertensives: bumetanide may potentiate The effect of various antihypertensive Drugs, necessitating a reduction in The dosage of these drugs.
DDI-DrugBank.d333.s7.p6	benzodiazepine class	None	group	thioxanthene classes of antipsychotic agents	None	True	effect	group	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
DDI-DrugBank.d334.s15.p0	PRINIVIL	None	brand	potassium-sparing diuretics	None	True	effect	group	Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
DDI-DrugBank.d334.s15.p4	PRINIVIL	None	brand	potassium	DB01345	True	effect	drug	Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
DDI-DrugBank.d335.s3.p4	benzodiazepines	None	group	antidepressants	None	True	effect	group	The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.
DDI-DrugBank.d338.s4.p2	estazolam	DB01215	drug	rifampin	None	True	mechanism	drug	While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.
DDI-DrugBank.d338.s8.p5	benzodiazepines	None	group	macrolide antibiotics	None	True	mechanism	group	The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, diltiazem, isoniazide, and some macrolide antibiotics.
DDI-DrugBank.d340.s32.p3	rifampin	None	drug	VIRACEPT	None	True	mechanism	brand	Rifampin: Coadministration of rifampin and VIRACEPT resulted in an 82% decrease in nelfinavir plasma A.C.
DDI-DrugBank.d340.s6.p2	VIRACEPT	None	brand	quinidine	DB00908	True	advise	drug	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
DDI-DrugBank.d344.s0.p0	calcium	DB01373	drug	L-lysine	DB00123	True	mechanism	drug	Concomitant use of calcium supplements and L-lysine may increase calcium absorption
DDI-DrugBank.d346.s4.p0	REVIA	None	brand	opioid	None	True	effect	group	Patients taking REVIA may not benefit from opioid containing medicines, such as cough and cold preparations, antidiarrheal preparations, and opioid analgesics.
DDI-DrugBank.d347.s1.p0	FACTIVE	None	brand	calcium carbonate	DB06724	True	mechanism	drug	Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.
DDI-DrugBank.d347.s1.p2	FACTIVE	None	brand	omeprazole	DB00338	True	mechanism	drug	Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.
DDI-DrugBank.d249.s5.p11	NSAID	None	group	cyclosporine	DB00091	True	effect	drug	Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.
DDI-DrugBank.d249.s5.p2	diclofenac	DB00586	drug	digoxin	DB00390	True	effect	drug	Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.
DDI-DrugBank.d25.s0.p0	Corticotropin	DB01285	drug	diuretic	None	True	effect	drug	Corticotropin may accentuate the electrolyte loss associated with diuretic therapy.
DDI-DrugBank.d250.s2.p14	succinylcholine	DB00202	drug	Coly-Mycin M	None	True	effect	brand	Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.
DDI-DrugBank.d250.s3.p0	Sodium cephalothin	None	drug	Coly-Mycin M	None	True	effect	brand	Sodium cephalothin may enhance the nephrotoxicity of Coly-Mycin M Parenteral.
DDI-DrugBank.d250.s4.p0	sodium cephalothin	None	drug	Coly-Mycin M	None	True	advise	brand	The concomitant use of sodium cephalothin and Coly-Mycin M Parenteral should be avoided.
DDI-DrugBank.d252.s1.p0	beta-blocker	None	group	reserpine	DB00206	True	advise	drug	Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope or postural hypotension.
DDI-DrugBank.d254.s0.p4	CNS depressant drugs	None	group	INAPSINE	None	True	effect	brand	Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.
DDI-DrugBank.d254.s2.p0	INAPSINE	None	brand	CNS depressant drugs	None	True	advise	group	Following the administration of INAPSINE, the dose of other CNS depressant drugs should be reduced.
DDI-DrugBank.d258.s4.p0	erythromycin	DB00199	drug	loratadine	DB00455	True	mechanism	drug	Plasma concentrations (AUC 0-24 hrs) of erythromycin decreased 15% with coadministration of loratadine relative to that observed with erythromycin alone.
DDI-DrugBank.d223.s25.p5	cimetidine	DB00501	drug	tricyclic antidepressant	None	True	mechanism	group	In patients who have been reported to be well controlled on tricyclic antidepressants receiving concurrent cimetidine therapy, discontinuation of cimetidine has been reported to decrease established steady-state serum tricyclic antidepressant levels and compromise their therapeutic effects.
DDI-DrugBank.d223.s9.p0	SSRI	None	group	TCA	None	True	int	group	The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.
DDI-DrugBank.d224.s1.p0	IOPIDINE	None	brand	CNS depressants	None	True	advise	group	Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.
DDI-DrugBank.d224.s1.p5	IOPIDINE	None	brand	anesthetics	None	True	advise	group	Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.
DDI-DrugBank.d225.s0.p0	sulfonylureas	None	group	nonsteroidal anti-inflammatory agents	None	True	effect	group	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
DDI-DrugBank.d225.s0.p8	sulfonylureas	None	group	beta adrenergic blocking agents	None	True	effect	group	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
DDI-DrugBank.d225.s9.p0	miconazole	DB01110	drug	hypoglycemic agents	None	True	int	group	A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.
DDI-DrugBank.d227.s0.p0	Isoflurane	DB00753	drug	muscle relaxants	None	True	effect	group	Isoflurane potentiates the muscle relaxant effect of all muscle relaxants, most notably nondepolarizing muscle relaxants, and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O.
DDI-DrugBank.d228.s2.p3	Antizol	None	brand	ketoconazole	DB01026	True	mechanism	drug	Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied
DDI-DrugBank.d231.s17.p0	indomethacin	DB00328	drug	furosemide	DB00695	True	advise	drug	Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.
DDI-DrugBank.d236.s0.p10	Gastrointestinal acidifying agents	None	group	amphetamines	None	True	mechanism	group	Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.
DDI-DrugBank.d236.s1.p4	ammonium chloride	None	drug	amphetamine	DB00182	True	mechanism	drug	Urinary acidifying agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.
DDI-DrugBank.d236.s1.p5	sodium acid phosphate	None	drug	amphetamine	DB00182	True	mechanism	drug	Urinary acidifying agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.
DDI-DrugBank.d236.s14.p2	Amphetamines	None	group	antihistamines	None	True	effect	group	Antihistamines: Amphetamines may counteract the sedative effect of antihistamines.
DDI-DrugBank.d236.s25.p2	Amphetamines	None	group	phenytoin	DB00252	True	mechanism	drug	Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;
DDI-DrugBank.d236.s27.p2	propoxyphene	None	drug	amphetamine	DB00182	True	effect	group	Propoxyphene: In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.
DDI-DrugBank.d236.s5.p1	acetazolamide	DB00819	drug	amphetamine	DB00182	True	mechanism	drug	Urinary alkalinizing agents (acetazolamide, some thiazides) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion.
DDI-DrugBank.d236.s7.p7	Amphetamines	None	group	tricyclic	None	True	effect	group	Antidepressants, tricyclic: Amphetamines may enhance the activity of tricyclic or sympathomimetic agents;
DDI-DrugBank.d236.s7.p8	Amphetamines	None	group	sympathomimetic agents	None	True	effect	group	Antidepressants, tricyclic: Amphetamines may enhance the activity of tricyclic or sympathomimetic agents;
DDI-DrugBank.d236.s8.p2	d-amphetamine	None	drug	tricyclics	None	True	mechanism	group	d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;
DDI-DrugBank.d237.s12.p5	indinavir	DB00224	drug	cisapride	DB00604	True	mechanism	drug	Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
DDI-DrugBank.d237.s3.p6	anticholinergic compounds	None	group	cisapride	DB00604	True	effect	drug	Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.
DDI-DrugBank.d237.s3.p8	belladonna alkaloids	None	group	cisapride	DB00604	True	effect	drug	Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.
DDI-DrugBank.d237.s9.p0	cisapride	DB00604	drug	ketoconazole	DB01026	True	effect	drug	A study in 14 normal male and female volunteers suggests that coadministration of cisapride and ketoconazole can result in prolongation of the QT interval on the ECG.
DDI-DrugBank.d238.s18.p0	SSRI	None	group	TCA	None	True	int	group	The extent to which SSRI-TCAinteractions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.
DDI-DrugBank.d238.s3.p1	Anafranil	None	brand	sympathomimetic drugs	None	True	advise	group	Close supervision and careful adjustment of dosage are required when Anafranil is administered with anticholinergic or sympathomimetic drugs.
DDI-DrugBank.d238.s6.p14	cimetidine	DB00501	drug	CMI	None	True	mechanism	drug	plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.
DDI-DrugBank.d241.s0.p1	FLOLAN	None	brand	antihypertensive agents	None	True	effect	group	Additional reductions in blood pressure may occur when FLOLAN is administered with diuretics, antihypertensive agents, or other vasodilators.
DDI-DrugBank.d242.s1.p3	quinolones	None	group	warfarin	DB00682	True	effect	drug	However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.
DDI-DrugBank.d245.s0.p0	sulfonylurea	None	group	nonsteroidal anti-inflammatory agents	None	True	effect	group	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
DDI-DrugBank.d245.s0.p2	sulfonylurea	None	group	sulfonamides	None	True	effect	group	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
DDI-DrugBank.d245.s0.p3	sulfonylurea	None	group	chloramphenicol	DB00446	True	effect	drug	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
DDI-DrugBank.d245.s0.p6	sulfonylurea	None	group	monoamine oxidase inhibitors	None	True	effect	group	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
DDI-DrugBank.d245.s9.p0	miconazole	DB01110	drug	hypoglycemic agents	None	True	effect	group	A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.
DDI-DrugBank.d249.s14.p4	Diclofenac	DB00586	drug	diuretics	None	True	effect	group	Diuretics: Diclofenac and other NSAIDs can inhibit the activity of diuretics.
DDI-DrugBank.d250.s2.p20	sodium citrate	None	drug	Coly-Mycin M	None	True	effect	brand	Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.
DDI-DrugBank.d252.s2.p0	beta-adrenergic blocking agents	None	group	calcium antagonists	None	True	advise	group	Patients receiving beta-adrenergic blocking agents along with either oral or intravenous calcium antagonists should be monitored for possible atrioventricular conduction disturbances, left ventricular failure and hypotension.
DDI-DrugBank.d254.s0.p11	tranquilizers	None	group	INAPSINE	None	True	effect	brand	Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.
DDI-DrugBank.d254.s0.p8	barbiturates	None	group	INAPSINE	None	True	effect	brand	Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.
DDI-DrugBank.d257.s0.p4	Levo-Dromoran	None	brand	opioids	None	True	effect	group	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
DDI-DrugBank.d26.s0.p7	narcotic analgesic	None	group	DILAUDID	None	True	effect	brand	Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.
DDI-DrugBank.d260.s0.p19	Probenecid	DB01032	drug	barbiturates	None	True	mechanism	group	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
DDI-DrugBank.d263.s1.p0	Zalcitabine	DB00943	drug	ZDV	None	True	effect	drug	Zalcitabine also has no significant effect on the intracellular phosphorylation of ZDV, as shown in vitro in peripheral blood mononuclear cells or in two other cell lines (U937 and Molt-4).
DDI-DrugBank.d263.s18.p20	amphotericin	None	drug	HIVID	None	True	effect	drug	Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).
DDI-DrugBank.d267.s3.p2	Isoflurane	DB00753	drug	NUROMAX	None	True	mechanism	brand	Isoflurane, enflurane, and halothane decrease the ED50 of NUROMAX by 30% to 45%.
DDI-DrugBank.d267.s3.p4	enflurane	DB00228	drug	NUROMAX	None	True	mechanism	brand	Isoflurane, enflurane, and halothane decrease the ED50 of NUROMAX by 30% to 45%.
DDI-DrugBank.d267.s5.p1	NUROMAX	None	brand	aminoglycosides	None	True	effect	group	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d267.s5.p11	NUROMAX	None	brand	anesthetics	None	True	effect	group	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d267.s5.p4	NUROMAX	None	brand	polymyxins	None	True	effect	group	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d269.s14.p0	Rifampin	None	drug	carvedilol	DB01136	True	mechanism	drug	Inducers and Inhibitors of Hepatic Metabolism: Rifampin reduced plasma concentrations of carvedilol by about 70%.
DDI-DrugBank.d269.s5.p0	agents with b-blocking properties	None	group	clonidine	DB00575	True	advise	drug	When concomitant treatment with agents with b-blocking properties and clonidine is to be terminated, the b-blocking agent should be discontinued first.
DDI-DrugBank.d270.s26.p0	contraceptives	None	group	nevirapine	DB00238	True	advise	drug	Oral contraceptives and other hormonalmethods of birth control should not be usedas the sole method of contraception inwomen taking nevirapine, since nevirapinemay lower the plasma levels of thesemedications.
DDI-DrugBank.d270.s39.p2	ritonavir	DB00503	drug	nevirapine	DB00238	True	advise	drug	A dose increase of lopinavir/ritonavir to 533/133 mg twice daily with food isrecommended in combination with nevirapine.
DDI-DrugBank.d270.s58.p0	nevirapine	DB00238	drug	methadone	DB00333	True	effect	drug	aBased on reports of narcotic withdrawal syndrome in patients treated with nevirapine and methadone concurrently, and evidence of decreased plasma concentrations of methadone.
DDI-DrugBank.d272.s2.p0	bromocriptine mesylate	None	drug	phenothiazines	None	True	effect	group	Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide.
DDI-DrugBank.d274.s2.p0	dobutamine	DB00841	drug	nitroprusside	DB00325	True	effect	drug	Preliminary studies indicate that the concomitant use of dobutamine and nitroprusside results in a higher cardiac output and, usually, a lower pulmonary wedge pressure than when either drug is used alone.
DDI-DrugBank.d275.s2.p0	Kineret	None	brand	etanercept	DB00005	True	effect	drug	In a study in which patients with active RA were treated for up to 24 weeks with concurrent Kineret and etanercept therapy, a 7% rate of serious infections was observed, which was higher than that observed with etanercept alone (0%).
DDI-DrugBank.d277.s23.p1	ethanol	DB00898	drug	tiagabine	DB00906	True	advise	drug	Because of the possible additive effects of drugs that may depress the nervous system, ethanol or triazolam should be used cautiously in combination with tiagabine.
DDI-DrugBank.d279.s11.p2	diuretics	None	group	CAMPTOSAR	None	True	effect	brand	In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by CAMPTOSAR, the physician may wish to withhold diuretics during dosing with CAMPTOSAR and, certainly, during periods of active vomiting or diarrhea.
DDI-DrugBank.d283.s0.p2	COUMARIN ANTICOAGULANTS	None	group	TRICOR	None	True	advise	brand	Oral Anticoagulants CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH TRICOR.
DDI-DrugBank.d283.s15.p1	fenofibrate	DB01039	drug	atorvastatin	DB01076	True	mechanism	drug	Concomitant administration of fenofibrate (equivalent to 145 mg TRICOR) with atorvastatin (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in atorvastatin AUC values in 22 healthy males.
DDI-DrugBank.d283.s6.p0	TRICOR	None	brand	immunosuppressants	None	True	advise	group	The benefits and risks of using TRICOR with immunosuppressants and other potentially nephrotoxic agents should be carefully considered, and the lowest effective dose employed
DDI-DrugBank.d284.s3.p4	methylxanthines	None	group	adrenergic agonists	None	True	effect	group	Concomitant treatment with methylxanthines (aminophylline, theophylline), steroids, or diuretics may potentiate any hypokalemic effect of adrenergic agonists.
DDI-DrugBank.d284.s4.p2	non-potassium sparing diuretics	None	group	beta-agonists	None	True	effect	group	The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded.
DDI-DrugBank.d284.s4.p5	loop diuretics	None	group	beta-agonists	None	True	effect	group	The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded.
DDI-DrugBank.d286.s0.p2	Ethoxzolamide	DB00311	drug	procainamide	DB01035	True	effect	drug	Ethoxzolamide may increase the action of tricyclics, amphetamines, procainamide, and quinidine.
DDI-DrugBank.d288.s0.p9	TAXOL	None	brand	cisplatin	DB00515	True	effect	drug	In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).
DDI-DrugBank.d289.s23.p3	bosentan	DB00559	drug	ketoconazole	DB01026	True	mechanism	drug	Ketoconazole: Co-administration of bosentan 125 mg b.i.d. and ketoconazole, a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan by approximately 2-fold.
DDI-DrugBank.d289.s29.p0	statins	None	group	TRACLEER	None	True	advise	brand	Patients using CYP3A4 metabolized statins should have cholesterol levels monitored after TRACLEER is initiated to see whether the statin dose needs adjustment.
DDI-DrugBank.d29.s12.p0	esomeprazole	DB00736	drug	ketoconazole	DB01026	True	mechanism	drug	Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).
DDI-DrugBank.d291.s11.p1	Perhexiline hydrogen maleate	None	drug	Bezalip	None	True	advise	brand	Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.
DDI-DrugBank.d296.s0.p1	Diphenhydramine hydrochloride	None	drug	CNS depressants	None	True	effect	group	Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).
DDI-DrugBank.d299.s6.p21	fluoxetine	DB00472	drug	5-HT1 agonists	None	True	effect	group	Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
DDI-DrugBank.d299.s6.p26	paroxetine	DB00715	drug	5-HT1 agonists	None	True	effect	group	Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
DDI-DrugBank.d299.s6.p27	sertraline	DB01104	drug	5-HT1 agonists	None	True	effect	group	Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
DDI-DrugBank.d3.s13.p4	methotrexate	DB00563	drug	NSAIDs	None	True	mechanism	group	Methotrexate: Concomitant administration of methotrexate and some NSAIDs has been reported to reduce the clearance of methotrexate, enhancing the toxicity of methotrexate.
DDI-DrugBank.d3.s18.p5	TORADOL	None	brand	phenytoin	DB00252	True	effect	drug	Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (phenytoin, carbamazepine).
DDI-DrugBank.d306.s0.p1	progestin	None	group	phenytoin	DB00252	True	effect	drug	The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.
DDI-DrugBank.d306.s0.p5	progestin	None	group	rifampin	None	True	effect	drug	The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.
DDI-DrugBank.d314.s18.p12	rifampin	None	drug	corticosteroids	None	True	mechanism	group	Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.
DDI-DrugBank.d314.s30.p3	corticosteroid	None	group	live vaccines	None	True	effect	group	Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response.
DDI-DrugBank.d314.s30.p4	corticosteroid	None	group	inactivated vaccines	None	True	effect	group	Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response.
DDI-DrugBank.d316.s14.p8	felodipine	DB01023	drug	phenobarbital	DB01174	True	mechanism	drug	Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.
DDI-DrugBank.d35.s0.p3	EPA	None	drug	Ginkgo biloba	DB01381	True	int	drug	Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).
DDI-DrugBank.d350.s7.p0	cyclosporine	DB00091	drug	caspofungin	DB00520	True	mechanism	drug	In two clinical studies, cyclosporine (one 4 mg/kg dose or two 3 mg/kg doses) increased the AUC of caspofungin by approximately 35%.
DDI-DrugBank.d351.s0.p7	loracarbef	DB00447	drug	probenecid	DB01032	True	mechanism	drug	Probenecid: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef.
DDI-DrugBank.d356.s2.p0	Lithium	DB01356	drug	diuretics	None	True	advise	group	Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity.
DDI-DrugBank.d357.s0.p25	apomorphine	DB00714	drug	ondansetron	DB00904	True	advise	drug	5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
DDI-DrugBank.d357.s0.p27	apomorphine	DB00714	drug	dolasetron	DB00757	True	advise	drug	5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
DDI-DrugBank.d362.s5.p0	ketoconazole	DB01026	drug	ciclesonide	DB01410	True	advise	drug	Therefore, ketoconazole should be administered with caution with intranasal ciclesonide.
DDI-DrugBank.d364.s10.p0	alosetron	DB00969	drug	clarithromycin	DB01211	True	advise	drug	Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
DDI-DrugBank.d368.s0.p1	DIAMOX	None	brand	phenytoin	DB00252	True	mechanism	drug	DIAMOX modifies phenytoin metabolism with increased serum levels of phenytoin.
DDI-DrugBank.d368.s13.p0	Acetazolamide	DB00819	drug	sodium bicarbonate	DB01390	True	effect	drug	Acetazolamide and sodium bicarbonate used concurrently increases the risk of renal calculus formation.
DDI-DrugBank.d372.s0.p0	Cytadren	None	brand	dexamethasone	DB01234	True	mechanism	drug	Cytadren accelerates the metabolism of dexamethasone;
DDI-DrugBank.d373.s2.p14	digoxin	DB00390	drug	nifedipine	DB01115	True	advise	drug	Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.
DDI-DrugBank.d373.s2.p9	digoxin	DB00390	drug	nifedipine	DB01115	True	int	drug	Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.
DDI-DrugBank.d374.s0.p2	Auranofin	DB00995	drug	Myochrysine	None	True	advise	brand	Auranofin should be avoided by patients with a history of serious reaction to any gold medication, including Solganal and Myochrysine.
DDI-DrugBank.d374.s1.p2	Auranofin	DB00995	drug	Cuprimine	None	True	advise	brand	Auranofin should not be used together with penicillamine (Depen, Cuprimine), another arthritis medication.
DDI-DrugBank.d377.s0.p1	Phospholine Iodide	None	drug	succinylcholine	DB00202	True	effect	drug	Phospholine Iodide potentiates other cholinesterase inhibitors such as succinylcholine or organophosphate and carbamate insecticides.
DDI-DrugBank.d380.s4.p0	buprenorphine	DB00921	drug	benzodiazepines	None	True	effect	drug	There have been a number of reports in the post-marketing experience of coma and death associated with the concomitant intravenous misuse of buprenorphine and benzodiazepines by addicts.
DDI-DrugBank.d380.s7.p1	benzodiazepines	None	group	SUBUTEX	None	True	advise	brand	Patients should be warned of the potential danger of the intravenous self-administration of benzodiazepines while under treatment with SUBOXONE or SUBUTEX.
DDI-DrugBank.d381.s0.p1	ERGAMISOL	None	brand	alcohol	None	True	effect	drug	ERGAMISOL  (levamisole hydrochloride) has been reported to produce ANTABUSE-like side effects when given concomitantly with alcohol.
DDI-DrugBank.d382.s31.p2	Aprepitant	DB00673	drug	nefazodone	DB01149	True	advise	drug	Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.
DDI-DrugBank.d382.s34.p3	Aprepitant	DB00673	drug	aprepitant	DB00673	True	mechanism	drug	therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.
DDI-DrugBank.d382.s5.p0	Aprepitant	DB00673	drug	phenytoin	DB00252	True	mechanism	drug	Coadministration of Aprepitant with these drugs or other drugs that are known to be metabolized by CYP2C9, such as phenytoin, may result in lower plasma concentrations of these drugs.
DDI-DrugBank.d382.s9.p18	Aprepitant	DB00673	drug	dexamethasone	DB01234	True	mechanism	drug	Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.
DDI-DrugBank.d384.s8.p2	Ketoconazole	DB01026	drug	vitamin D	None	True	mechanism	group	Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.
DDI-DrugBank.d386.s23.p32	desipramine	DB01151	drug	diazepam	DB00829	True	effect	drug	If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.
DDI-DrugBank.d386.s27.p0	tricyclic antidepressants	None	group	cimetidine	DB00501	True	mechanism	drug	Conversely, decreases in plasma levels of the tricyclic antidepressants have been reported upon discontinuation of cimetidine which may result in the loss of the therapeutic efficacy of the tricyclic antidepressant 6.
DDI-DrugBank.d387.s1.p0	Antihistamines	None	group	heparin	DB01109	True	effect	drug	Antihistamines may partially counteract the anticoagulation effects of heparin or warfarin.
DDI-DrugBank.d39.s1.p2	Colchicine	DB01394	drug	vitamin B12	None	True	mechanism	drug	Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.
DDI-DrugBank.d395.s0.p4	Bismuth subsalicylate	DB01294	drug	enoxacin	DB00467	True	mechanism	drug	Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.
DDI-DrugBank.d395.s3.p0	enoxacin	DB00467	drug	caffeine	DB00201	True	mechanism	drug	In a multiple-dose study, enoxacin caused a dose-related increase in the mean elimination half-life of caffeine, thereby decreasing the clearance of caffeine by up to 80% and leading to a five-fold increase in the AUC and the half-life of caffeine.
DDI-DrugBank.d396.s2.p1	MAO inhibitors	None	group	hydrocodone	DB00956	True	effect	drug	The use of MAO inhibitors or tricyclic antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone.
DDI-DrugBank.d397.s12.p0	terfenadine	DB00342	drug	erythromycin	DB00199	True	effect	drug	In addition, deaths have been reported rarely with concomitant administration of terfenadine and erythromycin.
DDI-DrugBank.d397.s8.p7	erythromycin	DB00199	drug	disopyramide	DB00280	True	int	drug	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
DDI-DrugBank.d397.s8.p9	erythromycin	DB00199	drug	bromocriptine	DB01200	True	int	drug	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
DDI-DrugBank.d398.s0.p2	codeine	DB00318	drug	psychotropics	None	True	effect	group	The use of codeine may result in additive CNS depressant effects when coadministered with alcohol, antihistamines, psychotropics or other drugs that produce CNS depression.
DDI-DrugBank.d398.s2.p1	dextromethorphan hydrobromide	None	drug	antihistamines	None	True	effect	group	The use of dextromethorphan hydrobromide may result in additive CNS depressant effects when coadministered with alcohol, antihistamines, psychotropics or other drugs that produce CNS depression.
DDI-DrugBank.d4.s0.p4	theophylline	DB00277	drug	sympathomimetic bronchodilators	None	True	effect	group	Synergism between xanthine bronchodilators (e.g., theophylline), ephedrine, and other sympathomimetic bronchodilators has been reported.
DDI-DrugBank.d40.s10.p13	phenytoin	DB00252	drug	methylphenidate	DB00422	True	mechanism	drug	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
DDI-DrugBank.d40.s14.p1	phenytoin	DB00252	drug	sodium valproate	None	True	mechanism	drug	Drugs that may either increase or decrease plasma Phenytoin concentrations include: phenobarbital, vaiproic acid, and sodium valproate.
DDI-DrugBank.d40.s19.p8	phenytoin	DB00252	drug	rifampin	None	True	effect	drug	Drugs whose efficacy is impaired by Phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
DDI-DrugBank.d400.s6.p3	NSAIDs	None	group	furosemide	DB00695	True	effect	drug	Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.
DDI-DrugBank.d401.s0.p15	AKINETON	None	brand	quinidine	DB00908	True	effect	drug	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
DDI-DrugBank.d401.s0.p2	anticholinergic	None	group	meperidine	None	True	effect	drug	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
DDI-DrugBank.d401.s0.p7	anticholinergic	None	group	quinidine	DB00908	True	effect	drug	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
DDI-DrugBank.d401.s0.p8	anticholinergic	None	group	antihistamines	None	True	effect	group	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
DDI-DrugBank.d404.s11.p2	vitamin D	None	group	corticosteroids	None	True	effect	group	Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.
DDI-DrugBank.d409.s1.p1	tetracycline class	None	group	penicillins	None	True	effect	group	Since bacteriostatic drugs, such as the tetracycline class of antibiotics, may interfere with the bactericidal action of penicillins, it is not advisable to administer these drugs concomitantly.
DDI-DrugBank.d41.s16.p2	ARAVA	None	brand	warfarin	DB00682	True	effect	drug	Warfarin: Increased INR (International Normalized Ratio) when ARAVA and warfarin were co-administered has been rarely reported.
DDI-DrugBank.d410.s2.p0	Sumatriptan	DB00669	drug	D.H.E. 45	None	True	advise	brand	Sumatriptan and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other..
DDI-DrugBank.d410.s5.p21	ergot alkaloid class	None	group	macrolide class	None	True	mechanism	group	Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.
DDI-DrugBank.d411.s3.p4	levothyroxine sodium	None	drug	estrogens	None	True	mechanism	group	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
DDI-DrugBank.d412.s11.p0	labetalol	DB00598	drug	calcium antagonist	None	True	advise	group	Care should be taken if labetalol is used concomitantly with calcium antagonists of the verapamil type.
DDI-DrugBank.d413.s16.p8	ampicillin	DB00415	drug	allopurinol	DB00437	True	effect	drug	Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.
DDI-DrugBank.d416.s0.p1	PAH	None	drug	procaine	DB00721	True	effect	drug	Renal clearance measurements of PAH cannot be made with any significant accuracy in patients receiving sulfonamides, procaine, or thiazolesulfone.
DDI-DrugBank.d417.s0.p0	Netilmicin	DB00955	drug	loop diuretics	None	True	advise	group	Netilmicin should not be administered concomitantly with potent loop diuretics such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.
DDI-DrugBank.d419.s1.p0	ampicillin	DB00415	drug	allopurinol	DB00437	True	effect	drug	It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients.
DDI-DrugBank.d419.s5.p2	AUGMENTIN XR	None	brand	contraceptives	None	True	effect	group	In common with other broad-spectrum antibiotics, AUGMENTIN XR may reduce the efficacy of oral contraceptives
DDI-DrugBank.d420.s5.p12	cefdinir	DB00535	drug	iron	DB01592	True	mechanism	drug	Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.
DDI-DrugBank.d423.s0.p10	MAOIs	None	group	fluoxetine	DB00472	True	effect	drug	In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
DDI-DrugBank.d423.s0.p13	MAOIs	None	group	sertraline	DB01104	True	effect	drug	In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
DDI-DrugBank.d423.s0.p9	MAOIs	None	group	serotoninergic agents	None	True	effect	group	In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
DDI-DrugBank.d423.s1.p2	dexfenfluramine	DB01191	drug	MAO inhibitor	None	True	advise	group	Because dexfenfluramine is a serotonin releaser and reuptake inhibitor, dexfenfluramine should not be used concomitantly with a MAO inhibitor.
DDI-DrugBank.d426.s1.p3	ergotamine	DB00696	drug	FROVA	None	True	advise	brand	Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).
DDI-DrugBank.d427.s13.p2	quinolones	None	group	cyclosporine	DB00091	True	mechanism	drug	Elevated serum levels of cyclosporine have been reported with the concomitant use of some quinolones and cyclosporine.
DDI-DrugBank.d427.s5.p4	nalidixic acid	DB00779	drug	warfarin	DB00682	True	effect	drug	Quinolones, including nalidixic acid, may enhance the effects of the oral anticoagulant warfarin or its derivatives.
DDI-DrugBank.d43.s15.p1	delavirdine	DB00705	drug	VIDEX	None	True	advise	brand	To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.
DDI-DrugBank.d43.s4.p7	antacids	None	group	VIDEX	None	True	effect	brand	Antacids: Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.
DDI-DrugBank.d43.s5.p1	ketoconazole	DB01026	drug	VIDEX	None	True	advise	brand	Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach: Drugs such as ketoconazole and itraconazole should be administered at least 2 hours prior to dosing with VIDEX.
DDI-DrugBank.d43.s8.p19	ciprofloxacin	DB00537	drug	magnesium	DB01378	True	mechanism	drug	Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.
DDI-DrugBank.d434.s22.p2	Felbatol	None	brand	valproate	None	True	mechanism	drug	Valproate: Felbatol  causes an increase in steady-state valproate concentrations.
DDI-DrugBank.d434.s33.p2	phenobarbital	DB01174	drug	felbamate	DB00949	True	mechanism	drug	Phenobarbital: It appears that phenobarbital may reduce plasma felbamate concentrations.
DDI-DrugBank.d434.s38.p0	Felbamate	DB00949	drug	gestodene	DB06730	True	mechanism	drug	Felbamate treatment resulted in a 42% decrease in the gestodene AUC 0-24, but no clinically relevant effect was observed on the pharmacokinetic parameters of ethinyl estradiol.
DDI-DrugBank.d440.s2.p1	Ibandronate	DB00710	drug	vitamins	None	True	advise	group	Ibandronate should be taken at least 60 minutes before any oral medications containing multivalent cations (including antacids, supplements or vitamins).
DDI-DrugBank.d441.s2.p4	ZYVOX	None	brand	sympathomimetic agents	None	True	effect	group	Adrenergic Agents:Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents.
DDI-DrugBank.d443.s3.p3	Pyrazolone Derivatives	None	group	aspirin	None	True	effect	drug	Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.
DDI-DrugBank.d443.s3.p6	phenylbutazone	DB00812	drug	aspirin	None	True	effect	drug	Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.
DDI-DrugBank.d443.s3.p8	oxyphenbutazone	DB03585	drug	aspirin	None	True	effect	drug	Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.
DDI-DrugBank.d448.s6.p0	Antacids	None	group	pseudoephedrine	DB00852	True	mechanism	drug	Antacids increase the rate of absorption of pseudoephedrine, while kaolin decreases it.
DDI-DrugBank.d448.s6.p2	pseudoephedrine	DB00852	drug	kaolin	DB01575	True	mechanism	drug	Antacids increase the rate of absorption of pseudoephedrine, while kaolin decreases it.
DDI-DrugBank.d449.s1.p2	Nafazodone	None	drug	Xanax	None	True	advise	brand	Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction).
DDI-DrugBank.d450.s2.p40	alprazolam	DB00404	drug	digoxin	DB00390	True	mechanism	drug	Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
DDI-DrugBank.d450.s6.p10	kaolin	DB01575	drug	digoxin	DB00390	True	mechanism	drug	Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.
DDI-DrugBank.d456.s1.p1	TARCEVA	None	brand	atazanavir	DB01072	True	advise	drug	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
DDI-DrugBank.d457.s0.p3	Barbiturates	None	group	theophylline	DB00277	True	effect	drug	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.
DDI-DrugBank.d462.s7.p2	Piperacillin sodium	None	drug	methotrexate	DB00563	True	mechanism	drug	Methotrexate: Piperacillin sodium may reduce the excretion of methotrexate.
DDI-DrugBank.d463.s1.p2	Desyrel	None	brand	buspirone HCl	None	True	effect	drug	There is one report suggesting that the concomitant use of trazodone hydrochloride (Desyrel) and buspirone HCl may have caused 3- to 6-fold elevations on SGPT (ALT) in a few patients.
DDI-DrugBank.d464.s0.p3	Codeine	DB00318	drug	tranquilizers	None	True	effect	group	Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.
DDI-DrugBank.d466.s1.p0	fexofenadine hydrochloride	None	drug	ketoconazole	DB01026	True	mechanism	drug	However, co  administration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine.
DDI-DrugBank.d466.s20.p1	ALLEGRA	None	brand	magnesium	DB01378	True	advise	drug	ALLEGRA should not be taken closely in time with aluminum and magnesium containing antacids.
DDI-DrugBank.d467.s3.p4	phenytoin	DB00252	drug	bexarotene	DB00307	True	mechanism	drug	Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.
DDI-DrugBank.d469.s7.p1	TRACRIUM	None	brand	isoflurane	DB00753	True	effect	drug	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.
DDI-DrugBank.d469.s7.p5	TRACRIUM	None	brand	polymyxins	None	True	effect	group	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.
DDI-DrugBank.d469.s7.p6	TRACRIUM	None	brand	lithium	DB01356	True	effect	drug	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.
DDI-DrugBank.d47.s5.p0	Iron	DB01592	drug	carbidopa	DB00190	True	mechanism	drug	Iron salts may reduce the bioavailability of carbidopa and levodopa.
DDI-DrugBank.d470.s1.p3	TRISENOX	None	brand	amphotericin B	DB00681	True	advise	drug	Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).
DDI-DrugBank.d476.s1.p2	guanethidine	DB01170	drug	ZEBETA	None	True	effect	brand	Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of ZEBETA may produce excessive reduction of sympathetic activity.
DDI-DrugBank.d480.s15.p5	nicotine	DB00184	drug	Clozapine	DB00363	True	mechanism	drug	Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.
DDI-DrugBank.d480.s21.p0	Paroxetine	DB00715	drug	clozapine	DB00363	True	mechanism	drug	Paroxetine produced only minor changes in the levels of clozapine and its metabolites.
DDI-DrugBank.d480.s23.p0	Clozapine	DB00363	drug	fluvoxamine	DB00176	True	advise	drug	Therefore, such combined treatment should be approached with caution and patients should be monitored closely when Clozapine is combined with these drugs, particularly with fluvoxamine.
DDI-DrugBank.d480.s30.p7	clozapine	DB00363	drug	quinidine	DB00908	True	advise	drug	Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
DDI-DrugBank.d484.s0.p1	Etonogestrel	DB00294	drug	Tylenol	None	True	int	brand	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d484.s0.p21	Etonogestrel	DB00294	drug	Neoral	None	True	int	brand	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d484.s0.p24	Etonogestrel	DB00294	drug	Agenerase	None	True	int	brand	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d484.s0.p26	Etonogestrel	DB00294	drug	Fortovase	None	True	int	brand	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d484.s0.p36	Etonogestrel	DB00294	drug	prednisolone	DB00860	True	int	drug	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d484.s0.p38	Etonogestrel	DB00294	drug	rifadin	None	True	int	brand	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d485.s12.p12	carbamazepine	DB00564	drug	progestins	None	True	mechanism	group	Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.
DDI-DrugBank.d485.s12.p20	phenobarbital	DB01174	drug	ethinyl estradiol	DB00977	True	mechanism	drug	Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.
DDI-DrugBank.d485.s12.p5	Anticonvulsants	None	group	ethinyl estradiol	DB00977	True	mechanism	drug	Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.
DDI-DrugBank.d485.s16.p4	Atorvastatin	DB01076	drug	ethinyl estradiol	DB00977	True	mechanism	drug	Atorvastatin: Atorvastatin increases the AUC for norethindrone and ethinyl estradiol.
DDI-DrugBank.d485.s17.p14	hormonal contraceptives	None	group	temazepam	DB00231	True	mechanism	drug	Benzodiazepines: Combination hormonal contraceptives may decrease the clearance of some benzodiazepines (alprazolam, chlordiazepoxide, diazepam) and increase the clearance of others (lorazepam, oxazepam, temazepam).
DDI-DrugBank.d485.s19.p2	hormonal contraceptives	None	group	cyclosporine	DB00091	True	mechanism	drug	Cyclosporine: Combination hormonal contraceptives may inhibit the metabolism of cyclosporine, leading to increased plasma concentrations;
DDI-DrugBank.d485.s2.p0	Acetaminophen	DB00316	drug	synthetic estrogens	None	True	mechanism	group	Acetaminophen: May increase plasma concentration of synthetic estrogens, possibly by inhibiting conjugation.
DDI-DrugBank.d485.s43.p5	combination hormonal contraceptives	None	group	caffeine	DB00201	True	effect	drug	ETHANOL / NUTRITION / HERB INTERACTIONS: Food: CNS effects of caffeine may be enhanced if combination hormonal contraceptives are used concurrently with caffeine.
DDI-DrugBank.d485.s6.p0	Aminoglutethimide	DB00357	drug	progestins	None	True	mechanism	group	Aminoglutethimide: May increase CYP metabolism of progestins leading to possible decrease in contraceptive effectiveness.
DDI-DrugBank.d487.s4.p0	Corticosteroids	None	group	aspirin	None	True	effect	brand	Corticosteroids may increase the clearance of chronic high dose aspirin.
DDI-DrugBank.d487.s6.p0	Aspirin	None	brand	cortico-steroids	None	True	advise	group	Aspirin should be used cautiously in conjunction with cortico-steroids in patients suffering from hypopro-thrombinemia.
DDI-DrugBank.d487.s8.p0	anticoagulants	None	group	corticosteroids	None	True	effect	group	There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids.
DDI-DrugBank.d488.s1.p1	heparin sodium	None	drug	warfarin sodium	None	True	advise	drug	Therefore, when heparin sodium is given with dicumarol or warfarin sodium, a period of at least 5 hours after the last intravenous dose or 24 hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained.
DDI-DrugBank.d488.s6.p11	tetracyclines	None	group	heparin sodium	None	True	effect	drug	Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.
DDI-DrugBank.d493.s4.p0	anakinra	DB00026	drug	TNF-blocking agents	None	True	effect	group	Therefore the, combination of anakinra with other TNF-blocking agents, including HUMIRA, may also result i n similar toxicities.
DDI-DrugBank.d495.s2.p9	Clonidine	DB00575	drug	alcohol	None	True	effect	drug	Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol, barbiturates or other sedating drugs.
DDI-DrugBank.d495.s6.p0	Beta blockers	None	group	clonidine	DB00575	True	effect	drug	Beta blockers may exacerbate the hypertensive response seen with clonidine withdrawl.
DDI-DrugBank.d497.s2.p0	carbonic anhydrase inhibitors	None	group	salicylate	None	True	int	drug	However, in patients treated with oral carbonic anhydrase inhibitors, rare instances of drug interactions have occurred with high-dose salicylate therapy.
DDI-DrugBank.d499.s6.p1	aspirin	None	brand	ketoprofen	DB01009	True	mechanism	drug	however, in a study of 12 normal subjects, concurrent administration of aspirin decreased ketoprofen protein binding and increased ketoprofen plasma clearance from 0.07 L/kg/h without aspirin to 0.11 L/kg/h with aspirin.
DDI-DrugBank.d499.s8.p0	aspirin	None	brand	ketoprofen	DB01009	True	advise	drug	Therefore, concurrent use of aspirin and ketoprofen is not recommended.
DDI-DrugBank.d5.s17.p12	bupropion	DB01156	drug	metoprolol	DB00264	True	advise	drug	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
DDI-DrugBank.d5.s17.p13	bupropion	DB01156	drug	Type 1C antiarrhythmics	None	True	advise	group	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
DDI-DrugBank.d5.s17.p4	bupropion	DB01156	drug	paroxetine	DB00715	True	advise	drug	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
DDI-DrugBank.d5.s17.p9	bupropion	DB01156	drug	risperidone	DB00734	True	advise	drug	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
DDI-DrugBank.d5.s20.p7	bupropion	DB01156	drug	levodopa	None	True	effect	drug	Levodopa and Amantadine: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either levodopa or amantadine.
DDI-DrugBank.d5.s21.p1	WELLBUTRIN	None	brand	amantadine	DB00915	True	advise	drug	Administration of WELLBUTRIN Tablets to patients receiving either levodopa or amantadine concurrently should be undertaken with caution, using small initial doses and small gradual dose increases.
DDI-DrugBank.d5.s22.p1	WELLBUTRIN	None	brand	antidepressants	None	True	advise	group	Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.
DDI-DrugBank.d5.s26.p0	alcohol	None	drug	WELLBUTRIN	None	True	advise	brand	The consumption of alcohol during treatment with WELLBUTRIN should be minimized or avoided (also see  a href= bupropz_od.htm#CI CONTRAINDICATIONS)
DDI-DrugBank.d260.s0.p16	Probenecid	DB01032	drug	acyclovir	None	True	mechanism	drug	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
DDI-DrugBank.d260.s0.p25	Probenecid	DB01032	drug	furosemide	DB00695	True	mechanism	drug	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
DDI-DrugBank.d260.s0.p26	Probenecid	DB01032	drug	nonsteroidal anti-inflammatory	None	True	mechanism	group	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
DDI-DrugBank.d260.s3.p6	VISTIDE	None	brand	pentamidine	DB00738	True	advise	drug	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
DDI-DrugBank.d260.s3.p8	VISTIDE	None	brand	non-steroidal anti-inflammatory agents	None	True	advise	group	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
DDI-DrugBank.d263.s18.p21	amphotericin	None	drug	zalcitabine	DB00943	True	mechanism	drug	Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).
DDI-DrugBank.d263.s20.p12	cimetidine	DB00501	drug	zalcitabine	DB00943	True	mechanism	drug	Probenecid or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.
DDI-DrugBank.d5.s3.p1	WELLBUTRIN	None	brand	cyclophosphamide	DB00531	True	int	drug	Therefore, the potential exists for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e.g., orphenadrine and cyclophosphamide).
DDI-DrugBank.d5.s8.p1	bupropion	DB01156	drug	phenobarbital	DB01174	True	mechanism	drug	While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., carbamazepine, phenobarbital, phenytoin).
DDI-DrugBank.d501.s6.p0	EXTRANEAL	None	brand	insulin	None	True	advise	drug	However, appropriate monitoring of blood glucose should be performed when initiating EXTRANEAL in diabetic patients and insulin dosage should be adjusted if needed.
DDI-DrugBank.d503.s2.p0	chlorprothixene	DB01239	drug	opioids	None	True	advise	group	If chlorprothixene is given concomitantly with opioids, the opioid dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of opioids massively.
DDI-DrugBank.d505.s2.p2	Dipyridamole	DB00975	drug	adenosine	DB00640	True	mechanism	drug	Adenosine: Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine.
DDI-DrugBank.d506.s9.p5	disopyramide	DB00280	drug	verapamil	DB00661	True	advise	drug	Until data on possible interactions between verapamil and disopyramide phosphate are obtained, disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration.
DDI-DrugBank.d508.s1.p4	heparin	DB01109	drug	Activase	None	True	effect	brand	In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole and Abciximab) may increase the risk of bleeding if administered prior to, during, or after Activase therapy.
DDI-DrugBank.d509.s28.p0	alcohol	None	drug	ABILIFY	None	True	advise	brand	As with most psychoactive medications, patients should be advised to avoid alcohol while taking ABILIFY
DDI-DrugBank.d509.s8.p8	fluoxetine	DB00472	drug	aripiprazole	DB01238	True	mechanism	drug	Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.
DDI-DrugBank.d511.s1.p0	FOSCAVIR	None	brand	pentamidine	DB00738	True	effect	drug	Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidine may have caused hypocalcemia;
DDI-DrugBank.d512.s6.p0	ketoconazole	DB01026	drug	cinacalcet	DB01012	True	mechanism	drug	Co-administration of ketoconazole, a strong inhibitor of CYP3A4, increased cinacalcet exposure following a single 90 mg dose of Sensipar by 2.3 fold.
DDI-DrugBank.d514.s1.p0	central nervous system depressants	None	group	heroin	DB01452	True	effect	drug_n	In combination with other central nervous system depressants, heroin may still kill even experienced users, particularly if their tolerance to the drug has reduced or the strength of their usual dose has increased.
DDI-DrugBank.d516.s11.p0	quinolones	None	group	caffeine	DB00201	True	mechanism	drug	Other quinolones have demonstrated moderate to marked interference with the metabolism of caffeine, resulting in a reduced clearance, a prolongation of plasma half-life, and an increase in symptoms that accompany high levels of caffeine.
DDI-DrugBank.d516.s4.p0	Sucralfate	DB00364	drug	lomefloxacin	DB00978	True	mechanism	drug	Sucralfate administered 2 hours before lomefloxacin resulted in a slower absorption (mean C max decreased by 30% and mean T max increased by 1 hour) and a lesser extent of absorption (mean AUC decreased by approximately 25%).
DDI-DrugBank.d518.s0.p2	narcotics	None	group	ketamine	DB01221	True	effect	drug	Prolonged recovery time may occur if barbiturates and/or narcotics are used concurrently with ketamine.
DDI-DrugBank.d521.s1.p0	glimepiride	DB00222	drug	aspirin	None	True	advise	brand	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
DDI-DrugBank.d522.s10.p0	terfenadine	DB00342	drug	macrolide antibiotics	None	True	effect	group	Serious cardiac dysrhythmias, some resulting in death, have occurred in patients receiving terfenadine concomitantly with other macrolide antibiotics.
DDI-DrugBank.d522.s19.p4	Erythromycin	DB00199	drug	triazolam	DB00897	True	effect	drug	Triazolam: Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of triazolam.
DDI-DrugBank.d522.s21.p2	erythromycin	DB00199	drug	anticoagulants	None	True	effect	group	Anticoagulants: There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly.
DDI-DrugBank.d523.s1.p0	baclofen	DB00181	drug	morphine	DB00295	True	effect	drug	Interactions attributed to the combined use of baclofen injection and epidural morphine include hypotension and dyspnea.
DDI-DrugBank.d526.s17.p2	Barbiturates	None	group	fludrocortisone acetate	None	True	mechanism	drug	Barbiturates, phenytoin, or rifampin increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes.
DDI-DrugBank.d527.s3.p3	Beta-blockers	None	group	insulin	None	True	effect	drug	Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.
DDI-DrugBank.d528.s0.p7	L-methionine	DB00134	drug	acetaminophen	DB00316	True	effect	drug	Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate.
DDI-DrugBank.d529.s10.p0	Flurbiprofen	DB00712	drug	propranolol	DB00571	True	int	drug	Flurbiprofen did not affect the pharmacokinetic profile of either drug, and the mechanism under lying the interference with propranolols hypotensive effect is unknown.
DDI-DrugBank.d529.s12.p20	flurbiprofen	DB00712	drug	cimetidine	DB00501	True	mechanism	drug	Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.
DDI-DrugBank.d529.s16.p1	nonsteroidal anti-inflammatory drugs	None	group	potassium-sparing diuretics	None	True	effect	group	Other nonsteroidal anti-inflammatory drugs that inhibit prostaglandin synthesis have been shown to interfere with thiazide diuretics in some studies and with potassium-sparing diuretics.
DDI-DrugBank.d53.s4.p0	azithromycin	DB00207	drug	warfarin	DB00682	True	advise	drug	However, prudent medical practice dictates careful monitoring of prothrombin time in all patients treated with azithromycin and warfarin concomitantly.
DDI-DrugBank.d53.s7.p8	azithromycin	DB00207	drug	rifabutin	DB00615	True	mechanism	drug	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
DDI-DrugBank.d531.s79.p0	SUSTIVA	None	brand	itraconazole	DB01167	True	mechanism	drug	SUSTIVA has the potential to decrease plasma concentrations of itraconazole and ketoconazole.
DDI-DrugBank.d54.s17.p2	Thyroid preparations	None	group	digitalis	None	True	effect	group	Digitalis: Thyroid preparations may potentiate the toxic effects of digitalis.
DDI-DrugBank.d544.s3.p1	Simulect	None	brand	mycophenolate mofetil	DB00688	True	mechanism	drug	Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids.
DDI-DrugBank.d545.s0.p2	carbenicillin indanyl sodium	None	drug	probenecid	DB01032	True	mechanism	drug	Geocillin (carbenicillin indanyl sodium) blood levels may be increased and prolonged by concurrent administration of probenecid.
DDI-DrugBank.d548.s9.p2	Duloxetine	DB00476	drug	TCAs	None	True	advise	group	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
DDI-DrugBank.d55.s2.p1	ISUPREL	None	brand	halothane	DB01159	True	advise	drug	ISUPREL should be used with caution, if at all, when potent inhalational anesthetics such as halothane are employed because of potential to sensitize the myocardium to effects of sympathomimetic amines.
DDI-DrugBank.d550.s4.p5	b-lactam antibiotics	None	group	cefditoren pivoxil	None	True	mechanism	drug	Probenecid: As with other b-lactam antibiotics, co-administration of probenecid with cefditoren pivoxil resulted in an increase in the plasma exposure of cefditoren, with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life.
DDI-DrugBank.d558.s25.p73	quinine	DB00468	drug	TIKOSYN	None	True	advise	brand	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
DDI-DrugBank.d558.s28.p0	digoxin	DB00390	drug	dofetilide	DB00204	True	effect	drug	In patients, the concomitant administration of digoxin with dofetilide was associated with a higher occurrence of torsade de pointes.
DDI-DrugBank.d559.s1.p22	caffeine	DB00201	drug	sedative-hypnotics	None	True	effect	group	Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
DDI-DrugBank.d559.s1.p23	caffeine	DB00201	drug	CNS depressants	None	True	effect	group	Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
DDI-DrugBank.d559.s1.p5	Butalbital	DB00241	drug	tranquilizers	None	True	effect	group	Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
DDI-DrugBank.d559.s1.p7	Butalbital	DB00241	drug	sedative-hypnotics	None	True	effect	group	Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
DDI-DrugBank.d559.s1.p8	Butalbital	DB00241	drug	CNS depressants	None	True	effect	group	Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
DDI-DrugBank.d561.s0.p2	diuretics	None	group	Lotensin	None	True	effect	brand	Diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with Lotensin.
DDI-DrugBank.d561.s7.p9	ACE inhibitors	None	group	lithium	DB01356	True	mechanism	drug	Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.
DDI-DrugBank.d562.s1.p2	theophylline	DB00277	drug	quinolone	None	True	effect	group	There have been reports of theophylline-related side-effects in patients on concomitant theophylline-quinolone therapy.
DDI-DrugBank.d562.s3.p0	Quinolones	None	group	caffeine	DB00201	True	mechanism	drug	Quinolones have also been shown to interfere with the metabolism of caffeine.
DDI-DrugBank.d562.s8.p2	Quinolones	None	group	warfarin	DB00682	True	effect	drug	Quinolones, including cinoxacin, may enhance the effects of oral anticoagulants, such as warfarin or its derivatives.
DDI-DrugBank.d564.s0.p6	epinephrine	DB00668	drug	tricyclic antidepressants	None	True	effect	group	The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.
DDI-DrugBank.d564.s0.p7	norepinephrine	DB00368	drug	monoamine oxidase inhibitors	None	True	effect	group	The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.
DDI-DrugBank.d565.s23.p0	anesthetics	None	group	calcium channel blockers	None	True	advise	group	When used concomitantly, anesthetics and calcium channel blockers should be titrated carefully.
DDI-DrugBank.d565.s34.p2	triazolam	DB00897	drug	diltiazem	DB00343	True	mechanism	drug	The elimination half life of midazolam and triazolam also increased (1.5-2.5 fold) during coadministration with diltiazem.
DDI-DrugBank.d565.s35.p1	diltiazem	DB00343	drug	triazolam	DB00897	True	effect	drug	These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and triazolam.
DDI-DrugBank.d565.s37.p0	diltiazem	DB00343	drug	lovastatin	DB00227	True	mechanism	drug	In a ten-subject study, coadministration of diltiazem (120 mg bid) with lovastatin resulted in a 3-4 times increase in mean lovastatin AUC and Cmax vs. lovastatin alone;
DDI-DrugBank.d566.s0.p3	Cholestyramine	DB01432	drug	thiazide diuretics	None	True	mechanism	group	Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
DDI-DrugBank.d566.s0.p5	Cholestyramine	DB01432	drug	tetracycline	DB00759	True	mechanism	drug	Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
DDI-DrugBank.d566.s0.p6	Cholestyramine	DB01432	drug	penicillin G	None	True	mechanism	drug	Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
DDI-DrugBank.d57.s0.p0	aminoglycoside	None	group	antibiotics	None	True	effect	group	In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation.
DDI-DrugBank.d57.s0.p1	aminoglycoside	None	group	penicillins	None	True	effect	group	In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation.
DDI-DrugBank.d57.s1.p0	aminoglycoside	None	group	penicillin	None	True	mechanism	group	Even when an aminoglycoside and a penicillin-type drug are administered separately by different routes, a reduction in aminoglycoside serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function.
DDI-DrugBank.d572.s1.p0	ezetimibe	DB00973	drug	cholestyramine	DB01432	True	effect	drug	The incremental LDL-C reduction due to adding ezetimibe to cholestyramine may be reduced by this interaction.
DDI-DrugBank.d572.s6.p2	fenofibrate	DB01039	drug	ezetimibe	DB00973	True	mechanism	drug	Fenofibrate: In a pharmacokinetic study, concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold.
DDI-DrugBank.d575.s0.p5	sulfamethizole	DB00576	drug	teniposide	DB00444	True	mechanism	drug	In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent.
DDI-DrugBank.d576.s4.p0	Salicylates	None	group	anticoagulant drugs	None	True	effect	group	Salicylates given concomitantly with anticoagulant drugs may predispose to systemic bleeding.
DDI-DrugBank.d576.s6.p2	Salicylate	None	group	thyroxine	None	True	mechanism	drug	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.
DDI-DrugBank.d578.s1.p0	cyclosporin	None	drug	methylprednisolone	DB00959	True	mechanism	drug	Mutual inhibition of metabolism occurs with concurrent use of cyclosporin and methylprednisolone;
DDI-DrugBank.d581.s2.p0	lithium	DB01356	drug	Neulasta	None	True	advise	brand	patients receiving lithium and Neulasta should have more frequent monitoring of neutrophil counts.
DDI-DrugBank.d584.s7.p0	warfarin	DB00682	drug	oxandrolone	DB00621	True	advise	drug	Furthermore, in patients receiving both drugs, careful monitoring of the INR or PT, and adjustment of the warfarin dosage if indicated are recommended when the oxandrolone dose is changed or discontinued.
DDI-DrugBank.d585.s0.p9	anticholinergic drugs	None	group	meperidine	None	True	effect	drug	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
DDI-DrugBank.d585.s1.p0	Anticholinergics	None	group	antiglaucoma agents	None	True	effect	group	Anticholinergics antagonize the effects of antiglaucoma agents.
DDI-DrugBank.d585.s6.p0	antacids	None	group	anticholinergic agents	None	True	mechanism	group	Because antacids may interfere with the absorption of anticholinergic agents, simultaneous use of these drugs should be avoided.
DDI-DrugBank.d588.s0.p5	loop diuretics	None	group	metolazone	DB00524	True	effect	drug	Diuretics: Furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes.
DDI-DrugBank.d588.s8.p3	Diuretic	None	group	curariform drugs	None	True	effect	group	Curariform Drugs: Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea.
DDI-DrugBank.d59.s1.p0	ERGOMAR	None	brand	vasoconstrictor drugs	None	True	effect	group	The pressor effects of ERGOMAR and other vasoconstrictor drugs can combine to cause dangerous hypertension.
DDI-DrugBank.d591.s3.p0	fluvoxamine	DB00176	drug	Ropivacaine	DB00296	True	int	drug	Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased ropivacaine plasma levels.
DDI-DrugBank.d597.s20.p3	lithium	DB01356	drug	meloxicam	DB00814	True	mechanism	drug	In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone.
DDI-DrugBank.d60.s12.p20	NIMBEX	None	brand	lincomycin	DB01627	True	effect	drug	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d60.s12.p27	NIMBEX	None	brand	procainamide	DB01035	True	effect	drug	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d60.s12.p3	nondepolarizing agents	None	group	tetracyclines	None	True	effect	group	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d60.s12.p6	nondepolarizing agents	None	group	lincomycin	DB01627	True	effect	drug	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d60.s13.p0	nondepolarizing neuromuscular blocking agents	None	group	phenytoin	DB00252	True	effect	drug	Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.
DDI-DrugBank.d60.s14.p2	carbamazepine	DB00564	drug	NIMBEX	None	True	effect	brand	While the effects of chronic phenytoin or carbamazepine therapy on the action of NIMBEX are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.
DDI-DrugBank.d60.s3.p3	succinylcholine	DB00202	drug	NIMBEX	None	True	effect	brand	Infusion requirements of NIMBEX in patients administered succinylcholine prior to infusions of NIMBEX were comparable to or slightly greater than when succinylcholine was not administered.
DDI-DrugBank.d60.s9.p2	isoflurane	DB00753	drug	NIMBEX	None	True	advise	brand	In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.
DDI-DrugBank.d601.s0.p3	Barbiturates	None	group	theophylline	DB00277	True	int	drug	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.
DDI-DrugBank.d601.s0.p6	Barbiturates	None	group	beta blockers	None	True	int	group	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.
DDI-DrugBank.d602.s1.p0	NEXAVAR	None	brand	doxorubicin	DB00997	True	mechanism	drug	Concomitant treatment with NEXAVAR resulted in a 21% increase in the AUC of doxorubicin.
DDI-DrugBank.d602.s2.p0	doxorubicin	DB00997	drug	NEXAVAR	None	True	advise	brand	Caution is recommended when administering doxorubicin with NEXAVAR.
DDI-DrugBank.d606.s1.p1	Sympathomimetics	None	group	mecamylamine	DB00657	True	effect	drug	Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.
DDI-DrugBank.d608.s2.p0	TOLECTIN	None	brand	anticoagulants	None	True	advise	group	Therefore, caution should be exercised when administering TOLECTIN to patients on anticoagulants.
DDI-DrugBank.d611.s0.p0	beta adrenergic aerosol bronchodilators	None	group	Alupent	None	True	advise	brand	Other beta adrenergic aerosol bronchodilators should not be used concomitantly with Alupent    (metaproterenol sulfate USP) because they may have additive effects.
DDI-DrugBank.d615.s0.p0	Triprolidine	DB00427	drug	central nervous system depressants	None	True	effect	group	Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.
DDI-DrugBank.d615.s0.p2	Triprolidine	DB00427	drug	barbiturates	None	True	effect	group	Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.
DDI-DrugBank.d615.s0.p4	Triprolidine	DB00427	drug	narcotic analgesics	None	True	effect	group	Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.
DDI-DrugBank.d615.s0.p5	Triprolidine	DB00427	drug	sedatives	None	True	effect	group	Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.
DDI-DrugBank.d619.s4.p5	selective serotonin reuptake inhibitors	None	group	ELDEPRYL	None	True	effect	brand	Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and selective serotonin reuptake inhibitors and ELDEPRYL.
DDI-DrugBank.d62.s0.p1	Dexbrompheniramine	DB00405	drug	CNS depressants	None	True	int	group	Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
DDI-DrugBank.d624.s0.p9	TOBI	None	brand	(beta)-agonists	None	True	effect	group	In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
DDI-DrugBank.d624.s2.p0	diuretics	None	group	aminoglycoside	None	True	effect	group	Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue.
DDI-DrugBank.d625.s0.p5	Nalidixic acid	DB00779	drug	melphalan	DB01042	True	effect	drug	DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.
DDI-DrugBank.d625.s1.p0	melphalan	DB01042	drug	cyclosporin	None	True	effect	drug	Impaired renal function has been described in bone marrow transplant patients who were conditioned with high-dose intravenous melphalan and who subsequently received cyclosporin to prevent graft-versus-host disease
DDI-DrugBank.d628.s0.p2	DIPRIVAN	None	brand	meperidine	None	True	effect	drug	The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.)
DDI-DrugBank.d628.s3.p0	DIPRIVAN	None	brand	analgesic agents	None	True	advise	group	During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids).
DDI-DrugBank.d633.s15.p8	magnesium-aluminum hydroxide	None	drug	digoxin	DB00390	True	mechanism	drug	Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels.
DDI-DrugBank.d633.s18.p8	Theophylline	DB00277	drug	Mexitil	None	True	mechanism	brand	This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed.
DDI-DrugBank.d633.s20.p0	caffeine	DB00201	drug	Mexitil	None	True	mechanism	brand	Additionally, in one controlled study in five normal subjects and seven patients, the clearance of caffeine was decreased 50% following the administration of Mexitil   .
DDI-DrugBank.d633.s9.p7	phenobarbital	DB01174	drug	Mexitil	None	True	mechanism	brand	When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported.
DDI-DrugBank.d636.s3.p2	Mephenytoin	DB00532	drug	anti-infective medicines	None	True	effect	group	Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.
DDI-DrugBank.d637.s0.p6	morphine	DB00295	drug	CNS depressants	None	True	effect	group	Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs.
DDI-DrugBank.d638.s2.p0	Ritalin	None	brand	coumarin anticoagulants	None	True	mechanism	group	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).
DDI-DrugBank.d638.s2.p6	Ritalin	None	brand	tricyclic drugs	None	True	mechanism	group	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).
DDI-DrugBank.d639.s0.p1	SUTENT	None	brand	itraconazole	DB01167	True	mechanism	drug	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
DDI-DrugBank.d639.s0.p7	SUTENT	None	brand	ritonavir	DB00503	True	mechanism	drug	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
DDI-DrugBank.d639.s2.p0	SUTENT	None	brand	dexamethasone	DB01234	True	mechanism	drug	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.
DDI-DrugBank.d639.s2.p1	SUTENT	None	brand	phenytoin	DB00252	True	mechanism	drug	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.
DDI-DrugBank.d639.s2.p2	SUTENT	None	brand	carbamazepine	DB00564	True	mechanism	drug	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.
DDI-DrugBank.d64.s29.p12	anticoagulant	None	group	glutethimide	DB01437	True	effect	drug	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
DDI-DrugBank.d64.s30.p0	anticoagulant	None	group	alcohol	None	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;
DDI-DrugBank.d64.s87.p31	anticoagulant	None	group	nalidixic acid	DB00779	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p33	anticoagulant	None	group	oxolinic acid	None	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p34	anticoagulant	None	group	oxyphenbutazone	DB03585	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p41	anticoagulant	None	group	quinidine	DB00908	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p46	anticoagulant	None	group	sulfonamides	None	True	effect	group	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s88.p0	anticoagulants	None	group	hypoglycemic agents	None	True	mechanism	group	Oral anticoagulants may potentiate the hypoglycemic action of hypoglycemic agents, eg, tolbutamide and chlorpropamide, by inhibiting their metabolism in the liver.
DDI-DrugBank.d64.s89.p0	anticoagulants	None	group	phenytoin	DB00252	True	mechanism	drug	Because oral anticoagulants may interfere with the hepatic metabolism of phenytoin, toxic levels of the anticonvulsant may occur when an oral anticoagulant and phenytoin are administered concurrently.
DDI-DrugBank.d641.s4.p0	NSAIDs	None	group	ALIMTA	None	True	advise	brand	Patients with mild to moderate renal insufficiency should avoid taking NSAIDs with short elimination half-lives for a period of 2 days before, the day of, and 2 days following administration of ALIMTA.
DDI-DrugBank.d647.s2.p0	doxorubicin	DB00997	drug	ZANOSAR	None	True	advise	brand	a reduction of the doxorubicin dosage should be considered in patients receiving ZANOSAR concurrently.
DDI-DrugBank.d648.s6.p1	EVISTA	None	brand	indomethacin	DB00328	True	advise	drug	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide.
DDI-DrugBank.d648.s6.p2	EVISTA	None	brand	naproxen	DB00788	True	advise	drug	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide.
DDI-DrugBank.d648.s6.p3	EVISTA	None	brand	ibuprofen	DB01050	True	advise	drug	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide.
DDI-DrugBank.d649.s0.p0	Sulfamethizole	DB00576	drug	barbiturates	None	True	effect	group	Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics.
DDI-DrugBank.d65.s0.p0	Sulfacetamide	DB00634	drug	silver	None	True	int	drug	Sulfacetamide preparations are incompatible with silver preparations.
DDI-DrugBank.d650.s0.p5	Dopamine antagonists	None	group	Permax	None	True	advise	brand	Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist);
DDI-DrugBank.d651.s0.p0	contraceptives	None	group	vitamin A	DB00162	True	mechanism	group	Drug Interactions: Women on oral contraceptives have shown a significant increase in plasma vitamin A levels.
DDI-DrugBank.d652.s1.p2	metoclopramide	DB01233	drug	hypnotics	None	True	effect	group	Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers.
DDI-DrugBank.d652.s1.p3	metoclopramide	DB01233	drug	narcotics	None	True	effect	group	Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers.
DDI-DrugBank.d653.s1.p5	phenytoin	DB00252	drug	corticosteroids	None	True	mechanism	group	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.
DDI-DrugBank.d653.s5.p2	salicylate	None	group	corticosteroid	None	True	effect	group	This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn.
DDI-DrugBank.d655.s0.p2	Methscopolamine	None	drug	MAO inhibitors	None	True	int	group	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
DDI-DrugBank.d655.s0.p9	Methscopolamine	None	drug	quinidine	DB00908	True	int	drug	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
DDI-DrugBank.d656.s2.p27	FELDENE	None	brand	lithium	DB01356	True	mechanism	drug	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels.
DDI-DrugBank.d670.s6.p1	paliperidone	DB01267	drug	centrally acting drugs	None	True	advise	group	Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol.
DDI-DrugBank.d676.s2.p0	Matulane	None	brand	sympathomimetic drugs	None	True	advise	group	Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.
DDI-DrugBank.d676.s2.p2	Matulane	None	brand	amitriptyline HCl	None	True	advise	drug	Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.
DDI-DrugBank.d676.s2.p3	Matulane	None	brand	imipramine HCl	None	True	advise	drug	Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.
DDI-DrugBank.d676.s2.p4	Matulane	None	brand	tyramine	None	True	advise	drug_n	Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.
DDI-DrugBank.d677.s0.p4	Phenothiazines	None	group	alcohol	None	True	effect	drug	Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.)
DDI-DrugBank.d680.s5.p2	pantoprazole	DB00213	drug	warfarin	DB00682	True	effect	drug	There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including pantoprazole, and warfarin concomitantly.
DDI-DrugBank.d318.s5.p2	amphotericin B	DB00681	drug	digitalis	None	True	effect	group	Digitalis glycosides: amphotericin B-induced hypokalemia may potentiate digitalis toxicity.
DDI-DrugBank.d324.s1.p4	Sonata	None	brand	ethanol	DB00898	True	effect	drug	CNS-Active Drugs Ethanol: Sonata 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.
DDI-DrugBank.d324.s4.p2	Sonata	None	brand	imipramine	DB00458	True	effect	drug	Imipramine: Coadministration of single doses of Sonata 20 mg and imipramine 75 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.
DDI-DrugBank.d324.s8.p2	Sonata	None	brand	thioridazine	DB00679	True	effect	drug	Thioridazine: Coadministration of single doses of Sonata 20 mg and thioridazine 50 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.
DDI-DrugBank.d325.s10.p0	dopamine HCl	None	drug	cyclopropane	None	True	advise	drug	Therefore, EXTREME CAUTION should be exercised when administering dopamine HCl to patients receiving cyclopropane or halogenated hydrocarbon anesthetics.
DDI-DrugBank.d325.s13.p0	phenytoin	DB00252	drug	dopamine HCl	None	True	effect	drug	Administration of phenytoin to patients receiving dopamine HCl has been reported to lead to hypotension and bradycardia.
DDI-DrugBank.d325.s14.p0	dopamine HCl	None	drug	phenytoin	DB00252	True	advise	drug	It is suggested that in patients receiving dopamine HCl, alternatives to phenytoin should be used if anticonvulsant therapy is needed.
DDI-DrugBank.d326.s1.p7	piperazine	DB00592	drug	pyrantel	None	True	effect	drug	Pyrantel (e.g., Antiminth) - Taking piperazine and pyrantel together may decrease the effects of piperazine.
DDI-DrugBank.d328.s29.p1	valdecoxib	DB00580	drug	ketoconazole	DB01026	True	mechanism	drug	Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.
DDI-DrugBank.d330.s2.p1	neomycin	DB00994	drug	vitamin B-12	None	True	mechanism	drug	Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.
DDI-DrugBank.d333.s3.p14	clonazepam	DB01068	drug	propantheline	DB00782	True	mechanism	drug	In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.
DDI-DrugBank.d680.s7.p0	proton pump inhibitors	None	group	warfarin	DB00682	True	advise	drug	Patients treated with proton pump inhibitors and warfarin concomitantly should be monitored for increases in INR and prothrombin time.
DDI-DrugBank.d686.s0.p0	Thiabendazole	DB00730	drug	theophylline	DB00277	True	mechanism	drug	Thiabendazole may compete with other drugs, such as theophylline, for sites of metabolism in the liver, thus elevating the serum levels of such compounds to potentially toxic levels.
DDI-DrugBank.d687.s0.p0	valproic acid	DB00313	drug	temozolomide	DB00853	True	mechanism	drug	Administration of valproic acid decreases oral clearance of temozolomide by about 5%.
DDI-DrugBank.d689.s0.p1	Vasopressors	None	group	halothane	DB01159	True	effect	drug	Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all.
DDI-DrugBank.d689.s0.p2	metaraminol	DB00610	drug	halothane	DB01159	True	effect	drug	Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all.
DDI-DrugBank.d689.s1.p4	sympathomimetic pressor amines	None	group	MAOI	None	True	effect	group	MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI).
DDI-DrugBank.d697.s0.p3	Vitamin B1	None	drug	Stavudine	DB00649	True	int	drug	Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants
DDI-DrugBank.d698.s1.p0	Probenecid	DB01032	drug	riboflavin	DB00140	True	mechanism	drug	Probenecid - concurrent use decreases gastrointestinal absorption of riboflavin;
DDI-DrugBank.d699.s0.p3	Mequitazine	DB01071	drug	MAOIs	None	True	int	group	Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.
DDI-DrugBank.d7.s0.p0	cyclophosphamide	DB00531	drug	phenobarbital	DB01174	True	mechanism	drug	The rate of metabolism and the leukopenic activity of cyclophosphamide reportedly are increased by chronic administration of high doses of phenobarbital.
DDI-DrugBank.d700.s11.p0	contraceptives	None	group	Myfortic	None	True	advise	brand	Therefore, it is recommended that oral contraceptives are co- administered with Myfortic with caution and additional birth control methods be considered.
DDI-DrugBank.d703.s0.p12	MEPERIDINE	None	drug	PHENOTHIAZINES	None	True	advise	group	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
DDI-DrugBank.d703.s0.p13	MEPERIDINE	None	drug	TRANQUILIZERS	None	True	advise	group	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
DDI-DrugBank.d703.s0.p18	MEPERIDINE	None	drug	ALCOHOL	None	True	advise	drug	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
DDI-DrugBank.d704.s4.p0	FLOMAX	None	brand	cimetidine	DB00501	True	advise	drug	Therefore, FLOMAX capsules should be used with caution in combination with cimetidine, particularly at doses higher than 0.4 mg.
DDI-DrugBank.d713.s2.p12	Sanctura	None	brand	vancomycin	DB00512	True	mechanism	drug	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).
DDI-DrugBank.d716.s0.p4	mazindol	DB00579	drug	tranylcypromine	DB00752	True	advise	drug	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.
DDI-DrugBank.d716.s0.p5	mazindol	DB00579	drug	Parnate	None	True	advise	brand	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.
DDI-DrugBank.d716.s1.p0	insulin	None	drug	mazindol	DB00579	True	advise	drug	Changes in insulin and other diabetes drug therapies may be necessary during treatment with mazindol.
DDI-DrugBank.d716.s2.p1	Mazindol	DB00579	drug	Ismelin	None	True	effect	brand	Mazindol may reduce the effects of guanethidine (Ismelin).
DDI-DrugBank.d720.s1.p3	ergotamine	DB00696	drug	sumatriptan	DB00669	True	advise	drug	Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided.
DDI-DrugBank.d720.s1.p8	dihydroergotamine	DB00320	drug	sumatriptan	DB00669	True	advise	drug	Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided.
DDI-DrugBank.d721.s0.p26	magnesium	DB01378	drug	SKELID	None	True	mechanism	brand	The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID.
DDI-DrugBank.d723.s0.p8	Miochol	None	brand	suprofen	DB00870	True	effect	drug	Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.
DDI-DrugBank.d725.s1.p3	sympathomimetic pressor amines	None	group	monoamine oxidase inhibitors	None	True	effect	group	MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI).
DDI-DrugBank.d726.s1.p54	paricalcitol	DB00910	drug	ketoconazole	DB01026	True	advise	drug	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
DDI-DrugBank.d726.s1.p59	paricalcitol	DB00910	drug	nefazodone	DB01149	True	advise	drug	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
DDI-DrugBank.d726.s1.p64	paricalcitol	DB00910	drug	voriconazole	DB00582	True	advise	drug	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
DDI-DrugBank.d728.s2.p0	5-FU	None	drug	ELOXATIN	None	True	mechanism	brand	Increases of 5-FU plasma concentrations by approximately 20% have been observed with doses of 130 mg/m2 ELOXATIN dosed every 3 weeks.
DDI-DrugBank.d73.s5.p5	beta blockers	None	group	clonidine	DB00575	True	advise	drug	If replacing clonidine by beta-blocker therapy, the introduction of beta blockers should be delayed for several days after clonidine administration has stopped.
DDI-DrugBank.d737.s6.p56	quinidine	DB00908	drug	pramipexole	DB00413	True	mechanism	drug	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
DDI-DrugBank.d737.s6.p80	cephalosporins	None	group	pramipexole	DB00413	True	mechanism	drug	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
DDI-DrugBank.d737.s6.p90	chlorpropamide	DB00672	drug	pramipexole	DB00413	True	mechanism	drug	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
DDI-DrugBank.d738.s0.p0	VESIcare	None	brand	ketoconazole	DB01026	True	advise	drug	Do not exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors.
DDI-DrugBank.d739.s15.p1	phenobarbital	DB01174	drug	montelukast	DB00471	True	advise	drug	It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.
DDI-DrugBank.d743.s8.p5	azole-type antifungal agents	None	group	terfenadine	DB00342	True	advise	drug	Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.
DDI-DrugBank.d747.s0.p1	Tetracycline	DB00759	group	penicillin	None	True	effect	drug	Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.
DDI-DrugBank.d75.s10.p0	fluvoxamine	DB00176	drug	anagrelide	DB00261	True	mechanism	drug	It is known that CYP1A2 is inhibited by several medicinal products, including fluvoxamine, and such medicinal products could theoretically adversely influence the clearance of anagrelide.
DDI-DrugBank.d75.s12.p0	Anagrelide	DB00261	drug	theophylline	DB00277	True	mechanism	drug	Anagrelide demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e.g. theophylline.
DDI-DrugBank.d75.s8.p0	Anagrelide	DB00261	drug	aspirin	None	True	effect	brand	Anagrelide alone had no effect on platelet aggregation, but did slightly enhance the inhibition of platelet aggregation by aspirin.
DDI-DrugBank.d750.s0.p0	alcohol	None	drug	phentermine hydrochloride	None	True	int	drug	Concomitant use of alcohol with phentermine hydrochloride may result in an adverse drug interaction.
DDI-DrugBank.d751.s1.p1	AGGRASTAT	None	brand	aspirin	None	True	effect	brand	The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see
DDI-DrugBank.d752.s0.p3	midazolam	DB00683	drug	macrolide antibiotics	None	True	advise	group	Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics).
DDI-DrugBank.d752.s1.p20	itraconazole	DB01167	drug	midazolam	DB00683	True	mechanism	drug	Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam.
DDI-DrugBank.d753.s4.p0	cimetidine	DB00501	drug	opioid analgesics	None	True	effect	group	In addition, CNS toxicity has been reported (confusion, disorientation, respiratory depression, apnea, seizures) following coadministration of cimetidine with opioid analgesics;
DDI-DrugBank.d756.s0.p2	levomepromazine	None	drug	opioids	None	True	effect	group	Dosages of concomitantly administered opioids should be reduced by approximately half, because levomepromazine amplifies the therapeutic actions and side-effects of opioids.
DDI-DrugBank.d76.s12.p13	midazolam	DB00683	drug	fluvoxamine	DB00176	True	mechanism	drug	Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.
DDI-DrugBank.d761.s4.p0	XENICAL	None	brand	vitamin E acetate	None	True	mechanism	drug	XENICAL inhibited absorption of a vitamin E acetate supplement by approximately 60%.
DDI-DrugBank.d762.s0.p0	Probenecid	DB01032	drug	meropenem	DB00760	True	mechanism	drug	Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem.
DDI-DrugBank.d765.s1.p38	erythromycin	DB00199	drug	DETROL LA	None	True	advise	brand	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.
DDI-DrugBank.d766.s1.p2	trimetrexate	DB01157	drug	rifabutin	DB00615	True	effect	drug	Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole.
DDI-DrugBank.d766.s2.p0	cimetidine	DB00501	drug	trimetrexate	DB01157	True	mechanism	drug	In vitro perfusion of isolated rat liver has shown that cimetidine caused a significant reduction in trimetrexate metabolism and that acetaminophen altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites.
DDI-DrugBank.d769.s2.p3	ZOLINZA	None	brand	HDAC inhibitors	None	True	effect	group	Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g., valproic acid).
DDI-DrugBank.d77.s16.p0	SSRI	None	group	TCA	None	True	int	group	The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition, and the pharmacokinetics of the SSRI involved.
DDI-DrugBank.d77.s4.p0	Imipramine hydrochloride	None	drug	CNS depressant drugs	None	True	effect	group	Imipramine hydrochloride may potentiate the effects of CNS depressant drugs.
DDI-DrugBank.d773.s2.p4	Anticoagulants	None	group	TNKase	None	True	effect	brand	Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.
DDI-DrugBank.d775.s10.p10	nondepolarizing agents	None	drug	magnesium	DB01378	True	int	group	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d775.s10.p12	nondepolarizing agents	None	drug	anesthetics	None	True	int	group	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d775.s10.p28	MIVACRON	None	brand	quinidine	DB00908	True	int	drug	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d775.s10.p5	nondepolarizing agents	None	drug	polymyxins	None	True	int	group	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d267.s5.p10	NUROMAX	None	brand	lithium	DB01356	True	effect	drug	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d267.s5.p9	NUROMAX	None	brand	magnesium	DB01378	True	effect	drug	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d269.s12.p0	digoxin	DB00390	drug	COREG	None	True	effect	brand	Both digoxin and COREG slow AV conduction.
DDI-DrugBank.d269.s4.p2	clonidine	DB00575	drug	agents with b-blocking properties	None	True	effect	group	Clonidine: Concomitant administration of clonidine with agents with b-blocking properties may potentiate blood-pressure- and heart-rate-lowering effects.
DDI-DrugBank.d270.s53.p0	Nevirapine	DB00238	drug	rifampin	None	True	advise	drug	Nevirapine and rifampin should not beadministered concomitantly becausedecreases in nevirapine plasmaconcentrations may reduce the efficacy ofthe drug.
DDI-DrugBank.d272.s2.p3	bromocriptine mesylate	None	drug	pimozide	DB01100	True	effect	drug	Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide.
DDI-DrugBank.d276.s2.p4	probenecid	DB01032	drug	nitrofurantoin	DB00698	True	mechanism	drug	Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.
DDI-DrugBank.d277.s11.p3	tiagabine	DB00906	drug	phenytoin	DB00252	True	mechanism	drug	Phenytoin: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenytoin with or without other enzyme- inducing AEDs.
DDI-DrugBank.d279.s10.p0	laxative	None	group	CAMPTOSAR	None	True	effect	brand	It would be expected that laxative use during therapy with CAMPTOSAR would worsen the incidence or severity of diarrhea, but this has not been studied.
DDI-DrugBank.d284.s3.p14	diuretics	None	group	adrenergic agonists	None	True	effect	group	Concomitant treatment with methylxanthines (aminophylline, theophylline), steroids, or diuretics may potentiate any hypokalemic effect of adrenergic agonists.
DDI-DrugBank.d775.s11.p18	neuromuscular blocking agents	None	group	phenytoin	DB00252	True	effect	drug	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.
DDI-DrugBank.d776.s17.p0	DIFLUCAN	None	brand	rifampin	None	True	advise	drug	Depending on clinical circumstances, consideration should be given to increasing the dose of DIFLUCAN when it is administered with rifampin.
DDI-DrugBank.d776.s26.p0	fluconazole	DB00196	drug	cisapride	DB00604	True	mechanism	drug	A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.
DDI-DrugBank.d776.s27.p0	fluconazole	DB00196	drug	cisapride	DB00604	True	advise	drug	The combined use of fluconazole with cisapride is contraindicated.
DDI-DrugBank.d776.s31.p2	fluconazole	DB00196	drug	rifabutin	DB00615	True	effect	drug	Rifabutin: There have been reports of uveitis in patients to whom fluconazole and rifabutin were coadministered.
DDI-DrugBank.d776.s36.p0	midazolam	DB00683	drug	fluconazole	DB00196	True	effect	drug	This effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously.
DDI-DrugBank.d776.s4.p1	DIFLUCAN	None	brand	glyburide	DB01016	True	mechanism	drug	DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents.
DDI-DrugBank.d777.s5.p0	aspirin	None	brand	Streptokinase	DB00086	True	effect	drug	The addition of aspirin to Streptokinase causes a minimal increase in the risk of minor bleeding (3.9% vs. 3.1%), but does not appear to increase the incidence of major bleeding (see
DDI-DrugBank.d78.s1.p7	quinolones	None	group	iron	DB01592	True	mechanism	drug	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
DDI-DrugBank.d78.s3.p10	Grepafloxacin	DB00365	drug	caffeine	DB00201	True	mechanism	drug	Caffeine Theobromine Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and theobromine.
DDI-DrugBank.d781.s11.p12	digoxin	DB00390	drug	perindopril	DB00790	True	mechanism	drug	Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded.
DDI-DrugBank.d8.s0.p0	ALFENTA	None	brand	CNS depressants	None	True	effect	group	Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as barbiturates, tranquilizers, opioids, or inhalation general anesthetics.
DDI-DrugBank.d81.s10.p0	rifampicin	DB01045	drug	isradipine	DB00270	True	mechanism	drug	If rifampicin therapy is required, isradipine concentrations and therapeutic effects are likely to be markedly reduced or abolished as a consequence of increased metabolism and higher clearance of isradipine.
DDI-DrugBank.d81.s9.p3	rifampicin	DB01045	drug	isradipine	DB00270	True	mechanism	drug	Rifampicin: In a study in healthy volunteers, a six-day course of rifampicin at 600 mg/day followed by a single 5 mg dose of isradipine resulted in a reduction in isradipine levels to below detectable limits.
DDI-DrugBank.d82.s16.p0	INDOCIN	None	brand	lithium	DB01356	True	mechanism	drug	Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.
DDI-DrugBank.d82.s2.p0	diflunisal	DB00861	drug	INDOCIN	None	True	advise	brand	Therefore, diflunisal and INDOCIN should not be used concomitantly.
DDI-DrugBank.d84.s1.p12	Exjade	None	brand	aluminum	None	True	advise	drug	Although deferasirox has a lower affinity for aluminum than for iron, Exjade should not be taken with aluminum-containing antacid preparations.
DDI-DrugBank.d85.s12.p5	naproxen sodium	None	drug	methotrexate	DB00563	True	mechanism	drug	Naproxen, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.
DDI-DrugBank.d86.s0.p11	antiparkinsonian drug	None	group	amitriptyline	DB00321	True	effect	drug	The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
DDI-DrugBank.d86.s0.p12	trihexyphenidyl	DB00376	drug	tricyclic antidepressant	None	True	effect	group	The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
DDI-DrugBank.d86.s0.p8	chlorpromazine	DB00477	drug	amitriptyline	DB00321	True	effect	drug	The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
DDI-DrugBank.d89.s3.p24	caffeine	DB00201	drug	phenytoin	DB00252	True	advise	drug	Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).
DDI-DrugBank.d94.s11.p10	EQUETROTM	None	brand	delavirdine	DB00705	True	mechanism	drug	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s11.p16	EQUETROTM	None	brand	felbamate	DB00949	True	mechanism	drug	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s11.p30	EQUETROTM	None	brand	oxcarbazepine	DB00776	True	mechanism	drug	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s11.p31	EQUETROTM	None	brand	Phenytoin	DB00252	True	mechanism	drug	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s13.p7	EQUETROTM	None	brand	primidone	DB00794	True	mechanism	drug	Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.
DDI-DrugBank.d94.s16.p2	anti-malarial drugs	None	group	carbamazepine	DB00564	True	effect	drug	Additionally, anti-malarial drugs, such as chloroquine and mefloquine, may antagonize the activity of carbamazepine.
DDI-DrugBank.d94.s4.p11	EQUETROTM	None	brand	isoniazid	DB00951	True	mechanism	drug	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
DDI-DrugBank.d95.s3.p2	L-arginine	DB00125	drug	sildenafil citrate	None	True	effect	drug	Sildenafil citrate - Theoretically, L-arginine supplements taken concomitantly with sildenafil citrate, may potentiate the effects of the drug.
DDI-DrugBank.d96.s0.p1	Dimenhydrinate	DB00985	drug	apomorphine	DB00714	True	effect	drug	Dimenhydrinate may decrease emetic response to apomorphine.
DDI-DrugBank.d97.s35.p0	CRIXIVAN	None	brand	delavirdine	DB00705	True	advise	drug	Dose reduction of CRIXIVAN to 600 mg every 8 hours should be considered when taking delavirdine 400 mg three times a day.
DDI-DrugBank.d97.s47.p0	Indinavir	DB00224	drug	nevirapine	DB00238	True	mechanism	drug	Indinavir concentrations may be decreased in the presence of nevirapine.
DDI-DrugBank.d97.s72.p4	atorvastatin	DB01076	drug	CRIXIVAN	None	True	advise	brand	Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA reductase inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin, fluvastatin, or rosuvastatin in combination with CRIXIVAN.
DDI-DrugBank.d97.s78.p0	CRIXIVAN	None	brand	itraconazole	DB01167	True	advise	drug	Dose reduction of CRIXIVAN to 600 mg every 8 hours is recommended when administering itraconazole concurrently.
DDI-DrugBank.d97.s93.p0	Vardenafil	DB00862	drug	indinavir	DB00224	True	advise	drug	Vardenafil dose should not exceed a maximum of 2.5 mg in a 24-hour period in patients receiving concomitant indinavir therapy.
DDI-DrugBank.d98.s11.p2	vitamin D analogues	None	group	corticosteroids	None	True	mechanism	group	Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.
DDI-DrugBank.d98.s15.p4	Magnesium	DB01378	drug	vitamin D	None	True	advise	group	Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.
DDI-DrugBank.d98.s5.p0	thiazides	None	group	vitamin D	None	True	effect	group	Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.
DDI-MedLine.d110.s9.p1	Ibogaine	None	drug_n	morphine	DB00295	True	effect	drug	Ibogaine attenuates, but 18-MC potentiates, the acute locomotor effects of morphine;
DDI-MedLine.d12.s0.p1	Dexamethasone	DB01234	drug	EGF	None	True	effect	drug_n	Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.
DDI-MedLine.d12.s7.p11	glucocorticoids	None	group	EGF	None	True	effect	drug_n	These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.
DDI-MedLine.d12.s7.p13	retinoids	None	group	EGF	None	True	effect	drug_n	These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.
DDI-MedLine.d126.s7.p0	cypermethrin	None	drug	allopurinol	DB00437	True	effect	drug	Thus, the results suggest that cypermethrin exposure of rats results in free radical-mediated tissue damage, as indicated by elevated cerebral and hepatic lipid peroxidation, which was prevented by allopurinol and Vitamin E.
DDI-MedLine.d131.s4.p0	neurotensin	None	drug_n	tuftsin	None	True	effect	drug_n	On the contrary, neurotensin and tuftsin were agonists in induction of analgesia.
DDI-MedLine.d16.s3.p0	halothane	DB01159	drug	ketamine	DB01221	True	mechanism	drug	However, halothane anesthetic requirement (i.e., MAC) was depressed in a dose-dependent fashion as much as 56% 1-2 hours and as much as 14% 5-6 hours after injection of ketamine, 50 mg/kg, im.
DDI-MedLine.d16.s5.p0	ketamine	DB01221	drug	halothane	DB01159	True	mechanism	drug	The half-life of ketamine in plasma and brain was longer in the presence of halothane than when ketamine was given alone.
DDI-MedLine.d164.s1.p0	lapatinib	DB01259	drug	Herceptin	None	True	effect	brand	Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.
DDI-MedLine.d164.s3.p0	lapatinib	DB01259	drug	Herceptin	None	True	effect	brand	In an in vitro assay, lapatinib induced HER2 expression at the cell surface of HER2-positive breast cancer cell lines, leading to the enhancement of Herceptin-mediated ADCC.
DDI-MedLine.d169.s10.p0	calcium	DB01373	drug	nonheme iron	None	True	mechanism	drug	In conclusion, we demonstrated an isolated effect of calcium (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and heme (as CRBC) iron.
DDI-MedLine.d169.s10.p1	calcium	DB01373	drug	heme iron	None	True	mechanism	drug	In conclusion, we demonstrated an isolated effect of calcium (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and heme (as CRBC) iron.
DDI-MedLine.d179.s7.p0	docetaxel	DB01248	drug	sunitinib	DB01268	True	effect	drug	When cells were exposed to docetaxel followed by sunitinib, synergism was observed.
DDI-MedLine.d181.s4.p0	levothyroxine	DB00451	drug	simeticone	None	True	int	drug	The authors report the case of an infant with confirmed congenital hypothyroidism on levothyroxine who experienced a possible drug interaction with simeticone.
DDI-MedLine.d190.s8.p1	AAV2	None	drug_n	chondroitin ABC lyase	None	True	effect	drug_n	AAV2-mediated retinal transduction is improved by co-injection of heparinase III or chondroitin ABC lyase.
DDI-MedLine.d193.s1.p2	ticagrelor	DB08816	drug	aspirin	None	True	effect	brand	The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).
DDI-MedLine.d194.s0.p0	dasatinib	DB01254	drug	paclitaxel	DB01229	True	effect	drug	The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.
DDI-MedLine.d194.s16.p0	dasatinib	DB01254	drug	paclitaxel	DB01229	True	effect	drug	Studies with forced expression and siRNA knockdown of Bcl-2 and Cdk1 suggest that dasatinib-mediated induction of p27(Kip1) enhanced paclitaxel-induced apoptosis by negatively regulating Bcl-2 and Cdk1 expression.
DDI-MedLine.d20.s4.p0	glycine	DB00145	drug	glutamate	None	True	effect	drug	The successive application of glycine (5 or 10 mg/kg egg weight (e.w.) and glutamate (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of glutamate alone.
DDI-MedLine.d208.s0.p0	Implanon	None	brand	antiretroviral	None	True	effect	group	Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.
DDI-MedLine.d209.s9.p2	tamoxifen	DB00675	drug	fluoxetine	DB00472	True	advise	drug	It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine.
DDI-MedLine.d214.s5.p0	hemantane	None	drug_n	doxycycline	DB00254	True	effect	drug	Acute administration of hemantane or doxycycline failed to influence locomotion in mice, while their combination normalized motor activity.
DDI-MedLine.d231.s8.p1	Moxifloxacin	DB00218	drug	sucralfate	DB00364	True	mechanism	drug	Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.
DDI-MedLine.d231.s8.p7	Lomefloxacin	DB00978	drug	erythromycin	DB00199	True	mechanism	drug	Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.
DDI-MedLine.d231.s8.p8	Lomefloxacin	DB00978	drug	multi-minerals	None	True	mechanism	group	Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.
DDI-MedLine.d3.s13.p0	Rifampin	None	drug	amprenavir	DB00701	True	mechanism	drug	Rifampin markedly increases the metabolic clearance of amprenavir, and coadministration is contraindicated.
DDI-MedLine.d3.s14.p0	Amprenavir	DB00701	drug	rifabutin	DB00615	True	mechanism	drug	Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated.
DDI-MedLine.d3.s7.p0	Amprenavir	DB00701	drug	rifabutin	DB00615	True	mechanism	drug	Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold.
DDI-MedLine.d3.s8.p0	Rifampin	None	drug	amprenavir	DB00701	True	mechanism	drug	Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics.
DDI-MedLine.d34.s7.p1	iron	DB01592	drug	cobalt	None	True	mechanism	drug	Additional iron significantly inhibited the absorption of cobalt in both dietary cobalt treatments.
DDI-MedLine.d39.s6.p0	estradiol	DB00783	drug	endotoxin	None	True	effect	drug_n	Exogenous estradiol also appeared to influence the percentage of endotoxin-induced deaths in a dose-dependent manner.
DDI-MedLine.d46.s13.p0	fluoxetine	DB00472	drug	cisapride	DB00604	True	mechanism	drug	Coadministration of fluoxetine significantly decreased cisapride plasma concentrations.
DDI-MedLine.d62.s4.p0	METH	None	drug	SCH-23390	None	True	effect	drug_n	Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical neuroleptic clozapine.
DDI-MedLine.d63.s6.p1	naloxone	DB01183	drug	morphine	DB00295	True	effect	drug	Intraventricular injection of naloxone at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and morphine.
DDI-MedLine.d67.s5.p0	Diazepam	DB00829	drug	morphine	DB00295	True	effect	drug	Diazepam at doses of 0.25 mg/kg and 2.5 mg/kg injected with morphine was found to decrease the antinociceptive effect of morphine.
DDI-MedLine.d67.s6.p1	diazepam	DB00829	drug	indomethacin	DB00328	True	effect	drug	Similarly, diazepam decreased the antinociceptive effect of metamizol (only in the tail-flick test) and indomethacin.
DDI-MedLine.d7.s1.p0	theophylline	DB00277	drug	phenytoin	DB00252	True	mechanism	drug	This report describes two cases in which theophylline clearance accelerated markedly with concomitant phenytoin administration.
DDI-MedLine.d73.s4.p1	Methamphetamine	DB01577	drug	pargyline	DB01626	True	effect	drug	Methamphetamine, like MPTP, produced depletions of striatal dopamine but these actions were potentiated by pargyline pretreatment.
DDI-MedLine.d82.s8.p0	Vitamin D3	None	drug	arsenate	None	True	mechanism	drug_n	Vitamin D3 administration to rachitic chicks was effective in significantly elevating duodenal arsenate absorption, acting primarily to enhance serosal transport.
DDI-MedLine.d86.s5.p0	sirolimus	DB00877	drug	diltiazem	DB00343	True	mechanism	drug	RESULTS: The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours.
DDI-MedLine.d87.s4.p0	Morphine	DB00295	drug	ADL 8-2698	None	True	effect	drug	Morphine prolonged gastrointestinal transit time from 69 to 103 minutes (P = .005); this was prevented by ADL 8-2698 (P = .004).
DDI-MedLine.d99.s9.p0	fluvoxamine	DB00176	drug	tolbutamide	DB01124	True	mechanism	drug	RESULTS: During treatment with fluvoxamine, there was a statistically significant decrease in the median of the total clearance of tolbutamide, from 845 mL/h to 688 mL/h, among the volunteers who received 75 mg/d.
DDI-DrugBank.d639.s0.p4	SUTENT	None	brand	indinavir	DB00224	True	mechanism	drug	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
DDI-DrugBank.d64.s29.p17	anticoagulant	None	group	paraldehyde	None	True	effect	drug	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
DDI-DrugBank.d64.s29.p21	anticoagulant	None	group	vitamin C	DB00126	True	effect	drug	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
DDI-DrugBank.d64.s87.p1	anticoagulant	None	group	allopurinol	DB00437	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p17	anticoagulant	None	group	disulfiram	DB00822	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p24	anticoagulant	None	group	anesthetics	None	True	effect	group	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p50	anticoagulant	None	group	triclofos sodium	None	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p51	anticoagulant	None	group	trimethoprim	DB00440	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p52	anticoagulant	None	group	sulfamethoxazole	DB01015	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s88.p1	anticoagulants	None	group	tolbutamide	DB01124	True	mechanism	drug	Oral anticoagulants may potentiate the hypoglycemic action of hypoglycemic agents, eg, tolbutamide and chlorpropamide, by inhibiting their metabolism in the liver.
DDI-DrugBank.d64.s88.p2	anticoagulants	None	group	chlorpropamide	DB00672	True	mechanism	drug	Oral anticoagulants may potentiate the hypoglycemic action of hypoglycemic agents, eg, tolbutamide and chlorpropamide, by inhibiting their metabolism in the liver.
DDI-DrugBank.d643.s0.p8	Melatonin	DB01065	drug	progestin	None	True	int	group	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
DDI-DrugBank.d645.s6.p0	terbinafine	DB00857	drug	warfarin	DB00682	True	effect	drug	There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and warfarin, however, a causal relationship between LAMISIL    Tablets and these changes has not been established.
DDI-DrugBank.d650.s0.p25	metoclopramide	DB01233	drug	Permax	None	True	advise	brand	Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist);
DDI-DrugBank.d652.s2.p0	metoclopramide	DB01233	drug	monoamine oxi-dase inhibitors	None	True	advise	group	The finding that metoclopramide releases catecholamines in patients with essential hypertension suggests that it should be used cautiously, if at all, in patients receiving monoamine oxi-dase inhibitors.
DDI-DrugBank.d653.s1.p6	phenytoin	DB00252	drug	corticosteroid	None	True	mechanism	group	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.
DDI-DrugBank.d653.s2.p1	troleandomycin	DB01361	drug	corticosteroids	None	True	mechanism	group	Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.
DDI-DrugBank.d654.s0.p1	ketoconazole	DB01026	drug	retapamulin	DB01256	True	mechanism	drug	Co-administration of oral ketoconazole 200 mg twice daily increased retapamulin geometric mean AUC(0-24) and Cmax by 81% after topical application of retapamulin ointment, 1% on the abraded skin of healthy adult males.
DDI-DrugBank.d655.s0.p1	Methscopolamine	None	drug	tricyclic	None	True	int	group	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
DDI-DrugBank.d655.s0.p18	Methscopolamine	None	drug	pectin	None	True	int	drug	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
DDI-DrugBank.d655.s0.p4	Methscopolamine	None	drug	linezolid	DB00601	True	int	drug	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
DDI-DrugBank.d659.s0.p1	TRENTAL	None	brand	platelet aggregation inhibitors	None	True	effect	group	Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without anticoagulants or platelet aggregation inhibitors.
DDI-DrugBank.d668.s2.p10	phenobarbital	DB01174	drug	mifepristone	DB00834	True	mechanism	drug	John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone).
DDI-DrugBank.d668.s2.p3	anticonvulsants	None	group	mifepristone	DB00834	True	mechanism	drug	John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone).
DDI-DrugBank.d671.s2.p0	CYLERT	None	brand	antiepileptic medications	None	True	effect	group	Decreased seizure threshold has been reported in patients receiving CYLERT concomitantly with antiepileptic medications.
DDI-DrugBank.d675.s7.p3	methylergonovine maleate	None	drug	vasoconstrictors	None	True	advise	group	Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.
DDI-DrugBank.d677.s0.p2	Phenothiazines	None	group	anesthetics	None	True	effect	group	Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.)
DDI-DrugBank.d680.s8.p2	pantoprazole	DB00213	drug	iron	DB01592	True	mechanism	drug	Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts).
DDI-DrugBank.d682.s0.p0	Sulfoxone	DB01145	drug	barbiturates	None	True	effect	group	Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics.
DDI-DrugBank.d682.s0.p2	Sulfoxone	DB01145	drug	uricosurics	None	True	effect	group	Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics.
DDI-DrugBank.d686.s1.p0	thiabendazole	DB00730	drug	xanthine derivatives	None	True	advise	group	Therefore, when concomitant use of thiabendazole and xanthine derivatives is anticipated, it may be necessary to monitor blood levels and/or reduce the dosage of such compounds.
DDI-DrugBank.d69.s2.p0	Cyclophosphamide	DB00531	drug	Cerubidine	None	True	effect	brand	Cyclophosphamide used concurrently with Cerubidine may also result in increased cardiotoxicity.
DDI-DrugBank.d696.s0.p0	Methysergide	DB00247	drug	narcotic analgesics	None	True	effect	group	Methysergide may reverse the analgesic activity of narcotic analgesics.
DDI-DrugBank.d697.s0.p6	Thiamine	DB00152	drug	Contraceptives	None	True	int	group	Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants
DDI-DrugBank.d698.s2.p0	riboflavin	DB00140	drug	probenecid	DB01032	True	effect	drug	requirements for riboflavin may be increased in patients receiving probenecid.
DDI-DrugBank.d700.s10.p0	levonorgesterol	None	drug	mycophenolate mofetil	DB00688	True	mechanism	drug	However, in a drug-drug interaction study, mean levonorgesterol AUC was decreased by 15% when coadministered with mycophenolate mofetil.
DDI-DrugBank.d709.s3.p3	roxithromycin	DB00778	drug	terfenadine	DB00342	True	advise	drug	Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended.
DDI-DrugBank.d711.s2.p4	tetracyclines	None	group	iron	DB01592	True	mechanism	drug	Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations.
DDI-DrugBank.d713.s2.p9	Sanctura	None	brand	procainamide	DB01035	True	mechanism	drug	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).
DDI-DrugBank.d716.s0.p6	mazindol	DB00579	drug	phenelzine	DB00780	True	advise	drug	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.
DDI-DrugBank.d720.s3.p0	sumatriptan succinate	None	drug	MAO-A inhibitors	None	True	advise	group	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.
DDI-DrugBank.d722.s0.p3	mercaptopurine	DB01033	drug	TABLOID	None	True	effect	brand	There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine.
DDI-DrugBank.d286.s2.p2	ethoxzolamide	DB00311	drug	corticosteroids	None	True	effect	group	Coadministration of ethoxzolamide with other diuretics, amphotericin B, and corticosteroids may cause hypokalemia.
DDI-DrugBank.d287.s0.p0	Cevimeline	DB00185	drug	beta adrenergic antagonists	None	True	advise	group	Cevimeline should be administered with caution to patients taking beta adrenergic antagonists, because of the possibility of conduction disturbances.
DDI-DrugBank.d289.s11.p0	bosentan	DB00559	drug	cyclosporine A	None	True	mechanism	drug	Steady-state bosentan plasma concentrations were 3- to 4-fold higher than in the absence of cyclosporine A.
DDI-DrugBank.d289.s16.p0	tacrolimus	DB00864	drug	bosentan	DB00559	True	advise	drug	Caution should be exercised if tacrolimus and bosentan are used together.
DDI-DrugBank.d289.s27.p1	Bosentan	DB00559	drug	lovastatin	DB00227	True	mechanism	drug	Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.
DDI-DrugBank.d289.s27.p2	Bosentan	DB00559	drug	atorvastatin	DB01076	True	mechanism	drug	Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.
DDI-DrugBank.d29.s12.p2	esomeprazole	DB00736	drug	digoxin	DB00390	True	mechanism	drug	Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).
DDI-DrugBank.d291.s1.p0	anticoagulant	None	drug	Bezalip	None	True	advise	brand	For this reason, the dose of the anticoagulant should be reduced by 30 - 50% at the start of treatment with Bezalip or Bezalip retard and then titrated according to the blood clotting parameters
DDI-DrugBank.d298.s0.p1	Cyclopentolate	DB00979	drug	pilocarpine	DB01085	True	effect	drug	Cyclopentolate may interfere with the anti-glaucoma action of carbachol or pilocarpine;
DDI-DrugBank.d3.s12.p5	lithium	DB01356	drug	TORADOL	None	True	mechanism	brand	The effect of TORADOL on plasma lithium has not been studied, but cases of increased lithium plasma levels during TORADOL therapy have been reported.
DDI-DrugBank.d3.s3.p0	salicylate	None	group	ketorolac	DB00465	True	mechanism	drug	In vitro studies indicate that, at therapeutic concentrations of salicylate (300 m g/mL), the binding of ketorolac was reduced from approximately 99.2% to 97.5%, representing a potential twofold increase in unbound ketorolac plasma levels.
DDI-DrugBank.d722.s0.p4	mercaptopurine	DB01033	drug	Thioguanine	DB00352	True	effect	drug	There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine.
DDI-DrugBank.d726.s2.p0	Zemplar	None	brand	ketoconazole	DB01026	True	advise	drug	Dose adjustment of Zemplar Capsules may be required, and iPTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor such as ketoconazole.
DDI-DrugBank.d73.s3.p0	Beta blockers	None	group	clonidine	DB00575	True	effect	drug	Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine.
DDI-DrugBank.d735.s5.p1	sirolimus	DB00877	drug	MYCAMINE	None	True	advise	brand	Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.
DDI-DrugBank.d737.s10.p34	neuroleptics	None	group	MIRAPEX	None	True	effect	brand	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.
DDI-DrugBank.d737.s10.p38	phenothiazines	None	group	MIRAPEX	None	True	effect	brand	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.
DDI-DrugBank.d737.s6.p39	triamterene	DB00384	drug	pramipexole	DB00413	True	mechanism	drug	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
DDI-DrugBank.d737.s6.p84	penicillins	None	group	pramipexole	DB00413	True	mechanism	drug	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
DDI-DrugBank.d741.s0.p0	methadone	DB00333	drug	PEG-Intron	None	True	mechanism	brand	In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving methadone, treatment with PEG-Intron once weekly for 4 weeks was associated with a mean increase of 16% in methadone AUC;
DDI-DrugBank.d743.s5.p7	terfenadine	DB00342	drug	itraconazole	DB01167	True	mechanism	drug	Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources.
DDI-DrugBank.d744.s1.p0	opioids	None	group	pegvisomant	DB00082	True	mechanism	drug	In clinical studies, patients on opioids often needed higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids.
DDI-DrugBank.d746.s1.p1	Monoamine oxidase inhibitors	None	group	sympathomimetic amines	None	True	effect	group	Monoamine oxidase inhibitors or tricyclic antidepressants may potentiate the action of sympathomimetic amines.
DDI-DrugBank.d75.s14.p13	olprinone	None	drug_n	anagrelide	DB00261	True	effect	drug	The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.
DDI-DrugBank.d752.s0.p2	midazolam	DB00683	drug	calcium channel antagonists	None	True	advise	group	Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics).
DDI-DrugBank.d752.s1.p14	verapamil	DB00661	drug	midazolam	DB00683	True	mechanism	drug	Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam.
DDI-DrugBank.d752.s10.p5	VERSED Syrup	None	brand	ketamine	DB01221	True	effect	drug	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.
DDI-DrugBank.d752.s10.p6	VERSED Syrup	None	brand	nitrous oxide	None	True	effect	drug	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.
DDI-DrugBank.d752.s10.p7	VERSED Syrup	None	brand	secobarbital	DB00418	True	effect	drug	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.
DDI-DrugBank.d756.s2.p1	levomepromazine	None	drug	barbiturates	None	True	effect	group	Additive sedative effects and confusional states may emerge if levomepromazine is given with benzodiazepines or barbiturates.
DDI-DrugBank.d756.s7.p5	amphetamine	DB00182	drug	levomepromazine	None	True	effect	drug	Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine.
DDI-DrugBank.d759.s0.p0	ascorbic acid	None	drug	bishydroxycoumarin	None	True	mechanism	drug	Limited evidence suggests that ascorbic acid may influence the intensity and duration of action of bishydroxycoumarin.
DDI-DrugBank.d76.s12.p8	Benzodiazepines	None	group	fluvoxamine	DB00176	True	mechanism	drug	Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.
DDI-DrugBank.d76.s30.p3	fluvoxamine maleate	None	drug	warfarin	DB00682	True	mechanism	drug	Warfarin: When fluvoxamine maleate (50 mg tid) was administered concomitantly with warfarin for two weeks, warfarin plasma concentrations increased by 98% and prothrombin times were prolonged.
DDI-DrugBank.d76.s31.p0	anticoagulants	None	group	Fluvoxamine	DB00176	True	advise	drug	Thus patients receiving oral anticoagulants and Fluvoxamine Tablets should have their prothrombin time monitored and their anticoagulant dose adjusted accordingly.
DDI-DrugBank.d76.s4.p0	Fluvoxamine	DB00176	drug	MAOIs	None	True	advise	group	Therefore, it is recommended that Fluvoxamine Tablets not be used in combination with MAOIs, or within 14 days of discontinuing treatment with a MAOI.
DDI-DrugBank.d76.s7.p4	astemizole	DB00637	drug	ketoconazole	DB01026	True	mechanism	drug	Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.
DDI-DrugBank.d761.s3.p2	beta-carotene	None	drug	XENICAL	None	True	mechanism	brand	Fat-soluble Vitamin Supplements and Analogues: A pharmacokinetic interaction study showed a 30% reduction in beta-carotene supplement absorption when concomitantly administered with XENICAL.
DDI-DrugBank.d765.s1.p29	miconazole	DB01110	drug	DETROL LA	None	True	advise	brand	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.
DDI-DrugBank.d766.s1.p1	trimetrexate	DB01157	drug	rifampin	None	True	effect	drug	Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole.
DDI-DrugBank.d769.s2.p4	ZOLINZA	None	brand	valproic acid	DB00313	True	effect	drug	Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g., valproic acid).
DDI-DrugBank.d770.s4.p0	diphosphonate	None	group	Calcitonin (salmon)	None	True	effect	drug	however, in patients with Paget's Disease prior diphosphonate use appears to reduce the anti-resorptive response to Calcitonin (salmon) nasal spray.
DDI-DrugBank.d771.s1.p0	Scopolamine	DB00747	drug	sedatives	None	True	advise	group	Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, tranquilizers, or alcohol.
DDI-DrugBank.d774.s0.p1	Trilostane	DB01108	drug	mitotane	DB00648	True	int	drug	Trilostane may interact with aminoglutethimide or mitotane (causing too great a decrease in adrenal function).
DDI-DrugBank.d775.s11.p19	neuromuscular blocking agents	None	group	carbamazepine	DB00564	True	effect	drug	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.
DDI-DrugBank.d776.s13.p2	DIFLUCAN	None	brand	cyclosporine	DB00091	True	mechanism	drug	Cyclosporine: DIFLUCAN may significantly increase cyclosporine levels in renal transplant patients with or without renal impairment.
DDI-DrugBank.d776.s16.p2	Rifampin	None	drug	DIFLUCAN	None	True	mechanism	brand	Rifampin: Rifampin enhances the metabolism of concurrently administered DIFLUCAN.
DDI-DrugBank.d776.s24.p0	fluconazole	DB00196	drug	terfenadine	DB00342	True	advise	drug	The coadministration of fluconazole at doses lower than 400 mg/day with terfenadine should be carefully monitored.
DDI-DrugBank.d777.s1.p13	Streptokinase	DB00086	drug	anticoagulants	None	True	effect	group	Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.
DDI-DrugBank.d78.s1.p3	quinolones	None	group	calcium	DB01373	True	mechanism	drug	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
DDI-DrugBank.d780.s0.p4	procaine hydrochloride	None	drug	anticholinesterase agents	None	True	effect	group	Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride.
DDI-DrugBank.d780.s5.p2	Hyaluronidase	DB00070	drug	procaine hydrochloride	None	True	mechanism	drug	Hyaluronidase: Hyaluronidase may increase the diffusion rate of procaine hydrochloride, resulting in a decreased time of onset, but an increase in systemic toxicity.
DDI-DrugBank.d780.s6.p5	procaine hydrochloride	None	drug	neuromuscular blocking agents	None	True	effect	group	Neuromuscular blocking agents (such as suxamethonium chloride): Concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade.
DDI-DrugBank.d781.s0.p2	diuretics	None	group	ACEON	None	True	effect	brand	Diuretics: Patients on diuretics, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of ACEON    Tablets therapy.
DDI-DrugBank.d781.s11.p13	digoxin	DB00390	drug	perindoprilat	None	True	mechanism	drug_n	Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded.
DDI-DrugBank.d781.s2.p0	diuretics	None	group	ACEON	None	True	advise	brand	If diuretics cannot be interrupted, close medical supervision should be provided with the first dose of ACEON    Tablets, for at least two hours and until blood pressure has stabilized for another hour.
DDI-DrugBank.d783.s0.p0	Posicor	None	brand	terfenadine	DB00342	True	mechanism	drug	Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants.
DDI-DrugBank.d783.s0.p2	Posicor	None	brand	cisapride	DB00604	True	mechanism	drug	Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants.
DDI-DrugBank.d783.s0.p4	Posicor	None	brand	tricyclic antidepressants	None	True	mechanism	group	Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants.
DDI-DrugBank.d8.s0.p2	ALFENTA	None	brand	tranquilizers	None	True	effect	group	Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as barbiturates, tranquilizers, opioids, or inhalation general anesthetics.
DDI-DrugBank.d81.s14.p3	fentanyl	DB00813	drug	beta blocker	None	True	effect	group	Fentanyl Anesthesia: Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a beta blocker and a calcium channel blocker.
DDI-DrugBank.d82.s0.p2	diflunisal	DB00861	drug	indomethacin	DB00328	True	mechanism	drug	In normal volunteers receiving indomethacin, the administration of diflunisal decreased the renal clearance and significantly increased the plasma levels of indomethacin.
DDI-DrugBank.d82.s12.p0	INDOCIN	None	brand	methotrexate	DB00563	True	advise	drug	Caution should be used if INDOCIN is administered simultaneously with methotrexate.
DDI-DrugBank.d82.s14.p0	non-steroidal anti-inflammatory drugs	None	group	cyclosporine	DB00091	True	effect	drug	Administration of non-steroidal anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.
DDI-DrugBank.d82.s32.p0	diuretics	None	group	INDOCIN	None	True	effect	brand	Most of the above effects concerning diuretics have been attributed, at least in part, to mechanisms involving inhibition of prostaglandin synthesis by INDOCIN.
DDI-DrugBank.d86.s0.p13	trihexyphenidyl	DB00376	drug	amitriptyline	DB00321	True	effect	drug	The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
DDI-DrugBank.d86.s0.p4	antipsychotic drug	None	group	amitriptyline	DB00321	True	effect	drug	The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
DDI-DrugBank.d86.s0.p5	chlorpromazine	DB00477	drug	antiparkinsonian drug	None	True	effect	group	The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
DDI-DrugBank.d87.s16.p0	quinidine	DB00908	drug	flecainide	DB01195	True	mechanism	drug	Drugs that inhibit cytochrome P450IID6, such as quinidine , might increase the plasma concentrations of flecainide in patients that are on chronic flecainide therapy;
DDI-DrugBank.d87.s3.p0	TAMBOCOR	None	brand	propranolol	DB00571	True	mechanism	drug	In a study involving healthy subjects receiving TAMBOCOR and propranolol concurrently, plasma flecainide levels were increased about 20% and propranolol levels were increased about 30% compared to control values.
DDI-DrugBank.d89.s3.p1	caffeine	DB00201	drug	cimetidine	DB00501	True	advise	drug	Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).
DDI-DrugBank.d91.s3.p0	Boric acid	None	drug	idoxuridine	DB00249	True	mechanism	drug	Boric acid may interact with the idoxuridine preparation causing a gritty substance to form or may interact with the preservative in the idoxuridine preparation causing a toxic effect in the eye.
DDI-DrugBank.d94.s11.p34	EQUETROTM	None	brand	quetiapine	DB01224	True	mechanism	drug	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s11.p38	EQUETROTM	None	brand	tiagabine	DB00906	True	mechanism	drug	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s11.p4	EQUETROTM	None	brand	buspirone	DB00490	True	mechanism	drug	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s11.p41	EQUETROTM	None	brand	valproate	None	True	mechanism	drug	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s11.p6	EQUETROTM	None	brand	clobazam	DB00349	True	mechanism	drug	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s4.p0	EQUETROTM	None	brand	Acetazolamide	DB00819	True	mechanism	drug	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
DDI-DrugBank.d94.s4.p2	EQUETROTM	None	brand	cimetidine	DB00501	True	mechanism	drug	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
DDI-DrugBank.d94.s4.p22	EQUETROTM	None	brand	troleandomycin	DB01361	True	mechanism	drug	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
DDI-DrugBank.d94.s4.p4	EQUETROTM	None	brand	dalfopristin	DB01764	True	mechanism	drug	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
DDI-DrugBank.d99.s23.p1	tricyclic antidepressants	None	drug	cimetidine	DB00501	True	mechanism	drug	Increases in plasma levels of tricyclic antidepressants, and in the frequency and severity of side effects, particularly anticholinergic, have been reported when cimetidine was added to the drug regimen.
DDI-DrugBank.d99.s26.p0	ethchlorvynol	DB00189	drug	amitriptyline HCl	None	True	effect	drug	Transient delirium has been reported in patients who were treated with one gram of ethchlorvynol and 75 - 150 mg of amitriptyline HCl.
DDI-MedLine.d102.s6.p0	estradiol	DB00783	drug	noradrenaline	None	True	effect	drug	Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively).
DDI-MedLine.d106.s6.p1	Barbiturates	None	group	coumarin drugs	None	True	advise	group	Barbiturates and glutethimide should not be administered to patients receiving coumarin drugs.
DDI-MedLine.d107.s9.p0	ethanol	DB00898	drug	acetaldehyde	None	True	effect	drug_n	These results suggest that the hepatoxicity of ethanol in alcoholic beverages is enhanced by interaction with its congeners and acetaldehyde;
DDI-MedLine.d111.s14.p9	phenobarbital	DB01174	drug	acetaminophen	DB00316	True	effect	drug	Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.
DDI-MedLine.d116.s0.p0	Rifampin	None	drug	warfarin	DB00682	True	int	drug	Rifampin and warfarin: a drug interaction.
DDI-MedLine.d116.s4.p0	rifampin	None	drug	warfarin	DB00682	True	mechanism	drug	Withdrawal of rifampin decreased the warfarin requirement by 50%.
DDI-MedLine.d12.s7.p7	retinyl acetate	None	drug	insulin	None	True	effect	drug	These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.
DDI-MedLine.d124.s1.p2	trovafloxacin	DB00685	drug	morphine	DB00295	True	mechanism	drug	Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine.
DDI-MedLine.d124.s1.p3	ciprofloxacin	DB00537	drug	opiate	None	True	mechanism	group	Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine.
DDI-MedLine.d125.s8.p0	4-methylpyrazole	None	drug	1,3-difluoro-2-propanol	None	True	effect	drug_n	We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway.
DDI-MedLine.d126.s0.p1	Cypermethrin	None	drug	allopurinol	DB00437	True	effect	drug	Cypermethrin-induced oxidative stress in rat brain and liver is prevented by vitamin E or allopurinol.
DDI-MedLine.d126.s7.p1	cypermethrin	None	drug	Vitamin E	DB00163	True	effect	drug	Thus, the results suggest that cypermethrin exposure of rats results in free radical-mediated tissue damage, as indicated by elevated cerebral and hepatic lipid peroxidation, which was prevented by allopurinol and Vitamin E.
DDI-MedLine.d128.s15.p0	N-methyllevallorphan	None	drug_n	loperamide	DB00836	True	effect	drug	N-methyllevallorphan (5 mg/kg, s.c.) completely antagonized the inhibitory effect of loperamide and partly antagonized the effect of morphine.
DDI-MedLine.d131.s0.p0	neurotensin	None	drug_n	enkephalins	None	True	effect	drug_n	Interaction on the antinociceptive effect between neurotensin and enkephalins or tuftsin.
DDI-MedLine.d133.s5.p0	Verapamil	DB00661	drug	bombesin	None	True	effect	drug_n	Verapamil also significantly decreased the incidence of lymphatic invasion of adenocarcinomas, which was enhanced by bombesin.
DDI-MedLine.d143.s6.p1	clopidogrel	DB00758	drug	esomeprazole	DB00736	True	advise	drug	Regulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors omeprazole and esomeprazole should be avoided.
DDI-MedLine.d161.s8.p2	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	None	drug_n	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	None	True	effect	drug_n	In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys.
DDI-MedLine.d166.s17.p0	cinacalcet	DB01012	drug	darbepoetin	None	True	effect	drug	Reduction of PTH by cinacalcet is associated with a decrease in darbepoetin requirement.
DDI-MedLine.d169.s2.p0	calcium	DB01373	drug	iron	DB01592	True	mechanism	drug	However, the evidence for a calcium effect on iron absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies.
DDI-MedLine.d17.s9.p0	PGF2alpha	None	drug	oxytocin	DB00107	True	effect	drug	There is thus an enhancement effect of PGF2alpha upon the reaction of placental vessels to oxytocin in vitro.
DDI-MedLine.d180.s12.p2	ABT-737	None	drug_n	DZNep	None	True	effect	drug_n	In addition, DZNep insensitivity might be associated with overexpression of Bcl-2, and the combination of ABT-737 and DZNep could synergistically induced apoptosis.
DDI-MedLine.d189.s10.p5	quinidine	DB00908	drug	precocene I	None	True	effect	drug_n	Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity.
DDI-MedLine.d193.s1.p4	Brilinta	None	brand	aspirin	None	True	effect	brand	The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).
DDI-MedLine.d194.s10.p0	dasatinib	DB01254	drug	paclitaxel	DB01229	True	effect	drug	Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014);
DDI-MedLine.d194.s17.p0	dasatinib	DB01254	drug	paclitaxel	DB01229	True	effect	drug	Inhibition of Src family and Abl kinases with either siRNAs or dasatinib enhances paclitaxel sensitivity of ovarian cancer cells through p27(Kip1)-mediated suppression of Bcl-2 and Cdk1 expression.
DDI-MedLine.d209.s11.p0	antidepressant	None	group	tamoxifen	DB00675	True	advise	drug	If in certain cases, an antidepressant is considered necessary, it may be advisable to replace tamoxifen with anastrozole.
DDI-MedLine.d216.s3.p0	Ticlopidine	DB00208	drug	ketamine	DB01221	True	mechanism	drug	Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine.
DDI-MedLine.d218.s10.p0	Warfarin	DB00682	drug	citalopram	DB00215	True	effect	drug	Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.
DDI-MedLine.d218.s10.p1	Warfarin	DB00682	drug	fluoxetine	DB00472	True	effect	drug	Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.
DDI-MedLine.d218.s8.p2	Warfarin	DB00682	drug	paroxetine	DB00715	True	effect	drug	Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]).
DDI-MedLine.d218.s8.p3	Warfarin	DB00682	drug	amitriptyline	DB00321	True	effect	drug	Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]).
DDI-MedLine.d231.s8.p3	Moxifloxacin	DB00218	drug	erythromycin	DB00199	True	mechanism	drug	Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.
DDI-MedLine.d231.s8.p4	Moxifloxacin	DB00218	drug	multi-minerals	None	True	mechanism	group	Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.
DDI-MedLine.d3.s7.p1	Amprenavir	DB00701	drug	25-O-desacetylrifabutin	None	True	mechanism	drug_n	Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold.
DDI-MedLine.d30.s9.p1	naloxone	DB01183	drug	morphine	DB00295	True	effect	drug	the doses of naloxone required to antagonize the effects of (-)-NANM were more than 100 times higher than those required to antagonize the effects of morphine.
DDI-MedLine.d39.s3.p0	estradiol	DB00783	drug	endotoxin	None	True	mechanism	drug_n	The serum estrogen concentrations of estradiol + endotoxin-treated rats decreased by 50%, while those of the endotoxin-treated rats increased (2- to 5-fold).
DDI-MedLine.d44.s6.p0	Etofibrate	None	drug	heparin	DB01109	True	effect	drug	Etofibrate elicited 62% enhancement of post-heparin lipolytic activity and 100% increase of 3H-triglyceride fractional clearance rate compared with placebo treatment.
DDI-MedLine.d49.s0.p0	clindamycin	DB01190	drug	gentamicin	DB00798	True	int	drug	Interaction of clindamycin and gentamicin in vitro.
DDI-MedLine.d5.s3.p0	trichlorfon	None	drug_n	coumaphos	None	True	effect	drug_n	The treatment of ewes with an intravenous (IV) injection of trichlorfon, insufficient to produce significant inhibition of erythrocyte acetylcholinesterase (AChE) activity, appeared to produce additive effects with those produced by subsequent treatment with 4 mg of coumaphos/kg/day.
DDI-MedLine.d5.s4.p0	phenobarbital sodium	None	drug	coumaphos	None	True	effect	drug_n	In ewes given 40 mg of phenobarbital sodium/kg for 5 days intraperitoneally (IP), the anticholinesterase effect of 4 mg of coumaphos/kg was significantly reduced and signs of toxicity were not present.
DDI-MedLine.d51.s4.p0	theophylline	DB00277	drug	CGS21680	None	True	effect	drug_n	However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA.
DDI-MedLine.d61.s4.p0	amiodarone	DB01118	drug	digoxin	DB00390	True	mechanism	drug	During amiodarone administration, systemic clearance of digoxin was reduced from 234 +/- 72 ml/min (mean +/- standard deviation) to 172 +/- 33 ml/min (p less than 0.01).
DDI-MedLine.d67.s7.p2	Midazolam	DB00683	drug	indomethacin	DB00328	True	effect	drug	Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.
DDI-MedLine.d73.s2.p0	MPTP	None	drug_n	pargyline	DB01626	True	effect	drug	It was observed that MPTP induced long lasting depletions of striatal dopamine concentrations and this neurotoxic effect could be prevented by pargyline pretreatment.
DDI-MedLine.d73.s3.p0	MPTP	None	drug	amphetamine	DB00182	True	effect	drug	The MPTP-induced neuronal damage produced a tolerance to the disruptive effects of amphetamine and a supersensitivity to the disruptive effects of apomorphine in rats responding in a schedule controlled paradigm.
DDI-MedLine.d79.s1.p0	indinavir	DB00224	drug	didanosine	DB00900	True	mechanism	drug	Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely.
DDI-MedLine.d79.s3.p0	indinavir	DB00224	drug	didanosine	DB00900	True	mechanism	drug	Median gastric pH was significantly higher when indinavir was taken after didanosine administration;
DDI-MedLine.d8.s6.p0	ofloxacin	DB01165	drug	KRM-1648	None	True	effect	drug_n	When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin.
DDI-MedLine.d86.s0.p0	diltiazem	DB00343	drug	sirolimus	DB00877	True	mechanism	drug	Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers.
DDI-MedLine.d87.s0.p0	ADL 8-2698	None	drug	morphine	DB00295	True	effect	drug	ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia.
DDI-MedLine.d89.s0.p0	99mTc-methylene diphosphonate	None	drug	gentamicin	DB00798	True	effect	drug	Therapeutic drug monitoring can avoid iatrogenic alterations caused by 99mTc-methylene diphosphonate (MDP)-gentamicin interaction.
DDI-MedLine.d94.s12.p1	cocaine	DB00907	drug	norepinephrine	DB00368	True	effect	drug	The uptake inhibitors cocaine and desipramine (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium.
DDI-DrugBank.d114.s5.p4	PROLEUKIN	None	brand	interferon-alfa	None	True	effect	drug	Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.
DDI-DrugBank.d115.s0.p11	Gleevec	None	brand	ketoconazole	DB01026	True	advise	drug	Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).
DDI-DrugBank.d115.s10.p1	Gleevec	None	brand	dihydropyridine calcium channel blockers	None	True	mechanism	group	Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.).
DDI-DrugBank.d115.s2.p2	Gleevec	None	brand	ketoconazole	DB01026	True	mechanism	drug	There is a significant increase in exposure to imatinib when Gleevec is coadministered with ketoconazole (CYP3A4 inhibitor).
DDI-DrugBank.d115.s6.p0	rifampin	None	drug	Gleevec	None	True	mechanism	brand	Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of Gleevec, increased Gleevec oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).
DDI-DrugBank.d115.s8.p3	Gleevec	None	brand	simvastatin	DB00641	True	mechanism	drug	Drugs that may have their plasma concentration altered by Gleevec Gleevec increases the mean cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by Gleevec.
DDI-DrugBank.d115.s9.p1	Gleevec	None	brand	pimozide	DB01100	True	advise	drug	Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or pimozide).
DDI-DrugBank.d116.s0.p0	amantadine	DB00915	drug	central nervous system stimulants	None	True	advise	group	Careful observation is required when amantadine is administered concurrently with central nervous system stimulants.
DDI-DrugBank.d12.s6.p0	fibrate	None	group	lovastatin	DB00227	True	effect	drug	Fulminant rhabdomyolysis has been seen as early as three weeks after initiation of combined therapy with another fibrate and lovastatin but may be seen after several months.
DDI-DrugBank.d123.s10.p0	ciprofloxacin	DB00537	drug	antacids	None	True	advise	group	This time window is different than for other oral formulations of ciprofloxacin, which are usually administered 2 hours before or 6 hours after antacids.
DDI-DrugBank.d123.s5.p3	methotrexate	DB00563	drug	ciprofloxacin	DB00537	True	mechanism	drug	Methotrexate Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of methotrexate.
DDI-DrugBank.d123.s7.p0	methotrexate	DB00563	drug	ciprofloxacin	DB00537	True	advise	drug	Therefore, patients under methotrexate therapy should be carefully monitored when concomitant ciprofloxacin therapy is indicated.
DDI-DrugBank.d123.s8.p17	ciprofloxacin	DB00537	drug	zinc	DB01593	True	mechanism	drug	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
DDI-DrugBank.d123.s8.p3	quinolone	None	group	antacids	None	True	mechanism	group	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
DDI-DrugBank.d123.s8.p4	quinolone	None	group	sucralfate	DB00364	True	mechanism	drug	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
DDI-DrugBank.d124.s26.p120	pimozide	DB01100	drug	saquinavir	DB01232	True	mechanism	drug	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DDI-DrugBank.d124.s26.p132	alfentanyl	None	drug	saquinavir	DB01232	True	mechanism	drug	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DDI-DrugBank.d124.s26.p80	quinidine	DB00908	drug	saquinavir	DB01232	True	mechanism	drug	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DDI-DrugBank.d124.s26.p90	warfarin	DB00682	drug	saquinavir	DB01232	True	mechanism	drug	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DDI-DrugBank.d124.s30.p6	phenytoin	DB00252	drug	saquinavir	DB01232	True	mechanism	drug	Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.
DDI-DrugBank.d131.s0.p5	alprazolam	DB00404	drug	psychotropic medications	None	True	effect	group	The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.
DDI-DrugBank.d131.s1.p2	desipramine	DB01151	drug	alprazolam	DB00404	True	mechanism	drug	The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.
DDI-DrugBank.d131.s10.p9	alprazolam	DB00404	drug	nicardipine	DB00622	True	int	drug	Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.
DDI-DrugBank.d131.s8.p63	alprazolam	DB00404	drug	diltiazem	DB00343	True	int	drug	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
DDI-DrugBank.d131.s8.p66	alprazolam	DB00404	drug	erythromycin	DB00199	True	int	drug	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
DDI-DrugBank.d132.s18.p3	nonsteroial anti-inflammatory drugs	None	group	cyclosporine	DB00091	True	mechanism	drug	Cyclosporine: Administration of nonsteroial anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.
DDI-DrugBank.d132.s21.p0	indomethacin	DB00328	drug	diflunisal	DB00861	True	effect	drug	In some patients the combined use of indomethacin and diflunisal has been associated with fatal gastrointestinal hemorrhage.
DDI-DrugBank.d132.s25.p5	diflunisal	DB00861	drug	aspirin	None	True	mechanism	brand	Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.
DDI-DrugBank.d132.s26.p2	diflunisal	DB00861	drug	sulindac	DB00605	True	mechanism	drug	Sulindac: The concomitant administration of diflunisal and sulindac in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.
DDI-DrugBank.d132.s8.p0	Diflunisal	DB00861	drug	furosemide	DB00695	True	effect	drug	Diflunisal decreased the hyperuricemic effect of furosemide.
DDI-DrugBank.d132.s9.p2	antacids	None	group	diflunisal	DB00861	True	mechanism	drug	Antacids: Concomitant administration of antacids may reduce plasma levels of diflunisal.
DDI-DrugBank.d137.s4.p2	bepridil hydrochloride	None	drug	digoxin	DB00390	True	mechanism	drug	Digoxin: In controlled studies in healthy volunteers, bepridil hydrochloride either had no effect (one study) or was associated with modest increases, about 30% (two studies) in steady-state serum digoxin concentrations.
DDI-DrugBank.d138.s0.p0	ALPHAGAN P	None	brand	CNS depressants	None	True	advise	group	Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.
DDI-DrugBank.d138.s0.p2	ALPHAGAN P	None	brand	barbiturates	None	True	advise	group	Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.
DDI-DrugBank.d138.s0.p4	ALPHAGAN P	None	brand	sedatives	None	True	advise	group	Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.
DDI-DrugBank.d140.s17.p0	HMG-CoA reductase inhibitor	None	group	ketoconazole	DB01026	True	advise	drug	Caution should be exercised if an HMG-CoA reductase inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, spironolactone, and cimetidine.
DDI-DrugBank.d143.s14.p0	Histamine H2 antagonists	None	group	Cimetidine	DB00501	True	mechanism	drug	Histamine H2 antagonists: Cimetidine inhibits CYP3A4 and can increase serum amiodarone levels.
DDI-DrugBank.d144.s1.p20	erythromycin	DB00199	drug	budesonide	DB01222	True	advise	drug	If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.
DDI-DrugBank.d15.s4.p0	coumarin	None	group	fondaparinux	None	True	mechanism	drug	In an in vitro study in human liver microsomes, inhibition of CYP2A6 hydroxylation of coumarin by fondaparinux (200 m m M i.e., 350 mg/L) was 17-28%.
DDI-DrugBank.d151.s2.p0	leucovorin	DB00650	drug	methotrexate	DB00563	True	effect	drug	However, high doses of leucovorin may reduce the efficacy of intrathecally administered methotrexate.
DDI-DrugBank.d154.s0.p0	aspirin	None	brand	fenoprofen	DB00573	True	mechanism	drug	The coadministration of aspirin decreases the biologic half-life of fenoprofen because of an increase in metabolic clearance that results in a greater amount of hydroxylated fenoprofen in the urine.
DDI-DrugBank.d154.s3.p0	phenobarbital	DB01174	drug	fenoprofen	DB00573	True	mechanism	drug	Chronic administration of phenobarbital, a known enzyme inducer, may be associated with a decrease in the plasma half-life of fenoprofen.
DDI-DrugBank.d158.s16.p2	Amphetamines	None	group	meperidine	None	True	effect	drug	Meperidine: Amphetamines potentiate the analgesic effect of meperidine.
DDI-DrugBank.d158.s24.p2	Amphetamines	None	group	veratrum alkaloids	None	True	effect	group	Veratrum alkaloids: Amphetamines inhibit the hypotensive effect of veratrum alkaloids.
DDI-DrugBank.d158.s4.p0	d-amphetamine	None	drug	desipramine	DB01151	True	mechanism	drug	d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;
DDI-DrugBank.d160.s0.p0	ethambutol	DB00330	drug	aluminum hydroxide	DB06723	True	mechanism	drug	The results of a study of coadministration of ethambutol (50 mg/kg) with an aluminum hydroxide containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.
DDI-DrugBank.d165.s24.p0	azole antifungal agents	None	group	isoniazid	DB00951	True	mechanism	drug	Plasma concentrations of azole antifungal agents are reduced when given concurrently with isoniazid.
DDI-DrugBank.d165.s27.p0	Itraconazole	DB01167	drug	hypoglycemic agents	None	True	advise	group	Blood glucose concentrations should be carefully monitored when Itraconazole and oral hypoglycemic agents are coadministered.
DDI-DrugBank.d165.s6.p5	astemizole	DB00637	drug	itraconazole	DB01167	True	advise	drug	Based on the chemical resemblance of itraconazole and ketoconazole, coadministration of astemizole with itraconazole is contraindicated.
DDI-DrugBank.d165.s7.p0	ketoconazole	DB01026	drug	cisapride	DB00604	True	mechanism	drug	Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of cisapride.
DDI-DrugBank.d17.s12.p0	thiazide diuretics	None	group	digitalis	None	True	effect	group	(Concurrent use with thiazide diuretics may enhance the possibility of digitalis toxicity associated with hypokalemia.)
DDI-DrugBank.d170.s2.p4	fentanyl	DB00813	drug	clarithromycin	DB01211	True	mechanism	drug	The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.
DDI-DrugBank.d170.s5.p31	fentanyl	DB00813	drug	skeletal muscle relaxants	None	True	effect	group	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
DDI-DrugBank.d170.s5.p32	fentanyl	DB00813	drug	alcohol	None	True	effect	drug	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
DDI-DrugBank.d170.s7.p4	DURAGESIC	None	brand	MAOI	None	True	advise	group	MAO Inhibitors: DURAGESIC  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics
DDI-DrugBank.d171.s0.p9	Tagamet	None	brand	metronidazole	DB00916	True	mechanism	drug	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
DDI-DrugBank.d172.s20.p0	lithium	DB01356	drug	CELEBREX	None	True	advise	brand	Patients on lithium treatment should be closely monitored when CELEBREX is introduced or withdrawn.
DDI-DrugBank.d172.s7.p2	nonsteroidal anti-inflammatory drugs	None	group	ACE inhibitors	None	True	int	group	Experience with nonsteroidal anti-inflammatory drugs (NSAIDs) suggests the potential for interactions with furosemide and ACE inhibitors.
DDI-DrugBank.d175.s1.p0	captopril	DB01197	drug	diuretic	None	True	effect	group	The possibility of hypotensive effects with captopril can be minimized by either discontinuing the diuretic or increasing the salt intake approximately one week prior to initiation of treatment with captopril (captopril tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).
DDI-DrugBank.d175.s12.p0	Beta-adrenergic blocking drugs	None	group	captopril	DB01197	True	effect	drug	Beta-adrenergic blocking drugs add some further antihypertensive effect to captopril, but the overall response is less than additive.
DDI-DrugBank.d175.s16.p0	indomethacin	DB00328	drug	captopril	DB01197	True	effect	drug	Inhibitors Of Endogenous Prostaglandin Synthesis It has been reported that indomethacin may reduce the antihypertensive effect of captopril, especially in cases of low renin hypertension.
DDI-DrugBank.d178.s0.p0	sulfonylureas	None	group	nonsteroidal anti-inflammatory agents	None	True	effect	group	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
DDI-DrugBank.d178.s0.p1	sulfonylureas	None	group	salicylates	None	True	effect	group	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
DDI-DrugBank.d178.s9.p0	miconazole	DB01110	drug	hypoglycemic agents	None	True	effect	group	A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.
DDI-DrugBank.d179.s39.p5	methyldopa	DB00968	drug	sulfapyridine	DB00891	True	effect	drug	Methyldopa (e.g., Aldomet) use of Methyldopa with sulfapyridine may increase The chance of side effects affecting The liver and/or The blood
DDI-DrugBank.d184.s0.p90	barbiturates	None	group	contraceptives	None	True	effect	group	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
DDI-DrugBank.d192.s0.p3	Dexbrompheniramine	DB00405	drug	anticholinergics	None	True	effect	group	Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
DDI-DrugBank.d195.s8.p0	anastrozole	DB01217	drug	tamoxifen	DB00675	True	mechanism	drug	Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.
DDI-DrugBank.d196.s4.p2	COPEGUS	None	brand	didanosine	DB00900	True	advise	drug	Nucleoside Analogues Didanosine Co-administration of COPEGUS and didanosine is not recommended.
DDI-DrugBank.d198.s11.p0	Vardenafil	DB00862	drug	indinavir	DB00224	True	advise	drug	It is recommended not to exceed a single 2.5 mg Vardenafil dose in a 24-hour period when used in combination with indinavir.
DDI-DrugBank.d198.s22.p3	nitrates	None	group	vardenafil	DB00862	True	mechanism	drug	In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.
DDI-DrugBank.d20.s12.p0	INSPRA	None	brand	NSAIDs	None	True	advise	group	Therefore, when INSPRA and NSAIDs are used concomitantly, patients should be observed to determine whether the desired effect on blood pressure is obtained.
DDI-DrugBank.d202.s16.p1	tricyclic antidepressants	None	group	phenothiazines	None	True	advise	group	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.
DDI-DrugBank.d202.s16.p6	tricyclic antidepressants	None	group	encainide	DB01228	True	advise	drug	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.
DDI-DrugBank.d202.s2.p0	tricyclic antidepressants	None	group	cimetidine	DB00501	True	mechanism	drug	In addition, higher-than expected steady-state serum concentrations of tricyclic antidepressants have been observed when therapy is initiated in patients already taking cimetidine.
DDI-DrugBank.d202.s8.p0	reserpine	DB00206	drug	tricyclic antidepressant	None	True	effect	group	Administration of reserpine during therapy with a tricyclic antidepressant has been shown to produce a  stimulating  effect in some depressed patients.
DDI-DrugBank.d207.s7.p2	histamine H2-receptor antagonists	None	group	IRESSA	None	True	mechanism	brand	Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as ranitidine or cimetidine) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.
DDI-DrugBank.d208.s0.p3	Benzthiazide	DB00562	drug	lithium	DB01356	True	int	drug	Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.
DDI-DrugBank.d208.s0.p5	Benzthiazide	DB00562	drug	NSAIDs	None	True	int	group	Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.
DDI-DrugBank.d21.s0.p0	ELSPAR	None	brand	methotrexate	DB00563	True	effect	drug	Tissue culture and animal studies indicate that ELSPAR can diminish or abolish the effect of methotrexate on malignant cells.14 This effect on methotrexate activity persists as long as plasma asparagine levels are suppressed.
DDI-DrugBank.d210.s33.p0	VIOXX	None	brand	warfarin	DB00682	True	effect	drug	In post-marketing experience, bleeding events have been reported, predominantly in the elderly, in association with increases in prothrombin time in patients receiving VIOXX concurrently with warfarin.
DDI-DrugBank.d211.s2.p14	tetracyclines	None	group	penicillins	None	True	effect	group	Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.
DDI-DrugBank.d215.s0.p3	anileridine	DB00913	drug	anesthetics	None	True	advise	group	Caution should be observed when anileridine is coadministered with other opioids, sedatives, phenothiazines, or anesthetics, as these agents may increase respiratory and circulatory depression.
DDI-DrugBank.d217.s11.p9	iron	DB01592	drug	norfloxacin	DB01059	True	advise	drug	Multivitamins, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.
DDI-DrugBank.d219.s1.p0	NSAIDs	None	group	ACE-inhibitors	None	True	advise	group	This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors.
DDI-DrugBank.d219.s19.p2	Phenylbutazone	DB00812	drug	etodolac	DB00749	True	mechanism	drug	Phenylbutazone: Phenylbutazone causes increase (by about 80%) in the free fraction of etodolac.
DDI-DrugBank.d219.s7.p6	NSAIDs	None	group	methotrexate	DB00563	True	mechanism	drug	Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.
DDI-DrugBank.d220.s11.p16	phenobarbital	DB01174	drug	Mefloquine	DB00358	True	effect	drug	In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.
DDI-DrugBank.d220.s11.p4	anticonvulsant	None	group	Mefloquine	DB00358	True	effect	drug	In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.
DDI-DrugBank.d220.s9.p0	Mefloquine	DB00358	drug	anti-arrhythmic	None	True	effect	drug	This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.
DDI-DrugBank.d220.s9.p4	Mefloquine	DB00358	drug	H1-blocking agents	None	True	effect	group	This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.
DDI-DrugBank.d223.s16.p2	quinidine	DB00908	drug	doxepin	DB01142	True	mechanism	drug	Inhibitors or substrates of CYP2D6 (i.e., quinidine, selective serotonin reuptake inhibitors [SSRIs]) may increase the plasma concentration of doxepin when administered concomitantly.
DDI-DrugBank.d224.s1.p1	IOPIDINE	None	brand	alcohol	None	True	advise	drug	Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.
DDI-DrugBank.d224.s8.p0	apraclonidine	DB00964	drug	beta-blockers	None	True	advise	group	Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), antihypertensives, and cardiac glycosides is advised.
DDI-DrugBank.d226.s1.p2	verapamil	DB00661	drug	Adenocard	None	True	effect	brand	Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard.
DDI-DrugBank.d226.s6.p0	Adenosine	DB00640	drug	dipyridamole	DB00975	True	effect	drug	Adenosine effects are potentiated by dipyridamole.
DDI-DrugBank.d228.s2.p0	Antizol	None	brand	phenytoin	DB00252	True	mechanism	drug	Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied
DDI-DrugBank.d231.s10.p0	sucralfate	DB00364	drug	furosemide	DB00695	True	effect	drug	Tablets Simultaneous administration of sucralfate and furosemide tablets may reduce the natriuretic and antihypertensive effects of furosemide.
DDI-DrugBank.d231.s12.p0	furosemide	DB00695	drug	sucralfate	DB00364	True	advise	drug	The intake of furosemide and sucralfate should be separated by at least two hours.
DDI-DrugBank.d231.s6.p0	Furosemide	DB00695	drug	antihypertensive drugs	None	True	effect	group	Furosemide may add to or potentiate the therapeutic effect of other antihypertensive drugs.
DDI-DrugBank.d236.s10.p4	MAOI antidepressants	None	group	amphetamine	DB00182	True	mechanism	group	MAO inhibitors: MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.
DDI-DrugBank.d237.s3.p9	dicyclomine	DB00804	drug	cisapride	DB00604	True	effect	drug	Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.
DDI-DrugBank.d238.s19.p0	TCAs	None	group	SSRIs	None	True	advise	group	Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other.
DDI-DrugBank.d238.s20.p0	TCA	None	group	fluoxetine	DB00472	True	advise	drug	Of particular importance, sufficient time must elapse before initiating TCAtreatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).
DDI-DrugBank.d238.s4.p0	tricyclic antidepressants	None	group	guanethidine	DB01170	True	effect	drug	Several tricyclic antidepressants have been reported to block the pharmacologic effects of guanethidine, clonidine, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.
DDI-DrugBank.d238.s6.p0	tricyclic antidepressants	None	group	methylphenidate	DB00422	True	mechanism	drug	plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.
DDI-DrugBank.d238.s6.p17	fluoxetine	DB00472	drug	CMI	None	True	mechanism	drug	plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.
DDI-DrugBank.d240.s0.p0	Ethopropazine	DB00392	drug	alcohol	None	True	effect	drug	Ethopropazine may interact with alcohol or other CNS depressants, causing increased sedative effects.
DDI-DrugBank.d242.s1.p0	quinolones	None	group	theophylline	DB00277	True	mechanism	drug	However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.
DDI-DrugBank.d245.s0.p1	sulfonylurea	None	group	salicylates	None	True	effect	group	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
DDI-DrugBank.d246.s0.p1	butorphanol	DB00611	drug	alcohol	None	True	effect	drug	Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.
DDI-DrugBank.d246.s14.p0	STADOL NS	None	brand	nasal vasoconstrictor	None	True	effect	group	Therefore, a slower onset can be anticipated if STADOL NS is administered concomitantly with, or immediately following, a nasal vasoconstrictor.
DDI-DrugBank.d247.s2.p1	Epinephrine	DB00668	drug	isoproterenol	None	True	advise	drug	Epinephrine should not be administered concomitantly with other sympathomimetic drugs (such as isoproterenol) because of possible additive effects and increased toxicity.
DDI-DrugBank.d249.s5.p10	NSAID	None	group	methotrexate	DB00563	True	effect	drug	Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.
DDI-DrugBank.d249.s5.p3	diclofenac	DB00586	drug	methotrexate	DB00563	True	effect	drug	Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.
DDI-DrugBank.d249.s5.p9	NSAID	None	group	digoxin	DB00390	True	effect	drug	Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.
DDI-DrugBank.d249.s8.p4	Diclofenac	DB00586	drug	lithium	DB01356	True	mechanism	drug	Lithium: Diclofenac decreases lithium renal clearance and increases lithium plasma levels.
DDI-DrugBank.d252.s5.p0	Phenothiazine-related compounds	None	group	beta-adrenergic blocking agents	None	True	mechanism	group	Phenothiazine-related compounds and beta-adrenergic blocking agents may have additive hypotensite effects due to the inhibition of each other s metabolism.
DDI-DrugBank.d257.s0.p11	Levo-Dromoran	None	brand	antihistamines	None	True	effect	group	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
DDI-DrugBank.d257.s6.p25	nalbuphine	DB00844	drug	Levo-Dromoran	None	True	advise	brand	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.
DDI-DrugBank.d257.s6.p29	butorphanol	DB00611	drug	Levo-Dromoran	None	True	advise	brand	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.
DDI-DrugBank.d26.s0.p20	phenothiazines	None	group	DILAUDID	None	True	effect	brand	Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.
DDI-DrugBank.d26.s0.p32	tricyclic antidepressants	None	group	DILAUDID	None	True	effect	brand	Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.
DDI-DrugBank.d260.s0.p17	Probenecid	DB01032	drug	angiotensin-converting enzyme inhibitors	None	True	mechanism	group	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
DDI-DrugBank.d260.s0.p21	Probenecid	DB01032	drug	bumetanide	DB00887	True	mechanism	drug	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
DDI-DrugBank.d260.s0.p22	Probenecid	DB01032	drug	clofibrate	DB00636	True	mechanism	drug	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
DDI-DrugBank.d260.s3.p2	VISTIDE	None	brand	gentamicin	DB00798	True	advise	drug	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
DDI-DrugBank.d260.s3.p3	VISTIDE	None	brand	amikacin	DB00479	True	advise	drug	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
DDI-DrugBank.d260.s3.p7	VISTIDE	None	brand	vancomycin	DB00512	True	advise	drug	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
DDI-DrugBank.d265.s0.p0	Chlorthalidone	DB00310	drug	antihypertensive drugs	None	True	effect	group	Chlorthalidone may add to or potentiate the action of other antihypertensive drugs.
DDI-DrugBank.d266.s1.p1	CASODEX	None	brand	anticoagulant	None	True	advise	group	It is recommended that if CASODEX is started in patients already receiving coumarin anticoagulants, prothrombin times should be closely monitored and adjustment of the anticoagulant dose may be necessary.
DDI-DrugBank.d267.s5.p12	NUROMAX	None	brand	procainamide	DB01035	True	effect	drug	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d267.s5.p6	NUROMAX	None	brand	clindamycin	DB01190	True	effect	drug	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d267.s6.p4	NUROMAX	None	brand	carbamazepine	DB00564	True	effect	drug	As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.
DDI-DrugBank.d269.s1.p14	quinidine	DB00908	drug	carvedilol	DB01136	True	effect	drug	poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .
DDI-DrugBank.d269.s10.p0	cyclosporine	DB00091	drug	carvedilol	DB01136	True	advise	drug	Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of carvedilol therapy and that the dose of cyclosporine be adjusted as appropriate.
DDI-DrugBank.d269.s17.p5	COREG	None	brand	verapamil	DB00661	True	advise	drug	As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.
DDI-DrugBank.d272.s1.p0	Bromocriptine mesylate	None	drug	dopamine antagonists	None	True	int	group	Bromocriptine mesylate may interact with dopamine antagonists, butyrophenones, and certain other agents.
DDI-DrugBank.d272.s3.p0	bromocriptine mesylate	None	drug	ergot alkaloids	None	True	advise	group	Concomitant use of bromocriptine mesylate with other ergot alkaloids is not recommended.
DDI-DrugBank.d274.s0.p0	dobutamine	DB00841	drug	b-blocking drug	None	True	effect	group	Animal studies indicate that dobutamine may be ineffective if the patient has recently received a b-blocking drug.
DDI-DrugBank.d277.s12.p10	tiagabine	DB00906	drug	primidone	DB00794	True	mechanism	drug	Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.
DDI-DrugBank.d277.s23.p2	triazolam	DB00897	drug	tiagabine	DB00906	True	advise	drug	Because of the possible additive effects of drugs that may depress the nervous system, ethanol or triazolam should be used cautiously in combination with tiagabine.
DDI-DrugBank.d283.s13.p1	fenofibrate	DB01039	drug	pravastatin	DB00175	True	mechanism	drug	Concomitant administration of fenofibrate (equivalent to 145mg TRICOR) with pravastatin (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for pravastatin by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.
DDI-DrugBank.d283.s15.p3	TRICOR	None	brand	atorvastatin	DB01076	True	mechanism	drug	Concomitant administration of fenofibrate (equivalent to 145 mg TRICOR) with atorvastatin (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in atorvastatin AUC values in 22 healthy males.
DDI-DrugBank.d284.s3.p8	aminophylline	DB01223	drug	adrenergic agonists	None	True	effect	group	Concomitant treatment with methylxanthines (aminophylline, theophylline), steroids, or diuretics may potentiate any hypokalemic effect of adrenergic agonists.
DDI-DrugBank.d284.s5.p0	beta-agonists	None	group	non-potassium sparing diuretics	None	True	advise	group	Although the clinical significance of these effects is not known, caution is advised in the co-administration of beta-agonists with non-potassium sparing diuretics.
DDI-DrugBank.d284.s6.p5	beta2-agonists	None	group	tricyclic antidepressants	None	True	advise	group	BROVANA, as with other beta2-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.
DDI-DrugBank.d29.s14.p0	clarithromycin	DB01211	drug	pimozide	DB01100	True	advise	drug	Concomitant administration of clarithromycin with pimozide is contraindicated.
DDI-DrugBank.d29.s8.p0	esomeprazole	DB00736	drug	diazepam	DB00829	True	mechanism	drug	Coadministration of esomeprazole 30 mg and diazepam, a CYP2C19 substrate, resulted in a 45% decrease in clearance of diazepam.
DDI-DrugBank.d291.s1.p1	anticoagulant	None	drug	Bezalip	None	True	advise	brand	For this reason, the dose of the anticoagulant should be reduced by 30 - 50% at the start of treatment with Bezalip or Bezalip retard and then titrated according to the blood clotting parameters
DDI-DrugBank.d291.s3.p4	insulin	None	drug	Bezalip retard	None	True	effect	brand	The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard.
DDI-DrugBank.d291.s9.p6	Bezalip retard	None	brand	cholestryramine	None	True	advise	drug	When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired
DDI-DrugBank.d299.s1.p8	dihydroergotamine	DB00320	drug	AXERT	None	True	advise	brand	Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.
DDI-DrugBank.d299.s11.p13	erythromycin	DB00199	drug	almotriptan	DB00918	True	advise	drug	Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.
DDI-DrugBank.d299.s11.p8	itraconazole	DB01167	drug	almotriptan	DB00918	True	advise	drug	Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.
DDI-DrugBank.d299.s4.p2	5-HT1B/1D agonists	None	group	AXERT	None	True	advise	brand	Other 5-HT1B/1D Agonists Concomitant use of other 5-HT1B/1D agonists within 24 hours of treatment with AXERT is contraindicated.
DDI-DrugBank.d299.s8.p3	almotriptan	DB00918	drug	verapamil	DB00661	True	mechanism	drug	Verapamil: Coadministration of almotriptan and verapamil resulted in a 24% increase in plasma concentrations of almotriptan.
DDI-DrugBank.d3.s9.p4	TORADOL	None	brand	probenecid	DB01032	True	mechanism	drug	Probenecid: Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.
DDI-DrugBank.d30.s1.p0	Rifampin	None	drug	losartan	DB00678	True	mechanism	drug	Rifampin, an inducer of drug metabolism, decreased the concentrations of losartan and its active metabolite.
DDI-DrugBank.d31.s2.p0	diazoxide	DB01119	drug	hydralazine	DB01275	True	effect	drug	Profound hypotensive episodes may occur when diazoxide infection and hydralazine are used concomitantly.
DDI-DrugBank.d313.s3.p8	lithium	DB01356	drug	insulin	None	True	effect	drug	Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.
DDI-DrugBank.d314.s19.p5	erythromycin	DB00199	drug	corticosteroids	None	True	mechanism	group	Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.
DDI-DrugBank.d314.s3.p2	Macrolide antibiotics	None	group	corticosteroid	None	True	mechanism	group	Antibiotics: Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance.
DDI-DrugBank.d314.s31.p0	Corticosteroids	None	group	live attenuated vaccines	None	True	effect	group	Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines.
DDI-DrugBank.d320.s3.p1	levobupivacaine	DB01002	drug	phenobarbital	DB01174	True	mechanism	drug	Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;
DDI-DrugBank.d320.s3.p3	levobupivacaine	DB01002	drug	ketoconazole	DB01026	True	mechanism	drug	Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;
DDI-DrugBank.d321.s1.p3	praziquantel	DB01058	drug	albendazole sulfoxide	None	True	mechanism	drug	Praziquantel: In the fed state, praziquantel (40 mg/kg) increased mean maximum plasma concentration and area under the curve of albendazole sulfoxide by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given albendazole alone.
DDI-DrugBank.d322.s1.p0	Clidinium	DB00771	drug	phenothiazines	None	True	effect	group	Clidinium may decrease the effect of phenothiazines, levodopa, and ketoconazole.
DDI-DrugBank.d324.s12.p3	zaleplon	DB00962	drug	promethazine	DB01069	True	mechanism	drug	Promethazine: Coadministration of a single dose of zaleplon and promethazine (10 and 25 mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of zaleplon, but no change in the area under the plasma concentration-time curve.
DDI-DrugBank.d325.s10.p1	dopamine HCl	None	drug	halogenated hydrocarbon anesthetics	None	True	advise	group	Therefore, EXTREME CAUTION should be exercised when administering dopamine HCl to patients receiving cyclopropane or halogenated hydrocarbon anesthetics.
DDI-DrugBank.d325.s12.p1	vasopressor	None	group	oxytocic drugs	None	True	effect	group	The concomitant use of vasopressors, vasoconstricting agents (such as ergonovine) and some oxytocic drugs may result in severe hypertension.
DDI-DrugBank.d325.s12.p2	ergonovine	DB01253	drug	oxytocic drugs	None	True	effect	group	The concomitant use of vasopressors, vasoconstricting agents (such as ergonovine) and some oxytocic drugs may result in severe hypertension.
DDI-DrugBank.d325.s2.p0	dopamine HCl	None	drug	diuretic agents	None	True	effect	group	Concurrent administration of low-dose dopamine HCl and diuretic agents may produce an additive or potentiating effect on urine flow.
DDI-DrugBank.d328.s24.p1	Valdecoxib	DB00580	drug	S-warfarin	None	True	mechanism	drug	Valdecoxib caused a statistically significant increase in plasma exposures of R-warfarin and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin.
DDI-DrugBank.d328.s35.p2	glyburide	DB01016	drug	valdecoxib	DB00580	True	advise	drug	Because changes in glucose concentrations with valdecoxib coadministration were within the normal variability and individual glucose concentrations were above or near 70 mg/dL, dose adjustment for glyburide (5 mg QD and 10 mg BID) with valdecoxib coadministration (up to 40 mg QD) is not indicated.
DDI-DrugBank.d328.s4.p3	aspirin	None	brand	valdecoxib	DB00580	True	effect	drug	Aspirin: Concomitant administration of aspirin with valdecoxib may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.
DDI-DrugBank.d328.s46.p5	contraceptive	None	group	valdecoxib	DB00580	True	advise	drug	These increased exposures of norethindrone and ethinyl estradiol should be taken into consideration when selecting an oral contraceptive for women taking valdecoxib.
DDI-DrugBank.d329.s3.p0	probenecid	DB01032	drug	ertapenem	DB00303	True	advise	drug	Because of the small effect on half-life, the coadministration with probenecid to extend the half-life of ertapenem is not recommended.
DDI-DrugBank.d330.s2.p2	neomycin	DB00994	drug	methotrexate	DB00563	True	mechanism	drug	Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.
DDI-DrugBank.d330.s5.p0	neomycin sulfate	None	drug	coumarin	None	True	effect	group	Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability.
DDI-DrugBank.d332.s0.p0	doxapram	DB00561	drug	sympathomimetic	None	True	effect	group	Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect .
DDI-DrugBank.d333.s3.p0	clonazepam	DB01068	drug	propantheline	DB00782	True	mechanism	drug	In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.
DDI-DrugBank.d333.s5.p5	carbamazepine	DB00564	drug	clonazepam	DB01068	True	mechanism	drug	Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.
DDI-DrugBank.d334.s0.p0	diuretics	None	group	PRINIVIL	None	True	effect	brand	Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with PRINIVIL.
DDI-DrugBank.d334.s15.p1	PRINIVIL	None	brand	spironolactone	DB00421	True	effect	drug	Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
DDI-DrugBank.d335.s3.p1	benzodiazepines	None	group	narcotics	None	True	effect	group	The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.
DDI-DrugBank.d338.s6.p0	estazolam	DB01215	drug	ketoconazole	DB01026	True	advise	drug	Consequently, estazolam should be avoided in patients receiving ketoconazole and itraconazole, which are very potent inhibitors of CYP3A.
DDI-DrugBank.d338.s8.p1	benzodiazepines	None	group	fluvoxamine	DB00176	True	mechanism	drug	The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, diltiazem, isoniazide, and some macrolide antibiotics.
DDI-DrugBank.d340.s26.p0	nelfinavir	DB00220	drug	didanosine	DB00900	True	advise	drug	therefore, nelfinavir should be administered (with food) one hour after or more than two hours before didanosine.
DDI-DrugBank.d340.s30.p4	rifabutin	DB00615	drug	VIRACEPT	None	True	mechanism	brand	Rifabutin: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.
DDI-DrugBank.d340.s6.p1	VIRACEPT	None	brand	amiodarone	DB01118	True	advise	drug	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
DDI-DrugBank.d340.s6.p7	VIRACEPT	None	brand	Antimycobacterial agents	None	True	advise	group	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
DDI-DrugBank.d340.s6.p8	VIRACEPT	None	brand	rifampin	None	True	advise	drug	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
DDI-DrugBank.d345.s17.p0	Bile acid binding resins	None	group	phosphate	None	True	mechanism	drug	Bile acid binding resins may also interfere with the absorption of oral phosphate supplements and hydrocortisone.
DDI-DrugBank.d347.s1.p5	FACTIVE	None	brand	contraceptive	None	True	mechanism	group	Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.
DDI-DrugBank.d347.s7.p16	aluminum	None	drug	FACTIVE	None	True	advise	brand	Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.
DDI-DrugBank.d350.s10.p0	rifampin	None	drug	caspofungin	DB00520	True	mechanism	drug	A drug-drug interaction study with rifampin in healthy volunteers has shown a 30% decrease in caspofungin trough concentrations.
DDI-DrugBank.d350.s12.p16	dexamethasone	DB01234	drug	CANCIDAS	None	True	mechanism	brand	In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.
DDI-DrugBank.d350.s14.p0	CANCIDAS	None	brand	efavirenz	DB00625	True	advise	drug	When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered
DDI-DrugBank.d350.s14.p2	CANCIDAS	None	brand	phenytoin	DB00252	True	advise	drug	When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered
DDI-DrugBank.d350.s9.p0	CANCIDAS	None	brand	cyclosporine	DB00091	True	effect	drug	There were transient increases in liver ALT and AST when CANCIDAS and cyclosporine were co-administered.
DDI-DrugBank.d353.s12.p8	vitamin A	DB00162	group	acitretin	DB00459	True	advise	drug	Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.
DDI-DrugBank.d353.s5.p0	acitretin	DB00459	drug	progestin	None	True	effect	drug	However, it has been established that acitretin interferes with the contraceptive effect of microdosed progestin minipill preparations.
DDI-DrugBank.d356.s6.p1	indomethacin	DB00328	drug	MIDAMOR	None	True	effect	brand	Since indomethacin and potassium-sparing diuretics, including MIDAMOR, may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently.
DDI-DrugBank.d357.s3.p41	butyrophenones	None	group	APOKYN	None	True	effect	brand	Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.
DDI-DrugBank.d358.s0.p6	PLETAL	None	brand	omeprazole	DB00338	True	advise	drug	Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.
DDI-DrugBank.d359.s3.p0	phenytoin	DB00252	drug	coumarin	None	True	mechanism	group	Presumably, phenytoin acts as a stimulator of coumarin metabolism and has been reported to cause decreased serum levels of the coumarin anticoagulants and increased prothrombin-proconvertin concentrations.
DDI-DrugBank.d36.s0.p0	aspirin	None	brand	carbonic anhydrase inhibitors	None	True	advise	group	Caution is advised in patients receiving concomitant high-dose aspirin and carbonic anhydrase inhibitors, as anorexia, tachypnea, lethargy and coma have been rarely reported due to a possible drug interaction.
DDI-DrugBank.d368.s11.p0	Acetazolamide	DB00819	drug	methenamine	None	True	effect	drug	Acetazolamide may prevent the urinary antiseptic effect of methenamine.
DDI-DrugBank.d374.s0.p1	Auranofin	DB00995	drug	Solganal	None	True	advise	brand	Auranofin should be avoided by patients with a history of serious reaction to any gold medication, including Solganal and Myochrysine.
DDI-DrugBank.d378.s0.p0	aminoglycosides	None	group	MAXIPIME	None	True	advise	brand	Renal function should be monitored carefully if high doses of aminoglycosides are to be administered with MAXIPIME because of the increased potential of nephrotoxicity and ototoxicity of aminoglycoside antibiotics.
DDI-DrugBank.d379.s1.p17	thiazide diuretics	None	group	LEVULAN KERASTICK	None	True	effect	brand	It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.
DDI-DrugBank.d379.s1.p24	phenothiazines	None	group	LEVULAN KERASTICK	None	True	effect	brand	It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.
DDI-DrugBank.d382.s25.p1	Aprepitant	DB00673	drug	midazolam	DB00683	True	mechanism	drug	Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.
DDI-DrugBank.d382.s41.p4	aprepitant	DB00673	drug	diltiazem	DB00343	True	mechanism	drug	Diltiazem: In patients with mild to moderate hypertension, administration of aprepitant once daily, as a tablet formulation comparable to 230 mg of the capsule formulation, with diltiazem 120 mg 3 times daily for 5 days, resulted in a 2-fold increase of aprepitant AUC and a simultaneous 1.7-fold increase of diltiazem AUC.
DDI-DrugBank.d384.s0.p27	Cholestyramine	DB01432	drug	fat soluble vitamins	None	True	mechanism	group	Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
DDI-DrugBank.d384.s11.p2	vitamin D analogues	None	group	corticosteroids	None	True	mechanism	group	Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.
DDI-DrugBank.d384.s15.p4	Magnesium	DB01378	drug	vitamin D	None	True	advise	group	Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.
DDI-DrugBank.d384.s2.p11	phenytoin	DB00252	drug	calcitriol	DB00136	True	mechanism	drug	Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
DDI-DrugBank.d386.s23.p3	desipramine hydrochloride	None	drug	hypnotics	None	True	effect	group	If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.
DDI-DrugBank.d388.s0.p1	Catecholamine-depleting drugs	None	group	beta-blocking agents	None	True	effect	group	Catecholamine-depleting drugs, such as reserpine, may have an additive effect when given with beta-blocking agents.
DDI-DrugBank.d389.s2.p3	Sympathomimetic amines	None	group	mecamylamine	DB00657	True	effect	drug	Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa and mecamylamine.
DDI-DrugBank.d395.s2.p2	Enoxacin	DB00467	drug	methylxanthines	None	True	mechanism	group	Caffeine: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.
DDI-DrugBank.d395.s20.p2	Enoxacin	DB00467	drug	methylxanthines	None	True	mechanism	group	Theophylline: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.
DDI-DrugBank.d397.s13.p0	erythromycin	DB00199	drug	cisapride	DB00604	True	effect	drug	There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.
DDI-DrugBank.d397.s15.p0	lovastatin	DB00227	drug	erythromycin	DB00199	True	advise	drug	Patients receiving concomitant lovastatin and erythromycin should be carefully monitored;
DDI-DrugBank.d397.s6.p0	Erythromycin	DB00199	drug	triazolam	DB00897	True	mechanism	drug	Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.
DDI-DrugBank.d397.s8.p3	erythromycin	DB00199	drug	hexobarbital	DB01355	True	int	drug	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
DDI-DrugBank.d4.s0.p5	ephedrine	DB01364	drug	sympathomimetic bronchodilators	None	True	effect	group	Synergism between xanthine bronchodilators (e.g., theophylline), ephedrine, and other sympathomimetic bronchodilators has been reported.
DDI-DrugBank.d40.s10.p1	phenytoin	DB00252	drug	amiodarone	DB01118	True	mechanism	drug	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
DDI-DrugBank.d40.s10.p11	phenytoin	DB00252	drug	halothane	DB01159	True	mechanism	drug	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
DDI-DrugBank.d40.s19.p3	phenytoin	DB00252	drug	digitoxin	DB01396	True	effect	drug	Drugs whose efficacy is impaired by Phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
DDI-DrugBank.d40.s19.p4	phenytoin	DB00252	drug	doxycycline	DB00254	True	effect	drug	Drugs whose efficacy is impaired by Phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
DDI-DrugBank.d400.s0.p5	Ponstel	None	brand	aspirin	None	True	advise	brand	Aspirin: As with other NSAIDs, concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects.
DDI-DrugBank.d400.s1.p2	NSAIDs	None	group	methotrexate	DB00563	True	mechanism	drug	Methotrexate: NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices.
DDI-DrugBank.d400.s9.p4	NSAIDs	None	group	lithium	DB01356	True	mechanism	drug	Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.
DDI-DrugBank.d404.s0.p27	Cholestyramine	DB01432	drug	fat soluble vitamins	None	True	mechanism	group	Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
DDI-DrugBank.d405.s1.p2	alcohol	None	drug	ethchlorvynol	DB00189	True	effect	drug	Other depressasnts such as alcohol, barbiturates, and MAOIs may enhance CNS depression when administered with ethchlorvynol.
DDI-DrugBank.d41.s0.p8	cholestyramine	DB01432	drug	leflunomide	DB01097	True	mechanism	drug	Cholestyramine and Charcoal Administration of cholestyramine or activated charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide) concentration .
DDI-DrugBank.d410.s0.p5	dihydroergotamine mesylate	None	drug	peripheral vasoconstrictors	None	True	effect	group	Vasoconstrictors: D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.
DDI-DrugBank.d410.s4.p2	Nicotine	DB00184	drug	ergot	None	True	effect	drug	Nicotine: Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy.
DDI-DrugBank.d411.s2.p7	levothyroxine sodium	None	drug	aluminum hydoxide	None	True	mechanism	drug	Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of levothyroxine sodium from the gastrointestinal tract: aluminum hydoxide, cholestyramine resin, colestipol hydrochloride, ferrous sulfate, sodium polystyrene sulfonate, soybean flour (e.g., infant formula), sucralfate.
DDI-DrugBank.d411.s3.p0	levothyroxine sodium	None	drug	androgens	None	True	mechanism	group	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
DDI-DrugBank.d411.s3.p14	levothyroxine sodium	None	drug	phenytoin	DB00252	True	mechanism	drug	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
DDI-DrugBank.d411.s3.p2	levothyroxine sodium	None	drug	asparaginase	DB00023	True	mechanism	drug	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
DDI-DrugBank.d413.s15.p0	thiazide diuretics	None	group	allopurinol	DB00437	True	advise	drug	Although a causal mechanism and a cause-and-effect relationship have not been established, current evidence suggests that renal function should be monitored in patients on thiazide diuretics and allopurinol even in the absence of renal failure, and dosage levels should be even more conservatively adjusted in those patients on such combined therapy if diminished renal function is detected..
DDI-DrugBank.d413.s21.p0	allopurinol	DB00437	drug	chlorpropamide	DB00672	True	effect	drug	The risk of hypoglycemia secondary to this mechanism may be increased if allopurinol and chlorpropamide are given concomitantly in the presence of renal insufficiency.
DDI-DrugBank.d414.s0.p0	Lithium	DB01356	drug	diuretics	None	True	mechanism	group	Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity.
DDI-DrugBank.d415.s6.p0	ibuprofen	DB01050	drug	methotrexate	DB00563	True	effect	drug	This may indicate that ibuprofen could enhance the toxicity of methotrexate.
DDI-DrugBank.d416.s0.p0	PAH	None	drug	sulfonamides	None	True	effect	group	Renal clearance measurements of PAH cannot be made with any significant accuracy in patients receiving sulfonamides, procaine, or thiazolesulfone.
DDI-DrugBank.d42.s1.p3	dolasetron	DB00757	drug	cimetidine	DB00501	True	mechanism	drug	Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.
DDI-DrugBank.d420.s3.p5	OMNICEF	None	brand	antacid	None	True	advise	group	If antacids are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the antacid.
DDI-DrugBank.d420.s4.p5	b-lactam antibiotics	None	group	cefdinir	DB00535	True	mechanism	drug	Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.
DDI-DrugBank.d420.s5.p14	cefdinir	DB00535	drug	iron	DB01592	True	mechanism	drug	Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.
DDI-DrugBank.d422.s10.p2	BREVIBLOC	None	brand	succinylcholine	DB00202	True	advise	drug	Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.
DDI-DrugBank.d423.s0.p18	selegiline hydrochloride	None	drug	paroxetine	DB00715	True	effect	drug	In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
DDI-DrugBank.d423.s4.p6	SSRIs	None	group	dihydroergotamine	DB00320	True	effect	drug	A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.
DDI-DrugBank.d426.s1.p9	methysergide	DB00247	drug	FROVA	None	True	advise	brand	Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).
DDI-DrugBank.d429.s6.p2	chloroquine	DB00608	drug	cyclosporin	None	True	mechanism	drug	Cyclosporin: After introduction of chloroquine (oral form), a sudden increase in serum cyclosporin level has been reported.
DDI-DrugBank.d43.s8.p7	VIDEX	None	brand	ciprofloxacin	DB00537	True	advise	drug	Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.
DDI-DrugBank.d303.s0.p4	cephalexin	DB00567	drug	metformin	DB00331	True	mechanism	drug	Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.
DDI-DrugBank.d305.s6.p0	dantrolene sodium	None	drug	calcium channel blockers	None	True	advise	group	It is recommended that the combination of intravenous dantrolene sodium and calcium channel blockers, such as verapamil, not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established.
DDI-DrugBank.d308.s0.p3	HYDROXYZINE	DB00557	drug	BARBITURATES	None	True	effect	group	THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES.
DDI-DrugBank.d310.s1.p0	Nimotop	None	brand	antihypertensive compounds	None	True	effect	group	In Europe, Nimotop  was observed to occasionally intensify the effect of antihypertensive compounds taken concomitantly by patients suffering from hypertension;
DDI-DrugBank.d313.s3.p6	clonidine	DB00575	drug	insulin	None	True	effect	drug	Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.
DDI-DrugBank.d313.s3.p9	alcohol	None	drug	insulin	None	True	effect	drug	Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.
DDI-DrugBank.d314.s1.p3	corticosteroids	None	group	amphotericin B	DB00681	True	advise	drug	Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia.
DDI-DrugBank.d314.s2.p0	amphotericin B	DB00681	drug	hydrocortisone	DB00741	True	effect	drug	In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure.
DDI-DrugBank.d314.s24.p9	nonsteroidal antiinflammatory agents	None	group	corticosteroids	None	True	effect	group	Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects.
DDI-DrugBank.d314.s26.p0	salicylates	None	group	corticosteroids	None	True	mechanism	group	The clearance of salicylates may be increased with concurrent use of corticosteroids.
DDI-DrugBank.d314.s8.p2	corticosteroids	None	group	antidiabetic agents	None	True	effect	group	Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required.
DDI-DrugBank.d316.s14.p6	felodipine	DB01023	drug	phenytoin	DB00252	True	mechanism	drug	Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.
DDI-DrugBank.d322.s1.p2	Clidinium	DB00771	drug	ketoconazole	DB01026	True	effect	drug	Clidinium may decrease the effect of phenothiazines, levodopa, and ketoconazole.
DDI-DrugBank.d324.s16.p0	rifampin	None	drug	zaleplon	DB00962	True	mechanism	drug	Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon Cmax and AUC by approximately 80%.
DDI-DrugBank.d324.s29.p0	Sonata	None	brand	cimetidine	DB00501	True	mechanism	drug	Concomitant administration of Sonata (10 mg) and cimetidine (800 mg) produced an 85% increase in the mean Cmax and AUC of zaleplon.
DDI-DrugBank.d325.s11.p0	dopamine	DB00988	drug	propranolol	DB00571	True	effect	drug	It has been reported that results of studies in animals indicate that dopamine-induced ventricular arrhythmias during anesthesia can be reversed by propranolol.
DDI-DrugBank.d325.s4.p2	dopamine	DB00988	drug	metoprolol	DB00264	True	effect	drug	Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.
DDI-DrugBank.d328.s10.p4	NSAIDs	None	group	thiazides	None	True	effect	group	Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.
DDI-DrugBank.d328.s18.p0	valdecoxib	DB00580	drug	dextromethorphan	DB00514	True	mechanism	drug	Coadministration with valdecoxib (40 mg BID for 7 days) resulted in a significant increase in dextromethorphan plasma levels suggesting that, at these doses, valdecoxib is a weak inhibitor of 2D6.
DDI-DrugBank.d328.s24.p2	Valdecoxib	DB00580	drug	warfarin	DB00682	True	effect	drug	Valdecoxib caused a statistically significant increase in plasma exposures of R-warfarin and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin.
DDI-DrugBank.d431.s12.p2	lansoprazole	DB00448	drug	iron	DB01592	True	mechanism	drug	therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).
DDI-DrugBank.d434.s17.p3	Felbatol	None	brand	carbamazepine	DB00564	True	mechanism	drug	Carbamazepine: Felbatol  causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration.
DDI-DrugBank.d434.s30.p21	Phenytoin	DB00252	drug	Felbatol	None	True	mechanism	brand	Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.
DDI-DrugBank.d434.s31.p12	carbamazepine	DB00564	drug	Felbatol	None	True	mechanism	brand	Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol  at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.
DDI-DrugBank.d435.s2.p3	rifampicin	DB01045	drug	exemestane	DB00990	True	mechanism	drug	Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John s wort) may significantly decrease exposure to exemestane.
DDI-DrugBank.d437.s14.p0	Amprenavir	DB00701	drug	ritonavir	DB00503	True	advise	drug	Appropriate laboratory testing should be considered prior to initiating combination therapy with Amprenavir and ritonavir and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy.
DDI-DrugBank.d437.s5.p0	Indinavir	DB00224	drug	amprenavir	DB00701	True	mechanism	drug	Indinavir steady-state Cmax, A.C. and Cmin were decreased by 22%, 38%, and 27%, respectively, by concomitant amprenavir.
DDI-DrugBank.d44.s1.p0	RAPTIVA	None	brand	immunosuppressive drugs	None	True	advise	group	RAPTIVA should not be used with other immunosuppressive drugs.
DDI-DrugBank.d441.s1.p0	linezolid	DB00601	drug	adrenergic	None	True	int	group	Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents.
DDI-DrugBank.d441.s2.p5	ZYVOX	None	brand	vasopressor	None	True	effect	group	Adrenergic Agents:Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents.
DDI-DrugBank.d441.s7.p0	ZYVOX	None	brand	serotonergic agents	None	True	effect	group	Patients who are treated with ZYVOX and concomitant serotonergic agents should be closely observed for signs and symptoms of serotonin syndrome (e.g., cognitive dysfunction, hyperpyrexia, hyperreflexia, incoordination).
DDI-DrugBank.d442.s0.p0	warfarin	DB00682	drug	flutamide	DB00499	True	effect	drug	Increases in prothrombin time have been noted in patients receiving long- term warfarin therapy after flutamide was initiated.
DDI-DrugBank.d443.s3.p9	dipyrone	None	drug	aspirin	None	True	effect	drug	Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.
DDI-DrugBank.d448.s1.p0	antihistamines	None	group	alcohol	None	True	effect	drug	Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.
DDI-DrugBank.d448.s3.p9	veratrum alkaloids	None	drug	sympathomimetics	None	True	effect	group	The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics.
DDI-DrugBank.d450.s2.p22	amiodarone	DB01118	drug	digoxin	DB00390	True	mechanism	drug	Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
DDI-DrugBank.d450.s2.p42	spironolactone	DB00421	drug	digoxin	DB00390	True	mechanism	drug	Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
DDI-DrugBank.d454.s0.p0	Lofexidine	DB04948	drug	alcohol	None	True	effect	drug	Lofexidine may enhance The CNS depressive effects of alcohol, barbiturates and other sedatives
DDI-DrugBank.d454.s0.p2	Lofexidine	DB04948	drug	sedatives	None	True	effect	group	Lofexidine may enhance The CNS depressive effects of alcohol, barbiturates and other sedatives
DDI-DrugBank.d456.s1.p12	TARCEVA	None	brand	voriconazole	DB00582	True	advise	drug	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
DDI-DrugBank.d456.s1.p5	TARCEVA	None	brand	nefazodone	DB01149	True	advise	drug	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
DDI-DrugBank.d456.s1.p6	TARCEVA	None	brand	nelfinavir	DB00220	True	advise	drug	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
DDI-DrugBank.d456.s1.p8	TARCEVA	None	brand	saquinavir	DB01232	True	advise	drug	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
DDI-DrugBank.d456.s1.p9	TARCEVA	None	brand	telithromycin	DB00976	True	advise	drug	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
DDI-DrugBank.d456.s2.p0	rifampicin	DB01045	drug	erlotinib	DB00530	True	mechanism	drug	Pre-treatment with the CYP3A4 inducer rifampicin decreased erlotinib AUC by about 2/3.
DDI-DrugBank.d458.s18.p0	digoxin	DB00390	drug	ketoconazole	DB01026	True	advise	drug	It is, therefore, advisable to monitor digoxin concentrations in patients receiving ketoconazole.
DDI-DrugBank.d458.s19.p1	imidazole compounds	None	group	coumarin	None	True	effect	group	When taken orally , imidazole compounds like ketoconazole may enhance the anticoagulant effect of coumarin-like drugs.
DDI-DrugBank.d458.s27.p0	ketoconazole	DB01026	drug	loratadine	DB00455	True	mechanism	drug	After the coadministration of 200 mg oral ketoconazole twice daily and one 20 mg dose of loratadine to 11 subjects, the AUC and Cmax of loratadine averaged 302% (  142 S.D.) and 251% (  68 S.D.), respectively, of those obtained after co-treatment with placebo.
DDI-DrugBank.d459.s0.p0	ENABLEX	None	brand	ketoconazole	DB01026	True	advise	drug	The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .
DDI-DrugBank.d459.s0.p3	ENABLEX	None	brand	nelfinavir	DB00220	True	advise	drug	The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .
DDI-DrugBank.d459.s0.p4	ENABLEX	None	brand	clarithromycin	DB01211	True	advise	drug	The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .
DDI-DrugBank.d459.s1.p2	ENABLEX	None	brand	tricyclic antidepressants	None	True	advise	group	Caution should be taken when ENABLEX is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants (see CLINICAL PHARMACOLOGY).
DDI-DrugBank.d46.s19.p6	non-steroidal anti-inflammatory agent	None	group	thiazide diuretics	None	True	effect	drug	Non-steroidal Anti-inflammatory Drugs: in some patients, The administration of a Non-steroidal Anti-inflammatory agent can reduce The diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.
DDI-DrugBank.d46.s7.p23	colestipol	DB00375	drug	thiazide diuretics	None	True	mechanism	group	Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have The potential of binding thiazide diuretics and reducing diuretic absorption from The gastrointestinal tract
DDI-DrugBank.d460.s14.p17	monoamine oxidase inhibitors	None	group	antidiabetic drugs	None	True	effect	group	Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.
DDI-DrugBank.d460.s14.p19	non-selective beta-adrenergic-blocking agents	None	group	antidiabetic drugs	None	True	effect	group	Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.
DDI-DrugBank.d460.s15.p11	thyroid products	None	group	antidiabetic drugs	None	True	effect	group	Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.
DDI-DrugBank.d460.s15.p12	sympathomimetics	None	group	Starlix	None	True	effect	brand	Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.
DDI-DrugBank.d460.s15.p4	thiazides	None	group	antidiabetic drugs	None	True	effect	group	Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.
DDI-DrugBank.d463.s6.p0	buspirone	DB00490	drug	warfarin	DB00682	True	effect	drug	However, there has been one report of prolonged prothrombin time when buspirone was added to the regimen of a patient treated with warfarin.
DDI-DrugBank.d468.s4.p2	calcium blockers	None	group	digitalis preparations	None	True	mechanism	group	Digoxin: Some calcium blockers may increase the concentration of digitalis preparations in the blood.
DDI-DrugBank.d468.s5.p5	digoxin	DB00390	drug	nicardipine HCl	None	True	advise	drug	Nicardipine HCl usually does not alter the plasma levels of digoxin, however, serum digoxin levels should be evaluated after concomitant therapy with nicardipine HCl is initiated.
DDI-DrugBank.d47.s2.p13	risperidone	DB00734	drug	levodopa	None	True	effect	drug	Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa.
DDI-DrugBank.d476.s2.p2	ZEBETA	None	brand	clonidine	DB00575	True	advise	drug	In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that ZEBETA be discontinued for several days before the withdrawal of clonidine.
DDI-DrugBank.d476.s3.p3	ZEBETA	None	brand	verapamil	DB00661	True	advise	drug	ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.
DDI-DrugBank.d477.s3.p0	Amphetamines	None	group	tricyclic antidepressants	None	True	effect	group	Amphetamines may enhance the effects of tricyclic antidepressants.
DDI-DrugBank.d478.s1.p6	ergot-type medications	None	group	naratriptan	DB00952	True	advise	drug	Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.
DDI-DrugBank.d48.s1.p1	SPRYCEL	None	brand	itraconazole	DB01167	True	mechanism	drug	Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
DDI-DrugBank.d48.s1.p5	SPRYCEL	None	brand	atazanavir	DB01072	True	mechanism	drug	Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
DDI-DrugBank.d48.s1.p7	SPRYCEL	None	brand	nefazodone	DB01149	True	mechanism	drug	Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
DDI-DrugBank.d48.s13.p4	H2 blockers	None	group	SPRYCEL	None	True	advise	brand	The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.
DDI-DrugBank.d48.s15.p75	quinidine	DB00908	drug	SPRYCEL	None	True	advise	brand	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
DDI-DrugBank.d48.s15.p89	ergotamine	DB00696	drug	SPRYCEL	None	True	advise	brand	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
DDI-DrugBank.d480.s30.p3	clozapine	DB00363	drug	Type 1C antiarrhythmics	None	True	advise	group	Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
DDI-DrugBank.d480.s30.p6	clozapine	DB00363	drug	encainide	DB01228	True	advise	drug	Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
DDI-DrugBank.d484.s0.p12	Etonogestrel	DB00294	drug	antifungals	None	True	int	group	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d484.s0.p22	Etonogestrel	DB00294	drug	Sandimmune	None	True	int	brand	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d484.s0.p25	Etonogestrel	DB00294	drug	Crixivan	None	True	int	brand	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d485.s12.p17	felbamate	DB00949	drug	progestins	None	True	mechanism	group	Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.
DDI-DrugBank.d485.s12.p23	phenytoin	DB00252	drug	ethinyl estradiol	DB00977	True	mechanism	drug	Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.
DDI-DrugBank.d485.s17.p10	hormonal contraceptives	None	group	chlordiazepoxide	DB00475	True	mechanism	drug	Benzodiazepines: Combination hormonal contraceptives may decrease the clearance of some benzodiazepines (alprazolam, chlordiazepoxide, diazepam) and increase the clearance of others (lorazepam, oxazepam, temazepam).
DDI-DrugBank.d485.s17.p13	hormonal contraceptives	None	group	oxazepam	DB00842	True	mechanism	drug	Benzodiazepines: Combination hormonal contraceptives may decrease the clearance of some benzodiazepines (alprazolam, chlordiazepoxide, diazepam) and increase the clearance of others (lorazepam, oxazepam, temazepam).
DDI-DrugBank.d485.s27.p5	Nevirapine	DB00238	drug	combination hormonal contraceptives	None	True	mechanism	group	Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Nevirapine may decrease plasma levels of combination hormonal contraceptives;
DDI-DrugBank.d485.s32.p14	ritonavir	DB00503	drug	combination hormonal contraceptives	None	True	mechanism	group	Protease inhibitors: Amprenavir, lopinavir, nelfinavir, and ritonavir have been shown to decrease plasma levels of combination hormonal contraceptives;
DDI-DrugBank.d485.s39.p2	Combination hormonal contraceptives	None	group	selegiline	DB01037	True	mechanism	drug	Selegiline: Combination hormonal contraceptives may increase the serum concentration of selegiline.
DDI-DrugBank.d487.s2.p1	troleandomycin	DB01361	drug	corticosteroids	None	True	mechanism	group	Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.
DDI-DrugBank.d488.s2.p14	acetylsalicylic acid	DB00945	drug	heparin sodium	None	True	effect	drug	Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.
DDI-DrugBank.d488.s2.p20	dextran	None	drug	heparin sodium	None	True	effect	drug	Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.
DDI-DrugBank.d488.s2.p35	hydroxychloroquine	DB01611	drug	heparin sodium	None	True	effect	drug	Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.
DDI-DrugBank.d489.s4.p5	beta-blocker	None	group	clonidine	DB00575	True	advise	drug	Should it be decided to discontinue therapy in patients receiving beta-blockers and clonidine concurrently, the beta-blocker should be discontinued slowly over several days before the gradual withdrawal of clonidine.
DDI-DrugBank.d495.s2.p10	Clonidine	DB00575	drug	barbiturates	None	True	effect	group	Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol, barbiturates or other sedating drugs.
DDI-DrugBank.d499.s10.p3	Hydrochlorothiazide	DB00999	drug	ketoprofen	DB01009	True	effect	drug	Diuretic: Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.
DDI-DrugBank.d499.s25.p2	ketoprofen	DB01009	drug	lithium	DB01356	True	advise	drug	It is recommended that plasma lithium levels be monitored when ketoprofen is coadministered with lithium.
DDI-DrugBank.d5.s20.p8	bupropion	DB01156	drug	amantadine	DB00915	True	effect	drug	Levodopa and Amantadine: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either levodopa or amantadine.
DDI-DrugBank.d500.s1.p2	tetracyclines	None	group	penicillin	None	True	advise	group	Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.
DDI-DrugBank.d503.s0.p0	Chlorprothixene	DB01239	drug	lithium	DB01356	True	mechanism	drug	Chlorprothixene may increase the plasma-level of concomitantly given lithium.
DDI-DrugBank.d506.s0.p0	phenytoin	DB00252	drug	Norpace	None	True	mechanism	brand	If phenytoin or other hepatic enzyme inducers are taken concurrently with Norpace or Norpace CR, lower plasma levels of disopyramide may occur.
DDI-DrugBank.d507.s0.p0	guanfacine	DB01018	drug	CNS-depressant drug	None	True	effect	group	The potential for increased sedation when guanfacine is given with other CNS-depressant drug should be appreciated.
DDI-DrugBank.d507.s5.p5	timolol	DB00373	drug	guanfacine	DB01018	True	effect	drug	Noncardioselective beta-blockers (nadolol,porpranolol,timolol) may exacerbate rebound hypertension when guanfacine is withdrawn.
DDI-DrugBank.d509.s15.p4	aripiprazole	DB01238	drug	quinidine	DB00908	True	mechanism	drug	Quinidine: Coadministration of a 10-mg single dose of aripiprazole with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite, dehydroaripiprazole, by 35%.
DDI-DrugBank.d509.s2.p0	aripiprazole	DB01238	drug	antihypertensive agents	None	True	effect	group	1- adrenergic receptor antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents.
DDI-DrugBank.d509.s20.p0	carbamazepine	DB00564	drug	aripiprazole	DB01238	True	advise	drug	When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled.
DDI-DrugBank.d511.s4.p5	FOSCAVIR	None	brand	amphotericin B	DB00681	True	advise	drug	Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.
DDI-DrugBank.d514.s2.p0	heroin	DB01452	drug_n	central nervous system depressants	None	True	effect	group	Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.
DDI-DrugBank.d514.s2.p2	heroin	DB01452	drug_n	benzodiazepines	None	True	effect	group	Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.
DDI-DrugBank.d516.s5.p7	antacids	None	group	lomefloxacin	DB00978	True	mechanism	drug	Magnesium- and aluminum-containing antacids, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of lomefloxacin.
DDI-DrugBank.d521.s1.p1	glimepiride	DB00222	drug	salicylate	None	True	advise	group	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
DDI-DrugBank.d521.s1.p3	glimepiride	DB00222	drug	Trilisate	None	True	advise	brand	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
DDI-DrugBank.d522.s24.p6	erythromycin	DB00199	drug	bromocriptine	DB01200	True	int	drug	Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.
DDI-DrugBank.d522.s24.p8	erythromycin	DB00199	drug	astemizole	DB00637	True	int	drug	Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.
DDI-DrugBank.d522.s5.p5	terfenadine	DB00342	drug	dirithromycin	DB00954	True	mechanism	drug	in one man, the C max of terfenadine was 8.1 ng/mL with terfenadine alone and 7.2 ng/mL with terfenadine plus dirithromycin.
DDI-DrugBank.d53.s2.p0	azithromycin	DB00207	drug	nelfinavir	DB00220	True	advise	drug	Although a dose adjustment of azithromycin is not recommended when administered in combination with nelfinavir, close monitoring for known side effects of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted.
DDI-DrugBank.d53.s7.p10	azithromycin	DB00207	drug	theophylline	DB00277	True	mechanism	drug	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
DDI-DrugBank.d53.s7.p2	azithromycin	DB00207	drug	cetirizine	DB00341	True	mechanism	drug	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
DDI-DrugBank.d530.s2.p4	L-phenylalanine	DB00120	drug	selegiline	DB01037	True	effect	drug	Selegiline - L-phenylalanine and the selective MAO inhibitor selegiline may have synergistic antidepressant activity if used concomitantly.
DDI-DrugBank.d531.s29.p0	SUSTIVA	None	brand	clarithromycin	DB01211	True	effect	drug	In uninfected volunteers, 46% developed rash while receiving SUSTIVA and clarithromycin.
DDI-DrugBank.d531.s42.p2	ritonavir	DB00503	drug	SUSTIVA	None	True	advise	brand	A dose increase of lopinavir/ritonavir to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with SUSTIVA.
DDI-DrugBank.d531.s52.p0	efavirenz	DB00625	drug	contraceptives	None	True	advise	group	Because the potential interaction of efavirenz with oral contraceptives has not been fully characterized, a reliable method of barrier contraception should be used in addition to oral contraceptives.
DDI-DrugBank.d533.s2.p0	irbesartan	DB01029	drug	aliskiren	DB01258	True	mechanism	drug	Co-administration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.
DDI-DrugBank.d533.s9.p3	aliskiren	DB01258	drug	furosemide	DB00695	True	mechanism	drug	Furosemide: When aliskiren was co-administered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.
DDI-DrugBank.d536.s10.p0	metformin	DB00331	drug	Acarbose	DB00284	True	mechanism	drug	However, the peak plasma level of metformin was reduced by approximately 20% when taking Acarbose due to a slight delay in the absorption of metformin.
DDI-DrugBank.d536.s4.p4	Intestinal adsorbents	None	group	Acarbose	DB00284	True	mechanism	drug	Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.
DDI-DrugBank.d537.s0.p13	Bentiromide	DB00522	drug	thiazide diuretics	None	True	int	group	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
DDI-DrugBank.d537.s0.p5	Bentiromide	DB00522	drug	benzocaine	DB01086	True	int	drug	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
DDI-DrugBank.d54.s10.p0	cholestyramine	DB01432	drug	thyroid hormones	None	True	advise	group	Therefore, 4 to 5 hours should elapse between administration of cholestyramine and thyroid hormones.
DDI-DrugBank.d54.s12.p0	levothyroxine	DB00451	drug	estrogens	None	True	mechanism	group	In a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy, free levothyroxine may be decreased when estrogens are started thus increasing thyroid requirements.
DDI-DrugBank.d547.s2.p8	lithium	DB01356	drug	angiotensin II receptor antagonists	None	True	mechanism	group	Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, and with some angiotensin II receptor antagonists.
DDI-DrugBank.d547.s3.p3	lithium	DB01356	drug	ATACAND	None	True	mechanism	brand	An increase in serum lithium concentration has been reported during concomitant administration of lithium with ATACAND, so careful monitoring of serum lithium levels is recommended during concomitant use.
DDI-DrugBank.d548.s11.p2	Duloxetine	DB00476	drug	thioridazine	DB00679	True	advise	drug	Because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of thioridazine, Duloxetine and thioridazine should not be co-administered.
DDI-DrugBank.d548.s9.p3	Duloxetine	DB00476	drug	nortriptyline	DB00540	True	advise	drug	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
DDI-DrugBank.d548.s9.p5	Duloxetine	DB00476	drug	imipramine	DB00458	True	advise	drug	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
DDI-DrugBank.d548.s9.p6	Duloxetine	DB00476	drug	phenothiazines	None	True	advise	group	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
DDI-DrugBank.d548.s9.p7	Duloxetine	DB00476	drug	Type 1C antiarrhythmics	None	True	advise	group	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
DDI-DrugBank.d558.s2.p0	Cimetidine	DB00501	drug	TIKOSYN	None	True	mechanism	brand	Cimetidine at 400 mg BID (the usual prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase dofetilide plasma levels by 58%.
DDI-DrugBank.d558.s25.p61	diltiazem	DB00343	drug	TIKOSYN	None	True	advise	brand	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
DDI-DrugBank.d558.s25.p66	nefazadone	None	drug	TIKOSYN	None	True	advise	brand	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
DDI-DrugBank.d559.s1.p10	acetaminophen	DB00316	drug	narcotic analgesic	None	True	effect	group	Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
DDI-DrugBank.d559.s1.p15	acetaminophen	DB00316	drug	sedative-hypnotics	None	True	effect	group	Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
DDI-DrugBank.d559.s1.p18	caffeine	DB00201	drug	alcohol	None	True	effect	drug	Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
DDI-DrugBank.d559.s1.p20	caffeine	DB00201	drug	tranquilizers	None	True	effect	group	Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
DDI-DrugBank.d559.s1.p4	Butalbital	DB00241	drug	anesthetics	None	True	effect	group	Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
DDI-DrugBank.d56.s0.p0	amyl nitrite	DB01612	drug	alcohol	None	True	effect	drug	Taking amyl nitrite after drinking alcohol may worsen side effects and may cause severe hypotension and cardiovascular collapse.
DDI-DrugBank.d562.s14.p2	quinolones	None	group	cyclosporine	DB00091	True	mechanism	drug	Elevated cyclosporine serum levels have been reported with the concomitant use of quinolones and cyclosporine.
DDI-DrugBank.d562.s7.p4	quinolones	None	group	didanosine	DB00900	True	mechanism	drug	Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.
DDI-DrugBank.d564.s0.p5	epinephrine	DB00668	drug	monoamine oxidase inhibitors	None	True	effect	group	The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.
DDI-DrugBank.d565.s15.p0	diltiazem	DB00343	drug	cimetidine	DB00501	True	advise	drug	Patients currently receiving diltiazem therapy should be carefully monitored for a change in pharmacological effect when initiating and discontinuing therapy with cimetidine.
DDI-DrugBank.d565.s33.p0	diltiazem	DB00343	drug	midazolam	DB00683	True	mechanism	drug	Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.
DDI-DrugBank.d565.s41.p0	rifampin	None	drug	diltiazem	DB00343	True	mechanism	drug	Coadministration of rifampin with diltiazem lowered the diltiazem plasma concentrations to undetectable levels.
DDI-DrugBank.d566.s0.p10	Cholestyramine	DB01432	drug	progestins	None	True	mechanism	group	Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
DDI-DrugBank.d566.s0.p7	Cholestyramine	DB01432	drug	phenobarbital	DB01174	True	mechanism	drug	Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
DDI-DrugBank.d567.s11.p2	danazol	DB01406	drug	lovastatin	DB00227	True	effect	drug	Danazol: The risk of myopathy/rhabdomyolysis is increased by concomitant administration of danazol particularly with higher doses of lovastatin (see WARNINGS, Myopathy/Rhabdomyolysis).
DDI-DrugBank.d567.s12.p9	verapamil	DB00661	drug	HMG-CoA reductase inhibitor class	None	True	effect	group	Amiodarone or Verapamil: The risk of myopathy/rhabdomyolysis is increased when either amiodarone or verapamil is used concomitantly with a closely related member of the HMG-CoA reductase inhibitor class (see WARNINGS, Myopathy/Rhabdomyolysis).
DDI-DrugBank.d568.s13.p7	pimozide	DB01100	drug	citalopram	DB00215	True	effect	drug	Pimozide and Celexa - In a controlled study, a single dose of pimozide 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.
DDI-DrugBank.d571.s4.p0	antidiabetic agents	None	group	VELCADE	None	True	advise	brand	Patients on oral antidiabetic agents receiving VELCADE treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their antidiabetic medication.
DDI-DrugBank.d573.s0.p2	minoxidil	DB00350	drug	guanethidine	DB01170	True	effect	drug	Interaction with Guanethidine: Although minoxidil does not itself cause orthostatic hypotension, its administration to patients already receiving guanethidine can result in profound orthostatic effects.
DDI-DrugBank.d576.s6.p5	Salicylate	None	group	sulfinpyrazone	DB01138	True	mechanism	drug	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.
DDI-DrugBank.d578.s4.p3	phenobarbital	DB01174	drug	methylprednisolone	DB00959	True	advise	drug	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response.
DDI-DrugBank.d584.s9.p2	Oxandrolone	DB00621	drug	hypoglycemic agents	None	True	mechanism	group	Oral hypoglycemic agents Oxandrolone may inhibit the metabolism of oral hypoglycemic agents.
DDI-DrugBank.d585.s0.p10	anticholinergic drugs	None	group	nitrates	None	True	effect	group	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
DDI-DrugBank.d585.s0.p2	anticholinergic drugs	None	group	quinidine	DB00908	True	effect	drug	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
DDI-DrugBank.d587.s0.p12	methsuximide	DB05246	drug	phenytoin	DB00252	True	mechanism	drug	Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).
DDI-DrugBank.d588.s0.p4	Furosemide	DB00695	drug	metolazone	DB00524	True	effect	drug	Diuretics: Furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes.
DDI-DrugBank.d588.s12.p0	Methenamine	None	drug	metolazone	DB00524	True	effect	drug	Methenamine: Efficacy may be decreased due to urinary alkalizing effect of metolazone.
DDI-DrugBank.d591.s6.p2	ketoconazole	DB01026	drug	ropivacaine	DB00296	True	mechanism	drug	Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.
DDI-DrugBank.d597.s2.p2	aspirin	None	brand	meloxicam	DB00814	True	mechanism	drug	Aspirin: Concomitant administration of aspirin (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of meloxicam.
DDI-DrugBank.d597.s7.p2	cholestyramine	DB01432	drug	meloxicam	DB00814	True	mechanism	drug	Cholestyramine: Pretreatment for four days with cholestyramine significantly increased the clearance of meloxicam by 50%.
DDI-DrugBank.d60.s12.p11	nondepolarizing agents	None	group	lithium	DB01356	True	effect	drug	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d60.s12.p14	nondepolarizing agents	None	group	quinidine	DB00908	True	effect	drug	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d60.s12.p18	NIMBEX	None	brand	bacitracin	DB00626	True	effect	drug	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d60.s14.p1	phenytoin	DB00252	drug	NIMBEX	None	True	effect	brand	While the effects of chronic phenytoin or carbamazepine therapy on the action of NIMBEX are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.
DDI-DrugBank.d60.s6.p11	nitrous oxide	None	drug	NIMBEX	None	True	effect	brand	Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.
DDI-DrugBank.d601.s0.p4	Barbiturates	None	group	corticosteroids	None	True	int	group	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.
DDI-DrugBank.d603.s5.p37	terazosin	DB01162	drug	ProAmatine	None	True	effect	brand	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.
DDI-DrugBank.d604.s5.p0	John's Wort	None	drug_n	hormonal contraceptive agents	None	True	effect	group	John's Wort with hormonal contraceptive agents may reduce the effectiveness of the contraception and up to one month after discontinuation of these concomitant therapies.
DDI-DrugBank.d606.s0.p1	MAO inhibitors	None	group	pseudoephedrine	DB00852	True	effect	drug	MAO inhibitors and beta adrenergic blockers increase the effects of pseudoephedrine.
DDI-DrugBank.d607.s1.p0	Leukine	None	brand	lithium	DB01356	True	effect	drug	Drugs which may potentiate the myeloproliferative effects of Leukine, such as lithium and corticosteroids, should be used with caution.
DDI-DrugBank.d607.s1.p1	Leukine	None	brand	corticosteroids	None	True	effect	group	Drugs which may potentiate the myeloproliferative effects of Leukine, such as lithium and corticosteroids, should be used with caution.
DDI-DrugBank.d609.s0.p0	gemfibrozil	DB01241	drug	rosiglitazone	DB00412	True	mechanism	drug	An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone.
DDI-DrugBank.d611.s1.p0	Beta adrenergic agonists	None	group	monoamine oxidase inhibitors	None	True	advise	group	Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.
DDI-DrugBank.d615.s1.p2	anticholinergic drugs	None	group	triprolidine	DB00427	True	effect	drug	The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine.
DDI-DrugBank.d615.s1.p5	tricyclic antidepressants	None	group	triprolidine	DB00427	True	effect	drug	The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine.
DDI-DrugBank.d616.s1.p0	ZADAXIN	None	brand	immunomodulating drugs	None	True	advise	group	Caution should be exercised when administering ZADAXIN therapy in combination with other immunomodulating drugs.
DDI-DrugBank.d624.s0.p10	TOBI	None	brand	corticosteroids	None	True	effect	group	In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
DDI-DrugBank.d633.s1.p0	mexiletine	DB00379	drug	fluvoxamine	DB00176	True	mechanism	drug	In a formal, single-dose interaction study (n = 6 males) the clearance of mexiletine was decreased by 38% following the coadministration of fluvoxamine, an inhibitor of CYP1A2.
DDI-DrugBank.d633.s16.p0	Mexitil	None	brand	theophylline	DB00277	True	mechanism	drug	Concurrent use of Mexitil    and theophylline may lead to increased plasma theophylline levels.
DDI-DrugBank.d633.s9.p2	phenytoin	DB00252	drug	Mexitil	None	True	mechanism	brand	When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported.
DDI-DrugBank.d635.s0.p0	short-acting beta adrenergic aerosol bronchodilators	None	group	MAXAIR AUTOHALER	None	True	advise	brand	Other short-acting beta adrenergic aerosol bronchodilators should not be used concomitantly with MAXAIR AUTOHALER because they may have additive effects.
DDI-DrugBank.d636.s3.p3	Mephenytoin	DB00532	drug	furosemide	DB00695	True	effect	drug	Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.
DDI-DrugBank.d638.s2.p2	Ritalin	None	brand	phenobarbital	DB01174	True	mechanism	drug	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).
DDI-DrugBank.d639.s2.p4	SUTENT	None	brand	rifabutin	DB00615	True	mechanism	drug	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.
DDI-DrugBank.d639.s2.p5	SUTENT	None	brand	rifapentin	None	True	mechanism	drug	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.
DDI-DrugBank.d64.s29.p10	anticoagulant	None	group	diuretics	None	True	effect	group	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
DDI-DrugBank.d64.s29.p20	anticoagulant	None	group	rifampin	None	True	effect	drug	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
DDI-DrugBank.d64.s6.p0	anticoagulant	None	group	adrenocortical steroids	None	True	effect	group	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;
DDI-DrugBank.d64.s87.p15	anticoagulant	None	group	diazoxide	DB01119	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p2	anticoagulant	None	group	aminosalicylic acid	DB00233	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p23	anticoagulant	None	group	influenza virus vaccine	None	True	effect	group	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p26	anticoagulant	None	group	methyldopa	DB00968	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p39	anticoagulant	None	group	prolonged narcotics	None	True	effect	group	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p42	anticoagulant	None	group	quinine	DB00468	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p47	anticoagulant	None	group	sulindac	DB00605	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s90.p17	non-steroidal anti-inflammatory drugs	None	group	anticoagulants	None	True	effect	group	Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal anti-inflammatory drugs, dipyridamole, hydrochloroquine, clofibrate, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.
DDI-DrugBank.d64.s90.p26	clofibrate	DB00636	drug	anticoagulants	None	True	effect	group	Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal anti-inflammatory drugs, dipyridamole, hydrochloroquine, clofibrate, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.
DDI-DrugBank.d64.s90.p6	antineoplastic agents	None	group	anticoagulants	None	True	effect	group	Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal anti-inflammatory drugs, dipyridamole, hydrochloroquine, clofibrate, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.
DDI-DrugBank.d64.s91.p0	antiplatelet medication	None	group	anticoagulant medication	None	True	advise	group	The beneficial effects on arterial thrombus formation from combined therapy with antiplatelet and anticoagulant medication must be weighed against an increased risk of inducing hemorrhage.
DDI-DrugBank.d640.s3.p13	amiloride	DB00594	drug	ACE inhibitors	None	True	effect	group	Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.
DDI-DrugBank.d642.s0.p0	tigecycline	DB00560	drug	warfarin	DB00682	True	advise	drug	Prothrombin time or other suitable anticoagulation test should be monitored if tigecycline is administered with warfarin.
DDI-DrugBank.d643.s0.p11	Melatonin	DB01065	drug	benzodiazepenes	None	True	int	group	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
DDI-DrugBank.d647.s1.p0	Streptozocin	DB00428	drug	doxorubicin	DB00997	True	mechanism	drug	Streptozocin has been reported to prolong the elimination half-life of doxorubicin and may lead to severe bone marrow suppression;
DDI-DrugBank.d648.s0.p3	Cholestyramine	DB01432	drug	raloxifene	DB00481	True	mechanism	drug	Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA.
DDI-DrugBank.d648.s3.p0	EVISTA	None	brand	warfarin	DB00682	True	advise	drug	If EVISTA is given concurrently with warfarin, prothrombin time should be monitored.
DDI-DrugBank.d649.s0.p1	Sulfamethizole	DB00576	drug	tolbutamide	DB01124	True	effect	drug	Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics.
DDI-DrugBank.d649.s0.p2	Sulfamethizole	DB00576	drug	uricosurics	None	True	effect	group	Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics.
DDI-DrugBank.d652.s0.p0	metoclopramide	DB01233	drug	anticholinergic drugs	None	True	effect	group	The effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics.
DDI-DrugBank.d652.s0.p1	metoclopramide	DB01233	drug	narcotic analgesics	None	True	effect	group	The effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics.
DDI-DrugBank.d655.s0.p10	Methscopolamine	None	drug	amantadine	DB00915	True	int	drug	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
DDI-DrugBank.d655.s0.p13	Methscopolamine	None	drug	anticholinergics	None	True	int	group	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
DDI-DrugBank.d655.s0.p19	Methscopolamine	None	drug	phenothiazines	None	True	int	group	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
DDI-DrugBank.d655.s0.p20	Methscopolamine	None	drug	chlorpromazine	DB00477	True	int	drug	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
DDI-DrugBank.d655.s0.p3	Methscopolamine	None	drug	phenelzine	DB00780	True	int	drug	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
DDI-DrugBank.d66.s2.p3	L-glutamine	DB00130	drug	indomethacin	DB00328	True	effect	drug	Indomethacin - Concomitant use of L-glutamine and indomethacin may ameliorate increased intestinal permeability caused by indomethacin.
DDI-DrugBank.d66.s5.p2	methotrexate	DB00563	drug	L-glutamine	DB00130	True	effect	drug	Methotrexate - There is one report that methotrexate may decrease the possible effectiveness of supplemental L-glutamine for chemotherapy-induced mucositis.
DDI-DrugBank.d661.s1.p0	ZEMURON	None	brand	succinylcholine	DB00202	True	advise	drug	If ZEMURON    is administered following administration of succinylcholine, it should not be given until recovery from succinylcholine has been observed.
DDI-DrugBank.d668.s2.p7	phenytoin	DB00252	drug	mifepristone	DB00834	True	mechanism	drug	John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone).
DDI-DrugBank.d679.s0.p0	cimetidine	DB00501	drug	mebendazole	DB00643	True	mechanism	drug	Preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole.
DDI-DrugBank.d680.s8.p0	pantoprazole	DB00213	drug	ketoconazole	DB01026	True	mechanism	drug	Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts).
DDI-DrugBank.d689.s3.p0	adrenergic agents	None	group	tricyclic antidepressants	None	True	effect	group	The pressor response of adrenergic agents may also be potentiated by tricyclic antidepressants.
DDI-DrugBank.d693.s0.p2	digoxin	DB00390	drug	sulfasalazine	DB00795	True	mechanism	drug	Reduced absorption of folic acid and digoxin have been reported when those agents were administered concomitantly with sulfasalazine.
DDI-DrugBank.d695.s1.p1	Cerezyme	None	brand	ZAVESCA	None	True	advise	brand	Combination therapy with Cerezyme    (imiglucerase) and ZAVESCA    is not indicated.
DDI-DrugBank.d704.s1.p0	FLOMAX	None	brand	alpha-adrenergic blocking agents	None	True	advise	group	However, interactions may be expected and FLOMAX capsules should NOT be used in combination with other alpha-adrenergic blocking agents.
DDI-DrugBank.d71.s5.p0	Lamivudine	DB00709	drug	zalcitabine	DB00943	True	effect	drug	Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of one another.
DDI-DrugBank.d710.s1.p0	rimantadine HCl	None	drug	Cimetidine	DB00501	True	mechanism	drug	When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine).
DDI-DrugBank.d710.s5.p0	acetaminophen	DB00316	drug	rimantadine	DB00478	True	mechanism	drug	Coadministration with acetaminophen reduced the peak concentration and AUC values for rimantadine by approximately 11%.
DDI-DrugBank.d711.s2.p3	tetracyclines	None	group	magnesium	DB01378	True	mechanism	drug	Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations.
DDI-DrugBank.d713.s2.p11	Sanctura	None	brand	morphine	DB00295	True	mechanism	drug	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).
DDI-DrugBank.d716.s0.p0	mazindol	DB00579	drug	monoamine oxidase inhibitor	None	True	advise	group	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.
DDI-DrugBank.d716.s0.p2	mazindol	DB00579	drug	isocarboxazid	DB01247	True	advise	drug	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.
DDI-DrugBank.d72.s3.p0	BUSULFEX	None	brand	phenytoin	DB00252	True	mechanism	drug	Since the pharmacokinetics of BUSULFEX were studied in patients treated with phenytoin, the clearance of BUSULFEX at the recommended dose may be lower and exposure (AUC) higher in patients not treated with phenytoin.
DDI-DrugBank.d72.s4.p4	acetaminophen	DB00316	drug	BUSULFEX	None	True	mechanism	brand	Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( 72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues.
DDI-DrugBank.d720.s3.p35	sertraline	DB01104	drug	sumatriptan	DB00669	True	effect	drug	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.
DDI-DrugBank.d720.s4.p0	sumatriptan	DB00669	drug	SSRI	None	True	advise	group	If concomitant treatment with sumatriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.
DDI-DrugBank.d722.s1.p3	aminosalicylate derivatives	None	group	thioguanine	DB00352	True	mechanism	drug	As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.
DDI-DrugBank.d722.s1.p6	olsalazine	DB01250	drug	thioguanine	DB00352	True	mechanism	drug	As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.
DDI-DrugBank.d722.s1.p8	mesalazine	DB00244	drug	thioguanine	DB00352	True	mechanism	drug	As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.
DDI-DrugBank.d723.s0.p14	Isopto Carbachol	None	brand	suprofen	DB00870	True	effect	drug	Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.
DDI-DrugBank.d726.s1.p56	paricalcitol	DB00910	drug	clarithromycin	DB01211	True	advise	drug	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
DDI-DrugBank.d726.s1.p62	paricalcitol	DB00910	drug	saquinavir	DB01232	True	advise	drug	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
DDI-DrugBank.d727.s1.p0	zidovudine	DB00495	drug	ZERIT	None	True	advise	brand	Therefore, use of zidovudine in combination with ZERIT should be avoided.
DDI-DrugBank.d727.s2.p0	stavudine	DB00649	drug	doxorubicin	DB00997	True	effect	drug	In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin.
DDI-DrugBank.d736.s5.p0	Thiazide drugs	None	group	tubocurarine	DB01199	True	effect	drug	Thiazide drugs may increase the responsiveness of tubocurarine.
DDI-DrugBank.d736.s6.p0	Lithium	DB01356	drug	thiazides	None	True	mechanism	group	Lithium renal clearance is reduced by thiazides, increasing the risk of lithium toxicity.
DDI-DrugBank.d737.s6.p87	indomethacin	DB00328	drug	pramipexole	DB00413	True	mechanism	drug	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
DDI-DrugBank.d74.s0.p0	FLUOTHANE	None	brand	non-depolarising muscle relaxant	None	True	effect	group	FLUOTHANE augments the action of non-depolarising muscle relaxants and the muscle relaxant effects of aminoglycosides.
DDI-DrugBank.d74.s0.p1	FLUOTHANE	None	brand	aminoglycosides	None	True	effect	group	FLUOTHANE augments the action of non-depolarising muscle relaxants and the muscle relaxant effects of aminoglycosides.
DDI-DrugBank.d74.s2.p0	adrenaline	None	drug	FLUOTHANE	None	True	advise	brand	Caution should be exercised during the administration of adrenaline to patients anaesthetised with FLUOTHANE as arrhythmias may be precipitated.
DDI-DrugBank.d742.s7.p2	alcohol	None	drug	mirtazapine	DB00370	True	mechanism	drug	Alcohol: Concomitant administration of alcohol (equivalent to 60 g) had a minimal effect on plasma levels of mirtazapine (15 mg) in 6 healthy male subjects.
DDI-DrugBank.d743.s12.p18	terfenadine	DB00342	drug	macrolide antibiotics	None	True	advise	group	Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.
DDI-DrugBank.d743.s12.p2	terfenadine	DB00342	drug	troleandomycin	DB01361	True	advise	drug	Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.
DDI-DrugBank.d328.s28.p1	valdecoxib	DB00580	drug	fluconazole	DB00196	True	mechanism	drug	Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.
DDI-DrugBank.d328.s29.p0	valdecoxib	DB00580	drug	fluconazole	DB00196	True	mechanism	drug	Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.
DDI-DrugBank.d328.s39.p0	valdecoxib	DB00580	drug	omeprazole	DB00338	True	mechanism	drug	Coadministration with valdecoxib increased exposure of omeprazole (AUC) by 46%.
DDI-DrugBank.d328.s49.p2	valdecoxib	DB00580	drug	diazepam	DB00829	True	effect	drug	Although the magnitude of changes in diazepam plasma exposure when coadministered with valdecoxib were not sufficient to warrant dosage adjustments, patients may experience enhanced sedative side effects caused by increased exposure of diazepam under this circumstance.
DDI-DrugBank.d332.s1.p2	doxapram	DB00561	drug	muscle relaxant drugs	None	True	effect	group	In patients who have received muscle relaxants, doxapram may temporarily mask the residual effects of muscle relaxant drugs.
DDI-DrugBank.d333.s5.p7	phenobarbital	DB01174	drug	clonazepam	DB01068	True	mechanism	drug	Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.
DDI-DrugBank.d333.s7.p1	benzodiazepine class	None	group	narcotics	None	True	effect	group	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
DDI-DrugBank.d333.s7.p2	benzodiazepine class	None	group	barbiturates	None	True	effect	group	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
DDI-DrugBank.d333.s7.p5	benzodiazepine class	None	group	phenothiazines classes of antipsychotic agents	None	True	effect	group	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
DDI-DrugBank.d752.s1.p19	fluconazole	DB00196	drug	midazolam	DB00683	True	mechanism	drug	Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam.
DDI-DrugBank.d752.s6.p4	carbamazepine	DB00564	drug	midazolam	DB00683	True	mechanism	drug	Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies.
DDI-DrugBank.d756.s0.p0	opioids	None	group	levomepromazine	None	True	effect	drug	Dosages of concomitantly administered opioids should be reduced by approximately half, because levomepromazine amplifies the therapeutic actions and side-effects of opioids.
DDI-DrugBank.d756.s4.p0	levomepromazine	None	drug	anticholinergic drugs	None	True	advise	group	Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.
DDI-DrugBank.d756.s4.p2	levomepromazine	None	drug	antiparkinsonian-agents	None	True	advise	group	Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.
DDI-DrugBank.d756.s7.p4	ephedrine	DB01364	drug	levomepromazine	None	True	effect	drug	Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine.
DDI-DrugBank.d758.s0.p0	oxycodone hydrochloride	None	drug	CNS depressants	None	True	effect	group	The CNS depressant effects of oxycodone hydrochloride may be additive with that of other CNS depressants..
DDI-DrugBank.d76.s11.p1	fluvoxamine	DB00176	drug	astemizole	DB00637	True	advise	drug	Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.
DDI-DrugBank.d76.s24.p0	alprazolam	DB00404	drug	fluvoxamine	DB00176	True	effect	drug	Moreover, as noted with alprazolam, the effect of fluvoxamine may even be more pronounced when it is administered at higher doses.
DDI-DrugBank.d76.s4.p1	Fluvoxamine	DB00176	drug	MAOI	None	True	advise	group	Therefore, it is recommended that Fluvoxamine Tablets not be used in combination with MAOIs, or within 14 days of discontinuing treatment with a MAOI.
DDI-DrugBank.d76.s7.p5	cisapride	DB00604	drug	ketoconazole	DB01026	True	mechanism	drug	Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.
DDI-DrugBank.d763.s3.p21	phenytoin	DB00252	drug	ondansetron	DB00904	True	mechanism	drug	Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.
DDI-DrugBank.d763.s3.p23	carbamazepine	DB00564	drug	ondansetron	DB00904	True	mechanism	drug	Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.
DDI-DrugBank.d763.s3.p26	rifampicin	DB01045	drug	ondansetron	DB00904	True	mechanism	drug	Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.
DDI-DrugBank.d763.s4.p18	ondansetron	DB00904	drug	tramadol	DB00193	True	effect	drug	However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.
DDI-DrugBank.d765.s0.p0	Ketoconazole	DB01026	drug	tolterodine	DB01036	True	mechanism	drug	CYP3A4 Inhibitors: Ketoconazole, an inhibitor of the drug metabolizing enzyme CYP3A4, significantly increased plasma concentrations of tolterodine when coadministered to subjects who were poor metabolizers (see CLINICAL PHARMACOLOGY, Variability in Metabolism and Drug-Drug Interactions).
DDI-DrugBank.d765.s1.p23	itraconazole	DB01167	drug	DETROL LA	None	True	advise	brand	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.
DDI-DrugBank.d766.s3.p8	ketoconazole	DB01026	drug	trimetrexate	DB01157	True	mechanism	drug	Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism.
DDI-DrugBank.d773.s2.p8	heparin	DB01109	drug	TNKase	None	True	effect	brand	Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.
DDI-DrugBank.d775.s10.p16	MIVACRON	None	brand	aminoglycosides	None	True	int	group	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d775.s10.p17	MIVACRON	None	brand	tetracyclines	None	True	int	group	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d775.s10.p2	nondepolarizing agents	None	drug	aminoglycosides	None	True	int	group	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d775.s10.p22	MIVACRON	None	brand	colistin	DB00803	True	int	drug	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d775.s10.p24	MIVACRON	None	brand	magnesium	DB01378	True	int	group	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d775.s10.p26	MIVACRON	None	brand	anesthetics	None	True	int	group	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d775.s10.p3	nondepolarizing agents	None	drug	tetracyclines	None	True	int	group	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d775.s10.p4	nondepolarizing agents	None	drug	bacitracin	DB00626	True	int	drug	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d776.s19.p2	DIFLUCAN	None	brand	theophylline	DB00277	True	advise	drug	Careful monitoring of serum theophylline concentrations in patients receiving DIFLUCAN and theophylline is recommended.
DDI-DrugBank.d776.s23.p0	fluconazole	DB00196	drug	terfenadine	DB00342	True	advise	drug	The combined use of fluconazole at doses of 400 mg or greater with terfenadine is contraindicated.
DDI-DrugBank.d776.s6.p2	DIFLUCAN	None	brand	coumarin-type anticoagulants	None	True	effect	group	Coumarin-type anticoagulants: Prothrombin time may be increased in patients receiving concomitant DIFLUCAN and coumarin-type anticoagulants.
DDI-DrugBank.d779.s0.p0	methyldopa	DB00968	drug	antihypertensive drugs	None	True	effect	group	When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur.
DDI-DrugBank.d779.s7.p0	methyldopa	DB00968	drug	ferrous sulfate	None	True	mechanism	drug	Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate.
DDI-DrugBank.d779.s9.p1	methyldopa	DB00968	drug	ferrous gluconate	None	True	advise	drug	Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended.
DDI-DrugBank.d78.s1.p8	quinolones	None	group	zinc	DB01593	True	mechanism	drug	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
DDI-DrugBank.d78.s1.p9	quinolones	None	group	VIDEX	None	True	mechanism	brand	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
DDI-DrugBank.d78.s10.p5	quinolone antimicrobial	None	group	warfarin	DB00682	True	advise	drug	However, because some quinolones have been reported to enhance the effects of warfarin or its derivatives, prothrombin time or other suitable anticoagulation test should be monitored closely if a quinolone antimicrobial is administered with warfarin or its derivatives.
DDI-DrugBank.d780.s7.p3	procaine hydrochloride	None	drug	sulfonamides	None	True	effect	group	Sulfonamides: Concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide.
DDI-DrugBank.d781.s12.p2	perindopril	DB00790	drug	gentamicin	DB00798	True	int	drug	Gentamicin: Animal data have suggested the possibility of interaction between perindopril and gentamicin.
DDI-DrugBank.d782.s0.p4	Vindesine	DB00309	drug	Killed virus vaccines	None	True	int	group	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine
DDI-DrugBank.d783.s0.p1	Posicor	None	brand	astemizole	DB00637	True	mechanism	drug	Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants.
DDI-DrugBank.d783.s0.p3	Posicor	None	brand	cyclosporine	DB00091	True	mechanism	drug	Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants.
DDI-DrugBank.d784.s3.p2	DITROPAN XL	None	brand	ketoconazole	DB01026	True	mechanism	drug	Mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when DITROPAN XL was administered with ketoconazole, a potent CYP3A4 inhibitor.
DDI-DrugBank.d784.s4.p5	antimycotic agents	None	group	oxybutynin	DB01062	True	mechanism	drug	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).
DDI-DrugBank.d81.s7.p3	cimetidine	DB00501	drug	isradipine	DB00270	True	mechanism	drug	Cimetidine: In a study in healthy volunteers, a one-week course of cimetidine at 400 mg b.i.d. with a single 5 mg dose of isradipine on the sixth day showed an increase in isradipine mean peak plasma concentrations (36%) and significant increase in area under the curve (50%).
DDI-DrugBank.d82.s18.p0	INDOCIN	None	brand	lithium	DB01356	True	advise	drug	As a consequence, when INDOCIN and lithium are given concomitantly, the patient should be carefully observed for signs of lithium toxicity.
DDI-DrugBank.d82.s28.p0	triamterene	DB00384	drug	INDOCIN	None	True	effect	brand	It has been reported that the addition of triamterene to a maintenance schedule of INDOCIN resulted in reversible acute renal failure in two of four healthy volunteers.
DDI-DrugBank.d82.s6.p0	INDOCIN	None	brand	anticoagulant	None	True	advise	group	However, when any additional drug, including INDOCIN, is added to the treatment of patients on anticoagulant therapy, the patients should be observed for alterations of the prothrombin time.
DDI-DrugBank.d86.s0.p3	antipsychotic drug	None	group	tricyclic antidepressant	None	True	effect	group	The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
DDI-DrugBank.d87.s2.p0	TAMBOCOR	None	brand	digoxin	DB00390	True	mechanism	drug	During administration of multiple oral doses of TAMBOCOR to healthy subjects stabilized on a maintenance dose of digoxin, a 13%-19% increase in plasma digoxin levels occurred at six hours postdose.
DDI-DrugBank.d88.s5.p2	5-fluorouracil	None	drug	leucovorin	DB00650	True	mechanism	drug	Leucovorin: The concentration of 5-fluorouracil is increased and its toxicity may be enhanced by leucovorin.
DDI-DrugBank.d89.s3.p2	caffeine	DB00201	drug	ketoconazole	DB01026	True	advise	drug	Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).
DDI-DrugBank.d89.s3.p23	caffeine	DB00201	drug	phenobarbital	DB01174	True	advise	drug	Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).
DDI-DrugBank.d9.s0.p3	Azlocillin	DB01061	drug	netilmicin	DB00955	True	advise	drug	Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.
DDI-DrugBank.d91.s2.p0	idoxuridine	DB00249	drug	boric acid	None	True	advise	drug	When you are using idoxuridine, it is especially important that your health care professional know if you are using the following: Eye product containing boric acid.
DDI-DrugBank.d94.s11.p11	EQUETROTM	None	brand	desipramine	DB01151	True	mechanism	drug	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s11.p14	EQUETROTM	None	brand	doxycycline	DB00254	True	mechanism	drug	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s11.p15	EQUETROTM	None	brand	ethosuximide	DB00593	True	mechanism	drug	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s11.p17	EQUETROTM	None	brand	felodipine	DB01023	True	mechanism	drug	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s11.p19	EQUETROTM	None	brand	haloperidol	DB00502	True	mechanism	drug	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s11.p44	EQUETROTM	None	brand	zonisamide	DB00909	True	mechanism	drug	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s11.p5	EQUETROTM	None	brand	citalopram	DB00215	True	mechanism	drug	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s18.p1	EQUETROTM	None	brand	alcohol	None	True	advise	drug	Because of its primary CNS effect, caution should be used when EQUETROTM is taken with other centrally acting drugs and alcohol.
DDI-DrugBank.d94.s4.p16	EQUETROTM	None	brand	niacinamide	None	True	mechanism	drug	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
DDI-DrugBank.d94.s4.p18	EQUETROTM	None	brand	protease inhibitors	None	True	mechanism	group	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
DDI-DrugBank.d94.s4.p23	EQUETROTM	None	brand	valproate	None	True	mechanism	drug	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
DDI-DrugBank.d94.s4.p3	EQUETROTM	None	brand	clarithromycin	DB01211	True	mechanism	drug	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
DDI-DrugBank.d94.s4.p8	EQUETROTM	None	brand	erythromycin	DB00199	True	mechanism	drug	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
DDI-DrugBank.d94.s8.p6	EQUETROTM	None	brand	primidone	DB00794	True	mechanism	drug	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
DDI-DrugBank.d97.s37.p0	Indinavir	DB00224	drug	didanosine	DB00900	True	advise	drug	Indinavir and didanosine formulations containing buffer should be administered at least one hour apart on an empty stomach.
DDI-DrugBank.d97.s59.p0	antiarrhythmics	None	group	CRIXIVAN	None	True	advise	brand	Caution is warranted and therapeutic concentration monitoring is recommended for antiarrhythmics when coadministered with CRIXIVAN.
DDI-DrugBank.d98.s0.p27	Cholestyramine	DB01432	drug	fat soluble vitamins	None	True	mechanism	group	Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
DDI-DrugBank.d99.s19.p0	amitriptyline HCl	None	drug	anticholinergic	None	True	effect	drug	Hyperpyrexia has been reported when amitriptyline HCl is administered with anticholinergic agents or with neuroleptic drugs, particularly during hot weather.
DDI-DrugBank.d99.s20.p0	tricyclic antidepressants	None	drug	anticholinergic	None	True	effect	drug	Paralytic ileus may occur in patients taking tricyclic antidepressants in combination with anticholinergic-type drugs.
DDI-DrugBank.d99.s21.p0	Cimetidine	DB00501	drug	tricyclic antidepressants	None	True	mechanism	drug	Cimetidine is reported to reduce hepatic metabolism of certain tricyclic antidepressants, thereby delaying elimination and increasing steady-state concentrations of these drugs.
DDI-MedLine.d1.s5.p1	Sildenafil	DB00203	drug	short-acting nitrates	None	True	advise	group	Sildenafil is contraindicated in patients using long-acting nitrates or who may need to use short-acting nitrates, because the combination may cause a sharp fall of the blood pressure.
DDI-MedLine.d113.s5.p0	alcohol	None	drug	3-hydroxy-1,4-benzodiazepine	None	True	mechanism	group	The results raise the possibility that the ethanolysis reaction may occur in the stomach of people who consume alcohol and 3-hydroxy-1,4-benzodiazepine on a regular basis.
DDI-MedLine.d116.s1.p0	warfarin	DB00682	drug	rifampin	None	True	int	drug	The drug interaction between warfarin and rifampin is not well known.
DDI-MedLine.d116.s3.p0	rifampin	None	drug	warfarin	DB00682	True	mechanism	drug	The concomitant administration of rifampin and warfarin resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect.
DDI-MedLine.d12.s2.p2	dexamethasone	DB01234	drug	EGF	None	True	effect	drug_n	Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin.
DDI-MedLine.d12.s2.p6	retinyl acetate	None	drug	insulin	None	True	effect	drug	Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin.
DDI-MedLine.d12.s7.p12	retinoids	None	group	insulin	None	True	effect	drug	These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.
DDI-MedLine.d12.s7.p4	dexamethasone	DB01234	drug	EGF	None	True	effect	drug_n	These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.
DDI-MedLine.d12.s7.p8	retinyl acetate	None	drug	EGF	None	True	effect	drug_n	These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.
DDI-MedLine.d128.s13.p1	Loperamide	DB00836	drug	dmPGE2	None	True	effect	drug_n	Loperamide and morphine (0.1 and 1.0 mg/kg, s.c.) inhibited the dmPGE2 (0.3 mg/kg, p.o.)-induced diarrhea in cecectomized rats.
DDI-MedLine.d147.s8.p0	Imexon	DB05003	drug	dacarbazine	DB00851	True	effect	drug	Imexon and dacarbazine show additive effects in vitro but not in vivo in human A375 melanoma cells.
DDI-MedLine.d159.s6.p0	acetyl-l-carnitine	None	drug	alpha-lipoic acid	None	True	effect	drug	(ii) acetyl-l-carnitine elicits a significant protective effect on DEB induced toxicity, which was potentiated by  alpha-lipoic acid.
DDI-MedLine.d17.s0.p0	prostaglandin F2alpha	None	drug	oxytocin	DB00107	True	int	drug	In vitro interaction of prostaglandin F2alpha and oxytocin in placental vessels.
DDI-MedLine.d17.s4.p0	PGF2alpha	None	drug	oxytocin	DB00107	True	effect	drug	PGF2alpha produced significantly increased vasoconstriction after a single administration of oxytocin.
DDI-MedLine.d184.s5.p0	quinpirole	None	drug_n	amphetamine	DB00182	True	effect	drug	In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine.
DDI-MedLine.d195.s7.p0	piperine	None	drug_n	ibuprofen	DB01050	True	effect	drug	From this study it can be concluded that piperine can be used as a bioenhancer along with ibuprofen.
DDI-MedLine.d20.s0.p0	glycine	DB00145	drug	glutamate	None	True	effect	drug	Interaction between glycine and glutamate in the development of spontaneous motility in chick embryos.
DDI-MedLine.d204.s9.p0	methylglyoxal	None	drug_n	piperacillin	DB00319	True	effect	drug	Distinct and statistically significant synergism was observed between methylglyoxal and piperacillin by disc diffusion tests when compared with their individual effects.
DDI-MedLine.d218.s10.p3	Warfarin	DB00682	drug	amitriptyline	DB00321	True	effect	drug	Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.
DDI-MedLine.d218.s8.p1	Warfarin	DB00682	drug	fluoxetine	DB00472	True	effect	drug	Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]).
DDI-MedLine.d227.s7.p0	dexmedetomidine	DB00633	drug	ephedrine	DB01364	True	effect	drug	In the hot plate test in mice, co-administration of 15     g/kg dexmedetomidine with 10   mg/kg ephedrine intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine.
DDI-MedLine.d23.s1.p16	Innovar Vet	None	brand	ouabain	DB01092	True	effect	drug	In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital.
DDI-MedLine.d23.s2.p1	ouabain	DB01092	drug	ketamine	DB01221	True	effect	drug	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.
DDI-MedLine.d23.s2.p2	ouabain	DB01092	drug	droperidol	DB00450	True	effect	drug	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.
DDI-MedLine.d25.s12.p1	Macrolide antibiotics	None	group	atorvastatin	DB01076	True	mechanism	drug	CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin).
DDI-MedLine.d25.s12.p4	Macrolide antibiotics	None	group	simvastatin	DB00641	True	mechanism	drug	CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin).
DDI-MedLine.d27.s0.p1	picrotoxin	DB00466	drug_n	phenazepam	None	True	effect	drug_n	[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine.
DDI-MedLine.d30.s8.p2	(-)-NANM	None	drug_n	naloxone	DB01183	True	effect	drug	In monkeys, the effects of (-)-NANM, but not (+)-NANM or PCP, were antagonized by naloxone;
DDI-MedLine.d34.s9.p0	iron	DB01592	drug	cobalt	None	True	mechanism	drug	Consequently, the effect of iron on the retention of cobalt was lower than on absorption.
DDI-MedLine.d36.s2.p0	carbamazepine	DB00564	drug	tricyclic antidepressant	None	True	effect	group	We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.
DDI-MedLine.d42.s9.p0	nitrate	None	group	sildenafil	DB00203	True	effect	drug	however, patients with moderate to severe cardiovascular disease or those taking nitrate therapy are at increased risk for potentially serious cardiovascular adverse effects with sildenafil therapy.
DDI-MedLine.d59.s5.p0	Cytochalasin D	None	drug_n	carbachol	DB00411	True	effect	drug	Cytochalasin D inhibited the carbachol-stimulated intracellular Ca(2+) concentration ([Ca(2+)](i)) increase due to release from the Ca(2+) store.
DDI-MedLine.d63.s4.p0	naloxone	DB01183	drug	beta-endorphin	None	True	effect	drug_n	Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms).
DDI-DrugBank.d333.s6.p2	antifungal agents	None	group	clonazepam	DB01068	True	advise	drug	Although clinical studies have not been performed, based on the involvement of the cytochrome P-450 3A family in clonazepam metabolism, inhibitors of this enzyme system, notably oral antifungal agents, should be used cautiously in patients receiving clonazepam.
DDI-DrugBank.d333.s7.p0	benzodiazepine class	None	group	alcohol	None	True	effect	drug	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
DDI-DrugBank.d333.s7.p7	benzodiazepine class	None	group	butyrophenone classes of antipsychotic agents	None	True	effect	group	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
DDI-DrugBank.d334.s19.p2	lithium	DB01356	drug	ACE inhibitor	None	True	effect	group	Lithium toxicity was usually reversible upon discontinuation of lithium and the ACE inhibitor.
DDI-DrugBank.d334.s3.p0	diuretic	None	group	PRINIVIL	None	True	effect	brand	When a diuretic is added to the therapy of a patient receiving PRINIVIL, an additional antihypertensive effect is usually observed.
DDI-DrugBank.d334.s7.p1	NSAIDs	None	group	lisinopril	DB00722	True	effect	drug	Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors, including lisinopril.
DDI-DrugBank.d334.s8.p0	NSAIDs	None	group	ACE inhibitors	None	True	advise	group	This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.
DDI-DrugBank.d338.s8.p0	benzodiazepines	None	group	nefazodone	DB01149	True	mechanism	drug	The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, diltiazem, isoniazide, and some macrolide antibiotics.
DDI-DrugBank.d338.s8.p4	benzodiazepines	None	group	isoniazide	None	True	mechanism	drug	The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, diltiazem, isoniazide, and some macrolide antibiotics.
DDI-DrugBank.d339.s2.p2	Anticoagulants	None	group	cefixime	DB00671	True	effect	drug	Warfarin and Anticoagulants: Increased prothrombin time, with or without clinical bleeding, has been reported when cefixime is administered concomitantly.
DDI-DrugBank.d34.s0.p0	dorzolamide	DB00869	drug	carbonic anhydrase inhibitors	None	True	effect	group	Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy).
DDI-DrugBank.d340.s6.p6	VIRACEPT	None	brand	ergot derivatives	None	True	advise	group	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
DDI-DrugBank.d341.s2.p0	ENBREL	None	brand	anakinra	DB00026	True	effect	drug	In a study in which patients with active RA were treated for up to 24 weeks with concurrent ENBREL  and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with ENBREL  alone (0%).
DDI-DrugBank.d347.s7.p43	Videx	None	brand	FACTIVE	None	True	advise	brand	Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.
DDI-DrugBank.d350.s12.p18	carbamazepine	DB00564	drug	CANCIDAS	None	True	mechanism	brand	In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.
DDI-DrugBank.d352.s3.p0	diethylpropion	DB00937	drug	antihypertensive drugs	None	True	int	group	conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa).
DDI-DrugBank.d353.s9.p0	methotrexate	DB00563	drug	acitretin	DB00459	True	advise	drug	Consequently, the combination of methotrexate with acitretin is also contraindicated.
DDI-DrugBank.d359.s4.p0	coumarin anticoagulants	None	group	phenytoin	DB00252	True	mechanism	drug	Conversely, the coumarin anticoagulants have been reported to increase the serum levels and prolong the serum half-life of phenytoin by inhibiting its metabolism.
DDI-DrugBank.d364.s10.p2	alosetron	DB00969	drug	protease inhibitors	None	True	advise	group	Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
DDI-DrugBank.d364.s10.p3	alosetron	DB00969	drug	voriconazole	DB00582	True	advise	drug	Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
DDI-DrugBank.d364.s15.p2	alosetron	DB00969	drug	hydralazine	DB01275	True	effect	drug	Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.
DDI-DrugBank.d364.s3.p0	Fluvoxamine	DB00176	drug	alosetron	DB00969	True	mechanism	drug	Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold.
DDI-DrugBank.d368.s12.p0	Acetazolamide	DB00819	drug	lithium	DB01356	True	mechanism	drug	Acetazolamide increases lithium excretion and the lithium may be decreased.
DDI-DrugBank.d368.s6.p0	Acetazolamide	DB00819	drug	folic acid antagonists	None	True	effect	group	Acetazolamide may increase the effects of other folic acid antagonists.
DDI-DrugBank.d372.s2.p0	Aminoglutethimide	DB00357	drug	coumarin	None	True	effect	group	Aminoglutethimide diminishes the effect of coumarin and warfarin.
DDI-DrugBank.d372.s2.p1	Aminoglutethimide	DB00357	drug	warfarin	DB00682	True	effect	drug	Aminoglutethimide diminishes the effect of coumarin and warfarin.
DDI-DrugBank.d373.s8.p3	quinidine	DB00908	drug	nifedipine	DB01115	True	mechanism	drug	Quinidine: Immediate Release Capsules: There have been rare reports of an interaction between quinidine and nifedipine (with a decreased plasma level of quinidine).
DDI-DrugBank.d374.s0.p0	Auranofin	DB00995	drug	gold medication	None	True	advise	group	Auranofin should be avoided by patients with a history of serious reaction to any gold medication, including Solganal and Myochrysine.
DDI-DrugBank.d379.s1.p26	sulfonamides	None	group	LEVULAN KERASTICK	None	True	effect	brand	It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.
DDI-MedLine.d67.s7.p0	Midazolam	DB00683	drug	morphine	DB00295	True	effect	drug	Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.
DDI-MedLine.d68.s0.p12	cimetidine	DB00501	drug	verografine	None	True	mechanism	drug	[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments.
DDI-MedLine.d85.s0.p0	Misonidazole	None	drug_n	CCNU	None	True	effect	drug	Misonidazole protects mouse tumour and normal tissues from the toxicity of oral CCNU.
DDI-MedLine.d86.s6.p2	sirolimus	DB00877	drug	diltiazem	DB00343	True	mechanism	drug	Apparent oral clearance and volume of distribution of sirolimus decreased with 38% and 45%, respectively, when sirolimus was given with diltiazem.
DDI-MedLine.d90.s9.p2	atracurium	DB00732	drug	gentamycin	None	True	effect	drug	At 75% recovery of fade, hoof twitch was 87 +/- 3% for atracurium alone and 82 +/- 4% for atracurium plus gentamycin.
DDI-MedLine.d97.s8.p0	thiabendazole	DB00730	drug	melarsoprol	None	True	effect	drug	Among the risk factors studied, two appear to increase the risk of ARE: the prescription of thiabendazole to treat strongyloidiasis during the melarsoprol cure and the bad general clinical conditions of patients.
DDI-DrugBank.d333.s7.p9	benzodiazepine class	None	group	tricyclic antidepressants	None	True	effect	group	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
DDI-DrugBank.d334.s5.p2	non-steroidal anti-inflammatory drugs	None	group	lisinopril	DB00722	True	effect	drug	Non-steroidal Anti-inflammatory Agents: In some patients with compromised renal function who are being treated with non-steroidal anti-inflammatory drugs, the co-administration of lisinopril may result in a further deterioration of renal function.
DDI-DrugBank.d338.s1.p0	benzodiazepines	None	group	anticonvulsants	None	True	effect	group	The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.
DDI-DrugBank.d338.s4.p3	estazolam	DB01215	drug	barbiturates	None	True	mechanism	group	While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.
DDI-DrugBank.d340.s18.p6	saquinavir	DB01232	drug	VIRACEPT	None	True	mechanism	brand	Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.
DDI-DrugBank.d340.s31.p0	rifabutin	DB00615	drug	VIRACEPT	None	True	advise	brand	It is recommended that the dose of rifabutin be reduced to one-half the usual dose when administered with VIRACEPT.
DDI-DrugBank.d340.s33.p0	VIRACEPT	None	brand	rifampin	None	True	advise	drug	VIRACEPT and rifampin should not be coadministered.
DDI-DrugBank.d340.s35.p9	VIRACEPT	None	brand	OVCON-35	None	True	mechanism	brand	Ethinyl Estradiol and Norethindrone: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.
DDI-DrugBank.d340.s6.p11	VIRACEPT	None	brand	triazolam	DB00897	True	advise	drug	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
DDI-DrugBank.d345.s10.p0	chlorothiazide	DB00880	drug	colestipol hydrochloride	None	True	mechanism	drug	Studies in humans show that the absorption of chlorothiazide as reflected in urinary excretion is markedly decreased even when administered one hour before colestipol hydrochloride.
DDI-DrugBank.d345.s11.p13	hydrochlorothiazide	DB00999	drug	colestipol hydrochloride	None	True	mechanism	drug	The absorption of tetracycline, furosemide, penicillin G, hydrochlorothiazide, and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride;
DDI-DrugBank.d345.s14.p0	digitalis preparations	None	group	colestipol hydrochloride	None	True	effect	drug	Particular caution should be observed with digitalis preparations since there are conflicting results for the effect of colestipol hydrochloride on the availability of digoxin and digitoxin.
DDI-DrugBank.d345.s14.p4	colestipol hydrochloride	None	drug	digitoxin	DB01396	True	mechanism	drug	Particular caution should be observed with digitalis preparations since there are conflicting results for the effect of colestipol hydrochloride on the availability of digoxin and digitoxin.
DDI-DrugBank.d345.s5.p0	colestipol hydrochloride	None	drug	propranolol	DB00571	True	mechanism	drug	Repeated doses of colestipol hydrochloride given prior to a single dose of propranolol in human trials have been reported to decrease propranolol absorption.
DDI-DrugBank.d346.s2.p0	REVIA	None	brand	disulfiram	DB00822	True	effect	drug	The safety and efficacy of concomitant use of REVIA and disulfiram is unknown, and the concomitant use of two potentially hepatotoxic medications is not ordinarily recommended unless the probable benefits outweigh the known risks.
DDI-DrugBank.d346.s3.p0	REVIA	None	brand	thioridazine	DB00679	True	effect	drug	Lethargy and somnolence have been reported following doses of REVIA and thioridazine.
DDI-DrugBank.d346.s5.p0	REVIA	None	brand	opioid	None	True	effect	group	In an emergency situation when opioid analgesia must be administered to a patient receiving REVIA, the amount of opioid required may be greater than usual, and the resulting respiratory depression may be deeper and more prolonged.
DDI-DrugBank.d347.s1.p1	FACTIVE	None	brand	cimetidine	DB00501	True	mechanism	drug	Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.
DDI-DrugBank.d347.s1.p4	FACTIVE	None	brand	progesterone	DB00396	True	mechanism	drug	Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.
DDI-DrugBank.d347.s4.p0	quinolones	None	group	warfarin	DB00682	True	effect	drug	However, because some quinolones have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone antimicrobial is administered concomitantly with warfarin or its derivatives.
DDI-DrugBank.d347.s6.p2	gemifloxacin	DB01155	drug	magnesium	DB01378	True	mechanism	drug	The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an antacid containing aluminum and magnesium.
DDI-DrugBank.d35.s0.p0	EPA	None	drug	aspirin	None	True	int	brand	Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).
DDI-DrugBank.d35.s0.p2	EPA	None	drug	ginkgo	None	True	int	drug	Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).
DDI-DrugBank.d350.s12.p9	nevirapine	DB00238	drug	CANCIDAS	None	True	mechanism	brand	In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.
DDI-DrugBank.d353.s1.p4	acitretin	DB00459	drug	glibenclamide	None	True	effect	drug	Glibenclamide: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects.
DDI-DrugBank.d354.s1.p0	nitazoxanide	DB00507	drug	warfarin	DB00682	True	mechanism	drug	Therefore, caution should be used when administering nitazoxanide concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices, as competition for binding sites may occur (e.g., warfarin).
DDI-DrugBank.d356.s4.p0	non-steroidal anti-inflammatory agent	None	group	loop diuretics	None	True	effect	group	In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.
DDI-DrugBank.d356.s4.p1	non-steroidal anti-inflammatory agent	None	group	potassium-sparing diuretics	None	True	effect	group	In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.
DDI-DrugBank.d357.s1.p5	antihypertensive medications	None	group	vasodilators	None	True	effect	group	Antihypertensive Medications and Vasodilators: The following adverse events were experienced more commonly in patients receiving concomitant antihypertensive medications or vasodilators (n = 94) compared to patients not receiving these concomitant drugs (n = 456): hypotension 10% vs 4%, myocardial infarction 3% vs 1%, serious pneumonia 5% vs 3%, serious falls 9% vs 3%, and bone and joint injuries 6% vs 2%.
DDI-DrugBank.d357.s3.p44	metoclopramide	DB01233	drug	APOKYN	None	True	effect	brand	Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.
DDI-DrugBank.d358.s0.p4	PLETAL	None	brand	ketoconazole	DB01026	True	advise	drug	Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.
DDI-DrugBank.d358.s1.p2	erythromycin	DB00199	drug	cilostazol	DB01166	True	mechanism	drug	Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites.
DDI-DrugBank.d359.s2.p0	hydantoin antiepileptic	None	group	phenytoin	DB00252	True	int	drug	A two-way interaction between the hydantoin antiepileptic, phenytoin, and the coumarin anticoagulants has been suggested.
DDI-DrugBank.d359.s2.p1	hydantoin antiepileptic	None	group	coumarin anticoagulant	None	True	int	group	A two-way interaction between the hydantoin antiepileptic, phenytoin, and the coumarin anticoagulants has been suggested.
DDI-DrugBank.d368.s0.p0	DIAMOX	None	brand	phenytoin	DB00252	True	mechanism	drug	DIAMOX modifies phenytoin metabolism with increased serum levels of phenytoin.
DDI-DrugBank.d371.s1.p4	docetaxel	DB01248	drug	troleandomycin	DB01361	True	mechanism	drug	In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and troleandomycin.
DDI-DrugBank.d373.s9.p2	coumarin anticoagulants	None	group	nifedipine	DB01115	True	effect	drug	Coumarin Anticoagulants: There have been rare reports of increased prothrombin time in patients taking coumarin anticoagulants to whom nifedipine was administered.
DDI-DrugBank.d377.s0.p0	Phospholine Iodide	None	drug	cholinesterase inhibitors	None	True	effect	group	Phospholine Iodide potentiates other cholinesterase inhibitors such as succinylcholine or organophosphate and carbamate insecticides.
DDI-DrugBank.d377.s0.p3	Phospholine Iodide	None	drug	carbamate insecticide	None	True	effect	drug_n	Phospholine Iodide potentiates other cholinesterase inhibitors such as succinylcholine or organophosphate and carbamate insecticides.
DDI-DrugBank.d380.s6.p1	SUBUTEX	None	brand	benzodiazepines	None	True	advise	group	SUBUTEX and SUBOXONE should be prescribed with caution to patients on benzodiazepines or other drugs that act on the central nervous system, regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse.
DDI-DrugBank.d381.s2.p0	levamisole	DB00848	drug	warfarin sodium	None	True	advise	drug	Because of reports of prolongation of the prothrombin time beyond the therapeutic range in patients taking concurrent levamisole and warfarin sodium, it is suggested that the prothrombin time be monitored carefully, and the dose of warfarin sodium or other coumarin-like drugs should be adjusted accordingly, in patients taking both drugs.
DDI-DrugBank.d382.s31.p1	Aprepitant	DB00673	drug	itraconazole	DB01167	True	advise	drug	Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.
DDI-DrugBank.d382.s31.p3	Aprepitant	DB00673	drug	troleandomycin	DB01361	True	advise	drug	Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.
DDI-DrugBank.d382.s38.p3	Aprepitant	DB00673	drug	rifampin	None	True	mechanism	drug	Rifampin: When a single 375-mg dose of Aprepitant was administered on Day9 of a 14-day regimen of 600 mg/day of rifampin, a strong CYP3A4 inducer, the AUC of aprepitant decreased approximately 11-fold and the mean terminal half-life decreased approximately 3-fold.
DDI-DrugBank.d384.s15.p5	antacids	None	group	vitamin D	None	True	advise	group	Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.
DDI-DrugBank.d384.s7.p2	Vitamin D	None	group	digitalis	None	True	advise	group	Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.
DDI-DrugBank.d386.s12.p0	T.A.	None	group	SSRIs	None	True	advise	group	Nevertheless, caution is indicated in the co-administration of T.A. with any of the SSRIs and also in switching from one class to the other.
DDI-DrugBank.d386.s28.p0	tricyclic antidepressants	None	group	fluoxetine	DB00472	True	mechanism	drug	There have been greater than two-fold increases of previously stable plasma levels of tricyclic antidepressants when fluoxetine has been administered in combination with these agents.
DDI-DrugBank.d389.s0.p1	Antihistamines	None	group	barbiturates	None	True	effect	group	Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.
DDI-DrugBank.d389.s1.p0	MAO inhibitors	None	group	antihistamines	None	True	effect	group	MAO inhibitors prolong and intensify the anticholinergic effects of antihistamines.
DDI-DrugBank.d389.s2.p0	Sympathomimetic amines	None	group	reserpine	DB00206	True	effect	drug	Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa and mecamylamine.
DDI-DrugBank.d392.s0.p0	Panretin	None	brand	DEET	None	True	advise	drug	Patients who are applying Panretin gel should not concurrently use products that contain DEET (N, N-diethyl-m-toluamide), a common component of insect repellent products.
DDI-DrugBank.d393.s5.p0	cetirizine	DB00341	drug	theophylline	DB00277	True	mechanism	drug	There was a small decrease in the clearance of cetirizine caused by a 400-mg dose of theophylline;
DDI-DrugBank.d395.s25.p0	warfarin	DB00682	drug	enoxacin	DB00467	True	advise	drug	Nevertheless, the prothrombin time or other suitable coagulation test should be monitored when warfarin or its derivatives and enoxacin are given concomitantly.
DDI-DrugBank.d395.s4.p2	caffeine	DB00201	drug	enoxacin	DB00467	True	mechanism	drug	Trough plasma enoxacin levels were also 20% higher when caffeine and enoxacin were administered concomitantly.
DDI-DrugBank.d397.s8.p2	erythromycin	DB00199	drug	tacrolimus	DB00864	True	int	drug	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
DDI-DrugBank.d4.s2.p0	dyphylline	DB00651	drug	probenecid	DB01032	True	mechanism	drug	Concurrent administration of dyphylline and probenecid, which competes for tubular secretion, has been shown to increase the plasma half-life of dyphylline .
DDI-DrugBank.d40.s10.p14	phenytoin	DB00252	drug	phenothiazines	None	True	mechanism	group	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
DDI-DrugBank.d40.s10.p17	phenytoin	DB00252	drug	succinimides	None	True	mechanism	group	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
DDI-DrugBank.d40.s10.p2	phenytoin	DB00252	drug	chlordiazepoxide	DB00475	True	mechanism	drug	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
DDI-DrugBank.d40.s10.p7	phenytoin	DB00252	drug	estrogens	None	True	mechanism	group	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
DDI-DrugBank.d40.s15.p2	phenytoin	DB00252	drug	valproate	None	True	effect	drug	Similarly, the effects of phenytoin on phenobarbital, valproic acid and sodium plasma valproate concentrations are unpredictable
DDI-DrugBank.d40.s19.p10	phenytoin	DB00252	drug	theophylline	DB00277	True	effect	drug	Drugs whose efficacy is impaired by Phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
DDI-DrugBank.d40.s19.p2	phenytoin	DB00252	drug	coumarin	None	True	effect	group	Drugs whose efficacy is impaired by Phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
DDI-DrugBank.d40.s19.p9	phenytoin	DB00252	drug	quinidine	DB00908	True	effect	drug	Drugs whose efficacy is impaired by Phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
DDI-DrugBank.d400.s3.p0	NSAIDs	None	group	methotrexate	DB00563	True	advise	drug	Caution should be used when NSAIDs are administered concomitantly with methotrexate.
DDI-DrugBank.d401.s0.p10	AKINETON	None	brand	meperidine	None	True	effect	drug	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
DDI-DrugBank.d401.s0.p13	AKINETON	None	brand	tricyclic antidepressants	None	True	effect	group	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
DDI-DrugBank.d401.s0.p5	anticholinergic	None	group	tricyclic antidepressants	None	True	effect	group	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
DDI-DrugBank.d401.s0.p6	anticholinergic	None	group	antiarrhythmics	None	True	effect	group	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
DDI-DrugBank.d41.s15.p2	ARAVA	None	brand	rifampin	None	True	advise	drug	Because of the potential for ARAVA levels to continue to increase with multiple dosing, caution should be used if patients are to be receiving both ARAVA and rifampin.
DDI-DrugBank.d410.s1.p3	Sumatriptan	DB00669	drug	D.H.E. 45	None	True	effect	brand	Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.
DDI-DrugBank.d410.s5.p24	D.H.E. 45	None	brand	macrolide class	None	True	mechanism	group	Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.
DDI-DrugBank.d411.s13.p2	levothyroxine sodium	None	drug	ketamine	DB01221	True	effect	drug	Ketamine: Marked hypertension and tachycardia have been reported in association with concomitant administration of levothyroxine sodium and ketamine.
DDI-DrugBank.d411.s3.p10	levothyroxine sodium	None	drug	mefenamic acid	DB00784	True	mechanism	drug	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
DDI-DrugBank.d411.s3.p15	levothyroxine sodium	None	drug	salicylates	None	True	mechanism	group	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
DDI-DrugBank.d411.s3.p3	levothyroxine sodium	None	drug	clofibrate	DB00636	True	mechanism	drug	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
DDI-DrugBank.d413.s16.p9	amoxicillin	DB01060	drug	allopurinol	DB00437	True	effect	drug	Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.
DDI-DrugBank.d413.s9.p5	uricosuric agents	None	group	oxipurinol	None	True	mechanism	drug	Uricosuric Agents: Since the excretion of oxipurinol is similar to that of urate, uricosuric agents, which increase the excretion of urate, are also likely to increase the excretion of oxipurinol and thus lower the degree of inhibition of xanthine oxidase.
DDI-DrugBank.d414.s2.p1	EDECRIN	None	brand	cephalosporin antibiotics	None	True	effect	group	EDECRIN may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics.
DDI-DrugBank.d414.s6.p0	non- steroidal antiinflammatory agent	None	group	loop diuretics	None	True	effect	group	In some patients, the administration of a non- steroidal antiinflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium- sparing and thiazide diuretics.
DDI-DrugBank.d415.s5.p4	Ibuprofen	DB01050	drug	methotrexate	DB00563	True	mechanism	drug	Methotrexate: Ibuprofen, as well as other nonsteroidal anti-inflammatory drugs, probably reduces the tubular secretion of methotrexate based on in vitro studies in rabbit kidney slices.
DDI-DrugBank.d419.s5.p1	broad-spectrum antibiotics	None	group	contraceptives	None	True	effect	group	In common with other broad-spectrum antibiotics, AUGMENTIN XR may reduce the efficacy of oral contraceptives
DDI-DrugBank.d422.s10.p3	BREVIBLOC	None	brand	warfarin	DB00682	True	advise	drug	Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.
DDI-DrugBank.d422.s4.p0	digoxin	DB00390	drug	BREVIBLOC	None	True	mechanism	brand	When digoxin and BREVIBLOC were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in digoxin blood levels at some time points.
DDI-DrugBank.d423.s0.p16	selegiline hydrochloride	None	drug	fluoxetine	DB00472	True	effect	drug	In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
DDI-DrugBank.d423.s0.p4	monoamine oxidase inhibitors	None	group	fluvoxamine	DB00176	True	effect	drug	In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
DDI-DrugBank.d423.s3.p0	dexfenfluramine	DB01191	drug	MAO inhibitor	None	True	advise	group	At least 3 weeks should elapse between discontinuation of dexfenfluramine and initiation of treatment with a MAO inhibitor.
DDI-DrugBank.d423.s4.p3	selective serotonin reuptake inhibitors	None	group	dihydroergotamine	DB00320	True	effect	drug	A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.
DDI-DrugBank.d426.s3.p10	SSRIs	None	group	5-HT1 agonists	None	True	effect	group	Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
DDI-DrugBank.d427.s5.p2	Quinolones	None	group	warfarin	DB00682	True	effect	drug	Quinolones, including nalidixic acid, may enhance the effects of the oral anticoagulant warfarin or its derivatives.
DDI-DrugBank.d428.s10.p0	Cimetidine	DB00501	drug	epirubicin	DB00445	True	mechanism	drug	Cimetidine increased the AUC of epirubicin by 50%.
DDI-DrugBank.d429.s0.p8	Antacids	None	group	chloroquine	DB00608	True	mechanism	drug	Antacids and kaolin: Antacids and kaolin can reduce absorption of chloroquine;
DDI-DrugBank.d429.s4.p2	chloroquine	DB00608	drug	ampicillin	DB00415	True	mechanism	drug	Ampicillin: In a study of healthy volunteers, chloroquine significantly reduced the bioavailability of ampicillin.
DDI-DrugBank.d43.s10.p2	ciprofloxacin	DB00537	drug	didanosine	DB00900	True	mechanism	drug	The AUC of ciprofloxacin was decreased an average of 15-fold in 12 healthy subjects given ciprofloxacin and didanosine-placebo tablets concurrently.
DDI-DrugBank.d43.s12.p2	quinolone antibiotics	None	group	calcium	DB01373	True	mechanism	drug	Plasma concentrations of quinolone antibiotics are decreased when administered with antacids containing magnesium, calcium, or aluminum.
DDI-DrugBank.d43.s8.p20	ciprofloxacin	DB00537	drug	calcium	DB01373	True	mechanism	drug	Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.
DDI-DrugBank.d430.s0.p0	ranitidine	DB00863	drug	alendronate	DB00630	True	mechanism	drug	Intravenous ranitidine was shown to double the bioavailability of oral alendronate.
DDI-DrugBank.d124.s26.p134	alprazolam	DB00404	drug	saquinavir	DB01232	True	mechanism	drug	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DDI-DrugBank.d124.s26.p30	dapsone	DB00250	drug	saquinavir	DB01232	True	mechanism	drug	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
DDI-DrugBank.d129.s2.p0	oxyphenbutazone	DB03585	drug	androgens	None	True	mechanism	group	Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.
DDI-DrugBank.d13.s0.p56	Flupenthixol	None	drug	Ethanol	DB00898	True	effect	drug	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants
DDI-DrugBank.d131.s0.p2	benzodiazepines	None	group	anticonvulsants	None	True	effect	group	The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.
DDI-DrugBank.d131.s0.p8	alprazolam	DB00404	drug	ethanol	DB00898	True	effect	drug	The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.
DDI-DrugBank.d131.s10.p1	benzodiazepines	None	group	ergotamine	DB00696	True	int	drug	Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.
DDI-DrugBank.d131.s9.p4	alprazolam	DB00404	drug	paroxetine	DB00715	True	int	drug	Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine.
DDI-DrugBank.d132.s14.p0	diflunisal	DB00861	drug	acetaminophen	DB00316	True	effect	drug	Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.
DDI-DrugBank.d132.s22.p0	indomethacin	DB00328	drug	diflunisal	DB00861	True	advise	drug	Therefore, indomethacin and diflunisal should not be used concomitantly.
DDI-DrugBank.d132.s5.p3	diflunisal	DB00861	drug	hydrochlorothiazide	DB00999	True	mechanism	drug	Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.
DDI-DrugBank.d133.s0.p1	BOTOX	None	brand	curare-like compounds	None	True	advise	group	Co-administration of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.
DDI-DrugBank.d137.s10.p1	Anti-arrhythmics	None	group	bepridil hydrochloride	None	True	effect	drug	Anti-arrhythmics and tricyclic anti-depressants could exaggerate the prolongation of the QT interval observed with bepridil hydrochloride.
DDI-DrugBank.d140.s17.p2	HMG-CoA reductase inhibitor	None	group	cimetidine	DB00501	True	advise	drug	Caution should be exercised if an HMG-CoA reductase inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, spironolactone, and cimetidine.
DDI-DrugBank.d141.s12.p2	cerivastatin	DB00439	drug	erythromycin	DB00199	True	mechanism	drug	ERYTHROMYCIN: In hypercholesterolemic patients, steady-state cerivastatin AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of erythromycin, a known inhibitor of cytochrome P450 3A4.
DDI-DrugBank.d142.s0.p4	LEVSIN	None	brand	monoamine oxidase (MAO) inhibitors	None	True	effect	group	Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.
DDI-DrugBank.d142.s0.p6	LEVSIN	None	brand	antihistamines	None	True	effect	group	Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.
DDI-DrugBank.d144.s1.p14	ritonavir	DB00503	drug	budesonide	DB01222	True	advise	drug	If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.
DDI-DrugBank.d150.s1.p1	FLEXERIL	None	brand	barbiturates	None	True	effect	group	FLEXERIL may enhance the effects of alcohol, barbiturates, and other CNS depressants.
DDI-DrugBank.d153.s0.p5	epinephrine	DB00668	drug	monoamine oxidase inhibitors	None	True	effect	group	The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.
DDI-DrugBank.d154.s10.p0	Nalfon	None	brand	loop diuretics	None	True	effect	group	Patients treated with Nalfon may be resistant to the effects of loop diuretics.
DDI-DrugBank.d154.s2.p9	aspirin	None	brand	Nalfon	None	True	mechanism	brand	Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.
DDI-DrugBank.d154.s8.p0	coumarin-type anticoagulants	None	group	Nalfon	None	True	effect	brand	In patients receiving coumarin-type anticoagulants, the addition of Nalfon to therapy could prolong the prothrombin time.
DDI-DrugBank.d158.s6.p4	MAOI antidepressants	None	group	amphetamine	DB00182	True	mechanism	drug	MAO inhibitors MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.
DDI-DrugBank.d162.s10.p0	Diuretic agents	None	group	lithium	DB01356	True	mechanism	drug	Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.
DDI-DrugBank.d165.s10.p0	Itraconazole	DB01167	drug	cisapride	DB00604	True	advise	drug	therefore concomitant administration of Itraconazole with cisapride is contraindicated.
DDI-DrugBank.d165.s15.p2	Itraconazole	DB01167	drug	digoxin	DB00390	True	mechanism	drug	Coadministration of Itraconazole and cyclosporine, tacrolimus or digoxin has led to increased plasma concentrations of the latter three drugs.
DDI-DrugBank.d165.s16.p2	Cyclosporine	DB00091	drug	Itraconazole	DB01167	True	advise	drug	Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.
DDI-DrugBank.d165.s4.p4	ketoconazole	DB01026	drug	astemizole	DB00637	True	mechanism	drug	Another oral azole antifungal, ketoconazole, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals.
DDI-DrugBank.d165.s8.p0	ketoconazole	DB01026	drug	cisapride	DB00604	True	effect	drug	Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.
DDI-DrugBank.d170.s2.p1	fentanyl	DB00813	drug	ketoconazole	DB01026	True	mechanism	drug	The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.
DDI-DrugBank.d170.s5.p14	DURAGESIC	None	brand	opioids	None	True	effect	group	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
DDI-DrugBank.d170.s5.p23	fentanyl	DB00813	drug	central nervous system depressants	None	True	effect	group	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
DDI-DrugBank.d171.s0.p5	Tagamet	None	brand	diazepam	DB00829	True	mechanism	drug	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
DDI-DrugBank.d171.s2.p0	anticoagulant	None	group	Tagamet	None	True	advise	brand	therefore, close monitoring of prothrombin time is recommended, and adjustment of the anticoagulant dose may be necessary when Tagamet is administered concomitantly.
DDI-DrugBank.d171.s4.p1	Tagamet	None	brand	Theo-Dur	None	True	mechanism	brand	However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.
DDI-DrugBank.d172.s13.p2	CELEBREX	None	brand	aspirin	None	True	advise	brand	Aspirin: CELEBREX can be used with low dose aspirin.
DDI-DrugBank.d172.s24.p0	CELEBREX	None	brand	warfarin	DB00682	True	advise	drug	However, caution should be used when administering CELEBREX with warfarin since these patients are at increased risk of bleeding complications.
DDI-DrugBank.d172.s6.p0	celecoxib	DB00482	drug	fluconazole	DB00196	True	int	drug	Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.
DDI-DrugBank.d175.s20.p0	diuretic	None	group	lithium	DB01356	True	effect	drug	If a diuretic is also used, it may increase the risk of lithium toxicity.
DDI-DrugBank.d176.s9.p44	antacids	None	group	fosinopril	DB00492	True	mechanism	drug	Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.
DDI-DrugBank.d18.s1.p35	scopolamine	DB00747	drug	lorazepam	DB00186	True	effect	drug	Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
DDI-DrugBank.d18.s1.p5	Lorazepam	DB00186	drug	antidepressants	None	True	effect	group	Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
DDI-DrugBank.d18.s1.p9	benzodiazepines	None	group	phenothiazines	None	True	effect	group	Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
DDI-DrugBank.d180.s1.p2	catecholamines	None	group	Bretylium Tosylate	None	True	effect	drug	The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium Tosylate.
DDI-DrugBank.d186.s0.p0	lithium	DB01356	drug	HALDOL	None	True	effect	brand	An encephalopathic syndrome (characterized by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN, and FBS) followed by irreversible brain damage has occurred in a few patients treated with lithium plus HALDOL.
DDI-DrugBank.d187.s14.p3	isoniazid	DB00951	drug	valproate	None	True	advise	drug	Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made.
DDI-DrugBank.d187.s7.p15	Carbamazepine	DB00564	drug	isoniazid	DB00951	True	advise	drug	Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.
DDI-DrugBank.d187.s8.p2	Ketoconazole	DB01026	drug	Isoniazid	DB00951	True	int	drug	Ketoconazole: Potential interaction of Ketoconazole and Isoniazid may exist.
DDI-DrugBank.d19.s6.p0	anticoagulants	None	group	disulfiram	DB00822	True	advise	drug	It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram. since disulfiram may prolong prothrombin time.
DDI-DrugBank.d191.s1.p0	Steroids	None	group	edetate calcium disodium	None	True	effect	drug	Steroids enhance the renal toxicity of edetate calcium disodium in animals. 7 Edetate calcium disodium interferes with the action of zinc insulin preparations by chelating the zinc. 7
DDI-DrugBank.d192.s0.p5	Dexbrompheniramine	DB00405	drug	monoamine oxidase (MAO) inhibitors	None	True	effect	group	Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
DDI-DrugBank.d196.s1.p2	theophylline	DB00277	drug	PEGASYS	None	True	advise	brand	Theophylline serum levels should be monitored and appropriate dose adjustments considered for patients given both theophylline and PEGASYS.
DDI-DrugBank.d435.s2.p9	phenobarbital	DB01174	drug	exemestane	DB00990	True	mechanism	drug	Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John s wort) may significantly decrease exposure to exemestane.
DDI-DrugBank.d438.s38.p0	gabapentin	DB00996	drug	Maalox	None	True	mechanism	brand	This decrease in bioavailability was about 5% when gabapentin was administered 2 hours after Maalox.
DDI-DrugBank.d439.s0.p0	Corticotropin	DB01285	drug	diuretic	None	True	effect	group	Corticotropin may accentuate the electrolyte loss associated with diuretic therapy.
DDI-DrugBank.d44.s2.p2	Acellular vaccines	None	group	RAPTIVA	None	True	advise	brand	Acellular, live and live-attenuated vaccines should not be administered during RAPTIVA treatment.
DDI-DrugBank.d440.s1.p3	calcium	DB01373	drug	Ibandronate	DB00710	True	mechanism	drug	Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.
DDI-DrugBank.d440.s13.p13	aspirin	None	brand	Ibandronate	DB00710	True	advise	drug	However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.
DDI-DrugBank.d441.s6.p1	ZYVOX	None	brand	antidepressants	None	True	effect	group	Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and serotonergic agents, including antidepressants such as selective serotonin reuptake inhibitors (SSRIs), have been reported.
DDI-DrugBank.d443.s2.p0	Corticosteroids	None	group	aspirin	None	True	effect	brand	Corticosteroids: Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration and may reduce serum salicylate levels.
DDI-DrugBank.d444.s0.p0	FLUDARA	None	brand	pentostatin	DB00552	True	advise	drug	The use of FLUDARA FOR INJECTION in combination with pentostatin is not recommended due to the risk of severe pulmonary toxicity.
DDI-DrugBank.d446.s0.p10	Chlorotrianisene	DB00269	drug	somatropin	None	True	int	drug	Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
DDI-DrugBank.d446.s0.p12	Chlorotrianisene	DB00269	drug	warfarin	DB00682	True	int	drug	Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
DDI-DrugBank.d446.s0.p4	Chlorotrianisene	DB00269	drug	calcium	DB01373	True	int	drug	Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
DDI-DrugBank.d448.s1.p1	antihistamines	None	group	tricyclic antidepressants	None	True	effect	group	Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.
DDI-DrugBank.d448.s1.p3	antihistamines	None	group	central nervous system depressants	None	True	effect	group	Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.
DDI-DrugBank.d448.s2.p0	sympathomimetic drugs	None	group	monoamine oxidase inhibitors	None	True	effect	group	When sympathomimetic drugs are given to patients receiving monoamine oxidase inhibitors, hypertensive reactions, including hypertensive crises, may occur.
DDI-DrugBank.d448.s4.p0	Beta-adrenergic blocking agents	None	group	sympathomimetics	None	True	int	group	Beta-adrenergic blocking agents may also interact with sympathomimetics.
DDI-DrugBank.d448.s5.p0	pseudoephedrine	DB00852	drug	digitalis	None	True	effect	group	Increased ectopic pacemaker activity can occur when pseudoephedrine is used concomitantly with digitalis.
DDI-DrugBank.d450.s3.p8	clarithromycin	DB01211	drug	digoxin	DB00390	True	mechanism	drug	Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.
DDI-DrugBank.d450.s6.p20	metoclopramide	DB01233	drug	digoxin	DB00390	True	mechanism	drug	Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.
DDI-DrugBank.d454.s0.p1	Lofexidine	DB04948	drug	barbiturates	None	True	effect	group	Lofexidine may enhance The CNS depressive effects of alcohol, barbiturates and other sedatives
DDI-DrugBank.d456.s1.p11	TARCEVA	None	brand	TAO	None	True	advise	drug	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
DDI-DrugBank.d456.s1.p4	TARCEVA	None	brand	itraconazole	DB01167	True	advise	drug	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
DDI-DrugBank.d456.s5.p0	TARCEVA	None	brand	rifampicin	DB01045	True	advise	drug	If the TARCEVA dose is adjusted upward, the dose will need to be reduced upon discontinuation of rifampicin or other inducers.
DDI-DrugBank.d457.s0.p0	Barbiturates	None	group	contraceptives	None	True	effect	group	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.
DDI-DrugBank.d458.s12.p1	NIZORAL	None	brand	triazolam	DB00897	True	mechanism	drug	Coadministration of NIZORAL  Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.
DDI-DrugBank.d458.s5.p0	ketoconazole	DB01026	drug	astemizole	DB00637	True	effect	drug	Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of astemizole, resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals.
DDI-DrugBank.d458.s6.p0	astemizole	DB00637	drug	ketoconazole	DB01026	True	advise	drug	Coadministration of astemizole with ketoconazole tablets is therefore contraindicated.
DDI-DrugBank.d458.s9.p0	ketoconazole	DB01026	drug	cisapride	DB00604	True	advise	drug	Therefore concomitant administration of ketoconazole tablets with cisapride is contraindicated.
DDI-DrugBank.d46.s19.p5	non-steroidal anti-inflammatory agent	None	group	potassium-sparing diuretics	None	True	effect	group	Non-steroidal Anti-inflammatory Drugs: in some patients, The administration of a Non-steroidal Anti-inflammatory agent can reduce The diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.
DDI-DrugBank.d460.s14.p16	monoamine oxidase inhibitors	None	group	Starlix	None	True	effect	brand	Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.
DDI-DrugBank.d460.s14.p5	nonsteroidal anti-inflammatory agents	None	group	antidiabetic drugs	None	True	effect	group	Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.
DDI-DrugBank.d463.s8.p0	buspirone	DB00490	drug	digoxin	DB00390	True	mechanism	drug	In vitro, buspirone may displace less firmly bound drugs like digoxin.
DDI-DrugBank.d464.s0.p4	Codeine	DB00318	drug	sedative-hypnotics	None	True	effect	group	Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.
DDI-DrugBank.d466.s17.p2	erythromycin	DB00199	drug	fexofenadine	DB00950	True	mechanism	drug	These studies indicate that ketoconazole or erythromycin co-administration enhances fexofenadine gastrointestinal absorption.
DDI-DrugBank.d466.s19.p9	fexofenadine hydrochloride	None	drug	Maalox	None	True	mechanism	brand	Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.
DDI-DrugBank.d47.s3.p1	levodopa	None	drug	papaverine	DB01113	True	effect	drug	In addition, the beneficial effects of levodopa in Parkinsons disease have been reported to be reversed by phenytoin and papaverine.
DDI-DrugBank.d471.s0.p1	Mineral oil	None	drug	vitamin D preparations	None	True	mechanism	group	Mineral oil interferes with the absorption of fat-soluble vitamins, including vitamin D preparations.
DDI-DrugBank.d475.s3.p1	aspirin	None	brand	nizatidine	DB00585	True	mechanism	drug	In patients given very high doses (3900 mg) of aspirin daily, increases in serum salicylate levels were seen when nizatidine, 150 mg b.i.d., was administered concurrently.
DDI-DrugBank.d477.s5.p0	Urinary acidifying	None	drug	amphetamines	None	True	mechanism	group	Urinary acidifying agents decrease blood levels and increase excretion of amphetamines.
DDI-DrugBank.d479.s2.p0	calcium channel blockers	None	group	organic nitrates	None	True	effect	group	Marked symptomatic orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used in combination.
DDI-DrugBank.d48.s11.p14	H2 blockers	None	group	dasatinib	DB01254	True	effect	drug	H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.
DDI-DrugBank.d48.s12.p1	H2 blockers	None	group	SPRYCEL	None	True	advise	brand	The concomitant use of H2 blockers or proton pump inhibitors with SPRYCEL is not recommended.
DDI-DrugBank.d48.s15.p80	sirolimus	DB00877	drug	SPRYCEL	None	True	advise	brand	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
DDI-DrugBank.d480.s17.p4	caffeine	DB00201	drug	Clozapine	DB00363	True	mechanism	drug	Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.
DDI-DrugBank.d480.s22.p6	clozapine	DB00363	drug	sertraline	DB01104	True	mechanism	drug	However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.
DDI-DrugBank.d480.s30.p0	clozapine	DB00363	drug	antidepressants	None	True	advise	group	Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
DDI-DrugBank.d480.s8.p13	clozapine	DB00363	drug	psychotropic drug	None	True	advise	group	Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics, caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic drug.
DDI-DrugBank.d484.s0.p0	Etonogestrel	DB00294	drug	acetaminophen	DB00316	True	int	drug	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d484.s0.p28	Etonogestrel	DB00294	drug	Kaletra	None	True	int	brand	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d484.s0.p34	Etonogestrel	DB00294	drug	MS Contin	None	True	int	brand	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d484.s0.p35	Etonogestrel	DB00294	drug	phenylbutazone	DB00812	True	int	drug	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d484.s0.p37	Etonogestrel	DB00294	drug	Prelone	None	True	int	brand	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d484.s0.p9	Etonogestrel	DB00294	drug	Trileptal	None	True	int	brand	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d485.s12.p25	topiramate	DB00273	drug	ethinyl estradiol	DB00977	True	mechanism	drug	Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.
DDI-DrugBank.d485.s14.p5	vitamin C	DB00126	drug	synthetic estrogens	None	True	mechanism	group	Ascorbic acid: Doses of ascorbic acid (vitamin C) 1 g/day have been reported to increase plasma concentration of synthetic estrogens by ~47%, possibly by inhibiting conjugation;
DDI-DrugBank.d485.s23.p2	Griseofulvin	DB00400	drug	combination hormonal contraceptives	None	True	mechanism	group	Griseofulvin: Griseofulvin may induce the metabolism of combination hormonal contraceptives causing menstrual changes;
DDI-DrugBank.d485.s3.p0	hormonal contraceptives	None	group	acetaminophen	DB00316	True	mechanism	drug	Combination hormonal contraceptives may also decrease the plasma concentration of acetaminophen.
DDI-DrugBank.d485.s31.p2	Ethinyl estradiol	DB00977	drug	prednisolone	DB00860	True	mechanism	drug	Prednisolone: Ethinyl estradiol may inhibit the metabolism of prednisolone, leading to increased plasma concentrations.
DDI-DrugBank.d487.s1.p7	rifampin	None	drug	corticosteroids	None	True	mechanism	group	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.
DDI-DrugBank.d488.s1.p0	heparin sodium	None	drug	dicumarol	None	True	advise	drug	Therefore, when heparin sodium is given with dicumarol or warfarin sodium, a period of at least 5 hours after the last intravenous dose or 24 hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained.
DDI-DrugBank.d488.s2.p34	dipyridamole	DB00975	drug	heparin sodium	None	True	effect	drug	Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.
DDI-DrugBank.d488.s3.p0	heparin	DB01109	drug	antithrombin III	None	True	effect	drug	The anticoagulant effect of heparin is enhanced by concurrent treatment with antithrombin III (human) in patients with hereditary antithrombin III deficiency.
DDI-DrugBank.d489.s8.p0	beta-blockers	None	group	epinephrine	DB00668	True	effect	drug	Risk of Anaphylactic Reaction: Although it is known that patients on beta-blockers may be refractory to epinephrine in the treatment of anaphylactic shock, beta-blockers can, in addition, interfere with the modulation of allergic reaction and lead to an increased severity and/or frequency of attacks.
DDI-DrugBank.d492.s1.p3	Antihistamines	None	group	sedatives	None	True	effect	group	Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.
DDI-DrugBank.d492.s1.p4	Antihistamines	None	group	tranquilizers	None	True	effect	group	Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.
DDI-DrugBank.d495.s7.p1	clonidine	DB00575	drug	calcium channel blockers	None	True	advise	group	Also, due to the potential for additive effects such as bradycardia and AV block, caution is warranted in patients receiving clonidine with agents known to affect sinus node function or AV nodal conduction (e.g., digitalis, calcium channel blockers, and beta-blockers.)
DDI-DrugBank.d495.s7.p2	clonidine	DB00575	drug	beta-blockers	None	True	advise	group	Also, due to the potential for additive effects such as bradycardia and AV block, caution is warranted in patients receiving clonidine with agents known to affect sinus node function or AV nodal conduction (e.g., digitalis, calcium channel blockers, and beta-blockers.)
DDI-DrugBank.d499.s22.p4	Ketoprofen	DB01009	drug	methotrexate	DB00563	True	mechanism	drug	Methotrexate: Ketoprofen, like other NSAIDs, may cause changes in the elimination of methotrexate leading to elevated serum levels of the drug and increased toxicity.
DDI-DrugBank.d499.s22.p5	NSAIDs	None	group	methotrexate	DB00563	True	mechanism	drug	Methotrexate: Ketoprofen, like other NSAIDs, may cause changes in the elimination of methotrexate leading to elevated serum levels of the drug and increased toxicity.
DDI-DrugBank.d5.s14.p0	bupropion	DB01156	drug	desipramine	DB01151	True	mechanism	drug	In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of bupropion given as 150 mg twice daily followed by a single dose of 50 mg desipramine increased the Cmax, AUC, and t1/2 of desipramine by an average of approximately 2-, 5- and 2-fold, respectively.
DDI-DrugBank.d5.s19.p4	bupropion	DB01156	drug	phenelzine	DB00780	True	effect	drug	MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the MAO inhibitor phenelzine .
DDI-DrugBank.d5.s22.p2	WELLBUTRIN	None	brand	theophylline	DB00277	True	advise	drug	Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.
DDI-DrugBank.d5.s25.p5	alcohol	None	drug	WELLBUTRIN	None	True	effect	brand	Alcohol: In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol during treatment with WELLBUTRIN.
DDI-DrugBank.d500.s4.p5	phenytoin	DB00252	drug	doxycycline	DB00254	True	mechanism	drug	Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.
DDI-DrugBank.d503.s3.p0	chlorprothixene	DB01239	drug	tramadol	DB00193	True	advise	drug	Avoid the concomitant use of chlorprothixene and tramadol (Ultram).
DDI-DrugBank.d503.s5.p0	chlorprothixene	DB01239	drug	benzodiazepines	None	True	effect	group	Consider additive sedative effects and confusional states to emerge, if chlorprothixene is given with benzodiazepines or barbituates.
DDI-DrugBank.d505.s4.p2	Dipyridamole	DB00975	drug	cholinesterase inhibitors	None	True	effect	group	Cholinesterase Inhibitors: Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis.
DDI-DrugBank.d507.s1.p0	guanfacine	DB01018	drug	phenobarbital	DB01174	True	mechanism	drug	The administration of guanfacine concomitantly with known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.
DDI-DrugBank.d507.s1.p1	guanfacine	DB01018	drug	phenytoin	DB00252	True	mechanism	drug	The administration of guanfacine concomitantly with known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.
DDI-DrugBank.d509.s11.p0	ketoconazole	DB01026	drug	aripiprazole	DB01238	True	advise	drug	When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to one-half of its normal dose.
DDI-DrugBank.d509.s8.p9	paroxetine	DB00715	drug	aripiprazole	DB01238	True	mechanism	drug	Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.
DDI-DrugBank.d509.s9.p3	ketoconazole	DB01026	drug	aripiprazole	DB01238	True	mechanism	drug	Ketoconazole: Coadministration of ketoconazole (200 mg/day for 14 days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively.
DDI-DrugBank.d51.s2.p2	ipratropium bromide	DB00332	drug	anticholinergic medications	None	True	effect	group	Anticholinergic agents: Although ipratropium bromide is minimally absorbed into the systemic circulation, there is some potential for an additive interaction with concomitantly used anticholinergic medications.
DDI-DrugBank.d516.s3.p32	aluminum	None	drug	lomefloxacin	DB00978	True	mechanism	drug	Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.
DDI-DrugBank.d521.s1.p8	glimepiride	DB00222	drug	magnesium salicylate	DB01397	True	advise	drug	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
DDI-DrugBank.d522.s11.p0	macrolides	None	group	terfenadine	DB00342	True	advise	drug	In addition, most macrolides are contraindicated in patients receiving terfenadine therapy who have pre-existing cardiac abnormalities (arrhythmia, bradycardia, QT c interval prolongation, ischemic heart disease, congestive heart failure, etc.) or electrolyte disturbances.
DDI-DrugBank.d522.s15.p9	dirithromycin	DB00954	drug	antacids	None	True	mechanism	group	Antacids or H 2 receptor antagonists: When dirithromycin is administered immediately following antacids or H 2 -receptor antagonists, the absorption of dirithromycin is slightly enhanced.
DDI-DrugBank.d522.s19.p3	Erythromycin	DB00199	drug	triazolam	DB00897	True	mechanism	drug	Triazolam: Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of triazolam.
DDI-DrugBank.d522.s20.p3	erythromycin	DB00199	drug	digoxin	DB00390	True	mechanism	drug	Digoxin: Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.
DDI-DrugBank.d522.s24.p0	erythromycin	DB00199	drug	cyclosporine	DB00091	True	int	drug	Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.
DDI-DrugBank.d522.s24.p7	erythromycin	DB00199	drug	valproate	None	True	int	drug	Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.
DDI-DrugBank.d522.s9.p0	erythromycin	DB00199	drug	terfenadine	DB00342	True	int	drug	Thus, the interaction observed between erythromycin and terfenadine is not expected for dirithromycin.
DDI-DrugBank.d526.s14.p2	steroids	None	group	aspirin	None	True	effect	brand	Rarely salicylate toxicity may occur in patients who discontinue steroids after concurrent high-dose aspirin therapy.
DDI-DrugBank.d527.s3.p8	lithium	DB01356	drug	insulin	None	True	effect	drug	Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.
DDI-DrugBank.d528.s2.p2	Methionine	None	drug	gentamicin	DB00798	True	effect	drug	Gentamicin - Methionine may protect against the ototoxic effects of gentamicin.
DDI-DrugBank.d529.s16.p0	nonsteroidal anti-inflammatory drugs	None	group	thiazide diuretics	None	True	effect	group	Other nonsteroidal anti-inflammatory drugs that inhibit prostaglandin synthesis have been shown to interfere with thiazide diuretics in some studies and with potassium-sparing diuretics.
DDI-DrugBank.d529.s19.p0	flurbiprofen	DB00712	drug	hypoglycemic agents	None	True	effect	group	Although there was a slight reduction in blood sugar concentrations during concomitant administration of flurbiprofen and hypoglycemic agents, there were no signs or symptoms of hypoglycemia.
DDI-DrugBank.d529.s2.p4	Flurbiprofen	DB00712	drug	anti-coagulants	None	True	effect	group	Anticoagulants: Flurbiprofen like other nonsteroidal anti-inflammatory drugs, has been shown to affect bleeding parameters in patients receiving anti-coagulants, and serious clinical bleeding has been reported.
DDI-DrugBank.d529.s6.p0	flurbiprofen	DB00712	drug	aspirin	None	True	advise	brand	Concurrent use of flurbiprofen and aspirin is therefore not recommended.
DDI-DrugBank.d53.s1.p0	nelfinavir	DB00220	drug	azithromycin	DB00207	True	effect	drug	Co-administration of nelfinavir at steady-state with a single dose of azithromycin (2 x 600 mg tablets) results in increased azithromycin serum concentrations.
DDI-DrugBank.d53.s7.p12	azithromycin	DB00207	drug	trimethoprim	DB00440	True	mechanism	drug	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
DDI-DrugBank.d53.s8.p1	efavirenz	DB00625	drug	azithromycin	DB00207	True	mechanism	drug	Co-administration with efavirenz or fluconazole had a modest effect on the pharmacokinetics of azithromycin.
DDI-DrugBank.d531.s42.p1	lopinavir	DB01601	drug	SUSTIVA	None	True	advise	brand	A dose increase of lopinavir/ritonavir to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with SUSTIVA.
DDI-DrugBank.d531.s79.p1	SUSTIVA	None	brand	ketoconazole	DB01026	True	mechanism	drug	SUSTIVA has the potential to decrease plasma concentrations of itraconazole and ketoconazole.
DDI-DrugBank.d533.s3.p0	atorvastatin	DB01076	drug	aliskiren	DB01258	True	mechanism	drug	Co-administration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.
DDI-DrugBank.d536.s4.p14	pancreatin	None	drug	Acarbose	DB00284	True	mechanism	drug	Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.
DDI-DrugBank.d536.s4.p8	charcoal	None	drug	Acarbose	DB00284	True	mechanism	drug	Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.
DDI-DrugBank.d537.s0.p9	Bentiromide	DB00522	drug	multivitamins	None	True	int	group	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
DDI-DrugBank.d54.s14.p2	thyroid	None	group	contraceptives	None	True	advise	group	Therefore, patients without a functioning thyroid gland who are on thyroid replacement therapy may need to increase their thyroid dose if estrogens or estrogen-containing oral contraceptives are given.
DDI-DrugBank.d54.s15.p3	thyroid products	None	group	imipramine	DB00458	True	effect	drug	Tricyclic Antidepressants: Use of thyroid products with imipramine and other tricyclic antidepressants may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed.
DDI-DrugBank.d137.s11.p0	Cardiac glycosides	None	group	bepridil hydrochloride	None	True	effect	drug	Cardiac glycosides could exaggerate the depression of AV nodal conduction observed with bepridil hydrochloride.
DDI-DrugBank.d140.s11.p0	contraceptive	None	group	atorvastatin	DB01076	True	advise	drug	These increases should be considered when selecting an oral contraceptive for a woman taking atorvastatin.
DDI-DrugBank.d140.s17.p1	HMG-CoA reductase inhibitor	None	group	spironolactone	DB00421	True	advise	drug	Caution should be exercised if an HMG-CoA reductase inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, spironolactone, and cimetidine.
DDI-DrugBank.d142.s0.p3	LEVSIN	None	brand	phenothiazines	None	True	effect	group	Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.
DDI-DrugBank.d143.s24.p0	amiodarone	DB01118	drug	digitalis	None	True	advise	group	On administration of oral amiodarone, the need for digitalis therapy should be reviewed and the dose reduced by approximately 50% or discontinued.
DDI-DrugBank.d144.s1.p19	saquinavir	DB01232	drug	budesonide	DB01222	True	advise	drug	If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.
DDI-DrugBank.d150.s0.p0	FLEXERIL	None	brand	MAO inhibitors	None	True	int	group	FLEXERIL may have life-threatening interactions with MAO inhibitors.
DDI-DrugBank.d150.s1.p2	FLEXERIL	None	brand	CNS depressants	None	True	effect	group	FLEXERIL may enhance the effects of alcohol, barbiturates, and other CNS depressants.
DDI-DrugBank.d151.s0.p0	Folic acid	DB00158	drug	phenobarbital	DB01174	True	effect	drug	Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.
DDI-DrugBank.d153.s0.p6	epinephrine	DB00668	drug	tricyclic antidepressants	None	True	effect	group	The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.
DDI-DrugBank.d153.s0.p8	norepinephrine	DB00368	drug	tricyclic antidepressants	None	True	effect	group	The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.
DDI-DrugBank.d158.s15.p2	amphetamines	None	group	lithium carbonate	None	True	effect	drug	Lithium carbonate: The anorectic and stimulatory effects of amphetamines may be inhibited by lithium carbonate.
DDI-DrugBank.d158.s2.p2	Adrenergic blockers	None	group	amphetamines	None	True	effect	group	Adrenergic blockers Adrenergic blockers are inhibited by amphetamines.
DDI-DrugBank.d158.s21.p2	Amphetamines	None	group	phenytoin	DB00252	True	mechanism	drug	Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;
DDI-DrugBank.d158.s23.p2	propoxyphene	None	drug	amphetamine	DB00182	True	effect	drug	Propoxyphene: In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.
DDI-DrugBank.d162.s13.p0	Hydrochlorothiazide	DB00999	drug	non-steroidal anti-inflammatory agents	None	True	advise	group	Therefore, when Hydrochlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.
DDI-DrugBank.d165.s11.p1	Itraconazole	DB01167	drug	triazolam	DB00897	True	mechanism	drug	Coadministration of Itraconazole with oral midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.
DDI-DrugBank.d165.s18.p1	Itraconazole	DB01167	drug	rifampin	None	True	mechanism	drug	When Itraconazole was coadministered with phenytoin, rifampin, or H2antagonists, reduced plasma concentrations of itraconazole were reported.
DDI-DrugBank.d165.s3.p0	terfenadine	DB00342	drug	Itraconazole	DB01167	True	mechanism	drug	Coadministration of terfenadine with Itraconazole has led to elevated plasma concentrations of terfenadine, resulting in rare instances of life- threatening cardiac dysrhythmias and one death.
DDI-DrugBank.d165.s5.p1	itraconazole	DB01167	drug	astemizole	DB00637	True	mechanism	drug	In vitro data suggest that itraconazole, when compared to ketoconazole, has a less pronounced effect on the biotransformation system responsible for the metabolism of astemizole.
DDI-DrugBank.d17.s18.p0	hypoglycemic medications	None	group	thiazide diuretic	None	True	advise	group	for adult-onset diabetics, dosage adjustment of hypoglycemic medications may be necessary during and after thiazide diuretic therapy;
DDI-DrugBank.d17.s25.p0	steroidal anti-inflammatory agent	None	group	loop diuretics	None	True	effect	group	(In some patients, the steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics.
DDI-DrugBank.d170.s5.p24	fentanyl	DB00813	drug	opioids	None	True	effect	group	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
DDI-DrugBank.d170.s7.p9	MAO inhibitors	None	group	opioid analgesics	None	True	advise	group	MAO Inhibitors: DURAGESIC  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics
DDI-DrugBank.d171.s0.p1	Tagamet	None	brand	phenytoin	DB00252	True	mechanism	drug	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
DDI-DrugBank.d171.s0.p2	Tagamet	None	brand	propranolol	DB00571	True	mechanism	drug	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
DDI-DrugBank.d171.s0.p8	Tagamet	None	brand	theophylline	DB00277	True	mechanism	drug	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
DDI-DrugBank.d172.s14.p0	aspirin	None	brand	CELEBREX	None	True	effect	brand	However, concomitant administration of aspirin with CELEBREX may result in an increased rate of GI ulceration or other complications, compared to use of CELEBREX alone.
DDI-DrugBank.d54.s2.p0	anticoagulants	None	group	thyroid	None	True	advise	group	Patients stabilized on oral anticoagulants who are found to require thyroid replacement therapy should be watched very closely when thyroid is started.
DDI-DrugBank.d543.s6.p0	Anticholinergic drugs	None	group	metoclopramide	DB01233	True	mechanism	drug	Anticholinergic drugs may antagonize the effects of the drugs that alter gastrointestinal motility, such as metoclopramide.
DDI-DrugBank.d546.s0.p2	fenoldopam	DB00800	drug	beta-blockers	None	True	advise	group	Drug Interactions with Beta-Blockers: Concomitant use of fenoldopam with beta-blockers should be avoided.
DDI-DrugBank.d548.s1.p0	duloxetine	DB00476	drug	fluvoxamine	DB00176	True	mechanism	drug	Inhibitors of CYP1A2: Concomitant use of duloxetine with fluvoxamine, an inhibitor of CYP1A2, results in approximately a 6-fold increase in AUC and about a 2.5-fold increase in Cmax of duloxetine.
DDI-DrugBank.d550.s4.p7	probenecid	DB01032	drug	cefditoren pivoxil	None	True	mechanism	drug	Probenecid: As with other b-lactam antibiotics, co-administration of probenecid with cefditoren pivoxil resulted in an increase in the plasma exposure of cefditoren, with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life.
DDI-DrugBank.d551.s2.p0	WelChol	None	brand	verapamil	DB00661	True	mechanism	drug	WelChol  decreased the Cmax and AUC of sustained-release verapamil (Calan SR ) by approximately 31% and 11%, respectively.
DDI-DrugBank.d552.s0.p0	Nabilone	DB00486	drug	psychoactive drugs	None	True	advise	group	Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).
DDI-DrugBank.d552.s0.p3	Nabilone	DB00486	drug	barbiturates	None	True	advise	group	Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).
DDI-DrugBank.d552.s1.p2	Nabilone	DB00486	drug	alcohol	None	True	effect	drug	Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.
DDI-DrugBank.d558.s10.p0	Ketoconazole	DB01026	drug	TIKOSYN	None	True	mechanism	brand	Ketoconazole at 400 mg daily (the maximum approved prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase dofetilide Cmax by 53% in males and 97% in females, and AUC by 41% in males and 69% in females.
DDI-DrugBank.d174.s1.p0	nabumetone	DB00461	drug	warfarin	DB00682	True	advise	drug	Caution should be exercised when administering nabumetone with warfarin since interactions have been seen with other NSAIDs.
DDI-DrugBank.d175.s0.p4	diuretics	None	group	captopril	DB01197	True	effect	drug	Hypotension   Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of captopril.
DDI-DrugBank.d175.s8.p0	Captopril	DB01197	drug	antihypertensive agents	None	True	effect	group	Agents Causing Renin Release Captopril's effect will be augmented by antihypertensive agents that cause renin release.
DDI-DrugBank.d176.s1.p0	diuretic	None	group	fosinopril sodium	None	True	effect	drug	The possibility of hypotensive effects can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium.
DDI-DrugBank.d176.s9.p12	antacid	None	group	fosinopril	DB00492	True	mechanism	drug	Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.
DDI-DrugBank.d179.s40.p7	phenytoin	DB00252	drug	sulfapyridine	DB00891	True	effect	drug	Phenytoin (e.g., Dilantin) use of Phenytoin with sulfapyridine may increase The chance of side effects affecting The liver and/or The side effects of Phenytoin
DDI-DrugBank.d18.s0.p4	lorazepam	DB00186	drug	alcohol	None	True	effect	drug	Tablets: The benzodiazepines, including lorazepam, produce CNS-depressant effects when administered with such medications as barbiturates or alcohol.
DDI-DrugBank.d18.s1.p12	benzodiazepines	None	group	antidepressants	None	True	effect	group	Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
DDI-DrugBank.d181.s0.p2	oxytocics	None	group	dinoprost	None	True	effect	drug	Oxytocin or other oxytocics (concurrent use with dinoprost may result in uterine hypertonus, possibly causing uterine rupture or cervical laceration, especially in the absence of adequate cervical dilatation;
DDI-DrugBank.d183.s2.p5	nitroglycerin	DB00727	drug	INOmax	None	True	effect	brand	Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.
DDI-DrugBank.d186.s3.p6	HALDOL	None	brand	anesthetics	None	True	effect	group	As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.
DDI-DrugBank.d186.s3.p7	HALDOL	None	brand	opiates	None	True	effect	group	As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.
DDI-DrugBank.d186.s3.p8	HALDOL	None	brand	alcohol	None	True	effect	drug	As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.
DDI-DrugBank.d187.s13.p2	valproate	None	drug	isoniazid	DB00951	True	mechanism	drug	Valproate: A recent case study has shown a possible increase in the plasma level of valproate when co administered with isoniazid.
DDI-DrugBank.d187.s5.p0	isoniazid	DB00951	drug	acetaminophen	DB00316	True	mechanism	drug	Furthermore it has been proposed that isoniazid resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested acetaminophen being converted to the toxic metabolites.
DDI-DrugBank.d188.s2.p1	pyridoxine	DB00165	drug	cisplatin	DB00515	True	advise	drug	however, it adversely affected response duration suggesting that pyridoxine should not be administered with HEXALEN and/or cisplatin.1
DDI-DrugBank.d19.s2.p3	DISULFIRAM	DB00822	drug	PHENYTOIN	DB00252	True	effect	drug	SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.
DDI-DrugBank.d19.s9.p5	disulfiram	DB00822	drug	nitrites	None	True	effect	group	In rats, simultaneous ingestion of disulfiram and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.
DDI-DrugBank.d195.s7.p0	tamoxifen	DB00675	drug	anastrozole	DB01217	True	advise	drug	Based on clinical and pharmacokinetic results from the ATAC trial, tamoxifen should not be administered with anastrozole (see CLINICAL PHARMACOLOGY   Drug Interactions and CLINICAL PHARMACOLOGY - Clinical Studies - Adjuvant Treatment of Breast Cancer in Postmenopausal Women subsections).
DDI-DrugBank.d196.s6.p8	Ribavirin	DB00811	drug	zidovudine	DB00495	True	effect	drug	Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.
DDI-DrugBank.d197.s1.p27	PRECEDEX	None	brand	sedatives	None	True	effect	group	Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.
DDI-DrugBank.d198.s13.p0	vardenafil	DB00862	drug	ritonavir	DB00503	True	mechanism	drug	The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir, a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9.
DDI-DrugBank.d198.s29.p0	Vardenafil	DB00862	drug	terazosin	DB01162	True	effect	drug	With simultaneous dosing of Vardenafil 10 mg and terazosin 10 mg, 6 of 8 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.
DDI-DrugBank.d198.s9.p2	Vardenafil	DB00862	drug	ketoconazole	DB01026	True	advise	drug	Since higher doses of ketoconazole (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of Vardenafil should not be exceeded in a 24-hour period when used in combination with ketoconazole 400 mg daily.
DDI-DrugBank.d2.s0.p0	PROSTIN E2	None	brand	oxytocic drugs	None	True	effect	group	PROSTIN E2 may augment the activity of other oxytocic drugs.
DDI-DrugBank.d20.s3.p3	eplerenone	DB00700	drug	fluconazole	DB00196	True	mechanism	drug	Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.
DDI-DrugBank.d202.s6.p2	nortriptyline	DB00540	drug	fluoxetine hydrochloride	None	True	mechanism	drug	There have been greater than 2-fold increases in previously stable plasma levels of other antidepressants, including nortriptyline, when fluoxetine hydrochloride has been administered in combination with these agents.
DDI-DrugBank.d204.s0.p0	beta-adrenergic receptor blocking agents	None	group	Anesthetics	None	True	int	group	When administered concurrently, the following drugs may interact with beta-adrenergic receptor blocking agents: Anesthetics, general: exaggeration of the hypotension induced by general anesthetics.
DDI-DrugBank.d205.s0.p6	ethosuximide	DB00593	drug	antiepileptic drugs	None	True	int	group	Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).
DDI-DrugBank.d207.s2.p0	warfarin	DB00682	drug	IRESSA	None	True	effect	brand	International Normalized Ratio (INR) elevations and/or bleeding events have been reported in some patients taking warfarin while on IRESSA therapy.
DDI-DrugBank.d208.s0.p1	Benzthiazide	DB00562	drug	blood thinner	None	True	int	group	Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.
DDI-DrugBank.d208.s0.p4	Benzthiazide	DB00562	drug	norepinephrine	DB00368	True	int	drug	Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.
DDI-DrugBank.d210.s13.p3	NSAIDs	None	group	furosemide	DB00695	True	effect	drug	Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.
DDI-DrugBank.d210.s25.p3	VIOXX	None	brand	rifampin	None	True	mechanism	drug	Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.
DDI-DrugBank.d211.s2.p13	sulfonamides	None	group	penicillins	None	True	effect	group	Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.
DDI-DrugBank.d213.s0.p9	iodine	None	drug	Carbimazole	DB00389	True	effect	drug	Iodine or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of Carbimazole.
DDI-DrugBank.d213.s3.p0	Antithyroid agents	None	group	sodium iodide I131	None	True	effect	drug	Antithyroid agents may decrease thyroidal uptake of sodium iodide I131, a rebound in uptake may occur up to 5 days after sudden withdrawal of Carbimazole.
DDI-DrugBank.d216.s0.p3	eszopiclone	DB00402	drug	ethanol	DB00898	True	effect	drug	CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of eszopiclone and ethanol 0.70 g/kg for up to 4 hours after ethanol administration.
DDI-DrugBank.d217.s11.p4	Multivitamins	None	group	norfloxacin	DB01059	True	advise	drug	Multivitamins, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.
DDI-DrugBank.d217.s12.p1	Videx	None	brand	norfloxacin	DB01059	True	advise	drug	Videx (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.
DDI-DrugBank.d217.s5.p2	Quinolones	None	group	warfarin	DB00682	True	effect	drug	Quinolones, including norfloxacin, may enhance the effects of oral anticoagulants, including warfarin or its derivatives or similar agents.
DDI-DrugBank.d217.s7.p1	quinolones	None	group	glyburide	DB01016	True	effect	drug	The concomitant administration of quinolones including norfloxacin with glyburide (a sulfonylurea agent) has, on rare occasions, resulted in severe hypoglycemia.
DDI-DrugBank.d217.s9.p2	probenecid	DB01032	drug	norfloxacin	DB01059	True	mechanism	drug	Diminished urinary excretion of norfloxacin has been reported during the concomitant administration of probenecid and norfloxacin.
DDI-DrugBank.d219.s7.p3	Lodine	None	brand	methotrexate	DB00563	True	mechanism	drug	Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.
DDI-DrugBank.d220.s9.p6	Mefloquine	DB00358	drug	phenothiazines	None	True	effect	group	This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.
DDI-DrugBank.d222.s1.p0	atropine	DB00572	drug	pralidoxime	DB00733	True	advise	drug	The following precautions should be kept in mind in the treatment of anticholinesterase poisoning although they do not bear directly on the use of atropine and pralidoxime.
DDI-DrugBank.d224.s0.p0	Apraclonidine	DB00964	drug	MAO inhibitors	None	True	advise	group	Apraclonidine should not be used in patients receiving MAO inhibitors..
DDI-DrugBank.d224.s2.p0	Tricyclic antidepressants	None	group	clonidine	DB00575	True	effect	drug	Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.
DDI-DrugBank.d225.s13.p0	glipizide	DB01067	drug	fluconazole	DB00196	True	mechanism	drug	The mean percentage increase in the glipizide AUC after fluconazole administration was 56.9% (range: 35 to 81).
DDI-DrugBank.d226.s9.p0	adenosine	DB00640	drug	carbamazepine	DB00564	True	effect	drug	As the primary effect of adenosine is to decrease conduction through the A-V node, higher degrees of heart block may be produced in the presence of carbamazepine.
DDI-DrugBank.d228.s0.p0	Antizol	None	brand	ethanol	DB00898	True	mechanism	drug	Oral doses of Antizol (10-20 mg/kg), via alcohol dehydrogenase inhibition, significantly reduced the rate of elimination of ethanol (by approximately 40%) given to healthy volunteers in moderate doses.
DDI-DrugBank.d228.s2.p2	Antizol	None	brand	cimetidine	DB00501	True	mechanism	drug	Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied
DDI-DrugBank.d231.s13.p0	furosemide	DB00695	drug	acetylsalicylic acid	DB00945	True	effect	drug	Tablets, Injection, and Oral Solution One study in six subjects demonstrated that the combination of furosemide and acetylsalicylic acid temporarily reduced creatinine clearance in patients with chronic renal insufficiency.
DDI-DrugBank.d231.s15.p0	indomethacin	DB00328	drug	furosemide	DB00695	True	effect	drug	Literature reports indicate that coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis.
DDI-DrugBank.d232.s0.p1	interferon beta-1a	DB00060	drug	TYSABRI	None	True	mechanism	brand	After multiple dosing, interferon beta-1a (AVONEX  30 mcg IM once weekly) reduced TYSABRI  clearance by approximately 30%.
DDI-DrugBank.d234.s4.p0	ROMAZICON	None	brand	benzodiazepine	None	True	effect	group	Although ROMAZICON exerts a slight intrinsic anticonvulsant effect, its abrupt suppression of the protective effect of a benzodiazepine agonist can give rise to convulsions in epileptic patients.
DDI-DrugBank.d236.s0.p17	reserpine	DB00206	drug	amphetamines	None	True	mechanism	group	Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.
DDI-DrugBank.d236.s18.p2	Haloperidol	DB00502	drug	amphetamines	None	True	effect	group	Haloperidol: Haloperidol blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines.
DDI-DrugBank.d236.s22.p2	Amphetamines	None	group	norepinephrine	DB00368	True	effect	drug	Norepinephrine: Amphetamines enhance the adrenergic effect of norepinephrine.
DDI-DrugBank.d237.s10.p4	Cimetidine	DB00501	drug	cisapride	DB00604	True	mechanism	drug	H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.
DDI-DrugBank.d237.s14.p1	Cisapride	DB00604	drug	quinidine	DB00908	True	advise	drug	Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);
DDI-DrugBank.d238.s24.p3	Anafranil	None	brand	warfarin	DB00682	True	mechanism	drug	Because Anafranil is highly bound to serum protein, the administration of Anafranil to patients taking other drugs that are highly bound to protein (e.g., warfarin, digoxin) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects.
DDI-DrugBank.d238.s5.p0	CMI	None	drug	haloperidol	DB00502	True	mechanism	drug	The plasma concentration of CMI has been reported to be increased by the concomitant administration of haloperidol;
DDI-DrugBank.d238.s6.p10	methylphenidate	DB00422	drug	CMI	None	True	mechanism	drug	plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.
DDI-DrugBank.d238.s6.p3	tricyclic antidepressants	None	group	barbiturates	None	True	mechanism	group	plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.
DDI-DrugBank.d241.s3.p46	furosemide	DB00695	drug	FLOLAN	None	True	mechanism	brand	In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
DDI-DrugBank.d245.s0.p4	sulfonylurea	None	group	probenecid	DB01032	True	effect	drug	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
DDI-DrugBank.d245.s0.p5	sulfonylurea	None	group	coumarins	None	True	effect	group	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
DDI-DrugBank.d249.s13.p1	diclofenac	DB00586	drug	hypoglycemic agents	None	True	effect	group	A direct causal relationship has not been established, but physicians should consider the possibility that diclofenac may alter a diabetic patient s response to insulin or oral hypoglycemic agents.
DDI-DrugBank.d249.s17.p2	phenobarbital	DB01174	drug	diclofenac	DB00586	True	effect	drug	Phenobarbital toxicity has been reported to have occurred in a patient on chronic phenobarbital treatment following the initiation of diclofenac therapy.
DDI-DrugBank.d249.s18.p1	diclofenac	DB00586	drug	tolbutamide	DB01124	True	mechanism	drug	Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.
DDI-DrugBank.d249.s18.p2	diclofenac	DB00586	drug	prednisolone	DB00860	True	mechanism	drug	Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.
DDI-DrugBank.d250.s2.p17	gallamine	None	drug	Coly-Mycin M	None	True	effect	brand	Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.
DDI-DrugBank.d254.s0.p13	opioids	None	group	INAPSINE	None	True	effect	brand	Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.
DDI-DrugBank.d257.s0.p1	Levo-Dromoran	None	brand	alcohol	None	True	effect	drug	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
DDI-DrugBank.d257.s0.p5	Levo-Dromoran	None	brand	anesthetics	None	True	effect	group	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
DDI-DrugBank.d257.s6.p32	dezocine	DB01209	drug	Levo-Dromoran	None	True	advise	brand	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.
DDI-DrugBank.d257.s6.p35	pure agonist opioid analgesic	None	group	Levo-Dromoran	None	True	advise	brand	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.
DDI-DrugBank.d260.s0.p15	Probenecid	DB01032	drug	acetaminophen	DB00316	True	mechanism	drug	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
DDI-DrugBank.d260.s0.p20	Probenecid	DB01032	drug	benzodiazepines	None	True	mechanism	group	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
DDI-DrugBank.d260.s0.p28	Probenecid	DB01032	drug	zidovudine	DB00495	True	mechanism	drug	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
DDI-DrugBank.d260.s3.p4	VISTIDE	None	brand	amphotericin B	DB00681	True	advise	drug	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
DDI-DrugBank.d263.s18.p24	foscarnet	DB00529	drug	zalcitabine	DB00943	True	mechanism	drug	Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).
DDI-DrugBank.d263.s23.p0	zalcitabine	DB00943	drug	magnesium	DB01378	True	advise	drug	The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.
DDI-DrugBank.d265.s7.p0	Chlorthalidone	DB00310	drug	tubocurarine	DB01199	True	effect	drug	Chlorthalidone and related drugs may increase the responsiveness to tubocurarine.
DDI-DrugBank.d265.s8.p0	Chlorthalidone	DB00310	drug	norepinephrine	DB00368	True	effect	drug	Chlorthalidone and related drugs may decrease arterial responsiveness to norepinephrine.
DDI-DrugBank.d266.s1.p0	CASODEX	None	brand	coumarin anticoagulants	None	True	advise	group	It is recommended that if CASODEX is started in patients already receiving coumarin anticoagulants, prothrombin times should be closely monitored and adjustment of the anticoagulant dose may be necessary.
DDI-DrugBank.d267.s3.p5	halothane	DB01159	drug	NUROMAX	None	True	mechanism	brand	Isoflurane, enflurane, and halothane decrease the ED50 of NUROMAX by 30% to 45%.
DDI-DrugBank.d267.s5.p3	NUROMAX	None	brand	bacitracin	DB00626	True	effect	group	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d269.s13.p0	digoxin	DB00390	drug	COREG	None	True	advise	brand	Therefore, increased monitoring of digoxin is recommended when initiating, adjusting, or discontinuing COREG.
DDI-DrugBank.d269.s16.p2	COREG	None	brand	diltiazem	DB00343	True	effect	drug	Calcium Channel Blockers: Isolated cases of conduction disturbance (rarely with hemodynamic compromise) have been observed when COREG is co-administered with diltiazem.
DDI-DrugBank.d269.s17.p6	COREG	None	brand	diltiazem	DB00343	True	advise	drug	As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.
DDI-DrugBank.d270.s36.p0	Nevirapine	DB00238	drug	ketoconazole	DB01026	True	advise	drug	Nevirapine and ketoconazole should not beadministered concomitantly becausedecreases in ketoconazole plasmaconcentrations may reduce the efficacy of the drug.
DDI-DrugBank.d272.s2.p1	bromocriptine mesylate	None	drug	haloperidol	DB00502	True	effect	drug	Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide.
DDI-DrugBank.d272.s2.p2	bromocriptine mesylate	None	drug	metoclopramide	DB01233	True	effect	drug	Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide.
DDI-DrugBank.d284.s12.p2	beta-blockers	None	group	BROVANA	None	True	effect	brand	Beta-adrenergic receptor antagonists (beta-blockers) and BROVANA may interfere with the effect of each other when administered concurrently.
DDI-DrugBank.d284.s13.p0	Beta-blockers	None	group	beta-agonists	None	True	effect	group	Beta-blockers not only block the therapeutic effects of beta-agonists, but may produce severe bronchospasm in COPD patients.
DDI-DrugBank.d284.s3.p11	theophylline	DB00277	drug	adrenergic agonists	None	True	effect	group	Concomitant treatment with methylxanthines (aminophylline, theophylline), steroids, or diuretics may potentiate any hypokalemic effect of adrenergic agonists.
DDI-DrugBank.d284.s3.p13	steroids	None	group	adrenergic agonists	None	True	effect	group	Concomitant treatment with methylxanthines (aminophylline, theophylline), steroids, or diuretics may potentiate any hypokalemic effect of adrenergic agonists.
DDI-DrugBank.d284.s6.p1	BROVANA	None	brand	monoamine oxidase inhibitors	None	True	advise	group	BROVANA, as with other beta2-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.
DDI-DrugBank.d284.s6.p2	BROVANA	None	brand	tricyclic antidepressants	None	True	advise	group	BROVANA, as with other beta2-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.
DDI-DrugBank.d284.s6.p9	tricyclic antidepressants	None	group	adrenergic agonists	None	True	effect	group	BROVANA, as with other beta2-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.
DDI-DrugBank.d289.s12.p0	bosentan	DB00559	drug	cyclosporine A	None	True	advise	drug	The concomitant administration of bosentan and cyclosporine A is contraindicated.
DDI-DrugBank.d289.s15.p0	tacrolimus	DB00864	drug	bosentan	DB00559	True	mechanism	drug	Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.
DDI-DrugBank.d289.s21.p0	Bosentan	DB00559	drug	hypoglycemic agents	None	True	mechanism	group	Bosentan is also expected to reduce plasma concentrations of other oral hypoglycemic agents that are predominantly metabolized by CYP2C9 or CYP3A4.
DDI-DrugBank.d289.s6.p12	bosentan	DB00559	drug	Ortho-Novum	None	True	mechanism	brand	Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.
DDI-DrugBank.d291.s11.p2	Perhexiline hydrogen maleate	None	drug	Bezalip retard	None	True	advise	brand	Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.
DDI-DrugBank.d291.s3.p1	sulphonylureas	None	group	Bezalip	None	True	effect	brand	The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard.
DDI-DrugBank.d296.s0.p0	Diphenhydramine hydrochloride	None	drug	alcohol	None	True	effect	drug	Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).
DDI-DrugBank.d297.s3.p0	TNF antagonist	None	group	ORENCIA	None	True	effect	brand	Concurrent administration of a TNF antagonist with ORENCIA has been associated with an increased risk of serious infections and no significant additional efficacy over use of the TNF antagonists alone.
DDI-DrugBank.d299.s6.p17	SSRIs	None	group	5-HT1 agonists	None	True	effect	group	Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
DDI-DrugBank.d3.s10.p0	TORADOL	None	brand	probenecid	DB01032	True	advise	drug	Therefore, concomitant use of TORADOL and probenecid is contraindicated.
DDI-DrugBank.d3.s18.p4	TORADOL	None	brand	antiepileptic drugs	None	True	effect	group	Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (phenytoin, carbamazepine).
DDI-DrugBank.d3.s7.p9	TORADOL	None	brand	anticoagulants	None	True	advise	group	Although these results do not indicate a significant interaction between TORADOL and warfarin or heparin, the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.
DDI-DrugBank.d304.s0.p3	colestipol	DB00375	drug	thiazide diuretics	None	True	effect	group	May interact with the following: cholestyramine, colestipol (use with thiazide diuretics may prevent the diuretic from working properly;
DDI-DrugBank.d307.s1.p0	AED	None	group	oxcarbazepine	DB00776	True	mechanism	drug	In addition, several AED s that are cytochrome P450 inducers can decrease plasma concentrations of oxcarbazepine and MHD.
DDI-DrugBank.d307.s37.p0	phenobarbital	DB01174	drug	Trileptal	None	True	mechanism	brand	The increase of phenobarbital level, however, is small (15%) when given with Trileptal.
DDI-DrugBank.d309.s0.p2	antihistamines	None	group	tranquilizers	None	True	effect	group	Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol.
DDI-DrugBank.d309.s1.p0	antihistamines	None	group	CNS depressant drugs	None	True	advise	group	Patients receiving antihistamines should be advised against the concurrent use of other CNS depressant drugs.
DDI-DrugBank.d31.s1.p0	antihypertensive drugs	None	group	diazoxide	DB01119	True	effect	drug	When other potent parental antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure.
DDI-DrugBank.d314.s0.p2	Aminoglutethimide	DB00357	drug	corticosteroids	None	True	effect	group	Aminoglutethimide: Aminoglutethimide may diminish adrenal suppression by corticosteroids.
DDI-DrugBank.d314.s11.p2	cyclosporine	DB00091	drug	corticosteroids	None	True	effect	group	Cyclosporine: Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently.
DDI-DrugBank.d314.s16.p3	Ephedrine	DB01364	drug	corticosteroids	None	True	mechanism	group	Ephedrine: Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage.
DDI-DrugBank.d314.s18.p7	phenytoin	DB00252	drug	corticosteroids	None	True	mechanism	group	Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.
DDI-DrugBank.d314.s25.p0	Aspirin	None	brand	corticosteroids	None	True	advise	group	Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia.
DDI-DrugBank.d314.s27.p2	phenytoin	DB00252	drug	dexamethasone	DB01234	True	mechanism	drug	Phenytoin: In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in seizure control.
DDI-DrugBank.d314.s32.p0	vaccines	None	group	corticosteroid	None	True	advise	group	Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible.
DDI-DrugBank.d314.s6.p3	corticosteroids	None	group	warfarin	DB00682	True	effect	drug	Anticoagulants, oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports.
DDI-DrugBank.d318.s0.p0	amphotericin B	DB00681	drug	Antineoplastic agents	None	True	effect	group	When administered concurrently, the following drugs may interact with amphotericin B: Antineoplastic agents: may enhance the potential for renal toxicity, bronchospasm and hypotension.
DDI-DrugBank.d318.s14.p2	amphotericin B	DB00681	drug	leukocyte transfusions	None	True	effect	drug_n	Leukocyte transfusions: acute pulmonary toxicity has been reported in patients receiving intravenous amphotericin B and leukocyte transfusions.
DDI-DrugBank.d321.s0.p5	dexamethasone	DB01234	drug	albendazole	DB00518	True	mechanism	drug	Dexamethasone: Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when 8 mg dexamethasone was coadministered with each dose of albendazole (15 mg/kg/day) in eight neurocysticercosis patients.
DDI-DrugBank.d325.s4.p0	dopamine	DB00988	drug	beta-adrenergic blocking agents	None	True	effect	group	Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.
DDI-DrugBank.d325.s5.p0	dopamine HCl	None	drug	alpha-adrenergic blocking agents	None	True	effect	group	The peripheral vasoconstriction caused by high doses of dopamine HCl is antagonized by alpha-adrenergic blocking agents.
DDI-DrugBank.d325.s8.p4	halogenated hydrocarbon anesthetics	None	group	dopamine	DB00988	True	effect	drug	Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.
DDI-DrugBank.d327.s0.p0	etidronate	None	drug	warfarin	DB00682	True	effect	drug	There have been isolated reports of patients experiencing increases in their prothrombin times when etidronate was added to warfarin therapy.
DDI-DrugBank.d328.s12.p5	valdecoxib	DB00580	drug	phenytoin	DB00252	True	mechanism	drug	Anticonvulsants (Phenytoin): Steady state plasma exposure (AUC) of valdecoxib (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of phenytoin (a CYP 3A4 inducer).
DDI-DrugBank.d328.s33.p0	valdecoxib	DB00580	drug	glyburide	DB01016	True	mechanism	drug	Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.
DDI-DrugBank.d330.s2.p0	neomycin	DB00994	drug	penicillin V	DB00417	True	mechanism	drug	Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.
DDI-DrugBank.d331.s5.p0	probenecid	DB01032	drug	bumetanide	DB00887	True	mechanism	drug	This antagonistic effect of probenecid on bumetanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.
DDI-DrugBank.d333.s5.p2	phenytoin	DB00252	drug	clonazepam	DB01068	True	mechanism	drug	Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.
DDI-DrugBank.d333.s7.p8	benzodiazepine class	None	group	monoamine oxidase inhibitors	None	True	effect	group	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
DDI-DrugBank.d334.s7.p0	NSAIDs	None	group	ACE inhibitors	None	True	effect	group	Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors, including lisinopril.
DDI-DrugBank.d335.s1.p0	clorazepate dipotassium	None	drug	hexobarbital	DB01355	True	effect	drug	Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition.
DDI-DrugBank.d558.s22.p2	triamterene	DB00384	drug	dofetilide	DB00204	True	advise	drug	In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.
DDI-DrugBank.d558.s25.p21	azole antifungal agents	None	group	TIKOSYN	None	True	advise	brand	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
DDI-DrugBank.d558.s7.p0	TIKOSYN	None	brand	verapamil	DB00661	True	mechanism	drug	Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.
DDI-DrugBank.d558.s8.p0	verapamil	DB00661	drug	dofetilide	DB00204	True	effect	drug	In an analysis of the supraventricular arrhythmia and DIAMOND patient populations, the concomitant administration of verapamil with dofetilide was associated with a higher occurrence of torsade de pointes.
DDI-DrugBank.d559.s1.p13	acetaminophen	DB00316	drug	tranquilizers	None	True	effect	group	Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
DDI-DrugBank.d559.s1.p16	acetaminophen	DB00316	drug	CNS depressants	None	True	effect	group	Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
DDI-DrugBank.d559.s1.p6	Butalbital	DB00241	drug	chlordiazepoxide	DB00475	True	effect	drug	Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
DDI-DrugBank.d560.s2.p0	bitolterol	DB00901	drug	steroid	None	True	effect	group	This allows bitolterol to open air passages, increasing the effectiveness of the steroid.
DDI-DrugBank.d561.s12.p1	Benazepril	DB00542	drug	beta-adrenergic blockers	None	True	effect	group	Benazepril, like other ACE inhibitors, has had less than additive effects with beta-adrenergic blockers, presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system
DDI-DrugBank.d335.s3.p2	benzodiazepines	None	group	phenothiazines	None	True	effect	group	The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.
DDI-DrugBank.d338.s1.p5	benzodiazepines	None	group	narcotics	None	True	effect	group	The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.
DDI-DrugBank.d338.s1.p7	benzodiazepines	None	group	psychotropic medications	None	True	effect	group	The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.
DDI-DrugBank.d338.s4.p0	estazolam	DB01215	drug	carbamazepine	DB00564	True	mechanism	drug	While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.
DDI-DrugBank.d340.s6.p12	VIRACEPT	None	brand	cisapride	DB00604	True	advise	drug	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
DDI-DrugBank.d345.s11.p8	furosemide	DB00695	drug	colestipol hydrochloride	None	True	mechanism	drug	The absorption of tetracycline, furosemide, penicillin G, hydrochlorothiazide, and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride;
DDI-DrugBank.d345.s17.p1	Bile acid binding resins	None	group	hydrocortisone	DB00741	True	mechanism	drug	Bile acid binding resins may also interfere with the absorption of oral phosphate supplements and hydrocortisone.
DDI-DrugBank.d345.s9.p0	propranolol	DB00571	drug	COLESTID	None	True	advise	brand	Therefore, patients on propranolol should be observed when COLESTID Tablets are either added or deleted from a therapeutic regimen.
DDI-DrugBank.d347.s1.p3	FACTIVE	None	brand	estrogen	None	True	mechanism	group	Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.
DDI-DrugBank.d347.s2.p0	FACTIVE	None	brand	probenecid	DB01032	True	mechanism	drug	Concomitant administration of FACTIVE with probenecid resulted in a 45% increase in systemic exposure to gemifloxacin.
DDI-DrugBank.d347.s4.p5	quinolone antimicrobial	None	group	warfarin	DB00682	True	advise	drug	However, because some quinolones have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone antimicrobial is administered concomitantly with warfarin or its derivatives.
DDI-DrugBank.d347.s6.p1	gemifloxacin	DB01155	drug	aluminum	None	True	mechanism	drug	The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an antacid containing aluminum and magnesium.
DDI-DrugBank.d347.s7.p38	multivitamin preparations	None	group	FACTIVE	None	True	advise	brand	Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.
DDI-DrugBank.d350.s12.p13	phenytoin	DB00252	drug	CANCIDAS	None	True	mechanism	brand	In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.
DDI-DrugBank.d352.s4.p0	phenothiazines	None	group	diethylpropion	DB00937	True	effect	drug	Concurrent use of phenothiazines may antagonize the anorectic effect of diethylpropion.
DDI-DrugBank.d353.s11.p2	acitretin	DB00459	drug	tetracyclines	None	True	effect	group	Tetracyclines: Since both acitretin and tetracyclines can cause increased intracranial pressure, their combined use is contraindicated.
DDI-DrugBank.d353.s12.p9	retinoids	None	group	acitretin	DB00459	True	advise	drug	Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.
DDI-DrugBank.d355.s2.p0	oxyphenbutazone	DB03585	drug	androgens	None	True	mechanism	group	Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.
DDI-DrugBank.d356.s4.p2	non-steroidal anti-inflammatory agent	None	group	thiazide diuretics	None	True	effect	group	In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.
DDI-DrugBank.d356.s6.p0	indomethacin	DB00328	drug	potassium-sparing diuretics	None	True	effect	group	Since indomethacin and potassium-sparing diuretics, including MIDAMOR, may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently.
DDI-DrugBank.d357.s0.p28	apomorphine	DB00714	drug	palonosetron	DB00377	True	advise	drug	5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
DDI-DrugBank.d358.s0.p5	PLETAL	None	brand	erythromycin	DB00199	True	advise	drug	Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.
DDI-DrugBank.d359.s1.p1	PEGANONE	None	brand	phenacemide	DB01121	True	advise	drug	Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.
DDI-DrugBank.d362.s4.p0	ciclesonide	DB01410	drug	ketoconazole	DB01026	True	mechanism	drug	In another drug interaction study, co-administration of orally inhaled ciclesonide and oral ketoconazole, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged.
DDI-DrugBank.d364.s10.p1	alosetron	DB00969	drug	telithromycin	DB00976	True	advise	drug	Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
DDI-DrugBank.d364.s10.p4	alosetron	DB00969	drug	itraconazole	DB01167	True	advise	drug	Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
DDI-DrugBank.d364.s15.p0	alosetron	DB00969	drug	isoniazid	DB00951	True	effect	drug	Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.
DDI-DrugBank.d364.s4.p0	alosetron	DB00969	drug	fluvoxamine	DB00176	True	advise	drug	Concomitant administration of alosetron and fluvoxamine is contraindicated.
DDI-DrugBank.d364.s8.p0	Ketoconazole	DB01026	drug	alosetron	DB00969	True	mechanism	drug	Ketoconazole increased mean alosetron plasma concentrations (AUC) by 29%.
DDI-DrugBank.d365.s0.p2	L-histidine	DB00117	drug	medroxyprogesterone acetate	DB00603	True	effect	drug	Medroxyprogesterone Acetate - L-histidine was observed to enhance (in tissue culture) the effect of medroxyprogesterone acetate in reducing the number of human breast cancer cells that were in the S phase.
DDI-DrugBank.d368.s4.p0	DIAMOX	None	brand	primidone	DB00794	True	advise	drug	Caution is advised when beginning, discontinuing, or changing the dose of DIAMOX in patients receiving primidone.
DDI-DrugBank.d371.s1.p0	docetaxel	DB01248	drug	cyclosporine	DB00091	True	mechanism	drug	In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and troleandomycin.
DDI-DrugBank.d371.s1.p2	docetaxel	DB01248	drug	ketoconazole	DB01026	True	mechanism	drug	In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and troleandomycin.
DDI-DrugBank.d373.s0.p2	nifedipine	DB01115	drug	beta-blocking agents	None	True	effect	group	Beta-adrenergic Blocking Agents: Experience in over 1400 patients in a non-comparative clinical trial has shown that concomitant administration of nifedipine and beta-blocking agents is usually well tolerated, but there have been occasional literature reports suggesting that the combination may increase the likelihood of congestive heart failure, severe hypotension or exacerbation of angina.
DDI-DrugBank.d373.s14.p0	nifedipine	DB01115	drug	cimetidine	DB00501	True	advise	drug	If nifedipine therapy is initiated in a patient currently receiving cimetidine, cautious titration is advised.
DDI-DrugBank.d377.s0.p2	Phospholine Iodide	None	drug	organophosphate insecticide	None	True	effect	drug_n	Phospholine Iodide potentiates other cholinesterase inhibitors such as succinylcholine or organophosphate and carbamate insecticides.
DDI-DrugBank.d382.s10.p0	dexamethasone	DB01234	drug	Aprepitant	DB00673	True	advise	drug	The oral dexamethasone doses should be reduced by approximately 50% when coadministered with Aprepitant, to achieve exposures of dexamethasone similar to those obtained when it is given without Aprepitant.
DDI-DrugBank.d382.s16.p9	S(-)warfarin	None	drug	Aprepitant	DB00673	True	mechanism	drug	Although there was no effect of Aprepitant on the plasma AUC of R(+) or S(-) warfarin determined on Day 3, there was a 34% decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with Aprepitant.
DDI-DrugBank.d382.s17.p0	warfarin	DB00682	drug	Aprepitant	DB00673	True	advise	drug	In patients on chronic warfarin therapy, the prothrombin time (INR) should be closely monitored in the 2-week period, particularly at 7 to 10 days, following initiation of the 3-day regimen of Aprepitant with each chemotherapy cycle.
DDI-DrugBank.d382.s18.p9	tolbutamide	DB01124	drug	Aprepitant	DB00673	True	mechanism	drug	Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.
DDI-DrugBank.d382.s19.p8	Aprepitant	DB00673	drug	norethindrone	DB00717	True	mechanism	drug	Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;
DDI-DrugBank.d382.s23.p9	triazolam	DB00897	drug	Aprepitant	DB00673	True	advise	drug	The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.
DDI-DrugBank.d382.s31.p0	Aprepitant	DB00673	drug	ketoconazole	DB01026	True	advise	drug	Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.
DDI-DrugBank.d382.s32.p0	diltiazem	DB00343	drug	aprepitant	DB00673	True	advise	drug	Because moderate CYP3A4 inhibitors (e.g., diltiazem) result in 2-fold increase in plasma concentrations of aprepitant, concomitant administration should also be approached with caution.
DDI-DrugBank.d382.s34.p0	Aprepitant	DB00673	drug	rifampin	None	True	mechanism	drug	therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.
DDI-DrugBank.d382.s36.p4	Aprepitant	DB00673	drug	ketoconazole	DB01026	True	mechanism	drug	Ketoconazole: When a single 125-mg dose of Aprepitant was administered on Day5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.
DDI-DrugBank.d382.s4.p1	Aprepitant	DB00673	drug	tolbutamide	DB01124	True	mechanism	drug	Aprepitant has been shown to induce the metabolism of S(-) warfarin and tolbutamide, which are metabolized through CYP2C9.
DDI-DrugBank.d382.s43.p4	aprepitant	DB00673	drug	paroxetine	DB00715	True	mechanism	drug	Paroxetine: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and paroxetine.
DDI-DrugBank.d384.s2.p13	phenobarbital	DB01174	drug	calcitriol	DB00136	True	mechanism	drug	Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
DDI-DrugBank.d384.s5.p0	thiazides	None	group	vitamin D	None	True	effect	group	Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.
DDI-DrugBank.d386.s23.p0	desipramine hydrochloride	None	drug	psychotropic agents	None	True	effect	group	If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.
DDI-DrugBank.d388.s0.p2	reserpine	DB00206	drug	beta-blocking agents	None	True	effect	group	Catecholamine-depleting drugs, such as reserpine, may have an additive effect when given with beta-blocking agents.
DDI-DrugBank.d388.s1.p0	acebutolol	DB01193	drug	catecholamine depletors	None	True	advise	group	Patients treated with acebutolol plus catecholamine depletors should, therefore, be observed closely for evidence of marked bradycardia or hypotension which may present as vertigo, syncope/presyncope, or orthostatic changes in blood pressure without compensatory tachycardia.
DDI-DrugBank.d389.s3.p1	sympathomimetics	None	group	beta adrenergic blockers	None	True	effect	group	Effects of sympathomimetics are increased with MAO inhibitors and beta adrenergic blockers.
DDI-DrugBank.d395.s9.p4	enoxacin	DB00467	drug	fenbufen	None	True	effect	drug	Non-steroidal anti-inflammatory agents: Seizures have been reported in patients taking enoxacin concomitantly with the nonsteroidal anti-inflammatory drug fenbufen.
DDI-DrugBank.d397.s8.p11	erythromycin	DB00199	drug	terfenadine	DB00342	True	int	drug	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
DDI-DrugBank.d397.s8.p12	erythromycin	DB00199	drug	astemizole	DB00637	True	int	drug	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
DDI-DrugBank.d397.s8.p6	erythromycin	DB00199	drug	cisapride	DB00604	True	int	drug	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
DDI-DrugBank.d398.s0.p0	codeine	DB00318	drug	alcohol	None	True	effect	drug	The use of codeine may result in additive CNS depressant effects when coadministered with alcohol, antihistamines, psychotropics or other drugs that produce CNS depression.
DDI-DrugBank.d398.s2.p2	dextromethorphan hydrobromide	None	drug	psychotropics	None	True	effect	group	The use of dextromethorphan hydrobromide may result in additive CNS depressant effects when coadministered with alcohol, antihistamines, psychotropics or other drugs that produce CNS depression.
DDI-DrugBank.d40.s10.p0	phenytoin	DB00252	drug	alcohol	None	True	mechanism	drug	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
DDI-DrugBank.d40.s10.p10	phenytoin	DB00252	drug	H2-antagonists	None	True	mechanism	group	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
DDI-DrugBank.d40.s10.p19	phenytoin	DB00252	drug	tolbutamide	DB01124	True	mechanism	drug	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
DDI-DrugBank.d40.s10.p3	phenytoin	DB00252	drug	cimetidine	DB00501	True	mechanism	drug	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
DDI-DrugBank.d40.s10.p4	phenytoin	DB00252	drug	diazepam	DB00829	True	mechanism	drug	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
DDI-DrugBank.d40.s10.p9	phenytoin	DB00252	drug	fluoxetine	DB00472	True	mechanism	drug	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
DDI-DrugBank.d40.s12.p0	phenytoin	DB00252	drug	carbamazepine	DB00564	True	mechanism	drug	Drugs that may decrease plasma Phenytoin concentrations include: carbamazepine, chronic alcohol abuse, reserpine
DDI-DrugBank.d40.s12.p1	phenytoin	DB00252	drug	alcohol	None	True	mechanism	drug	Drugs that may decrease plasma Phenytoin concentrations include: carbamazepine, chronic alcohol abuse, reserpine
DDI-DrugBank.d40.s19.p5	phenytoin	DB00252	drug	estrogens	None	True	effect	group	Drugs whose efficacy is impaired by Phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
DDI-DrugBank.d400.s13.p2	warfarin	DB00682	drug	NSAIDs	None	True	effect	group	Warfarin: The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone.
DDI-DrugBank.d401.s0.p11	AKINETON	None	brand	phenothiazines	None	True	effect	group	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
DDI-DrugBank.d401.s0.p14	AKINETON	None	brand	antiarrhythmics	None	True	effect	group	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
DDI-DrugBank.d404.s15.p5	antacids	None	group	vitamin D	None	True	effect	group	Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.
DDI-DrugBank.d409.s2.p0	tetracyclines	None	group	contraceptives	None	True	effect	group	Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.
DDI-DrugBank.d410.s6.p0	ergotamine	DB00696	drug	antibiotics	None	True	effect	group	Vasospastic reactions have been reported with therapeutic doses of ergotamine-containing drugs when co-administered with these antibiotics.
DDI-DrugBank.d411.s3.p6	levothyroxine sodium	None	drug	5-fluorouracil	None	True	mechanism	drug	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
DDI-DrugBank.d412.s0.p0	labetalol HCl	None	drug	tricyclic antidepressants	None	True	effect	group	In one survey, 2.3% of patients taking labetalol HCl in combination with tricyclic antidepressants experienced tremor, as compared to 0.7% reported to occur with labetalol HCl alone.
DDI-DrugBank.d412.s6.p0	halothane	DB01159	drug	labetalol HCl	None	True	effect	drug	Synergism has been shown between halothane anesthesia and intravenously administered labetalol HCl.
DDI-DrugBank.d412.s9.p0	Labetalol HCl	None	drug	nitroglycerin	DB00727	True	effect	drug	Labetalol HCl blunts the reflex tachycardia produced by nitroglycerin without preventing its hypotensive effect.
DDI-DrugBank.d413.s10.p0	uricosuric agents	None	group	allopurinol	DB00437	True	mechanism	drug	The concomitant administration of uricosuric agents and allopurinol has been associated with a decrease in the excretion of oxypurines (hypoxanthine and xanthine) and an increase in urinary uric acid excretion compared with that observed with allopurinol alone.
DDI-DrugBank.d413.s18.p4	cyclophosphamide	DB00531	drug	allopurinol	DB00437	True	effect	drug	Cytotoxic Agents: Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol.
DDI-DrugBank.d413.s4.p19	allopurinol	DB00437	drug	azathioprine	DB00993	True	advise	drug	In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.
DDI-DrugBank.d413.s6.p4	allopurinol	DB00437	drug	dicumarol	None	True	mechanism	drug	Dicumarol: It has been reported that allopurinol prolongs the half-life of the anticoagulant, dicumarol.
DDI-DrugBank.d415.s1.p4	nonsteroidal anti-inflammatory agents	None	group	coumarin-type anticoagulants	None	True	effect	group	However, because bleeding has been reported when ibuprofen and other nonsteroidal anti-inflammatory agents have been administered to patients on coumarin-type anticoagulants, the physician should be cautious when administering ibuprofen to patients on anticoagulants.
DDI-DrugBank.d415.s1.p9	ibuprofen	DB01050	drug	anticoagulants	None	True	advise	group	However, because bleeding has been reported when ibuprofen and other nonsteroidal anti-inflammatory agents have been administered to patients on coumarin-type anticoagulants, the physician should be cautious when administering ibuprofen to patients on anticoagulants.
DDI-DrugBank.d415.s5.p5	nonsteroidal anti-inflammatory drugs	None	group	methotrexate	DB00563	True	mechanism	drug	Methotrexate: Ibuprofen, as well as other nonsteroidal anti-inflammatory drugs, probably reduces the tubular secretion of methotrexate based on in vitro studies in rabbit kidney slices.
DDI-DrugBank.d198.s35.p0	Vardenafil	DB00862	drug	alpha-blocker	None	True	advise	group	Based on these data, Vardenafil should not be used in patients on alpha-blocker therapy.
DDI-DrugBank.d198.s5.p0	Erythromycin	DB00199	drug	vardenafil	DB00862	True	mechanism	drug	Erythromycin (500 mg t.i.d) produced a 4-fold increase in vardenafil AUC and a 3-fold increase in Cmax when co-administered with Vardenafil 5 mg in healthy volunteers.
DDI-DrugBank.d20.s11.p0	potassium-sparing antihypertensives	None	group	NSAIDs	None	True	effect	group	The administration of other potassium-sparing antihypertensives with NSAIDs has been shown to reduce the antihypertensive effect in some patients and result in severe hyperkalemia in patients with impaired renal function.
DDI-DrugBank.d20.s6.p8	INSPRA	None	brand	angiotensin II receptor antagonists	None	True	effect	group	ACE Inhibitors and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).
DDI-DrugBank.d202.s16.p4	tricyclic antidepressants	None	group	propafenone	DB01182	True	advise	drug	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.
DDI-DrugBank.d207.s4.p1	ketoconazole	DB01026	drug	gefitinib	DB00317	True	mechanism	drug	Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.
DDI-DrugBank.d210.s1.p1	VIOXX	None	brand	benazepril	DB00542	True	effect	drug	In patients with mild to moderate hypertension, administration of 25 mg daily of VIOXX with the ACE inhibitor benazepril, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone.
DDI-DrugBank.d210.s2.p0	VIOXX	None	brand	ACE inhibitors	None	True	advise	group	This interaction should be given consideration in patients taking VIOXX concomitantly with ACE inhibitors.
DDI-DrugBank.d210.s20.p0	VIOXX	None	brand	methotrexate	DB00563	True	mechanism	drug	At higher than recommended doses, VIOXX 75 mg administered once daily for 10 days increased plasma concentrations by 23% as measured by AUC0-24hr in patients receiving methotrexate 7.5 to 15 mg/week for rheumatoid arthritis.
DDI-DrugBank.d211.s5.p0	Probenecid	DB01032	drug	ampicillin	DB00415	True	mechanism	drug	Probenecid: May decrease renal tubular secretion of ampicillin resulting in increased blood levels and/or ampicillin toxicity.
DDI-DrugBank.d212.s13.p2	levetiracetam	DB01202	drug	AEDs	None	True	mechanism	group	Effect of AEDs in Pediatric Patients There was about a 22% increase of apparent total body clearance of levetiracetam when it was co-administered with enzyme-inducing AEDs.
DDI-DrugBank.d217.s1.p2	norfloxacin	DB01059	drug	theophylline	DB00277	True	effect	drug	There have been reports of theophylline-related side effects in patients on concomitant therapy with norfloxacin and theophylline.
DDI-DrugBank.d217.s10.p2	nitrofurantoin	DB00698	drug	Norfloxacin	DB01059	True	effect	drug	The concomitant use of nitrofurantoin is not recommended since nitrofurantoin may antagonize the antibacterial effect of Norfloxacin in the urinary tract.
DDI-DrugBank.d217.s11.p13	zinc	DB01593	drug	norfloxacin	DB01059	True	advise	drug	Multivitamins, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.
DDI-DrugBank.d217.s11.p16	antacids	None	group	norfloxacin	DB01059	True	advise	drug	Multivitamins, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.
DDI-DrugBank.d219.s0.p2	NSAIDs	None	group	ACE-inhibitors	None	True	effect	group	ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors.
DDI-DrugBank.d219.s11.p0	Lodine	None	brand	furosemide	DB00695	True	effect	drug	Nevertheless, clinical studies, as well as postmarketing observations have shown that Lodine can reduce the natriuretic effect of furosemide and thiazides in some patients.
DDI-DrugBank.d219.s7.p5	NSAIDs	None	group	digoxin	DB00390	True	mechanism	drug	Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.
DDI-DrugBank.d220.s13.p0	Mefloquine	DB00358	drug	live typhoid vaccines	None	True	effect	group	When Mefloquine is taken concurrently with oral live typhoid vaccines, attenuation of immunization cannot be excluded.
DDI-DrugBank.d223.s24.p0	tricyclic antidepressant	None	group	cimetidine	DB00501	True	mechanism	drug	Additionally, higher than expected tricyclic antidepressant levels have been observed when they are begun in patients already taking cimetidine.
DDI-DrugBank.d223.s28.p2	tolazamide	DB00839	drug	doxepin	DB01142	True	effect	drug	Tolazamide: A case of severe hypoglycemia has been reported in a type II diabetic patient maintained on tolazamide (1 gm/day) 11 days after the addition of doxepin (75 mg/day).
DDI-DrugBank.d224.s1.p2	IOPIDINE	None	brand	barbiturates	None	True	advise	group	Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.
DDI-DrugBank.d225.s0.p4	sulfonylureas	None	group	chloramphenicol	DB00446	True	effect	drug	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
DDI-DrugBank.d225.s0.p5	sulfonylureas	None	group	probenecid	DB01032	True	effect	drug	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
DDI-DrugBank.d225.s0.p6	sulfonylureas	None	group	coumarins	None	True	effect	group	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
DDI-DrugBank.d226.s3.p0	Adenocard	None	brand	digitalis	None	True	effect	group	The use of Adenocard in patients receiving digitalis may be rarely associated with ventricular fibrillation.
DDI-DrugBank.d226.s7.p0	adenosine	DB00640	drug	dipyridamole	DB00975	True	effect	drug	Thus, smaller doses of adenosine may be effective in the presence of dipyridamole.
DDI-DrugBank.d228.s2.p1	Antizol	None	brand	carbamazepine	DB00564	True	mechanism	drug	Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied
DDI-DrugBank.d23.s0.p0	HEMABATE	None	brand	oxytocic agents	None	True	effect	group	HEMABATE may augment the activity of other oxytocic agents.
DDI-DrugBank.d231.s4.p0	Furosemide	DB00695	drug	tubocurarine	DB01199	True	effect	drug	Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine.
DDI-DrugBank.d231.s8.p0	Furosemide	DB00695	drug	norepinephrine	DB00368	True	effect	drug	Furosemide may decrease arterial responsiveness to norepinephrine.
DDI-DrugBank.d233.s3.p2	angiotensin converting enzyme inhibitors	None	group	azathioprine	DB00993	True	effect	drug	Use with Angiotensln Converting Enzyme Inhibitors: The use of angiotensin converting enzyme inhibitors to control hypertension in patients on azathioprine has been reported to induce severe leukopenia.
DDI-DrugBank.d234.s2.p0	ROMAZICON	None	brand	cyclic antidepressants	None	True	effect	group	Particular caution is necessary when using ROMAZICON in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially cyclic antidepressants) may emerge with the reversal of the benzodiazepine effect by flumazenil.
DDI-DrugBank.d234.s5.p0	ROMAZICON	None	brand	benzodiazepines	None	True	effect	group	ROMAZICON blocks the central effects of benzodiazepines by competitive interaction at the receptor level.
DDI-DrugBank.d236.s19.p2	amphetamines	None	group	lithium carbonate	None	True	effect	drug	Lithium carbonate: The stimulatory effects of amphetamines may be inhibited by lithium carbonate.
DDI-DrugBank.d237.s11.p1	cimetidine	DB00501	drug	cisapride	DB00604	True	mechanism	drug	The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.
DDI-DrugBank.d237.s14.p3	Cisapride	DB00604	drug	sotalol	DB00489	True	advise	drug	Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);
DDI-DrugBank.d238.s2.p0	Anafranil	None	brand	MAO inhibitors	None	True	advise	group	Anafranil should not be used with MAO inhibitors.
DDI-DrugBank.d238.s24.p4	Anafranil	None	brand	digoxin	DB00390	True	mechanism	drug	Because Anafranil is highly bound to serum protein, the administration of Anafranil to patients taking other drugs that are highly bound to protein (e.g., warfarin, digoxin) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects.
DDI-DrugBank.d238.s6.p20	phenytoin	DB00252	drug	CMI	None	True	mechanism	drug	plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.
DDI-DrugBank.d238.s6.p4	tricyclic antidepressants	None	group	phenytoin	DB00252	True	mechanism	drug	plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.
DDI-DrugBank.d240.s2.p0	Ethopropazine	DB00392	drug	chlorpromazine	DB00477	True	mechanism	drug	Ethopropazine can interact with chlorpromazine, increasing the metabolism of chlorpromazine.
DDI-DrugBank.d241.s0.p0	FLOLAN	None	brand	diuretics	None	True	effect	group	Additional reductions in blood pressure may occur when FLOLAN is administered with diuretics, antihypertensive agents, or other vasodilators.
DDI-DrugBank.d241.s1.p2	anticoagulants	None	group	FLOLAN	None	True	effect	brand	When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for FLOLAN to increase the risk of bleeding.
DDI-DrugBank.d246.s0.p4	butorphanol	DB00611	drug	antihistamines	None	True	effect	group	Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.
DDI-DrugBank.d246.s3.p2	STADOL NS	None	brand	sumatriptan	DB00669	True	mechanism	drug	However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL NS was administered 1 minute after a 20-mg dose of sumatriptan nasal spray.
DDI-DrugBank.d247.s5.p2	epinephrine	DB00668	drug	halothane	DB01159	True	effect	drug	Administration of epinephrine to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..
DDI-DrugBank.d249.s11.p2	hypoglycemic agents	None	group	diclofenac	DB00586	True	effect	drug	There are rare reports, however, from marketing experiences, of changes in effects of insulin or oral hypoglycemic agents in the presence of diclofenac that necessitated changes in the doses of such agents.
DDI-DrugBank.d249.s18.p3	diclofenac	DB00586	drug	warfarin	DB00682	True	mechanism	drug	Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.
DDI-DrugBank.d249.s4.p2	diclofenac	DB00586	drug	cyclosporine	DB00091	True	effect	drug	Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.
DDI-DrugBank.d249.s5.p4	diclofenac	DB00586	drug	cyclosporine	DB00091	True	effect	drug	Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.
DDI-DrugBank.d250.s2.p10	tubocurarine	DB01199	drug	Coly-Mycin M	None	True	effect	brand	Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.
DDI-DrugBank.d250.s2.p19	decamethonium	DB01245	drug	Coly-Mycin M	None	True	effect	brand	Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.
DDI-DrugBank.d252.s0.p2	BETAGAN	None	brand	epinephrine	DB00668	True	effect	drug	Although BETAGAN used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with BETAGAN and epinephrine may occur.
DDI-DrugBank.d254.s0.p14	anesthetics	None	group	INAPSINE	None	True	effect	brand	Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.
DDI-DrugBank.d257.s0.p2	Levo-Dromoran	None	brand	sedatives	None	True	effect	group	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
DDI-DrugBank.d562.s8.p3	cinoxacin	DB00827	drug	anticoagulants	None	True	effect	group	Quinolones, including cinoxacin, may enhance the effects of oral anticoagulants, such as warfarin or its derivatives.
DDI-DrugBank.d564.s0.p8	norepinephrine	DB00368	drug	tricyclic antidepressants	None	True	effect	group	The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.
DDI-DrugBank.d565.s1.p2	digitalis	None	group	Tiazac	None	True	effect	brand	Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or digitalis concomitantly with Tiazac.
DDI-DrugBank.d565.s18.p0	diltiazem hydrochloride	None	drug	digoxin	DB00390	True	mechanism	drug	Administration of diltiazem hydrochloride with digoxin in 24 healthy male subjects increased plasma digoxin concentrations approximately 20%.
DDI-DrugBank.d566.s0.p4	Cholestyramine	DB01432	drug	propranolol	DB00571	True	mechanism	drug	Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
DDI-DrugBank.d568.s17.p2	sumatriptan	DB00669	drug	fluvoxamine	DB00176	True	advise	drug	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.
DDI-DrugBank.d568.s23.p5	carbamazepine	DB00564	drug	escitalopram	DB01175	True	mechanism	drug	Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of escitalopram should be considered if the two drugs are coadministered.
DDI-DrugBank.d572.s10.p0	ezetimibe	DB00973	drug	cyclosporine	DB00091	True	advise	drug	Patients who take both ezetimibe and cyclosporine should be carefully monitored.
DDI-DrugBank.d578.s11.p0	anticoagulant	None	group	corticosteroids	None	True	effect	group	There are reports of enhanced as well as diminished effects of anticoagulant when given concurrently with corticosteroids.
DDI-DrugBank.d578.s3.p0	methylprednisolone	DB00959	drug	cyclosporin	None	True	effect	drug	convulsions have been reported with concurrent use of methylprednisolone and cyclosporin.
DDI-DrugBank.d578.s5.p2	ketoconazole	DB01026	drug	methylprednisolone	DB00959	True	mechanism	drug	Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance.
DDI-DrugBank.d578.s8.p2	salicylate	None	group	methylprednisolone	DB00959	True	effect	drug	This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn.
DDI-DrugBank.d579.s0.p2	sulfonamides	None	group	ganglion blockers	None	True	advise	group	Patients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers.
DDI-DrugBank.d579.s1.p1	Mecamylamine	DB00657	drug	alcohol	None	True	effect	drug	The action of Mecamylamine may be potentiated by anesthesia, other antihypertensive drugs and alcohol.
DDI-DrugBank.d584.s0.p2	Anabolic steroids	None	group	anticoagulants	None	True	effect	group	Anticoagulants Anabolic steroids may increase sensitivity to oral anticoagulants.
DDI-DrugBank.d584.s3.p4	oxandrolone	DB00621	drug	warfarin	DB00682	True	mechanism	drug	Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected.
DDI-DrugBank.d584.s6.p0	oxandrolone	DB00621	drug	warfarin	DB00682	True	advise	drug	When oxandrolone therapy is initiated in a patient already receiving treatment with warfarin, the INR or prothrombin time (PT) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target INR or PT has been achieved.
DDI-DrugBank.d585.s0.p6	anticholinergic drugs	None	group	benzodiazepines	None	True	effect	group	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
DDI-DrugBank.d585.s2.p0	Anticholinergic drugs	None	group	corticosteroids	None	True	effect	group	Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corticosteroids.
DDI-DrugBank.d587.s0.p5	methsuximide	DB05246	drug	antiepileptic drugs	None	True	advise	group	Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).
DDI-DrugBank.d590.s2.p1	antacid	None	group	TRITEC	None	True	mechanism	brand	Coadministration with a high dose of antacid (170 mEq) results in a 28% decrease in plasma concentrations of ranitidine and may decrease plasma concentrations of bismuth from TRITEC.
DDI-DrugBank.d595.s1.p1	norepinephrine	DB00368	drug	sodium bicarbonate	DB01390	True	int	drug	norepinephrine and dobutamine are incompatible with sodium bicarbonate solution.
DDI-DrugBank.d596.s8.p2	cholinesterase inhibitors	None	group	anticholinergic medications	None	True	int	group	Use with Anticholinergics: Because of their mechanism of action, cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications.
DDI-DrugBank.d597.s1.p0	NSAIDs	None	group	ACE inhibitors	None	True	advise	group	This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.
DDI-DrugBank.d599.s7.p0	GH	None	drug	corticosteroids	None	True	mechanism	group	These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin).
DDI-DrugBank.d60.s12.p16	NIMBEX	None	brand	aminoglycosides	None	True	effect	group	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d60.s12.p24	NIMBEX	None	brand	magnesium	DB01378	True	effect	group	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d603.s2.p9	pseudoephedrine	DB00852	drug	ProAmatine	None	True	effect	brand	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction.
DDI-DrugBank.d603.s5.p46	doxazosin	DB00590	drug	ProAmatine	None	True	effect	brand	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.
DDI-DrugBank.d257.s6.p14	Agonist/antagonist analgesics	None	group	Levo-Dromoran	None	True	advise	brand	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.
DDI-DrugBank.d257.s6.p34	buprenorphine	DB00921	drug	Levo-Dromoran	None	True	advise	brand	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.
DDI-DrugBank.d26.s0.p25	tranquilizers	None	group	DILAUDID	None	True	effect	brand	Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.
DDI-DrugBank.d26.s0.p34	CNS depressants	None	group	DILAUDID	None	True	effect	brand	Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.
DDI-DrugBank.d260.s0.p24	Probenecid	DB01032	drug	famotidine	DB00927	True	mechanism	drug	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
DDI-DrugBank.d260.s3.p5	VISTIDE	None	brand	foscarnet	DB00529	True	advise	drug	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
DDI-DrugBank.d263.s14.p0	HIVID	None	drug	didanosine	DB00900	True	advise	drug	Concomitant use of HIVID with didanosine is not recommended.
DDI-DrugBank.d263.s18.p23	foscarnet	DB00529	drug	HIVID	None	True	effect	drug	Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).
DDI-DrugBank.d263.s18.p26	aminoglycosides	None	group	zalcitabine	DB00943	True	mechanism	drug	Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).
DDI-DrugBank.d263.s23.p2	zalcitabine	DB00943	drug	antacids	None	True	advise	group	The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.
DDI-DrugBank.d263.s7.p0	zalcitabine	DB00943	drug	lamivudine	DB00709	True	effect	drug	These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased antiretroviral effect of zalcitabine.
DDI-DrugBank.d263.s9.p0	zalcitabine	DB00943	drug	lamivudine	DB00709	True	advise	drug	Concomitant use of zalcitabine and lamivudine is not recommended.
DDI-DrugBank.d266.s0.p1	CASODEX	None	brand	warfarin	DB00682	True	mechanism	drug	In vitro studies have shown CASODEX can displace coumarin anticoagulants, such as warfarin, from their protein-binding sites.
DDI-DrugBank.d267.s5.p2	NUROMAX	None	brand	tetracyclines	None	True	effect	group	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d269.s1.p19	paroxetine	DB00715	drug	carvedilol	DB01136	True	effect	drug	poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .
DDI-DrugBank.d269.s1.p20	propafenone	DB01182	drug	carvedilol	DB01136	True	effect	drug	poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .
DDI-DrugBank.d273.s1.p0	UROXATRAL	None	brand	alpha-blockers	None	True	advise	group	However, interactions may be expected, and UROXATRAL should NOT be used in combination with other alpha-blockers.
DDI-DrugBank.d277.s12.p9	tiagabine	DB00906	drug	phenobarbital	DB01174	True	mechanism	drug	Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.
DDI-DrugBank.d277.s7.p2	Tiagabine	DB00906	drug	valproate	None	True	mechanism	drug	Valproate: Tiagabine causes a slight decrease (about 10%) in steady-state valproate concentrations.
DDI-DrugBank.d282.s0.p3	DOSTINEX	None	brand	metoclopramide	DB01233	True	advise	drug	DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.
DDI-DrugBank.d283.s12.p0	fenofibrate	DB01039	drug	bile acid binding resin	None	True	advise	group	Therefore, fenofibrate should be taken at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption .
DDI-DrugBank.d284.s12.p1	Beta-adrenergic receptor antagonists	None	group	BROVANA	None	True	effect	brand	Beta-adrenergic receptor antagonists (beta-blockers) and BROVANA may interfere with the effect of each other when administered concurrently.
DDI-DrugBank.d284.s6.p4	beta2-agonists	None	group	monoamine oxidase inhibitors	None	True	advise	group	BROVANA, as with other beta2-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.
DDI-DrugBank.d286.s0.p0	Ethoxzolamide	DB00311	drug	tricyclics	None	True	effect	group	Ethoxzolamide may increase the action of tricyclics, amphetamines, procainamide, and quinidine.
DDI-DrugBank.d286.s2.p0	ethoxzolamide	DB00311	drug	diuretics	None	True	effect	group	Coadministration of ethoxzolamide with other diuretics, amphotericin B, and corticosteroids may cause hypokalemia.
DDI-DrugBank.d289.s30.p3	bosentan	DB00559	drug	S-warfarin	None	True	mechanism	drug	Warfarin: Co-administration of bosentan 500 mg b.i.d. for 6 days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29 and 38%, respectively.
DDI-DrugBank.d291.s9.p1	Bezalip	None	brand	anion-exchange resins	None	True	advise	group	- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired
DDI-DrugBank.d296.s0.p3	Diphenhydramine hydrochloride	None	drug	sedatives	None	True	effect	group	Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).
DDI-DrugBank.d296.s0.p4	Diphenhydramine hydrochloride	None	drug	tranquilizers	None	True	effect	group	Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).
DDI-DrugBank.d298.s0.p0	Cyclopentolate	DB00979	drug	carbachol	DB00411	True	effect	drug	Cyclopentolate may interfere with the anti-glaucoma action of carbachol or pilocarpine;
DDI-DrugBank.d299.s10.p0	almotriptan	DB00918	drug	ketoconazole	DB01026	True	mechanism	drug	Coadministration of almotriptan and the potent CYP3A4 inhibitor ketoconazole (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of almotriptan.
DDI-DrugBank.d299.s6.p24	fluvoxamine	DB00176	drug	5-HT1 agonists	None	True	effect	group	Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
DDI-DrugBank.d299.s7.p0	AXERT	None	brand	SSRI	None	True	advise	group	If concomitant treatment with AXERT and an SSRI is clinically warranted, appropriate observation of the patient is advised.
DDI-DrugBank.d3.s19.p5	TORADOL	None	brand	psychoactive drugs	None	True	effect	group	Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).
DDI-DrugBank.d3.s19.p7	TORADOL	None	brand	thiothixene	DB01623	True	effect	drug	Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).
DDI-DrugBank.d303.s3.p2	cephalexin	DB00567	drug	metformin	DB00331	True	advise	drug	Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.
DDI-DrugBank.d307.s40.p4	Trileptal	None	brand	contraceptive	None	True	mechanism	group	Hormonal contraceptives Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG).
DDI-DrugBank.d307.s45.p2	Trileptal	None	brand	felodipine	DB01023	True	mechanism	drug	Calcium Antagonists: After repeated co-administration of Trileptal, the AUC of felodipine was lowered by 28% [90% CI: 20-33].
DDI-DrugBank.d309.s0.p1	antihistamines	None	group	barbiturates	None	True	effect	group	Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol.
DDI-DrugBank.d31.s0.p0	MAO inhibitors	None	group	hydralazine	DB01275	True	advise	drug	MAO inhibitors should be used with caution in patients receiving hydralazine.
DDI-DrugBank.d31.s1.p1	antihypertensive drugs	None	group	hydralazine	DB01275	True	effect	drug	When other potent parental antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure.
DDI-DrugBank.d31.s5.p0	Propranolol	DB00571	drug	hydralazine	DB01275	True	mechanism	drug	Propranolol increases hydralazines serum concentrations.
DDI-DrugBank.d310.s3.p2	cimetidine	DB00501	drug	nimodipine	DB00393	True	mechanism	drug	A study in eight healthy volunteers has shown a 50% increase in mean peak nimodipine plasma concentrations and a 90% increase in mean area under the curve, after a one week course of cimetidine at 1,000 mg/day and nimodipine at 90 mg/day.
DDI-DrugBank.d313.s3.p3	Beta-blockers	None	group	insulin	None	True	effect	drug	Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.
DDI-DrugBank.d314.s1.p4	corticosteroids	None	group	diuretics	None	True	advise	group	Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia.
DDI-DrugBank.d314.s19.p4	macrolide antibiotics	None	group	corticosteroids	None	True	mechanism	group	Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.
DDI-DrugBank.d314.s5.p0	anticholinesterase agents	None	group	corticosteroid	None	True	advise	group	If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy.
DDI-DrugBank.d315.s1.p0	digoxin	DB00390	drug	VAPRISOL	None	True	mechanism	brand	Therefore, if digoxin is administered with VAPRISOL, the clinician should be alert to the possibility of increases in digoxin levels.
DDI-DrugBank.d318.s7.p2	amphotericin B	DB00681	drug	flucytosine	DB01099	True	effect	drug	Flucytosine: while a synergistic relationship with amphotericin B has been reported, concomitant use may increase the toxicity of flucytosine by possibly increasing its cellular uptake and/or impairing its renal excretion.
DDI-DrugBank.d416.s0.p2	PAH	None	drug	thiazolesulfone	None	True	effect	drug	Renal clearance measurements of PAH cannot be made with any significant accuracy in patients receiving sulfonamides, procaine, or thiazolesulfone.
DDI-DrugBank.d417.s0.p1	Netilmicin	DB00955	drug	furosemide	DB00695	True	advise	drug	Netilmicin should not be administered concomitantly with potent loop diuretics such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.
DDI-DrugBank.d419.s0.p0	allopurinol	DB00437	drug	ampicillin	DB00415	True	effect	drug	The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.
DDI-DrugBank.d420.s6.p1	iron supplements	None	group	OMNICEF	None	True	advise	brand	If iron supplements are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the supplement.
DDI-DrugBank.d422.s15.p0	BREVIBLOC	None	brand	dopamine	DB00988	True	advise	drug	Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.
DDI-DrugBank.d422.s15.p2	BREVIBLOC	None	brand	norepinephrine	DB00368	True	advise	drug	Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.
DDI-DrugBank.d422.s6.p9	BREVIBLOC	None	brand	morphine	DB00295	True	mechanism	drug	When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.
DDI-DrugBank.d423.s0.p20	selegiline hydrochloride	None	drug	venlafaxine	DB00285	True	effect	drug	In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
DDI-DrugBank.d423.s4.p1	selective serotonin reuptake inhibitors	None	group	Imitrex	None	True	effect	brand	A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.
DDI-DrugBank.d424.s4.p0	rifampin	None	drug	MEPRON	None	True	advise	brand	Alternatives to rifampin should be considered during the course of PCP treatment with MEPRON.
DDI-DrugBank.d426.s3.p17	fluvoxamine	DB00176	drug	5-HT1 agonists	None	True	effect	group	Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
DDI-DrugBank.d427.s1.p2	quinolones	None	group	theophylline	DB00277	True	effect	drug	There have been reports of theophylline-related side effects in patients on concomitant therapy with quinolones and theophylline.
DDI-DrugBank.d427.s11.p1	Videx	None	brand	quinolones	None	True	mechanism	group	and Videx , (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of quinolones, resulting in systemic levels considerably lower than desired.
DDI-DrugBank.d428.s1.p0	ELLENCE	None	brand	calcium channel blockers	None	True	advise	group	Concomitant use of ELLENCE with other cardioactive compounds that could cause heart failure (e.g., calcium channel blockers), requires close monitoring of cardiac function throughout treatment.
DDI-DrugBank.d43.s14.p5	indinavir	DB00224	drug	VIDEX	None	True	mechanism	brand	Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.
DDI-DrugBank.d43.s5.p2	itraconazole	DB01167	drug	VIDEX	None	True	advise	brand	Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach: Drugs such as ketoconazole and itraconazole should be administered at least 2 hours prior to dosing with VIDEX.
DDI-DrugBank.d43.s7.p2	VIDEX	None	brand	ganciclovir	DB01004	True	mechanism	drug	A 21 (17)% decrease in the steady-state AUC of ganciclovir was observed when VIDEX was administered 2 hours prior to ganciclovir, but not when the two drugs were administered simultaneously (n = 12).
DDI-DrugBank.d43.s8.p21	ciprofloxacin	DB00537	drug	aluminum	None	True	mechanism	drug	Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.
DDI-DrugBank.d431.s8.p0	proton pump inhibitors	None	group	sucralfate	DB00364	True	advise	drug	Therefore, proton pump inhibitors should be taken at least 30 minutes prior to sucralfate.
DDI-DrugBank.d434.s28.p5	felbamate	DB00949	drug	phenobarbital	DB01174	True	mechanism	drug	Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.
DDI-DrugBank.d434.s31.p5	Carbamazepine	DB00564	drug	Felbatol	None	True	mechanism	brand	Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol  at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.
DDI-DrugBank.d435.s2.p6	phenytoin	DB00252	drug	exemestane	DB00990	True	mechanism	drug	Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John s wort) may significantly decrease exposure to exemestane.
DDI-DrugBank.d435.s2.p8	carbamazepine	DB00564	drug	exemestane	DB00990	True	mechanism	drug	Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John s wort) may significantly decrease exposure to exemestane.
DDI-DrugBank.d437.s10.p0	amprenavir	DB00701	drug	methadone	DB00333	True	mechanism	drug	Coadministration of amprenavir and methadone as compared to a non-matched historicalcontrol group resulted in a 30%, 27%, and 25% decrease in serum amprenavir AUC, Cmax, andCmin, respectively.
DDI-DrugBank.d438.s26.p5	morphine	DB00295	drug	Neurontin	None	True	mechanism	brand	Morphine: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine.
DDI-DrugBank.d438.s39.p0	gabapentin	DB00996	drug	Maalox	None	True	advise	brand	It is recommended that gabapentin be taken at least 2 hours following Maalox administration.
DDI-DrugBank.d443.s7.p2	phenytoin	DB00252	drug	aspirin	None	True	effect	brand	Phenytoin: Serum phenytoin levels may be increased by aspirin.
DDI-DrugBank.d443.s9.p2	Aspirin	None	brand	antacids	None	True	advise	group	Antacids: Enteric Coated Aspirin should not be given concurrently with antacids, since an increase in the pH of the stomach may effect the enteric coating of the tablets.
DDI-DrugBank.d446.s0.p3	Chlorotrianisene	DB00269	drug	bromocriptine	DB01200	True	int	drug	Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
DDI-DrugBank.d448.s0.p0	MAO inhibitors	None	group	antihistamines	None	True	effect	group	MAO inhibitors prolong and intensify the effects of antihistamines.
DDI-DrugBank.d45.s1.p2	REMICADE	None	brand	anakinra	DB00026	True	effect	drug	Other TNFa-blocking agents (including REMICADE) used in combination with anakinra may also result in similar toxicities.
DDI-DrugBank.d453.s0.p1	Cytosine arabinoside	None	drug	flucytosine	DB01099	True	effect	drug	Cytosine arabinoside, a cytostatic agent, has been reported to inactivate the antifungal activity of flucytosine by competitive inhibition.
DDI-DrugBank.d456.s1.p10	TARCEVA	None	brand	troleandomycin	DB01361	True	advise	drug	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
DDI-DrugBank.d458.s10.p1	Ketoconazole	DB01026	drug	tacrolimus	DB00864	True	mechanism	drug	Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.
DDI-DrugBank.d458.s12.p0	NIZORAL	None	brand	midazolam	DB00683	True	mechanism	drug	Coadministration of NIZORAL  Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.
DDI-DrugBank.d458.s21.p1	miconazole	DB01110	drug	hypoglycemic agents	None	True	effect	group	Because severe hypoglycemia has been reported in patients concomitantly receiving oral miconazole (an imidazole) and oral hypoglycemic agents, such a potential interaction involving the latter agents when used concomitantly with ketoconazole tablets (an imidazole) can not be ruled out.
DDI-DrugBank.d458.s23.p0	ketoconazole	DB01026	drug	phenytoin	DB00252	True	advise	drug	It is suggested to monitor both ketoconazole and phenytoin.
DDI-DrugBank.d458.s3.p3	Ketoconazole	DB01026	drug	terfenadine	DB00342	True	mechanism	drug	The following drug interactions have been identified involving NIZORAL Tablets and other drugs metabolized by the cytochrome P450 3A4 enzyme system: Ketoconazole tablets inhibit the metabolism of terfenadine, resulting in an increased plasma concentration of terfenadine and a delay in the elimination of its acid metabolite.
DDI-DrugBank.d458.s8.p0	ketoconazole	DB01026	drug	cisapride	DB00604	True	effect	drug	Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.
DDI-DrugBank.d46.s16.p0	Diuretic agents	None	group	lithium	DB01356	True	mechanism	drug	Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.
DDI-DrugBank.d460.s15.p3	thiazides	None	group	Starlix	None	True	effect	brand	Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.
DDI-DrugBank.d462.s1.p2	piperacillin	DB00319	drug	vecuronium	DB01339	True	effect	drug	Vecuronium: When used in the perioperative period, piperacillin has been implicated in the prolongation of the neuromuscular blockade of vecuronium.
DDI-DrugBank.d462.s3.p0	piperacillin	DB00319	drug	vecuronium	DB01339	True	effect	drug	In one controlled clinical study, the ureidopenicillins, including piperacillin, were reported to prolong the action of vecuronium.
DDI-DrugBank.d464.s0.p0	Codeine	DB00318	drug	narcotic analgesics	None	True	effect	group	Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.
DDI-DrugBank.d466.s1.p1	fexofenadine hydrochloride	None	drug	erythromycin	DB00199	True	mechanism	drug	However, co  administration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine.
DDI-DrugBank.d466.s19.p8	fexofenadine hydrochloride	None	drug	antacid	None	True	mechanism	group	Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.
DDI-DrugBank.d467.s2.p11	itraconazole	DB01167	drug	bexarotene	DB00307	True	mechanism	drug	On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.
DDI-DrugBank.d467.s2.p13	erythromycin	DB00199	drug	bexarotene	DB00307	True	mechanism	drug	On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.
DDI-DrugBank.d468.s2.p2	Cimetidine	DB00501	drug	nicardipine HCl	None	True	mechanism	drug	Cimetidine: Cimetidine increases nicardipine HCl plasma levels.
DDI-DrugBank.d47.s2.p11	butyrophenones	None	group	levodopa	None	True	effect	drug	Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa.
DDI-DrugBank.d47.s2.p8	phenothiazines	None	group	levodopa	None	True	effect	drug	Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa.
DDI-DrugBank.d47.s5.p1	Iron	DB01592	drug	levodopa	None	True	mechanism	drug	Iron salts may reduce the bioavailability of carbidopa and levodopa.
DDI-DrugBank.d471.s1.p0	thiazide diuretics	None	group	ergocalciferol	DB00153	True	effect	drug	Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with ergocalciferol may cause hypercalcemia.
DDI-DrugBank.d476.s0.p0	ZEBETA	None	brand	beta-blocking agents	None	True	advise	group	ZEBETA should not be combined with other beta-blocking agents.
DDI-DrugBank.d477.s0.p0	sympathomimetic amines	None	group	monoamine oxidase inhibitors	None	True	effect	group	Hypertensive crises have resulted when sympathomimetic amines have been used concomitantly within14 days following use of monoamine oxidase inhibitors.
DDI-DrugBank.d478.s5.p0	naratriptan	DB00952	drug	SSRI	None	True	advise	group	If concomitant treatment with naratriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.
DDI-DrugBank.d48.s1.p0	SPRYCEL	None	brand	ketoconazole	DB01026	True	mechanism	drug	Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
DDI-DrugBank.d48.s1.p10	SPRYCEL	None	brand	telithromycin	DB00976	True	mechanism	drug	Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
DDI-DrugBank.d48.s13.p5	proton pump inhibitors	None	group	SPRYCEL	None	True	advise	brand	The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.
DDI-DrugBank.d48.s15.p45	cisapride	DB00604	drug	SPRYCEL	None	True	advise	brand	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
DDI-DrugBank.d480.s15.p2	Phenytoin	DB00252	drug	Clozapine	DB00363	True	mechanism	drug	Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.
DDI-DrugBank.d480.s17.p5	erythromycin	DB00199	drug	Clozapine	DB00363	True	mechanism	drug	Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.
DDI-DrugBank.d480.s18.p0	Clozapine	DB00363	drug	carbamazepine	DB00564	True	advise	drug	Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels.
DDI-DrugBank.d480.s18.p5	carbamazepine	DB00564	drug	Clozapine	DB00363	True	mechanism	drug	Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels.
DDI-DrugBank.d480.s22.p4	clozapine	DB00363	drug	paroxetine	DB00715	True	mechanism	drug	However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.
DDI-DrugBank.d480.s30.p2	clozapine	DB00363	drug	carbamazepine	DB00564	True	advise	drug	Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
DDI-DrugBank.d480.s30.p4	clozapine	DB00363	drug	propafenone	DB01182	True	advise	drug	Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
DDI-DrugBank.d481.s0.p0	calcium	DB01373	drug	EMCYT	None	True	mechanism	brand	Milk, milk products, and calcium-rich foods or drugs may impair the absorption of EMCYT.
DDI-DrugBank.d484.s0.p14	Etonogestrel	DB00294	drug	Nizoral	None	True	int	brand	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d484.s0.p29	Etonogestrel	DB00294	drug	Norvir	None	True	int	brand	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d484.s0.p30	Etonogestrel	DB00294	drug	Viracept	None	True	int	brand	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d484.s0.p31	Etonogestrel	DB00294	drug	morphine	DB00295	True	int	drug	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d484.s0.p32	Etonogestrel	DB00294	drug	Astramorph	None	True	int	brand	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d484.s0.p40	Etonogestrel	DB00294	drug	temazepam	DB00231	True	int	drug	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d484.s0.p43	Etonogestrel	DB00294	drug	vitamin C	DB00126	True	int	drug	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d485.s17.p12	hormonal contraceptives	None	group	lorazepam	DB00186	True	mechanism	drug	Benzodiazepines: Combination hormonal contraceptives may decrease the clearance of some benzodiazepines (alprazolam, chlordiazepoxide, diazepam) and increase the clearance of others (lorazepam, oxazepam, temazepam).
DDI-DrugBank.d487.s1.p2	phenobarbital	DB01174	drug	corticosteroids	None	True	mechanism	group	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.
DDI-DrugBank.d492.s0.p0	MAO inhibitors	None	group	antihistamines	None	True	effect	group	MAO inhibitors prolong and intensify the anticholinergic effects of antihistamines.
DDI-DrugBank.d493.s2.p4	anakinra	DB00026	drug	TNF-blocking agent	None	True	effect	group	Anakinra: Concurrent administration of anakinra (an interleukin-1 antagonist) and another TNF-blocking agent has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.
DDI-DrugBank.d495.s1.p1	Clonidine hydrochloride	None	drug	barbiturates	None	True	effect	group	Clonidine hydrochloride may enhance the CNS-depressive effects of alcohol, barbiturates or other sedatives.
DDI-DrugBank.d495.s2.p0	Amitriptyline	DB00321	drug	clonidine	DB00575	True	effect	drug	Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol, barbiturates or other sedating drugs.
DDI-DrugBank.d495.s8.p0	fluphenazine	DB00623	drug	clonidine	DB00575	True	effect	drug	There is one reported case of a patient with acute delirium associated with the simultaneous use of fluphenazine and oral clonidine.
DDI-DrugBank.d499.s17.p2	ketoprofen	DB01009	drug	warfarin	DB00682	True	advise	drug	Because prostaglandina play an important role in hemostasis and ketoprofen has an effect on platelet function as well, concurent therapy with ketoprofen and warfarin requires close monitoring of patients on both drugs.
DDI-DrugBank.d499.s6.p0	aspirin	None	brand	ketoprofen	DB01009	True	mechanism	drug	however, in a study of 12 normal subjects, concurrent administration of aspirin decreased ketoprofen protein binding and increased ketoprofen plasma clearance from 0.07 L/kg/h without aspirin to 0.11 L/kg/h with aspirin.
DDI-DrugBank.d5.s17.p10	bupropion	DB01156	drug	thioridazine	DB00679	True	advise	drug	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
DDI-DrugBank.d5.s17.p2	bupropion	DB01156	drug	imipramine	DB00458	True	advise	drug	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
DDI-DrugBank.d5.s17.p7	bupropion	DB01156	drug	antipsychotics	None	True	advise	group	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
DDI-DrugBank.d5.s8.p0	bupropion	DB01156	drug	carbamazepine	DB00564	True	mechanism	drug	While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., carbamazepine, phenobarbital, phenytoin).
DDI-DrugBank.d500.s0.p0	tetracyclines	None	group	anticoagulant	None	True	advise	group	Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.
DDI-DrugBank.d500.s2.p1	tetracyclines	None	group	aluminum	None	True	mechanism	drug	Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.
DDI-DrugBank.d500.s2.p2	tetracyclines	None	group	calcium	DB01373	True	mechanism	drug	Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.
DDI-DrugBank.d502.s0.p0	Ocupress	None	brand	beta-adrenergic blocking agent	None	True	advise	group	Ocupress should be used with caution in patients who are receiving a beta-adrenergic blocking agent orally because of the potential for additive effects on systemic beta-blockade.
DDI-DrugBank.d503.s5.p1	chlorprothixene	DB01239	drug	barbituates	None	True	effect	group	Consider additive sedative effects and confusional states to emerge, if chlorprothixene is given with benzodiazepines or barbituates.
DDI-DrugBank.d503.s7.p0	chlorprothixene	DB01239	drug	anticholinergic drugs	None	True	advise	group	Exert particular caution in combining chlorprothixene with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.
DDI-DrugBank.d504.s0.p0	loxapine	DB00408	drug	lorazepam	DB00186	True	effect	drug	There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of loxapine and lorazepam.
DDI-DrugBank.d507.s5.p4	nadolol	DB01203	drug	guanfacine	DB01018	True	effect	drug	Noncardioselective beta-blockers (nadolol,porpranolol,timolol) may exacerbate rebound hypertension when guanfacine is withdrawn.
DDI-DrugBank.d511.s4.p4	FOSCAVIR	None	brand	aminoglycosides	None	True	advise	group	Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.
DDI-DrugBank.d318.s8.p35	imidazoles	None	group	amphotericin B	DB00681	True	effect	drug	Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.
DDI-DrugBank.d320.s3.p0	levobupivacaine	DB01002	drug	phenytoin	DB00252	True	mechanism	drug	Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;
DDI-DrugBank.d323.s0.p0	MYOBLOC	None	brand	aminoglycosides	None	True	advise	group	Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.
DDI-DrugBank.d324.s22.p0	ketoconazole	DB01026	drug	zaleplon	DB00962	True	mechanism	drug	Other strong selective CYP3A4 inhibitors such as ketoconazole can also be expected to increase the exposure of zaleplon.
DDI-DrugBank.d325.s7.p4	haloperidol	DB00502	drug	dopamine	DB00988	True	effect	drug	Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.
DDI-DrugBank.d325.s7.p5	phenothiazines	None	group	dopamine	DB00988	True	effect	drug	Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.
DDI-DrugBank.d328.s19.p0	dextromethorphan	DB00514	drug	valdecoxib	DB00580	True	mechanism	drug	Even so dextromethorphan plasma concentrations in the presence of high doses of valdecoxib were almost 5-fold lower than those seen in CYP 2D6 poor metabolizers suggesting that dose adjustment is not necessary.
DDI-DrugBank.d328.s21.p2	BEXTRA	None	brand	lithium	DB01356	True	advise	drug	Lithium serum concentrations should be monitored closely when initiating or changing therapy with BEXTRA in patients receiving lithium.
DDI-DrugBank.d328.s24.p0	Valdecoxib	DB00580	drug	R-warfarin	None	True	mechanism	drug	Valdecoxib caused a statistically significant increase in plasma exposures of R-warfarin and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin.
DDI-DrugBank.d328.s26.p2	BEXTRA	None	brand	warfarin	DB00682	True	advise	drug	Anticoagulant therapy should be monitored, particularly during the first few weeks, after initiating therapy with BEXTRA in patients receiving warfarin or similar agents.
DDI-DrugBank.d512.s3.p4	cinacalcet	DB01012	drug	amitriptyline	DB00321	True	mechanism	drug	Amitriptyline: Concurrent administration of 25 mg or 100 mg cinacalcet with 50 mg amitriptyline increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.
DDI-DrugBank.d514.s2.p1	heroin	DB01452	drug_n	alcohol	None	True	effect	drug	Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.
DDI-DrugBank.d516.s12.p2	Cimetidine	DB00501	drug	quinolones	None	True	mechanism	group	Cimetidine: Cimetidine has been demonstrated to interfere with the elimination of other quinolones.
DDI-DrugBank.d516.s24.p3	Quinolones	None	group	anticoagulant	None	True	effect	group	Warfarin: Quinolones may enhance the effects of the oral anticoagulant, warfarin, or its derivatives.
DDI-DrugBank.d516.s3.p29	magnesium	DB01378	drug	lomefloxacin	DB00978	True	mechanism	drug	Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.
DDI-DrugBank.d516.s5.p2	Magnesium	DB01378	drug	lomefloxacin	DB00978	True	mechanism	drug	Magnesium- and aluminum-containing antacids, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of lomefloxacin.
DDI-DrugBank.d521.s1.p2	glimepiride	DB00222	drug	magnesium/choline salicylate	None	True	advise	drug	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
DDI-DrugBank.d521.s1.p9	glimepiride	DB00222	drug	Magan	None	True	advise	brand	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
DDI-DrugBank.d522.s24.p2	erythromycin	DB00199	drug	carbamazepine	DB00564	True	int	drug	Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.
DDI-DrugBank.d527.s3.p6	clonidine	DB00575	drug	insulin	None	True	effect	drug	Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.
DDI-DrugBank.d527.s3.p9	alcohol	None	drug	insulin	None	True	effect	drug	Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.
DDI-DrugBank.d529.s17.p1	flurbiprofen	DB00712	drug	diuretics	None	True	advise	group	Patients receiving flurbiprofen and furosemide or other diuretics should be observed closely to determine if the desired effect is obtained.
DDI-DrugBank.d53.s7.p4	azithromycin	DB00207	drug	efavirenz	DB00625	True	mechanism	drug	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
DDI-DrugBank.d53.s7.p6	azithromycin	DB00207	drug	indinavir	DB00224	True	mechanism	drug	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
DDI-DrugBank.d530.s1.p0	L-phenylalanine	DB00120	drug	non-selective MAO inhibitors	None	True	effect	group	Concomitant use of L-phenylalanine and non-selective MAO inhibitors may cause hypertension.
DDI-DrugBank.d530.s3.p0	Neuroleptic Drugs	None	group	L-phenylalanine	DB00120	True	effect	drug	Neuroleptic Drugs - L-phenylalanine may potentiate the tardive dyskinesia side reactions of neuroleptic drugs if used concomitantly with them.
DDI-DrugBank.d531.s5.p5	rifabutin	DB00615	drug	efavirenz	DB00625	True	mechanism	drug	Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.
DDI-DrugBank.d536.s5.p0	Acarbose	DB00284	drug	digoxin	DB00390	True	mechanism	drug	Acarbose has been shown to change the bioavailabillty digoxin when they are co-administered, which may require digoxin dose adjustment.
DDI-DrugBank.d537.s0.p11	Bentiromide	DB00522	drug	Pronestyl	None	True	int	brand	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
DDI-DrugBank.d54.s15.p4	thyroid products	None	group	tricyclic antidepressants	None	True	effect	group	Tricyclic Antidepressants: Use of thyroid products with imipramine and other tricyclic antidepressants may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed.
DDI-DrugBank.d54.s21.p4	Thyroxine	None	drug	norepinephrine	DB00368	True	effect	drug	Vasopressors: Thyroxine increases the adrenergic effect of catecholamines such as epinephrine and norepinephrine.
DDI-DrugBank.d543.s4.p0	Anticholinergic agents	None	group	digoxin	DB00390	True	mechanism	drug	Anticholinergic agents may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of digoxin;
DDI-DrugBank.d543.s7.p0	antacids	None	group	anticholinergic agents	None	True	mechanism	group	Because antacids may interfere with the absorption of anticholinergic agents, simultaneous use of these drugs should be avoided.
DDI-DrugBank.d558.s22.p5	amiloride	DB00594	drug	dofetilide	DB00204	True	advise	drug	In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.
DDI-DrugBank.d559.s1.p17	caffeine	DB00201	drug	narcotic analgesic	None	True	effect	group	Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
DDI-DrugBank.d559.s1.p19	caffeine	DB00201	drug	anesthetics	None	True	effect	group	Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
DDI-DrugBank.d560.s1.p2	bitolterol	DB00901	drug	steroid	None	True	advise	group	If you are also using a steroid inhaler, take bitolterol first and then wait about 15 minutes before using the steroid inhaler.
DDI-DrugBank.d562.s10.p0	quinolone class antimicrobial	None	group	nonsteroidal anti-inflammatory drug	None	True	effect	group	Seizures have been reported in patients taking another quinolone class antimicrobial and the nonsteroidal anti-inflammatory drug fenbufen concurrently.
DDI-DrugBank.d562.s10.p1	quinolone class antimicrobial	None	group	fenbufen	None	True	effect	drug	Seizures have been reported in patients taking another quinolone class antimicrobial and the nonsteroidal anti-inflammatory drug fenbufen concurrently.
DDI-DrugBank.d563.s0.p0	ETHYOL	None	brand	antihypertensive medications	None	True	advise	group	Special consideration should be given to the administration of ETHYOL in patients receiving antihypertensive medications or other drugs that could cause or potentiate hypotension.
DDI-DrugBank.d564.s1.p1	Phenothiazines	None	group	epinephrine	DB00668	True	effect	drug	Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.
DDI-DrugBank.d565.s14.p0	cimetidine	DB00501	drug	diltiazem	DB00343	True	mechanism	drug	The effect may be mediated by cimetidines known inhibition of hepatic cytochrome P-450, the enzyme system responsible for the first-pass metabolism of diltiazem.
DDI-DrugBank.d565.s22.p0	anesthetics	None	group	calcium channel blockers	None	True	effect	group	The depression of cardiac contractility, conductivity, and automaticity as well as the vascular dilation associated with anesthetics may be potentiated by calcium channel blockers.
DDI-DrugBank.d565.s25.p0	diltiazem	DB00343	drug	cyclosporine	DB00091	True	int	drug	A pharmacokinetic interaction between diltiazem and cyclosporine has been observed during studies involving renal and cardiac transplant patients.
DDI-DrugBank.d565.s26.p1	cyclosporine	DB00091	drug	diltiazem	DB00343	True	mechanism	drug	In renal and cardiac transplant recipients, a reduction of cyclosporine dose ranging from 15% to 48% was necessary to maintain cyclosporine trough concentrations similar to those seen prior to the addition of diltiazem.
DDI-DrugBank.d565.s42.p0	diltiazem	DB00343	drug	rifampin	None	True	advise	drug	Coadministration of diltiazem with rifampin or any known CYP3A4 inducer should be avoided when possible, and alternative therapy considered.
DDI-DrugBank.d566.s0.p9	Cholestyramine	DB01432	drug	estrogens	None	True	mechanism	group	Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
DDI-DrugBank.d567.s12.p8	amiodarone	DB01118	drug	HMG-CoA reductase inhibitor class	None	True	effect	group	Amiodarone or Verapamil: The risk of myopathy/rhabdomyolysis is increased when either amiodarone or verapamil is used concomitantly with a closely related member of the HMG-CoA reductase inhibitor class (see WARNINGS, Myopathy/Rhabdomyolysis).
DDI-DrugBank.d567.s15.p0	coumarin anticoagulant	None	group	lovastatin	DB00227	True	effect	drug	Also, bleeding and/or increased prothrombin time have been reported in a few patients taking coumarin anticoagulants concomitantly with lovastatin.
DDI-DrugBank.d328.s48.p0	diazepam	DB00829	drug	valdecoxib	DB00580	True	mechanism	drug	Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.
DDI-DrugBank.d33.s0.p2	cephalosporins	None	group	aminoglycosides	None	True	effect	group	Although the occurrence has not been reported with Cefizox, nephrotoxicity has been reported following concomitant administration of other cephalosporins and aminoglycosides.
DDI-DrugBank.d330.s5.p1	neomycin sulfate	None	drug	anticoagulants	None	True	effect	group	Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability.
DDI-DrugBank.d331.s4.p2	probenecid	DB01032	drug	bumetanide	DB00887	True	effect	drug	Probenecid: Pretreatment with Probenecid reduces both The natriuresis and hyperreninemia produced by bumetanide.
DDI-DrugBank.d331.s7.p4	Indomethacin	DB00328	drug	bumetanide	DB00887	True	effect	drug	Indomethacin: Indomethacin blunts The increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits The bumetanide-induced increase in plasma renin activity.
DDI-DrugBank.d333.s7.p10	benzodiazepine class	None	group	anticonvulsant drugs	None	True	effect	group	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
DDI-DrugBank.d333.s7.p4	benzodiazepine class	None	group	antianxiety agents	None	True	effect	group	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
DDI-DrugBank.d334.s14.p0	PRINIVIL	None	brand	thiazide-type diuretics	None	True	effect	group	Agents Increasing Serum Potassium: PRINIVIL attenuates potassium loss caused by thiazide-type diuretics.
DDI-DrugBank.d334.s18.p5	lithium	DB01356	drug	ACE inhibitors	None	True	effect	group	Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.
DDI-DrugBank.d568.s12.p0	lithium	DB01356	drug	escitalopram	DB01175	True	effect	drug	Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.
DDI-DrugBank.d568.s12.p5	LEXAPRO	None	brand	lithium	DB01356	True	advise	drug	Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.
DDI-DrugBank.d568.s16.p4	selective serotonin reuptake inhibitor	None	group	sumatriptan	DB00669	True	effect	drug	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.
DDI-DrugBank.d568.s17.p1	sumatriptan	DB00669	drug	fluoxetine	DB00472	True	advise	drug	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.
DDI-DrugBank.d568.s17.p5	sumatriptan	DB00669	drug	citalopram	DB00215	True	advise	drug	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.
DDI-DrugBank.d568.s39.p7	escitalopram	DB01175	drug	citalopram	DB00215	True	advise	drug	Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered.
DDI-DrugBank.d575.s0.p2	tolbutamide	DB01124	drug	teniposide	DB00444	True	mechanism	drug	In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent.
DDI-DrugBank.d575.s0.p4	sodium salicylate	None	drug	teniposide	DB00444	True	mechanism	drug	In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent.
DDI-DrugBank.d576.s6.p0	Salicylate	None	group	penicillin	None	True	mechanism	drug	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.
DDI-DrugBank.d576.s6.p1	Salicylate	None	group	thiopental	DB00599	True	mechanism	drug	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.
DDI-DrugBank.d576.s6.p7	Salicylate	None	group	warfarin	DB00682	True	mechanism	drug	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.
DDI-DrugBank.d585.s0.p4	anticholinergic drugs	None	group	antipsychotic agents	None	True	effect	group	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
DDI-DrugBank.d585.s3.p0	Anticholinergic agents	None	group	digoxin	DB00390	True	mechanism	drug	Anticholinergic agents may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of digoxin;
DDI-DrugBank.d585.s5.p0	Anticholinergic drugs	None	group	metoclopramide	DB01233	True	effect	drug	Anticholinergic drugs may antagonize the effects of drugs that alter gastrointestinal motility, such as metoclopramide.
DDI-DrugBank.d587.s0.p1	Celontin	None	brand	antiepileptic drugs	None	True	advise	group	Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).
DDI-DrugBank.d597.s0.p2	NSAIDs	None	group	angiotensin-converting enzyme (ACE) inhibitors	None	True	effect	group	ACE inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of angiotensin-converting enzyme (ACE) inhibitors.
DDI-DrugBank.d597.s18.p0	furosemide	DB00695	drug	MOBIC	None	True	advise	brand	Nevertheless, during concomitant therapy with furosemide and MOBIC, patients should be observed closely for signs of declining renal function, as well as to assure diuretic efficacy.
DDI-DrugBank.d597.s26.p2	MOBIC	None	brand	warfarin	DB00682	True	advise	drug	Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing MOBIC therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding.
DDI-DrugBank.d599.s7.p2	GH	None	drug	anticonvulsants	None	True	mechanism	group	These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin).
DDI-DrugBank.d60.s12.p0	nondepolarizing agents	None	group	NIMBEX	None	True	effect	brand	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d60.s12.p10	nondepolarizing agents	None	group	magnesium	DB01378	True	effect	group	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d60.s12.p15	NIMBEX	None	brand	antibiotics	None	True	effect	group	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d60.s12.p2	nondepolarizing agents	None	group	aminoglycosides	None	True	effect	group	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d60.s12.p21	NIMBEX	None	brand	clindamycin	DB01190	True	effect	drug	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d60.s12.p26	NIMBEX	None	brand	anesthetics	None	True	effect	group	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d60.s13.p1	nondepolarizing neuromuscular blocking agents	None	group	carbamazepine	DB00564	True	effect	drug	Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.
DDI-DrugBank.d601.s0.p0	Barbiturates	None	group	contraceptives	None	True	int	group	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.
DDI-DrugBank.d602.s0.p0	NEXAVAR	None	brand	irinotecan	DB00762	True	advise	drug	Caution is recommended when administering NEXAVAR with compounds that are metabolized/eliminated predominantly by the UGT1A1 pathway (e.g. irinotecan).
DDI-DrugBank.d603.s0.p0	ProAmatine	None	brand	cardiac glycosides	None	True	effect	group	When administered concomitantly with ProAmatine   , cardiac glycosides may enhance or precipitate bradycardia, A.V.
DDI-DrugBank.d603.s2.p16	phenylpropanolamine	DB00397	drug	ProAmatine	None	True	effect	brand	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction.
DDI-DrugBank.d603.s5.p64	desglymidodrine	None	drug_n	cimetidine	DB00501	True	mechanism	drug	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.
DDI-DrugBank.d603.s5.p68	desglymidodrine	None	drug_n	flecainide	DB01195	True	mechanism	drug	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.
DDI-DrugBank.d603.s5.p69	desglymidodrine	None	drug_n	quinidine	DB00908	True	mechanism	drug	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.
DDI-DrugBank.d605.s0.p0	SKELAXIN	None	brand	alcohol	None	True	effect	drug	SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.
DDI-DrugBank.d606.s1.p3	Sympathomimetics	None	group	veratrum alkaloids	None	True	effect	group	Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.
DDI-DrugBank.d608.s1.p0	TOLECTIN	None	brand	warfarin	DB00682	True	effect	drug	However, increased prothrombin time and bleeding have been reported in patients on concomitant TOLECTIN and warfarin therapy.
DDI-DrugBank.d609.s0.p5	rifampin	None	drug	rosiglitazone	DB00412	True	mechanism	drug	An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone.
DDI-DrugBank.d610.s3.p0	Ethanol	DB00898	drug	abacavir	DB01048	True	mechanism	drug	Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir.
DDI-DrugBank.d611.s1.p1	Beta adrenergic agonists	None	group	tricyclic antidepressants	None	True	advise	group	Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.
DDI-DrugBank.d615.s0.p3	Triprolidine	DB00427	drug	hypnotics	None	True	effect	group	Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.
DDI-DrugBank.d615.s1.p4	atropine	DB00572	drug	triprolidine	DB00427	True	effect	drug	The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine.
DDI-DrugBank.d618.s1.p11	aspirin	None	brand	Retavase	None	True	effect	brand	In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.
DDI-DrugBank.d619.s0.p0	selegiline	DB01037	drug	meperidine	None	True	effect	drug	The occurrence of stupor, muscular rigidity, severe agitation, and elevated temperature has been reported in some patients receiving the combination of selegiline and meperidine.
DDI-DrugBank.d62.s0.p0	Dexbrompheniramine	DB00405	drug	alcohol	None	True	int	drug	Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
DDI-DrugBank.d624.s3.p2	TOBI	None	brand	urea	DB03904	True	advise	drug	TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.
DDI-DrugBank.d624.s3.p3	TOBI	None	brand	mannitol	DB00742	True	advise	drug	TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.
DDI-DrugBank.d632.s0.p0	SYMLIN	None	brand	anticholinergic agents	None	True	advise	group	Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors).
DDI-DrugBank.d634.s0.p2	anticoagulants	None	group	methimazole	DB00763	True	effect	drug	Anticoagulants (oral): The activity of oral anticoagulants may be potentiated by anti-vitamin-K activity attributed to methimazole.
DDI-DrugBank.d637.s0.p10	morphine	DB00295	drug	psychotropic drugs	None	True	effect	group	Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs.
DDI-DrugBank.d637.s2.p14	pentazocine	DB00652	drug	opioid agonist analgesic	None	True	advise	group	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.
DDI-DrugBank.d637.s2.p19	butorphanol	DB00611	drug	opioid agonist analgesic	None	True	advise	group	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.
DDI-DrugBank.d638.s2.p9	Ritalin	None	brand	desipramine	DB01151	True	mechanism	drug	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).
DDI-DrugBank.d64.s29.p16	anticoagulant	None	group	contraceptives	None	True	effect	group	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
DDI-DrugBank.d64.s29.p18	anticoagulant	None	group	primidone	DB00794	True	effect	drug	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
DDI-DrugBank.d64.s29.p8	anticoagulant	None	group	cholestyramine	DB01432	True	effect	drug	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
DDI-DrugBank.d64.s87.p19	anticoagulant	None	group	fenoprofen	DB00573	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p27	anticoagulant	None	group	methylphenidate	DB00422	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p32	anticoagulant	None	group	naproxen	DB00788	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p36	anticoagulant	None	group	phenylbutazone	DB00812	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p44	anticoagulant	None	group	salicylates	None	True	effect	group	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d640.s3.p14	potassium	DB01345	drug	ACE inhibitors	None	True	effect	group	Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.
DDI-DrugBank.d643.s0.p1	Melatonin	DB01065	drug	NSAIDs	None	True	int	group	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
DDI-DrugBank.d650.s0.p23	thioxanthines	None	group	Permax	None	True	advise	brand	Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist);
DDI-DrugBank.d653.s1.p2	phenobarbital	DB01174	drug	corticosteroids	None	True	mechanism	group	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.
DDI-DrugBank.d653.s7.p0	corticosteroids	None	group	anticoagulants	None	True	effect	group	The effect of corticosteroids on oral anticoagulants is variable.
DDI-DrugBank.d655.s0.p11	Methscopolamine	None	drug	antihistamines	None	True	int	group	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
DDI-DrugBank.d655.s0.p21	Methscopolamine	None	drug	promethazine	DB01069	True	int	drug	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
DDI-DrugBank.d658.s0.p0	testolactone	DB00894	drug	anticoagulants	None	True	effect	group	When administered concurrently, testolactone may increase the effects of oral anticoagulants;
DDI-DrugBank.d66.s0.p2	L-glutamine	DB00130	drug	human growth hormone	None	True	mechanism	drug	Human growth hormone - Concomitant use of L-glutamine and human growth hormone may enhance nutrient absorption in those with severe short bowel syndrome.
DDI-DrugBank.d665.s6.p0	Penicillin	None	group	probenecid	DB01032	True	mechanism	drug	Penicillin blood levels may be prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of penicillins.
DDI-DrugBank.d666.s0.p0	reserpine	DB00206	drug	beta-blocking agents	None	True	effect	group	Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents.
DDI-DrugBank.d666.s3.p0	Pindolol	DB00960	drug	thioridazine	DB00679	True	mechanism	drug	Pindolol has been shown to increase serum thioridazine levels when both drugs are co-administered.
DDI-DrugBank.d670.s6.p4	INVEGA	None	brand	alcohol	None	True	advise	drug	Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol.
DDI-DrugBank.d675.s7.p1	Methergine	None	brand	vasoconstrictors	None	True	advise	group	Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.
DDI-DrugBank.d677.s0.p1	Phenothiazines	None	group	barbiturates	None	True	effect	group	Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.)
DDI-DrugBank.d680.s8.p1	pantoprazole	DB00213	drug	ampicillin	DB00415	True	mechanism	drug	Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts).
DDI-DrugBank.d69.s1.p0	Cerubidine	None	brand	doxorubicin	DB00997	True	advise	drug	Cerubidine should not be used in patients who have previously received the recommended maximum cumulative doses of doxorubicin or Cerubidine.
DDI-DrugBank.d690.s0.p0	propoxyphene	None	drug	CNS depressants	None	True	effect	group	The CNS-depressant effect of propoxyphene is additive with that of other CNS depressants, including alcohol.
DDI-DrugBank.d694.s0.p2	digoxin	DB00390	drug	sitagliptin	DB01261	True	mechanism	drug	Digoxin: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days.
DDI-DrugBank.d697.s0.p2	Vitamin B1	None	drug	Contraceptives	None	True	int	group	Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants
DDI-DrugBank.d697.s0.p7	Thiamine	DB00152	drug	Stavudine	DB00649	True	int	drug	Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants
DDI-DrugBank.d700.s0.p6	Myfortic	None	brand	aluminum	None	True	mechanism	drug	Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.
DDI-DrugBank.d700.s6.p19	Myfortic	None	brand	mycophenolate mofetil	DB00688	True	advise	drug	Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.
DDI-DrugBank.d703.s0.p11	MEPERIDINE	None	drug	ANESTHETICS	None	True	advise	group	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
DDI-DrugBank.d709.s1.p7	macrolides	None	group	terfenadine	DB00342	True	int	drug	Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter.
DDI-DrugBank.d709.s3.p4	roxithromycin	DB00778	drug	astemizole	DB00637	True	advise	drug	Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended.
DDI-DrugBank.d709.s4.p8	cisapride	DB00604	drug	macrolide antibacterials	None	True	mechanism	group	Cisapride, pimozide: other Drugs such as Cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of The isozyme, including some macrolide antibacterials.
DDI-DrugBank.d711.s4.p0	tetracyclines	None	group	contraceptives	None	True	effect	group	Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.
DDI-DrugBank.d713.s2.p8	Sanctura	None	brand	digoxin	DB00390	True	mechanism	drug	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).
DDI-DrugBank.d715.s1.p1	DEMSER	None	brand	CNS depressants	None	True	effect	drug	Concurrent use of DEMSER with alcohol or other CNS depressants can increase their sedative effects.
DDI-DrugBank.d717.s0.p0	Mitotane	DB00648	drug	warfarin	DB00682	True	mechanism	drug	Mitotane has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for warfarin.
DDI-DrugBank.d717.s1.p2	Mitotane	DB00648	drug	coumarin-type anticoagulants	None	True	advise	group	Therefore, physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering Mitotane to patients on coumarin-type anticoagulants.
DDI-DrugBank.d721.s0.p24	aluminum	None	drug	SKELID	None	True	mechanism	brand	The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID.
DDI-DrugBank.d721.s2.p0	SKELID	None	brand	indomethacin	DB00328	True	mechanism	drug	The bioavailability of SKELID is increased 2-4 fold by indomethacin but is not significantly altered by coadministration of diclofenac.
DDI-DrugBank.d723.s0.p13	Carboptic	None	brand	suprofen	DB00870	True	effect	drug	Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.
DDI-DrugBank.d723.s0.p4	acetylcholine chloride	None	drug	suprofen	DB00870	True	effect	drug	Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.
DDI-DrugBank.d725.s1.p4	sympathomimetic pressor amines	None	group	MAOI	None	True	effect	group	MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI).
DDI-DrugBank.d726.s1.p63	paricalcitol	DB00910	drug	telithromycin	DB00976	True	advise	drug	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
DDI-DrugBank.d73.s2.p0	Calcium channel blockers	None	group	TENORMIN	None	True	effect	brand	Calcium channel blockers may also have an additive effect when given with TENORMIN .
DDI-DrugBank.d737.s10.p41	butyrophenones	None	group	MIRAPEX	None	True	effect	brand	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.
DDI-DrugBank.d737.s6.p48	verapamil	DB00661	drug	pramipexole	DB00413	True	mechanism	drug	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
DDI-DrugBank.d737.s6.p6	cimetidine	DB00501	drug	pramipexole	DB00413	True	mechanism	drug	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
DDI-DrugBank.d743.s8.p17	miconazole	DB01110	drug	terfenadine	DB00342	True	advise	drug	Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.
DDI-DrugBank.d744.s0.p1	insulin	None	drug	SOMAVERT	None	True	advise	brand	Acromegalic patients with diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT.
DDI-DrugBank.d75.s14.p8	enoximone	DB04880	drug	anagrelide	DB00261	True	effect	drug	The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.
DDI-DrugBank.d752.s0.p0	midazolam	DB00683	drug	azole antimycotics	None	True	advise	group	Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics).
DDI-DrugBank.d752.s1.p17	ketoconazole	DB01026	drug	midazolam	DB00683	True	mechanism	drug	Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam.
DDI-DrugBank.d752.s10.p1	VERSED Syrup	None	brand	morphine	DB00295	True	effect	drug	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.
DDI-DrugBank.d752.s10.p8	VERSED Syrup	None	brand	droperidol	DB00450	True	effect	drug	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.
DDI-DrugBank.d752.s6.p2	rifampin	None	drug	midazolam	DB00683	True	mechanism	drug	Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies.
DDI-DrugBank.d752.s6.p5	phenytoin	DB00252	drug	midazolam	DB00683	True	mechanism	drug	Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies.
DDI-DrugBank.d756.s2.p0	levomepromazine	None	drug	benzodiazepines	None	True	effect	group	Additive sedative effects and confusional states may emerge if levomepromazine is given with benzodiazepines or barbiturates.
DDI-DrugBank.d756.s7.p2	Caffeine	DB00201	drug	levomepromazine	None	True	effect	drug	Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine.
DDI-DrugBank.d76.s19.p2	Fluvoxamine	DB00176	drug	diazepam	DB00829	True	advise	drug	Diazepam: The co-administration of Fluvoxamine Tablets and diazepam is generally not advisable.
DDI-DrugBank.d76.s20.p0	fluvoxamine	DB00176	drug	diazepam	DB00829	True	mechanism	drug	Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.
DDI-DrugBank.d76.s28.p0	theophylline	DB00277	drug	fluvoxamine maleate	None	True	advise	drug	Therefore, if theophylline is co-administered with fluvoxamine maleate, its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of theophylline should to monitored.
DDI-DrugBank.d761.s13.p0	vitamin K	None	group	XENICAL	None	True	mechanism	brand	Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.
DDI-DrugBank.d765.s1.p43	cyclosporine	DB00091	drug	DETROL LA	None	True	advise	brand	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.
DDI-DrugBank.d77.s2.p13	epinephrine	DB00668	drug	tricyclic antidepressants	None	True	advise	group	Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.
DDI-DrugBank.d773.s2.p13	acetylsalicylic acid	DB00945	drug	TNKase	None	True	effect	brand	Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.
DDI-DrugBank.d775.s10.p21	MIVACRON	None	brand	clindamycin	DB01190	True	int	drug	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d775.s10.p23	MIVACRON	None	brand	sodium colistimethate	None	True	int	drug	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d775.s11.p0	MIVACRON	None	brand	contraceptives	None	True	effect	group	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.
DDI-DrugBank.d776.s14.p2	DIFLUCAN	None	brand	cyclosporine	DB00091	True	advise	drug	Careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving DIFLUCAN and cyclosporine.
DDI-DrugBank.d776.s18.p2	DIFLUCAN	None	brand	theophylline	DB00277	True	mechanism	drug	Theophylline: DIFLUCAN increases the serum concentrations of theophylline.
DDI-DrugBank.d776.s32.p0	rifabutin	DB00615	drug	fluconazole	DB00196	True	advise	drug	Patients receiving rifabutin and fluconazole concomitantly should be carefully monitored.
DDI-DrugBank.d776.s33.p2	fluconazole	DB00196	drug	tacrolimus	DB00864	True	effect	drug	Tacrolimus: There have been reports of nephrotoxicity in patients to whom fluconazole and tacrolimus were coadministered.
DDI-DrugBank.d776.s8.p0	DIFLUCAN	None	brand	coumarin-type anticoagulants	None	True	advise	group	Careful monitoring of prothrombin time in patients receiving DIFLUCAN and coumarin-type anticoagulants is recommended.
DDI-DrugBank.d777.s1.p11	Streptase	None	brand	anticoagulants	None	True	effect	group	Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.
DDI-DrugBank.d777.s1.p12	Streptokinase	DB00086	drug	antiplatelet agents	None	True	effect	group	Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.
DDI-DrugBank.d78.s1.p10	quinolones	None	group	didanosine	DB00900	True	mechanism	drug	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
DDI-DrugBank.d784.s4.p17	macrolide antibiotics	None	group	oxybutynin	DB01062	True	mechanism	drug	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).
DDI-DrugBank.d79.s0.p1	lymecycline	DB00256	drug	zinc	DB01593	True	mechanism	drug	The absorption of lymecycline may be affected by the simultaneous administration of indigestion remedies, iron or zinc supplements.
DDI-DrugBank.d8.s0.p3	ALFENTA	None	brand	opioids	None	True	effect	group	Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as barbiturates, tranquilizers, opioids, or inhalation general anesthetics.
DDI-DrugBank.d8.s4.p0	Cimetidine	DB00501	drug	ALFENTA	None	True	mechanism	brand	Cimetidine reduces the clearance of ALFENTA.
DDI-DrugBank.d81.s14.p4	fentanyl	DB00813	drug	calcium channel blocker	None	True	effect	group	Fentanyl Anesthesia: Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a beta blocker and a calcium channel blocker.
DDI-DrugBank.d82.s13.p0	INDOCIN	None	brand	methotrexate	DB00563	True	mechanism	drug	INDOCIN has been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity.
DDI-DrugBank.d165.s16.p5	digoxin	DB00390	drug	Itraconazole	DB01167	True	advise	drug	Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.
DDI-DrugBank.d165.s17.p0	HMG-CoA reductase inhibitors	None	group	immunosuppressive drugs	None	True	effect	group	Rhabdomyolysis has been observed in patients receiving HMG-CoA reductase inhibitors administered alone (at recommended dosages) or concomitantly with immunosuppressive drugs including cyclosporine.
DDI-DrugBank.d165.s21.p0	phenytoin	DB00252	drug	Itraconazole	DB01167	True	advise	drug	therefore, plasma concentrations of phenytoin should also be monitored when it is given concurrently with Itraconazole.
DDI-DrugBank.d165.s26.p0	azole antifungal agents	None	group	hypoglycemic agents	None	True	effect	group	Severe hypoglycemia has been reported in patients concomitantly receiving azole antifungal agents and oral hypoglycemic agents.
DDI-DrugBank.d165.s28.p0	Itraconazole	DB01167	drug	quinidine	DB00908	True	effect	drug	Tinnitus and decreased hearing have been reported in patients concomitantly receiving Itraconazole and quinidine.
DDI-DrugBank.d165.s29.p0	Itraconazole	DB01167	drug	dihydropyridine calcium channel blockers	None	True	effect	group	Edema has been reported in patients concomitantly receiving Itraconazole and dihydropyridine calcium channel blockers.
DDI-DrugBank.d170.s2.p2	fentanyl	DB00813	drug	itraconazole	DB01167	True	mechanism	drug	The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.
DDI-DrugBank.d170.s3.p1	diltiazem	DB00343	drug	fentanyl	DB00813	True	mechanism	drug	The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.
DDI-DrugBank.d170.s5.p17	DURAGESIC	None	brand	tranquilizers	None	True	effect	group	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
DDI-DrugBank.d334.s20.p2	PRINIVIL	None	brand	lithium	DB01356	True	advise	drug	It is recommended that serum lithium levels be monitored frequently if PRINIVIL is administered concomitantly with lithium.
DDI-DrugBank.d335.s1.p2	clorazepate dipotassium	None	drug	chlorpromazine	DB00477	True	effect	drug	Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition.
DDI-DrugBank.d335.s3.p3	benzodiazepines	None	group	monoamine oxidase inhibitors	None	True	effect	group	The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.
DDI-DrugBank.d336.s0.p0	anticoagulants	None	group	chlordiazepoxide	DB00475	True	effect	drug	Although clinical studies have not established a cause and effect relationship, physicians should be aware that variable effects an blood coagulation have been reported very rarely in patients receiving oral anticoagulants and chlordiazepoxide.
DDI-DrugBank.d337.s3.p5	HMG-CoA reductase inhibitors	None	group	Fentanyl	DB00813	True	advise	drug	Experience with co-administration of HMG-CoA reductase inhibitors and Fentanyl in patients is limited,therefore,consideration should be given to temporarily suspending use of HMG-CoA reductase inhibitors in patients receiving Fentanyl.
DDI-DrugBank.d338.s1.p2	benzodiazepines	None	group	alcohol	None	True	effect	drug	The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.
DDI-DrugBank.d340.s16.p4	ritonavir	DB00503	drug	VIRACEPT	None	True	mechanism	brand	Ritonavir: Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A.C.
DDI-DrugBank.d340.s7.p1	VIRACEPT	None	brand	rifabutin	DB00615	True	advise	drug	Drugs Which Require a Dose Reduction When Coadminstered With VIRACEPT Antimycobacterial agents: rifabutin
DDI-DrugBank.d341.s4.p0	sulfasalazine	DB00795	drug	ENBREL	None	True	effect	brand	Patients in a clinical study who were on established therapy with sulfasalazine, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone.
DDI-DrugBank.d345.s11.p11	penicillin G	None	drug	colestipol hydrochloride	None	True	mechanism	drug	The absorption of tetracycline, furosemide, penicillin G, hydrochlorothiazide, and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride;
DDI-DrugBank.d347.s8.p0	Sucralfate	DB00364	drug	FACTIVE	None	True	advise	brand	Sucralfate should not be taken within 2 hours of FACTIVE.
DDI-DrugBank.d350.s12.p4	efavirenz	DB00625	drug	CANCIDAS	None	True	mechanism	brand	In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.
DDI-DrugBank.d350.s14.p3	CANCIDAS	None	brand	dexamethasone	DB01234	True	advise	drug	When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered
DDI-DrugBank.d353.s0.p5	acitretin	DB00459	drug	ethanol	DB00898	True	mechanism	drug	Ethanol:Clinical evidence has shown that etretinate can be formed with concurrent ingestion of acitretin and ethanol.
DDI-DrugBank.d353.s8.p2	methotrexate	DB00563	drug	etretinate	DB00926	True	effect	drug	Methotrexate: An increased risk of hepatitis has been reported to result from combined use of methotrexate and etretinate.
DDI-DrugBank.d355.s3.p0	androgens	None	group	insulin	None	True	effect	drug	In diabetic patients, the metabolic effects of androgens may decrease blood glucose and therefore, insulin requirements.
DDI-DrugBank.d356.s5.p0	MIDAMOR	None	brand	non-steroidal anti-inflammatory agents	None	True	advise	group	Therefore, when MIDAMOR and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.
DDI-DrugBank.d357.s0.p26	apomorphine	DB00714	drug	granisetron	DB00889	True	advise	drug	5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
DDI-DrugBank.d357.s3.p28	dopamine antagonists	None	group	metoclopramide	DB01233	True	effect	drug	Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.
DDI-DrugBank.d357.s3.p38	phenothiazines	None	group	APOKYN	None	True	effect	brand	Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.
DDI-DrugBank.d357.s4.p0	neuroleptics	None	group	dopamine agonists	None	True	advise	group	Patients with major psychotic disorders, treated with neuroleptics, should be treated with dopamine agonists only if the potential benefits outweigh the risks.
DDI-DrugBank.d358.s2.p0	cilostazol	DB01166	drug	diltiazem	DB00343	True	mechanism	drug	Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of C.P.A..
DDI-DrugBank.d364.s9.p0	alosetron	DB00969	drug	ketoconazole	DB01026	True	advise	drug	Caution should be used when alosetron and ketoconazole are administered concomitantly.
DDI-DrugBank.d367.s4.p0	doxazosin	DB00590	drug	cimetidine	DB00501	True	mechanism	drug	In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of doxazosin on day 1 of a four-day regimen of oral cimetidine (400 mg twice daily) resulted in a 10% increase in mean AUC of doxazosin (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of doxazosin.
DDI-DrugBank.d368.s14.p0	Acetazolamide	DB00819	drug	cyclosporine	DB00091	True	mechanism	drug	Acetazolamide may elevate cyclosporine levels.
DDI-DrugBank.d368.s3.p2	DIAMOX	None	brand	primidone	DB00794	True	mechanism	drug	By decreasing the gastrointestinal absorption of primidone, DIAMOX may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect.
DDI-DrugBank.d369.s3.p1	Factrel	None	brand	dopamine antagonists	None	True	effect	group	The response to Factrel may be blunted by phenothiazines and dopamine antagonists which cause a rise in prolactin.
DDI-DrugBank.d371.s1.p3	docetaxel	DB01248	drug	erythromycin	DB00199	True	mechanism	drug	In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and troleandomycin.
DDI-DrugBank.d374.s1.p1	Auranofin	DB00995	drug	Depen	None	True	advise	brand	Auranofin should not be used together with penicillamine (Depen, Cuprimine), another arthritis medication.
DDI-DrugBank.d380.s7.p0	benzodiazepines	None	group	SUBOXONE	None	True	advise	brand	Patients should be warned of the potential danger of the intravenous self-administration of benzodiazepines while under treatment with SUBOXONE or SUBUTEX.
DDI-DrugBank.d170.s5.p19	DURAGESIC	None	brand	anesthetics	None	True	effect	group	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
DDI-DrugBank.d170.s5.p26	fentanyl	DB00813	drug	hypnotics	None	True	effect	group	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
DDI-DrugBank.d170.s5.p28	fentanyl	DB00813	drug	benzodiazepines	None	True	effect	group	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
DDI-DrugBank.d171.s4.p0	Tagamet	None	brand	theophylline	DB00277	True	mechanism	drug	However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.
DDI-DrugBank.d172.s16.p2	fluconazole	DB00196	drug	celecoxib	DB00482	True	mechanism	drug	Fluconazole: Concomitant administration of fluconazole at 200 mg QD resulted in a two-fold increase in celecoxib plasma concentration.
DDI-DrugBank.d172.s19.p7	lithium	DB01356	drug	CELEBREX	None	True	mechanism	brand	Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.
DDI-DrugBank.d172.s7.p3	NSAIDs	None	group	furosemide	DB00695	True	int	drug	Experience with nonsteroidal anti-inflammatory drugs (NSAIDs) suggests the potential for interactions with furosemide and ACE inhibitors.
DDI-DrugBank.d381.s0.p2	levamisole hydrochloride	None	drug	alcohol	None	True	effect	drug	ERGAMISOL  (levamisole hydrochloride) has been reported to produce ANTABUSE-like side effects when given concomitantly with alcohol.
DDI-DrugBank.d382.s20.p0	contraceptives	None	group	Aprepitant	DB00673	True	effect	drug	therefore, the efficacy of oral contraceptives during administration of Aprepitant may be reduced.
DDI-DrugBank.d382.s22.p4	Aprepitant	DB00673	drug	midazolam	DB00683	True	mechanism	drug	Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.
DDI-DrugBank.d382.s23.p3	midazolam	DB00683	drug	Aprepitant	DB00673	True	advise	drug	The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.
DDI-DrugBank.d382.s23.p6	benzodiazepines	None	group	Aprepitant	DB00673	True	advise	drug	The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.
DDI-DrugBank.d382.s23.p8	alprazolam	DB00404	drug	Aprepitant	DB00673	True	advise	drug	The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.
DDI-DrugBank.d382.s31.p4	Aprepitant	DB00673	drug	clarithromycin	DB01211	True	advise	drug	Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.
DDI-DrugBank.d386.s24.p0	major tranquilizers	None	group	desipramine	DB01151	True	effect	drug	Both the sedative and anticholinergic effects of the major tranquilizers are also additive to those of desipramine.
DDI-DrugBank.d386.s26.p0	cimetidine	DB00501	drug	tricyclic antidepressants	None	True	mechanism	group	Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma levels of the tricyclic antidepressants.
DDI-DrugBank.d387.s0.p2	doxylamine	DB00366	drug	CNS depressant drugs	None	True	effect	group	Potential drug interactions for doxylamine include, increased sedation if doxylamine is combined with other CNS depressant drugs.
DDI-DrugBank.d603.s5.p67	desglymidodrine	None	drug_n	triamterene	DB00384	True	mechanism	drug	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.
DDI-DrugBank.d615.s0.p1	Triprolidine	DB00427	drug	alcohol	None	True	effect	drug	Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.
DDI-DrugBank.d618.s1.p13	dipyridamole	DB00975	drug	Retavase	None	True	effect	brand	In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.
DDI-DrugBank.d618.s1.p8	vitamin K antagonists	None	group	Retavase	None	True	effect	brand	In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.
DDI-DrugBank.d62.s0.p5	Dexbrompheniramine	DB00405	drug	monoamine oxidase (MAO) inhibitors	None	True	int	group	Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
DDI-DrugBank.d624.s0.p12	TOBI	None	brand	aminoglycosides	None	True	effect	group	In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
DDI-DrugBank.d624.s3.p1	TOBI	None	brand	furosemide	DB00695	True	advise	drug	TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.
DDI-DrugBank.d628.s3.p2	DIPRIVAN	None	brand	opioids	None	True	advise	group	During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids).
DDI-DrugBank.d630.s1.p0	aspirin	None	brand	methazolamide	DB00703	True	advise	drug	Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.
DDI-DrugBank.d632.s0.p1	SYMLIN	None	brand	atropine	DB00572	True	advise	drug	Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors).
DDI-DrugBank.d637.s0.p8	morphine	DB00295	drug	sedatives	None	True	effect	group	Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs.
DDI-DrugBank.d637.s2.p10	Agonist/antagonist analgesics	None	group	opioid agonist analgesic	None	True	advise	group	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.
DDI-DrugBank.d637.s2.p20	buprenorphine	DB00921	drug	opioid agonist analgesic	None	True	advise	group	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.
DDI-DrugBank.d639.s0.p0	SUTENT	None	brand	ketoconazole	DB01026	True	mechanism	drug	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
DDI-DrugBank.d639.s0.p8	SUTENT	None	brand	saquinavir	DB01232	True	mechanism	drug	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
DDI-DrugBank.d639.s0.p9	SUTENT	None	brand	telithromycin	DB00976	True	mechanism	drug	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
DDI-DrugBank.d639.s2.p6	SUTENT	None	brand	phenobarbital	DB01174	True	mechanism	drug	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.
DDI-DrugBank.d64.s29.p3	anticoagulant	None	group	antihistamines	None	True	effect	group	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
DDI-DrugBank.d64.s29.p6	anticoagulant	None	group	chloral hydrate	DB01563	True	effect	drug	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
DDI-DrugBank.d64.s29.p9	anticoagulant	None	group	vitamin K	None	True	effect	group	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
DDI-DrugBank.d64.s87.p0	anticoagulant	None	group	alcohol	None	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d175.s18.p9	lithium	DB01356	drug	ACE inhibitor	None	True	effect	group	Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy.
DDI-DrugBank.d176.s3.p5	Fosinopril sodium	None	drug	thiazide diuretics	None	True	effect	group	Potassium Supplements and Potassium-Sparing Diuretics: Fosinopril sodium can attenuate potassium loss caused by thiazide diuretics.
DDI-DrugBank.d176.s6.p9	ACE inhibitors	None	group	lithium	DB01356	True	effect	drug	Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.
DDI-DrugBank.d176.s9.p25	magnesium hydroxide	None	drug	fosinopril	DB00492	True	mechanism	drug	Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.
DDI-DrugBank.d178.s0.p2	sulfonylureas	None	group	sulfonamides	None	True	effect	group	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
DDI-DrugBank.d178.s0.p4	sulfonylureas	None	group	probenecid	DB01032	True	effect	drug	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
DDI-DrugBank.d18.s1.p10	benzodiazepines	None	group	barbiturates	None	True	effect	group	Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
DDI-DrugBank.d18.s1.p11	benzodiazepines	None	group	MAO inhibitors	None	True	effect	group	Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
DDI-DrugBank.d18.s1.p8	benzodiazepines	None	group	ethyl alcohol	None	True	effect	drug	Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
DDI-DrugBank.d180.s1.p4	dopamine	DB00988	drug	Bretylium Tosylate	None	True	effect	drug	The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium Tosylate.
DDI-DrugBank.d183.s2.p4	sodium nitroprusside	None	drug	INOmax	None	True	effect	brand	Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.
DDI-DrugBank.d186.s3.p3	antipsychotic agents	None	group	opiates	None	True	effect	group	As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.
DDI-DrugBank.d186.s5.p5	rifampin	None	drug	haloperidol	DB00502	True	mechanism	drug	In 5 other schizophrenic patients treated with oral haloperidol and rifampin, discontinuation of rifampin produced a mean 3.3-fold increase in haloperidol concentrations.
DDI-DrugBank.d187.s11.p0	isoniazid	DB00951	drug	theophylline	DB00277	True	mechanism	drug	Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid.
DDI-DrugBank.d187.s2.p2	acetaminophen	DB00316	drug	Isoniazid	DB00951	True	effect	drug	Acetaminophen: A report of severe acetaminophen toxicity was reported in a patient receiving Isoniazid.
DDI-DrugBank.d187.s3.p0	isoniazid	DB00951	drug	acetaminophen	DB00316	True	effect	drug	It is believed that the toxicity may have resulted from a previously unrecognized interaction between isoniazid and acetaminophen and a molecular basis for this interaction has been proposed.
DDI-DrugBank.d187.s9.p2	Isoniazid	DB00951	drug	phenytoin	DB00252	True	mechanism	drug	Phenytoin: Isoniazid may increase serum levels of phenytoin.
DDI-DrugBank.d188.s0.p0	HEXALEN	None	brand	antidepressants of the MAO inhibitor class	None	True	effect	group	Concurrent administration of HEXALEN and antidepressants of the MAO inhibitor class may cause severe orthostatic hypotension.Cimetidine, an inhibitor of microsomal drug metabolism, increased altretamines half-life and toxicity in a rat model.
DDI-DrugBank.d188.s1.p0	HEXALEN	None	brand	cisplatin	DB00515	True	effect	drug	Data from a randomized trial of HEXALEN and cisplatin plus or minus pyridoxine in ovarian cancer indicated that pyridoxine significantly reduced neurotoxicity;
DDI-DrugBank.d188.s2.p0	pyridoxine	DB00165	drug	HEXALEN	None	True	advise	brand	however, it adversely affected response duration suggesting that pyridoxine should not be administered with HEXALEN and/or cisplatin.1
DDI-DrugBank.d195.s9.p0	Estrogen	None	group	ARIMIDEX	None	True	advise	brand	Estrogen-containing therapies should not be used with ARIMIDEX as they may diminish its pharmacologic action.
DDI-DrugBank.d197.s1.p29	PRECEDEX	None	brand	opioids	None	True	effect	group	Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.
DDI-DrugBank.d197.s4.p5	PRECEDEX	None	brand	anesthetic	None	True	advise	group	However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, hypnotic or opioid may be required.
DDI-DrugBank.d198.s10.p5	Indinavir	DB00224	drug	Vardenafil	DB00862	True	mechanism	drug	HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.
DDI-DrugBank.d198.s15.p0	Vardenafil	DB00862	drug	ritonavir	DB00503	True	advise	drug	Consequently, it is recommended not to exceed a single 2.5 mg Vardenafil dose in a 72-hour period when used in combination with ritonavir.
DDI-DrugBank.d198.s33.p0	Vardenafil	DB00862	drug	tamsulosin	DB00706	True	effect	drug	Two of 16 subjects dosed simultaneously with Vardenafil 10 mg and tamsulosin 0.4 mg experienced a standing systolic blood pressure below 85 mm Hg.
DDI-DrugBank.d20.s3.p0	eplerenone	DB00700	drug	erythromycin	DB00199	True	mechanism	drug	Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.
DDI-DrugBank.d20.s3.p1	eplerenone	DB00700	drug	verapamil	DB00661	True	mechanism	drug	Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.
DDI-DrugBank.d20.s3.p2	eplerenone	DB00700	drug	saquinavir	DB01232	True	mechanism	drug	Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.
DDI-DrugBank.d20.s9.p2	INSPRA	None	brand	lithium	DB01356	True	advise	drug	Serum lithium levels should be monitored frequently if INSPRA is administered concomitantly with lithium.
DDI-DrugBank.d202.s1.p0	tricyclic antidepressants	None	group	cimetidine	DB00501	True	effect	drug	Serious anticholinergic symptoms (severe dry mouth, urinary retention, blurred vision) have been associated with elevations in the serum levels of tricyclic antidepressants when cimetidine is added to the drug regimen.
DDI-DrugBank.d202.s16.p3	tricyclic antidepressants	None	group	Type 1C antiarrhythmics	None	True	advise	group	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.
DDI-DrugBank.d202.s16.p7	tricyclic antidepressants	None	group	quinidine	DB00908	True	advise	drug	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.
DDI-DrugBank.d202.s3.p0	cimetidine	DB00501	drug	tricyclic antidepressants	None	True	mechanism	group	In well-controlled patients undergoing concurrent therapy with cimetidine, a decrease in the steady-state serum concentrations of tricyclic antidepressants may occur when cime-tidine therapy is discontinued.
DDI-DrugBank.d205.s0.p1	Zarontin	None	brand	antiepileptic drugs	None	True	int	group	Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).
DDI-DrugBank.d206.s0.p0	antacids	None	group	lactulose	DB00581	True	mechanism	drug	Results of preliminary studies in humans and rats suggest that nonabsorbable antacids given concurrently with lactulose may inhibit the desired lactulose-induced drop in colonic pH.
DDI-DrugBank.d207.s4.p2	ketoconazole	DB01026	drug	gefitinib	DB00317	True	mechanism	drug	Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.
DDI-DrugBank.d207.s4.p3	itraconazole	DB01167	drug	gefitinib	DB00317	True	mechanism	drug	Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.
DDI-DrugBank.d208.s0.p0	Benzthiazide	DB00562	drug	alcohol	None	True	int	drug	Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.
DDI-DrugBank.d210.s22.p2	VIOXX	None	brand	methotrexate	DB00563	True	advise	drug	Standard monitoring of methotrexate-related toxicity should be continued if VIOXX and methotrexate are administered concomitantly.
DDI-DrugBank.d211.s2.p8	Chloramphenicol	DB00446	drug	penicillins	None	True	effect	group	Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.
DDI-DrugBank.d215.s0.p1	anileridine	DB00913	drug	sedatives	None	True	advise	group	Caution should be observed when anileridine is coadministered with other opioids, sedatives, phenothiazines, or anesthetics, as these agents may increase respiratory and circulatory depression.
DDI-DrugBank.d216.s10.p2	zopiclone	DB01198	drug	rifampicin	DB01045	True	mechanism	drug	Drugs That Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant useof rifampicin, a potent inducer of CYP3A4.
DDI-DrugBank.d217.s11.p18	sucralfate	DB00364	drug	norfloxacin	DB01059	True	advise	drug	Multivitamins, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.
DDI-DrugBank.d217.s3.p2	cyclosporine	DB00091	drug	norfloxacin	DB01059	True	mechanism	drug	Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with norfloxacin.
DDI-DrugBank.d217.s7.p3	norfloxacin	DB01059	drug	glyburide	DB01016	True	effect	drug	The concomitant administration of quinolones including norfloxacin with glyburide (a sulfonylurea agent) has, on rare occasions, resulted in severe hypoglycemia.
DDI-DrugBank.d219.s18.p0	NSAIDs	None	group	lithium	DB01356	True	effect	drug	Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.
DDI-DrugBank.d219.s26.p0	etodolac	DB00749	drug	warfarin	DB00682	True	effect	drug	However, caution should be exercised because there have been a few spontaneous reports of prolonged prothrombin times, with or without bleeding, in etodolac-treated patients receiving concomitant warfarin therapy.
DDI-DrugBank.d220.s4.p0	halofantrine	DB01218	drug	Mefloquine	DB00358	True	advise	drug	Because of the danger of a potentially fatal prolongation of the QTc interval, halofantrine must not be given simultaneously with or subsequent to Mefloquine.
DDI-DrugBank.d222.s0.p9	pralidoxime	DB00733	drug	atropine	DB00572	True	effect	drug	When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.
DDI-DrugBank.d223.s16.p4	selective serotonin reuptake inhibitors	None	group	doxepin	DB01142	True	mechanism	drug	Inhibitors or substrates of CYP2D6 (i.e., quinidine, selective serotonin reuptake inhibitors [SSRIs]) may increase the plasma concentration of doxepin when administered concomitantly.
DDI-DrugBank.d224.s8.p2	apraclonidine	DB00964	drug	cardiac glycosides	None	True	advise	group	Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), antihypertensives, and cardiac glycosides is advised.
DDI-DrugBank.d225.s11.p0	fluconazole	DB00196	drug	glipizide	DB01067	True	int	drug	The effect of concomitant administration of fluconazole and glipizide has been demonstrated in a placebo-controlled crossover study in normal volunteers.
DDI-DrugBank.d226.s4.p1	adenosine	DB00640	drug	caffeine	DB00201	True	effect	drug	The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.
DDI-DrugBank.d226.s5.p0	methylxanthines	None	group	adenosine	DB00640	True	advise	drug	In the presence of these methylxanthines, larger doses of adenosine may be required or adenosine may not be effective.
DDI-DrugBank.d226.s5.p1	methylxanthines	None	group	adenosine	DB00640	True	advise	drug	In the presence of these methylxanthines, larger doses of adenosine may be required or adenosine may not be effective.
DDI-DrugBank.d231.s14.p0	furosemide	DB00695	drug	NSAIDs	None	True	effect	group	There are case reports of patients who developed increased BUN, serum creatinine and serum potassium levels, and weight gain when furosemide was used in conjunction with NSAIDs.
DDI-DrugBank.d231.s4.p1	Furosemide	DB00695	drug	succinylcholine	DB00202	True	effect	drug	Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine.
DDI-DrugBank.d233.s0.p2	azathioprine	DB00993	drug	allopurinol	DB00437	True	mechanism	drug	Use with Allopurinol: The principal pathway for detoxification of azathioprine is inhibited by allopurinol.
DDI-DrugBank.d234.s6.p0	zopiclone	DB01198	drug	ROMAZICON	None	True	effect	brand	The effects of nonbenzodiazepine agonists at benzodiazepine receptors, such as zopiclone, triazolopyridazines and others, are also blocked by ROMAZICON.
DDI-DrugBank.d236.s0.p14	guanethidine	DB01170	drug	amphetamines	None	True	mechanism	group	Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.
DDI-DrugBank.d236.s15.p2	Amphetamines	None	group	antihypertensives	None	True	effect	group	Antihypertensives: Amphetamines may antagonize the hypotensive effects of antihypertensives.
DDI-DrugBank.d237.s7.p7	fluconazole	DB00196	drug	cisapride	DB00604	True	mechanism	drug	Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
DDI-DrugBank.d238.s17.p0	Fluvoxamine	DB00176	drug	TCA	None	True	mechanism	group	Fluvoxamine has also been shown to inhibit P450 1A2, an isoform also involved in TCAmetabolism.
DDI-DrugBank.d238.s3.p0	Anafranil	None	brand	anticholinergic	None	True	advise	group	Close supervision and careful adjustment of dosage are required when Anafranil is administered with anticholinergic or sympathomimetic drugs.
DDI-DrugBank.d238.s4.p2	tricyclic antidepressants	None	group	CMI	None	True	effect	drug	Several tricyclic antidepressants have been reported to block the pharmacologic effects of guanethidine, clonidine, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.
DDI-DrugBank.d238.s6.p1	tricyclic antidepressants	None	group	cimetidine	DB00501	True	mechanism	drug	plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.
DDI-DrugBank.d240.s0.p1	Ethopropazine	DB00392	drug	CNS depressants	None	True	effect	group	Ethopropazine may interact with alcohol or other CNS depressants, causing increased sedative effects.
DDI-DrugBank.d242.s1.p1	quinolones	None	group	caffeine	DB00201	True	mechanism	drug	However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.
DDI-DrugBank.d245.s7.p0	barbiturates	None	group	chlorpropamide	DB00672	True	effect	drug	Since animal studies suggest that the action of barbiturates may be prolonged by therapy with chlorpropamide, barbiturates should be employed with caution.
DDI-DrugBank.d246.s0.p3	butorphanol	DB00611	drug	tranquilizers	None	True	effect	group	Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.
DDI-DrugBank.d246.s12.p0	butorphanol	DB00611	drug	erythromycin	DB00199	True	advise	drug	It is not known if the effects of butorphanol are altered by concomitant medications that affect hepatic metabolism of drugs (erythromycin, etc.), but physicians should be alert to the possibility that a smaller initial dose and longer intervals between doses may be needed.
DDI-DrugBank.d247.s1.p0	vasopressors	None	group	monoamine oxidase (MAO) inhibitors	None	True	advise	group	All vasopressors should be used cautiously in patients taking monoamine oxidase (MAO) inhibitors.
DDI-DrugBank.d247.s5.p0	epinephrine	DB00668	drug	cyclopropane	None	True	effect	drug	Administration of epinephrine to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..
DDI-DrugBank.d247.s7.p0	Epinephrine	DB00668	drug	digitalis	None	True	advise	group	Epinephrine also should be used cautiously with other drugs (e.g., digitalis, glycosides) that sensitize the myocardium to the actions of sympathomimetic drugs.
DDI-DrugBank.d247.s8.p0	Diuretic agents	None	group	epinephrine	DB00668	True	effect	drug	Diuretic agents may decrease vascular response to pressor drugs such as epinephrine.
DDI-DrugBank.d247.s9.p0	Epinephrine	DB00668	drug	guanethidine	DB01170	True	effect	drug	Epinephrine may antagonize the neuron blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter.
DDI-DrugBank.d249.s2.p5	NSAIDs	None	group	warfarin	DB00682	True	advise	drug	Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.
DDI-DrugBank.d252.s4.p0	beta-adrenergic blocking agents	None	group	digitalis	None	True	effect	group	The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects on prolonging atrioventricular conduction time.
DDI-DrugBank.d257.s0.p3	Levo-Dromoran	None	brand	hypnotics	None	True	effect	group	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
DDI-DrugBank.d26.s0.p29	sedative-hypnotics	None	group	DILAUDID	None	True	effect	brand	Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.
DDI-DrugBank.d26.s0.p35	alcohol	None	drug	DILAUDID	None	True	effect	brand	Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.
DDI-DrugBank.d260.s0.p23	Probenecid	DB01032	drug	methotrexate	DB00563	True	mechanism	drug	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
DDI-DrugBank.d260.s3.p0	VISTIDE	None	brand	aminoglycosides	None	True	advise	group	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
DDI-DrugBank.d260.s3.p1	VISTIDE	None	brand	tobramycin	DB00684	True	advise	drug	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
DDI-DrugBank.d263.s23.p1	zalcitabine	DB00943	drug	aluminum	None	True	advise	drug	The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.
DDI-DrugBank.d266.s0.p0	CASODEX	None	brand	coumarin anticoagulant	None	True	mechanism	group	In vitro studies have shown CASODEX can displace coumarin anticoagulants, such as warfarin, from their protein-binding sites.
DDI-DrugBank.d267.s5.p5	NUROMAX	None	brand	lincomycin	DB01627	True	effect	drug	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d267.s5.p8	NUROMAX	None	brand	sodium colistimethate	None	True	effect	drug	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d267.s6.p2	nondepolarizing neuromuscular blocking agents	None	group	carbamazepine	DB00564	True	effect	drug	As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.
DDI-DrugBank.d269.s1.p17	fluoxetine	DB00472	drug	carvedilol	DB01136	True	effect	drug	poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .
DDI-DrugBank.d269.s11.p5	digoxin	DB00390	drug	carvedilol	DB01136	True	mechanism	drug	Digoxin: Digoxin concentrations are increased by about 15% when digoxin and carvedilol are administered concomitantly.
DDI-DrugBank.d269.s18.p7	Agents with b-blocking properties	None	group	insulin	None	True	effect	drug	Insulin or Oral Hypoglycemics: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics.
DDI-DrugBank.d269.s7.p2	cyclosporine	DB00091	drug	carvedilol	DB01136	True	mechanism	drug	Cyclosporine: Modest increases in mean trough cyclosporine concentrations were observed following initiation of carvedilol treatment in 21 renal transplant patients suffering from chronic vascular rejection.
DDI-DrugBank.d270.s18.p0	Clarithromycin	DB01211	drug	nevirapine	DB00238	True	mechanism	drug	Clarithromycin exposure was significantly decreased by nevirapine;
DDI-DrugBank.d270.s42.p7	Methadone	DB00333	drug	nevirapine	DB00238	True	advise	drug	Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. Methadone maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.
DDI-DrugBank.d275.s3.p0	Kineret	None	brand	etanercept	DB00005	True	effect	drug	Two percent of patients treated concurrently with Kineret and etanercept developed neutropenia (ANC  1 x 109/L).
DDI-DrugBank.d277.s13.p14	valproate	None	drug	tiagabine	DB00906	True	mechanism	drug	Valproate: The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.
DDI-DrugBank.d279.s0.p0	CAMPTOSAR	None	brand	antineoplastic agents	None	True	effect	group	The adverse effects of CAMPTOSAR, such as myelosuppression and diarrhea, would be expected to be exacerbated by other antineoplastic agents having similar adverse effects.
DDI-DrugBank.d279.s3.p0	CAMPTOSAR	None	brand	dexamethasone	DB01234	True	effect	drug	Lymphocytopenia has been reported in patients receiving CAMPTOSAR, and it is possible that the administration of dexamethasone as antiemetic prophylaxis may have enhanced the likelihood of this effect.
DDI-DrugBank.d281.s0.p0	Probenecid	DB01032	drug	cephalosporins	None	True	mechanism	group	Probenecid may decrease renal tubular secretion of cephalosporins when used concurrently, resulting in increased and more prolonged cephalosporin blood levels.
DDI-DrugBank.d283.s13.p3	TRICOR	None	brand	pravastatin	DB00175	True	mechanism	drug	Concomitant administration of fenofibrate (equivalent to 145mg TRICOR) with pravastatin (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for pravastatin by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.
DDI-DrugBank.d283.s5.p4	cyclosporine	DB00091	drug	TRICOR	None	True	effect	brand	Cyclosporine: Because cyclosporine can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including TRICOR, there is a risk that an interaction will lead to deterioration.
DDI-DrugBank.d284.s6.p8	monoamine oxidase inhibitors	None	group	adrenergic agonists	None	True	effect	group	BROVANA, as with other beta2-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.
DDI-DrugBank.d288.s11.p1	cyclosporin	None	drug	TAXOL	None	True	advise	brand	Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor  EL (eg, cyclosporin for injection concentrate and teniposide for injection concentrate) should not be treated with TAXOL.
DDI-DrugBank.d288.s11.p2	teniposide	DB00444	drug	TAXOL	None	True	advise	brand	Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor  EL (eg, cyclosporin for injection concentrate and teniposide for injection concentrate) should not be treated with TAXOL.
DDI-DrugBank.d289.s18.p0	TRACLEER	None	brand	glyburide	DB01016	True	advise	drug	Therefore, the concomitant administration of TRACLEER and glyburide is contraindicated, and alternative hypoglycemic agents should be considered.
DDI-DrugBank.d289.s19.p0	bosentan	DB00559	drug	glyburide	DB01016	True	mechanism	drug	Co-administration of bosentan decreased the plasma concentrations of glyburide by approximately 40%.
DDI-DrugBank.d289.s8.p0	hormonal contraceptives	None	group	TRACLEER	None	True	effect	brand	Therefore, hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable when TRACLEER is co-administered.
DDI-DrugBank.d291.s3.p2	sulphonylureas	None	group	Bezalip retard	None	True	effect	brand	The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard.
DDI-DrugBank.d291.s6.p0	immuno-suppressant	None	group	bezafibrate	DB01393	True	effect	drug	in isolated cases, a pronounced though reversible, impairment of renal function (accompanied by a corresponding increase in The serum creatinine level) has been reported in organ transplant patients receiving immuno-suppressant therapy and Concomitant bezafibrate.
DDI-DrugBank.d299.s1.p6	ergot-type medications	None	group	AXERT	None	True	advise	brand	Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.
DDI-DrugBank.d299.s1.p9	methysergide	DB00247	drug	AXERT	None	True	advise	brand	Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.
DDI-DrugBank.d3.s1.p18	warfarin	DB00682	drug	ketorolac tromethamine	None	True	mechanism	drug	Warfarin, Digoxin, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.
DDI-DrugBank.d3.s19.p8	TORADOL	None	brand	alprazolam	DB00404	True	effect	drug	Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).
DDI-DrugBank.d3.s8.p4	TORADOL	None	brand	furosemide	DB00695	True	effect	drug	Furosemide: TORADOL IV/IM reduced the diuretic response to furosemide in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).
DDI-DrugBank.d30.s4.p0	Fluconazole	DB00196	drug	losartan	DB00678	True	mechanism	drug	Fluconazole, an inhibitor of P450 2C9, decreased active metabolite concentration and increased losartan concentration.
DDI-DrugBank.d306.s0.p2	progestin	None	group	carbamazepine	DB00564	True	effect	drug	The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.
DDI-DrugBank.d306.s0.p3	progestin	None	group	barbiturates	None	True	effect	group	The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.
DDI-DrugBank.d308.s0.p1	HYDROXYZINE	DB00557	drug	NARCOTICS	None	True	effect	group	THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES.
DDI-DrugBank.d309.s0.p0	antihistamines	None	group	CNS depressants	None	True	effect	group	Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol.
DDI-DrugBank.d309.s2.p0	Monoamine oxidase (MAO) inhibitors	None	group	antihistamines	None	True	effect	group	Monoamine oxidase (MAO) inhibitors prolong and intensify the anticholinergic effects of antihistamines.
DDI-DrugBank.d64.s87.p10	anticoagulant	None	group	cimetidine	DB00501	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p22	anticoagulant	None	group	indomethacin	DB00328	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p28	anticoagulant	None	group	metronidazole	DB00916	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p29	anticoagulant	None	group	miconazole	DB01110	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p4	anticoagulant	None	group	anabolic steroids	None	True	effect	group	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p40	anticoagulant	None	group	pyrazolones	None	True	effect	group	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p5	anticoagulant	None	group	antibiotics	None	True	effect	group	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p9	anticoagulant	None	group	chymotrypsin	None	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d640.s3.p8	spironolactone	DB00421	drug	ACE inhibitors	None	True	effect	group	Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.
DDI-DrugBank.d641.s2.p0	probenecid	DB01032	drug	ALIMTA	None	True	mechanism	brand	Concomitant administration of substances that are also tubularly secreted (e.g., probenecid) could potentially result in delayed clearance of ALIMTA.
DDI-DrugBank.d641.s3.p5	ibuprofen	DB01050	drug	ALIMTA	None	True	advise	brand	Although ibuprofen (400 mg qid) can be administered with ALIMTA in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering ibuprofen concurrently with ALIMTA to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min).
DDI-DrugBank.d314.s10.p2	Cholestyramine	DB01432	drug	corticosteroids	None	True	mechanism	group	Cholestyramine: Cholestyramine may increase the clearance of corticosteroids.
DDI-DrugBank.d314.s18.p10	carbamazepine	DB00564	drug	corticosteroids	None	True	mechanism	group	Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.
DDI-DrugBank.d314.s4.p2	anticholinesterase agents	None	group	corticosteroids	None	True	effect	group	Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis.
DDI-DrugBank.d315.s0.p3	digoxin	DB00390	drug	conivaptan	DB00872	True	mechanism	drug	Digoxin: Coadministration of digoxin, a P-glycoprotein substrate, with oral conivaptan resulted in a reduction in clearance and an increase in digoxin Cmax and AUC values.
DDI-DrugBank.d316.s14.p7	felodipine	DB01023	drug	carbamazepine	DB00564	True	mechanism	drug	Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.
DDI-DrugBank.d32.s7.p0	ranitidine	DB00863	drug	ceftibuten	DB01415	True	mechanism	drug	however, 150 mg of ranitidine q12h for 3 days increased the ceftibuten C max by 23% and ceftibuten AUC by 16%.
DDI-DrugBank.d322.s0.p2	Amantadine	DB00915	drug	clidinium	DB00771	True	effect	drug	Amantadine, tricyclic antidepressants, and MAOIs may increase anticholinergic effect of clidinium.
DDI-DrugBank.d322.s1.p1	Clidinium	DB00771	drug	levodopa	None	True	effect	drug	Clidinium may decrease the effect of phenothiazines, levodopa, and ketoconazole.
DDI-DrugBank.d323.s0.p1	MYOBLOC	None	brand	curare-like compounds	None	True	advise	group	Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.
DDI-DrugBank.d325.s8.p2	Cyclopropane	None	drug	dopamine	DB00988	True	effect	drug	Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.
DDI-DrugBank.d328.s10.p3	NSAIDs	None	group	furosemide	DB00695	True	effect	drug	Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.
DDI-DrugBank.d328.s9.p0	BEXTRA	None	brand	ACE-inhibitors	None	True	advise	group	This interaction should be given consideration in patients taking BEXTRA concomitantly with ACE-inhibitors.
DDI-DrugBank.d331.s7.p3	Indomethacin	DB00328	drug	bumetanide	DB00887	True	mechanism	drug	Indomethacin: Indomethacin blunts The increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits The bumetanide-induced increase in plasma renin activity.
DDI-DrugBank.d333.s7.p3	benzodiazepine class	None	group	nonbarbiturate hypnotics	None	True	effect	group	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
DDI-DrugBank.d334.s2.p0	diuretic	None	group	PRINIVIL	None	True	advise	brand	If it is necessary to continue the diuretic, initiate therapy with PRINIVIL at a dose of 5 mg daily, and provide close medical supervision after the initial dose until blood pressure has stabilized.
DDI-DrugBank.d334.s4.p5	ACE inhibitor	None	group	diuretic	None	True	advise	group	Studies with ACE inhibitors in combination with diuretics indicate that the dose of the ACE inhibitor can be reduced when it is given with a diuretic.
DDI-DrugBank.d335.s1.p1	clorazepate dipotassium	None	drug	ethyl alcohol	None	True	effect	drug	Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition.
DDI-DrugBank.d335.s3.p0	benzodiazepines	None	group	barbiturates	None	True	effect	group	The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.
DDI-DrugBank.d338.s1.p1	benzodiazepines	None	group	antihistamines	None	True	effect	group	The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.
DDI-DrugBank.d338.s1.p6	benzodiazepines	None	group	phenothiazines	None	True	effect	group	The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.
DDI-DrugBank.d338.s4.p1	estazolam	DB01215	drug	phenytoin	DB00252	True	mechanism	drug	While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.
DDI-DrugBank.d338.s6.p1	estazolam	DB01215	drug	itraconazole	DB01167	True	advise	drug	Consequently, estazolam should be avoided in patients receiving ketoconazole and itraconazole, which are very potent inhibitors of CYP3A.
DDI-DrugBank.d339.s0.p2	carbamazepine	DB00564	drug	SUPRAX	None	True	mechanism	brand	Carbamazepine: Elevated carbamazepine levels have been reported in postmarketing experience when SUPRAX is administered concomitantly.
DDI-DrugBank.d340.s12.p0	VIRACEPT	None	brand	astemizole	DB00637	True	advise	drug	Because a similar interaction is likely, VIRACEPT should also not be administered concurrently with astemizole.
DDI-DrugBank.d340.s22.p3	ketoconazole	DB01026	drug	VIRACEPT	None	True	mechanism	brand	Ketoconazole: Coadministration of ketoconazole with VIRACEPT resulted in a 35% increase in nelfinavir plasma A.C.
DDI-DrugBank.d340.s6.p0	VIRACEPT	None	brand	Antiarrhythmics	None	True	advise	group	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
DDI-DrugBank.d340.s6.p3	VIRACEPT	None	brand	Antihistamines	None	True	advise	group	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
DDI-DrugBank.d340.s6.p5	VIRACEPT	None	brand	terfenadine	DB00342	True	advise	drug	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
DDI-DrugBank.d340.s6.p9	VIRACEPT	None	brand	Benzodiazepines	None	True	advise	group	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
DDI-DrugBank.d340.s7.p0	VIRACEPT	None	brand	Antimycobacterial agents	None	True	advise	group	Drugs Which Require a Dose Reduction When Coadminstered With VIRACEPT Antimycobacterial agents: rifabutin
DDI-DrugBank.d341.s3.p0	ENBREL	None	brand	anakinra	DB00026	True	effect	drug	Two percent of patients treated concurrently with ENBREL  and anakinra developed neutropenia (ANC   1 x 109/L).
DDI-DrugBank.d345.s14.p3	colestipol hydrochloride	None	drug	digoxin	DB00390	True	mechanism	drug	Particular caution should be observed with digitalis preparations since there are conflicting results for the effect of colestipol hydrochloride on the availability of digoxin and digitoxin.
DDI-DrugBank.d347.s7.p34	iron	DB01592	drug	FACTIVE	None	True	advise	brand	Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.
DDI-DrugBank.d347.s7.p41	zinc	DB01593	drug	FACTIVE	None	True	advise	brand	Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.
DDI-DrugBank.d347.s7.p44	didanosine	DB00900	drug	FACTIVE	None	True	advise	brand	Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.
DDI-DrugBank.d350.s11.p0	rifampin	None	drug	CANCIDAS	None	True	advise	brand	Patients on rifampin should receive 70 mg of CANCIDAS daily.
DDI-DrugBank.d350.s14.p4	CANCIDAS	None	brand	carbamazepine	DB00564	True	advise	drug	When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered
DDI-DrugBank.d350.s5.p0	CANCIDAS	None	brand	tacrolimus	DB00864	True	mechanism	drug	CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.
DDI-DrugBank.d351.s0.p5	b-lactam antibiotics	None	group	probenecid	DB01032	True	mechanism	drug	Probenecid: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef.
DDI-DrugBank.d352.s3.p1	diethylpropion	DB00937	drug	guanethidine	DB01170	True	int	drug	conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa).
DDI-DrugBank.d352.s3.p2	diethylpropion	DB00937	drug	a-methyldopa	None	True	int	drug	conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa).
DDI-DrugBank.d357.s0.p9	apomorphine	DB00714	drug	ondansetron	DB00904	True	effect	drug	5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
DDI-DrugBank.d359.s1.p0	PEGANONE	None	brand	Phenurone	None	True	advise	brand	Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.
DDI-DrugBank.d364.s5.p1	alosetron	DB00969	drug	cimetidine	DB00501	True	advise	drug	Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.
DDI-DrugBank.d365.s1.p7	L-histidine	DB00117	drug	H1 blockers	None	True	effect	group	H1 and H2 Blockers - Although not reported, L-histidine, via its metabolism to histamine, might decrease the efficacy of H1 and H2 blockers.
DDI-DrugBank.d365.s1.p8	L-histidine	DB00117	drug	H2 blockers	None	True	effect	group	H1 and H2 Blockers - Although not reported, L-histidine, via its metabolism to histamine, might decrease the efficacy of H1 and H2 blockers.
DDI-DrugBank.d368.s10.p0	Acetazolamide	DB00819	drug	quinidine	DB00908	True	mechanism	drug	Acetazolamide reduces urinary excretion of quinidine and may enhance its effect.
DDI-DrugBank.d369.s3.p0	Factrel	None	brand	phenothiazines	None	True	effect	group	The response to Factrel may be blunted by phenothiazines and dopamine antagonists which cause a rise in prolactin.
DDI-DrugBank.d373.s3.p2	digoxin	DB00390	drug	digoxin	DB00390	True	mechanism	drug	Extended Release Tablets: Administration of nifedipine with digoxin increased digoxin levels in 9 of 12 normal volunteers.
DDI-DrugBank.d374.s1.p0	Auranofin	DB00995	drug	penicillamine	DB00859	True	advise	drug	Auranofin should not be used together with penicillamine (Depen, Cuprimine), another arthritis medication.
DDI-DrugBank.d379.s1.p12	griseofulvin	DB00400	drug	LEVULAN KERASTICK	None	True	effect	brand	It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.
DDI-DrugBank.d379.s1.p27	tetracyclines	None	group	LEVULAN KERASTICK	None	True	effect	brand	It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.
DDI-DrugBank.d380.s3.p0	buprenorphine	DB00921	drug	benzodiazepines	None	True	int	group	Based on anecdotal reports, there may be an interaction between buprenorphine and benzodiazepines.
DDI-DrugBank.d380.s6.p2	SUBOXONE	None	brand	benzodiazepines	None	True	advise	group	SUBUTEX and SUBOXONE should be prescribed with caution to patients on benzodiazepines or other drugs that act on the central nervous system, regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse.
DDI-DrugBank.d382.s14.p4	methylprednisolone	DB00959	drug	Aprepitant	DB00673	True	advise	drug	The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.
DDI-DrugBank.d382.s21.p0	Aprepitant	DB00673	drug	contraceptives	None	True	advise	group	Although a 3-day regimen of Aprepitant given concomitantly with oral contraceptives has not been studied, alternative or back-up methods of contraception should be used.
DDI-DrugBank.d82.s33.p1	beta-adrenoceptor blocking agents	None	group	INDOCIN	None	True	effect	brand	Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by non-steroidal antiinflammatory drugs including INDOCIN has been reported.
DDI-DrugBank.d82.s4.p0	INDOCIN	None	brand	NSAIDs	None	True	advise	group	The concomitant use of INDOCIN with other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.
DDI-DrugBank.d83.s0.p0	warfarin-type anticoagulant	None	group	griseofulvin	DB00400	True	advise	drug	Patients on warfarin-type anticoagulant therapy may require dosage adjustment of the anticoagulant during and after griseofulvin therapy.
DDI-DrugBank.d83.s1.p0	barbiturates	None	group	griseofulvin	DB00400	True	effect	drug	Concomitant use of barbiturates usually depresses griseofulvin activity and may necessitate raising the dosage.
DDI-DrugBank.d83.s2.p0	griseofulvin	DB00400	drug	contraceptives	None	True	effect	group	The concomitant administration of griseofulvin has been reported to reduce the efficacy of oral contraceptives and to increase the incidence of breakthrough bleeding.
DDI-DrugBank.d85.s10.p0	Probenecid	DB01032	drug	naproxen	DB00788	True	mechanism	drug	Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly.
DDI-DrugBank.d85.s11.p0	naproxen	DB00788	drug	methotrexate	DB00563	True	advise	drug	Caution should be used if naproxen is administered concomitantly with methotrexate.
DDI-DrugBank.d85.s9.p1	Naproxen	DB00788	drug	propranolol	DB00571	True	effect	drug	Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers.
DDI-DrugBank.d85.s9.p3	NSAIDs	None	group	propranolol	DB00571	True	effect	drug	Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers.
DDI-DrugBank.d87.s19.p5	verapamil	DB00661	drug	TAMBOCOR	None	True	advise	brand	Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.
DDI-DrugBank.d9.s0.p0	Azlocillin	DB01061	drug	amikacin	DB00479	True	advise	drug	Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.
DDI-DrugBank.d94.s11.p0	EQUETROTM	None	brand	Acetaminophen	DB00316	True	mechanism	drug	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s11.p21	EQUETROTM	None	brand	lamotrigine	DB00555	True	mechanism	drug	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s11.p22	EQUETROTM	None	brand	levothyroxine	DB00451	True	mechanism	drug	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s11.p26	EQUETROTM	None	brand	mirtazapine	DB00370	True	mechanism	drug	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s11.p32	EQUETROTM	None	brand	praziquantel	DB01058	True	mechanism	drug	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s11.p35	EQUETROTM	None	brand	risperidone	DB00734	True	mechanism	drug	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s11.p7	EQUETROTM	None	brand	clonazepam	DB01068	True	mechanism	drug	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s16.p5	mefloquine	DB00358	drug	carbamazepine	DB00564	True	effect	drug	Additionally, anti-malarial drugs, such as chloroquine and mefloquine, may antagonize the activity of carbamazepine.
DDI-DrugBank.d94.s4.p19	EQUETROTM	None	brand	propoxyphene	None	True	mechanism	drug	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
DDI-DrugBank.d94.s4.p24	EQUETROTM	None	brand	verapamil	DB00661	True	mechanism	drug	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
DDI-DrugBank.d94.s4.p7	EQUETROTM	None	brand	diltiazem	DB00343	True	mechanism	drug	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
DDI-DrugBank.d94.s8.p5	EQUETROTM	None	brand	Phenytoin	DB00252	True	mechanism	drug	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
DDI-DrugBank.d97.s26.p0	CRIXIVAN	None	brand	atazanavir	DB01072	True	advise	drug	Combinations of these drugs have not been studied and coadministration of CRIXIVAN and atazanavir is not recommended.
DDI-DrugBank.d97.s72.p8	HMG-CoA reductase inhibitors	None	group	CRIXIVAN	None	True	advise	brand	Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA reductase inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin, fluvastatin, or rosuvastatin in combination with CRIXIVAN.
DDI-DrugBank.d98.s15.p5	antacids	None	group	vitamin D	None	True	advise	group	Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.
DDI-DrugBank.d98.s2.p13	phenobarbital	DB01174	drug	calcitriol	DB00136	True	mechanism	drug	Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
DDI-DrugBank.d99.s24.p3	tricyclic antidepressants	None	drug	cimetidine	DB00501	True	mechanism	drug	Discontinuation of cimetidine in well-controlled patients receiving tricyclic antidepressants and cimetidine may decrease the plasma levels and efficacy of the antidepressants.
DDI-MedLine.d1.s5.p0	Sildenafil	DB00203	drug	long-acting nitrates	None	True	advise	group	Sildenafil is contraindicated in patients using long-acting nitrates or who may need to use short-acting nitrates, because the combination may cause a sharp fall of the blood pressure.
DDI-MedLine.d105.s7.p2	Azithromycin	DB00207	drug	zidovudine	DB00495	True	mechanism	drug	Azithromycin had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%.
DDI-MedLine.d106.s8.p1	Chloral hydrate	DB01563	drug	anticoagulant agents	None	True	int	group	Chloral hydrate and methaqualone interact pharmacologically with orally administered anticoagulant agents, but the effect is not clinically significant.
DDI-MedLine.d111.s10.p0	Theophylline	DB00277	drug	acetaminophen	DB00316	True	mechanism	drug	Theophylline decreased the binding of acetaminophen by a net change of 6.8% (percentage increase in FDF, 8.8%) at 277.5 micromol/L;
DDI-MedLine.d119.s16.p0	cholestyramine	DB01432	drug	fluvastatin	DB01095	True	effect	drug	Although this effect was noted even when cholestyramine was given 4 hours prior to fluvastatin, this regimen did not result in diminished efficacy.
DDI-MedLine.d12.s7.p3	dexamethasone	DB01234	drug	insulin	None	True	effect	drug	These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.
DDI-MedLine.d125.s6.p0	4-methylpyrazole	None	drug	1,3-difluoro-2-propanol	None	True	effect	drug_n	Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol-intoxicated animals.
DDI-MedLine.d126.s6.p1	allopurinol	DB00437	drug	cypermethrin	None	True	effect	drug	Pretreatment of rats with allopurinol (100 mg/kg, ip) or Vitamin E (100 mg/kg per day, ig, for 3 days and a dose of 40 mg/kg on the 4th day) provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues, induced by single high dose of oral cypermethrin administration within 4 h.
DDI-MedLine.d126.s6.p2	Vitamin E	DB00163	drug	cypermethrin	None	True	effect	drug	Pretreatment of rats with allopurinol (100 mg/kg, ip) or Vitamin E (100 mg/kg per day, ig, for 3 days and a dose of 40 mg/kg on the 4th day) provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues, induced by single high dose of oral cypermethrin administration within 4 h.
DDI-MedLine.d143.s4.p0	Pantoprazole	DB00213	drug	clopidogrel	DB00758	True	mechanism	drug	Pantoprazole has a much weaker effect on clopidogrel's pharmacokinetics and on platelet reactivity during concomitant use.
DDI-MedLine.d143.s6.p0	clopidogrel	DB00758	drug	omeprazole	DB00338	True	advise	drug	Regulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors omeprazole and esomeprazole should be avoided.
DDI-MedLine.d16.s0.p0	ketamine	DB01221	drug	halothane	DB01159	True	int	drug	Interaction of ketamine and halothane in rats.
DDI-MedLine.d161.s6.p0	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	None	drug_n	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	None	True	effect	drug_n	These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated animals than in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated monkeys.
DDI-MedLine.d161.s7.p0	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	None	drug_n	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	None	True	effect	drug_n	The 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine treatment also had a significant effect on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced loss of norepinephrine neurons in the locus coeruleus and adjoining A5 and A7 noradrenaline cell groups.
DDI-MedLine.d169.s8.p0	Calcium	DB01373	drug	nonheme iron	None	True	mechanism	drug	Calcium doses   1000 mg diminished nonheme iron absorption by an average of 49.6%.
DDI-MedLine.d179.s8.p0	docetaxel	DB01248	drug	sunitinib	DB01268	True	effect	drug	The molecular basis of this synergism is that the signaling pathways that were initially activated by docetaxel exposure were efficiently suppressed by the subsequent exposure to sunitinib.
DDI-MedLine.d189.s7.p0	ABT	None	drug_n	precocene I	None	True	effect	drug_n	ABT decreased the toxicity of precocene I, increased exposure to parent compound, and decreased metabolite levels in a dose-dependent manner.
DDI-MedLine.d204.s11.p1	methylglyoxal	None	drug_n	amikacin	DB00479	True	effect	drug	Synergism was also noted when methylglyoxal was combined with carbenicillin and amikacin.
DDI-MedLine.d208.s3.p0	antiretroviral	None	group	Implanon	None	True	effect	brand	We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.
DDI-MedLine.d209.s5.p1	Paroxetine	DB00715	drug	endoxifen	None	True	mechanism	drug_n	Paroxetine and fluoxetine reduce the plasma concentration of endoxifen by about 50%.
DDI-MedLine.d216.s0.p1	S-ketamine	None	drug	ticlopidine	DB00208	True	effect	drug	Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine.
DDI-MedLine.d217.s5.p2	celecoxib	DB00482	drug	doxorubicin	DB00997	True	effect	drug	We found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and doxorubicin in all cell lines except for two combinations in HCT116 cells.
DDI-MedLine.d218.s9.p0	mirtazapine	DB00370	drug	warfarin	DB00682	True	effect	drug	Also mirtazapine, which is not believed to interact with warfarin, increased the risk of GI bleeding (OR   =   1.75 [95% CI, 1.30-2.35]).
DDI-MedLine.d227.s0.p0	Ephedrine	DB01364	drug	dexmedetomidine	DB00633	True	effect	drug	Ephedrine enhances the antinociceptive effect of dexmedetomidine in mice.
DDI-MedLine.d231.s8.p6	Lomefloxacin	DB00978	drug	gelusil	None	True	mechanism	brand	Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.
DDI-MedLine.d25.s12.p3	Macrolide antibiotics	None	group	lovastatin	DB00227	True	mechanism	drug	CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin).
DDI-MedLine.d25.s9.p0	Clarithromycin	DB01211	drug	simvastatin	DB00641	True	mechanism	drug	DISCUSSION: Clarithromycin is a potent inhibitor of CYP3A4, the major enzyme responsible for simvastatin metabolism.
DDI-MedLine.d29.s2.p1	penicillins	None	group	probenecid	DB01032	True	mechanism	drug	(1968, 1970), the higher serum concentrations of penicillins and cephaloridine reached after administration of probenecid are due not only to slower renal elimination but also to an altered distribution in the body.
DDI-MedLine.d29.s2.p2	cephaloridine	None	drug	probenecid	DB01032	True	mechanism	drug	(1968, 1970), the higher serum concentrations of penicillins and cephaloridine reached after administration of probenecid are due not only to slower renal elimination but also to an altered distribution in the body.
DDI-MedLine.d30.s7.p1	(-)-NANM	None	drug_n	morphine	DB00295	True	effect	drug	In both species, (-)-NANM, but not (+)-NANM, antagonized the rate-decreasing effects of morphine on FI and FR responding.
DDI-MedLine.d36.s2.p5	carbamazepine	DB00564	drug	tricyclic antidepressants	None	True	advise	group	We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.
DDI-MedLine.d47.s4.p0	Buforin II	None	drug_n	azithromycin	DB00207	True	effect	drug	Buforin II may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either azithromycin or minocycline.
DDI-MedLine.d47.s4.p1	Buforin II	None	drug_n	minocycline	DB01017	True	effect	drug	Buforin II may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either azithromycin or minocycline.
DDI-MedLine.d51.s3.p0	theophylline	DB00277	drug	CGS 21680	None	True	effect	drug_n	The anxiogenic effects of theophylline were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by N6-cyclopentyladenosine (CPA), an A1-selective agonist.
DDI-MedLine.d55.s0.p0	acetaminophen	DB00316	drug	caffeine	DB00201	True	effect	drug	Increased hepatotoxicity of acetaminophen by concomitant administration of caffeine in the rat.
DDI-MedLine.d63.s6.p0	naloxone	DB01183	drug	beta-endorphin	None	True	effect	drug_n	Intraventricular injection of naloxone at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and morphine.
DDI-MedLine.d67.s7.p1	Midazolam	DB00683	drug	metamizol	None	True	effect	drug	Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.
DDI-MedLine.d69.s3.p0	Echistatin	None	drug_n	contortrostatin	None	True	effect	drug_n	Echistatin alone had no effect on tyrosine phosphorylation in T24 cells, but dose-dependently inhibits the effects of contortrostatin when both are added simultaneously.
DDI-MedLine.d7.s4.p0	phenytoin	DB00252	drug	theophylline	DB00277	True	effect	drug	With combined use, clinicians should be aware, when phenytoin is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum theophylline concentrations.
DDI-MedLine.d87.s1.p1	ADL-8-2698	None	drug	opioid	None	True	effect	group	ADL-8-2698 is a novel peripherally restricted opioid antagonist that may selectively prevent opioid-induced gastrointestinal effects without reversing analgesia.
DDI-MedLine.d87.s8.p0	ADL 8-2698	None	drug	morphine	DB00295	True	effect	drug	We conclude that ADL 8-2698 prevents morphine-induced increases in gastrointestinal transit time by means of selective peripheral opioid anitagonism without affecting central opioid analgesia.
DDI-MedLine.d89.s2.p0	gentamicin	DB00798	drug	99mTc-MDP	None	True	mechanism	drug	Due to its nephrotoxicity, gentamicin may cause abnormal renal uptake to be seen on 99mTc-MDP bone scintigraphy.
DDI-MedLine.d90.s0.p0	gentamycin	None	drug	atracurium	DB00732	True	int	drug	Interaction of gentamycin and atracurium in anaesthetised horses.
DDI-DrugBank.d382.s34.p2	Aprepitant	DB00673	drug	phenytoin	DB00252	True	mechanism	drug	therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.
DDI-DrugBank.d386.s23.p30	desipramine	DB01151	drug	benzodiazepines	None	True	effect	group	If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.
DDI-DrugBank.d387.s1.p1	Antihistamines	None	group	warfarin	DB00682	True	effect	drug	Antihistamines may partially counteract the anticoagulation effects of heparin or warfarin.
DDI-DrugBank.d387.s2.p0	Doxylamine	DB00366	drug	epinephrine	DB00668	True	effect	drug	Doxylamine may enhance the effects of epinephrine.
DDI-DrugBank.d388.s2.p0	beta-adrenergic antagonists	None	group	alpha-adrenergic stimulants	None	True	effect	group	Exaggerated hypertensive responses have been reported from the combined use of beta-adrenergic antagonists and alpha-adrenergic stimulants, including those contained in proprietary cold remedies and vasoconstrictive nasal drops.
DDI-DrugBank.d39.s1.p4	para-aminosalicylic acid	None	drug	vitamin B12	None	True	mechanism	drug	Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.
DDI-DrugBank.d39.s1.p5	alcohol	None	drug	vitamin B12	None	True	mechanism	drug	Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.
DDI-DrugBank.d393.s2.p0	theophylline	DB00277	drug	cetirizine	DB00341	True	mechanism	drug	In a multiple dose study of theophylline (400 mg once daily for 3 days) and cetirizine (20 mg once daily for 3 days), a 16% decrease in the clearance of cetirizine was observed.
DDI-DrugBank.d394.s0.p0	sodium nitroprusside	None	drug	hypotensive drugs	None	True	effect	group	The hypotensive effect of sodium nitroprusside is augmented by that of most other hypotensive drugs, including ganglionic blocking agents, negative inotropic agents, and inhaled anesthetics.
DDI-DrugBank.d395.s17.p4	aluminum hydroxide	DB06723	drug	enoxacin	DB00467	True	mechanism	drug	Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.
DDI-DrugBank.d395.s23.p5	Quinolones	None	group	R-warfarin	None	True	mechanism	drug	Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.
DDI-DrugBank.d395.s5.p2	caffeine	DB00201	drug	enoxacin	DB00467	True	effect	drug	Caffeine-related adverse effects have occurred in patients consuming caffeine while on therapy with enoxacin.
DDI-DrugBank.d396.s0.p4	narcotic analgesics	None	group	hydrocodone	DB00956	True	effect	drug	Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.
DDI-DrugBank.d397.s5.p0	erythromycin	DB00199	drug	ergotamine	DB00696	True	effect	drug	Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.
DDI-DrugBank.d397.s8.p1	erythromycin	DB00199	drug	cyclosporine	DB00091	True	int	drug	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
DDI-DrugBank.d397.s8.p4	erythromycin	DB00199	drug	phenytoin	DB00252	True	int	drug	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
DDI-DrugBank.d398.s0.p1	codeine	DB00318	drug	antihistamines	None	True	effect	group	The use of codeine may result in additive CNS depressant effects when coadministered with alcohol, antihistamines, psychotropics or other drugs that produce CNS depression.
DDI-DrugBank.d398.s1.p0	dextromethorphan	DB00514	drug	monoamine oxidase inhibitors	None	True	effect	group	Serious toxicity may result if dextromethorphan is coadministered with monoamine oxidase inhibitors (MAOIs).
DDI-DrugBank.d398.s2.p0	dextromethorphan hydrobromide	None	drug	alcohol	None	True	effect	drug	The use of dextromethorphan hydrobromide may result in additive CNS depressant effects when coadministered with alcohol, antihistamines, psychotropics or other drugs that produce CNS depression.
DDI-DrugBank.d40.s10.p8	phenytoin	DB00252	drug	ethosuximide	DB00593	True	mechanism	drug	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
DDI-DrugBank.d40.s19.p7	phenytoin	DB00252	drug	contraceptives	None	True	effect	group	Drugs whose efficacy is impaired by Phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
DDI-DrugBank.d400.s12.p0	NSAIDs	None	group	lithium	DB01356	True	advise	drug	Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.
DDI-DrugBank.d400.s6.p4	NSAIDs	None	group	thiazides	None	True	effect	group	Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.
DDI-DrugBank.d404.s5.p0	thiazides	None	group	vitamin D	None	True	effect	group	Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.
DDI-DrugBank.d41.s0.p9	activated charcoal	None	drug	leflunomide	DB01097	True	mechanism	drug	Cholestyramine and Charcoal Administration of cholestyramine or activated charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide) concentration .
DDI-DrugBank.d410.s1.p4	Sumatriptan	DB00669	drug	dihydroergotamine mesylate	None	True	effect	drug	Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.
DDI-DrugBank.d410.s2.p1	Sumatriptan	DB00669	drug	dihydroergotamine mesylate	None	True	advise	drug	Sumatriptan and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other..
DDI-DrugBank.d410.s5.p26	dihydroergotamine mesylate	None	drug	macrolide class	None	True	mechanism	group	Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.
DDI-DrugBank.d411.s3.p1	levothyroxine sodium	None	drug	anabolic hormones	None	True	mechanism	group	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
DDI-DrugBank.d412.s10.p0	labetalol HCl	None	drug	nitroglycerin	DB00727	True	effect	drug	If labetalol HCl is used with nitroglycerin in patients with angina pectoris, additional antihypertensive effects may occur.
DDI-DrugBank.d412.s7.p0	labetalol HCl	None	drug	halothane	DB01159	True	effect	drug	During controlled hypotensive anesthesia using labetalol HCl in association with halothane, high concentrations (3% or above) of halothane should not be used because the degree of hypotension will be increased and because of the possibility of a large reduction in cardiac output and an increase in central venous pressure.
DDI-DrugBank.d415.s7.p0	ibuprofen	DB01050	drug	methotrexate	DB00563	True	advise	drug	Caution should be used if ibuprofen is administered concomitantly with methotrexate.
DDI-DrugBank.d415.s9.p3	ibuprofen	DB01050	drug	furosemide	DB00695	True	effect	drug	Furosemide: Clinical studies, as well as random observations, have shown that ibuprofen can reduce the natriuretic effect of furosemide and thiazides in some patients.
DDI-DrugBank.d42.s1.p4	dolasetron	DB00757	drug	rifampin	None	True	mechanism	drug	Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.
DDI-DrugBank.d420.s0.p9	cefdinir	DB00535	drug	Maalox TC	None	True	mechanism	brand	Antacids (aluminum- or magnesium-containing): Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.
DDI-DrugBank.d423.s0.p12	MAOIs	None	group	paroxetine	DB00715	True	effect	drug	In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
DDI-DrugBank.d423.s0.p3	monoamine oxidase inhibitors	None	group	fluoxetine	DB00472	True	effect	drug	In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
DDI-DrugBank.d426.s4.p0	frovatriptan	DB00998	drug	SSRI	None	True	advise	group	If concomitant treatment with frovatriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.
DDI-DrugBank.d429.s0.p9	kaolin	DB01575	drug	chloroquine	DB00608	True	mechanism	drug	Antacids and kaolin: Antacids and kaolin can reduce absorption of chloroquine;
DDI-DrugBank.d43.s11.p0	ciprofloxacin	DB00537	drug	didanosine	DB00900	True	mechanism	drug	In a single subject given one dose of ciprofloxacin 2 hours after a dose of didanosine-placebo tablets, a greater than 50% reduction in the AUC of ciprofloxacin was observed.
DDI-DrugBank.d43.s4.p10	magnesium	DB01378	drug	VIDEX	None	True	effect	brand	Antacids: Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.
DDI-DrugBank.d430.s3.p1	calcium	DB01373	drug	alendronate	DB00630	True	mechanism	drug	Products containing calcium and other multivalent cations likely will interfere with absorption of alendronate.
DDI-DrugBank.d430.s3.p2	multivalent cations	None	drug	alendronate	DB00630	True	mechanism	drug	Products containing calcium and other multivalent cations likely will interfere with absorption of alendronate.
DDI-DrugBank.d434.s25.p0	felbamate	DB00949	drug	valproate	None	True	mechanism	drug	Increasing the felbamate dose to 2400 mg/day increased the steadystate valproate Cmin to 96 25 micrograms/mL.
DDI-DrugBank.d434.s30.p22	Phenytoin	DB00252	drug	felbamate	DB00949	True	mechanism	drug	Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.
DDI-DrugBank.d438.s29.p2	cimetidine	DB00501	drug	gabapentin	DB00996	True	mechanism	drug	Cimetidine: In the presence of cimetidine at 300 mg QID (N=12) the mean apparent oral clearance of gabapentin fell by 14% and creatinine clearance fell by 10%.
DDI-DrugBank.d438.s30.p0	cimetidine	DB00501	drug	gabapentin	DB00996	True	mechanism	drug	Thus cimetidine appeared to alter the renal excretion of both gabapentin and creatinine, an endogenous marker of renal function.
DDI-DrugBank.d438.s31.p0	gabapentin	DB00996	drug	cimetidine	DB00501	True	mechanism	drug	This small decrease in excretion of gabapentin by cimetidine is not expected to be of clinical importance.
DDI-DrugBank.d440.s1.p9	iron	DB01592	drug	Ibandronate	DB00710	True	mechanism	drug	Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.
DDI-DrugBank.d440.s13.p14	NSAIDs	None	group	Ibandronate	DB00710	True	advise	drug	However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.
DDI-DrugBank.d440.s2.p0	Ibandronate	DB00710	drug	antacids	None	True	advise	group	Ibandronate should be taken at least 60 minutes before any oral medications containing multivalent cations (including antacids, supplements or vitamins).
DDI-DrugBank.d441.s6.p0	ZYVOX	None	brand	serotonergic agents	None	True	effect	group	Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and serotonergic agents, including antidepressants such as selective serotonin reuptake inhibitors (SSRIs), have been reported.
DDI-DrugBank.d441.s6.p2	ZYVOX	None	brand	selective serotonin reuptake inhibitors	None	True	effect	group	Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and serotonergic agents, including antidepressants such as selective serotonin reuptake inhibitors (SSRIs), have been reported.
DDI-DrugBank.d442.s1.p2	EULEXIN	None	brand	warfarin	DB00682	True	advise	drug	Therefore, close monitoring of prothrombin time is recommended and adjustment of the anticoagulant dose may be necessary when EULEXIN Capsules are administered concomitantly with warfarin.
DDI-DrugBank.d446.s0.p0	Chlorotrianisene	DB00269	drug	antidepressants	None	True	int	group	Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
DDI-DrugBank.d446.s0.p1	Chlorotrianisene	DB00269	drug	aspirin	None	True	int	brand	Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
DDI-DrugBank.d446.s0.p9	Chlorotrianisene	DB00269	drug	nicotine	DB00184	True	int	drug	Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
DDI-DrugBank.d382.s13.p0	Aprepitant	DB00673	drug	methylprednisolone	DB00959	True	mechanism	drug	Aprepitant, when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, increased the AUC of methylprednisolone, a CYP3A4 substrate, by 1.34-fold on Day 1 and by 2.5-fold on Day 3, when methylprednisolone was coadministered intravenously as 125 mg on Day 1 and orally as 40 mg on Days 2 and 3.
DDI-DrugBank.d382.s25.p0	Aprepitant	DB00673	drug	midazolam	DB00683	True	mechanism	drug	Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.
DDI-DrugBank.d382.s31.p5	Aprepitant	DB00673	drug	ritonavir	DB00503	True	advise	drug	Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.
DDI-DrugBank.d382.s9.p11	Aprepitant	DB00673	drug	dexamethasone	DB01234	True	mechanism	drug	Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.
DDI-DrugBank.d386.s11.p0	SSRI	None	group	TCA	None	True	int	group	The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.
DDI-DrugBank.d386.s23.p1	desipramine hydrochloride	None	drug	tranquilizers	None	True	effect	group	If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.
DDI-DrugBank.d386.s23.p31	desipramine	DB01151	drug	chlordiazepoxide	DB00475	True	effect	drug	If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.
DDI-DrugBank.d389.s2.p1	Sympathomimetic amines	None	group	veratrum alkaloids	None	True	effect	group	Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa and mecamylamine.
DDI-DrugBank.d395.s16.p2	zinc	DB01593	drug	quinolone	None	True	mechanism	group	or with multivitamins containing zinc may substantially interfere with drug absorption and result in insufficient plasma and tissue quinolone concentrations.
DDI-DrugBank.d395.s17.p5	magnesium hydroxide	None	drug	enoxacin	DB00467	True	mechanism	drug	Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.
DDI-DrugBank.d395.s18.p0	enoxacin	DB00467	drug	ranitidine	DB00863	True	mechanism	drug	The oral bioavailability of enoxacin is reduced by 60% with coadministration of ranitidine.
DDI-DrugBank.d395.s7.p2	Enoxacin	DB00467	drug	digoxin	DB00390	True	mechanism	drug	Digoxin: Enoxacin may raise serum digoxin levels in some individuals.
DDI-DrugBank.d396.s0.p13	antianxiety agents	None	group	hydrocodone	DB00956	True	effect	drug	Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.
DDI-DrugBank.d396.s0.p18	alcohol	None	drug	hydrocodone	DB00956	True	effect	drug	Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.
DDI-DrugBank.d397.s10.p1	Erythromycin	DB00199	drug	terfenadine	DB00342	True	mechanism	drug	Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.
DDI-DrugBank.d397.s3.p0	erythromycin	DB00199	drug	anticoagulants	None	True	effect	group	There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly.
DDI-DrugBank.d397.s8.p5	erythromycin	DB00199	drug	alfentanil	DB00802	True	int	drug	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
DDI-DrugBank.d4.s0.p2	xanthine bronchodilators	None	group	sympathomimetic bronchodilators	None	True	effect	group	Synergism between xanthine bronchodilators (e.g., theophylline), ephedrine, and other sympathomimetic bronchodilators has been reported.
DDI-DrugBank.d400.s0.p4	NSAIDs	None	group	aspirin	None	True	advise	brand	Aspirin: As with other NSAIDs, concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects.
DDI-DrugBank.d400.s4.p2	NSAIDs	None	group	ACE inhibitors	None	True	effect	group	ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors.
DDI-DrugBank.d401.s0.p1	anticholinergic	None	group	narcotic analgesics	None	True	effect	group	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
DDI-DrugBank.d401.s0.p16	AKINETON	None	brand	antihistamines	None	True	effect	group	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
DDI-DrugBank.d401.s0.p3	anticholinergic	None	group	phenothiazines	None	True	effect	group	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
DDI-DrugBank.d41.s14.p3	ARAVA	None	brand	rifampin	None	True	mechanism	drug	Rifampin: Following concomitant administration of a single dose of ARAVA to subjects receiving multiple doses of rifampin, M1 peak levels were increased (~40%) over those seen when ARAVA was given alone.
DDI-DrugBank.d41.s3.p0	ARAVA	None	brand	methotrexate	DB00563	True	effect	drug	In a small (n=30) combination study of ARAVA with methotrexate, a 2- to 3-fold elevation in liver enzymes was seen in 5 of 30 patients.
DDI-DrugBank.d411.s2.p12	levothyroxine sodium	None	drug	sucralfate	DB00364	True	mechanism	drug	Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of levothyroxine sodium from the gastrointestinal tract: aluminum hydoxide, cholestyramine resin, colestipol hydrochloride, ferrous sulfate, sodium polystyrene sulfonate, soybean flour (e.g., infant formula), sucralfate.
DDI-DrugBank.d411.s2.p8	levothyroxine sodium	None	drug	cholestyramine	DB01432	True	mechanism	drug	Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of levothyroxine sodium from the gastrointestinal tract: aluminum hydoxide, cholestyramine resin, colestipol hydrochloride, ferrous sulfate, sodium polystyrene sulfonate, soybean flour (e.g., infant formula), sucralfate.
DDI-DrugBank.d411.s2.p9	levothyroxine sodium	None	drug	colestipol hydrochloride	None	True	mechanism	drug	Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of levothyroxine sodium from the gastrointestinal tract: aluminum hydoxide, cholestyramine resin, colestipol hydrochloride, ferrous sulfate, sodium polystyrene sulfonate, soybean flour (e.g., infant formula), sucralfate.
DDI-DrugBank.d411.s3.p12	levothyroxine sodium	None	drug	perphenazine	DB00850	True	mechanism	drug	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
DDI-DrugBank.d411.s3.p5	levothyroxine sodium	None	drug	estrogen-containing compounds	None	True	mechanism	group	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
DDI-DrugBank.d412.s4.p0	Cimetidine	DB00501	drug	labetalol HCl	None	True	mechanism	drug	Cimetidine has been shown to increase the bioavailability of labetalol HCl.
DDI-DrugBank.d413.s20.p4	Chlorpropamide	DB00672	drug	allopurinol	DB00437	True	mechanism	drug	Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.
DDI-DrugBank.d413.s20.p9	allopurinol	DB00437	drug	chlorpropamide	DB00672	True	mechanism	drug	Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.
DDI-DrugBank.d414.s2.p0	EDECRIN	None	brand	aminoglycoside	None	True	effect	group	EDECRIN may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics.
DDI-DrugBank.d415.s12.p3	Ibuprofen	DB01050	drug	lithium	DB01356	True	mechanism	drug	Lithium: Ibuprofen produced an elevation of plasma lithium levels and a reduction in renal lithium clearance in a study of eleven normal volunteers.
DDI-DrugBank.d415.s9.p4	ibuprofen	DB01050	drug	thiazides	None	True	effect	group	Furosemide: Clinical studies, as well as random observations, have shown that ibuprofen can reduce the natriuretic effect of furosemide and thiazides in some patients.
DDI-DrugBank.d416.s2.p0	Probenecid	DB01032	drug	PAH	None	True	mechanism	drug	Probenecid depresses tubular secretion of certain weak acids such as PAH.
DDI-DrugBank.d417.s0.p2	Netilmicin	DB00955	drug	ethacrynic acid	DB00903	True	advise	drug	Netilmicin should not be administered concomitantly with potent loop diuretics such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.
DDI-DrugBank.d422.s10.p0	BREVIBLOC	None	brand	digoxin	DB00390	True	advise	drug	Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.
DDI-DrugBank.d422.s13.p0	BREVIBLOC	None	brand	verapamil	DB00661	True	advise	drug	Caution should be exercised when considering the use of BREVIBLOC and verapamil in patients with depressed myocardial function.
DDI-DrugBank.d423.s0.p14	MAOIs	None	group	venlafaxine	DB00285	True	effect	drug	In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
DDI-DrugBank.d423.s0.p19	selegiline hydrochloride	None	drug	sertraline	DB01104	True	effect	drug	In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
DDI-DrugBank.d423.s0.p6	monoamine oxidase inhibitors	None	group	sertraline	DB01104	True	effect	drug	In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
DDI-DrugBank.d423.s2.p0	MAO inhibitor	None	group	dexfenfluramine	DB01191	True	advise	drug	At least 14 days should elapse between discontinuation of a MAO inhibitor and initiation of treatment with dexfenfluramine.
DDI-DrugBank.d448.s1.p2	antihistamines	None	group	barbiturates	None	True	effect	group	Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.
DDI-DrugBank.d45.s1.p1	TNFa-blocking agents	None	group	anakinra	DB00026	True	effect	drug	Other TNFa-blocking agents (including REMICADE) used in combination with anakinra may also result in similar toxicities.
DDI-DrugBank.d450.s5.p1	Propantheline	DB00782	drug	digoxin	DB00390	True	mechanism	drug	Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.
DDI-DrugBank.d450.s5.p2	diphenoxylate	DB01081	drug	digoxin	DB00390	True	mechanism	drug	Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.
DDI-DrugBank.d450.s6.p5	Antacids	None	group	digoxin	DB00390	True	mechanism	drug	Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.
DDI-DrugBank.d458.s22.p0	ketoconazole	DB01026	drug	phenytoin	DB00252	True	mechanism	drug	Concomitant administration of ketoconazole tablets with phenytoin may alter the metabolism of one or both of the drugs.
DDI-DrugBank.d46.s19.p4	non-steroidal anti-inflammatory agent	None	group	loop diuretics	None	True	effect	group	Non-steroidal Anti-inflammatory Drugs: in some patients, The administration of a Non-steroidal Anti-inflammatory agent can reduce The diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.
DDI-DrugBank.d460.s1.p0	Starlix	None	brand	tolbutamide	DB01124	True	mechanism	drug	Starlix is a potential inhibitor of the CYP2C9 isoenzyme in vivo as indicated by its ability to inhibit the in vitro metabolism of tolbutamide.
DDI-DrugBank.d460.s14.p18	non-selective beta-adrenergic-blocking agents	None	group	Starlix	None	True	effect	brand	Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.
DDI-DrugBank.d460.s14.p9	NSAIDs	None	group	Starlix	None	True	effect	brand	Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.
DDI-DrugBank.d460.s15.p10	thyroid products	None	group	Starlix	None	True	effect	brand	Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.
DDI-DrugBank.d462.s4.p0	non-depolarizing muscle relaxants	None	group	piperacillin	DB00319	True	effect	drug	Due to their similar mechanism of action, it is expected that the neuromuscular blockade produced by any of the non-depolarizing muscle relaxants could be prolonged in the presence of piperacillin.
DDI-DrugBank.d462.s5.p3	probenecid	DB01032	drug	PIPRACIL	None	True	mechanism	brand	Probenecid: The oral combination of probenecid before intramuscular injection of PIPRACIL produces an increase in piperacillin peak serum level of about 30%.
DDI-DrugBank.d464.s0.p6	Codeine	DB00318	drug	alcohol	None	True	effect	drug	Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.
DDI-DrugBank.d466.s18.p3	ketoconazole	DB01026	drug	fexofenadine	DB00950	True	mechanism	drug	This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein. in vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.
DDI-DrugBank.d467.s3.p2	rifampin	None	drug	bexarotene	DB00307	True	mechanism	drug	Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.
DDI-DrugBank.d469.s7.p4	TRACRIUM	None	brand	aminoglycosides	None	True	effect	group	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.
DDI-DrugBank.d47.s2.p14	isoniazid	DB00951	drug	levodopa	None	True	effect	drug	Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa.
DDI-DrugBank.d47.s2.p4	Dopamine D2 receptor antagonists	None	group	levodopa	None	True	effect	drug	Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa.
DDI-DrugBank.d47.s3.p0	levodopa	None	drug	phenytoin	DB00252	True	effect	drug	In addition, the beneficial effects of levodopa in Parkinsons disease have been reported to be reversed by phenytoin and papaverine.
DDI-DrugBank.d476.s3.p0	ZEBETA	None	brand	myocardial depressants	None	True	advise	group	ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.
DDI-DrugBank.d476.s3.p1	ZEBETA	None	brand	calcium antagonists	None	True	advise	group	ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.
DDI-DrugBank.d478.s1.p3	ergotamine	DB00696	drug	naratriptan	DB00952	True	advise	drug	Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.
DDI-DrugBank.d478.s3.p0	naratriptan	DB00952	drug	5-HT1 agonists	None	True	advise	group	Because their vasospastic effects may be additive, coadministration of naratriptan and other 5-HT1 agonists within 24 hours of each other is not recommended.
DDI-DrugBank.d48.s1.p2	SPRYCEL	None	brand	erythromycin	DB00199	True	mechanism	drug	Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
DDI-DrugBank.d48.s15.p12	alfentanil	DB00802	drug	SPRYCEL	None	True	advise	brand	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
DDI-DrugBank.d48.s15.p87	ergot alkaloids	None	group	SPRYCEL	None	True	advise	brand	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
DDI-DrugBank.d48.s15.p90	dihydroergotamine	DB00320	drug	SPRYCEL	None	True	advise	brand	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
DDI-DrugBank.d480.s30.p5	clozapine	DB00363	drug	flecainide	DB01195	True	advise	drug	Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
DDI-DrugBank.d480.s9.p0	Clozapine	DB00363	drug	antihypertensive drugs	None	True	effect	group	Clozapine may potentiate the hypotensive effects of antihypertensive drugs and the anticholinergic effects of atropine-type drugs.
DDI-DrugBank.d484.s0.p10	Etonogestrel	DB00294	drug	Topamax	None	True	int	brand	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d484.s0.p11	Etonogestrel	DB00294	drug	Felbatol	None	True	int	brand	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d484.s0.p13	Etonogestrel	DB00294	drug	Gris-PEG	None	True	int	brand	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d484.s0.p17	Etonogestrel	DB00294	drug	Lipitor	None	True	int	brand	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d484.s0.p19	Etonogestrel	DB00294	drug	Atromid-S	None	True	int	brand	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d484.s0.p3	Etonogestrel	DB00294	drug	ampicillin	DB00415	True	int	drug	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d484.s0.p33	Etonogestrel	DB00294	drug	Kadian	None	True	int	brand	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d484.s0.p41	Etonogestrel	DB00294	drug	theophylline	DB00277	True	int	drug	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d484.s0.p8	Etonogestrel	DB00294	drug	Tegretol	None	True	int	brand	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d485.s12.p16	felbamate	DB00949	drug	ethinyl estradiol	DB00977	True	mechanism	drug	Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.
DDI-DrugBank.d485.s17.p9	hormonal contraceptives	None	group	alprazolam	DB00404	True	mechanism	drug	Benzodiazepines: Combination hormonal contraceptives may decrease the clearance of some benzodiazepines (alprazolam, chlordiazepoxide, diazepam) and increase the clearance of others (lorazepam, oxazepam, temazepam).
DDI-DrugBank.d485.s18.p2	hormonal contraceptives	None	group	clofibric acid	None	True	mechanism	drug_n	Clofibric acid: Combination hormonal contraceptives may increase the clearance of clofibric acid.
DDI-DrugBank.d485.s26.p2	hormonal contraceptives	None	group	morphine	DB00295	True	mechanism	drug	Morphine: Combination hormonal contraceptives may increase the clearance of morphine.
DDI-DrugBank.d485.s32.p13	nelfinavir	DB00220	drug	combination hormonal contraceptives	None	True	mechanism	group	Protease inhibitors: Amprenavir, lopinavir, nelfinavir, and ritonavir have been shown to decrease plasma levels of combination hormonal contraceptives;
DDI-DrugBank.d485.s32.p8	Amprenavir	DB00701	drug	combination hormonal contraceptives	None	True	mechanism	group	Protease inhibitors: Amprenavir, lopinavir, nelfinavir, and ritonavir have been shown to decrease plasma levels of combination hormonal contraceptives;
DDI-DrugBank.d485.s34.p0	Indinavir	DB00224	drug	combination hormonal contraceptives	None	True	mechanism	group	Indinavir has been shown to increase plasma levels of combination hormonal contraceptives.
DDI-DrugBank.d485.s36.p4	Rifampin	None	drug	ethinyl estradiol	DB00977	True	mechanism	drug	Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.
DDI-DrugBank.d485.s38.p2	hormonal contraceptives	None	group	salicylic acid	None	True	mechanism	drug	Salicylic acid: Combination hormonal contraceptives may increase the clearance of salicylic acid.
DDI-DrugBank.d485.s41.p12	nortriptyline	DB00540	drug	combination hormonal contraceptives	None	True	mechanism	group	Tricyclic antidepressants (amitriptyline, imipramine, nortriptyline): Metabolism may be inhibited by combination hormonal contraceptives, increasing plasma levels of antidepressant;
DDI-DrugBank.d485.s41.p3	Tricyclic antidepressants	None	group	combination hormonal contraceptives	None	True	mechanism	group	Tricyclic antidepressants (amitriptyline, imipramine, nortriptyline): Metabolism may be inhibited by combination hormonal contraceptives, increasing plasma levels of antidepressant;
DDI-DrugBank.d487.s5.p2	salicylate	None	group	corticosteroid	None	True	effect	drug	This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn.
DDI-DrugBank.d488.s6.p14	antihistamines	None	group	heparin sodium	None	True	effect	drug	Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.
DDI-DrugBank.d489.s2.p0	reserpine	DB00206	drug	beta-blocking	None	True	effect	drug	Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents.
DDI-DrugBank.d492.s1.p5	Antihistamines	None	group	antianxiety agents	None	True	effect	group	Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.
DDI-DrugBank.d493.s4.p1	anakinra	DB00026	drug	HUMIRA	None	True	effect	brand	Therefore the, combination of anakinra with other TNF-blocking agents, including HUMIRA, may also result i n similar toxicities.
DDI-DrugBank.d495.s3.p0	Narcotic analgesics	None	group	clonidine	DB00575	True	effect	drug	Narcotic analgesics may potentiate the hypotensive effects of clonidine.
DDI-DrugBank.d5.s17.p11	bupropion	DB01156	drug	beta-blockers	None	True	advise	group	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
DDI-DrugBank.d5.s17.p15	bupropion	DB01156	drug	flecainide	DB01195	True	advise	drug	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
DDI-DrugBank.d5.s22.p3	WELLBUTRIN	None	brand	steroids	None	True	advise	group	Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.
DDI-DrugBank.d500.s2.p4	tetracyclines	None	group	iron	DB01592	True	mechanism	drug	Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.
DDI-DrugBank.d500.s6.p0	tetracycline	DB00759	drug	contraceptives	None	True	effect	group	Concurrent use of tetracycline may render oral contraceptives less effective.
DDI-DrugBank.d503.s7.p1	chlorprothixene	DB01239	drug	tricyclic antidepressants	None	True	advise	group	Exert particular caution in combining chlorprothixene with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.
DDI-DrugBank.d506.s5.p0	Norpace	None	brand	quinidine	DB00908	True	mechanism	drug	Concomitant administration of Norpace and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels.
DDI-DrugBank.d507.s4.p0	TCAs	None	group	guanfacine	DB01018	True	effect	drug	TCAs decrease the hypotensive effect of guanfacine.
DDI-DrugBank.d508.s1.p11	acetylsalicylic acid	DB00945	drug	Activase	None	True	int	brand	In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole and Abciximab) may increase the risk of bleeding if administered prior to, during, or after Activase therapy.
DDI-DrugBank.d509.s0.p4	ABILIFY	None	brand	alcohol	None	True	advise	drug	Drug-Drug Interactions Given the primary CNS effects of aripiprazole, caution should be used when ABILIFY is taken in combination with other centrally acting drugs and alcohol.
DDI-DrugBank.d509.s19.p4	carbamazepine	DB00564	drug	aripiprazole	DB01238	True	mechanism	drug	Carbamazepine: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole.
DDI-DrugBank.d509.s8.p6	quinidine	DB00908	drug	aripiprazole	DB01238	True	mechanism	drug	Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.
DDI-DrugBank.d51.s3.p0	ATROVENT	None	brand	anticholinergic	None	True	advise	group	Caution is therefore advised in the coadministration of ATROVENT Inhalation Aerosol with other anticholinergic-containing drugs.
DDI-DrugBank.d512.s7.p2	Sensipar	None	brand	itraconazole	DB01167	True	advise	drug	Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, erythromycin, itraconazole;
DDI-DrugBank.d516.s15.p5	cyclosporine	DB00091	drug	quinolone class	None	True	mechanism	group	Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class.
DDI-DrugBank.d516.s3.p20	Sucralfate	DB00364	drug	lomefloxacin	DB00978	True	mechanism	drug	Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.
DDI-DrugBank.d516.s6.p0	antacid	None	group	lomefloxacin	DB00978	True	mechanism	drug	Separating the doses of antacid and lomefloxacin minimizes this decrease in bioavailability;
DDI-DrugBank.d521.s1.p4	glimepiride	DB00222	drug	salsalate	DB01399	True	advise	drug	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
DDI-DrugBank.d522.s24.p4	erythromycin	DB00199	drug	disopyramide	DB00280	True	int	drug	Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.
DDI-DrugBank.d529.s14.p5	nonsteroidal anti-inflammatory drugs	None	group	furosemide	DB00695	True	effect	drug	Diuretics: Studies in normal volunteers have shown that flurbiprofen like other nonsteroidal anti-inflammatory drugs, can interfere with the effects of furosemide.
DDI-DrugBank.d529.s17.p0	flurbiprofen	DB00712	drug	furosemide	DB00695	True	advise	drug	Patients receiving flurbiprofen and furosemide or other diuretics should be observed closely to determine if the desired effect is obtained.
DDI-DrugBank.d529.s3.p0	flurbiprofen	DB00712	drug	anticoagulants	None	True	advise	group	The physician should be cautious when administering flurbiprofen to patients taking anticoagulants.
DDI-DrugBank.d53.s7.p11	azithromycin	DB00207	drug	triazolam	DB00897	True	mechanism	drug	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
DDI-DrugBank.d53.s7.p14	azithromycin	DB00207	drug	zidovudine	DB00495	True	mechanism	drug	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
DDI-DrugBank.d53.s7.p5	azithromycin	DB00207	drug	fluconazole	DB00196	True	mechanism	drug	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
DDI-DrugBank.d388.s4.p0	beta-adrenoceptor blocking agents	None	group	nonsteroidal anti-inflammatory drugs	None	True	effect	group	Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by nonsteroidal anti-inflammatory drugs has been reported.
DDI-DrugBank.d394.s0.p2	sodium nitroprusside	None	drug	anesthetics	None	True	effect	group	The hypotensive effect of sodium nitroprusside is augmented by that of most other hypotensive drugs, including ganglionic blocking agents, negative inotropic agents, and inhaled anesthetics.
DDI-DrugBank.d395.s22.p2	theophylline	DB00277	drug	enoxacin	DB00467	True	effect	drug	Theophylline-related adverse effects have occurred in patients when theophylline and enoxacin were coadministered.
DDI-DrugBank.d396.s0.p16	CNS depressants	None	group	hydrocodone	DB00956	True	effect	drug	Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.
DDI-DrugBank.d396.s2.p4	tricyclic antidepressants	None	group	hydrocodone	DB00956	True	effect	drug	The use of MAO inhibitors or tricyclic antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone.
DDI-DrugBank.d397.s0.p0	Erythromycin	DB00199	drug	theophylline	DB00277	True	effect	drug	Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity.
DDI-DrugBank.d397.s1.p5	theophylline	DB00277	drug	erythromycin	DB00199	True	advise	drug	In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.
DDI-DrugBank.d397.s10.p2	Erythromycin	DB00199	drug	astemizole	DB00637	True	mechanism	drug	Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.
DDI-DrugBank.d397.s13.p5	cisapride	DB00604	drug	erythromycin	DB00199	True	mechanism	drug	There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.
DDI-DrugBank.d536.s10.p2	Acarbose	DB00284	drug	metformin	DB00331	True	mechanism	drug	However, the peak plasma level of metformin was reduced by approximately 20% when taking Acarbose due to a slight delay in the absorption of metformin.
DDI-DrugBank.d537.s0.p0	Bentiromide	DB00522	drug	acetaminophen	DB00316	True	int	drug	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
DDI-DrugBank.d537.s0.p1	Bentiromide	DB00522	drug	Tylenol	None	True	int	brand	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
DDI-DrugBank.d537.s0.p4	Bentiromide	DB00522	drug	anesthetics	None	True	int	group	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
DDI-DrugBank.d537.s0.p7	Bentiromide	DB00522	drug	para-aminobenzoic acid	None	True	int	drug_n	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
DDI-DrugBank.d538.s1.p1	Diphenoxylate HCl	None	drug	MAO inhibitors	None	True	int	group	Diphenoxylate HCl and atropine sulfate may interact with MAO inhibitors In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day.
DDI-DrugBank.d54.s19.p2	thyroid preparation	None	group	anesthetic	None	True	effect	group	Ketamine: When administered to patients on a thyroid preparation, this parenteral anesthetic may cause hypertension and tachycardia.
DDI-DrugBank.d54.s21.p3	Thyroxine	None	drug	epinephrine	DB00668	True	effect	drug	Vasopressors: Thyroxine increases the adrenergic effect of catecholamines such as epinephrine and norepinephrine.
DDI-DrugBank.d54.s8.p5	Cholestyramine	DB01432	drug	T3	None	True	mechanism	drug	Cholestyramine: Cholestyramine binds both T4 and T3 in the intestine, thus impairing absorption of these thyroid hormones.
DDI-DrugBank.d548.s4.p0	Paroxetine	DB00715	drug	duloxetine	DB00476	True	mechanism	drug	Paroxetine (20 mg QD) increased the concentration of duloxetine (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine.
DDI-DrugBank.d549.s1.p1	iloprost	DB01088	drug	antihypertensive agents	None	True	effect	group	However, iloprost has the potential to increase the hypotensive effect of vasodilators and antihypertensive agents.
DDI-DrugBank.d552.s0.p4	Nabilone	DB00486	drug	narcotic analgesics	None	True	advise	group	Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).
DDI-DrugBank.d552.s1.p1	Nabilone	DB00486	drug	secobarbitone sodium	None	True	effect	brand	Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.
DDI-DrugBank.d558.s5.p6	TIKOSYN	None	brand	cimetidine	DB00501	True	advise	drug	If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.
DDI-DrugBank.d559.s0.p0	butalbital	DB00241	drug	monoamine oxidase (MAO) inhibitors	None	True	effect	group	The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors.
DDI-DrugBank.d559.s1.p14	acetaminophen	DB00316	drug	chlordiazepoxide	DB00475	True	effect	drug	Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
DDI-DrugBank.d561.s1.p2	diuretic	None	group	Lotensin	None	True	advise	brand	The possibility of hypotensive effects with Lotensin can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with Lotensin.
DDI-DrugBank.d562.s5.p2	cinoxacin	DB00827	drug	caffeine	DB00201	True	advise	drug	Although this interaction has not been reported with cinoxacin, caution should be exercised when cinoxacin is given concomitantly with caffeine-containing products.
DDI-DrugBank.d562.s6.p1	Antacids	None	group	quinolones	None	True	mechanism	group	Antacids or sucralfate substantially interfere with the absorption of some quinolones, resulting in low urine levels.
DDI-DrugBank.d562.s6.p2	sucralfate	DB00364	drug	quinolones	None	True	mechanism	group	Antacids or sucralfate substantially interfere with the absorption of some quinolones, resulting in low urine levels.
DDI-DrugBank.d562.s7.p2	quinolones	None	group	zinc	DB01593	True	mechanism	drug	Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.
DDI-DrugBank.d562.s7.p3	quinolones	None	group	Videx	None	True	mechanism	brand	Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.
DDI-DrugBank.d562.s8.p4	cinoxacin	DB00827	drug	warfarin	DB00682	True	effect	drug	Quinolones, including cinoxacin, may enhance the effects of oral anticoagulants, such as warfarin or its derivatives.
DDI-DrugBank.d565.s30.p0	diltiazem	DB00343	drug	carbamazepine	DB00564	True	mechanism	drug	Concomitant administration of diltiazem with carbamazepine has been reported to result in elevated serum levels of carbamazepine (40% to 72% increase), resulting in toxicity in some cases.
DDI-DrugBank.d565.s33.p1	diltiazem	DB00343	drug	triazolam	DB00897	True	mechanism	drug	Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.
DDI-DrugBank.d566.s0.p2	Cholestyramine	DB01432	drug	warfarin	DB00682	True	mechanism	drug	Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
DDI-DrugBank.d566.s0.p8	Cholestyramine	DB01432	drug	thyroxine	None	True	mechanism	drug	Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
DDI-DrugBank.d567.s16.p0	anticoagulants	None	group	lovastatin	DB00227	True	advise	drug	It is recommended that in patients taking anticoagulants, prothrombin time be determined before starting lovastatin and frequently enough during early therapy to insure that no significant alteration of prothrombin time occurs.
DDI-DrugBank.d568.s1.p14	alcohol	None	drug	LEXAPRO	None	True	advise	brand	Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.
DDI-DrugBank.d568.s17.p0	sumatriptan	DB00669	drug	SSRI	None	True	advise	group	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.
DDI-DrugBank.d568.s17.p4	sumatriptan	DB00669	drug	sertraline	DB01104	True	advise	drug	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.
DDI-DrugBank.d568.s7.p3	citalopram	DB00215	drug	cimetidine	DB00501	True	mechanism	drug	Cimetidine - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively.
DDI-DrugBank.d572.s9.p2	ezetimibe	DB00973	drug	cyclosporine	DB00091	True	mechanism	drug	Cyclosporine: The total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications, including cyclosporine.
DDI-DrugBank.d576.s1.p3	SALICYLATE DRUGS	None	group	DISALCID	None	True	effect	brand	ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS.
DDI-DrugBank.d576.s6.p4	Salicylate	None	group	phenytoin	DB00252	True	mechanism	drug	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.
DDI-DrugBank.d577.s1.p1	sulfamethoxazole	DB01015	drug	warfarin	DB00682	True	effect	drug	It has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin.
DDI-DrugBank.d578.s4.p6	phenytoin	DB00252	drug	methylprednisolone	DB00959	True	advise	drug	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response.
DDI-DrugBank.d578.s4.p7	rifampin	None	drug	methylprednisolone	DB00959	True	mechanism	drug	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response.
DDI-DrugBank.d585.s0.p11	anticholinergic drugs	None	group	nitrites	None	True	effect	group	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
DDI-DrugBank.d585.s0.p8	anticholinergic drugs	None	group	narcotic analgesics	None	True	effect	group	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
DDI-DrugBank.d587.s0.p13	methsuximide	DB05246	drug	phenobarbital	DB01174	True	mechanism	drug	Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).
DDI-DrugBank.d588.s10.p1	Salicylates	None	group	MYKROX	None	True	effect	brand	Salicylates and Other Non-Steroidal Anti-Inflammatory Drugs: May decrease the antihypertensive effects of MYKROX Tablets.
DDI-DrugBank.d588.s13.p4	Metolazone	DB00524	drug	anticoagulants	None	True	effect	group	Anticoagulants: Metolazone, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to anticoagulants;
DDI-DrugBank.d591.s0.p0	Ropivacaine	DB00296	drug	anesthetics	None	True	advise	group	Ropivacaine should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics, since the toxic effects of these drugs are additive.
DDI-DrugBank.d591.s2.p0	ropivacaine	DB00296	drug	fluvoxamine	DB00176	True	mechanism	drug	In vivo, the plasma clearance of ropivacaine was reduced by 70% during coadministration of fluvoxamine (25 mg bid for 2 days), a selective and potent CYP1A2 inhibitor.
DDI-DrugBank.d596.s9.p13	cholinesterase inhibitors	None	group	cholinergic agonists	None	True	effect	group	Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.
DDI-DrugBank.d597.s19.p3	NSAIDs	None	group	lithium	DB01356	True	mechanism	drug	Lithium: In clinical trials, NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.
DDI-DrugBank.d597.s30.p0	MOBIC	None	brand	warfarin	DB00682	True	advise	drug	Caution should be used when administering MOBIC with warfarin since patients on warfarin may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.
DDI-DrugBank.d597.s5.p0	aspirin	None	brand	MOBIC	None	True	effect	brand	Concomitant administration of low-dose aspirin with MOBIC may result in an increased rate of GI ulceration or other complications, compared to use of MOBIC alone.
DDI-DrugBank.d599.s7.p1	GH	None	drug	sex steroids	None	True	mechanism	group	These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin).
DDI-DrugBank.d60.s0.p0	NIMBEX	None	brand	succinylcholine	DB00202	True	effect	drug	Administration of 0.1-mg/kg (2 x ED95) NIMBEX at 10% or 95% recovery following an intubating dose of succinylcholine (1 mg/kg) produced  95% neuromuscular block.
DDI-DrugBank.d60.s12.p17	NIMBEX	None	brand	tetracyclines	None	True	effect	group	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d60.s12.p25	NIMBEX	None	brand	lithium	DB01356	True	effect	drug	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d60.s12.p28	NIMBEX	None	brand	quinidine	DB00908	True	effect	drug	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d60.s12.p5	nondepolarizing agents	None	group	polymyxins	None	True	effect	group	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d60.s6.p3	Isoflurane	DB00753	drug	NIMBEX	None	True	effect	brand	Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.
DDI-DrugBank.d600.s1.p2	CNS depression-producing drugs	None	group	methyprylon	DB01107	True	effect	drug	Concurrent use of alcohol and other CNS depression-producing drugs may increase the CNS depressant effects of methyprylon or these other medications.
DDI-DrugBank.d601.s0.p5	Barbiturates	None	group	anticoagulants	None	True	int	group	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.
DDI-DrugBank.d603.s2.p4	phenylephrine	DB00388	drug	ProAmatine	None	True	effect	brand	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction.
DDI-DrugBank.d603.s5.p65	desglymidodrine	None	drug_n	ranitidine	DB00863	True	mechanism	drug	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.
DDI-DrugBank.d605.s0.p2	SKELAXIN	None	brand	CNS depressants	None	True	effect	group	SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.
DDI-DrugBank.d613.s0.p0	vigabatrin	DB01080	drug	carbamazepine	DB00564	True	mechanism	drug	A study published in 2002 found that vigabatrin causes a statistically significant increase in plasma clearance of carbamazepine.
DDI-DrugBank.d618.s1.p14	abciximab	DB00054	drug	Retavase	None	True	effect	brand	In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.
DDI-DrugBank.d624.s0.p7	TOBI	None	brand	dornase alfa	DB00003	True	effect	drug	In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
DDI-DrugBank.d624.s0.p8	TOBI	None	brand	PULMOZYME	None	True	effect	brand	In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
DDI-DrugBank.d627.s0.p0	Pilocarpine	DB01085	drug	beta adrenergic antagonists	None	True	advise	group	Pilocarpine should be administered with caution to patients taking beta adrenergic antagonists because of the possibility of conduction disturbances.
DDI-DrugBank.d628.s0.p3	DIPRIVAN	None	brand	fentanyl	DB00813	True	effect	drug	The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.)
DDI-DrugBank.d629.s0.p1	metronidazole	DB00916	drug	warfarin	DB00682	True	effect	drug	Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time.
DDI-DrugBank.d630.s1.p5	aspirin	None	brand	carbonic anhydrase inhibitors	None	True	effect	group	Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.
DDI-DrugBank.d633.s13.p0	cimetidine	DB00501	drug	Mexitil	None	True	mechanism	brand	Concurrent administration of cimetidine and Mexitil    has been reported to increase, decrease, or leave unchanged Mexitil    plasma levels;
DDI-DrugBank.d633.s9.p5	rifampin	None	drug	Mexitil	None	True	mechanism	brand	When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported.
DDI-DrugBank.d636.s3.p0	Mephenytoin	DB00532	drug	steroid medications	None	True	effect	group	Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.
DDI-DrugBank.d637.s1.p0	neuroleptics	None	group	morphine	DB00295	True	effect	drug	Use of neuroleptics in conjunction with oral morphine may increase the risk of respiratory depression, hypotension and profound sedation or coma.
DDI-DrugBank.d637.s2.p17	nalbuphine	DB00844	drug	opioid agonist analgesic	None	True	advise	group	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.
DDI-DrugBank.d638.s2.p3	Ritalin	None	brand	diphenylhydantoin	None	True	mechanism	drug	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).
DDI-DrugBank.d638.s2.p8	Ritalin	None	brand	clomipramine	DB01242	True	mechanism	drug	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).
DDI-DrugBank.d639.s0.p3	SUTENT	None	brand	atazanavir	DB01072	True	mechanism	drug	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
DDI-DrugBank.d639.s0.p5	SUTENT	None	brand	nefazodone	DB01149	True	mechanism	drug	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
DDI-DrugBank.d639.s0.p6	SUTENT	None	brand	nelfinavir	DB00220	True	mechanism	drug	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
DDI-DrugBank.d64.s29.p11	anticoagulant	None	group	ethchlorvynol	DB00189	True	effect	drug	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
DDI-DrugBank.d64.s29.p14	anticoagulant	None	group	haloperidol	DB00502	True	effect	drug	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
DDI-DrugBank.d64.s29.p15	anticoagulant	None	group	meprobamate	DB00371	True	effect	drug	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
DDI-DrugBank.d64.s29.p2	anticoagulant	None	group	antacids	None	True	effect	group	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
DDI-DrugBank.d64.s29.p22	anticoagulant	None	group	warfarin sodium	None	True	effect	drug	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
DDI-DrugBank.d64.s29.p5	anticoagulant	None	group	carbamazepine	DB00564	True	effect	drug	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
DDI-DrugBank.d64.s3.p0	cholestyramine	DB01432	drug	anticoagulants	None	True	mechanism	group	For example, since cholestyramine may reduce the gastrointestinal absorption of both the oral anticoagulants and vitamin K, the net effects are unpredictable.
DDI-DrugBank.d64.s3.p1	cholestyramine	DB01432	drug	vitamin K	None	True	mechanism	group	For example, since cholestyramine may reduce the gastrointestinal absorption of both the oral anticoagulants and vitamin K, the net effects are unpredictable.
DDI-DrugBank.d64.s87.p11	anticoagulant	None	group	cinchophen	None	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p13	anticoagulant	None	group	dextran	None	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p14	anticoagulant	None	group	dextrothyroxine	DB00509	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p16	anticoagulant	None	group	diflunisal	DB00861	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p18	anticoagulant	None	group	ethacrynic acid	DB00903	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p21	anticoagulant	None	group	ibuprofen	DB01050	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p3	anticoagulant	None	group	amiodarone	DB01118	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p38	anticoagulant	None	group	phenytoin	DB00252	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p49	anticoagulant	None	group	tolbutamide	DB01124	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p53	anticoagulant	None	group	warfarin sodium	None	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p7	anticoagulant	None	group	chloral hydrate	DB01563	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s90.p21	dipyridamole	DB00975	drug	anticoagulants	None	True	effect	group	Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal anti-inflammatory drugs, dipyridamole, hydrochloroquine, clofibrate, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.
DDI-DrugBank.d640.s3.p11	triamterene	DB00384	drug	ACE inhibitors	None	True	effect	group	Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.
DDI-DrugBank.d640.s8.p0	diuretic	None	group	lithium	DB01356	True	effect	drug	If a diuretic is also used, the risk of lithium toxicity may be increased.
DDI-DrugBank.d641.s5.p5	NSAIDs	None	group	ALIMTA	None	True	advise	brand	In the absence of data regarding potential interaction between ALIMTA and NSAIDs with longer half-lives, all patients taking these NSAIDs should interrupt dosing for at least 5 days before, the day of, and 2 days following ALIMTA administration.
DDI-DrugBank.d643.s0.p115	melatonin	DB01065	drug	progestin	None	True	effect	group	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
DDI-DrugBank.d643.s0.p0	Melatonin	DB01065	drug	aspirin	None	True	int	brand	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
DDI-DrugBank.d645.s7.p0	Terbinafine	DB00857	drug	rifampin	None	True	mechanism	drug	Terbinafine clearance is increased 100% by rifampin, a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor.
DDI-DrugBank.d648.s6.p0	EVISTA	None	brand	clofibrate	DB00636	True	advise	drug	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide.
DDI-DrugBank.d648.s6.p4	EVISTA	None	brand	diazepam	DB00829	True	advise	drug	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide.
DDI-DrugBank.d650.s0.p20	butyrophenones	None	group	Permax	None	True	advise	brand	Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist);
DDI-DrugBank.d652.s6.p0	metoclopramide	DB01233	drug	insulin	None	True	advise	drug	Because the action of metoclopramide will influence the delivery of food to the intestines and thus the rate of absorption, insulin dosage or timing of dosage may require adjustment.
DDI-DrugBank.d653.s2.p2	ketoconazole	DB01026	drug	corticosteroids	None	True	mechanism	group	Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.
DDI-DrugBank.d653.s6.p0	Aspirin	None	brand	corticosteroids	None	True	advise	group	Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia.
DDI-DrugBank.d653.s8.p0	anticoagulants	None	group	corticosteroids	None	True	effect	group	There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids.
DDI-DrugBank.d643.s0.p133	melatonin	DB01065	drug	corticosteroids	None	True	effect	group	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
DDI-DrugBank.d643.s0.p3	Melatonin	DB01065	drug	fluvoxamine	DB00176	True	int	drug	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
DDI-DrugBank.d645.s5.p0	Terbinafine	DB00857	drug	cyclosporine	DB00091	True	mechanism	drug	Terbinafine increases the clearance of cyclosporine by 15%.
DDI-DrugBank.d648.s6.p5	EVISTA	None	brand	diazoxide	DB01119	True	advise	drug	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide.
DDI-DrugBank.d652.s1.p0	metoclopramide	DB01233	drug	alcohol	None	True	effect	drug	Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers.
DDI-DrugBank.d652.s3.p0	digoxin	DB00390	drug	metoclopramide	DB01233	True	mechanism	drug	Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).
DDI-DrugBank.d653.s4.p0	Corticosteroids	None	group	aspirin	None	True	mechanism	brand	Corticosteroids may increase the clearance of chronic high dose aspirin.
DDI-DrugBank.d655.s0.p12	Methscopolamine	None	drug	diphenhydramine	DB01075	True	int	drug	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
DDI-DrugBank.d655.s0.p6	Methscopolamine	None	drug	isocarboxazid	DB01247	True	int	drug	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
DDI-DrugBank.d659.s0.p0	TRENTAL	None	brand	anticoagulants	None	True	effect	group	Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without anticoagulants or platelet aggregation inhibitors.
DDI-DrugBank.d665.s0.p2	bacteriostatic antibiotics	None	group	penicillins	None	True	effect	group	Concurrent administration of bacteriostatic antibiotics (e.g., erythromycin, tetracycline) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth.
DDI-DrugBank.d668.s0.p6	ketoconazole	DB01026	drug	mifepristone	DB00834	True	mechanism	drug	Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone).
DDI-DrugBank.d668.s2.p12	carbamazepine	DB00564	drug	mifepristone	DB00834	True	mechanism	drug	John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone).
DDI-DrugBank.d675.s7.p2	Methergine	None	brand	ergot alkaloids	None	True	advise	group	Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.
DDI-DrugBank.d688.s2.p0	indinavir	DB00224	drug	megestrol acetate	DB00351	True	advise	drug	Administration of a higher dose of indinavir should be considered when coadministering with megestrol acetate.
DDI-DrugBank.d699.s0.p1	Mequitazine	DB01071	drug	antichlolinergic	None	True	int	group	Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.
DDI-DrugBank.d699.s0.p2	Mequitazine	DB01071	drug	TCA	None	True	int	group	Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.
DDI-DrugBank.d699.s0.p4	Mequitazine	DB01071	drug	alcohol	None	True	int	drug	Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.
DDI-DrugBank.d7.s2.p0	Cyclophosphamide	DB00531	drug	succinylcholine chloride	None	True	effect	drug	Cyclophosphamide treatment, which causes a marked and persistent inhibition of cholinesterase activity, potentiates the effect of succinylcholine chloride.
DDI-DrugBank.d700.s0.p5	Myfortic	None	brand	magnesium	DB01378	True	mechanism	drug	Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.
DDI-DrugBank.d700.s1.p0	Myfortic	None	drug	antacids	None	True	advise	group	It is recommended that Myfortic and antacids not be administered simultaneously.
DDI-DrugBank.d700.s8.p0	Myfortic	None	drug	cholestyramine	DB01432	True	advise	drug	Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic.
DDI-DrugBank.d703.s0.p14	MEPERIDINE	None	drug	SEDATIVE-HYPNOTICS	None	True	advise	group	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
DDI-DrugBank.d703.s0.p16	MEPERIDINE	None	drug	TRICYCLIC ANTIDEPRESSANTS	None	True	advise	group	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
DDI-DrugBank.d709.s4.p6	pimozide	DB01100	drug	macrolide antibacterials	None	True	mechanism	group	Cisapride, pimozide: other Drugs such as Cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of The isozyme, including some macrolide antibacterials.
DDI-DrugBank.d710.s9.p0	rimantadine	DB00478	drug	aspirin	None	True	mechanism	brand	Peak plasma concentrations and AUC of rimantadine were reduced approximately 10% in the presence of aspirin.
DDI-DrugBank.d711.s1.p2	tetracycline class drugs	None	group	penicillin	None	True	advise	drug	Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline class drugs in conjunction with penicillin.
DDI-DrugBank.d711.s2.p1	tetracyclines	None	group	aluminum	None	True	mechanism	drug	Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations.
DDI-DrugBank.d711.s2.p2	tetracyclines	None	group	calcium	DB01373	True	mechanism	drug	Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations.
DDI-DrugBank.d713.s2.p14	Sanctura	None	brand	tenofovir	DB00300	True	mechanism	drug	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).
DDI-DrugBank.d715.s1.p0	DEMSER	None	brand	alcohol	None	True	effect	drug	Concurrent use of DEMSER with alcohol or other CNS depressants can increase their sedative effects.
DDI-DrugBank.d716.s0.p7	mazindol	DB00579	drug	Nardil	None	True	advise	brand	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.
DDI-DrugBank.d720.s2.p0	MAO-A inhibitors	None	group	sumatriptan	DB00669	True	mechanism	drug	MAO-A inhibitors reduce sumatriptan clearance, significantly increasing systemic exposure.
DDI-DrugBank.d720.s3.p25	SSRIs	None	group	sumatriptan	DB00669	True	effect	drug	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.
DDI-DrugBank.d720.s3.p29	fluoxetine	DB00472	drug	sumatriptan	DB00669	True	effect	drug	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.
DDI-DrugBank.d722.s0.p1	PURINETHOL	None	brand	TABLOID	None	True	effect	brand	There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine.
DDI-DrugBank.d722.s0.p2	PURINETHOL	None	brand	Thioguanine	DB00352	True	effect	drug	There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine.
DDI-DrugBank.d723.s0.p11	carbachol	DB00411	drug	suprofen	DB00870	True	effect	drug	Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.
DDI-DrugBank.d726.s1.p0	ketoconazole	DB01026	drug	paricalcitol	DB00910	True	mechanism	drug	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
DDI-DrugBank.d726.s1.p61	paricalcitol	DB00910	drug	ritonavir	DB00503	True	advise	drug	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
DDI-DrugBank.d726.s3.p0	fat-soluble vitamins	None	group	cholestyramine	DB01432	True	mechanism	drug	Drugs that impair intestinal absorption of fat-soluble vitamins, such as cholestyramine, may interfere with the absorption of Zemplar Capsules.
DDI-DrugBank.d73.s0.p0	reserpine	DB00206	drug	beta-blocking agent	None	True	effect	group	Catecholamine-depleting drugs (eg, reserpine) may have an additive effect when given with beta-blocking agents.
DDI-DrugBank.d73.s6.p0	indomethacin	DB00328	drug	beta blockers	None	True	effect	group	Concomitant use of prostaglandin synthase inhibiting drugs, eg, indomethacin, may decrease the hypotensive effects of beta blockers.
DDI-DrugBank.d732.s2.p0	CHEMET	None	brand	CaNa 2 EDTA	None	True	advise	drug	Concomitant administration of CHEMET with other chelation therapy, such as CaNa 2 EDTA is not recommended.
DDI-DrugBank.d734.s0.p0	Thiazide diuretics	None	group	phenothiazines	None	True	effect	group	Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines.
DDI-DrugBank.d734.s2.p0	propranolol	DB00571	drug	phenothiazines	None	True	mechanism	group	Concomitant administration of propranolol with phenothiazines results in increased plasma levels of both drugs.
DDI-DrugBank.d735.s3.p0	Sirolimus	DB00877	drug	MYCAMINE	None	True	mechanism	brand	Sirolimus AUC was increased by 21% with no effect on Cmax in the presence of steady-state MYCAMINE compared with sirolimus alone.
DDI-DrugBank.d735.s4.p0	Nifedipine	DB01115	drug	MYCAMINE	None	True	mechanism	brand	Nifedipine AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state MYCAMINE compared with nifedipine alone.
DDI-DrugBank.d737.s6.p29	diltiazem	DB00343	drug	pramipexole	DB00413	True	mechanism	drug	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
DDI-DrugBank.d742.s10.p0	REMERON	None	brand	diazepam	DB00829	True	effect	drug	However, the impairment of motor skills produced by REMERON has been shown to be additive with those caused by diazepam.
DDI-DrugBank.d742.s8.p0	REMERON	None	brand	alcohol	None	True	effect	drug	However, the impairment of cognitive and motor skills produced by REMERON    were shown to be additive with those produced by alcohol.
DDI-DrugBank.d746.s1.p2	tricyclic antidepressants	None	group	sympathomimetic amines	None	True	effect	group	Monoamine oxidase inhibitors or tricyclic antidepressants may potentiate the action of sympathomimetic amines.
DDI-DrugBank.d75.s14.p4	milrinone	DB00235	drug	anagrelide	DB00261	True	effect	drug	The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.
DDI-DrugBank.d752.s3.p2	nelfinavir	DB00220	drug	midazolam	DB00683	True	mechanism	drug	Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam.
DDI-DrugBank.d655.s0.p14	Methscopolamine	None	drug	potassium chloride	DB00761	True	int	drug	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
DDI-DrugBank.d655.s0.p16	Methscopolamine	None	drug	absorbent-type anti-diarrhea medicines	None	True	int	group	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
DDI-DrugBank.d655.s0.p5	Methscopolamine	None	drug	tranylcypromine	DB00752	True	int	drug	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
DDI-DrugBank.d655.s0.p7	Methscopolamine	None	drug	selegiline	DB01037	True	int	drug	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
DDI-DrugBank.d670.s6.p2	paliperidone	DB01267	drug	alcohol	None	True	advise	drug	Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol.
DDI-DrugBank.d680.s5.p1	proton pump inhibitors	None	group	warfarin	DB00682	True	effect	drug	There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including pantoprazole, and warfarin concomitantly.
DDI-DrugBank.d688.s1.p0	megestrol acetate	DB00351	drug	indinavir	DB00224	True	mechanism	drug	A pharmacokinetic study demonstrated that coadministration of megestrol acetate and indinavir results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of indinavir.
DDI-DrugBank.d689.s1.p3	sympathomimetic pressor amines	None	group	monoamine oxidase inhibitors	None	True	effect	group	MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI).
DDI-DrugBank.d69.s0.p0	Cerubidine	None	brand	doxorubicin	DB00997	True	effect	drug	Use of Cerubidine in a patient who has previously received doxorubicin increases the risk of cardiotoxicity.
DDI-DrugBank.d690.s0.p1	propoxyphene	None	drug	alcohol	None	True	effect	drug	The CNS-depressant effect of propoxyphene is additive with that of other CNS depressants, including alcohol.
DDI-DrugBank.d695.s0.p0	ZAVESCA	None	brand	Cerezyme	None	True	mechanism	brand	While co-administration of ZAVESCA    appeared to increase the clearance of Cerezyme by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme.
DDI-DrugBank.d697.s0.p5	Thiamine	DB00152	drug	Loop Diuretics	None	True	int	group	Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants
DDI-DrugBank.d700.s6.p18	Myfortic	None	brand	azathioprine	DB00993	True	advise	drug	Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.
DDI-DrugBank.d703.s0.p15	MEPERIDINE	None	drug	BARBITURATES	None	True	advise	group	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
DDI-DrugBank.d704.s6.p0	warfarin	DB00682	drug	FLOMAX	None	True	advise	brand	Therefore, caution should be exercised with concomitant administration of warfarin and FLOMAX capsules.
DDI-DrugBank.d706.s0.p0	reserpine	DB00206	drug	beta-blocking agents	None	True	effect	group	Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents.
DDI-DrugBank.d71.s6.p0	lamivudine	DB00709	drug	zalcitabine	DB00943	True	advise	drug	Therefore, use of lamivudine in combination with zalcitabine is not recommended
DDI-DrugBank.d711.s3.p0	tetracycline	DB00759	group	methoxyflurane	DB01028	True	effect	drug	The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.
DDI-DrugBank.d713.s2.p10	Sanctura	None	brand	pancuronium	DB01337	True	mechanism	drug	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).
DDI-DrugBank.d713.s2.p13	Sanctura	None	brand	metformin	DB00331	True	mechanism	drug	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).
DDI-DrugBank.d715.s0.p0	DEMSER	None	brand	phenothiazines	None	True	advise	group	Caution should be observed in administering DEMSER to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis.
DDI-DrugBank.d715.s0.p1	DEMSER	None	brand	haloperidol	DB00502	True	advise	drug	Caution should be observed in administering DEMSER to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis.
DDI-DrugBank.d716.s2.p0	Mazindol	DB00579	drug	guanethidine	DB01170	True	effect	drug	Mazindol may reduce the effects of guanethidine (Ismelin).
DDI-DrugBank.d72.s2.p0	Phenytoin	DB00252	drug	busulfan	DB01008	True	mechanism	drug	Phenytoin increases the clearance of busulfan by 15% or more, possibly due to the induction of glutathione-S-transferase.
DDI-DrugBank.d721.s0.p0	SKELID	None	brand	calcium	DB01373	True	mechanism	drug	The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID.
DDI-DrugBank.d725.s0.p1	Vasopressors	None	group	halothane	DB01159	True	effect	drug	Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all.
DDI-DrugBank.d726.s1.p55	paricalcitol	DB00910	drug	atazanavir	DB01072	True	advise	drug	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
DDI-DrugBank.d397.s5.p1	erythromycin	DB00199	drug	dihydroergotamine	DB00320	True	effect	drug	Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.
DDI-DrugBank.d397.s8.p10	erythromycin	DB00199	drug	valproate	None	True	int	drug	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
DDI-DrugBank.d397.s8.p8	erythromycin	DB00199	drug	lovastatin	DB00227	True	int	drug	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
DDI-DrugBank.d399.s1.p0	dapsone	DB00250	drug	clofazimine	DB00845	True	advise	drug	If leprosy-associated inflammatory reactions develop in patients being treated with dapsone and clofazimine, it is still advisable to continue treatment with both drugs.
DDI-DrugBank.d40.s10.p12	phenytoin	DB00252	drug	isoniazid	DB00951	True	mechanism	drug	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
DDI-DrugBank.d40.s10.p16	phenytoin	DB00252	drug	salicylates	None	True	mechanism	group	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
DDI-DrugBank.d40.s10.p5	phenytoin	DB00252	drug	dicumarol	None	True	mechanism	drug	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
DDI-DrugBank.d76.s1.p1	serotonin reuptake inhibitor drug	None	group	MAOI	None	True	effect	group	In patients receiving another serotonin reuptake inhibitor drug in combination with monoamine oxidase inhibitors (MAOI), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma.
DDI-DrugBank.d76.s10.p2	fluvoxamine	DB00176	drug	alprazolam	DB00404	True	int	drug	Although it has not been definitively demonstrated that fluvoxamine is a potent IIIA4 inhibitor, it is likely to be, given the substantial interaction of fluvoxamine with alprazolam.
DDI-DrugBank.d76.s11.p0	fluvoxamine	DB00176	drug	terbinafine	DB00857	True	advise	drug	Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.
DDI-DrugBank.d76.s11.p2	fluvoxamine	DB00176	drug	cisapride	DB00604	True	advise	drug	Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.
DDI-DrugBank.d763.s3.p25	rifampicin	DB01045	drug	ondansetron	DB00904	True	mechanism	drug	Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.
DDI-DrugBank.d765.s1.p41	clarithromycin	DB01211	drug	DETROL LA	None	True	advise	brand	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.
DDI-DrugBank.d765.s1.p8	ketoconazole	DB01026	drug	DETROL LA	None	True	advise	brand	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.
DDI-DrugBank.d766.s1.p4	trimetrexate	DB01157	drug	fluconazole	DB00196	True	effect	drug	Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole.
DDI-DrugBank.d766.s3.p6	clotrimazole	DB00257	drug	trimetrexate	DB01157	True	mechanism	drug	Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism.
DDI-DrugBank.d769.s0.p2	ZOLINZA	None	brand	coumarin-derivative anticoagulants	None	True	effect	group	Coumarin-Derivative Anticoagulants: Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving ZOLINZA concomitantly with coumarin-derivative anticoagulants.
DDI-DrugBank.d77.s2.p11	sympathomimetic amine	None	group	tricyclic antidepressants	None	True	advise	group	Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.
DDI-DrugBank.d77.s2.p14	norepinephrine	DB00368	drug	tricyclic antidepressants	None	True	advise	group	Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.
DDI-DrugBank.d77.s2.p4	decongestants	None	group	tricyclic antidepressants	None	True	advise	group	Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.
DDI-DrugBank.d77.s2.p8	anesthetics	None	group	tricyclic antidepressants	None	True	advise	group	Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.
DDI-DrugBank.d773.s2.p11	vitamin K antagonists	None	group	TNKase	None	True	effect	brand	Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.
DDI-DrugBank.d775.s1.p0	succinylcholine	DB00202	drug	nondepolarizing agents	None	True	effect	group	Prior administration of succinylcholine can potentiate the neuromuscular blocking effects of nondepolarizing agents.
DDI-DrugBank.d775.s10.p1	nondepolarizing agents	None	drug	antibiotics	None	True	int	group	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d726.s1.p58	paricalcitol	DB00910	drug	itraconazole	DB01167	True	advise	drug	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
DDI-DrugBank.d726.s3.p2	cholestyramine	DB01432	drug	Zemplar	None	True	mechanism	brand	Drugs that impair intestinal absorption of fat-soluble vitamins, such as cholestyramine, may interfere with the absorption of Zemplar Capsules.
DDI-DrugBank.d735.s5.p6	nifedipine	DB01115	drug	MYCAMINE	None	True	advise	brand	Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.
DDI-DrugBank.d736.s3.p0	Thiazides	None	group	norepinephrine	DB00368	True	effect	drug	Thiazides may decrease arterial responsiveness to norepinephrine.
DDI-DrugBank.d737.s10.p29	dopamine antagonists	None	group	MIRAPEX	None	True	effect	brand	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.
DDI-DrugBank.d737.s10.p43	thioxanthenes	None	group	MIRAPEX	None	True	effect	brand	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.
DDI-DrugBank.d737.s6.p18	ranitidine	DB00863	drug	pramipexole	DB00413	True	mechanism	drug	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
DDI-DrugBank.d742.s9.p0	alcohol	None	drug	REMERON SolTab	None	True	advise	brand	Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects.
DDI-DrugBank.d775.s10.p19	MIVACRON	None	brand	polymyxins	None	True	int	group	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d775.s10.p7	nondepolarizing agents	None	drug	clindamycin	DB01190	True	int	drug	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d775.s11.p1	MIVACRON	None	brand	glucocorticoids	None	True	effect	group	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.
DDI-DrugBank.d776.s10.p2	DIFLUCAN	None	brand	phenytoin	DB00252	True	mechanism	drug	Phenytoin: DIFLUCAN increases the plasma concentrations of phenytoin.
DDI-DrugBank.d776.s20.p2	azole antifungals	None	group	terfenadine	DB00342	True	effect	drug	Terfenadine: Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving azole antifungals in conjunction with terfenadine, interaction studies have been performed.
DDI-DrugBank.d776.s35.p3	midazolam	DB00683	drug	fluconazole	DB00196	True	mechanism	drug	Short-acting Benzodiazepines: Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects.
DDI-DrugBank.d776.s37.p0	short-acting benzodiazepines	None	group	fluconazole	DB00196	True	advise	drug	If short-acting benzodiazepines, which are metabolized by the cytochrome P450 system, are concomitantly administered with fluconazole, consideration should be given to decreasing the benzodiazepine dosage, and the patients should be appropriately monitored.
DDI-DrugBank.d78.s1.p1	quinolones	None	group	aluminum	None	True	mechanism	drug	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
DDI-DrugBank.d40.s15.p0	phenytoin	DB00252	drug	phenobarbital	DB01174	True	effect	drug	Similarly, the effects of phenytoin on phenobarbital, valproic acid and sodium plasma valproate concentrations are unpredictable
DDI-DrugBank.d40.s19.p0	phenytoin	DB00252	drug	anticoagulants	None	True	effect	group	Drugs whose efficacy is impaired by Phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
DDI-DrugBank.d40.s19.p1	phenytoin	DB00252	drug	corticosteroids	None	True	effect	group	Drugs whose efficacy is impaired by Phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
DDI-DrugBank.d40.s19.p11	phenytoin	DB00252	drug	vitamin D	None	True	effect	group	Drugs whose efficacy is impaired by Phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
DDI-DrugBank.d400.s8.p0	Ponstel	None	brand	furosemide	DB00695	True	advise	drug	During concomitant therapy of Ponstel with furosemide, the patient should be observed closely for signs of renal failure, as well as to assure diuretic efficacy.
DDI-DrugBank.d400.s9.p3	NSAIDs	None	group	lithium	DB01356	True	mechanism	drug	Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.
DDI-DrugBank.d401.s0.p12	AKINETON	None	brand	antipsychotics	None	True	effect	group	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
DDI-DrugBank.d401.s0.p9	AKINETON	None	brand	narcotic analgesics	None	True	effect	group	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
DDI-DrugBank.d404.s8.p2	Ketoconazole	DB01026	drug	vitamin D	None	True	mechanism	group	Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.
DDI-DrugBank.d743.s12.p0	terfenadine	DB00342	drug	clarithromycin	DB01211	True	advise	drug	Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.
DDI-DrugBank.d743.s12.p1	terfenadine	DB00342	drug	erythromycin	DB00199	True	advise	drug	Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.
DDI-DrugBank.d743.s12.p19	terfenadine	DB00342	drug	azithromycin	DB00207	True	advise	drug	Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.
DDI-DrugBank.d744.s0.p2	hypoglycemic	None	group	SOMAVERT	None	True	advise	brand	Acromegalic patients with diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT.
DDI-DrugBank.d746.s0.p2	digitalis	None	group	sympathomimetic amines	None	True	effect	group	ARAMINE should be used with caution in digitalized patients, since the combination of digitalis and sympathomimetic amines may cause ectopic arrhythmias.
DDI-DrugBank.d75.s15.p0	sucralfate	DB00364	drug	anagrelide	DB00261	True	mechanism	drug	There is a single case report, which suggests that sucralfate may interfere with anagrelide absorption.
DDI-DrugBank.d753.s2.p0	Anticholinergics	None	group	opioid analgesics	None	True	effect	group	Anticholinergics or other medications with anticholinergic activity when used concurrently with opioid analgesics may result in increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.
DDI-DrugBank.d753.s3.p0	oxymorphone	DB01192	drug	propofol	DB00818	True	effect	drug	It has been reported that the incidence of bradycardia was increased when oxymorphone was combined with propofol for induction of anesthesia.
DDI-DrugBank.d76.s1.p0	serotonin reuptake inhibitor drug	None	group	monoamine oxidase inhibitors	None	True	effect	group	In patients receiving another serotonin reuptake inhibitor drug in combination with monoamine oxidase inhibitors (MAOI), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma.
DDI-DrugBank.d423.s4.p4	SSRIs	None	group	Imitrex	None	True	effect	brand	A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.
DDI-DrugBank.d425.s1.p44	vitamin B12	None	drug	folic acid	DB00158	True	int	drug	Medications can interfere with folate utilization, including: anticonvulsant medications (such as phenytoin, and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic) Methotrexate There has been concern about the interaction between vitamin B12 and folic acid.
DDI-DrugBank.d426.s1.p6	ergot-type medications	None	group	FROVA	None	True	advise	brand	Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).
DDI-DrugBank.d426.s3.p14	fluoxetine	DB00472	drug	5-HT1 agonists	None	True	effect	group	Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
DDI-DrugBank.d426.s3.p20	sertraline	DB01104	drug	5-HT1 agonists	None	True	effect	group	Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
DDI-DrugBank.d427.s0.p0	theophylline	DB00277	drug	quinolone	None	True	mechanism	group	Elevated plasma levels of theophylline have been reported with concomitant quinolone use.
DDI-DrugBank.d427.s7.p0	Nitrofurantoin	DB00698	drug	nalidixic acid	DB00779	True	effect	drug	Nitrofurantoin interferes with the therapeutic action of nalidixic acid.
DDI-DrugBank.d43.s14.p4	delavirdine	DB00705	drug	VIDEX	None	True	mechanism	brand	Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.
DDI-DrugBank.d43.s4.p12	aluminum	None	drug	VIDEX	None	True	effect	brand	Antacids: Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.
DDI-DrugBank.d410.s0.p4	D.H.E. 45	None	brand	peripheral vasoconstrictors	None	True	effect	group	Vasoconstrictors: D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.
DDI-DrugBank.d410.s3.p14	propranolol	DB00571	drug	ergotamine	DB00696	True	effect	drug	Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.
DDI-DrugBank.d410.s7.p2	5-HT1 agonists	None	group	SSRIs	None	True	effect	group	SSRIs: Weakness hyperreflexia, and incoordination have been reported rarely when 5-HT1 agonists have been co-administered with SSRIs (e. g.
DDI-DrugBank.d411.s2.p10	levothyroxine sodium	None	drug	ferrous sulfate	None	True	mechanism	drug	Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of levothyroxine sodium from the gastrointestinal tract: aluminum hydoxide, cholestyramine resin, colestipol hydrochloride, ferrous sulfate, sodium polystyrene sulfonate, soybean flour (e.g., infant formula), sucralfate.
DDI-DrugBank.d411.s2.p11	levothyroxine sodium	None	drug	sodium polystyrene sulfonate	None	True	mechanism	drug	Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of levothyroxine sodium from the gastrointestinal tract: aluminum hydoxide, cholestyramine resin, colestipol hydrochloride, ferrous sulfate, sodium polystyrene sulfonate, soybean flour (e.g., infant formula), sucralfate.
DDI-DrugBank.d411.s3.p11	levothyroxine sodium	None	drug	methadone	DB00333	True	mechanism	drug	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
DDI-DrugBank.d413.s12.p3	allopurinol	DB00437	drug	thiazide diuretics	None	True	effect	group	Thiazide Diuretics: The reports that the concomitant use of allopurinol and thiazide diuretics may contribute to the enhancement of allopurinol toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation.
DDI-DrugBank.d413.s18.p5	cytotoxic agents	None	group	allopurinol	DB00437	True	effect	drug	Cytotoxic Agents: Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol.
DDI-DrugBank.d413.s2.p10	Allopurinol	DB00437	drug	azathioprine	DB00993	True	mechanism	drug	Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.
DDI-DrugBank.d413.s4.p18	allopurinol	DB00437	drug	mercaptopurine	DB01033	True	advise	drug	In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.
DDI-DrugBank.d414.s4.p0	ethacrynic acid	DB00903	drug	warfarin	DB00682	True	mechanism	drug	A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein;
DDI-DrugBank.d414.s6.p2	non- steroidal antiinflammatory agent	None	group	thiazide diuretics	None	True	effect	group	In some patients, the administration of a non- steroidal antiinflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium- sparing and thiazide diuretics.
DDI-DrugBank.d415.s1.p1	ibuprofen	DB01050	drug	coumarin-type anticoagulants	None	True	effect	group	However, because bleeding has been reported when ibuprofen and other nonsteroidal anti-inflammatory agents have been administered to patients on coumarin-type anticoagulants, the physician should be cautious when administering ibuprofen to patients on anticoagulants.
DDI-DrugBank.d415.s2.p3	aspirin	None	brand	nonsteroidal anti-inflammatory agents	None	True	effect	group	Aspirin: Animal studies wshow that aspirin given with nonsteroidal anti-inflammatory agents, including ibuprofen, yields a net decrease in anti-inflammatory activity with lowered blood levels of the non-aspirin drug.
DDI-DrugBank.d416.s3.p0	probenecid	DB01032	drug	PAH	None	True	effect	drug	Therefore, patients receiving probenecid will have erroneously low ERPF and Tm PAH values.
DDI-DrugBank.d420.s11.p0	cefdinir	DB00535	drug	iron	DB01592	True	mechanism	drug	The reddish color is due to the formation of a nonabsorbable complex between cefdinir or its breakdown products and iron in the gastrointestinal tract.
DDI-DrugBank.d420.s4.p7	probenecid	DB01032	drug	cefdinir	DB00535	True	mechanism	drug	Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.
DDI-DrugBank.d422.s0.p0	reserpine	DB00206	drug	beta blocking agents	None	True	effect	group	Catecholamine-depleting drugs, e.g., reserpine, may have an additive effect when given with beta blocking agents.
DDI-DrugBank.d422.s10.p1	BREVIBLOC	None	brand	morphine	DB00295	True	advise	drug	Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.
DDI-DrugBank.d422.s3.p0	BREVIBLOC	None	brand	warfarin	DB00682	True	mechanism	drug	BREVIBLOC concentrations were equivocally higher when given with warfarin, but this is not likely to be clinically important.
DDI-DrugBank.d423.s0.p11	MAOIs	None	group	fluvoxamine	DB00176	True	effect	drug	In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
DDI-DrugBank.d423.s0.p5	monoamine oxidase inhibitors	None	group	paroxetine	DB00715	True	effect	drug	In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
DDI-DrugBank.d423.s0.p7	monoamine oxidase inhibitors	None	group	venlafaxine	DB00285	True	effect	drug	In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
DDI-DrugBank.d423.s4.p5	SSRIs	None	group	sumatriptan succinate	None	True	effect	drug	A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.
DDI-DrugBank.d424.s3.p3	rifampin	None	drug	MEPRON	None	True	mechanism	brand	Rifampin: Coadministration of rifampin and MEPRON Suspension results in a significant decrease in average steady- state plasma atovaquone concentrations.
DDI-DrugBank.d426.s3.p19	paroxetine	DB00715	drug	5-HT1 agonists	None	True	effect	group	Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
DDI-DrugBank.d76.s25.p0	diazepam	DB00829	drug	fluvoxamine	DB00176	True	advise	drug	Accordingly, diazepam and fluvoxamine should not ordinarily be co-administered.
DDI-DrugBank.d763.s3.p20	phenytoin	DB00252	drug	ondansetron	DB00904	True	mechanism	drug	Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.
DDI-DrugBank.d763.s3.p24	carbamazepine	DB00564	drug	ondansetron	DB00904	True	mechanism	drug	Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.
DDI-DrugBank.d765.s1.p16	azole antifungals	None	group	DETROL LA	None	True	advise	brand	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.
DDI-DrugBank.d77.s5.p2	imipramine	DB00458	drug	barbiturates	None	True	mechanism	group	The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.
DDI-DrugBank.d771.s1.p1	Scopolamine	DB00747	drug	tranquilizers	None	True	advise	group	Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, tranquilizers, or alcohol.
DDI-DrugBank.d773.s2.p14	dipyridamole	DB00975	drug	TNKase	None	True	effect	brand	Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.
DDI-DrugBank.d775.s10.p13	nondepolarizing agents	None	drug	procainamide	DB01035	True	int	drug	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d427.s11.p2	Didanosine	DB00900	drug	quinolones	None	True	mechanism	group	and Videx , (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of quinolones, resulting in systemic levels considerably lower than desired.
DDI-DrugBank.d427.s3.p0	Quinolones	None	group	caffeine	DB00201	True	mechanism	drug	Quinolones have been shown to interfere with the metabolism of caffeine.
DDI-DrugBank.d428.s11.p0	Cimetidine	DB00501	drug	ELLENCE	None	True	advise	brand	Cimetidine treatment should be stopped during treatment with ELLENCE.
DDI-DrugBank.d429.s2.p2	Cimetidine	DB00501	drug	chloroquine	DB00608	True	mechanism	drug	Cimetidine: Cimetidine can inhibit the metabolism of chloroquine, increasing its plasma level.
DDI-DrugBank.d43.s12.p3	quinolone antibiotics	None	group	aluminum	None	True	mechanism	drug	Plasma concentrations of quinolone antibiotics are decreased when administered with antacids containing magnesium, calcium, or aluminum.
DDI-DrugBank.d43.s15.p2	indinavir	DB00224	drug	VIDEX	None	True	advise	brand	To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.
DDI-DrugBank.d431.s12.p0	lansoprazole	DB00448	drug	ketoconazole	DB01026	True	mechanism	drug	therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).
DDI-DrugBank.d431.s12.p1	lansoprazole	DB00448	drug	ampicillin	DB00415	True	mechanism	drug	therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).
DDI-DrugBank.d431.s3.p0	lansoprazole	DB00448	drug	theophylline	DB00277	True	mechanism	drug	When lansoprazole was administered concomitantly with theophylline (CYP1A2, CYP3A), a minor increase (10%) in the clearance of theophylline was seen.
DDI-DrugBank.d434.s1.p4	Felbatol	None	brand	antiepileptic drugs	None	True	mechanism	group	Use in Conjunction with Other Antiepileptic Drugs: The addition of Felbatol  to antiepileptic drugs (AEDs) affects the steady-state plasma concentrations of AEDs.
DDI-DrugBank.d434.s1.p5	Felbatol	None	brand	AEDs	None	True	mechanism	group	Use in Conjunction with Other Antiepileptic Drugs: The addition of Felbatol  to antiepileptic drugs (AEDs) affects the steady-state plasma concentrations of AEDs.
DDI-DrugBank.d434.s11.p9	Felbatol	None	brand	phenytoin	DB00252	True	mechanism	drug	Specific Effects of Felbatol  on Other Antiepileptic Drugs Phenytoin: Felbatol  causes an increase in steady-state phenytoin plasma concentrations.
DDI-DrugBank.d434.s14.p0	felbamate	DB00949	drug	phenytoin	DB00252	True	mechanism	drug	Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25 7 micrograms/mL.
DDI-DrugBank.d437.s7.p0	Saquinavir	DB01232	drug	amprenavir	DB00701	True	mechanism	drug	Saquinavir steady-state Cmax, A.C. and Cmin were increased 21%, decreased 19%, and decreased 48%, respectively, by concomitant amprenavir.
DDI-DrugBank.d438.s24.p0	Hydrocodone	DB00956	drug	gabapentin	DB00996	True	mechanism	drug	Hydrocodone increases gabapentin AUC values by 14%.
DDI-DrugBank.d441.s8.p0	ZYVOX	None	brand	serotonergic agents	None	True	advise	group	If any signs or symptoms occur physicians should consider discontinuation of either one or both agents (ZYVOX or concomitant serotonergic agents).
DDI-DrugBank.d446.s0.p5	Chlorotrianisene	DB00269	drug	corticosteroids	None	True	int	group	Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
DDI-DrugBank.d446.s0.p8	Chlorotrianisene	DB00269	drug	dantrolene	DB01219	True	int	drug	Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
DDI-DrugBank.d449.s1.p4	fluvoxamine	DB00176	drug	Xanax	None	True	advise	brand	Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction).
DDI-DrugBank.d450.s12.p1	beta-adrenergic blockers	None	group	digoxin	DB00390	True	effect	drug	Although beta-adrenergic blockers or calcium channel blockers and digoxin may be useful in combination to control atrial fibrillation, their additive effects on AV node conduction can result in advanced or complete heart block.
DDI-DrugBank.d450.s2.p28	propafenone	DB01182	drug	digoxin	DB00390	True	mechanism	drug	Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
DDI-DrugBank.d43.s6.p3	VIDEX	None	brand	ganciclovir	DB01004	True	mechanism	drug	Ganciclovir: Administration of VIDEX 2 hours prior to or concurrent with oral ganciclovir was associated with a 111 (114)% increase in the steady-state AUC of didanosine (n = 12).
DDI-DrugBank.d434.s15.p2	felbamate	DB00949	drug	phenytoin	DB00252	True	advise	drug	In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.
DDI-DrugBank.d434.s19.p0	carbamazepine	DB00564	drug	felbamate	DB00949	True	mechanism	drug	The carbamazepine steady-state Cmin decreased 31% to 5 1 micrograms/mL when felbamate (3000 mg/day, divided into three doses) was coadministered.
DDI-DrugBank.d438.s15.p3	naproxen sodium	None	drug	Neurontin	None	True	mechanism	brand	Naproxen: Coadministration (N=18) of naproxen sodium capsules (250 mg) with Neurontin (125 mg) appears to increase the amount of gabapentin absorbed by 12% to 15%.
DDI-DrugBank.d438.s35.p0	norethindrone	DB00717	drug	gabapentin	DB00996	True	mechanism	drug	The Cmax of norethindrone was 13% higher when it was coadministered with gabapentin;
DDI-DrugBank.d440.s1.p8	magnesium	DB01378	drug	Ibandronate	DB00710	True	mechanism	drug	Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.
DDI-DrugBank.d443.s0.p5	Aspirin	None	brand	sulfinpyrazone	DB01138	True	effect	drug	Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.
DDI-DrugBank.d443.s0.p6	Aspirin	None	brand	phenylbutazone	DB00812	True	effect	drug	Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.
DDI-DrugBank.d443.s4.p2	Aspirin	None	drug	nonsteroidal anti-inflammatory	None	True	advise	drug	Nonsteroidal Antiinflammatory Agents: Aspirin is contraindicated in patients who are hypersensitive to nonsteroidal anti-inflammatory agents.
DDI-DrugBank.d443.s6.p0	Phenobarbital	DB01174	drug	aspirin	None	True	mechanism	brand	Phenobarbital: Decreases aspirin effectiveness by enzyme induction.
DDI-DrugBank.d443.s8.p0	Propranolol	DB00571	drug	aspirins	None	True	effect	brand	Propranolol: May decrease aspirins anti-inflammatory action by competing for the same receptors.
DDI-DrugBank.d446.s0.p11	Chlorotrianisene	DB00269	drug	tamoxifen	DB00675	True	int	drug	Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
DDI-DrugBank.d446.s0.p7	Chlorotrianisene	DB00269	drug	cyclosporine	DB00091	True	int	drug	Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
DDI-DrugBank.d448.s3.p3	methyldopa	DB00968	drug	sympathomimetics	None	True	effect	group	The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics.
DDI-DrugBank.d448.s3.p6	mecamylamine	DB00657	drug	sympathomimetics	None	True	effect	group	The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics.
DDI-DrugBank.d450.s0.p0	Potassium-depleting diuretics	None	group	digitalis	None	True	effect	group	Potassium-depleting diuretics are a major contributing factor to digitalis toxicity.
DDI-DrugBank.d450.s2.p15	verapamil	DB00661	drug	digoxin	DB00390	True	mechanism	drug	Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
DDI-DrugBank.d450.s2.p7	Quinidine	DB00908	drug	digoxin	DB00390	True	mechanism	drug	Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
DDI-DrugBank.d450.s6.p14	sulfasalazine	DB00795	drug	digoxin	DB00390	True	mechanism	drug	Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.
DDI-DrugBank.d457.s0.p2	Barbiturates	None	group	quinidine	DB00908	True	effect	drug	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.
DDI-DrugBank.d458.s19.p2	ketoconazole	DB01026	drug	coumarin	None	True	effect	group	When taken orally , imidazole compounds like ketoconazole may enhance the anticoagulant effect of coumarin-like drugs.
DDI-DrugBank.d458.s20.p0	imidazole drugs	None	group	coumarin drugs	None	True	advise	group	In simultaneous treatment with imidazole drugs and coumarin drugs, the anticoagulant effect should be carefully titrated and monitored.
DDI-DrugBank.d459.s1.p1	ENABLEX	None	brand	thioridazine	DB00679	True	advise	drug	Caution should be taken when ENABLEX is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants (see CLINICAL PHARMACOLOGY).
DDI-DrugBank.d464.s0.p5	Codeine	DB00318	drug	CNS depressants	None	True	effect	group	Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.
DDI-DrugBank.d465.s0.p0	isosorbide dinitrate	DB00883	drug	vasodilators	None	True	effect	group	The vasodilating effects of isosorbide dinitrate may be additive with those of other vasodilators.
DDI-DrugBank.d466.s19.p6	fexofenadine hydrochloride	None	drug	aluminum	None	True	mechanism	drug	Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.
DDI-DrugBank.d466.s20.p0	ALLEGRA	None	brand	aluminum	None	True	advise	drug	ALLEGRA should not be taken closely in time with aluminum and magnesium containing antacids.
DDI-DrugBank.d467.s6.p0	gemfibrozil	DB01241	drug	Targretin	None	True	advise	brand	Concomitant administration of gemfibrozil with Targretin capsules is not recommended.
DDI-DrugBank.d469.s7.p0	TRACRIUM	None	brand	enflurane	DB00228	True	effect	drug	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.
DDI-DrugBank.d469.s7.p3	TRACRIUM	None	brand	antibiotics	None	True	effect	group	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.
DDI-DrugBank.d469.s7.p8	TRACRIUM	None	brand	procainamide	DB01035	True	effect	drug	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.
DDI-DrugBank.d470.s1.p0	TRISENOX	None	brand	antiarrhythmics	None	True	advise	group	Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).
DDI-DrugBank.d78.s1.p4	quinolones	None	group	sucralfate	DB00364	True	mechanism	drug	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
DDI-DrugBank.d78.s10.p0	quinolones	None	group	warfarin	DB00682	True	effect	drug	However, because some quinolones have been reported to enhance the effects of warfarin or its derivatives, prothrombin time or other suitable anticoagulation test should be monitored closely if a quinolone antimicrobial is administered with warfarin or its derivatives.
DDI-DrugBank.d78.s20.p2	quinolones	None	group	antidiabetic agent	None	True	effect	group	Antidiabetic Agents: Disturbances of blood glucose, including hyperglycemia and hypoglycemia, have been reported in patients treated concomitantly with quinolones and an antidiabetic agent.
DDI-DrugBank.d78.s6.p2	Grepafloxacin	DB00365	drug	theophylline	DB00277	True	mechanism	drug	Theophylline: Grepafloxacin is a competitive inhibitor of the metabolism of theophylline.
DDI-DrugBank.d78.s7.p2	grepafloxacin	DB00365	drug	theophylline	DB00277	True	mechanism	drug	Serum theophylline concentrations increase when grepafloxacin is initiated in a patient maintained on theophylline.
DDI-DrugBank.d780.s0.p9	anticholinesterases	None	group	procaine hydrochloride	None	True	mechanism	drug	Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride.
DDI-DrugBank.d780.s4.p2	procaine hydrochloride	None	drug	CNS depressant medications	None	True	effect	group	CNS depressant medications: Concurrent use of procaine hydrochloride and CNS depressant medications may result in additive depressant effects.
DDI-DrugBank.d782.s0.p0	Vindesine	DB00309	drug	Phenytoin	DB00252	True	int	drug	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine
DDI-DrugBank.d470.s1.p1	TRISENOX	None	brand	thioridazine	DB00679	True	advise	drug	Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).
DDI-DrugBank.d471.s0.p0	Mineral oil	None	drug	fat-soluble vitamins	None	True	mechanism	group	Mineral oil interferes with the absorption of fat-soluble vitamins, including vitamin D preparations.
DDI-DrugBank.d476.s3.p2	ZEBETA	None	brand	phenylalkylamine	None	True	advise	group	ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.
DDI-DrugBank.d476.s3.p5	ZEBETA	None	brand	diltiazem	DB00343	True	advise	drug	ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.
DDI-DrugBank.d479.s0.p0	isosorbide mononitrate	DB01020	drug	vasodilators	None	True	effect	group	The vasodilating effects of isosorbide mononitrate may be additive with those of other vasodilators.
DDI-DrugBank.d48.s1.p4	SPRYCEL	None	brand	ritonavir	DB00503	True	mechanism	drug	Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
DDI-DrugBank.d48.s11.p17	proton pump inhibitors	None	group	dasatinib	DB01254	True	effect	drug	H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.
DDI-DrugBank.d48.s15.p62	fentanyl	DB00813	drug	SPRYCEL	None	True	advise	brand	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
DDI-DrugBank.d482.s10.p0	MAO inhibitor	None	group	escitalopram	DB01175	True	advise	drug	Wait 2 weeks after stopping an MAO inhibitor before starting escitalopram.
DDI-DrugBank.d782.s0.p3	Vindesine	DB00309	drug	Mitomycin-C	None	True	int	drug	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine
DDI-DrugBank.d8.s3.p0	volatile inhalation anesthetics	None	group	ALFENTA	None	True	mechanism	brand	Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.
DDI-DrugBank.d82.s1.p0	INDOCIN	None	brand	diflunisal	DB00861	True	effect	drug	In some patients, combined use of INDOCIN and diflunisal has been associated with fatal gastrointestinal hemorrhage.
DDI-DrugBank.d82.s15.p0	NSAIDs	None	group	cyclosporine	DB00091	True	advise	drug	NSAIDs should be used with caution in patients taking cyclosporine, and renal function should be carefully monitored.
DDI-DrugBank.d82.s23.p0	INDOCIN	None	brand	loop diuretics	None	True	effect	group	In some patients, the administration of INDOCIN can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing, and thiazide diuretics.
DDI-DrugBank.d85.s12.p7	NSAIDs	None	group	methotrexate	DB00563	True	mechanism	drug	Naproxen, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.
DDI-DrugBank.d85.s6.p0	naproxen	DB00788	drug	aspirin	None	True	advise	brand	Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.
DDI-DrugBank.d85.s9.p4	NSAIDs	None	group	beta-blockers	None	True	effect	group	Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers.
DDI-DrugBank.d86.s0.p7	chlorpromazine	DB00477	drug	tricyclic antidepressant	None	True	effect	group	The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
DDI-DrugBank.d87.s13.p2	phenytoin	DB00252	drug	flecainide	DB01195	True	mechanism	drug	Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination.
DDI-DrugBank.d88.s6.p0	leucovorin	DB00650	drug	fluorouracil	DB00544	True	effect	drug	Deaths from severe enterocolitis, diarrhea, and dehydration have been reported in elderly patients receiving weekly leucovorin and fluorouracil.
DDI-DrugBank.d94.s11.p1	EQUETROTM	None	brand	alprazolam	DB00404	True	mechanism	drug	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s11.p13	EQUETROTM	None	brand	dicumarol	None	True	mechanism	drug	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s11.p23	EQUETROTM	None	brand	lorazepam	DB00186	True	mechanism	drug	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d450.s2.p33	indomethacin	DB00328	drug	digoxin	DB00390	True	mechanism	drug	Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
DDI-DrugBank.d450.s3.p12	macrolide antibiotics	None	group	digoxin	DB00390	True	mechanism	drug	Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.
DDI-DrugBank.d450.s3.p15	tetracycline	DB00759	drug	digoxin	DB00390	True	mechanism	drug	Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.
DDI-DrugBank.d450.s3.p3	Erythromycin	DB00199	drug	digoxin	DB00390	True	mechanism	drug	Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.
DDI-DrugBank.d450.s6.p17	neomycin	DB00994	drug	digoxin	DB00390	True	mechanism	drug	Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.
DDI-DrugBank.d450.s9.p0	Thyroid	None	group	digoxin	DB00390	True	advise	drug	Thyroid administration to a digitalized, hypothyroid patient may increase the dose requirement of digoxin.
DDI-DrugBank.d452.s0.p0	thiazide diuretics	None	group	dihydrotachysterol	DB01070	True	effect	drug	Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with dihydrotachysterol may cause hypercalcemia.
DDI-DrugBank.d454.s2.p0	Lofexidine	DB04948	drug	anti-hypertensive drug	None	True	effect	group	Lofexidine may enhance The effects of Anti-hypertensive drug therapy
DDI-DrugBank.d456.s0.p0	ketoconazole	DB01026	drug	erlotinib	DB00530	True	mechanism	drug	Co-treatment with the potent CYP3A4 inhibitor ketoconazole increases erlotinib AUC by 2/3.
DDI-DrugBank.d456.s1.p2	TARCEVA	None	brand	clarithromycin	DB01211	True	advise	drug	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
DDI-DrugBank.d482.s9.p0	escitalopram	DB01175	drug	non-selective MAO inhibitor	None	True	advise	group	Wait 5 weeks after stopping escitalopram before starting a non-selective MAO inhibitor.
DDI-DrugBank.d483.s1.p0	CEFOTAN	None	brand	aminoglycoside	None	True	effect	group	If CEFOTAN and an aminoglycoside are used concomitantly, renal function should be carefully monitored, because nephrotoxicity may be potentiated.
DDI-DrugBank.d484.s0.p16	Etonogestrel	DB00294	drug	atorvastatin	DB01076	True	int	drug	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d484.s0.p27	Etonogestrel	DB00294	drug	Invirase	None	True	int	brand	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d484.s0.p4	Etonogestrel	DB00294	drug	tetracycline	DB00759	True	int	drug	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d484.s0.p5	Etonogestrel	DB00294	drug	anticonvulsants	None	True	int	group	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d456.s1.p3	TARCEVA	None	brand	indinavir	DB00224	True	advise	drug	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
DDI-DrugBank.d456.s1.p7	TARCEVA	None	brand	ritonavir	DB00503	True	advise	drug	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
DDI-DrugBank.d457.s0.p1	Barbiturates	None	group	antibiotics	None	True	effect	group	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.
DDI-DrugBank.d457.s0.p5	Barbiturates	None	group	anticoagulants	None	True	effect	group	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.
DDI-DrugBank.d458.s10.p2	Ketoconazole	DB01026	drug	methylprednisolone	DB00959	True	mechanism	drug	Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.
DDI-DrugBank.d458.s24.p0	rifampin	None	drug	ketoconazole	DB01026	True	mechanism	drug	Concomitant administration of rifampin with ketoconazole tablets reduces the blood levels of the latter.
DDI-DrugBank.d459.s1.p0	ENABLEX	None	brand	flecainide	DB01195	True	advise	drug	Caution should be taken when ENABLEX is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants (see CLINICAL PHARMACOLOGY).
DDI-DrugBank.d46.s16.p1	Diuretic agents	None	group	lithium	DB01356	True	mechanism	drug	Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.
DDI-DrugBank.d46.s7.p20	Cholestytamine	None	drug	thiazide diuretics	None	True	mechanism	group	Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have The potential of binding thiazide diuretics and reducing diuretic absorption from The gastrointestinal tract
DDI-DrugBank.d460.s14.p10	NSAIDs	None	group	antidiabetic drugs	None	True	effect	group	Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.
DDI-DrugBank.d775.s10.p15	MIVACRON	None	brand	antibiotics	None	True	int	group	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d775.s10.p8	nondepolarizing agents	None	drug	colistin	DB00803	True	int	drug	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d775.s11.p2	MIVACRON	None	brand	monoamine oxidase inhibitors	None	True	effect	group	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.
DDI-DrugBank.d775.s12.p1	phenytoin	DB00252	drug	MIVACRON	None	True	effect	brand	While the effects of chronic phenytoin or carbamazepine therapy on the action of MIVACRON are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.
DDI-DrugBank.d775.s12.p2	carbamazepine	DB00564	drug	MIVACRON	None	True	effect	brand	While the effects of chronic phenytoin or carbamazepine therapy on the action of MIVACRON are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.
DDI-DrugBank.d775.s2.p0	succinylcholine	DB00202	drug	MIVACRON	None	True	advise	brand	Evidence of spontaneous recovery from succinylcholine should be observed before the administration of MIVACRON.
DDI-DrugBank.d776.s2.p104	DIFLUCAN	None	brand	hypoglycemic agents	None	True	effect	group	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
DDI-DrugBank.d460.s14.p13	salicylates	None	group	Starlix	None	True	effect	brand	Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.
DDI-DrugBank.d460.s14.p14	salicylates	None	group	antidiabetic drugs	None	True	effect	group	Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.
DDI-DrugBank.d460.s14.p4	nonsteroidal anti-inflammatory agents	None	group	Starlix	None	True	effect	brand	Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.
DDI-DrugBank.d460.s15.p8	corticosteroids	None	group	antidiabetic drugs	None	True	effect	group	Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.
DDI-DrugBank.d462.s0.p3	piperacillin	DB00319	drug	aminoglycoside	None	True	effect	group	Aminoglycosides: The mixing of piperacillin with an aminoglycoside in vitro can result in substantial inactivation of the aminoglycoside.
DDI-DrugBank.d466.s19.p7	fexofenadine hydrochloride	None	drug	magnesium	DB01378	True	mechanism	drug	Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.
DDI-DrugBank.d467.s4.p0	Targretin	None	brand	gemfibrozil	DB01241	True	mechanism	drug	Concomitant administration of Targretin capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.
DDI-DrugBank.d468.s9.p0	cyclosporine	DB00091	drug	nicardipine	DB00622	True	advise	drug	Plasma concentrations of cyclosporine should therefore be closely monitored, and its dosage reduced accordingly, in patients treated with nicardipine.
DDI-DrugBank.d469.s10.p0	TRACRIUM	None	brand	succinylcholine	DB00202	True	advise	drug	TRACRIUM should not be administered until a patient has recovered from succinylcholine-induced neuromuscular block.
DDI-DrugBank.d469.s7.p2	TRACRIUM	None	brand	halothane	DB01159	True	effect	drug	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.
DDI-DrugBank.d469.s9.p0	succinylcholine	DB00202	drug	TRACRIUM	None	True	effect	brand	The prior administration of succinylcholine does not enhance the duration, but quickens the onset and may increase the depth, of neuromuscular block induced by TRACRIUM.
DDI-DrugBank.d47.s7.p0	metoclopramide	DB01233	drug	levodopa	None	True	mechanism	drug	Although metoclopramide may increase the bioavailability of levodopa by increasing gastric emptying, metoclopramide may also adversely affect disease control by its dopamine receptor antagonistic properties.
DDI-DrugBank.d470.s1.p2	TRISENOX	None	brand	diuretics	None	True	advise	group	Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).
DDI-DrugBank.d476.s3.p4	ZEBETA	None	brand	benzothiazepine	None	True	advise	group	ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.
DDI-DrugBank.d476.s4.p0	rifampin	None	drug	ZEBETA	None	True	mechanism	brand	Concurrent use of rifampin increases the metabolic clearance of ZEBETA, resulting in a shortened elimination half-life of ZEBETA.
DDI-DrugBank.d477.s2.p0	Amphetamines	None	group	antihypertensives	None	True	effect	group	Amphetamines may decrease the hypotensive effect of antihypertensives.
DDI-DrugBank.d48.s1.p6	SPRYCEL	None	brand	indinavir	DB00224	True	mechanism	drug	Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
DDI-DrugBank.d48.s1.p8	SPRYCEL	None	brand	nelfinavir	DB00220	True	mechanism	drug	Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
DDI-DrugBank.d48.s10.p0	antacid	None	group	SPRYCEL	None	True	advise	brand	If antacid therapy is needed, the antacid dose should be administered at least 2 hours prior to or 2 hours after the dose of SPRYCEL.
DDI-DrugBank.d48.s11.p20	omeprazole	DB00338	drug	dasatinib	DB01254	True	effect	drug	H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.
DDI-DrugBank.d48.s12.p2	proton pump inhibitors	None	group	SPRYCEL	None	True	advise	brand	The concomitant use of H2 blockers or proton pump inhibitors with SPRYCEL is not recommended.
DDI-DrugBank.d48.s15.p24	astemizole	DB00637	drug	SPRYCEL	None	True	advise	brand	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
DDI-DrugBank.d48.s15.p35	terfenadine	DB00342	drug	SPRYCEL	None	True	advise	brand	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
DDI-DrugBank.d48.s15.p54	cyclosporine	DB00091	drug	SPRYCEL	None	True	advise	brand	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
DDI-DrugBank.d48.s15.p69	pimozide	DB01100	drug	SPRYCEL	None	True	advise	brand	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
DDI-DrugBank.d480.s22.p5	clozapine	DB00363	drug	fluoxetine	DB00472	True	mechanism	drug	However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.
DDI-DrugBank.d480.s8.p12	clozapine	DB00363	drug	benzodiazepine	None	True	advise	group	Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics, caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic drug.
DDI-DrugBank.d484.s0.p6	Etonogestrel	DB00294	drug	Dilantin	None	True	int	brand	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d485.s12.p6	Anticonvulsants	None	group	progestins	None	True	mechanism	group	Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.
DDI-DrugBank.d485.s14.p4	ascorbic acid	None	drug	synthetic estrogens	None	True	mechanism	group	Ascorbic acid: Doses of ascorbic acid (vitamin C) 1 g/day have been reported to increase plasma concentration of synthetic estrogens by ~47%, possibly by inhibiting conjugation;
DDI-DrugBank.d485.s16.p3	Atorvastatin	DB01076	drug	norethindrone	DB00717	True	mechanism	drug	Atorvastatin: Atorvastatin increases the AUC for norethindrone and ethinyl estradiol.
DDI-DrugBank.d485.s17.p8	hormonal contraceptives	None	group	benzodiazepines	None	True	mechanism	group	Benzodiazepines: Combination hormonal contraceptives may decrease the clearance of some benzodiazepines (alprazolam, chlordiazepoxide, diazepam) and increase the clearance of others (lorazepam, oxazepam, temazepam).
DDI-DrugBank.d485.s36.p6	Rifampin	None	drug	norethindrone	DB00717	True	mechanism	drug	Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.
DDI-DrugBank.d485.s40.p2	Ethinyl estradiol	DB00977	drug	theophylline	DB00277	True	mechanism	drug	Theophylline: Ethinyl estradiol may inhibit the metabolism of theophylline, leading to increased plasma concentrations.
DDI-DrugBank.d485.s41.p10	imipramine	DB00458	drug	combination hormonal contraceptives	None	True	mechanism	group	Tricyclic antidepressants (amitriptyline, imipramine, nortriptyline): Metabolism may be inhibited by combination hormonal contraceptives, increasing plasma levels of antidepressant;
DDI-DrugBank.d487.s1.p8	rifampin	None	drug	corticosteroid	None	True	advise	group	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.
DDI-DrugBank.d484.s0.p18	Etonogestrel	DB00294	drug	clofibrate	DB00636	True	int	drug	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d484.s0.p2	Etonogestrel	DB00294	drug	antibiotics	None	True	int	group	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d484.s0.p42	Etonogestrel	DB00294	drug	Theo-Dur	None	True	int	brand	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d484.s0.p7	Etonogestrel	DB00294	drug	Phenobarbital	DB01174	True	int	drug	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
DDI-DrugBank.d485.s12.p11	carbamazepine	DB00564	drug	ethinyl estradiol	DB00977	True	mechanism	drug	Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.
DDI-DrugBank.d485.s12.p26	topiramate	DB00273	drug	progestins	None	True	mechanism	group	Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.
DDI-DrugBank.d485.s17.p11	hormonal contraceptives	None	group	diazepam	DB00829	True	mechanism	drug	Benzodiazepines: Combination hormonal contraceptives may decrease the clearance of some benzodiazepines (alprazolam, chlordiazepoxide, diazepam) and increase the clearance of others (lorazepam, oxazepam, temazepam).
DDI-DrugBank.d485.s32.p11	lopinavir	DB01601	drug	combination hormonal contraceptives	None	True	mechanism	group	Protease inhibitors: Amprenavir, lopinavir, nelfinavir, and ritonavir have been shown to decrease plasma levels of combination hormonal contraceptives;
DDI-DrugBank.d485.s36.p5	Rifampin	None	drug	progestins	None	True	mechanism	group	Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.
DDI-DrugBank.d485.s4.p0	Acitretin	DB00459	drug	progestin	None	True	effect	group	Acitretin: Interferes with the contraceptive effect of microdosed progestin-containing minipill preparations.
DDI-DrugBank.d485.s41.p7	amitriptyline	DB00321	drug	combination hormonal contraceptives	None	True	mechanism	group	Tricyclic antidepressants (amitriptyline, imipramine, nortriptyline): Metabolism may be inhibited by combination hormonal contraceptives, increasing plasma levels of antidepressant;
DDI-DrugBank.d487.s1.p6	phenytoin	DB00252	drug	corticosteroid	None	True	advise	group	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.
DDI-DrugBank.d488.s2.p25	phenylbutazone	DB00812	drug	heparin sodium	None	True	effect	drug	Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.
DDI-DrugBank.d776.s22.p2	DIFLUCAN	None	brand	terfenadine	DB00342	True	mechanism	drug	Another study at a 400-mg and 800-mg daily dose of fluconazole demonstrated that DIFLUCAN taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly.
DDI-DrugBank.d776.s28.p2	fluconazole	DB00196	drug	astemizole	DB00637	True	mechanism	drug	Astemizole: The use of fluconazole in patients concurrently taking astemizole or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs.
DDI-DrugBank.d776.s38.p1	Fluconazole	DB00196	drug	levonorgestrel	DB00367	True	mechanism	drug	Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels;
DDI-DrugBank.d776.s4.p2	DIFLUCAN	None	brand	glipizide	DB01067	True	mechanism	drug	DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents.
DDI-DrugBank.d776.s7.p2	fluconazole	DB00196	drug	warfarin	DB00682	True	effect	drug	In post-marketing experience, as with other azole antifungals, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving fluconazole concurrently with warfarin.
DDI-DrugBank.d777.s1.p10	Streptase	None	brand	antiplatelet agents	None	True	effect	group	Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.
DDI-DrugBank.d779.s5.p0	methyldopa	DB00968	drug	lithium	DB01356	True	advise	drug	When methyldopa and lithium are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity.
DDI-DrugBank.d78.s1.p2	quinolones	None	group	magnesium	DB01378	True	mechanism	drug	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
DDI-DrugBank.d78.s14.p0	quinolones	None	group	cyclosporine	DB00091	True	mechanism	drug	In addition, other quinolones have been reported to decrease the CYP3A4-mediated metabolism of cyclosporine.
DDI-DrugBank.d487.s2.p2	ketoconazole	DB01026	drug	corticosteroids	None	True	mechanism	group	Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.
DDI-DrugBank.d488.s6.p8	Digitalis	None	group	heparin sodium	None	True	effect	drug	Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.
DDI-DrugBank.d489.s5.p0	calcium antagonists	None	group	beta-adrenergic blocking agents	None	True	advise	group	Literature reports suggest that oral calcium antagonists may be used in combination with beta-adrenergic blocking agents when heart function is normal, but should be avoided in patients with impaired cardiac function.
DDI-DrugBank.d492.s1.p1	Antihistamines	None	group	CNS depressants	None	True	effect	group	Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.
DDI-DrugBank.d498.s1.p0	antibiotics	None	group	anticholinesterase	None	True	advise	group	These antibiotics should be used in the myasthenic patient only where definitely indicated, and then careful adjustment should be made of adjunctive anticholinesterase dosage.
DDI-DrugBank.d499.s24.p2	Nonsteroidal anti-inflammatory agents	None	group	lithium	DB01356	True	mechanism	drug	Lithium: Nonsteroidal anti-inflammatory agents have been reported to increase steadystate plasma lithium levels.
DDI-DrugBank.d5.s17.p0	bupropion	DB01156	drug	antidepressants	None	True	advise	group	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
DDI-DrugBank.d5.s17.p14	bupropion	DB01156	drug	propafenone	DB01182	True	advise	drug	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
DDI-DrugBank.d488.s2.p29	ibuprofen	DB01050	drug	heparin sodium	None	True	effect	drug	Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.
DDI-DrugBank.d488.s2.p32	indomethacin	DB00328	drug	heparin sodium	None	True	effect	drug	Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.
DDI-DrugBank.d489.s6.p0	beta-adrenergic blocking agents	None	group	calcium antagonist	None	True	effect	group	Hypotension, AV conduction disturbances, and left ventricular failure have been reported in some patients receiving beta-adrenergic blocking agents when an oral calcium antagonist was added to the treatment regimen.
DDI-DrugBank.d492.s1.p0	Antihistamines	None	group	alcohol	None	True	effect	drug	Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.
DDI-DrugBank.d493.s2.p5	interleukin-1 antagonist	None	group	TNF-blocking agent	None	True	effect	group	Anakinra: Concurrent administration of anakinra (an interleukin-1 antagonist) and another TNF-blocking agent has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.
DDI-DrugBank.d495.s1.p2	Clonidine hydrochloride	None	drug	sedatives	None	True	effect	group	Clonidine hydrochloride may enhance the CNS-depressive effects of alcohol, barbiturates or other sedatives.
DDI-DrugBank.d495.s2.p11	Clonidine	DB00575	drug	sedating drugs	None	True	effect	group	Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol, barbiturates or other sedating drugs.
DDI-DrugBank.d499.s19.p3	Probenecid	DB01032	drug	ketoprofen	DB01009	True	mechanism	drug	Probenecid: Probenecid increases both free and bound ketoprofen by reducing the plasma clearance of ketoprofen to about one-third, as well as decreasing its protein binding.
DDI-DrugBank.d499.s20.p0	ketoprofen	DB01009	drug	probenecid	DB01032	True	advise	drug	Therefore, the combination of ketoprofen and probenecid is not recommended.
DDI-DrugBank.d5.s17.p5	bupropion	DB01156	drug	fluoxetine	DB00472	True	advise	drug	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
DDI-DrugBank.d500.s2.p3	tetracyclines	None	group	magnesium	DB01378	True	mechanism	drug	Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.
DDI-DrugBank.d500.s5.p0	tetracycline	DB00759	drug	Penthrane	None	True	effect	brand	The concurrent use of tetracycline and Penthrane (methoxyflurane) has been reported to result in fatal renal toxicity.
DDI-DrugBank.d502.s1.p0	beta-blocker	None	group	reserpine	DB00206	True	advise	drug	Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.
DDI-DrugBank.d503.s2.p9	chlorprothixene	DB01239	drug	opioids	None	True	effect	group	If chlorprothixene is given concomitantly with opioids, the opioid dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of opioids massively.
DDI-DrugBank.d506.s0.p1	phenytoin	DB00252	drug	Norpace CR	None	True	mechanism	brand	If phenytoin or other hepatic enzyme inducers are taken concurrently with Norpace or Norpace CR, lower plasma levels of disopyramide may occur.
DDI-DrugBank.d507.s5.p2	Noncardioselective beta-blockers	None	group	guanfacine	DB01018	True	effect	drug	Noncardioselective beta-blockers (nadolol,porpranolol,timolol) may exacerbate rebound hypertension when guanfacine is withdrawn.
DDI-DrugBank.d508.s1.p13	dipyridamole	DB00975	drug	Activase	None	True	effect	brand	In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole and Abciximab) may increase the risk of bleeding if administered prior to, during, or after Activase therapy.
DDI-DrugBank.d508.s1.p8	vitamin K antagonists	None	group	Activase	None	True	effect	brand	In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole and Abciximab) may increase the risk of bleeding if administered prior to, during, or after Activase therapy.
DDI-DrugBank.d510.s0.p0	Robinul	None	brand	anticholinergics	None	True	effect	group	The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.
DDI-DrugBank.d510.s0.p3	Robinul	None	brand	tricyclic antidepressants	None	True	effect	group	The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.
DDI-DrugBank.d511.s4.p6	FOSCAVIR	None	brand	pentamidine	DB00738	True	advise	drug	Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.
DDI-DrugBank.d514.s4.p0	Cocaine	DB00907	drug	heroin	DB01452	True	effect	drug_n	Cocaine sometimes proves to be fatal when used in combination with heroin.
DDI-DrugBank.d517.s0.p1	Tetracycline	DB00759	drug	penicillin	None	True	effect	drug	Tetracycline, a bacteriostatic antibiotic, may antagonize the bactercidal effect of penicillin and concurrent use of these drugs should be avoided.
DDI-DrugBank.d521.s1.p7	glimepiride	DB00222	drug	Arthropan	None	True	advise	drug	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
DDI-DrugBank.d522.s23.p3	erythromycin	DB00199	drug	ergotamine	DB00696	True	effect	drug	Ergotamine: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.
DDI-DrugBank.d522.s24.p3	erythromycin	DB00199	drug	alfentanil	DB00802	True	int	drug	Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.
DDI-DrugBank.d529.s11.p0	flurbiprofen	DB00712	drug	beta-blocker	None	True	advise	group	Patients taking both flurbiprofen and a beta-blocker should be monitored to ensure that a satisfactory hypotensive effect is achieved.
DDI-DrugBank.d529.s4.p3	aspirin	None	brand	flurbiprofen	DB00712	True	mechanism	drug	Aspirin: Concurrent administration of aspirin and flurbiprofen resulted in 50% lower serum flurbiprofen concentrations.
DDI-DrugBank.d529.s8.p0	Flurbiprofen	DB00712	drug	propranolol	DB00571	True	effect	drug	Flurbiprofen pretreatment attenuated the hypotensive effect of a single dose of propranolol but not atenolol.
DDI-DrugBank.d53.s7.p1	azithromycin	DB00207	drug	carbamazepine	DB00564	True	mechanism	drug	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
DDI-DrugBank.d53.s7.p7	azithromycin	DB00207	drug	midazolam	DB00683	True	mechanism	drug	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
DDI-DrugBank.d531.s5.p4	rifampin	None	drug	efavirenz	DB00625	True	mechanism	drug	Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.
DDI-DrugBank.d537.s0.p2	Bentiromide	DB00522	drug	chloramphenicol	DB00446	True	int	drug	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
DDI-DrugBank.d538.s1.p3	atropine sulfate	None	drug	MAO inhibitors	None	True	int	group	Diphenoxylate HCl and atropine sulfate may interact with MAO inhibitors In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day.
DDI-DrugBank.d548.s9.p4	Duloxetine	DB00476	drug	amitriptyline	DB00321	True	advise	drug	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
DDI-DrugBank.d548.s9.p8	Duloxetine	DB00476	drug	propafenone	DB01182	True	advise	drug	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
DDI-DrugBank.d55.s0.p0	Isoproterenol hydrochloride	None	drug	epinephrine	DB00668	True	advise	drug	Isoproterenol hydrochloride injection and epinephrine should not be administered simultaneously because both drugs are direct cardiac stimulants and their combined effects may induce serious arrhythmias.
DDI-DrugBank.d55.s2.p0	ISUPREL	None	brand	anesthetics	None	True	advise	group	ISUPREL should be used with caution, if at all, when potent inhalational anesthetics such as halothane are employed because of potential to sensitize the myocardium to effects of sympathomimetic amines.
DDI-DrugBank.d550.s2.p2	famotidine	DB00927	drug	cefditoren pivoxil	None	True	mechanism	drug	H2-Receptor Antagonists: Co-administration of a single dose of intravenously administered famotidine (20 mg) reduced the oral absorption of a single 400 mg dose of cefditoren pivoxil administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC.
DDI-DrugBank.d552.s1.p3	Nabilone	DB00486	drug	codeine	DB00318	True	effect	drug	Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.
DDI-DrugBank.d558.s14.p0	HCTZ	None	drug	dofetilide	DB00204	True	mechanism	drug	In patients receiving HCTZ alone, dofetilide AUC increased by 27% and Cmax by 21%.
DDI-DrugBank.d558.s25.p31	protease inhibitors	None	group	TIKOSYN	None	True	advise	brand	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
DDI-DrugBank.d559.s1.p12	acetaminophen	DB00316	drug	anesthetics	None	True	effect	group	Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
DDI-DrugBank.d5.s17.p1	bupropion	DB01156	drug	nortriptyline	DB00540	True	advise	drug	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
DDI-DrugBank.d5.s17.p6	bupropion	DB01156	drug	sertraline	DB01104	True	advise	drug	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
DDI-DrugBank.d5.s21.p0	WELLBUTRIN	None	brand	levodopa	None	True	advise	drug	Administration of WELLBUTRIN Tablets to patients receiving either levodopa or amantadine concurrently should be undertaken with caution, using small initial doses and small gradual dose increases.
DDI-DrugBank.d5.s22.p0	WELLBUTRIN	None	brand	antipsychotics	None	True	advise	group	Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.
DDI-DrugBank.d5.s3.p0	WELLBUTRIN	None	brand	orphenadrine	DB01173	True	int	drug	Therefore, the potential exists for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e.g., orphenadrine and cyclophosphamide).
DDI-DrugBank.d5.s8.p2	bupropion	DB01156	drug	phenytoin	DB00252	True	mechanism	drug	While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., carbamazepine, phenobarbital, phenytoin).
DDI-DrugBank.d500.s4.p2	Barbiturates	None	group	doxycycline	DB00254	True	mechanism	drug	Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.
DDI-DrugBank.d503.s3.p1	chlorprothixene	DB01239	drug	Ultram	None	True	advise	brand	Avoid the concomitant use of chlorprothixene and tramadol (Ultram).
DDI-DrugBank.d503.s7.p2	chlorprothixene	DB01239	drug	antiparkinsonian agents	None	True	advise	group	Exert particular caution in combining chlorprothixene with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.
DDI-DrugBank.d559.s1.p2	Butalbital	DB00241	drug	narcotic analgesic	None	True	effect	group	Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
DDI-DrugBank.d561.s3.p2	Potassium-Sparing Diuretics	None	group	thiazide diuretics	None	True	effect	group	Potassium Supplements and Potassium-Sparing Diuretics Lotensin can attenuate potassium loss caused by thiazide diuretics.
DDI-DrugBank.d562.s13.p0	cinoxacin	DB00827	drug	nonsteroidal anti-inflammatory agents	None	True	advise	group	Physicians are provided this information to increase awareness of the potential for serious interactions when cinoxacin and certain nonsteroidal anti-inflammatory agents are administered concomitantly.
DDI-DrugBank.d562.s7.p0	quinolones	None	group	iron	DB01592	True	mechanism	drug	Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.
DDI-DrugBank.d565.s27.p0	cyclosporine	DB00091	drug	diltiazem	DB00343	True	advise	drug	If these agents are to be administered concurrently, cyclosporine concentrations should be monitored, especially when diltiazem therapy is initiated, adjusted, or discontinued.
DDI-DrugBank.d566.s0.p11	Cholestyramine	DB01432	drug	digitalis	None	True	mechanism	group	Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
DDI-DrugBank.d566.s2.p12	cholestyramine	DB01432	drug	digitalis	None	True	mechanism	group	Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine resin.
DDI-DrugBank.d568.s32.p5	escitalopram	DB01175	drug	desipramine	DB01151	True	mechanism	drug	However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine.
DDI-DrugBank.d568.s35.p4	LEXAPRO	None	brand	metoprolol	DB00264	True	mechanism	drug	Metoprolol - Administration of 20 mg/day LEXAPRO for 21 days in healthy volunteers resulted in a 50% increase in Cmax and 82% increase in AUC of the beta-adrenergic blocker metoprolol (given in a single dose of 100 mg).
DDI-DrugBank.d568.s5.p0	psychotropic drugs	None	group	NSAID	None	True	effect	group	Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin potentiated the risk of bleeding.
DDI-DrugBank.d568.s5.p1	psychotropic drugs	None	group	aspirin	None	True	effect	brand	Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin potentiated the risk of bleeding.
DDI-DrugBank.d569.s1.p0	Angiomax	None	brand	heparin	DB01109	True	effect	drug	In clinical trials in patients undergoing PTCA/PCI, co-administration of Angiomax with heparin, warfarin, thrombolytics or glycoprotein IIb/IIIa inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications.
DDI-DrugBank.d572.s5.p0	ZETIA	None	brand	fibrates	None	True	advise	group	Co-administration of ZETIA with fibrates is not recommended until use in patients is studied.
DDI-DrugBank.d573.s1.p0	guanethidine	DB01170	drug	minoxidil	DB00350	True	advise	drug	If at all possible guanethidine should be discontinued well before minoxidil is begun.
DDI-DrugBank.d576.s1.p1	ASPIRIN	None	brand	DISALCID	None	True	effect	brand	ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS.
DDI-DrugBank.d576.s6.p8	Salicylate	None	group	methotrexate	DB00563	True	mechanism	drug	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.
DDI-DrugBank.d576.s6.p9	Salicylate	None	group	corticosteroids	None	True	mechanism	group	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.
DDI-DrugBank.d577.s3.p0	Sulfamethoxazole	DB01015	drug	phenytoin	DB00252	True	mechanism	drug	Sulfamethoxazole may inhibit the hepatic metabolism of phenytoin.
DDI-DrugBank.d577.s4.p0	sulfamethoxazole	DB01015	drug	phenytoin	DB00252	True	mechanism	drug	At a 1.6-g dose, sulfamethoxazole produced a slight but significant increase in the half-life of phenytoin but did not produce a corresponding decrease in the metabolic clearance rate.
DDI-DrugBank.d578.s4.p2	phenobarbital	DB01174	drug	methylprednisolone	DB00959	True	mechanism	drug	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response.
DDI-DrugBank.d578.s7.p0	Methylprednisolone	DB00959	drug	aspirin	None	True	mechanism	brand	Methylprednisolone may increase the clearance of chronic high dose aspirin.
DDI-DrugBank.d580.s1.p0	ketoconazole	DB01026	drug	mometasone furoate	None	True	mechanism	drug	However, ketoconazole, a potent inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing.
DDI-DrugBank.d585.s0.p1	anticholinergic drugs	None	group	antiarrhythmic agents of class I	None	True	effect	group	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
DDI-DrugBank.d588.s10.p2	Non-Steroidal Anti-Inflammatory Drugs	None	group	MYKROX	None	True	effect	brand	Salicylates and Other Non-Steroidal Anti-Inflammatory Drugs: May decrease the antihypertensive effects of MYKROX Tablets.
DDI-DrugBank.d588.s8.p4	Diuretic	None	group	tubocurarine	DB01199	True	effect	drug	Curariform Drugs: Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea.
DDI-DrugBank.d59.s0.p0	ERGOMAR	None	brand	triacetyloleandomycin	None	True	mechanism	drug	The effects of ERGOMAR may be potentiated by triacetyloleandomycin which inhibits the metabolism of ergotamine.
DDI-DrugBank.d590.s2.p0	antacid	None	group	ranitidine	DB00863	True	mechanism	drug	Coadministration with a high dose of antacid (170 mEq) results in a 28% decrease in plasma concentrations of ranitidine and may decrease plasma concentrations of bismuth from TRITEC.
DDI-DrugBank.d595.s1.p2	dobutamine	DB00841	drug	sodium bicarbonate	DB01390	True	int	drug	norepinephrine and dobutamine are incompatible with sodium bicarbonate solution.
DDI-DrugBank.d596.s9.p12	cholinesterase inhibitors	None	group	neuromuscular blocking agents	None	True	effect	group	Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.
DDI-DrugBank.d596.s9.p14	cholinesterase inhibitors	None	group	bethanechol	DB01019	True	effect	drug	Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.
DDI-DrugBank.d597.s14.p4	NSAIDs	None	group	thiazide diuretics	None	True	effect	group	Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients.
DDI-DrugBank.d597.s22.p0	lithium	DB01356	drug	MOBIC	None	True	advise	brand	Patients on lithium treatment should be closely monitored when MOBIC is introduced or withdrawn.
DDI-DrugBank.d597.s4.p2	meloxicam	DB00814	drug	aspirin	None	True	advise	brand	however, as with other NSAIDs, concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.
DDI-DrugBank.d599.s6.p0	GH	None	drug	antipyrine	DB01435	True	mechanism	drug	Limited published data indicate that GH treatment increases cytochrome P450 (CP450) mediated antipyrine clearance in man.
DDI-DrugBank.d599.s7.p3	GH	None	drug	cyclosporin	None	True	mechanism	drug	These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin).
DDI-DrugBank.d60.s12.p1	nondepolarizing agents	None	group	antibiotics	None	True	effect	group	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d60.s12.p7	nondepolarizing agents	None	group	clindamycin	DB01190	True	effect	drug	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d506.s7.p0	disopyramide phosphate	None	drug	erythromycin	DB00199	True	mechanism	drug	Patients taking disopyramide phosphate and erythromycin concomitantly may develop increased serum concentrations of disopyramide resulting in excessive widening of the QRS complex and/or prolongation of the Q-T interval.
DDI-DrugBank.d509.s0.p3	ABILIFY	None	brand	centrally acting drugs	None	True	advise	group	Drug-Drug Interactions Given the primary CNS effects of aripiprazole, caution should be used when ABILIFY is taken in combination with other centrally acting drugs and alcohol.
DDI-DrugBank.d509.s22.p0	carbamazepine	DB00564	drug	aripiprazole	DB01238	True	advise	drug	When carbamazepine is withdrawn from the combination therapy, aripiprazole dose should then be reduced.
DDI-DrugBank.d509.s7.p0	carbamazepine	DB00564	drug	aripiprazole	DB01238	True	mechanism	drug	Agents that induce CYP3A4 (eg, carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels.
DDI-DrugBank.d509.s8.p3	ketoconazole	DB01026	drug	aripiprazole	DB01238	True	mechanism	drug	Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.
DDI-DrugBank.d510.s0.p1	Robinul	None	brand	phenothiazines	None	True	effect	group	The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.
DDI-DrugBank.d510.s0.p2	Robinul	None	brand	antiparkinson drugs	None	True	effect	group	The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.
DDI-DrugBank.d510.s1.p0	Robinul	None	brand	potassium chloride	DB00761	True	mechanism	drug	Concomitant administration of Robinul Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.
DDI-DrugBank.d512.s7.p0	Sensipar	None	brand	ketoconazole	DB01026	True	advise	drug	Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, erythromycin, itraconazole;
DDI-DrugBank.d512.s7.p1	Sensipar	None	brand	erythromycin	DB00199	True	advise	drug	Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, erythromycin, itraconazole;
DDI-DrugBank.d514.s2.p3	heroin	DB01452	drug_n	diazepam	DB00829	True	effect	drug	Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.
DDI-DrugBank.d516.s3.p35	didanosine	DB00900	drug	lomefloxacin	DB00978	True	mechanism	drug	Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.
DDI-DrugBank.d516.s5.p5	aluminum	None	drug	lomefloxacin	DB00978	True	mechanism	drug	Magnesium- and aluminum-containing antacids, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of lomefloxacin.
DDI-DrugBank.d521.s1.p6	glimepiride	DB00222	drug	choline salicylate	None	True	advise	drug	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
DDI-DrugBank.d522.s15.p10	dirithromycin	DB00954	drug	H 2 -receptor antagonists	None	True	mechanism	group	Antacids or H 2 receptor antagonists: When dirithromycin is administered immediately following antacids or H 2 -receptor antagonists, the absorption of dirithromycin is slightly enhanced.
DDI-DrugBank.d522.s24.p1	erythromycin	DB00199	drug	hexobarbital	DB01355	True	int	drug	Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.
DDI-DrugBank.d522.s24.p5	erythromycin	DB00199	drug	phenytoin	DB00252	True	int	drug	Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.
DDI-DrugBank.d60.s12.p9	nondepolarizing agents	None	group	sodium colistemethate	None	True	effect	drug	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d60.s6.p7	enflurane	DB00228	drug	NIMBEX	None	True	effect	brand	Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.
DDI-DrugBank.d600.s1.p1	alcohol	None	drug	methyprylon	DB01107	True	effect	drug	Concurrent use of alcohol and other CNS depression-producing drugs may increase the CNS depressant effects of methyprylon or these other medications.
DDI-DrugBank.d603.s5.p63	desglymidodrine	None	drug_n	metformin	DB00331	True	mechanism	drug	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.
DDI-DrugBank.d603.s5.p66	desglymidodrine	None	drug_n	procainamide	DB01035	True	mechanism	drug	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.
DDI-DrugBank.d604.s0.p0	Thalidomide	DB01041	drug	barbiturates	None	True	effect	group	Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine.
DDI-DrugBank.d606.s0.p2	beta adrenergic blockers	None	group	pseudoephedrine	DB00852	True	effect	drug	MAO inhibitors and beta adrenergic blockers increase the effects of pseudoephedrine.
DDI-DrugBank.d608.s4.p0	TOLECTIN	None	brand	methotrexate	DB00563	True	advise	drug	Caution should be used if TOLECTIN is administered concomitantly with methotrexate.
DDI-DrugBank.d78.s3.p11	Grepafloxacin	DB00365	drug	theobromine	DB01412	True	mechanism	drug	Caffeine Theobromine Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and theobromine.
DDI-DrugBank.d78.s3.p13	quinolones	None	group	theobromine	DB01412	True	mechanism	drug	Caffeine Theobromine Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and theobromine.
DDI-DrugBank.d78.s8.p7	theophylline	DB00277	drug	grepafloxacin	DB00365	True	advise	drug	When initiating a multi-day course of grepafloxacin in a patient maintained on theophylline, the theophylline maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.
DDI-DrugBank.d782.s0.p1	Vindesine	DB00309	drug	Live virus vaccines	None	True	int	group	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine
DDI-DrugBank.d784.s0.p0	oxybutynin	DB01062	drug	anticholinergic drugs	None	True	effect	group	The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects.
DDI-DrugBank.d784.s4.p10	itraconazole	DB01167	drug	oxybutynin	DB01062	True	mechanism	drug	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).
DDI-DrugBank.d784.s4.p14	miconazole	DB01110	drug	oxybutynin	DB01062	True	mechanism	drug	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).
DDI-DrugBank.d79.s0.p0	lymecycline	DB00256	drug	iron	DB01592	True	mechanism	drug	The absorption of lymecycline may be affected by the simultaneous administration of indigestion remedies, iron or zinc supplements.
DDI-DrugBank.d79.s1.p0	contraceptives	None	group	lymecycline	DB00256	True	effect	drug	Oral contraceptives may be less effective while you are taking lymecycline.
DDI-DrugBank.d8.s0.p1	ALFENTA	None	brand	barbiturates	None	True	effect	group	Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as barbiturates, tranquilizers, opioids, or inhalation general anesthetics.
DDI-DrugBank.d82.s33.p0	beta-adrenoceptor blocking agents	None	group	non-steroidal antiinflammatory drugs	None	True	effect	group	Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by non-steroidal antiinflammatory drugs including INDOCIN has been reported.
DDI-DrugBank.d85.s12.p2	Naproxen	DB00788	drug	methotrexate	DB00563	True	mechanism	drug	Naproxen, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.
DDI-DrugBank.d85.s9.p2	Naproxen	DB00788	drug	beta-blockers	None	True	effect	group	Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers.
DDI-DrugBank.d86.s0.p10	antiparkinsonian drug	None	group	tricyclic antidepressant	None	True	effect	group	The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
DDI-DrugBank.d86.s0.p2	antipsychotic drug	None	group	trihexyphenidyl	DB00376	True	effect	drug	The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
DDI-DrugBank.d87.s13.p4	phenobarbital	DB01174	drug	flecainide	DB01195	True	mechanism	drug	Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination.
DDI-DrugBank.d87.s13.p5	carbamazepine	DB00564	drug	flecainide	DB01195	True	mechanism	drug	Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination.
DDI-DrugBank.d88.s3.p6	capecitabine	DB01101	drug	phenprocoumon	DB00946	True	effect	drug	Coumarin Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon.
DDI-DrugBank.d88.s4.p0	coumarin-derivative anticoagulants	None	group	capecitabine	DB01101	True	advise	drug	Patients taking coumarin-derivative anticoagulants concomitantly with capecitabine should be monitored regularly for alterations in their coagulation parameters (PT or INR).
DDI-DrugBank.d9.s0.p1	Azlocillin	DB01061	drug	ciprofloxacin	DB00537	True	advise	drug	Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.
DDI-DrugBank.d9.s0.p2	Azlocillin	DB01061	drug	gentamicin	DB00798	True	advise	drug	Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.
DDI-DrugBank.d94.s11.p12	EQUETROTM	None	brand	diazepam	DB00829	True	mechanism	drug	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s11.p2	EQUETROTM	None	brand	amitriptyline	DB00321	True	mechanism	drug	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s11.p24	EQUETROTM	None	brand	methadone	DB00333	True	mechanism	drug	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s11.p27	EQUETROTM	None	brand	nortriptyline	DB00540	True	mechanism	drug	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s11.p29	EQUETROTM	None	brand	contraceptives	None	True	mechanism	group	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s11.p3	EQUETROTM	None	brand	bupropion	DB01156	True	mechanism	drug	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s13.p6	EQUETROTM	None	brand	Phenytoin	DB00252	True	mechanism	drug	Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.
DDI-DrugBank.d94.s14.p2	carbamazepine	DB00564	drug	lithium	DB01356	True	effect	drug	Pharmacological/Pharmacodynamic Interactions with Carbamazepine Concomitant administration of carbamazepine and lithium may increase the risk of neurotoxic side effects.
DDI-DrugBank.d94.s16.p4	chloroquine	DB00608	drug	carbamazepine	DB00564	True	effect	drug	Additionally, anti-malarial drugs, such as chloroquine and mefloquine, may antagonize the activity of carbamazepine.
DDI-DrugBank.d94.s18.p0	EQUETROTM	None	brand	centrally acting drugs	None	True	advise	group	Because of its primary CNS effect, caution should be used when EQUETROTM is taken with other centrally acting drugs and alcohol.
DDI-DrugBank.d94.s4.p1	EQUETROTM	None	brand	azole antifungals	None	True	mechanism	group	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
DDI-DrugBank.d94.s4.p10	EQUETROTM	None	brand	fluvoxamine	DB00176	True	mechanism	drug	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
DDI-DrugBank.d94.s4.p13	EQUETROTM	None	brand	ketoconazole	DB01026	True	mechanism	drug	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
DDI-DrugBank.d610.s4.p0	methadone	DB00333	drug	ZIAGEN	None	True	mechanism	brand	In a study of 11 HIV-infected patients receiving methadone-maintenance therapy (40 mg and 90 mg daily) with 600 mg of ZIAGEN twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% CI 6% to 42%).
DDI-DrugBank.d615.s0.p6	Triprolidine	DB00427	drug	tranquillisers	None	True	effect	group	Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.
DDI-DrugBank.d619.s4.p0	tricyclic antidepressants	None	group	ELDEPRYL	None	True	effect	brand	Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and selective serotonin reuptake inhibitors and ELDEPRYL.
DDI-DrugBank.d619.s5.p0	selegiline	DB01037	drug	sympathomimetic medication	None	True	effect	group	One case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a sympathomimetic medication (ephedrine).
DDI-DrugBank.d622.s0.p0	atropine	DB00572	drug	pralidoxime	DB00733	True	effect	drug	When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone.
DDI-DrugBank.d624.s3.p0	TOBI	None	brand	ethacrynic acid	DB00903	True	advise	drug	TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.
DDI-DrugBank.d628.s0.p0	DIPRIVAN	None	brand	narcotics	None	True	effect	group	The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.)
DDI-DrugBank.d628.s3.p1	DIPRIVAN	None	brand	nitrous oxide	None	True	advise	drug	During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids).
DDI-DrugBank.d633.s18.p22	Mexitil	None	brand	theophylline	DB00277	True	advise	drug	This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed.
DDI-DrugBank.d94.s4.p15	EQUETROTM	None	brand	nefazodone	DB01149	True	mechanism	drug	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
DDI-DrugBank.d94.s4.p5	EQUETROTM	None	brand	danazol	DB01406	True	mechanism	drug	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
DDI-DrugBank.d94.s8.p3	EQUETROTM	None	brand	rifampin	None	True	mechanism	drug	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
DDI-DrugBank.d97.s63.p0	CRIXIVAN	None	brand	indinavir	DB00224	True	effect	drug	CRIXIVAN may not be effective due to decreased indinavir concentrations in patients taking these agents concomitantly.
DDI-DrugBank.d98.s2.p11	phenytoin	DB00252	drug	calcitriol	DB00136	True	mechanism	drug	Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
DDI-MedLine.d102.s5.p0	estradiol	DB00783	drug	noradrenaline	None	True	effect	drug	Aortic rings with intact endothelium from the high-dose (4 mg/kg/day) estradiol group were supersensitive to noradrenaline compared to the vehicle or low-dose (10 microg/kg/day) estradiol groups (pD2 values = 7.86+/-0.09, 7.30+/-0.11 and 7.35+/-0.04, respectively).
DDI-MedLine.d106.s8.p2	methaqualone	DB04833	drug	anticoagulant agents	None	True	int	group	Chloral hydrate and methaqualone interact pharmacologically with orally administered anticoagulant agents, but the effect is not clinically significant.
DDI-MedLine.d110.s6.p1	ibogaine	None	drug_n	morphine	DB00295	True	effect	drug	Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens;
DDI-MedLine.d110.s6.p2	ibogaine	None	drug_n	nicotine	DB00184	True	effect	drug	Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens;
DDI-MedLine.d111.s14.p0	acetaminophen	DB00316	drug	theophylline	DB00277	True	effect	drug	Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.
DDI-MedLine.d12.s0.p4	retinyl acetate	None	drug	insulin	None	True	effect	drug	Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.
DDI-MedLine.d12.s2.p3	dexamethasone	DB01234	drug	insulin	None	True	effect	drug	Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin.
DDI-MedLine.d12.s4.p1	dexamethasone	DB01234	drug	EGF	None	True	effect	drug_n	Higher concentrations of dexamethasone (10(-8) - 10(-6) M) or retinyl acetate (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of EGF.
DDI-MedLine.d130.s8.p0	thiosulfate	None	drug	cisplatin	DB00515	True	mechanism	drug	This study demonstrates that concurrent administration of thiosulfate permits at least a twofold increase in dose and total exposure to cisplatin.
DDI-MedLine.d131.s0.p1	neurotensin	None	drug_n	tuftsin	None	True	effect	drug_n	Interaction on the antinociceptive effect between neurotensin and enkephalins or tuftsin.
DDI-MedLine.d131.s3.p0	neurotensin	None	drug_n	enkephalins	None	True	effect	drug_n	It was shown that neurotensin antagonized evidently the antinociceptive effect of enkephalins and their analogue.
DDI-MedLine.d134.s2.p0	perchlorate	None	drug_n	pertechnetate	None	True	mechanism	drug	An intravenous injection of perchlorate given later also produces a complete and immediately beginning depletion of pertechnetate already accumulated in the thyroid, within a period of 195 min after 99m-TcO-4-injection with a corresponding increase in blood levels.
DDI-MedLine.d154.s5.p0	GSLS	None	drug_n	inactivated AI vaccines	None	True	effect	drug	In experiment 2, the same regimen of GSLS was administered to chickens inoculated with inactivated AI vaccines, and an enhanced serum antibody response to AI vaccination was also observed.
DDI-MedLine.d164.s0.p0	Lapatinib	DB01259	drug	herceptin	None	True	effect	brand	Lapatinib enhances herceptin-mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression.
DDI-MedLine.d164.s4.p0	Herceptin	None	brand	lapatinib	DB01259	True	effect	drug	Furthermore, we present a case report in which a second Herceptin treatment following lapatinib resulted in the marked shrinkage of multiple metastatic tumors in HER2-positive breast cancer.
DDI-MedLine.d169.s1.p1	Calcium	DB01373	drug	heme iron	None	True	mechanism	drug	Calcium is the only known component in the diet that may affect absorption of both nonheme and heme iron.
DDI-MedLine.d180.s10.p3	DZNep	None	drug_n	ABT-737	None	True	effect	drug_n	We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells.
DDI-MedLine.d199.s4.p0	ketamine	DB01221	drug	propofol	DB00818	True	effect	drug	Based on this experience, we suggest that low-dose ketamine added to propofol may be associated with prevention of EA in children with a history of EA with propofol TIVA.
DDI-MedLine.d204.s11.p0	methylglyoxal	None	drug_n	carbenicillin	DB00578	True	effect	drug	Synergism was also noted when methylglyoxal was combined with carbenicillin and amikacin.
DDI-MedLine.d209.s9.p1	tamoxifen	DB00675	drug	paroxetine	DB00715	True	advise	drug	It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine.
DDI-MedLine.d213.s3.p0	midazolam	DB00683	drug	cyclosporine	DB00091	True	mechanism	drug	Systemic and apparent oral midazolam clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20).
DDI-MedLine.d216.s6.p0	S-ketamine	None	drug	ticlopidine	DB00208	True	advise	drug	The findings suggest that the dosage of S-ketamine should be reduced in patients receiving ticlopidine.
DDI-MedLine.d218.s10.p2	Warfarin	DB00682	drug	paroxetine	DB00715	True	effect	drug	Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.
DDI-DrugBank.d522.s7.p2	terfenadine	DB00342	drug	dirithromycin	DB00954	True	effect	drug	The mean QT c interval (msec) was 369 with terfenadine alone and 367 with terfenadine plus dirithromycin.
DDI-DrugBank.d526.s17.p4	phenytoin	DB00252	drug	fludrocortisone acetate	None	True	mechanism	drug	Barbiturates, phenytoin, or rifampin increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes.
DDI-DrugBank.d526.s17.p5	rifampin	None	drug	fludrocortisone acetate	None	True	mechanism	drug	Barbiturates, phenytoin, or rifampin increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes.
DDI-DrugBank.d528.s0.p8	L-methionine	DB00134	drug	methotrexate	DB00563	True	effect	drug	Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate.
DDI-DrugBank.d529.s14.p4	flurbiprofen	DB00712	drug	furosemide	DB00695	True	effect	drug	Diuretics: Studies in normal volunteers have shown that flurbiprofen like other nonsteroidal anti-inflammatory drugs, can interfere with the effects of furosemide.
DDI-DrugBank.d53.s5.p0	macrolides	None	group	warfarin	DB00682	True	effect	drug	Concurrent use of macrolides and warfarin in clinical practice has been associated with increased anticoagulant effects.
DDI-DrugBank.d53.s7.p0	azithromycin	DB00207	drug	atorvastatin	DB01076	True	mechanism	drug	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
DDI-DrugBank.d53.s7.p13	azithromycin	DB00207	drug	sulfamethoxazole	DB01015	True	mechanism	drug	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
DDI-DrugBank.d53.s7.p3	azithromycin	DB00207	drug	didanosine	DB00900	True	mechanism	drug	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
DDI-DrugBank.d636.s0.p0	anticonvulsants	None	group	Mephenytoin	DB00532	True	int	drug	Some anticonvulsants may interact with Mephenytoin.
DDI-DrugBank.d636.s3.p4	Mephenytoin	DB00532	drug	theophylline	DB00277	True	effect	drug	Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.
DDI-DrugBank.d637.s0.p7	morphine	DB00295	drug	alcohol	None	True	effect	drug	Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs.
DDI-DrugBank.d637.s0.p9	morphine	DB00295	drug	antihistaminics	None	True	effect	group	Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs.
DDI-DrugBank.d638.s0.p0	Ritalin	None	brand	guanethidine	DB01170	True	effect	drug	Ritalin may decrease the hypotensive effect of guanethidine.
DDI-DrugBank.d639.s2.p3	SUTENT	None	brand	rifampin	None	True	mechanism	drug	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.
DDI-DrugBank.d64.s29.p0	anticoagulant	None	group	adrenocortical steroids	None	True	effect	group	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
DDI-DrugBank.d64.s29.p13	anticoagulant	None	group	griseofulvin	DB00400	True	effect	drug	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
DDI-DrugBank.d64.s29.p7	anticoagulant	None	group	chlordiazepoxide	DB00475	True	effect	drug	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
DDI-DrugBank.d64.s4.p0	Chloral hydrate	DB01563	drug	anticoagulant	None	True	mechanism	group	Chloral hydrate may cause an increased prothrombin response by displacing the anticoagulant from protein binding sites or a diminished prothrombin response through increased metabolism of the unbound drug by hepatic enzyme induction, thus leading to inter-patient variation in ultimate prothrombin effect.
DDI-DrugBank.d64.s87.p12	anticoagulant	None	group	clofibrate	DB00636	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p20	anticoagulant	None	group	glucagon	None	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p37	anticoagulant	None	group	phenyramidol	None	True	effect	drug_n	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p48	anticoagulant	None	group	thyroid drugs	None	True	effect	group	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p6	anticoagulant	None	group	bromelains	None	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s90.p12	aspirin	None	brand	anticoagulants	None	True	effect	group	Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal anti-inflammatory drugs, dipyridamole, hydrochloroquine, clofibrate, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.
DDI-DrugBank.d64.s90.p24	hydrochloroquine	None	drug	anticoagulants	None	True	effect	group	Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal anti-inflammatory drugs, dipyridamole, hydrochloroquine, clofibrate, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.
DDI-DrugBank.d640.s3.p4	potassium-sparing diuretics	None	group	ACE inhibitors	None	True	effect	group	Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.
DDI-DrugBank.d640.s6.p9	ACE inhibitors	None	group	lithium	DB01356	True	effect	drug	Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.
DDI-DrugBank.d643.s0.p7	Melatonin	DB01065	drug	fluoxetine	DB00472	True	int	drug	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
DDI-DrugBank.d648.s0.p4	Cholestyramine	DB01432	drug	EVISTA	None	True	advise	brand	Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA.
DDI-DrugBank.d650.s0.p11	neuroleptics	None	group	Permax	None	True	advise	brand	Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist);
DDI-DrugBank.d650.s0.p16	phenothiazines	None	group	Permax	None	True	advise	brand	Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist);
DDI-DrugBank.d652.s3.p6	metoclopramide	DB01233	drug	acetaminophen	DB00316	True	mechanism	drug	Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).
DDI-DrugBank.d653.s1.p7	rifampin	None	drug	corticosteroids	None	True	mechanism	group	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.
DDI-DrugBank.d655.s0.p15	Methscopolamine	None	drug	antacids	None	True	int	group	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
DDI-DrugBank.d655.s0.p17	Methscopolamine	None	drug	kaolin	DB01575	True	int	drug	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
DDI-DrugBank.d655.s0.p8	Methscopolamine	None	drug	furazolidone	DB00614	True	int	drug	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
DDI-DrugBank.d656.s2.p26	Nonsteroidal anti-inflammatory agents	None	group	lithium	DB01356	True	mechanism	drug	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels.
DDI-MedLine.d25.s0.p0	simvastatin	DB00641	drug	clarithromycin	DB01211	True	effect	drug	Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin.
DDI-MedLine.d29.s8.p0	probenecid	DB01032	drug	cloxacillin	DB01147	True	mechanism	drug	This might be explained by a blockade by probenecid of the elimination of cloxacillin by the liver.
DDI-MedLine.d30.s9.p0	naloxone	DB01183	drug	(-)-NANM	None	True	effect	drug_n	the doses of naloxone required to antagonize the effects of (-)-NANM were more than 100 times higher than those required to antagonize the effects of morphine.
DDI-MedLine.d34.s0.p0	cobalt	None	drug	iron	DB01592	True	mechanism	drug	Interactions of cobalt and iron in absorption and retention.
DDI-MedLine.d34.s7.p0	iron	DB01592	drug	cobalt	None	True	mechanism	drug	Additional iron significantly inhibited the absorption of cobalt in both dietary cobalt treatments.
DDI-MedLine.d45.s6.p0	tripelennamine	DB00792	drug	pentazocine	DB00652	True	effect	drug	Dose-response curves (derived from the results of using the tablets as well as pure powders) showed that tripelennamine was responsible for the inhibitory activity, which was partially antagonized by pentazocine.
DDI-MedLine.d53.s4.p0	TAM	None	drug_n	1,25(OH)2D3	None	True	effect	drug	Our data suggest that TAM significantly potentiates the reduction in cell number induced by 1,25(OH)2D3 alone.
DDI-MedLine.d53.s5.p0	1,25(OH)2D3	None	drug	TAM	None	True	effect	drug_n	Combined treatment with 1,25(OH)2D3 and TAM enhances the degree of apoptosis assessed using morphological markers that identify chromatin and nuclear matrix protein condensation.
DDI-MedLine.d55.s4.p0	acetaminophen	DB00316	drug	caffeine	DB00201	True	effect	drug	Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.
DDI-MedLine.d59.s4.p0	Cytochalasin D	None	drug_n	carbachol	DB00411	True	effect	drug	Cytochalasin D at 10 microM preferentially blocked the secretory effect of carbachol and its synergism with cAMP, whereas it had no effect on histamine- or cAMP-stimulated acid secretion within 15 min.
DDI-MedLine.d63.s5.p0	naloxone	DB01183	drug	morphine	DB00295	True	effect	drug	On the other hand, intrathecal naloxone (12-120 micrograms) had only a very weak effect on the tail-flick inhibition induced by intraventricular morphine (40 micrograms).
DDI-MedLine.d79.s5.p0	Indinavir	DB00224	drug	didanosine	DB00900	True	advise	drug	Indinavir may be taken with a light meal 1 h following the administration of 400 mg of didanosine.
DDI-DrugBank.d53.s7.p9	azithromycin	DB00207	drug	sildenafil	DB00203	True	mechanism	drug	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
DDI-DrugBank.d531.s38.p2	indinavir	DB00224	drug	SUSTIVA	None	True	mechanism	brand	Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to SUSTIVA.
DDI-DrugBank.d531.s5.p2	phenobarbital	DB01174	drug	efavirenz	DB00625	True	mechanism	drug	Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.
DDI-DrugBank.d531.s63.p0	SUSTIVA	None	brand	ritonavir	DB00503	True	advise	drug	Monitoring of liver enzymes is recommended when SUSTIVA is used in combination with ritonavir.
DDI-DrugBank.d531.s75.p0	anticonvulsant	None	group	efavirenz	DB00625	True	mechanism	drug	Potential for reduction in anticonvulsant and/or efavirenz plasma levels;
DDI-DrugBank.d537.s0.p10	Bentiromide	DB00522	drug	procainamide	DB01035	True	int	drug	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
DDI-DrugBank.d537.s0.p12	Bentiromide	DB00522	drug	sulfonamides	None	True	int	group	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
DDI-DrugBank.d537.s0.p8	Bentiromide	DB00522	drug	PABA	None	True	int	drug_n	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
DDI-MedLine.d8.s6.p8	rifampicin	DB01045	drug	ofloxacin	DB01165	True	effect	drug	When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin.
DDI-MedLine.d84.s4.p0	GL	None	drug_n	antibiotics	None	True	effect	group	The antimicrobial combinations of GL with four antibiotics resulted in additive effect in most instances, synergism in two instances, and antagonism in two instances.
DDI-MedLine.d84.s5.p0	GL	None	drug_n	cefazolin	DB01327	True	effect	drug	Synergism was observed when GL was combined with cefazolin against Bacillus subtilis and Klebsiella oxytoca.
DDI-MedLine.d85.s7.p0	Misonidazole	None	drug_n	CCNU	None	True	effect	drug	Misonidazole reduced the antitumour activity of oral CCNU by dose modifying factors (DMF) of 0.58-0.71.
DDI-MedLine.d85.s9.p0	Misonidazole	None	drug_n	CCNU	None	True	mechanism	drug	Misonidazole has a complex effect on oral CCNU pharmacokinetics.
DDI-DrugBank.d542.s1.p2	aspirin	None	brand	nicotinic acid	None	True	mechanism	drug	Aspirin: Concomitant aspirin may decrease the metabolic clearance of nicotinic acid.
DDI-DrugBank.d545.s0.p1	Geocillin	None	brand	probenecid	DB01032	True	mechanism	drug	Geocillin (carbenicillin indanyl sodium) blood levels may be increased and prolonged by concurrent administration of probenecid.
DDI-DrugBank.d548.s9.p1	Duloxetine	DB00476	drug	tricyclic antidepressants	None	True	advise	group	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
DDI-DrugBank.d552.s0.p1	Nabilone	DB00486	drug	CNS depressants	None	True	advise	group	Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).
DDI-DrugBank.d556.s0.p0	cephalosporins	None	group	aminoglycoside antibiotics	None	True	effect	group	Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.
DDI-DrugBank.d558.s25.p40	serotonin reuptake inhibitors	None	group	TIKOSYN	None	True	advise	brand	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
DDI-DrugBank.d558.s25.p48	amiodarone	DB01118	drug	TIKOSYN	None	True	advise	brand	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
DDI-DrugBank.d558.s25.p55	cannabinoids	None	group	TIKOSYN	None	True	advise	brand	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
DDI-DrugBank.d558.s25.p70	norfloxacin	DB01059	drug	TIKOSYN	None	True	advise	brand	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
DDI-DrugBank.d558.s25.p75	zafirlukast	DB00549	drug	TIKOSYN	None	True	advise	brand	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
DDI-DrugBank.d558.s37.p0	dofetilide	DB00204	drug	thiazide diuretics	None	True	mechanism	group	The mean clearances of dofetilide were 16% and 15% lower in patients on thiazide diuretics and inhibitors of tubular organic cation transport, respectively.
DDI-DrugBank.d559.s1.p3	Butalbital	DB00241	drug	alcohol	None	True	effect	drug	Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
DDI-DrugBank.d561.s12.p2	ACE inhibitors	None	group	beta-adrenergic blockers	None	True	effect	group	Benazepril, like other ACE inhibitors, has had less than additive effects with beta-adrenergic blockers, presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system
DDI-DrugBank.d562.s8.p1	Quinolones	None	group	anticoagulants	None	True	effect	group	Quinolones, including cinoxacin, may enhance the effects of oral anticoagulants, such as warfarin or its derivatives.
DDI-DrugBank.d565.s1.p1	beta-blockers	None	group	Tiazac	None	True	effect	brand	Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or digitalis concomitantly with Tiazac.
DDI-DrugBank.d565.s12.p2	cimetidine	DB00501	drug	diltiazem	DB00343	True	mechanism	drug	A study in six healthy volunteers has shown a significant increase in peak diltiazem plasma levels (58%) and AUC (53%) after a 1-week course of cimetidine 1200 mg/day and a single dose of diltiazem 60mg.
DDI-DrugBank.d565.s20.p2	digoxin	DB00390	drug	diltiazem hydrochloride	None	True	advise	drug	Since there have been conflicting results regarding the effect of digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing diltiazem hydrochloride therapy to avoid possible over- or under-digitalization.
DDI-DrugBank.d94.s11.p33	EQUETROTM	None	brand	protease inhibitors	None	True	mechanism	group	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s11.p40	EQUETROTM	None	brand	triazolam	DB00897	True	mechanism	drug	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s11.p42	EQUETROTM	None	brand	warfarin	DB00682	True	mechanism	drug	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s11.p9	EQUETROTM	None	brand	cyclosporin	None	True	mechanism	drug	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d565.s8.p0	diltiazem hydrochloride	None	drug	propranolol	DB00571	True	mechanism	drug	Administration of diltiazem hydrochloride concomitantly with propranolol in five normal volunteers resulted in increased propranolol levels in all subjects and bioavailability of propranolol was increased approximately 50%.
DDI-DrugBank.d565.s9.p0	propranolol	DB00571	drug	diltiazem	DB00343	True	mechanism	drug	In vitro, propranolol appears to be displaced from its binding sites by diltiazem.
DDI-DrugBank.d566.s0.p1	Cholestyramine	DB01432	drug	phenylbutazone	DB00812	True	mechanism	group	Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
DDI-DrugBank.d567.s14.p0	HMG-CoA reductase inhibitor	None	group	warfarin	DB00682	True	effect	drug	However, another HMG-CoA reductase inhibitor has been found to produce a less than two-second increase in prothrombin time in healthy volunteers receiving low doses of warfarin.
DDI-DrugBank.d568.s1.p13	psychotropic medications	None	group	LEXAPRO	None	True	advise	brand	Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.
DDI-DrugBank.d568.s17.p6	sumatriptan	DB00669	drug	escitalopram	DB01175	True	advise	drug	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.
DDI-DrugBank.d568.s39.p8	escitalopram	DB01175	drug	Celexa	None	True	advise	brand	Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered.
DDI-DrugBank.d57.s0.p2	aminoglycoside	None	group	cephalosporins	None	True	effect	group	In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation.
DDI-DrugBank.d575.s5.p0	methotrexate	DB00563	drug	teniposide	DB00444	True	mechanism	drug	An increase in intracellular levels of methotrexate was observed in vitro in the presence of teniposide.
DDI-DrugBank.d576.s6.p3	Salicylate	None	group	triiodothyronine	None	True	mechanism	drug	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.
DDI-DrugBank.d94.s13.p5	EQUETROTM	None	brand	Clomipramine HCl	None	True	mechanism	drug	Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.
DDI-DrugBank.d94.s4.p14	EQUETROTM	None	brand	loratadine	DB00455	True	mechanism	drug	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
DDI-DrugBank.d94.s4.p17	EQUETROTM	None	brand	nicotinamide	DB02701	True	mechanism	drug	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
DDI-DrugBank.d94.s4.p9	EQUETROTM	None	brand	fluoxetine	DB00472	True	mechanism	drug	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
DDI-DrugBank.d94.s8.p7	EQUETROTM	None	brand	methsuximide	DB05246	True	mechanism	drug	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
DDI-DrugBank.d576.s6.p6	Salicylate	None	group	naproxen	DB00788	True	mechanism	drug	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.
DDI-DrugBank.d578.s4.p5	phenytoin	DB00252	drug	methylprednisolone	DB00959	True	mechanism	drug	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response.
DDI-DrugBank.d578.s5.p1	troleandomycin	DB01361	drug	methylprednisolone	DB00959	True	mechanism	drug	Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance.
DDI-DrugBank.d578.s9.p0	Aspirin	None	brand	corticosteroids	None	True	advise	group	Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia.
DDI-DrugBank.d579.s0.p1	antibiotics	None	group	ganglion blockers	None	True	advise	group	Patients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers.
DDI-DrugBank.d579.s1.p0	Mecamylamine	DB00657	drug	antihypertensive drugs	None	True	effect	group	The action of Mecamylamine may be potentiated by anesthesia, other antihypertensive drugs and alcohol.
DDI-DrugBank.d585.s0.p0	anticholinergic drugs	None	group	amantadine	DB00915	True	effect	drug	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
DDI-DrugBank.d585.s0.p12	anticholinergic drugs	None	group	sympathomimetic agents	None	True	effect	group	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
DDI-DrugBank.d585.s0.p5	anticholinergic drugs	None	group	phenothiazines	None	True	effect	group	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
DDI-DrugBank.d588.s4.p2	Diuretic	None	group	digitalis	None	True	effect	group	Digitalis Glycosides: Diuretic-induced hypokalemia can increase the sensitivity of the myocardium to digitalis.
DDI-DrugBank.d590.s0.p0	TRITEC	None	brand	clarithromycin	DB01211	True	mechanism	drug	Coadministration of TRITEC with clarithromycin resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%).
DDI-DrugBank.d596.s9.p11	cholinesterase inhibitors	None	group	succinylcholine	DB00202	True	effect	drug	Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.
DDI-DrugBank.d597.s4.p1	NSAIDs	None	group	aspirin	None	True	advise	brand	however, as with other NSAIDs, concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.
DDI-DrugBank.d598.s0.p0	Trimethoprim	DB00440	drug	phenytoin	DB00252	True	mechanism	drug	Trimethoprim may inhibit the hepatic metabolism of phenytoin.
DDI-DrugBank.d598.s1.p0	Trimethoprim	DB00440	drug	phenytoin	DB00252	True	mechanism	drug	Trimethoprim, given at a common clinical dosage, increased the phenytoin half-life by 51% and decreased the phenytoin metabolic clearance rate by 30%.
DDI-DrugBank.d598.s1.p1	Trimethoprim	DB00440	drug	phenytoin	DB00252	True	mechanism	drug	Trimethoprim, given at a common clinical dosage, increased the phenytoin half-life by 51% and decreased the phenytoin metabolic clearance rate by 30%.
DDI-DrugBank.d60.s12.p12	nondepolarizing agents	None	group	anesthetics	None	True	effect	group	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d60.s12.p13	nondepolarizing agents	None	group	procainamide	DB01035	True	effect	drug	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d60.s12.p22	NIMBEX	None	brand	colistin	DB00803	True	effect	drug	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d60.s6.p10	nitrous oxide	None	drug	NIMBEX	None	True	effect	brand	Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.
DDI-DrugBank.d60.s6.p4	Isoflurane	DB00753	drug	NIMBEX	None	True	effect	brand	Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.
DDI-DrugBank.d60.s6.p8	enflurane	DB00228	drug	NIMBEX	None	True	effect	brand	Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.
DDI-DrugBank.d601.s0.p1	Barbiturates	None	group	antibiotics	None	True	int	group	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.
DDI-DrugBank.d601.s0.p2	Barbiturates	None	group	quinidine	DB00908	True	int	group	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.
DDI-DrugBank.d603.s5.p16	Alpha-adrenergic blocking agents	None	group	ProAmatine	None	True	effect	brand	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.
DDI-DrugBank.d603.s5.p27	prazosin	DB00457	drug	ProAmatine	None	True	effect	brand	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.
DDI-DrugBank.d94.s8.p8	EQUETROTM	None	brand	theophylline	DB00277	True	mechanism	drug	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
DDI-DrugBank.d97.s90.p0	Tadalafil	DB00820	drug	indinavir	DB00224	True	advise	drug	Tadalafil dose should not exceed a maximum of 10 mg in a 72- hour period in patients receiving concomitant indinavir therapy.
DDI-DrugBank.d99.s9.p0	SSRI	None	group	TCA	None	True	effect	group	The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.
DDI-MedLine.d0.s4.p0	phenytoin	DB00252	drug	quetiapine	DB01224	True	mechanism	drug	This study demonstrated that the potent cytochrome P450 enzyme-inducer phenytoin did indeed have a marked effect on the metabolism of quetiapine, resulting in a 5-fold increase in clearance when administered concomitantly to patients with DSM-IV-diagnosed schizophrenia, schizoaffective disorder, or bipolar disorder.
DDI-MedLine.d104.s4.p0	DCG-IV	None	drug_n	PCP	None	True	effect	drug_n	The effects of DCG-IV were very strong and completely depressed the PCP-induced hyperlocomotion.
DDI-MedLine.d110.s6.p4	18-MC	None	drug_n	nicotine	DB00184	True	effect	drug	Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens;
DDI-MedLine.d110.s7.p0	ibogaine	None	drug_n	cocaine	DB00907	True	effect	drug	only ibogaine enhances cocaine-induced increases in accumbal dopamine.
DDI-MedLine.d111.s14.p14	valproic acid	DB00313	drug	phenobarbital	DB01174	True	effect	drug	Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.
DDI-MedLine.d113.s0.p0	temazepam	DB00231	drug	ethanol	DB00898	True	mechanism	drug	Acid-catalyzed ethanolysis of temazepam in anhydrous and aqueous ethanol solutions.
DDI-MedLine.d113.s3.p1	temazepam	DB00231	drug	ethanol	DB00898	True	mechanism	drug	In addition to this pharmacological interaction, this report describes a novel chemical reaction between temazepam (a benzodiazepine) and ethanol under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product.
DDI-MedLine.d115.s14.p0	antiretroviral drugs	None	group	antineoplastic drugs	None	True	advise	group	However, careful attention must be directed to cross toxicity and possible pharmacokinetic interactions between antiretroviral and antineoplastic drugs.
DDI-MedLine.d116.s6.p0	rifampin	None	drug	warfarin	DB00682	True	effect	drug	The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal.
DDI-MedLine.d119.s15.p0	Cholestyramine	DB01432	drug	fluvastatin	DB01095	True	mechanism	drug	Cholestyramine, an anionic-binding resin, has a considerable effect in lowering the rate and extent of fluvastatin bioavailability.
DDI-MedLine.d12.s0.p3	retinyl acetate	None	drug	EGF	None	True	effect	drug_n	Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.
DDI-MedLine.d12.s3.p1	Dexamethasone	DB01234	drug	EGF	None	True	effect	drug_n	Dexamethasone at 10(-10) M or retinyl acetate at about 3 X 10(-9) M inhibits proliferation stimulated by EGF.
DDI-MedLine.d124.s1.p1	trovafloxacin	DB00685	drug	opiate	None	True	mechanism	group	Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine.
DDI-MedLine.d124.s1.p4	ciprofloxacin	DB00537	drug	morphine	DB00295	True	mechanism	drug	Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine.
DDI-MedLine.d126.s0.p0	Cypermethrin	None	drug	vitamin E	DB00163	True	effect	drug	Cypermethrin-induced oxidative stress in rat brain and liver is prevented by vitamin E or allopurinol.
DDI-MedLine.d133.s0.p0	verapamil	DB00661	drug	bombesin	None	True	effect	drug_n	Suppression by verapamil of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in wistar rats.
DDI-MedLine.d161.s5.p5	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	None	drug_n	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	None	True	effect	drug_n	After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected.
DDI-MedLine.d161.s9.p0	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	None	drug_n	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	None	True	effect	drug_n	Our data demonstrate that chronic treatment with the metabotropic glutamate receptor 5 antagonist, 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine, significantly reduces 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity towards dopaminergic and noradrenergic cell groups in non-human primates.
DDI-MedLine.d163.s7.p0	minocycline	DB01017	drug	fosfomycin	DB00828	True	effect	drug	The combination of minocycline and fosfomycin can be synergistic against MRSA.
DDI-MedLine.d179.s10.p4	docetaxel	DB01248	drug	sunitinib	DB01268	True	effect	drug	Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.
DDI-MedLine.d179.s6.p0	sunitinib	DB01268	drug	docetaxel	DB01248	True	effect	drug	Although single or concurrent use of sunitinib and docetaxel has some anti-proliferative effects, the sequential administrations of both drugs remarkably enhanced anti-tumor activity.
DDI-MedLine.d185.s7.p0	ketoconazole	DB01026	drug	panobinostat	None	True	mechanism	drug	In the presence of ketoconazole, there was 1.6- and 1.8-fold increase in C (max) and AUC of panobinostat, respectively.
DDI-MedLine.d2.s1.p1	neomycin	DB00994	drug	ACTH	None	True	effect	drug	Studies in rats have shown that neomycin administration attenuates certain types of adrenocortical steroid dependent hypertension, including ACTH hypertension.
DDI-MedLine.d200.s10.p0	amlodipine	DB00381	drug	valsartan	DB00177	True	effect	drug	We have demonstrated appropriateness of inhospital administration of fixed amlodipine/valsartan combination as an approach allowing to achieve target BP in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment.
DDI-MedLine.d200.s8.p0	amlodipine	DB00381	drug	valsartan	DB00177	True	effect	drug	But the use of fixed combination amlodipine/valsartan compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of antihypertensive drugs (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05).
DDI-MedLine.d211.s2.p0	lenalidomide	DB00480	drug	CCI-779	None	True	effect	drug	The preclinical combination of lenalidomide with the mTOR inhibitor CCI-779 has displayed synergy in vitro and represents a novel combination in MM.
DDI-DrugBank.d606.s1.p0	Sympathomimetics	None	group	methyldopa	DB00968	True	effect	drug	Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.
DDI-DrugBank.d606.s1.p2	Sympathomimetics	None	group	reserpine	DB00206	True	effect	drug	Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.
DDI-DrugBank.d608.s5.p1	TOLECTIN	None	brand	methotrexate	DB00563	True	mechanism	drug	TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate.
DDI-DrugBank.d619.s2.p0	meperidine	None	drug	MAOIs	None	True	int	group	This is typical of the interaction of meperidine and MAOIs.
DDI-DrugBank.d624.s0.p11	TOBI	None	brand	anti-pseudomonal antibiotics	None	True	effect	group	In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
DDI-DrugBank.d629.s0.p0	metronidazole	DB00916	drug	coumarin	None	True	effect	group	Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time.
DDI-DrugBank.d638.s2.p4	Ritalin	None	brand	primidone	DB00794	True	mechanism	drug	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).
DDI-DrugBank.d64.s29.p1	anticoagulant	None	group	alcohol	None	True	effect	drug	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
DDI-DrugBank.d64.s29.p19	anticoagulant	None	group	ranitidine	DB00863	True	effect	drug	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
DDI-DrugBank.d656.s3.p0	lithium	DB01356	drug	FELDENE	None	True	advise	brand	It is recommended that plasma lithium levels be monitored when initiating, adjusting and discontinuing FELDENE.
DDI-DrugBank.d659.s2.p0	TRENTAL	None	brand	theophylline	DB00277	True	mechanism	drug	Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals.
DDI-DrugBank.d66.s6.p0	methotrexate	DB00563	drug	L-glutamine	DB00130	True	effect	drug	In another report, nine patients with breast cancer were reported to have decreased symptoms of methotrexate-related toxicity when given supplemental L-glutamine at a dose of 0.5 gram/kilogram/day.
DDI-DrugBank.d665.s0.p4	erythromycin	DB00199	drug	penicillins	None	True	effect	group	Concurrent administration of bacteriostatic antibiotics (e.g., erythromycin, tetracycline) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth.
DDI-DrugBank.d669.s0.p0	vancomycin	DB00512	drug	anesthetic agents	None	True	effect	group	Concomitant administration of vancomycin and anesthetic agents has been associated with erythema and histamine-like flushing and anaphylactoid reactions.
DDI-DrugBank.d670.s6.p3	INVEGA	None	brand	centrally acting drugs	None	True	advise	group	Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol.
DDI-DrugBank.d678.s4.p1	Metopirone	None	brand	acetaminophen	DB00316	True	effect	drug	Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.
DDI-DrugBank.d682.s0.p1	Sulfoxone	DB01145	drug	tolbutamide	DB01124	True	effect	drug	Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics.
DDI-DrugBank.d695.s1.p2	imiglucerase	DB00053	drug	ZAVESCA	None	True	advise	brand	Combination therapy with Cerezyme    (imiglucerase) and ZAVESCA    is not indicated.
DDI-DrugBank.d697.s0.p8	Thiamine	DB00152	drug	Tricyclic Antidepressants	None	True	int	group	Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants
DDI-DrugBank.d698.s0.p5	Alcohol	None	drug	riboflavin	DB00140	True	mechanism	drug	Interactions for Vitamin B2 (Riboflavin):  Alcohol - impairs the intestinal absorption of riboflavin
DDI-DrugBank.d699.s0.p0	Mequitazine	DB01071	drug	CNS depressant	None	True	int	group	Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.
DDI-MedLine.d217.s0.p0	celecoxib	DB00482	drug	anti-cancer drugs	None	True	effect	group	Interaction of celecoxib with different anti-cancer drugs is antagonistic in breast but not in other cancer cells.
DDI-MedLine.d218.s8.p0	Warfarin	DB00682	drug	citalopram	DB00215	True	effect	drug	Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]).
DDI-MedLine.d227.s9.p0	dexmedetomidine	DB00633	drug	ephedrine	DB01364	True	effect	drug	We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.
DDI-MedLine.d23.s1.p21	pentobarbital	DB00312	drug	ouabain	DB01092	True	effect	drug	In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital.
DDI-MedLine.d23.s2.p0	ouabain	DB01092	drug	Innovar	None	True	effect	brand	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.
DDI-MedLine.d231.s8.p2	Moxifloxacin	DB00218	drug	gelusil	None	True	mechanism	brand	Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.
DDI-MedLine.d27.s0.p2	picrotoxin	DB00466	drug_n	phenibut	None	True	effect	drug_n	[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine.
DDI-MedLine.d27.s0.p4	picrotoxin	DB00466	drug_n	phentolamine	DB00692	True	effect	drug	[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine.
DDI-MedLine.d30.s11.p0	Haloperidol	DB00502	drug	(+)-NANM	None	True	effect	drug_n	Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM.
DDI-MedLine.d30.s11.p1	Haloperidol	DB00502	drug	PCP	None	True	effect	drug_n	Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM.
DDI-MedLine.d34.s8.p1	Fe	None	drug	cobalt	None	True	mechanism	drug	The lower rate of absorption in the groups receiving 446 mg Fe instead of 48 mg of Fe per kg diet resulted in a decreased renal excretion of cobalt.
DDI-MedLine.d56.s2.p0	ouabain	DB01092	drug	PTX	None	True	effect	drug_n	In the presence of ouabain (10(-5) M), PTX (10(-8) M) failed to cause the first contraction;
DDI-MedLine.d56.s8.p0	ouabain	DB01092	drug	PTX	None	True	effect	drug_n	Exposure of the muscle to ouabain (10(-5) M) markedly increased the PTX-induced release.
DDI-MedLine.d61.s9.p0	digoxin	DB00390	drug	amiodarone	DB01118	True	mechanism	drug	These alterations in digoxin pharmacokinetics produced by amiodarone explain the increase in serum digoxin level that has been observed when this drug combination has been used clinically.
DDI-MedLine.d68.s0.p13	cimetidine	DB00501	drug	iodamide	None	True	mechanism	drug	[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments.
DDI-MedLine.d73.s3.p1	MPTP	None	drug	apomorphine	DB00714	True	effect	drug	The MPTP-induced neuronal damage produced a tolerance to the disruptive effects of amphetamine and a supersensitivity to the disruptive effects of apomorphine in rats responding in a schedule controlled paradigm.
DDI-MedLine.d81.s2.p0	ethanol	DB00898	drug	disulfiram	DB00822	True	effect	drug	Core temperature was decreased in rats in a dose-dependent manner when ethanol was administered to rats treated with disulfiram 8 hours before the ethanol challenge.
DDI-MedLine.d85.s14.p0	CCNU	None	drug	misonidazole	None	True	mechanism	drug_n	We propose these pharmacokinetic changes to be the underlying mechanism for the reduction of oral CCNU cytotoxicity by misonidazole.
DDI-MedLine.d90.s7.p2	atracurium	DB00732	drug	gentamycin	None	True	effect	drug	Recovery of hoof twitch from 50% to 75% took 7.7 +/- 0.7 min for atracurium alone and 11.5 +/- 2.7 min for atracurium plus gentamycin (P = 0.03).
DDI-DrugBank.d700.s12.p2	Myfortic	None	drug	live attenuated vaccines	None	True	advise	group	Live Vaccines: During treatment with Myfortic, the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective.
DDI-DrugBank.d700.s8.p1	Myfortic	None	drug	activated charcoal	None	True	advise	drug	Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic.
DDI-DrugBank.d703.s0.p10	MEPERIDINE	None	drug	NARCOTIC ANALGESICS	None	True	advise	group	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
DDI-DrugBank.d703.s0.p17	MEPERIDINE	None	drug	CNS DEPRESSANTS	None	True	advise	group	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
DDI-DrugBank.d712.s1.p0	paclitaxel	DB01229	drug	HERCEPTIN	None	True	mechanism	brand	Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.
DDI-DrugBank.d713.s0.p0	Sanctura	None	brand	anticholinergic agents	None	True	effect	group	The concomitant use of Sanctura with other anticholinergic agents that produce dry mouth, constipation, and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects.
DDI-DrugBank.d716.s0.p1	mazindol	DB00579	drug	MAOI	None	True	advise	group	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.
DDI-DrugBank.d720.s3.p20	Selective serotonin reuptake inhibitors	None	group	sumatriptan	DB00669	True	effect	drug	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.
DDI-DrugBank.d64.s29.p4	anticoagulant	None	group	barbiturates	None	True	effect	group	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
DDI-DrugBank.d64.s87.p25	anticoagulant	None	group	mefenamic acid	DB00784	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p30	anticoagulant	None	group	monoamine oxidase inhibitors	None	True	effect	group	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p35	anticoagulant	None	group	pentoxifylline	DB00806	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d720.s3.p32	fluvoxamine	DB00176	drug	sumatriptan	DB00669	True	effect	drug	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.
DDI-DrugBank.d722.s1.p9	sulphasalazine	None	drug	thioguanine	DB00352	True	mechanism	drug	As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.
DDI-DrugBank.d725.s0.p2	metaraminol	DB00610	drug	halothane	DB01159	True	effect	drug	Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all.
DDI-DrugBank.d725.s3.p0	adrenergic agents	None	group	tricyclic antidepressants	None	True	effect	group	The pressor response of adrenergic agents may also be potentiated by tricyclic antidepressants.
DDI-DrugBank.d726.s1.p57	paricalcitol	DB00910	drug	indinavir	DB00224	True	advise	drug	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
DDI-DrugBank.d727.s0.p0	Zidovudine	DB00495	drug	stavudine	DB00649	True	effect	drug	Zidovudine competitively inhibits the intracellular phosphorylation of stavudine.
DDI-DrugBank.d734.s1.p0	guanethidine	DB01170	drug	phenothiazines	None	True	effect	group	Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concomitantly.
DDI-DrugBank.d736.s7.p0	Thiazides	None	group	antihypertensive drugs	None	True	effect	group	Thiazides may add to or potentiate the action of other antihypertensive drugs.
DDI-DrugBank.d737.s10.p44	metoclopramide	DB01233	group	MIRAPEX	None	True	effect	brand	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.
DDI-DrugBank.d64.s87.p43	anticoagulant	None	group	ranitidine	DB00863	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p45	anticoagulant	None	group	sulfinpyrazone	DB01138	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s87.p8	anticoagulant	None	group	chlorpropamide	DB00672	True	effect	drug	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium o
DDI-DrugBank.d64.s89.p9	anticoagulant	None	group	phenytoin	DB00252	True	mechanism	drug	Because oral anticoagulants may interfere with the hepatic metabolism of phenytoin, toxic levels of the anticonvulsant may occur when an oral anticoagulant and phenytoin are administered concurrently.
DDI-DrugBank.d64.s90.p27	dextran	None	drug	anticoagulants	None	True	effect	group	Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal anti-inflammatory drugs, dipyridamole, hydrochloroquine, clofibrate, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.
DDI-DrugBank.d642.s1.p0	antibacterial drugs	None	group	contraceptives	None	True	effect	group	Concurrent use of antibacterial drugs with oral contraceptives may render oral contraceptives less effective.
DDI-DrugBank.d643.s0.p12	Melatonin	DB01065	drug	corticosteroids	None	True	int	group	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
DDI-DrugBank.d643.s0.p5	Melatonin	DB01065	drug	beta blockers	None	True	int	group	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
DDI-DrugBank.d645.s4.p0	Terbinafine	DB00857	drug	caffeine	DB00201	True	mechanism	drug	Terbinafine decreases the clearance of caffeine by 19%.
DDI-DrugBank.d645.s7.p1	Terbinafine	DB00857	drug	cimetidine	DB00501	True	mechanism	drug	Terbinafine clearance is increased 100% by rifampin, a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor.
DDI-DrugBank.d737.s4.p2	Cimetidine	DB00501	drug	pramipexole	DB00413	True	mechanism	drug	Cimetidine: Cimetidine, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in pramipexole AUC and a 40% increase in half-life (N= 12).
DDI-DrugBank.d737.s6.p63	quinine	DB00468	drug	pramipexole	DB00413	True	mechanism	drug	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
DDI-DrugBank.d737.s6.p89	hydrochlorothiazide	DB00999	drug	pramipexole	DB00413	True	mechanism	drug	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
DDI-DrugBank.d739.s8.p1	phenobarbital	DB01174	drug	montelukast	DB00471	True	advise	drug	It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.
DDI-DrugBank.d739.s8.p2	rifampin	None	drug	montelukast	DB00471	True	advise	drug	It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.
DDI-DrugBank.d742.s11.p0	diazepam	DB00829	drug	REMERON SolTab	None	True	advise	brand	Accordingly, patients should be advised to avoid diazepam and other similar drugs while taking REMERON SolTab.
DDI-DrugBank.d743.s0.p2	ketoconazole	DB01026	drug	terfenadine	DB00342	True	effect	drug	Ketoconazole: Spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of terfenadine demonstrate QT interval prolongation and rare serious cardiac events, e.g.
DDI-DrugBank.d743.s4.p0	ketoconazole	DB01026	drug	terfenadine	DB00342	True	advise	drug	Concomitant administration of ketoconazole and terfenadine is contraindicated.
DDI-DrugBank.d743.s7.p0	itraconazole	DB01167	drug	terfenadine	DB00342	True	advise	drug	Concomitant administration of itraconazole and terfenadine is contraindicated.
DDI-DrugBank.d743.s8.p10	fluconazole	DB00196	drug	terfenadine	DB00342	True	advise	drug	Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.
DDI-DrugBank.d743.s8.p14	metronidazole	DB00916	drug	terfenadine	DB00342	True	advise	drug	Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.
DDI-DrugBank.d743.s9.p5	erythromycin	DB00199	drug	terfenadine	DB00342	True	mechanism	drug	Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent.
DDI-DrugBank.d75.s14.p11	amrinone	DB01427	drug	anagrelide	DB00261	True	effect	drug	The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.
DDI-DrugBank.d75.s14.p14	cilostazol	DB01166	drug	anagrelide	DB00261	True	effect	drug	The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.
DDI-DrugBank.d752.s10.p0	VERSED Syrup	None	brand	narcotics	None	True	effect	group	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.
DDI-DrugBank.d752.s10.p2	VERSED Syrup	None	brand	meperidine	None	True	effect	drug	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.
DDI-DrugBank.d647.s3.p0	streptozocin	DB00428	drug	phenytoin	DB00252	True	effect	drug	The concurrent use of streptozocin and phenytoin has been reported in one case to result in reduced streptozocin cytotoxicity.
DDI-DrugBank.d652.s1.p1	metoclopramide	DB01233	drug	sedatives	None	True	effect	group	Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers.
DDI-DrugBank.d652.s1.p4	metoclopramide	DB01233	drug	tranquilizers	None	True	effect	group	Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers.
DDI-DrugBank.d653.s1.p3	phenobarbital	DB01174	drug	corticosteroid	None	True	mechanism	group	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.
DDI-DrugBank.d653.s1.p8	rifampin	None	drug	corticosteroid	None	True	mechanism	group	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.
DDI-DrugBank.d656.s1.p4	coumarin-type anticoagulants	None	group	FELDENE	None	True	int	brand	Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs.
DDI-DrugBank.d656.s1.p9	FELDENE	None	brand	coumarin-type anticoagulants	None	True	advise	group	Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs.
DDI-DrugBank.d656.s2.p7	FELDENE	None	brand	aspirin	None	True	mechanism	brand	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels.
DDI-DrugBank.d66.s7.p3	L-glutamine	DB00130	drug	paclitaxel	DB01229	True	effect	drug	Paclitaxel - In one report, L-glutamine at a dose of 10 grams three times daily, given 24 hours after receiving paclitaxel, appeared to prevent the development of myalgia and arthralgia, adverse reactions of paclitaxel.
DDI-DrugBank.d665.s0.p5	tetracycline	DB00759	drug	penicillins	None	True	effect	group	Concurrent administration of bacteriostatic antibiotics (e.g., erythromycin, tetracycline) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth.
DDI-DrugBank.d668.s0.p8	itraconazole	DB01167	drug	mifepristone	DB00834	True	mechanism	drug	Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone).
DDI-DrugBank.d668.s0.p9	erythromycin	DB00199	drug	mifepristone	DB00834	True	mechanism	drug	Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone).
DDI-DrugBank.d670.s7.p0	Paliperidone	DB01267	drug	levodopa	None	True	effect	drug	Paliperidone may antagonize the effect of levodopa and other dopamine agonists.
DDI-DrugBank.d670.s7.p1	Paliperidone	DB01267	drug	dopamine agonists	None	True	effect	group	Paliperidone may antagonize the effect of levodopa and other dopamine agonists.
DDI-DrugBank.d676.s2.p1	Matulane	None	brand	tricyclic antidepressant	None	True	advise	group	Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.
DDI-DrugBank.d677.s0.p0	Phenothiazines	None	group	CNS depressants	None	True	effect	group	Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.)
DDI-DrugBank.d677.s0.p3	Phenothiazines	None	group	opiates	None	True	effect	group	Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.)
DDI-DrugBank.d678.s1.p0	Metopirone	None	brand	phenytoin	DB00252	True	mechanism	drug	The metabolism of Metopirone is accelerated by phenytoin;
DDI-DrugBank.d752.s10.p3	VERSED Syrup	None	brand	fentanyl	DB00813	True	effect	drug	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.
DDI-DrugBank.d756.s4.p1	levomepromazine	None	drug	tricyclic antidepressants	None	True	advise	group	Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.
DDI-DrugBank.d76.s12.p11	alprazolam	DB00404	drug	fluvoxamine	DB00176	True	mechanism	drug	Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.
DDI-DrugBank.d76.s14.p4	fluvoxamine maleate	None	drug	alprazolam	DB00404	True	mechanism	drug	Alprazolam: When fluvoxamine maleate (100 mg qd) and alprazolam (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of alprazolam were approximately twice those observed when alprazolam was administered alone;
DDI-DrugBank.d76.s21.p0	fluvoxamine	DB00176	drug	diazepam	DB00829	True	advise	drug	Evidence supporting the conclusion that it is inadvisable to co-administer fluvoxamine and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam.
DDI-DrugBank.d76.s5.p0	Fluvoxamine	DB00176	drug	MAOI	None	True	advise	group	After stopping Fluvoxamine Tablets, at least 2 weeks should be allowed before starting a MAOI.
DDI-DrugBank.d76.s7.p2	Terfenadine	DB00342	drug	ketoconazole	DB01026	True	mechanism	drug	Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.
DDI-DrugBank.d762.s2.p0	probenecid	DB01032	drug	meropenem	DB00760	True	advise	drug	Therefore, the coadministration of probenecid with meropenem is not recommended.
DDI-DrugBank.d762.s3.p0	meropenem	DB00760	drug	valproic acid	DB00313	True	mechanism	drug	There is evidence that meropenem may reduce serum levels of valproic acid to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total valproate).
DDI-DrugBank.d765.s1.p34	macrolide antibiotics	None	group	DETROL LA	None	True	advise	brand	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.
DDI-DrugBank.d766.s1.p3	trimetrexate	DB01157	drug	ketoconazole	DB01026	True	effect	drug	Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole.
DDI-DrugBank.d766.s3.p3	imidazole drugs	None	group	trimetrexate	DB01157	True	mechanism	drug	Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism.
DDI-DrugBank.d769.s1.p0	ZOLINZA	None	brand	coumarin derivatives	None	True	advise	group	Physicians should carefully monitor PT and INR in patients concurrently administered ZOLINZA and coumarin derivatives.
DDI-DrugBank.d77.s5.p1	imipramine	DB00458	drug	fluoxetine	DB00472	True	mechanism	drug	The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.
DDI-DrugBank.d775.s10.p18	MIVACRON	None	brand	bacitracin	DB00626	True	int	drug	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d775.s10.p20	MIVACRON	None	brand	lincomycin	DB01627	True	int	drug	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d775.s10.p27	MIVACRON	None	brand	procainamide	DB01035	True	int	drug	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d775.s10.p9	nondepolarizing agents	None	drug	sodium colistimethate	None	True	int	drug	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d776.s25.p2	fluconazole	DB00196	drug	cisapride	DB00604	True	effect	drug	Cisapride: There have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and cisapride were coadministered.
DDI-DrugBank.d776.s3.p0	DIFLUCAN	None	brand	glyburide	DB01016	True	effect	drug	one fatality has been reported from hypoglycemia in association with combined DIFLUCAN and glyburide use.
DDI-DrugBank.d776.s38.p0	Fluconazole	DB00196	drug	ethinyl estradiol	DB00977	True	mechanism	drug	Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels;
DDI-DrugBank.d779.s2.p0	anesthetics	None	group	methyldopa	DB00968	True	advise	drug	Patients may require reduced doses of anesthetics when on methyldopa.
DDI-DrugBank.d779.s9.p0	methyldopa	DB00968	drug	ferrous sulfate	None	True	advise	drug	Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended.
DDI-DrugBank.d78.s1.p5	quinolones	None	group	iron	DB01592	True	mechanism	drug	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
DDI-DrugBank.d78.s11.p5	grepafloxacin	DB00365	drug	theophylline	DB00277	True	mechanism	drug	Drugs Metabolized by Cytochrome P450 Enzymes The drug interaction study evaluating the effect of grepafloxacin on theophylline indicates that grepafloxacin inhibits theophylline metabolism, which is mediated by CYP1A2.
DDI-DrugBank.d78.s19.p5	nonsteroidal anti inflammatory drug	None	group	quinolone	None	True	effect	group	Nonsteroidal Anti-inflammatory Drugs (NSAIDs): The concomitant administration of a nonsteroidal anti inflammatory drug with a quinolone may increase the risks of CNS stimulation and convulsions.
DDI-DrugBank.d78.s3.p12	quinolones	None	group	caffeine	DB00201	True	mechanism	drug	Caffeine Theobromine Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and theobromine.
DDI-DrugBank.d780.s8.p3	acetazolamide	DB00819	drug	procaine hydrochloride	None	True	mechanism	drug	Acetazolamide: Concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of procaine.
DDI-DrugBank.d781.s1.p0	diuretic	None	group	perindopril	DB00790	True	effect	drug	The possibility of hypotensive effects can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with perindopril.
DDI-DrugBank.d784.s4.p19	erythromycin	DB00199	drug	oxybutynin	DB01062	True	mechanism	drug	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).
DDI-DrugBank.d784.s4.p20	clarithromycin	DB01211	drug	oxybutynin	DB01062	True	mechanism	drug	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).
DDI-DrugBank.d8.s0.p4	ALFENTA	None	brand	anesthetics	None	True	effect	group	Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as barbiturates, tranquilizers, opioids, or inhalation general anesthetics.
DDI-DrugBank.d8.s3.p7	erythromycin	DB00199	drug	ALFENTA	None	True	mechanism	brand	Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.
DDI-DrugBank.d82.s22.p0	INDOCIN	None	brand	digoxin	DB00390	True	advise	drug	Therefore, when INDOCIN and digoxin are used concomitantly, serum digoxin levels should be closely monitored.
DDI-DrugBank.d82.s23.p2	INDOCIN	None	brand	thiazide diuretics	None	True	effect	group	In some patients, the administration of INDOCIN can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing, and thiazide diuretics.
DDI-DrugBank.d678.s4.p0	Metopirone	None	brand	acetaminophen	DB00316	True	mechanism	drug	Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.
DDI-DrugBank.d693.s0.p1	folic acid	DB00158	drug	sulfasalazine	DB00795	True	mechanism	drug	Reduced absorption of folic acid and digoxin have been reported when those agents were administered concomitantly with sulfasalazine.
DDI-DrugBank.d697.s0.p1	Vitamin B1	None	drug	Loop Diuretics	None	True	int	group	Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants
DDI-DrugBank.d697.s0.p4	Vitamin B1	None	drug	Tricyclic Antidepressants	None	True	int	group	Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants
DDI-DrugBank.d702.s2.p0	SPIRIVA	None	brand	anticholinergic	None	True	advise	group	However, the co   administration of SPIRIVA with other anticholinergic   containing drugs (e.g., ipratropium) has not been studied and is therefore not recommended.
DDI-DrugBank.d702.s2.p1	SPIRIVA	None	brand	ipratropium	None	True	advise	drug	However, the co   administration of SPIRIVA with other anticholinergic   containing drugs (e.g., ipratropium) has not been studied and is therefore not recommended.
DDI-DrugBank.d709.s1.p8	macrolides	None	group	astemizole	DB00637	True	int	drug	Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter.
DDI-DrugBank.d711.s0.p0	tetracyclines	None	group	anticoagulant	None	True	advise	group	Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.
DDI-DrugBank.d716.s0.p3	mazindol	DB00579	drug	Marplan	None	True	advise	brand	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.
DDI-DrugBank.d72.s0.p0	Itraconazole	DB01167	drug	busulfan	DB01008	True	mechanism	drug	Itraconazole decreases busulfan clearance by up to 25%, and may produce AUCs   1500  M min in some patients.
DDI-DrugBank.d720.s1.p6	ergot-type medications	None	group	sumatriptan	DB00669	True	advise	drug	Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided.
DDI-DrugBank.d82.s29.p0	INDOCIN	None	brand	triamterene	DB00384	True	advise	drug	INDOCIN and triamterene should not be administered together.
DDI-DrugBank.d82.s31.p0	INDOCIN	None	brand	potassium-sparing diuretics	None	True	effect	group	The potential effects of INDOCIN and potassium-sparing diuretics on potassium kinetics and renal function should be considered when these agents are administered concurrently.
DDI-DrugBank.d82.s35.p1	INDOCIN	None	brand	losartan	DB00678	True	effect	drug	INDOCIN can reduce the antihypertensive effects of captopril and losartan.
DDI-DrugBank.d82.s7.p0	anticoagulants	None	group	INDOCIN	None	True	effect	brand	In post-marketing experience, bleeding has been reported in patients on concomitant treatment with anticoagulants and INDOCIN.
DDI-DrugBank.d82.s8.p0	INDOCIN	None	brand	anticoagulants	None	True	advise	group	Caution should be exercised when INDOCIN and anticoagulants are administered concomitantly.
DDI-DrugBank.d82.s9.p0	INDOCIN	None	brand	probenecid	DB01032	True	mechanism	drug	When INDOCIN is given to patients receiving probenecid, the plasma levels of indomethacin are likely to be increased.
DDI-DrugBank.d85.s0.p0	NSAIDs	None	group	ACE inhibitors	None	True	effect	group	The use of NSAIDs in patients who are receiving ACE inhibitors may potentiate renal disease states.
DDI-DrugBank.d86.s0.p6	chlorpromazine	DB00477	drug	trihexyphenidyl	DB00376	True	effect	drug	The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
DDI-DrugBank.d87.s15.p0	amiodarone	DB01118	drug	flecainide	DB01195	True	mechanism	drug	When amiodarone is added to flecainide therapy, plasma flecainide levels may increase two-fold or more in some patients, if flecainide dosage is not reduced.
DDI-DrugBank.d87.s19.p4	disopyramide	DB00280	drug	TAMBOCOR	None	True	advise	brand	Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.
DDI-DrugBank.d87.s8.p0	beta blockers	None	group	flecainide	DB01195	True	effect	drug	Nevertheless, the possibility of additive negative inotropic effects of beta blockers and flecainide should be recognized.
DDI-DrugBank.d89.s4.p0	Caffeine	DB00201	drug	ketoprofen	DB01009	True	effect	drug	Caffeine administered concurrently with ketoprofen reduced the urine volume in 4 healthy volunteers.
DDI-DrugBank.d9.s0.p4	Azlocillin	DB01061	drug	tobramycin	DB00684	True	advise	drug	Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.
DDI-DrugBank.d94.s11.p25	EQUETROTM	None	brand	midazolam	DB00683	True	mechanism	drug	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s11.p37	EQUETROTM	None	brand	topiramate	DB00273	True	mechanism	drug	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s11.p39	EQUETROTM	None	brand	tramadol	DB00193	True	mechanism	drug	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d720.s1.p9	methysergide	DB00247	drug	sumatriptan	DB00669	True	advise	drug	Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided.
DDI-DrugBank.d720.s3.p34	paroxetine	DB00715	drug	sumatriptan	DB00669	True	effect	drug	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.
DDI-DrugBank.d721.s1.p0	Aspirin	None	brand	SKELID	None	True	mechanism	brand	Aspirin may decrease bioavailability of SKELID by up to 50% when taken 2 hours after SKELID.
DDI-DrugBank.d726.s1.p60	paricalcitol	DB00910	drug	nelfinavir	DB00220	True	advise	drug	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
DDI-DrugBank.d727.s2.p1	stavudine	DB00649	drug	ribavirin	DB00811	True	effect	drug	In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin.
DDI-DrugBank.d73.s4.p0	beta blocker	None	group	clonidine	DB00575	True	advise	drug	If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine.
DDI-DrugBank.d739.s15.p2	rifampin	None	drug	montelukast	DB00471	True	advise	drug	It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.
DDI-DrugBank.d74.s1.p0	FLUOTHANE	None	brand	tubocurarine	DB01199	True	effect	drug	FLUOTHANE may augment the hypotension caused by the ganglionic-blocking effect of tubocurarine.
DDI-DrugBank.d742.s9.p9	diazepam	DB00829	drug	mirtazapine	DB00370	True	mechanism	drug	Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects.
DDI-DrugBank.d743.s2.p0	ketoconazole	DB01026	drug	terfenadine	DB00342	True	mechanism	drug	Pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of terfenadine, resulting in elevated plasma terfenadine levels.
DDI-DrugBank.d743.s9.p7	clarithromycin	DB01211	drug	terfenadine	DB00342	True	mechanism	drug	Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent.
DDI-DrugBank.d751.s1.p0	AGGRASTAT	None	brand	heparin	DB01109	True	effect	drug	The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see
DDI-DrugBank.d752.s0.p1	midazolam	DB00683	drug	protease inhibitors	None	True	advise	group	Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics).
DDI-DrugBank.d752.s1.p10	diltiazem	DB00343	drug	midazolam	DB00683	True	mechanism	drug	Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam.
DDI-DrugBank.d752.s1.p5	erythromycin	DB00199	drug	midazolam	DB00683	True	mechanism	drug	Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam.
DDI-DrugBank.d752.s10.p4	VERSED Syrup	None	brand	propofol	DB00818	True	effect	drug	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.
DDI-DrugBank.d752.s3.p1	ritonavir	DB00503	drug	midazolam	DB00683	True	mechanism	drug	Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam.
DDI-DrugBank.d757.s0.p2	alcohol	None	drug	pentazocine	DB00652	True	advise	drug	Usage with Alcohol: Due to the potential for increased CNS depressants effects, alcohol should be used with caution in patients who are currently receiving pentazocine.
DDI-DrugBank.d94.s4.p12	EQUETROTM	None	brand	itraconazole	DB01167	True	mechanism	drug	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
DDI-DrugBank.d94.s4.p20	EQUETROTM	None	brand	quinine	DB00468	True	mechanism	drug	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
DDI-DrugBank.d94.s4.p21	EQUETROTM	None	brand	quinupristin	DB01369	True	mechanism	drug	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
DDI-DrugBank.d94.s4.p25	EQUETROTM	None	brand	zileuton	DB00744	True	mechanism	drug	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
DDI-DrugBank.d94.s8.p1	EQUETROTM	None	brand	doxorubicin HCL	None	True	mechanism	drug	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
DDI-DrugBank.d94.s8.p2	EQUETROTM	None	brand	felbamate	DB00949	True	mechanism	drug	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
DDI-DrugBank.d95.s0.p2	L-arginine	DB00125	drug	cyclosporin	None	True	effect	drug	Cyclosporine - L-arginine may counteract the antinaturetic effect of cyclosporin.
DDI-DrugBank.d95.s1.p2	L-arginine	DB00125	drug	ibuprofen	DB01050	True	mechanism	drug	Ibuprofen - L-arginine may increase the absorption of ibuprofen if taken concomitantly.
DDI-DrugBank.d97.s41.p2	indinavir	DB00224	drug	efavirenz	DB00625	True	mechanism	drug	Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to efavirenz.
DDI-DrugBank.d97.s84.p5	rifabutin	DB00615	drug	CRIXIVAN	None	True	advise	brand	Dose reduction of rifabutin to half the standard dose and a dose increase of CRIXIVAN to 1000 mg (three 333-mg capsules) every 8 hours are recommended when rifabutin and CRIXIVAN are coadministered.
DDI-DrugBank.d97.s87.p0	Sildenafil	DB00203	drug	indinavir	DB00224	True	advise	drug	Sildenafil dose should not exceed a maximum of 25 mg in a 48- hour period in patients receiving concomitant indinavir therapy.
DDI-DrugBank.d99.s10.p0	TCAs	None	group	SSRIs	None	True	advise	group	Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other.
DDI-DrugBank.d99.s22.p0	tricyclic antidepressants	None	drug	cimetidine	DB00501	True	effect	drug	Clinically significant effects have been reported with the tricyclic antidepressants when used concomitantly with cimetidine.
DDI-MedLine.d105.s7.p1	Azithromycin	DB00207	drug	zidovudine	DB00495	True	mechanism	drug	Azithromycin had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%.
DDI-MedLine.d106.s0.p0	warfarin	DB00682	drug	sedatives	None	True	int	group	Clinical implications of warfarin interactions with five sedatives.
DDI-DrugBank.d76.s12.p14	triazolam	DB00897	drug	fluvoxamine	DB00176	True	mechanism	drug	Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.
DDI-DrugBank.d76.s17.p7	alprazolam	DB00404	drug	Fluvoxamine	DB00176	True	advise	drug	This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.
DDI-DrugBank.d76.s20.p1	fluvoxamine	DB00176	drug	N-desmethyldiazepam	None	True	mechanism	drug_n	Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.
DDI-DrugBank.d761.s1.p14	XENICAL	None	brand	cyclosporine	DB00091	True	mechanism	drug	Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine.
DDI-DrugBank.d761.s13.p5	warfarin	DB00682	drug	XENICAL	None	True	advise	brand	Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.
DDI-DrugBank.d765.s1.p44	vinblastine	DB00570	drug	DETROL LA	None	True	advise	brand	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.
DDI-DrugBank.d766.s1.p0	trimetrexate	DB01157	drug	erythromycin	DB00199	True	effect	drug	Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole.
DDI-DrugBank.d766.s3.p9	miconazole	DB01110	drug	trimetrexate	DB01157	True	mechanism	drug	Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism.
DDI-MedLine.d106.s6.p2	glutethimide	DB01437	drug	coumarin drugs	None	True	advise	group	Barbiturates and glutethimide should not be administered to patients receiving coumarin drugs.
DDI-MedLine.d110.s9.p2	18-MC	None	drug_n	morphine	DB00295	True	effect	drug	Ibogaine attenuates, but 18-MC potentiates, the acute locomotor effects of morphine;
DDI-MedLine.d111.s12.p0	Valproic acid	DB00313	drug	phenobarbital	DB01174	True	mechanism	drug	Valproic acid diminished binding of phenobarbital by a net change of 9.9% (percentage increase in FDF, 21.2%) at 1732 micromol/L.
DDI-MedLine.d116.s2.p0	Rifampin	None	drug	warfarin	DB00682	True	mechanism	drug	Rifampin has been reported to increase the warfarin requirements in human subjects ingesting these agents simultaneously.
DDI-MedLine.d116.s5.p0	rifampin	None	drug	warfarin	DB00682	True	mechanism	drug	This effect may be mediated by the ability of rifampin to induce microsomal enzymes and, thus, the catabolism of warfarin.
DDI-MedLine.d12.s0.p2	Dexamethasone	DB01234	drug	insulin	None	True	effect	drug	Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.
DDI-MedLine.d12.s3.p2	retinyl acetate	None	drug	EGF	None	True	effect	drug_n	Dexamethasone at 10(-10) M or retinyl acetate at about 3 X 10(-9) M inhibits proliferation stimulated by EGF.
DDI-MedLine.d12.s4.p2	retinyl acetate	None	drug	EGF	None	True	effect	drug_n	Higher concentrations of dexamethasone (10(-8) - 10(-6) M) or retinyl acetate (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of EGF.
DDI-MedLine.d12.s6.p0	retinyl acetate	None	drug	insulin	None	True	effect	drug	However, retinyl acetate stimulated, but did not significantly inhibit, proliferation in the presence of insulin.
DDI-MedLine.d12.s7.p10	glucocorticoids	None	group	insulin	None	True	effect	drug	These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.
DDI-MedLine.d128.s15.p1	N-methyllevallorphan	None	drug_n	morphine	DB00295	True	effect	drug	N-methyllevallorphan (5 mg/kg, s.c.) completely antagonized the inhibitory effect of loperamide and partly antagonized the effect of morphine.
DDI-MedLine.d130.s0.p0	cisplatin	DB00515	drug	sodium thiosulfate	None	True	effect	drug	High-dose cisplatin with sodium thiosulfate protection.
DDI-MedLine.d130.s2.p0	Sodium thiosulfate	None	drug	cisplatin	DB00515	True	effect	drug	Sodium thiosulfate is a neutralizing agent for cisplatin that protects against renal damage.
DDI-MedLine.d131.s5.p0	neurotensin	None	drug_n	tuftsin	None	True	effect	drug_n	It is concluded that neurotensin modulates in an opposite way the function of the enkephalinergic neurons and the central action of tuftsin.
DDI-MedLine.d16.s6.p0	ketamine	DB01221	drug	halothane	DB01159	True	effect	drug	It is concluded that ketamine is not a short-acting drug and that concomitant use with halothane would be expected to prolong further the duration of its action on the central nervous system.
DDI-MedLine.d169.s1.p0	Calcium	DB01373	drug	nonheme iron	None	True	mechanism	drug	Calcium is the only known component in the diet that may affect absorption of both nonheme and heme iron.
DDI-MedLine.d169.s9.p0	calcium	DB01373	drug	heme iron	None	True	mechanism	drug	A calcium dose of 800 mg diminished absorption of 5 mg heme iron by 37.7%.
DDI-MedLine.d194.s9.p0	dasatinib	DB01254	drug	paclitaxel	DB01229	True	effect	drug	HEY cells treated with dasatinib plus paclitaxel formed fewer colonies than did cells treated with either agent alone.
DDI-MedLine.d195.s4.p0	piperine	None	drug_n	ibuprofen	DB01050	True	effect	drug	In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test, when it was administered with ibuprofen.
DDI-MedLine.d195.s5.p0	Ibuprofen	DB01050	drug	piperine	None	True	mechanism	drug_n	Ibuprofen plasma concentration was also increased when it was administered with piperine.
DDI-MedLine.d195.s6.p0	ibuprofen	DB01050	drug	piperine	None	True	mechanism	drug_n	The synergistic antinociception activity of ibuprofen when administered with piperine can be attributed to increased plasma concentration of ibuprofen.
DDI-MedLine.d201.s9.p2	CRM197	None	drug_n	doxorubicin	DB00997	True	effect	drug	CRM197 induced apoptosis, and furthermore, the combination of CRM197 plus doxorubicin enhanced cytotoxicity in a T-ALL cell line.
DDI-MedLine.d21.s2.p0	antidepressant drugs	None	group	hypoglycemic agents	None	True	int	group	Treatment with antidepressant drugs can directly interfere with blood glucose levels or may interact with hypoglycemic agents.
DDI-MedLine.d218.s10.p4	Warfarin	DB00682	drug	mirtazapine	DB00370	True	effect	drug	Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.
DDI-DrugBank.d77.s5.p0	imipramine	DB00458	drug	cimetidine	DB00501	True	mechanism	drug	The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.
DDI-DrugBank.d77.s5.p3	imipramine	DB00458	drug	phenytoin	DB00252	True	mechanism	drug	The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.
DDI-DrugBank.d771.s1.p2	Scopolamine	DB00747	drug	alcohol	None	True	advise	drug	Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, tranquilizers, or alcohol.
DDI-DrugBank.d774.s0.p0	Trilostane	DB01108	drug	aminoglutethimide	DB00357	True	int	drug	Trilostane may interact with aminoglutethimide or mitotane (causing too great a decrease in adrenal function).
DDI-DrugBank.d775.s10.p11	nondepolarizing agents	None	drug	lithium	DB01356	True	int	drug	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d775.s10.p14	nondepolarizing agents	None	drug	quinidine	DB00908	True	int	drug	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d775.s10.p25	MIVACRON	None	brand	lithium	DB01356	True	int	drug	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-DrugBank.d775.s10.p6	nondepolarizing agents	None	drug	lincomycin	DB01627	True	int	drug	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
DDI-MedLine.d27.s0.p0	picrotoxin	DB00466	drug_n	diazepam	DB00829	True	effect	drug	[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine.
DDI-MedLine.d27.s0.p3	picrotoxin	DB00466	drug_n	amizyl	None	True	effect	drug_n	[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine.
DDI-MedLine.d3.s12.p0	Amprenavir	DB00701	drug	rifabutin	DB00615	True	effect	drug	Amprenavir plus rifabutin was poorly tolerated, and 5 of 11 subjects discontinued therapy.
DDI-MedLine.d45.s5.p2	pentazocine	DB00652	drug	tripelennamine	DB00792	True	effect	drug	Twelve strains of Staphylococcus aureus (a frequent cause of infection in heroin, but not in pentazocine and tripelennamine, addicts) were completely inhibited by the drug combination.
DDI-MedLine.d56.s5.p0	ouabain	DB01092	drug	phentolamine	DB00692	True	effect	drug	When ouabain was applied to the muscle in the presence of phentolamine, both first and second contractile responses to PTX were abolished.
DDI-MedLine.d63.s4.p5	naloxone	DB01183	drug	beta-endorphin	None	True	effect	drug_n	Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms).
DDI-MedLine.d67.s6.p0	diazepam	DB00829	drug	metamizol	None	True	effect	drug	Similarly, diazepam decreased the antinociceptive effect of metamizol (only in the tail-flick test) and indomethacin.
DDI-MedLine.d69.s5.p0	Flavoridin	None	drug_n	contortrostatin	None	True	effect	drug_n	Flavoridin alone was found to have no effect on CAS, but can completely block contortrostatin-induced phosphorylation of this protein in MDA-MB-435 cells.
DDI-MedLine.d8.s6.p9	rifabutin	DB00615	drug	ofloxacin	DB01165	True	effect	drug	When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin.
DDI-MedLine.d86.s8.p0	diltiazem	DB00343	drug	sirolimus	DB00877	True	mechanism	drug	CONCLUSIONS: Single-dose diltiazem coadministration leads to higher sirolimus exposure, presumably by inhibition of the first-pass metabolism of sirolimus.
DDI-DrugBank.d776.s11.p2	DIFLUCAN	None	brand	phenytoin	DB00252	True	advise	drug	Careful monitoring of phenytoin concentrations in patients receiving DIFLUCAN and phenytoin is recommended.
DDI-DrugBank.d776.s34.p0	tacrolimus	DB00864	drug	fluconazole	DB00196	True	advise	drug	Patients receiving tacrolimus and fluconazole concomitantly should be carefully monitored.
DDI-DrugBank.d776.s4.p0	DIFLUCAN	None	brand	tolbutamide	DB01124	True	mechanism	drug	DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents.
DDI-DrugBank.d776.s41.p0	fluconazole	DB00196	drug	ethinyl estradiol	DB00977	True	mechanism	drug	While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism.
DDI-DrugBank.d776.s41.p1	fluconazole	DB00196	drug	levonorgestrel	DB00367	True	mechanism	drug	While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism.
DDI-DrugBank.d776.s5.p0	DIFLUCAN	None	brand	sulfonylurea oral hypoglycemic agents	None	True	advise	group	When DIFLUCAN is used concomitantly with these or other sulfonylurea oral hypoglycemic agents, blood glucose concentrations should be carefully monitored and the dose of the sulfonylurea should be adjusted as necessary.
DDI-DrugBank.d779.s7.p1	methyldopa	DB00968	drug	ferrous gluconate	None	True	mechanism	drug	Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate.
DDI-DrugBank.d78.s1.p6	quinolones	None	group	multivitamins	None	True	mechanism	group	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
DDI-DrugBank.d81.s8.p0	isradipine	DB00270	drug	cimetidine	DB00501	True	advise	drug	If isradipine therapy is initiated in a patient currently receiving cimetidine careful monitoring for adverse reactions is advised and downward dose adjustment may be required.
DDI-MedLine.d86.s9.p0	sirolimus	DB00877	drug	diltiazem	DB00343	True	advise	drug	Because of the pronounced intersubject variability in the extent of the sirolimus-diltiazem interaction, whole blood sirolimus concentrations should be monitored closely in patients treated with the two drugs.
DDI-MedLine.d93.s9.p0	lead	None	drug_n	alcohol	None	True	effect	drug	These results suggest that exposure to environmental lead may alter the biological and behavioral responsiveness of an animal to alcohol.
DDI-MedLine.d94.s12.p2	desipramine	DB01151	drug	norepinephrine	DB00368	True	effect	drug	The uptake inhibitors cocaine and desipramine (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium.
DDI-DrugBank.d82.s21.p0	INDOCIN	None	brand	digoxin	DB00390	True	mechanism	drug	INDOCIN given concomitantly with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.
DDI-DrugBank.d82.s23.p1	INDOCIN	None	brand	potassium-sparing diuretics	None	True	effect	group	In some patients, the administration of INDOCIN can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing, and thiazide diuretics.
DDI-DrugBank.d82.s3.p0	aspirin	None	brand	indomethacin	DB00328	True	mechanism	drug	In a study in normal volunteers, it was found that chronic concurrent administration of 3.6 g of aspirin per day decreases indomethacin blood levels approximately 20%.
DDI-DrugBank.d82.s35.p0	INDOCIN	None	brand	captopril	DB01197	True	effect	drug	INDOCIN can reduce the antihypertensive effects of captopril and losartan.
DDI-DrugBank.d85.s6.p5	naproxen	DB00788	drug	aspirin	None	True	advise	brand	Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.
DDI-DrugBank.d86.s0.p1	antipsychotic drug	None	group	antiparkinsonian drug	None	True	effect	group	The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
DDI-DrugBank.d87.s14.p0	cimetidine	DB00501	drug	flecainide	DB01195	True	mechanism	drug	In healthy subjects receiving cimetidine (1 gm daily) for one week, plasma flecainide levels increased by about 30% and half-life increased by about 10%.
DDI-DrugBank.d87.s6.p0	TAMBOCOR	None	brand	propranolol	DB00571	True	effect	drug	The effects of concomitant administration of TAMBOCOR and propranolol on the PR interval were less than additive.
DDI-DrugBank.d88.s3.p4	capecitabine	DB01101	drug	coumarin-derivative anticoagulants	None	True	effect	group	Coumarin Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon.
DDI-DrugBank.d94.s11.p18	EQUETROTM	None	brand	glucocorticoids	None	True	mechanism	group	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s11.p20	EQUETROTM	None	brand	itraconazole	DB01167	True	mechanism	drug	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s11.p28	EQUETROTM	None	brand	olanzapine	DB00334	True	mechanism	drug	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s11.p36	EQUETROTM	None	brand	theophylline	DB00277	True	mechanism	drug	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s11.p43	EQUETROTM	None	brand	ziprasidone	DB00246	True	mechanism	drug	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s11.p8	EQUETROTM	None	brand	clozapine	DB00363	True	mechanism	drug	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
DDI-DrugBank.d94.s4.p6	EQUETROTM	None	brand	delavirdine	DB00705	True	mechanism	drug	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
DDI-DrugBank.d94.s8.p0	EQUETROTM	None	brand	Cisplatin	DB00515	True	mechanism	drug	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
DDI-DrugBank.d94.s8.p4	EQUETROTM	None	brand	phenobarbital	DB01174	True	mechanism	drug	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
DDI-DrugBank.d95.s2.p2	L-arginine	DB00125	drug	nitrates	None	True	effect	drug	Organic nitrates - L-arginine supplements theoretically may potentiate the effects of organic nitrates if taken concomitantly.
DDI-DrugBank.d97.s52.p0	indinavir	DB00224	drug	ritonavir	DB00503	True	effect	drug	Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving indinavir in combination with ritonavir than those receiving CRIXIVAN 800 mg q8h.
DDI-DrugBank.d98.s7.p2	Vitamin D	None	group	digitalis	None	True	advise	group	Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.
DDI-DrugBank.d98.s8.p2	Ketoconazole	DB01026	drug	vitamin D	None	True	mechanism	group	Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.
DDI-MedLine.d110.s6.p3	18-MC	None	drug_n	morphine	DB00295	True	effect	drug	Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens;
DDI-MedLine.d111.s9.p0	Acetaminophen	DB00316	drug	theophylline	DB00277	True	mechanism	drug	Acetaminophen diminished the binding of theophylline to human serum by a net change of 5.7% (percentage increase in free drug fraction [FDF], 11.0%) at 662 micromol/L and by a net change of 7.1% (percentage increase in FDF, 13.7%) at 1324 micromol/L.
DDI-MedLine.d114.s3.p0	InsP(3)	None	drug_n	RR	None	True	effect	drug_n	Administering InsP(3) together with RR (100-500 microM) inhibited InsP(3)-induced responses (both Ca(2+) and current responses) in a dose-dependent fashion.
DDI-MedLine.d114.s4.p0	RR	None	drug_n	InsP(3)	None	True	effect	drug_n	Pretreatment of megakaryocytes with extracellular RR (50 microM) also inhibited InsP(3)-induced responses.
DDI-MedLine.d12.s2.p5	retinyl acetate	None	drug	EGF	None	True	effect	drug_n	Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin.
DDI-MedLine.d128.s13.p2	morphine	DB00295	drug	dmPGE2	None	True	effect	drug_n	Loperamide and morphine (0.1 and 1.0 mg/kg, s.c.) inhibited the dmPGE2 (0.3 mg/kg, p.o.)-induced diarrhea in cecectomized rats.
DDI-MedLine.d143.s3.p0	omeprazole	DB00338	drug	clopidogrel	DB00758	True	mechanism	drug	Concomitant use of omeprazole and clopidogrel was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by omeprazole of CYP2C19, a cytochrome P450 (CYP) enzyme.
DDI-MedLine.d179.s0.p0	sunitinib	DB01268	drug	docetaxel	DB01248	True	int	drug	Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.
DDI-MedLine.d190.s8.p0	AAV2	None	drug_n	heparinase III	None	True	effect	drug_n	AAV2-mediated retinal transduction is improved by co-injection of heparinase III or chondroitin ABC lyase.
DDI-MedLine.d209.s5.p2	fluoxetine	DB00472	drug	endoxifen	None	True	mechanism	drug_n	Paroxetine and fluoxetine reduce the plasma concentration of endoxifen by about 50%.
DDI-MedLine.d209.s9.p0	tamoxifen	DB00675	drug	SSRI antidepressants	None	True	advise	group	It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine.
DDI-MedLine.d227.s8.p0	dexmedetomidine	DB00633	drug	ephedrine	DB01364	True	effect	drug	At the same time, the locomotor inhibitory effect of dexmedetomidine was counteracted by ephedrine.
DDI-MedLine.d23.s1.p10	ketamine	DB01221	drug	ouabain	DB01092	True	effect	drug	In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital.
DDI-MedLine.d231.s8.p5	Lomefloxacin	DB00978	drug	sucralfate	DB00364	True	mechanism	drug	Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.
DDI-MedLine.d25.s10.p0	macrolide antibiotics	None	group	hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors	None	True	effect	group	The concomitant administration of macrolide antibiotics and other hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors have resulted in previous reports of rhabdomyolysis.
DDI-MedLine.d25.s12.p2	Macrolide antibiotics	None	group	cerivastatin	DB00439	True	mechanism	drug	CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin).
DDI-MedLine.d3.s14.p1	Amprenavir	DB00701	drug	25-O-desacetylrifabutin	None	True	mechanism	drug_n	Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated.
DDI-MedLine.d39.s2.p0	estradiol	DB00783	drug	endotoxin	None	True	effect	drug_n	Injection of estradiol 5 min before a nonlethal dose of endotoxin changed the serum sex steroid hormone response of male rats to endotoxin.
DDI-MedLine.d49.s6.p0	clindamycin	DB01190	drug	gentamicin	DB00798	True	effect	drug	Combinations of clindamycin and gentamicin were indifferent for 29 strains and synergistic for 33 strains.
DDI-MedLine.d49.s8.p0	clindamycin	DB01190	drug	gentamicin	DB00798	True	effect	drug	Combinations of clindamycin and gentamicin were indifferent for 16 and synergistic for 11 of the resistant strains.
DDI-MedLine.d54.s8.p0	Physostigmine	DB00981	drug	alcohol	None	True	effect	drug	Physostigmine pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating alcohol's influence on components P2 and P3.
DDI-MedLine.d54.s8.p1	Physostigmine	DB00981	drug	alcohol	None	True	effect	drug	Physostigmine pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating alcohol's influence on components P2 and P3.
DDI-MedLine.d61.s1.p0	Amiodarone	DB01118	drug	digoxin	DB00390	True	mechanism	drug	Amiodarone is known to raise serum digoxin levels.
DDI-MedLine.d7.s0.p0	theophylline	DB00277	drug	phenytoin	DB00252	True	mechanism	drug	Enhanced theophylline clearance secondary to phenytoin therapy.
DDI-MedLine.d90.s11.p0	gentamycin	None	drug	atracurium	DB00732	True	effect	drug	It was concluded that, although gentamycin did augment the neuromuscular blockade of atracurium, the effect was minimal.
DDI-MedLine.d90.s8.p2	atracurium	DB00732	drug	gentamycin	None	True	effect	drug	Recovery from 50% twitch to 75% fade recovery took 13.8 +/- 0.8 min for atracurium alone and 13.7 +/- 1.2 min for atracurium plus gentamycin.
DDI-MedLine.d99.s0.p0	Fluvoxamine	DB00176	drug	tolbutamide	DB01124	True	mechanism	drug	Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide.
